<SEC-DOCUMENT>0001171843-17-001159.txt : 20170227
<SEC-HEADER>0001171843-17-001159.hdr.sgml : 20170227
<ACCEPTANCE-DATETIME>20170227160425
ACCESSION NUMBER:		0001171843-17-001159
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		81
CONFORMED PERIOD OF REPORT:	20161231
FILED AS OF DATE:		20170227
DATE AS OF CHANGE:		20170227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOCRYST PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000882796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621413174
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23186
		FILM NUMBER:		17641648

	BUSINESS ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-859-1302

	MAIL ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>f10k_022717p.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML><HEAD>
     <TITLE></TITLE>
</HEAD><BODY STYLE="font: 10pt Times New Roman, Times, Serif">





<p style="margin: 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Rule-Page --><div align="LEFT" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>UNITED STATES</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Washington,&nbsp;D.C. 20549</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">________________________</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Form 10-K</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">________________________</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 4%; font-size: 10pt"><font style="font-size: 10pt">&#9746;</font></td>
    <td style="width: 96%; font-size: 10pt"><font style="font-size: 10pt"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></font></td></tr>
</table>
<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>For the fiscal year ended December&nbsp;31, 2016</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>OR</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 4%; font-size: 10pt"><font style="font-size: 10pt">&#9744;</font></td>
    <td style="width: 96%; font-size: 10pt"><font style="font-size: 10pt"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</b></font></td></tr>
</table>
<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Commission File Number 000-23186</b> &nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">________________________</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(Exact name of registrant as specified in its charter)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">________________________</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 49%; font-size: 10pt">&nbsp;</td>
    <td style="vertical-align: bottom; width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 49%; font-size: 10pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><font style="font-size: 10pt"><b>DELAWARE</b></font></td>
    <td style="vertical-align: bottom; font-size: 10pt">&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><font style="font-size: 10pt"><b>62-1413174</b></font></td></tr>
<tr>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 2.4pt 0pt 0"><b>(State of other jurisdiction of</b></p>
        <p style="font-size: 10pt; text-align: center; margin: 0pt 2.4pt 0pt 0"><b>incorporation or organization)</b></p></td>
    <td style="vertical-align: bottom; font-size: 10pt">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 2.4pt 0pt 0"><b>(I.R.S. employer</b></p>
        <p style="font-size: 10pt; text-align: center; margin: 0pt 2.4pt 0pt 0"><b>identification no.)</b></p></td></tr>
</table>
<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>4505 Emperor Blvd., Suite&nbsp;200, Durham, North Carolina 27703</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(Address of principal executive offices)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(919)&nbsp;859-1302</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(Registrant&#8217;s telephone number, including area code)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Securities registered pursuant to Section&nbsp;12(b) of the Act:</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 49%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="width: 49%">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-decoration: underline; text-align: center"><font style="font-size: 10pt"><b><u>Title of Each Class</u></b></font></td>
    <td>&nbsp;</td>
    <td style="text-decoration: underline; text-align: center"><font style="font-size: 10pt"><b><u>Name of Each Exchange on Which Registered</u></b></font></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><font style="font-size: 10pt"><b>Common Stock, $.01&nbsp;Par Value</b></font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><font style="font-size: 10pt"><b>The NASDAQ Global Select Market</b></font></td></tr>
</table>
<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Securities registered pursuant to Section&nbsp;12(g) of the Act:</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Title of class</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>None</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">________________________</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by a check mark if the registrant is a well-known seasoned issuer, as defined
in Rule&nbsp;405 of the Securities Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744; &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by a check mark if the registrant is not required to file reports pursuant to
Section&nbsp;13 or Section&nbsp;15(d) of the Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744; &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">Indicate by a check mark whether the registrant (1)&nbsp;has filed
all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&nbsp;months
(or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing
requirements for the past 90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746; &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by a check mark whether the registrant submitted electronically and posted on
its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T
(Section&nbsp;232.405 of this chapter) during the preceding 12&nbsp;months (or for such shorter period that the registrant was
required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746; &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><p style="margin: 0pt">&nbsp;</p></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">Indicate by check mark if disclosure of delinquent filers pursuant
to Item&nbsp;405 of Regulation&nbsp;S-K (Section&nbsp;229.405 of this chapter) is not contained herein, and will not be contained,
to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part&nbsp;III
of this Form&nbsp;10-K or any amendment to this Form&nbsp;10-K.&nbsp;&nbsp;&#9746;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated
filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule&nbsp;12b-2 of the Exchange Act.
(Check one):</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 24%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="width: 46%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="width: 24%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap><font style="font-size: 10pt">Large&nbsp;accelerated&nbsp;filer</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">&#9744;</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Accelerated&nbsp;filer</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">&#9746;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 10pt">Non-accelerated filer</font></td>
    <td>&nbsp;</td>
    <td nowrap><font style="font-size: 10pt">&#9744;&nbsp;&nbsp;(Do not check if a smaller reporting company)</font></td>
    <td>&nbsp;</td>
    <td nowrap><font style="font-size: 10pt">Smaller&nbsp;reporting&nbsp;company</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">&#9744;</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by a check mark whether the registrant is a shell company (as defined in Exchange
Act Rule 12b-2).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744; &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp; &#9746;.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">The Registrant estimates that the aggregate market value of the Common Stock on June&nbsp;30,
2016 (based upon the closing price shown on the NASDAQ Global Select Market on June&nbsp;30, 2016)&nbsp;held by non-affiliates
was $206,175,247.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">The number of shares of Common Stock, par value $.01, of the Registrant outstanding as
of January&nbsp;31, 2017 was 73,955,169 shares.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Portions of the Registrant&#8217;s definitive Proxy Statement to be filed in connection
with the solicitation of proxies for its 2017 Annual Meeting of Stockholders are incorporated by reference into Items&nbsp;10,
11, 12, 13 and 14 under Part&nbsp;III hereof.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>



<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><p style="margin: 0pt">&nbsp;</p></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><u>TABLE OF CONTENTS</u></b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 97%; text-align: center"><font style="font-size: 10pt"><b>PART&nbsp;I</b></font></td>
    <td style="width: 3%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-decoration: underline"><a href="#a_001"><font style="font-size: 10pt"><u>ITEM&nbsp;1. BUSINESS</u></font></a></td>
    <td style="vertical-align: bottom; text-decoration: underline; text-align: right"><a href="#a_001"><font style="font-size: 10pt"><u>4</u></font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-decoration: underline"><a href="#a_002"><font style="font-size: 10pt"><u>ITEM&nbsp;1A. RISK FACTORS</u></font></a></td>
    <td style="vertical-align: bottom; text-decoration: underline; text-align: right"><a href="#a_002"><font style="font-size: 10pt"><u>18</u></font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-decoration: underline"><a href="#a_003"><font style="font-size: 10pt"><u>ITEM&nbsp;1B. UNRESOLVED STAFF COMMENTS</u></font></a></td>
    <td style="vertical-align: bottom; text-decoration: underline; text-align: right"><a href="#a_003"><font style="font-size: 10pt"><u>34</u></font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-decoration: underline"><a href="#a_004"><font style="font-size: 10pt"><u>ITEM&nbsp;2. PROPERTIES</u></font></a></td>
    <td style="vertical-align: bottom; text-decoration: underline; text-align: right"><a href="#a_004"><font style="font-size: 10pt"><u>34</u></font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-decoration: underline"><a href="#a_005"><font style="font-size: 10pt"><u>ITEM&nbsp;3. LEGAL PROCEEDINGS</u></font></a></td>
    <td style="vertical-align: bottom; text-decoration: underline; text-align: right"><a href="#a_005"><font style="font-size: 10pt"><u>34</u></font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-decoration: underline"><a href="#a_006"><font style="font-size: 10pt"><u>ITEM&nbsp;4. MINE SAFETY DISCLOSURES</u></font></a></td>
    <td style="vertical-align: bottom; text-decoration: underline; text-align: right"><a href="#a_006"><font style="font-size: 10pt"><u>35</u></font></a></td></tr>
<tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt"><b>PART&nbsp;II</b></font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-decoration: underline"><a href="#a_007"><font style="font-size: 10pt"><u>ITEM&nbsp;5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</u></font></a></td>
    <td style="vertical-align: bottom; text-decoration: underline; text-align: right"><a href="#a_007"><font style="font-size: 10pt"><u>35</u></font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-decoration: underline"><a href="#a_008"><font style="font-size: 10pt"><u>ITEM&nbsp;6. SELECTED FINANCIAL DATA</u></font></a></td>
    <td style="vertical-align: bottom; text-decoration: underline; text-align: right"><a href="#a_008"><font style="font-size: 10pt"><u>36</u></font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-decoration: underline"><a href="#a_009"><font style="font-size: 10pt"><u>ITEM&nbsp;7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</u></font></a></td>
    <td style="vertical-align: bottom; text-decoration: underline; text-align: right"><a href="#a_009"><font style="font-size: 10pt"><u>36</u></font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-decoration: underline"><a href="#a_010"><font style="font-size: 10pt"><u>ITEM&nbsp;7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</u></font></a></td>
    <td style="vertical-align: bottom; text-decoration: underline; text-align: right"><a href="#a_010"><font style="font-size: 10pt"><u>48</u></font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-decoration: underline"><a href="#a_011"><font style="font-size: 10pt"><u>ITEM&nbsp;8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</u></font></a></td>
    <td style="vertical-align: bottom; text-decoration: underline; text-align: right"><a href="#a_011"><font style="font-size: 10pt"><u>49</u></font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-decoration: underline"><a href="#a_012"><font style="font-size: 10pt"><u>ITEM&nbsp;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</u></font></a></td>
    <td style="vertical-align: bottom; text-decoration: underline; text-align: right"><a href="#a_012"><font style="font-size: 10pt"><u>75</u></font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-decoration: underline"><a href="#a_013"><font style="font-size: 10pt"><u>ITEM&nbsp;9A. CONTROLS AND PROCEDURES</u></font></a></td>
    <td style="vertical-align: bottom; text-decoration: underline; text-align: right"><a href="#a_013"><font style="font-size: 10pt"><u>75</u></font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-decoration: underline"><a href="#a_014"><font style="font-size: 10pt"><u>ITEM&nbsp;9B. OTHER INFORMATION</u></font></a></td>
    <td style="vertical-align: bottom; text-decoration: underline; text-align: right"><a href="#a_014"><font style="font-size: 10pt"><u>76</u></font></a></td></tr>
<tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt"><b>PART&nbsp;III</b></font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-decoration: underline"><a href="#a_015"><font style="font-size: 10pt"><u>ITEM&nbsp;10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</u></font></a></td>
    <td style="vertical-align: bottom; text-decoration: underline; text-align: right"><a href="#a_015"><font style="font-size: 10pt"><u>76</u></font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-decoration: underline"><a href="#a_016"><font style="font-size: 10pt"><u>ITEM&nbsp;11. EXECUTIVE COMPENSATION</u></font></a></td>
    <td style="vertical-align: bottom; text-decoration: underline; text-align: right"><a href="#a_016"><font style="font-size: 10pt"><u>76</u></font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-decoration: underline"><a href="#a_017"><font style="font-size: 10pt"><u>ITEM&nbsp;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</u></font></a></td>
    <td style="vertical-align: bottom; text-decoration: underline; text-align: right"><a href="#a_017"><font style="font-size: 10pt"><u>76</u></font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-decoration: underline"><a href="#a_018"><font style="font-size: 10pt"><u>ITEM&nbsp;13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</u></font></a></td>
    <td style="vertical-align: bottom; text-decoration: underline; text-align: right"><a href="#a_018"><font style="font-size: 10pt"><u>76</u></font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-decoration: underline"><a href="#a_019"><font style="font-size: 10pt"><u>ITEM&nbsp;14. PRINCIPAL ACCOUNTING FEES AND SERVICES</u></font></a></td>
    <td style="vertical-align: bottom; text-decoration: underline; text-align: right"><a href="#a_019"><font style="font-size: 10pt"><u>76</u></font></a></td></tr>
<tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt"><b>PART&nbsp;IV</b></font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-decoration: underline"><a href="#a_020"><font style="font-size: 10pt"><u>ITEM&nbsp;15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</u></font></a></td>
    <td style="vertical-align: bottom; text-decoration: underline; text-align: right"><a href="#a_020"><font style="font-size: 10pt"><u>76</u></font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-decoration: underline"><a href="#a_021"><font style="font-size: 10pt"><u>SIGNATURES</u></font></a></td>
    <td style="vertical-align: bottom; text-decoration: underline; text-align: right"><a href="#a_021"><font style="font-size: 10pt"><u>77</u></font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-decoration: underline"><a href="#a_022"><font style="font-size: 10pt"><u>INDEX TO EXHIBITS</u></font></a></td>
    <td style="vertical-align: bottom; text-decoration: underline; text-align: right"><a href="#a_022"><font style="font-size: 10pt"><u>78</u></font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-indent: 10pt"><font style="font-size: 10pt">EX-10.74</font></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-indent: 10pt"><font style="font-size: 10pt">EX-10.77</font></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-indent: 10pt"><font style="font-size: 10pt">EX-21</font></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-indent: 10pt"><font style="font-size: 10pt">EX-23</font></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-indent: 10pt"><font style="font-size: 10pt">EX-31.1</font></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-indent: 10pt"><font style="font-size: 10pt">EX-31.2</font></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-indent: 10pt"><font style="font-size: 10pt">EX-32.1</font></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-indent: 10pt"><font style="font-size: 10pt">EX-32.2</font></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-indent: 10pt"><font style="font-size: 10pt">EX-101</font></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>PART I</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><b><a name="a_001"></a>ITEM 1.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b><i>BUSINESS</i></b></td>
</tr></table>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Forward-Looking Statements</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">This report includes forward-looking statements within the meaning
of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#8220;safe harbor&#8221; created
in Section&nbsp;21E. In particular, statements about our expectations, beliefs, plans, objectives or assumptions of future events
or performance are contained or incorporated by reference in this report. All statements other than statements of historical facts
contained herein are forward-looking statements. We have based these forward-looking statements on our current expectations about
future events. While we believe these expectations are reasonable, forward-looking statements are inherently subject to risks and
uncertainties, many of which are beyond our control. Our actual results may differ materially from those suggested by these forward-looking
statements for various reasons, including those discussed in this report under the heading &#8220;Risk Factors.&#8221; Given these
risks and uncertainties, you are cautioned not to place undue reliance on our forward-looking statements. The forward-looking statements
included in this report are made only as of the date hereof. We do not undertake, and specifically decline, any obligation to update
any of these statements or to publicly announce the results of any revisions to any forward-looking statements to reflect future
events or developments. When used in the report, unless otherwise indicated, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221;
the &#8220;Company&#8221; and &#8220;BioCryst&#8221; refer to BioCryst Pharmaceuticals, Inc.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Our Business</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are a biotechnology company that designs, optimizes and develops
novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. We focus on the treatment of rare diseases
in which significant unmet medical needs exist and align with our capabilities and expertise. We integrate the disciplines of biology,
crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process
known as structure-guided drug design. Structure-guided drug design is a drug discovery approach by which we design synthetic compounds
from detailed structural knowledge of the active sites of enzyme targets associated with particular diseases. We use X-ray crystallography,
computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure
and active site characteristics of the enzymes that control cellular biology. Enzymes are proteins that act as catalysts for many
vital biological reactions. Our goal generally is to design a compound that will fit in the active site of an enzyme and thereby
prevent its catalytic activity. Molecules from our discovery efforts which are commercially available or that are in active development
are summarized in the table below:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
    <td style="width: 17%; border-bottom: black 1pt solid"><font style="font-size: 10pt">Drug/Drug Candidate</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 34%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Drug Class</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 19%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Therapeutic</font><br>
<font style="font-size: 10pt">Area(s)</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 11%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Phase</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 15%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Rights</font></td></tr>
<tr>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">RAPIVAB<sup>&#174;</sup></p>
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">(peramivir injection)</p></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Intravenous Neuraminidase Inhibitor</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Acute uncomplicated Influenza</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">Approved</p>
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">(US &amp; Canada)</p>
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">&nbsp;</p></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Seqirus (worldwide, except Japan, Taiwan, Korea and Israel) BioCryst retains full U.S. Government stockpiling rights</font></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">ALPIVAB<sup>TM</sup></p>
        <p style="font-size: 10pt; margin: 0pt 0.8pt 0pt 0">(peramivir injection)</p></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Intravenous Neuraminidase Inhibitor</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Acute uncomplicated Influenza</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">MAA filed and being reviewed by the EMA</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Seqirus (worldwide, except Japan, Taiwan, Korea and Israel) </font></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">RAPIACTA<sup>&#174;</sup></p>
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">(peramivir injection)</p>
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">&nbsp;</p></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Intravenous Neuraminidase Inhibitor</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Uncomplicated seasonal influenza</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">Approved</p>
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">(Japan &amp; Taiwan)</p></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">Shionogi</p>
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">(Japan &amp; Taiwan)</p>
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">&nbsp;</p></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">PERAMIFLU<sup>&#174;</sup></p>
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">(peramivir injection)</p></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Intravenous Neuraminidase Inhibitor</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Uncomplicated seasonal influenza</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">Approved</p>
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">(Korea)</p></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">Green Cross</p>
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">(Korea)</p></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">BCX7353</p></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">Oral Serine Protease Inhibitor Targeting Kallikrein (intended to be
a once-daily treatment)</p></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">HAE</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">Phase 2</p>
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">&nbsp;</p></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">BioCryst</p>
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">(worldwide)</p></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Other 2<sup>nd</sup> generation&nbsp;</font><br>
<font style="font-size: 10pt">HAE compounds</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Oral Serine Protease Inhibitors Targeting Kallikrein</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">HAE and other indications</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Preclinical</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">BioCryst</font><br>
<font style="font-size: 10pt">(worldwide)</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Galidesivir (formerly BCX4430)</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">RNA dependent-RNA Polymerase Inhibitor</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Broad spectrum antiviral for 20 RNA viruses, including Ebola, Marburg, and Zika </font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Phase 1</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">BioCryst</p>
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">(worldwide)</p></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Forodesine</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Oral Purine Nucleoside Phosphorylase Inhibitor</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Oncology- PTCL</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">JNDA filed and being reviewed by the PMDA in Japan</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">Mundipharma</p>
        <p style="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">(worldwide)</p></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 4; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b>Business Strategy</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our business strategy is to create shareholder value by focusing our
discovery and development efforts on oral drugs for rare diseases for which a significant unmet medical need exists. We select
disease targets and product candidates in which a small molecule would offer a significant benefit over existing products or would
be the first to market. We strive to advance our product candidate portfolio from discovery to commercial markets efficiently by
utilizing a small group of talented and highly-skilled employees working in conjunction with strategic outsource partners. BioCryst
is unique in its approach to treat orphan diseases with orally-administered, small molecules utilizing crystallography and structure-guided
drug design. The principal elements of our strategy are:&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt"><i>Focusing on High Value-Added Structure-Guided Drug Design Technologies.</i> We utilize structure-guided drug design in order to most efficiently develop new therapeutic candidates. Structure-guided drug design is a process by which we design a product candidate through detailed analysis of the enzyme target, which the product candidate must inhibit in order to stop the progression of the disease or disorder. We believe that structure-guided drug design is a powerful tool for the efficient development of small-molecule product candidates that have the potential to be safe and effective. Our structure-guided drug design technologies typically allow us to design and synthesize multiple product candidates that inhibit the same enzyme target, with the goal of establishing broad patent protection and formulating compounds with competitive advantages.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt"><i>Selecting Inhibitors that are Promising Product Candidates.</i> We start by selecting disease targets with well-understood biology and characteristics that fit with our ability to utilize structure-guided drug design capabilities to build potent and specific enzyme inhibitors. Next, we narrow our selection of these product candidates based on product characteristics, such as initial indications of safety and biologic activity on the target.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt"><i>Developing our Product Candidates Efficiently.</i> An important element of our business strategy is to efficiently progress our product candidates through the development process. In order to accomplish this, we strive for disease targets with a defined clinical and regulatory pathway for approval. In addition, we control fixed costs and overhead by outsourcing with strategic partners and contractors or entering into license agreements with third parties, including the U.S. Government. We maintain a streamlined corporate infrastructure that focuses our expertise. By contracting with the U.S. Government and outsourcing certain aspects of our operations, we are able to control overhead costs and focus financial resources directly where they provide the most benefit and reduce our business risk.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are a Delaware corporation originally founded in 1986. Our corporate
headquarters is located at 4505 Emperor Blvd., Suite&nbsp;200, Durham, North Carolina 27703 and the corporate telephone number
is (919)&nbsp;859-1302. For more information about us, please visit our website at www.biocryst.com. The information on our website
is not incorporated into this Form&nbsp;10-K.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Peramivir injection </b>(RAPIVAB<sup>&#174;</sup>, RAPIACTA<sup>&#174;</sup>, PERAMIFLU<sup>&#174;</sup>,
ALPIVAB<sup>TM</sup>)&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Peramivir is an intravenous neuraminidase inhibitor approved in multiple
countries for the treatment of patients with influenza. Influenza is a seasonal virus with the highest infection rates generally
observed in colder months. In countries for which peramivir is commercially available, influenza occurs primarily during the September
to April timeframe.&nbsp;Peramivir is available commercially in the United States and has been approved for commercial use in Canada
under the name RAPIVAB<sup>&#174;</sup>, in Japan and Taiwan as RAPIACTA<sup>&#174;</sup>, and in Korea as PERAMIFLU<sup>&#174;</sup>.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Peramivir was most recently approved in Canada in January 2017,
and was approved in the United States in December 2014, in each case for the treatment of acute uncomplicated influenza in
patients 18 years and older who have been symptomatic for no more than two days. Data from over 2,700 subjects treated with
peramivir in 27 clinical trials was utilized to support regulatory approval in these countries. We made RAPIVAB available for
commercial sale in the U.S. through agreements with specialty distributorships during the 2014-2015 influenza season. On June
17, 2015, we announced that we licensed RAPIVAB (peramivir injection) for the treatment of influenza to CSL Limited
(&ldquo;CSL&ldquo;), a global biopharmaceutical company. RAPIVAB is being commercialized by a subsidiary of CSL called
Seqirus UK Limited (&ldquo;SUL&rdquo; or &ldquo;Seqirus&rdquo;), which specializes in influenza prevention through the supply of seasonal and
pandemic influenza vaccine to global markets. Under the terms of the agreement, SUL obtained worldwide rights to
commercialize RAPIVAB, with the exception of Japan, Korea, Taiwan and Israel. BioCryst retained all rights to pursue pandemic
stockpiling orders for RAPIVAB from the U.S. Government, while SUL is responsible for government stockpiling outside the U.S.
With the out-license of RAPIVAB to SUL, and our recent Canadian regulatory approval, our current goals for RAPIVAB are to:
(1) obtain a stockpiling procurement contract with the U.S. Government (2) fulfill our post-approval development
requirements, including conducting a pediatric trial in the United States and submitting a supplemental New Drug Application
(&ldquo;sNDA&rdquo;) for a pediatric indication; and receiving regulatory approval for our Marketing Authorization
Application (&ldquo;MAA&rdquo;) in the European Union.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In January 2017, we announced that the European Medicines Agency (&#8220;EMA&#8221;)
has accepted the filing of our peramivir injection MAA for treatment of symptoms typical of influenza in adults 18&nbsp;years and
older. If the MAA is approved, Seqirus will commercialize peramivir as ALPIVAB<sup>TM</sup> in the European Union. The acceptance
of the MAA begins the review process by the EMA under the centralized licensing procedure for all 28 member states of the European
Union, Norway and Iceland.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">RAPIVAB was developed under a $234.8 million contract from the Biomedical
Advanced Research and Development Authority within the United States Department of Health and Human Services (&#8220;BARDA/HHS&#8221;),
which expired on June 30, 2014. See &#8220;Collaborations and In-License Relationships&#8212;BARDA/HHS&#8221; below for a further
discussion of this development contract.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In January 2010, our partner Shionogi&nbsp;&amp; Co., Ltd. (&#8220;Shionogi&#8221;)
received the first approval for peramivir injection and launched it in Japan under the commercial name RAPIACTA. It is approved
for the treatment of adults, children and infants with uncomplicated seasonal influenza and those patients at high-risk for complications
associated with influenza. In August 2010, Green Cross Corporation (&#8220;Green Cross&#8221;) received marketing and manufacturing
approval from the Korean Food&nbsp;&amp; Drug Administration under the commercial name PERAMIFLU to treat patients with influenza
A &amp; B viruses, including pandemic H1N1 and avian influenza. In addition, we have a regional collaboration for the development
and commercialization of peramivir in Israel.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><B>Hereditary Angioedema (&#8220;HAE&#8221;) Drug Candidates</B></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><I><U>2nd generation HAE compounds:</U></I> The goal of our second
generation HAE discovery program is to discover and develop oral molecules for the prevention of HAE attacks which have a superior
selectivity and bioavailability profile while maintaining similar potency as compared to avoralstat. HAE is a rare, severely debilitating
and potentially fatal genetic condition that occurs in approximately 1 in 50,000 people. HAE symptoms include recurrent episodes
of edema in various locations, including the hands, feet, face, genitalia and airway. Airway swelling is particularly dangerous
and can lead to death by asphyxiation. In addition, patients often have bouts of excruciating abdominal pain, nausea and vomiting
caused by swelling in the intestinal wall.&nbsp;By inhibiting plasma kallikrein, our HAE drug candidates suppress bradykinin production.
Bradykinin is the mediator of acute swelling attacks in HAE patients.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In December 2013, we announced the selection of two optimized plasma
kallikrein inhibitors to advance into preclinical development as potential once-daily, oral prophylactic treatments for HAE. Based
on early preclinical development studies, these structurally different molecules have a similar mechanism of action as avoralstat
and have achieved the principal goal of improved bioavailability. Both BCX7353 and the other compound had roughly five times better
bioavailability than avoralstat, our first oral drug candidate to treat HAE. These compounds demonstrated sub-nanomolar potency
on the isolated enzyme and single digit nanomolar potency in suppressing kallikrein activity in an ex-vivo activated normal human
plasma kallikrein inhibition (&ldquo;aPKI&rdquo;) assay. Plasma concentrations of each of the optimized compounds exceeded the
aPKI assay EC80 concentration at 24 hours after a single oral dose of 10 mg/kg in rats, indicating potential for once-daily dosing.
In January 2015, we selected BCX7353 to advance into Phase 1 development as a once-daily, oral prophylactic HAE treatment. In
addition to BCX7353, we continue to work on and advance other second generation compounds. These molecules are in preclinical
development and are being assessed for safety and efficacy in prophylactic HAE treatment as well as for other potential indications.
We will provide additional information on these molecules as we approach an Investigational New Drug (&ldquo;IND&rdquo;) filing
or we obtain data suggesting efficacy and safety surrounding these molecules in HAE and other therapeutic indications.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><I><U>BCX7353:</U></I> BCX7353 is structurally different from and
is expected to have superior efficacy as compared to avoralstat, but has a similar mechanism of action targeting plasma kallikrein.
On May 13, 2015, we announced the initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics
of orally-administered BCX7353 in healthy volunteers.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0; color: #333333">&nbsp;</p>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In October 2015, we successfully completed a Phase
1 clinical trial of BCX7353 in Western and Japanese healthy volunteers. In the Western portion of this trial, we studied BCX7353
single doses of up to 1000mg, once-daily doses of up to 500mg for seven days, and once-daily doses of 350mg for 14 days in healthy
Western volunteers. Plasma levels increased in approximate proportion to dose, and drug exposure was not affected by dosing with
food. The half-life of BCX7353 was estimated at 50-60 hours. After daily dosing, blood levels met or exceeded a predicted target
therapeutic range throughout the 24 hour dosing interval. Inhibition of the target enzyme, plasma kallikrein, was measured in
a sensitive and specific bioassay. Daily dosing with BCX7353 strongly inhibited plasma kallikrein at all four dose levels; the
degree of inhibition was dose-related (p &lt; 0.0001) and inhibition was sustained throughout the 24 hour dosing interval. This
pharmacodynamic effect correlated strongly to the achieved drug concentration (r = 0.91, p &lt; 0.0001).</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0; color: #333333">&nbsp;</p>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In the Japanese portion of this trial, we enrolled
cohorts of healthy Japanese volunteers and gave single oral doses of BCX7353 of 100mg and 500mg, and daily doses of 250mg of BCX7353
for seven days. Compared to Western subjects administered the same dose level, plasma drug levels in Japanese subjects were moderately
higher. Kallikrein inhibition on day seven of daily dosing with 250mg in Japanese subjects was similar to that seen at the 350mg
daily and 500mg daily dose levels in Western subjects.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0; color: #333333">&nbsp;</p>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The combined data from all Phase 1 clinical trials
completed as of July 2016 indicates that oral BCX7353 has been generally safe and well tolerated in a total of 117 healthy volunteers,
46 receiving single doses of up to 1000 mg, and 71 receiving once-daily doses of up to 500 mg for 7 days and 350 mg for 14 days.
In our Phase 1 trials, we have observed an approximate 5% rate of drug-related rash in healthy volunteers administered daily doses
of BCX7353 for at least 7 days. This drug-related rash appears within the first 14 days of drug administration and resolves within
a few days after discontinuing the drug. No serious adverse events have been seen and no dose-limiting toxicity has been identified.
There have been no clinically significant laboratory abnormalities, ECG changes, or vital sign changes observed.</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The safety, tolerability, drug exposure and on-target plasma kallikrein
inhibition results strongly supported advancing the development program into a Phase 2 study in HAE patients. In August 2016, we
commenced a Phase 2 trial (&#8220;APeX-1&#8221;) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy
of BCX7353 as a preventative treatment to reduce the frequency of attacks in HAE patients.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0; color: #333333">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><I><U></U></I></P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"><I><U>APEX-1 trial</U>: </I>In August 2016, we announced that we
had dosed the first subject in the APeX-1 clinical trial of BCX7353 for the oral treatment of HAE. APeX-1 is a multi-part, Phase
2, randomized, double-blind, placebo-controlled, dose ranging trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics
and efficacy of BCX7353 as a preventative treatment to eliminate or reduce the frequency of angioedema attacks in HAE patients.
APEX-1 is being conducted in several European countries, Australia and Canada. In part 1 of APeX-1, subjects with HAE were randomized
in a 1:1 ratio to receive an oral dose of either 350 mg of BCX7353 once daily (&ldquo;QD&rdquo;) or placebo QD for 28 days. The
primary efficacy endpoints of APeX-1 are the number of angioedema attacks; attack rate per week, counts of attacks, proportion
of subjects with no attacks, and number of attack-free days. Efficacy analyses will be conducted for HAE attacks reported over
the entire dosing interval (Days 1 through 28) and during the dosing period in which plasma concentrations of BCX7353 should be
at steady-state conditions (Days 8 through 28). Secondary efficacy endpoints include severity and duration of angioedema attacks
and measures of health-related quality of life. Safety will be characterized through evaluation of adverse events and laboratory
testing. Pharmacokinetics and pharmacodynamic effects will be assessed through measurement of plasma drug levels and kallikrein
inhibition. A total of approximately 36 subjects have been enrolled in part 1.</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0; background-color: white">On February 27, 2017, we reported statistically
significant and clinically meaningful reductions in attack frequency from an interim analysis of part 1 of our ongoing multi-part
APeX-1 clinical trial in HAE patients. In the interim analysis, twenty-eight subjects, randomized equally to receive BCX7353 350&nbsp;mg
QD or placebo for 28 days. The baseline attack rate was approximately 1/week and average C1 inhibitor levels were less than
20% of the normal mean, indicating a severely affected patient population. Baseline characteristics of trial participants were
generally well balanced between the two groups with the exception of prior androgen use, which was more common in the BCX7353 group
(11 of 14 compared with 6 of 14 on placebo). Compliance with study drug dosing in the trial was excellent and was greater than
98%.</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0; background-color: white">The pre-specified per-protocol (&ldquo;PP&rdquo;)
interim analysis included data on 24 subjects with confirmed Type 1 or Type 2 HAE and completing 28 days of treatment (11 on BCX7353
and 13 on placebo). The mean rate of independently-adjudicated angioedema attacks for the pre-defined effective dosing period (weeks
2 through 4) in BCX7353-treated subjects was 0.34/week compared to 0.92/week for placebo, a reduction of 0.57/week (63%), p&nbsp;=&nbsp;0.006.
In the intent-to-treat (&ldquo;ITT&rdquo;) population of 28 subjects, the rate of attack for the effective dosing period for BCX7353
and placebo groups was 0.44/week and 0.91/week, a reduction of 0.47/week (52%), p&nbsp;=&nbsp;0.035.</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0; background-color: white">A pre-planned analysis of peripheral and
abdominal attacks showed reductions of 88% and 24%, respectively, for BCX7353 compared with placebo (PP analysis, weeks 2 through
4). To understand this difference, patient diaries were reviewed and abdominal attacks (n&nbsp;=&nbsp;9, BCX7353 and n&nbsp;=&nbsp;14,
placebo) were subdivided into two groups: attacks with abdominal symptoms only and attacks with a combination of abdominal and
peripheral symptoms (mixed attacks). This post-hoc analysis showed that there were 2, 2 and 7 peripheral, mixed and abdominal-only
attacks on BCX7353 compared with 22, 12 and 2 attacks, respectively, for placebo. Based on this distribution, it is likely that
subjects recorded abdominal adverse events as HAE attack symptoms in their diary. Accordingly, this post-hoc analysis
indicated an 88% reduction in the number of attacks for subjects treated with BCX7353, as compared to the placebo arm, characterized
by either peripheral symptoms-only or a combination of peripheral and abdominal symptoms.</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Pharmacokinetic and pharmacodynamic analyses indicate steady state
BCX7353 plasma levels in HAE subjects were similar to those in healthy subjects administered the same dose in a previously completed
Phase 1 trial. Steady state trough drug levels (24 hours after dosing) were 11&nbsp;&ndash;&nbsp;32 times the 50% effective concentration
(EC<SUB>50</SUB>) for plasma kallikrein inhibition. These observed steady state drug levels greatly exceeded our proposed therapeutic
target range of 4&nbsp;&ndash;&nbsp;8 times the EC<SUB>50. </SUB>Daily oral dosing with BCX7353 strongly inhibited plasma kallikrein
throughout the 24-hour dosing interval and the degree of inhibition was similar to that seen with this dose in the healthy subject
Phase 1 trial.</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0; background-color: white">Oral BCX7353 350 mg QD for 28 days
was generally safe and well tolerated in subjects with HAE. There were no serious adverse events (AEs) and no related severe
AEs. Two subjects in the BCX7353 treatment group discontinued study drug before day 28, one due to an unrelated pre-existing
liver disorder, and one due to an adverse event of gastroenteritis associated with elevated liver enzymes. Treatment-emergent
adverse events occurring in at least two subjects overall, enumerated by treatment group (BCX7353 [n=14] and placebo [n=14]),
respectfully, were: common cold (3,&nbsp;4); diarrhea (4, 2); flatulence (2,&nbsp;0); and fatigue (2,&nbsp;0). No clinically
significant changes in hematology parameters, renal function tests, electrolytes, or urinalysis were observed. One subject
treated with BCX7353, with pre-existing colitis, hepatic steatosis (i.e., a fatty liver) and more than 20 years of prior
androgen use, had an elevation of alanine aminotransferase (ALT) &gt; 3 times the upper limit of normal at the end of
treatment, which resolved.</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Based upon this interim analysis, the efficacy, safety and
tolerability profile of BCX7353 observed strongly supports its continued development as a prophylactic treatment for HAE.
Furthermore, the steady state drug levels observed greatly exceeded our proposed therapeutic target range of
4&nbsp;&ndash;&nbsp;8 times the EC<SUB>50</SUB>, thereby supporting and prompting us to evaluate doses of BCX7353 lower than
the 350 QD tested in part 1 of the trial. Therefore, the APeX-1 trial has been amended to add a 62.5 mg QD dose level, and to
increase the number of subjects at the 125&nbsp;mg QD and 250&nbsp;mg&nbsp;QD dose levels, in order to more fully
characterize dose response. Specifically, part 2 of APeX-1 will enroll 14 additional subjects with HAE and they will be
randomized to 250mg of BCX7353 QD (n=6), 125mg of BCX7353 QD (n=6) or placebo (n=2) and part 3 of APeX-1 will enroll 20
additional subjects with HAE and they will be randomized to 250mg of BCX7353QD (n=6), 125mg of BCX7353 QD (n=6), 62.5mg of
BCX7353 QD (n=6) or placebo (n=2).</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On October 27, 2015 The Japanese Ministry of Health Labor &amp; Welfare
(&ldquo;MHLW&rdquo;) announced that BioCryst&rsquo;s BCX7353 was one of six products designated under MLHW&rsquo;s new Sakigake
fast track review system. The Sakigake Designation System promotes R&amp;D in Japan, aiming at early market availability for innovative
pharmaceutical products. This designation provides for additional interactions with the regulatory agency in Japan from early
development through filing, prioritized development and review, and introduction of the product as soon as possible to address
a serious unmet medical need. We expect the results of APeX-1 to help us and the MHLW determine the regulatory pathway and timeline
for BCX7353 in Japan.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><I><U>Avoralstat</U>:</I> Avoralstat was BioCryst&#8217;s first drug
candidate as an oral prophylactic treatment for HAE, from a suite of molecules being developed for the prevention of HAE attacks.
In December 2014, we began dosing patients in OPuS-2 (<B>O</B>ral <B>P</B>rophylaxi<B>S-2</B>), a blinded, randomized, placebo-controlled
clinical trial of orally-administered avoralstat in patients with HAE. OPuS-2 was a 12-week, three-arm, parallel cohort design
trial to evaluate the efficacy and safety of two doses of avoralstat, 300 mg and 500 mg, administered three-times daily compared
with placebo. This trial was conducted in the U.S. and select European countries, and it enrolled approximately 100 HAE patients.
In the OPuS-2 study, HAE patients with a historical attack frequency of greater than 0.45 attacks per week were randomized to
treatment with either 500 mg or 300 mg of avoralstat, or placebo, administered three times daily for 12 weeks. The primary goals
of the trial were to characterize the efficacy of avoralstat in reducing the frequency of angioedema attacks, and to evaluate
the safety and tolerability of 12 weeks of avoralstat treatment. The primary efficacy endpoint was angioedema attack frequency.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In February 2016, we announced results from OPuS-2. Thirty-eight
subjects received avoralstat 500 mg, 36 subjects received avoralstat 300 mg, and 36 subjects received placebo. Treatment with
500 mg and 300 mg of avoralstat three times daily failed to demonstrate a statistically significantly lower mean attack rate versus
placebo. The mean (standard deviation) attack rates per week were 0.63 (0.57) on avoralstat 500 mg and 0.71 (0.66) on avoralstat
300 mg, compared to 0.61 (0.41) on placebo. Statistically significant improvements in duration of attacks and in the Angioedema
Quality of Life total score were observed comparing the 500 mg three times a day avoralstat arm to placebo. Following the analysis
of OPuS-2 results, the decision was made to discontinue further development of softgel avoralstat formulation <FONT>in
order to focus development efforts on novel dosage forms of avoralstat to achieve meaningfully better drug exposure. In August
2016, we reported a clinical pharmacology study of several avoralstat dosage formulations. Cohorts of healthy volunteers received single doses ranging from 200 mg to 2000 mg of avoralstat in tablet or suspension formulations, with no clinically significant
adverse events reported. While these dosing formulations improved total avoralstat exposure by up to approximately five times
compared to a 500 mg dose given as soft gel capsules, the plasma concentration-time profile did not met our objectives of twice-daily
dosing with drug levels at or above the target range. Therefore, we decided to stop further development of avoralstat.</FONT></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Galidesivir (formerly BCX4430)</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Galidesivir is a broad-spectrum antiviral (&#8220;BSAV&#8221;) research
program and is currently being developed under contracts with the National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;)
and the U.S.&nbsp;Department of Health and Human Services (&#8220;BARDA/HHS&#8221;). The objective of our BSAV program is to develop
galidesivir as a broad-spectrum therapeutic for viruses that pose a threat to national health and security. The primary focus of
the program is treatment of hemorrhagic fever viruses. NIAID/HHS funding has supported galidesivir&#8217;s development as a treatment
for Marburg virus and Ebola virus. In March 2014, galidesivir was featured in an online <I>Nature</I> publication depicting successful
efficacy results in animal models of infection with Marburg virus and Ebola virus.&nbsp;Galidesivir completely protected cynomolgus
macaques from Marburg virus infection when administered by intramuscular (&#8220;i.m.&#8221;) injection 48 hours post-infection.&nbsp;Post-exposure
i.m. administration of galidesivir also protected rodents against Marburg virus and Ebola virus infections.&nbsp;In addition, galidesivir
was shown to be active in vitro against a broad range of other RNA viruses, including the emerging viral pathogen Middle East Respiratory
Syndrome Coronavirus (&#8220;MERS-CoV&#8221;).&nbsp;The publication, which reported the protection of non-human primates from filovirus
disease by galidesivir, describes efficacy results generated from an ongoing collaboration between scientists in the U.S. Army
Medical Research Institute of Infection Diseases (&#8220;USAMRIID&#8221;) and us.&nbsp;Galidesivir has been shown to be active
against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses,
coronaviruses and flaviviruses.&nbsp;In tests conducted at USAMRIID, galidesivir protected animals against parenteral exposures
to Marburg, Ebola and Rift Valley Fever viruses and from exposures to aerosolized Marburg virus, an experimental condition designed
to mimic an exposure scenario that could result during a bioterrorist attack.</P>


<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On December 15, 2014, we announced the dosing of the first subject
in a randomized, placebo-controlled Phase 1 clinical trial to evaluate i.m. administration of galidesivir in healthy volunteers.
The main goals of this first-in-human study are to evaluate the safety, tolerability and pharmacokinetics of escalating doses of
galidesivir administered via i.m. injection in healthy subjects. In part one of the study, subjects received a single dose of galidesivir;
in part two of the study, subjects received galidesivir for seven days. There were six single-dose cohorts and four multiple-dose
cohorts evaluated, and 91 healthy volunteers participated. In August 2016, we reported the results of this study. Galidesivir administered
by i.m. injection was generally safe and well tolerated over the range of doses up to 10 mg/kg, and durations tested (up to 7 days).
Fifty subjects received doses of study drug and there were no serious or severe adverse events. The most frequently reported adverse
event across all cohorts was injection site pain and there were no clinically significant laboratory abnormalities which occurred
at any doses. In addition, co-administration of lidocaine with galidesivir was determined to ameliorate injection site pain without
altering the plasma pharmacokinetics profile of galidesivir. From this clinical trial, we determined galidesivir was safe and well
tolerated, and that exposure was dose-proportional and supported the continued development of this BSAV drug candidate for serious
emerging viral infections.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On December 23, 2014, we announced results from a successful proof-of-concept
study of galidesivir for the treatment of experimental Ebola virus infection in Rhesus macaques, conducted at USAMRIID. The primary
goal of the study was to assess the effect of galidesivir treatment on survival through Day 41 in animals infected with Ebola virus.
Dosing of&nbsp;placebo or galidesivir by i.m. injection was initiated 30-120 minutes after virus challenge and continued twice
a day (&#8220;BID&#8221;) for 14 days. Animals were dosed with either placebo, 16 mg/kg of galidesivir BID or 25 mg/kg of galidesivir
BID. Survival at day 41 in the 16 mg/kg BID group of galidesivir treated animals was 4 of 6 (66.7%, p &lt; 0.001 compared to 0%
survival in controls) and 6 of 6 in the 25 mg/kg BID group (100%, p &lt; 0.001 compared to controls). The overall survival rate
for galidesivir treated animals at day 41 was 10 of 12 (83%, p &lt; 0.001 compared to controls). Preliminary evaluation of the
quantity of virus in the blood showed an approximate 3-log reduction in Ebola virus RNA copies/mL of plasma, compared with control
animals. This Rhesus macaque study was conducted following the completion, in November 2014, of a dose-ranging study of galidesivir
for the experimental treatment of cynomolgus macaques infected with Ebola virus. The cynomolgus macaque study was designed to evaluate
whether galidesivir showed a meaningful benefit for survival in Ebola virus non-human primate (&#8220;NHP&#8221;) disease models
and explore a dose range. In this study galidesivir demonstrated a statistically significant prolongation of survival for the animals
at the highest dose regimen tested, but no animals survived beyond 21 days.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March 7, 2016, results from a preclinical study
of our antiviral galidesivir in interferon-receptor-deficient mice infected with Zika virus were presented at a World Health Organization
(&#8220;WHO&#8221;) conference in Geneva, Switzerland. The primary goal of the study was to assess the effect of galidesivir treatment
on survival through Day 28 in interferon-receptor-deficient mice infected with the Zika virus. Galidesivir was administered by
i.m. injection twice a day beginning four hours prior to virus challenge and continuing for eight days; two dose levels were tested.
In the standard dose galidesivir group, 7 of 8 mice survived through Day 28. In the low dose galidesivir group (n=8), and in control
groups administered vehicle placebo (n=8) or ribavirin at two dose levels (n=16); no animals survived to Day 28. Overall survival
for the standard dose level of galidesivir was superior to both the placebo and the ribavirin treatment control groups (p &lt;
0.0001). For both dose levels of galidesivir, median survival was superior to both control groups (&gt;28 days for galidesivir
standard dose and 23 days for low dose) compared to 14 to 17 days for controls.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0; color: #333333">&nbsp; &nbsp;</p>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additional studies of galidesivir in the same mouse
model were conducted at Utah State University. In one study, surviving mice that were previously treated with the standard dose
of galidesivir after initial Zika virus challenge were re-challenged with the Zika virus on Day 28, without additional galidesivir
treatment. All the re-challenged mice survived through day 56 with no disease signs observed, indicating the development of effective
immune responses. A further experiment using the same AG129 mouse model tested the delayed treatment with galidesivir after viral
challenge. Groups of mice received galidesivir 150 mg/kg twice-daily by i.m. injection starting on days 1, 3, 5, or 7 post infection,
or vehicle (control group). All galidesivir treated groups showed a statistically significant survival benefit compared to vehicle
controls.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; color: #333333">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On October 29, 2016, galidesivir nonclinical results from a Zika virus infection model were presented
in a late-breaker scientific session at IDWeek by Dr. James B. Whitney, PhD, Assistant Professor of Medicine, Harvard Medical School,
and Principal Investigator in the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston. Three
groups of five healthy animals were inoculated with a Puerto Rico strain of Zika virus and administered either galidesivir by i.m.
injection 100 mg/kg BID loading dose followed by 25 mg/kg BID for nine days, galidesivir loading dose of 100 mg/kg BID, or vehicle
control. Both galidesivir groups showed reduction in the proportion of animals viremic and in the amount of virus shed of into
cerebrospinal fluid, saliva and urine. Galidesivir dosing in rhesus macaques was well-tolerated and offered significant protection
against Zika virus infection. In a follow-on experiment, the same animals were rechallenged with a Thai strain of Zika virus, 72
days after initial inoculation. All animals demonstrated immune responses, and the initial treatments with galidesivir did not
impair the generation of immunity.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 8; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b>Forodesine</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Forodesine is a Purine Nucleoside Phosphorylase
(&#8220;PNP&#8221;) inhibitor in development by Mundipharma as a treatment for cancer under a world-wide license agreement.
PNP is a purine salvage pathway enzyme. High doses of PNP inhibitors could be useful in the treatment of hematological
malignancies. Mundipharma has received orphan drug status for forodesine, and following its successful completion of a Phase
2 pivotal study in recurrent/refractory peripheral T-cell lymphoma (&ldquo;PTCL&rdquo;) patients in Japan, and has filed a Japanese New Drug
Application (&#8220;JNDA&#8221;) with the Japanese Pharmaceuticals and Medical Devices Agency (&#8220;PMDA&#8221;). This JNDA
is currently under review for regulatory approval in Japan.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On November&nbsp;11, 2011, we entered into an Amended and Restated
License and Development Agreement (the &#8220;Amended and Restated Agreement&#8221;) with Mundipharma, amending and restating the
February&nbsp;1, 2006 exclusive, royalty-bearing Development and License Agreement for the development and commercialization of
forodesine for use in the field of oncology. Under the terms of the Amended and Restated Agreement, Mundipharma obtained worldwide
rights to forodesine, so Mundipharma controls the worldwide development and commercialization of forodesine and assumes all future
development and commercialization costs.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have licensed the PNP technology from Albert Einstein College of
Medicine of Yeshiva University (&#8220;AECOM&#8221;) and Industrial Research, Ltd. (&#8220;IRL&#8221;) and will owe sublicense
payments to AECOM/IRL based on the future milestone payments and royalties received by us from Mundipharma and any other partners
for which we out-license our PNP inhibitors. On November&nbsp;17, 2011, we amended our agreement with AECOM/IRL whereby AECOM/IRL
agreed to accept a reduction of one-half of the percentage of Net Proceeds (as defined in the license agreement) received by us
under our Amended and Restated Agreement with Mundipharma. This reduction does not apply to royalty payments made as a result of
sales of licensed products by our sub licensees.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Collaborations and In-License Relationships</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i><u>U.S.&nbsp;Department of Health and Human Services (&#8220;BARDA/HHS&#8221;)</u>.</i>
In January 2007, BARDA/HHS awarded us a $102.6 million, four-year contract for the advanced development of peramivir for the treatment
of influenza. During 2009, peramivir clinical development shifted to focus on intravenous delivery and the treatment of hospitalized
patients. To support this focus, a September 2009 contract modification was awarded to extend the i.v. peramivir program and to
increase funding by $77.2 million. On February&nbsp;24, 2011, we announced that BARDA/HHS had awarded us a $55.0 million contract
modification, intended to fund completion of the Phase 3 development of i.v. peramivir for the treatment of patients hospitalized
with influenza. That contract modification brought the total contract award from BARDA/HHS to $234.8 million and provided funding
to support the filing of an NDA to seek regulatory approval for i.v. peramivir in the U.S. In December 2014, the FDA approved the
NDA. The BARDA/HHS contract expired on June 30, 2014 according to its terms, but final governmental audits have not been conducted
to close out the contract.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March 31, 2015, we announced that BARDA/HHS awarded us a contract
for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&nbsp;This
BARDA/HHS contract has a potential value of $39.1 million if all contract options are exercised. As of December 31, 2016, a total
of $20.6 million has been awarded under exercised options within this contract.</p>

<p style="font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i><u>National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;)</u>.</i>
In September 2013, NIAID/HHS contracted with us for the development of galidesivir as a treatment for Marburg, and subsequently,
Ebola virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of $5.0 million to us. All options
under this contract have been awarded and the total contract value is $39.5 million. The goals of this contract, including amendments,
are to file IND applications for i.v. and i.m. galidesivir for the treatment of Marburg virus disease and other hemorrhagic fever
viruses, to study galidesivir as a treatment for Ebola virus disease, and to conduct a Phase 1 human clinical trial.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee
contracts. That is, we are entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions
that are related to the development of peramivir and galidesivir plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make
periodic assessments of progress and the continuation of the contract is based on our performance, the timeliness and quality of
deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts
are also terminable by the government at any time for breach or without cause.</p>

<p style="font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i><u>Seqirus UK Limited</u>.</i> On June 16, 2015, we and SUL, a
limited company organized under the laws of the United Kingdom and a subsidiary of CSL Limited, a company organized under the laws
of Australia, entered into a License Agreement (the "SUL Agreement") granting SUL and its affiliates worldwide rights
to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to
conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the "Territory").
RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is currently approved for use in the United States, Canada,
Japan, Taiwan and Korea. RAPIVAB is the first and only intravenous influenza treatment in the world and was approved by the U.S.
Food and Drug Administration in December 2014 for the treatment of acute uncomplicated influenza in patients 18 years and older
who have been symptomatic for no more than two days. Peramivir was approved by Health Canada in January 2017. We retain all rights
and associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to
pursue government stockpiling outside the U.S.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 9; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Pursuant to the SUL Agreement, RAPIVAB will be commercialized by CSL's
subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets.
SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization
of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion. We will exercise sole
decision-making authority with regard to the development and commercialization of RAPIVAB outside of the Territory and are responsible
for all associated costs.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, we are responsible for fulfilling
all post-marketing approval commitments in connection with the FDA's approval of the NDA, and upon fulfillment will transfer ownership
of and financial responsibility for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB/ALPIVAB in Canada and the EU, we are also
responsible for regulatory filings and interactions with the Health Canada and the European Medicines Agency until marketing approval
for RAPIVAB/ALPIVAB is obtained and assigned to SUL. In accordance with the SUL Agreement, we and SUL formed a joint steering committee,
composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the
commercialization of RAPIVAB in the Territory and any additional development.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, we received an upfront payment
of $33.7 million, and may receive up to $12.0 million in additional milestone payments related to the successful achievement of
regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication
in the EU and (iii) by Health Canada for an adult indication in Canada. We expect to receive a $2.0 million milestone payment
as a result of the Health Canada approval of RAPIVAB in the first quarter of 2017. We are also entitled under the SUL Agreement
to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net
sales, as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically,
we receive tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year
(defined as July 1 - June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory,
other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events impacting
the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire, on a country-by-country
basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from the date of the SUL Agreement
(the &quot;Royalty Term&quot;). We developed RAPIVAB under a license from UAB and will owe sublicense payments to them on any
future milestone payments and/or royalties received by us from SUL.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The term of the SUL Agreement shall continue on a country-by-country
basis until the expiration of the last-to-expire Royalty Term in any such country in the Territory. Either party may terminate
the SUL Agreement in its entirety if the other party breaches a payment obligation, otherwise materially breaches the SUL Agreement,
subject to applicable cure periods, or if the other party suffers an insolvency event. We may also terminate the SUL Agreement
if SUL or any of its affiliates seek to challenge the validity of our patents. Termination does not affect a party's rights which
have accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations
previously accrued. For all terminations exercised by us, the SUL Agreement provides for the termination of any sublicenses granted
by SUL to third parties, and in the case of termination by us for cause, the ceasing of SUL's activities with respect to RAPIVAB,
the discontinued use of all of our intellectual property and the termination of licenses and rights previously granted to SUL.
If requested by us, SUL shall also promptly sell to us all licensed product it then holds in stock, otherwise, SUL may continue
to sell such licensed product for designated periods.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i><u>Shionogi&nbsp;&amp; Co., Ltd. (&#8220;Shionogi&#8221;)</u>.</i>
On February&nbsp;28, 2007, we entered into a License, Development and Commercialization Agreement (as amended, supplemented or
otherwise modified, the &#8220;Shionogi Agreement&#8221;), an exclusive license agreement with Shionogi to develop and commercialize
peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. In October 2008, we and Shionogi
amended the Shionogi Agreement to expand the territory covered by the agreement to include Taiwan. Under the terms of the Shionogi
Agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan in exchange for a $14.0&nbsp;million upfront
payment. The license provided for development milestone payments (up to $21.0&nbsp;million), which have all been paid, and for
commercial milestone payments (up to $95.0&nbsp;million) in addition to double-digit (between 10% and 20%) royalty payments on
product sales of peramivir.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Generally, all payments under the Shionogi Agreement are non-refundable
and non-creditable, but they are subject to audit. Shionogi is responsible for all development, regulatory, and marketing costs
in Japan. The term of the Shionogi Agreement is from February&nbsp;28, 2007 until terminated. Either party may terminate in the
event of an uncured breach. Shionogi has the right of termination without cause. In the event of termination, all license and rights
granted to Shionogi shall terminate and shall revert back to us. We developed peramivir under a license from the University of
Alabama Birmingham (&#8220;UAB&#8221;) and have paid sublicense payments to UAB on the upfront payments and will owe sublicense
payments on any future event payments and/or royalties received by us from Shionogi.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i><u>Shionogi Royalty Monetization and Non-Recourse Notes Payable</u></i>.
On March&nbsp;9, 2011, we completed a $30.0 million&nbsp;financing transaction to monetize certain future royalty and milestone
payments under the Shionogi Agreement, pursuant to which JPR Royalty Sub LLC (&#8220;Royalty Sub&#8221;) a wholly-owned subsidiary
of BioCryst, issued the PhaRMA Notes discussed below. We received net proceeds of $22.7 million&nbsp;from this transaction.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As part of the transaction, we entered into a purchase and sale agreement
dated as of March&nbsp;9, 2011 with Royalty Sub, whereby we transferred to Royalty Sub, among other things, (i)&nbsp;its rights
to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&nbsp;the right to
receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#8220;Currency
Hedge Agreement&#8221;) put into place by us in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese
yen and milestone payments will be paid in U.S. dollars. Our collaboration with Shionogi was not impacted by this transaction.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 10; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March 9, 2011, Royalty Sub completed a private placement to institutional
investors of $30.0 million in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &#8220;PhaRMA Notes&#8221;).
The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March&nbsp;9, 2011 (the &#8220;Indenture&#8221;), by
and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable
from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by us to Royalty
Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14%&nbsp;per
annum, payable annually in arrears on September&nbsp;1st of each year (the &#8220;Payment Date&#8221;). We remain entitled to receive
any royalties and milestone payments related to sales of peramivir by Shionogi following repayment by Royalty Sub of the PhaRMA
Notes.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Royalty Sub&#8217;s obligations to pay principal and interest on the
PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except
to the extent of our pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. We may, but are not obligated
to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall
on, the PhaRMA Notes.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In September&nbsp;2013, Royalty Sub paid $1.8 million of interest
on the PhaRMA Notes from royalty payments received from RAPIACTA sales from the preceding four calendar quarters. This payment
resulted in an obligation shortfall of approximately $2.4 million associated with accrued interest due September&nbsp;3, 2013.
As stipulated under the PhaRMA Notes Indenture, if the amount available for payment on any Payment Date is insufficient to pay
all of the interest due on a Payment Date, the shortfall in interest will accrue interest at the interest rate applicable to the
PhaRMA Notes compounded annually. Accordingly, commencing in September&nbsp;2013, interest began to accrue at 14%&nbsp;per annum
on the interest shortfall of $2.4 million. In March, June and August of 2014, Royalty Sub paid additional interest of $446,000,
$1.9 million and $70,000, respectively, bringing the shortfall down to $222,000 as of September 30, 2014. Under the terms of the
Indenture, Royalty Sub&#8217;s inability to pay the full amount of interest payable in September&nbsp;2013 by the next succeeding
Payment Date for the PhaRMA Notes, which was September&nbsp;1, 2014, constituted an event of default. Accordingly, we have classified
the PhaRMA Notes and related accrued interest as current liabilities on our balance sheet. As a result of the event of default
under the PhaRMA Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral
securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture
in respect of the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise accrue
to us following repayment of the PhaRMA Notes and we might otherwise be adversely affected. Due to the non-recourse nature of the
PhaRMA Notes, in the event of any potential acceleration or foreclosure, we believe the primary impact to us would be the loss
of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, we may incur costs
associated with liquidating the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure
or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub, we do not currently expect
the event of default on the PhaRMA Notes to have a significant impact on our future results of operations or cash flows. As of
December 31, 2016, the PhaRMA Notes remain in default.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Indenture does not contain any financial covenants. The Indenture
includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of
Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters
typical for indentures used in structured financings of this type. The PhaRMA Notes are redeemable at the option of Royalty Sub
at any time at a redemption price equal to 100% of the outstanding principal balance of the PhaRMA Notes being redeemed, plus accrued
and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i><u>Foreign Currency Hedge</u>.</i> In connection with the issuance
by Royalty Sub of the PhaRMA Notes, we entered into a Currency Hedge Agreement to hedge certain risks associated with changes in
the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, we have the right to purchase dollars
and sell yen at a rate of 100 yen per dollar for which we may be required to pay a premium in each year from 2017 through 2020.
A payment of $2.0 million&nbsp;will be required if, on May&nbsp;18 of the relevant year, the U.S. dollar is worth 100 yen or less,
as determined in accordance with the Currency Hedge Agreement.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Currency Hedge Agreement does not qualify for hedge accounting
treatment; therefore, mark-to-market adjustments are recognized in our Consolidated Statement of Comprehensive Loss. Cumulative
mark-to-market adjustments resulted in losses of $1.7 million and $0.6 million and a gain of $5.5 million for the twelve months
ended December&nbsp;30, 2016, 2015 and 2014, respectively. In addition, realized currency exchange gains of $0.8 million and $1.7
million were recognized in 2016 and 2015, respectively, related to the exercise of a U.S. dollar/Japanese yen currency option under
our foreign currency hedge. We are also required to post collateral in connection with the mark-to-market adjustments based on
defined thresholds. As of December 31, 2016, no collateral was posted under the Currency Hedge Agreement. We will not be required
at any time to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreement. The
maximum amount of hedge collateral we would be required to post is $7.8 million. We are required to maintain a foreign currency
hedge at 100 yen per dollar under the agreements governing the PhaRMA Notes.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i><u>Green Cross</u>.</i> In June 2006, we entered into an agreement
with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross is responsible
for all development, regulatory, and commercialization costs in Korea. We received a one-time license fee of $250,000. The license
provides that we will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean
government for stockpiling purposes. Furthermore, Green Cross will pay us a premium over its cost to supply peramivir for development
and any future marketing of peramivir products in Korea. Both parties have the right to terminate in the event of an uncured material
breach. In the event of termination, all rights, data, materials, products and other information would be transferred to us.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 11; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In August 2010, we announced that Green Cross had received marketing
and manufacturing approval from the Korean Food&nbsp;&amp; Drug Administration for i.v. peramivir, under the commercial name PERAMIFLU<sup>&#174;</sup>.
PERAMIFLU is intended to treat patients with influenza A&nbsp;&amp; B viruses, including pandemic H1N1 and avian influenza. Green
Cross received the indication of single dose administration of 300&nbsp;mg i.v. peramivir.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i><u>Other Peramivir Collaborations</u>.</i> In addition to our collaborations
with Shionogi and Green Cross, in March 2011 we entered into an arrangement with Neopharm Scientific Limited, granting certain
commercial and distribution rights for peramivir in Israel.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i><u>Mundipharma</u>.</i> In February 2006, we entered into an exclusive,
royalty bearing right and license agreement with Mundipharma for the development and commercialization of forodesine, a PNP inhibitor,
for use in oncology (the &#8220;Original Agreement&#8221;). Under the terms of the Original Agreement, Mundipharma obtained rights
to forodesine in markets across Europe, Asia, and Australasia in exchange for a $10.0&nbsp;million up-front payment. In addition,
Mundipharma contributed $10.0&nbsp;million of the documented out-of-pocket development costs incurred by us in respect of the current
and planned trials as of the effective date of the agreement, and Mundipharma would conduct additional clinical trials at their
own cost up to a maximum of $15.0&nbsp;million. The Original Agreement provided for the possibility of future event payments totaling
$155.0&nbsp;million for achieving specified development, regulatory and commercial events (including certain sales level amounts
following a product&#8217;s launch) for certain indications. In addition, the Original Agreement provided that we would receive
royalties (ranging from single digits to mid-teens) based on a percentage of net product sales, which varies depending upon when
certain indications receive NDA approval in a major market country and can vary by country depending on the patent coverage or
sales of generic compounds in a particular country. Generally, all payments under the Original Agreement were nonrefundable and
non-creditable, but they are subject to audit. We licensed forodesine and other PNP inhibitors from AECOM/IRL and will owe sublicense
payments to AECOM/IRL on all milestone payments and royalties received by us from Mundipharma.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On November&nbsp;11, 2011, we entered into the Amended and Restated
Agreement with Mundipharma (the &#8220;Amended and Restated Agreement&#8221;). Under the terms of this Amended and Restated Agreement,
Mundipharma obtained worldwide rights to forodesine in the field of oncology. Mundipharma will control the development and commercialization
of forodesine and assume all future development and commercialization costs. The Amended and Restated Agreement provides for the
possibility of future event payments totaling $15.0&nbsp;million for achieving specified regulatory events for certain indications.
In addition, the Amended and Restated Agreement provides that we will receive tiered royalties ranging from mid- to high-single
digit percentages of net product sales in each country where forodesine is sold by Mundipharma. These royalties are subject to
downward adjustments based on the then-existing patent coverage and/or the availability of generic compounds in each country. Generally,
all payments under the Amended and Restated Agreement are nonrefundable and non-creditable, but they are subject to audit.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Mundipharma will also have a right of exclusive negotiations with
us for a limited period of time if they initiate negotiations for a specified backup PNP inhibitor. Otherwise, they will be able
to participate in the same negotiations process we enter into with another company for the backup PNP inhibitor. The Amended and
Restated Agreement will continue for the commercial life of the licensed products, but may be terminated by either party following
an uncured material breach by the other party or in the event the pre-existing third party license with AECOM/IRL expires. It may
be terminated by Mundipharma upon 60&nbsp;days written notice without cause or under certain other conditions as specified in the
Amended and Restated Agreement. If Mundipharma terminates the Amended and Restated Agreement, Mundipharma would no longer have
any rights in forodesine and the rights would revert back to us; provided, however, that in the event the we determine to subsequently
use the data developed under the Amended and Restated Agreement for development and commercialization of forodesine in the field
of oncology, then we would have to pay Mundipharma 150% of the cost of such data for such use.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i><u>Albert Einstein College of Medicine of Yeshiva University and
Industrial Research, Ltd. (&#8220;AECOM&#8221; and &#8220;IRL&#8221; respectively)</u>.&nbsp;</i> In June 2000, we licensed a series
of potent inhibitors of PNP from AECOM and IRL, (collectively, the &#8220;Licensors&#8221;). The lead product candidate from this
collaboration is forodesine. We have obtained worldwide exclusive rights to develop and ultimately distribute it, or any other,
product candidates that might arise from research on these inhibitors. We have the option to expand our license agreement with
the Licensors to include other inventions in the field made by the investigators or employees of the Licensors. We agreed to use
commercially reasonable efforts to develop these drugs. In addition, we have agreed to pay certain milestone payments for each
licensed product (which range in the aggregate from $1.4 million to almost $4.0 million&nbsp;per indication) for future development
of these inhibitors, single digit royalties on net sales of any resulting product made by us, and to share approximately one quarter
of future payments received from other third-party partners, if any. In addition, we have agreed to pay annual license fees, which
can range from $150,000 to $500,000, that are creditable against actual royalties and other payments due to the Licensors. This
agreement may be terminated by us at any time by giving 60&nbsp;days advance notice or in the event of material uncured breach
by the Licensors.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In May 2010, we amended the license agreement through which we obtained
worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series
of PNP inhibitors, including forodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of one-half
in the percentage of future payments received from third-party sub licensees of the licensed PNP inhibitors that must be paid to
the Licensors. This reduction does not apply to (i)&nbsp;any milestone payments we may receive in the future under our license
agreement with Mundipharma and (ii)&nbsp;royalties received from its sub licensees in connection with the sale of licensed products,
for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales of
any resulting product made by us remains unchanged. At our sole option and subject to certain agreed upon conditions, any future
non-royalty payments due to be paid by us to the Licensors under the license agreement may be made either in cash, in shares of
our common stock, or in a combination of cash and shares.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 12; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On November&nbsp;17, 2011, we further amended our agreements with
the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined in the
license agreement) received by us under our Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL. &nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On June&nbsp;19, 2012, we further amended our agreements with the
Licensors whereby the parties clarified the definition of the field with respect to PNP inhibition and the Licensors agreed to
grant an exclusive worldwide license of galidesivir to us for any antiviral use.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i><u>The University of Alabama at Birmingham (&#8220;UAB&#8221;)</u>.</i>
We currently have agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements,
UAB performed specific research for us in return for research payments and license fees. UAB has granted us certain rights to any
discoveries in these areas resulting from research developed by UAB or jointly developed with us. We have agreed to pay single
digit royalties on sales of any resulting product and to share in future payments received from other third-party partners. We
have completed the research under the UAB agreements. These two agreements have initial 25-year terms, are automatically renewable
for five-year terms throughout the life of the last patent and are terminable by us upon three months&#8217; notice and by UAB
under certain circumstances. Upon termination both parties shall cease using the other parties&#8217; proprietary and confidential
information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed
products. There is currently no activity between us and UAB on these agreements, but when we license this technology, such as in
the case of the Shionogi and Green Cross agreements, or commercialize products related to these programs, we will owe sublicense
fees or royalties on amounts it receives.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Government Contracts</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"><i><u>U.S.&nbsp;Department of Health and Human Services (&#8220;BARDA/HHS&#8221;)</u>.</i>
In January 2007, BARDA/HHS awarded us a $102.6 million four-year contract for the advanced development of peramivir for the treatment
of influenza. During 2009, peramivir clinical development shifted to focus on intravenous delivery and the treatment of hospitalized
patients. To support this focus, a September 2009 contract modification was awarded to extend the i.v. peramivir program and to
increase funding by $77.2 million. On February&nbsp;24, 2011, we announced that BARDA/HHS had awarded us a $55.0 million contract
modification, intended to fund completion of the Phase 3 development of i.v. peramivir for the treatment of patients hospitalized
with influenza. That contract modification brought the total contract award from BARDA/HHS to $234.8 million and provided funding
to support the filing of an NDA to seek regulatory approval for i.v. peramivir in the U.S. In December 2013, we submitted an NDA
filing for i.v. peramivir to the FDA and the NDA was approved in December 2014. The BARDA/HHS contract expired on June 30, 2014
according to its terms.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March 31, 2015, we announced that BARDA/HHS awarded us a contract
for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&nbsp;This
BARDA/HHS contract has a potential value of $39.1 million if all contract options are exercised. As of December 31, 2016, a total
of $20.6 million has been awarded under exercised options within this contract.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i><u>National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;)</u>.</i>
In September 2013, NIAID/HHS contracted with us for the development of galidesivir as a treatment for Marburg, and subsequently,
Ebola virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of $5.0 million to us. All options
under this contract have been awarded and the total contract value is $39.5 million. The goals of this contract, including amendments,
are to file IND applications for i.v. and i.m. galidesivir for the treatment of Marburg virus disease and other hemorrhagic fever
viruses, to study galidesivir as a treatment for Ebola virus disease and to conduct a Phase 1 human clinical trial.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee
contracts. That is, we are entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions
that are related to the development of peramivir and galidesivir plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make
periodic assessments of progress and the continuation of the contract is based on our performance, the timeliness and quality of
deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts
are also terminable by the government at any time for breach or without cause.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Patents and Proprietary Information</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our success will depend in part on our ability to obtain and enforce
patent protection for our products, methods, processes and other proprietary technologies, preserve our trade secrets, and operate
without infringing on the proprietary rights of other parties, both in the United States and in other countries. We own or have
rights to certain proprietary information, proprietary technology, issued and allowed patents and patent applications which relate
to compounds we are developing. We actively seek, when appropriate, protection for our products, proprietary technology and proprietary
information by means of U.S.&nbsp;and foreign patents, trademarks and contractual arrangements. In addition, we rely upon trade
secrets and contractual arrangements to protect certain of our proprietary information, proprietary technology and products.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 13; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The patent positions of companies like ours are generally uncertain
and involve complex legal and factual questions. Our ability to maintain and solidify our proprietary position for our technology
will depend on our success in obtaining effective patent claims and enforcing those claims once granted. We do not know whether
any of our patent applications or those patent applications that we license will result in the issuance of any patents. Our issued
patents and those that may issue in the future, or those licensed to us, may be challenged, invalidated, rendered unenforceable
or circumvented, which could limit our ability to stop competitors from marketing related products or the length of term of patent
protection that we may have for our products. In addition, the rights granted under any issued patents may not provide us with
competitive advantages against competitors with similar compounds or technology. Furthermore, our competitors may independently
develop similar technologies or duplicate any technology developed by us in a manner that does not infringe our patents or other
intellectual property. Because of the extensive time required for development, testing and regulatory review of a potential product,
it is possible that, before any of our product candidates or those developed by our partners can be commercialized, any related
patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of the
patent.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of December&nbsp;31, 2016, we have been issued approximately 15
U.S.&nbsp;patents that expire between 2017 and 2034 and that relate to our HAE program compounds, neuraminidase inhibitor compounds,
BSAV compounds and PNP compounds. We have licensed a number of compounds protected by certain composition of matter patents from
AECOM and IRL, plus additional manufacturing patents, totaling 14 additional U.S. patents that expire between 2017 and 2029. Additionally,
we have approximately 13 Patent Cooperation Treaty or U.S.&nbsp;patent applications pending related to HAE program compounds,
neuraminidase inhibitor compounds, BSAV compounds and PNP compounds. Our pending applications may not result in issued patents,
our patents may not cover the products of interest or may not be enforceable in all, or any jurisdictions and our patents may
not provide us with sufficient protection against competitive products or otherwise be commercially viable. After expiration of
composition of matter patents for our products and product candidates, we may rely on data exclusivity, or in some cases, method
of use patents. The enforceability of these patents varies from jurisdiction to jurisdiction and may not be allowed or enforceable
in some territories where we may seek approval. We may not have the funds to continue patent prosecution or to defend all of our
existing patents in our current patent estate and may selectively abandon patents or patent families worldwide or in certain territories.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our success is also dependent upon the skills, knowledge and experience
of our scientific and technical personnel, none of which is patentable. To help protect our rights, we require all employees, consultants,
advisors and partners to enter into confidentiality agreements, which prohibit the disclosure of confidential information to anyone
outside of BioCryst and, where possible, require disclosure and assignment to us of their ideas, developments, discoveries and
inventions. These agreements may not provide adequate protection for our trade secrets, know-how or other proprietary information
in the event of any unauthorized use or disclosure or the lawful development by others of such information. <b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Competition</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The pharmaceutical and biotechnology industries are intensely competitive.
Many companies, including biotechnology, chemical and pharmaceutical companies, are actively engaged in activities similar to ours,
including research, development, and commercialization of drugs for the treatment of rare medical conditions. Many of these companies
have substantially greater financial and other resources, larger research and development staffs, and more extensive commercial
and manufacturing organizations than we do. In addition, many have considerable experience in preclinical testing, clinical trials
and other regulatory approval procedures. In addition, there are also academic institutions, governmental agencies and other research
organizations who conduct research in areas in which we are working. We expect to encounter significant competition for any of
the pharmaceutical products we plan to develop. Companies that successfully complete clinical trials, obtain required regulatory
approvals and commence commercial marketing and sales of their products may achieve a significant competitive advantage.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i><u>Antivirals</u>:</i> The pharmaceutical market for products that
prevent or treat influenza is very competitive. Key competitive factors for RAPIVAB (peramivir injection) include, among others,
efficacy, ease of use, safety, price and cost-effectiveness, storage and handling requirements and reimbursement. A number of neuraminidase
inhibitors are currently available in the U.S.&nbsp;and/or other counties, including Japan, for the prevention or treatment of
influenza, including seasonal flu vaccines and F. Hoffmann-La Roche Ltd.&#8217;s (&#8220;Roche&#8221;) TAMIFLU<sup>&#174;</sup>
(oseltamivir), generic oseltamivir, GlaxoSmithKline plc&#8217;s (&#8220;GSK&#8221;) RELENZA<sup>&#174;</sup> and Daiichi Sankyo
Co., Ltd.&#8217;s INAVIR<sup>&#174;</sup> . In addition, FUJIFILM Corporation&#8217;s favipiravir, a polymerase inhibitor, is approved
in Japan. Roche&#8217;s neuraminidase inhibitor is also approved for prophylaxis of influenza.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In January 2011, GSK announced initiation of a multi-country Phase
3 study of i.v. zanamivir (the same active ingredient as in RELENZA) in hospitalized patients with influenza. The GSK study was
completed during the 2014-2015 flu season. In addition to these companies with neuraminidase inhibitors, there are other companies
working to develop additional antiviral drugs to be used against various strains of influenza. Currently, there are a number of
other companies developing potential new influenza therapies. Various government entities throughout the world are offering incentives,
grants and contracts to encourage additional investment into preventative and therapeutic agents against influenza, which may have
the effect of further increasing the number of our competitors and/or providing advantages to certain competitors.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Galidesivir is a product candidate in our BSAV research program and
is currently being developed under contracts with NIAID/HHS and BARDA/HHS. The objective of our BSAV program is to develop galidesivir
as a broad-spectrum therapeutic for viruses that pose a threat to national health and security. The U.S. Government is investing
in a number of programs intended to address gaps in its medical countermeasure plan. Therapeutic products with potentially promising
data to treat Ebola include FUJIFILM Corporation&#8217;s favipiravir (polymerase inhibitor), Tekmira Pharmaceuticals Corporation&#8217;s
TKM-Ebola (RNAi interference based) and Mapp Biopharmaceutical, Inc.&#8217;s ZMapp (antibody-based). Both TKM-Ebola and ZMapp have
been used in Ebola patients. Gilead Sciences, Inc announced in October 2015 that it had provided the investigational compound,
GS-5734, to two patients with Ebola for compassionate use.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 14; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i><u>HAE</u>:</i> HAE is an autosomal dominant disease characterized
by painful, unpredictable, recurrent attacks of inflammation affecting the hands, feet, face, abdomen, urogenital tract, and the
larynx. The inflammation can be disfiguring, debilitating, or in the case of laryngeal attacks, life-threatening. Prevalence for
HAE is uncertain but is estimated to be approximately 1 case per 50,000 persons without known differences among ethnic groups and
is caused by deficient (Type I) or dysfunctional (Type II) levels of C1-Inhibitor (&#8220;C1-INH&#8221;), a naturally occurring
molecule that is known to inhibit kallikrein, bradykinin, and other serine proteases in the blood. If left untreated, HAE can result
in a mortality rate as high as 40% primarily due to upper airway obstruction. There are a number of licensed therapies for HAE,
including the following:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%">&#8226;</td>
    <td style="width: 90%"><font style="font-size: 10pt">C1-INH therapy is available as an acute therapy (Berinert<sup>&#174;</sup>) and as a prophylactic therapy (Cinryze<sup>&#174;</sup>). These therapies are available intravenously and work by replacing the missing or malfunctioning C1-INH protein in patients. Recominant C1-INH (Ruconest<sup>&#174;</sup>) is also available as an acute therapy.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&#8226;</td>
    <td><font style="font-size: 10pt">Kallikrein Inhibition <b>-</b> Kalbitor<sup>&#174;</sup> (ecallantide) is a specific recombinant plasma kallikrein inhibitor that halts the production of bradykinin and can be dosed subcutaneously in an inpatient setting.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&#8226;</td>
    <td><font style="font-size: 10pt">Bradykinin receptor antagonist <b>-</b> Firazyr<sup>&#174;</sup> (icatibant) is a competitive antagonist of the bradykinin B2 receptor. Firazyr is approved for the treatment of acute attacks and is administered by subcutaneous administration.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&#8226;</td>
    <td><font style="font-size: 10pt">Other medications - Prophylactic administration of synthetic attenuated androgens (generically available as danazol or stanozolol) has been utilized to reduce the frequency or severity of attacks. However, long-term use of danazol or stanozolol may result in virilization and arterial hypertension. Six-month liver function tests, annual lipid profiles, and biennial hepatic ultrasound are recommended because these medications increase production of C1-INH in the liver.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition to BCX7353 and our other second generation compounds,
there are a number of other HAE therapies in development. These include a prophylactic plasma derived C1-INH delivered by subcutaneous
injection developed by CSL (Biologics License Application accepted for review by FDA in August 2016); SHP643 (DX2930), a monoclonal
antibody administered by subcutaneous injection for prophylactic treatment of HAE in Phase 3 (Shire PLC); ISIS-PKK, a RNA-targeted
antisense drug to inhibit prekallikrein for prophylactic treatment of HAE in Phase 1 (ISIS Pharmaceuticals, Inc.); and one oral
kallikrein inhibitor being developed by KalVista (Phase 1 commenced in 2016).</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In order to compete successfully in these and other therapeutic areas,
we must develop proprietary positions in patented drugs for therapeutic markets that have not been satisfactorily addressed by
conventional research strategies and, in the process, expand our expertise in structure-based drug design. Our product candidates,
even if successfully tested and developed, may not be adopted by physicians over other products and may not offer economically
feasible alternatives to other therapies.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Research and Development</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We initiated our research and development activities in 1986. We have
assembled a scientific research staff with expertise in a broad base of advanced research technologies including protein biochemistry,
X-ray crystallography, chemistry and pharmacology. Our research facilities, located in Birmingham, Alabama, include protein biochemistry
and organic synthesis laboratories, testing facilities, X-ray crystallography, computer and graphics equipment and facilities to
make product candidates on a small scale for early stage clinical trials. During the years ended December 31, 2016, 2015 and 2014,
our research and development expenses were $61.0 million, $72.8 million and $51.8 million, respectively.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Compliance</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We conduct our business in an ethical, fair, honest and lawful manner.
We act responsibly, respectfully and with integrity in our relationships with patients, health care professionals, collaborators,
governments, regulatory entities, stockholders, suppliers and vendors.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In order to ensure compliance with applicable laws and regulations,
our Chief Financial Officer, General Counsel and Vice President of Human Resources oversee compliance training, education, auditing
and monitoring; enforce disciplinary guidelines for any infractions of our corporate polices; implement new policies and procedures;
respond to any detected issues; and undertake corrective action procedures. Our controls address compliance with laws and regulations
that govern public pharmaceutical companies including, but not limited to, the following: federal and state law, such as the Sarbanes-Oxley
Act of 2002 and the U.S. Foreign Corrupt Practices Act of 1977; NASDAQ listing requirements; the regulations of the Financial Industry
Regulatory Authority; the Securities and Exchange Commission (&#8220;SEC&#8221;); the FDA; and the United States Department of
Health and Human Services. Our standard operating procedures are designed to provide a framework for corporate governance in accordance
with ethical standards and best legal practices.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Government Regulation</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The FDA regulates the pharmaceutical and biotechnology industries
in the U.S., and our product candidates are subject to extensive and rigorous domestic government regulations prior to commercialization.
The FDA regulates, among other things, the development, testing, manufacture, safety, efficacy, record-keeping, labeling, storage,
approval, advertising, promotion, sale and distribution of pharmaceutical products. In foreign countries, our products are also
subject to extensive regulation by foreign governments. These government regulations will be a significant factor in the production
and marketing of any pharmaceutical products that we develop. Failure to comply with applicable FDA and other regulatory requirements
at any stage during the regulatory process may subject us to sanctions, including:</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 15; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">delays;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">warning letters;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">fines;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">product recalls or seizures;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">injunctions;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">penalties;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">refusal of the FDA to review pending market approval applications or supplements to approval applications;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">total or partial suspension of production;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">civil penalties;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">withdrawals of previously approved marketing applications;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">criminal prosecutions.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The regulatory review and approval process is lengthy, expensive and
uncertain. Before obtaining regulatory approvals for the commercial sale of any products, we or our partners must demonstrate that
our product candidates are safe and effective for use in humans. The approval process takes many years, substantial expenses may
be incurred and significant time may be devoted to clinical development.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Before testing potential product candidates in humans, we carry out
laboratory and animal studies to determine safety and biological activity. After completing preclinical trials, we must file an
IND, including a proposal to begin clinical trials, with the FDA. Thirty days after filing an IND, a Phase 1 human clinical trial
can start, unless the FDA places a hold on the trial.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Clinical trials to support a NDA are typically conducted in three
sequential phases, but the phases may overlap.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Phase 1&#8212;During Phase 1, the initial introduction of the drug
into healthy volunteers, the drug is tested to assess metabolism, pharmacokinetics and pharmacological actions and safety, including
side effects associated with increasing doses.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Phase 2&#8212;Phase 2 usually involves trials in a limited patient
population to: (1)&nbsp;assess the efficacy of the drug in specific, targeted indications; (2)&nbsp;assess dosage tolerance and
optimal dosage; and (3)&nbsp;identify possible adverse effects and safety risks.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Phase 3 (pivotal)&#8212;If a compound is found to be potentially effective
and to have an acceptable safety profile in Phase 2 evaluations, Phase 3 clinical trials, also called pivotal studies, major studies
or advanced clinical trials, are undertaken to further demonstrate clinical efficacy and to further test for safety within an expanded
patient population at geographically dispersed clinical trial sites. In general, the FDA requires that at least two adequate and
well-controlled Phase 3 clinical trials be conducted.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Initiation and completion of the clinical trial phases are dependent
on several factors including things that are beyond our control. For example, the clinical trials cannot begin at a particular
site until that site receives approval from its Institutional Review Board (&#8220;IRB&#8221;), which reviews the protocol and
related documents. This process can take from several weeks to several months. In addition, clinical trials are dependent on patient
enrollment, but the rate at which patients enroll in the study depends on:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">willingness of investigators to participate in a study;</font></td></tr>

<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">ability of clinical sites to obtain approval from their IRB;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the availability of the required number of eligible subjects to be enrolled in a given trial;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the availability of existing or other experimental drugs for the disease we intend to treat;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the willingness of patients to participate;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the patients meeting the eligibility criteria.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Delays in planned patient enrollment may result in increased expense
and longer development timelines.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 16; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">After successful completion of the required clinical testing, generally
an NDA is submitted. Upon receipt of the NDA, the FDA will review the application for completeness. Within 60 days, the FDA will
determine if the application is sufficiently complete to warrant full review and will consider the application &#8220;filed&#8221;
at that time. Also upon receipt of the application, the FDA will assign a review priority to the application. Priority review applications
are usually reviewed within 8 months; standard review applications are usually reviewed within 12 months. The FDA will usually
refer NDAs for new molecular entities to an appropriate advisory committee for review and evaluation in regards to providing a
recommendation as to whether the application should be approved. The FDA is not bound to follow the recommendation of an advisory
committee.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Following the review of the application, which may include requests
for additional information from the sponsor and&nbsp;results from inspections of manufacturing and clinical sites, the FDA will
issue an &#8220;action letter&#8221; on the application. The action letter will either be an &#8220;approval letter,&#8221; in
which case the product may be lawfully marketed in the United States, or a &#8220;complete response letter.&#8221; A complete response
letter will state that the FDA cannot approve the NDA in its present form and, usually, will describe all of the specific deficiencies
that the FDA has identified in the application. The complete response letter, when possible, will include the FDA&#8217;s recommended
actions to place the application in a condition for approval. Deficiencies can be minor (e.g., labeling changes) or major (e.g.,
requiring additional clinical trials). A complete response letter may also be issued before the FDA conducts the required facility
inspection and/or reviews labeling, leaving the possibility that additional deficiencies in the original NDA could be subsequently
cited. An applicant receiving a complete response letter is permitted to resubmit the NDA addressing the identified deficiencies
(in which case a new two or six month review cycle will begin), or withdraw the NDA. The FDA may consider a failure to take action
within one year of a complete response letter to be a request to withdraw, unless the applicant has requested an extension of time
in which to resubmit. If the FDA approves an NDA, the marketing of the product will be limited to the particular disease states
and conditions of use that are described in the product label.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We and all of our contract manufacturers are also required to comply
with the applicable FDA current Good Manufacturing Practice, or cGMP, regulations during clinical development and to ensure that
the product can be consistently manufactured to meet the specifications submitted in an NDA. The cGMP regulations include requirements
relating to product quality as well as the corresponding maintenance of records and documentation. Manufacturing facilities must
be approved by the FDA before they can be used to manufacture our products. Based on an inspection, the FDA determines whether
manufacturing facilities are in compliance with applicable regulations. Manufacturing facilities in non-United States countries
that are utilized to manufacture drugs for distribution into the United States are also subject to inspection by the FDA. Additionally,
failure to comply with local regulatory requirements could affect production and availability of product in relevant markets.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Human Resources</b></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of January&nbsp;31, 2017, we had approximately 65&nbsp;employees,
of whom approximately 45 were engaged in the research and development function of our operations. Our research and development
staff, 25 of whom hold Ph.D. or M.D. degrees, have diversified experience in biochemistry, pharmacology, X-ray crystallography,
synthetic organic chemistry, computational chemistry, medicinal chemistry, clinical development and regulatory affairs.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our employees are not represented by any collective bargaining agreements,
and we have never experienced a work stoppage. Employees are required to execute confidentiality and assignment of intellectual
property agreements. We consider our relations with our employees to be satisfactory.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Available Information</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our website address is www.biocryst.com. We make available, free of
charge, at our website our Annual Reports on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q, Current Reports on Form&nbsp;8-K,
and amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act as soon as reasonably
practicable after we electronically file such material with, or furnish it to, the SEC. We also make available at our website copies
of our audit committee charter, compensation committee charter, corporate governance and nominating committee charter and our code
of business conduct, which applies to all our employees as well as the members of our Board of Directors. Any amendment to, or
waiver from, our code of business conduct will be posted on our website.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Financial Information</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For information related to our revenues, profits, net loss and total
assets, in addition to other financial information, please refer to the Financial Statements and Notes to Financial Statements
contained in this Annual Report. Financial information about revenues derived from foreign countries is included in Note&nbsp;1
to the Financial Statements contained in this Annual Report.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 17; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><b><a name="a_002"></a>ITEM 1A.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b> <i>RISK FACTORS</i></b></td>
</tr></table>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>An investment in our stock involves risks. You should carefully
read this entire report and consider the following uncertainties and risks, which may adversely affect our business, financial
condition or results of operations, along with all of the other information included in our other filings with the Securities and
Exchange Commission, before deciding to buy our common stock.</i></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Risks Relating to Our Business</b> &nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We have incurred losses since our inception, expect to continue to incur
such losses, and may never be profitable.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Since our inception, we have not achieved sustained profitability.
We expect to incur additional losses for the foreseeable future, and our losses could increase as our research and development
efforts progress. We expect that such losses will fluctuate from quarter to quarter and losses and fluctuations may be substantial.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">To become profitable, we, or our collaborative partners, must successfully
manufacture and develop product candidates, receive regulatory approval, and successfully commercialize and/or enter into profitable
agreements with other parties. It could be several years, if ever, before we receive significant revenue from any current or future
license agreements or revenues directly from product sales.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Because of the numerous risks and uncertainties associated with developing
our product candidates and their potential for commercialization, we are unable to predict the extent of any future losses. Even
if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we are
unable to achieve and sustain profitability, the market value of our common stock will likely decline.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Our success depends upon our ability to advance our products through
the various stages of development, especially through the clinical trial process.</i></b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">To receive the regulatory approvals necessary for the sale of our
product candidates, we or our partners must demonstrate through preclinical studies and clinical trials that each product candidate
is safe and effective. The development process and related regulatory process are complex and uncertain. Because of the cost and
duration of clinical trials, we may decide to discontinue development of product candidates that are unlikely to show good results
in the clinical trials, unlikely to help advance a product to the point of a meaningful collaboration, or unlikely to have reasonable
commercial potential. We may suffer significant setbacks in pivotal pre-clinical studies and clinical trials (e.g. galidesivir,
BCX7353, other kallikrein inhibitors and our other rare disease product candidates), even after earlier clinical trials show promising
results. The development of our product candidates, including our clinical trials, may not be adequately designed or executed,
which could affect the potential outcome and analysis of study results. Any of our product candidates may produce undesirable side
effects in humans. The pre-clinical and clinical data from our product candidates could cause us or regulatory authorities to interrupt,
delay, modify or halt preclinical or clinical trials of a product candidate. Undesirable or inconclusive data or side effects in
humans could also result in the FDA or foreign regulatory authorities refusing to approve the product candidate for any targeted
indications. In addition, the FDA or other regulatory agencies may determine that study data from our product candidates necessitates
additional studies or study designs which differ from our planned development strategy, and regulatory agencies may also require
patient monitoring and testing or may implement restrictions or other conditions on our development activities, any of which could
materially impact the cost and timing of our planned development strategy. We, our partners, the FDA or foreign regulatory authorities
may suspend or terminate clinical trials at any time if we or they believe the trial participants face unacceptable health risks.
Clinical trials may fail to demonstrate that our product candidates are safe or effective and have acceptable commercial viability.
Regulatory authorities may interrupt, delay or halt clinical trials for a product candidate for any number of reasons.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our ability to successfully complete clinical trials is dependent
upon many factors, including but not limited to:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom; width: 95%"><font style="font-size: 10pt">our ability to find suitable clinical sites and investigators to enroll patients;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">the ability to maintain contact with patients to provide complete data after treatment;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">our product candidates may not prove to be either safe or effective;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">clinical protocols or study procedures may not be adequately designed or followed by the investigators;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">formulation improvements may not work as expected, which could negatively impact commercial demand for our product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">manufacturing or quality control problems could affect the supply of product candidates for our trials; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">delays or changes in our planned development strategy, the regulations or guidelines, or other unexpected conditions or requirements of government agencies.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 18; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Clinical trials are lengthy and expensive. We or our partners incur
substantial expense for, and devote significant time to, preclinical testing and clinical trials, yet we cannot be certain that
the tests and trials will ever result in the commercial sale of a product. For example, clinical trials require adequate supplies
of drug and sufficient patient enrollment. Lack of adequate drug supply or delays in patient enrollment can result in increased
costs and longer development times. Even if we or our partners successfully complete clinical trials for our product candidates,
we or our partners might not file the required regulatory submissions in a timely manner and may not receive regulatory approval
for the product candidates.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>We focus on rare diseases, which may create additional risks and challenges.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Because we focus on developing drugs as treatments for rare diseases,
we may seek orphan drug, breakthrough therapy or fast track designations for our product candidates in the United States or the
equivalent designations elsewhere in the world. Often, regulatory agencies have broad discretion in determining whether or not
to grant such designations. We cannot guarantee that we will be able to receive orphan drug status from the FDA or equivalent regulatory
designations elsewhere. We also cannot guarantee that we will obtain breakthrough therapy or fast track designation, which may
provide certain potential benefits such as more frequent meetings with the FDA to discuss the development plan, intensive guidance
on an efficient drug development program, and potential eligibility for rolling review or priority review. Even if we are successful
in obtaining any such designation by the FDA or other regulatory agency for our product candidates, such designations may not lead
to faster development or regulatory review or approval, and it does not increase the likelihood that our product candidates will
receive marketing approval. We may not be able to obtain or maintain such designations for our product candidates, and our competitors
may obtain these designations for their product candidates, which could impact our ability to develop and commercialize our product
candidates or compete with such competitors, which may adversely impact our business, financial condition or results of operations.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Although we have received Sakigake designation for BCX7353 in Japan,
we may not experience a faster development, review or approval process compared to the conventional process.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Our clinical trials may not adequately show that our product candidates
are safe or effective.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Progression of our product candidates through the clinical development
process is dependent upon our trials indicating our product candidates have adequate safety and efficacy in the patients being
treated by achieving pre-determined safety and efficacy endpoints according to the clinical trial protocols. Failure to achieve
any of these endpoints in any of our programs, including BCX7353, and our other rare disease product candidates, could result in
delays in our trials or require the performance of additional unplanned trials. This could result in delays in the development
of our product candidates and could result in significant unexpected costs or the termination of programs.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>If our development collaborations with third parties, such as our development
partners and contract research organizations, fail, the development of our product candidates will be delayed or stopped.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 20pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We rely heavily upon third parties for many important stages of our
product candidate development, including but not limited to:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">discovery of compounds that cause or enable biological reactions necessary for the progression of the disease or disorder, called enzyme targets;</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="3">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">licensing or designing of enzyme inhibitors for development as product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">execution of certain preclinical studies and late-stage development for our compounds and product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">management of our clinical trials, including medical monitoring and data management;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">execution of additional toxicology studies that may be required to obtain approval for our product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">formulation improvement strategies and methods; and</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">manufacturing the starting materials and drug substance required to formulate our products and the product candidates to be used in our clinical trials, toxicology studies and any potential commercial product.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our failure to engage in successful collaborations at any one of these
stages would greatly impact our business. If we do not license enzyme targets or inhibitors from academic institutions or from
other biotechnology companies on acceptable terms, our drug development efforts would suffer. Similarly, if the contract research
organizations that conduct our initial or late-stage clinical trials, conduct our toxicology studies, manufacture our starting
materials, drug substance and product candidates or manage our regulatory function breached their obligations to us or perform
their services inconsistent with industry standards and not in accordance with the required regulations, this would delay or prevent
both the development of our product candidates and the availability of any potential commercial product.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we lose our relationship with any one or more of these parties,
we could experience a significant delay in both identifying another comparable provider and then contracting for its services.
We may be unable to retain an alternative provider on reasonable terms, if at all. Even if we locate an alternative provider, it
is likely that this provider may need additional time to respond to our needs and may not provide the same type or level of service
as the original provider. In addition, any provider that we retain will be subject to applicable FDA current Good Laboratory Practices
(&#8220;cGLP&#8221;), current Good Manufacturing Practices (&#8220;cGMP&#8221;) and current Good Clinical Practices (&#8220;cGCP&#8221;),
and comparable foreign standards. We do not have control over compliance with these regulations by these providers. Consequently,
if these practices and standards are not adhered to by these providers, the development and commercialization of our product candidates
could be delayed. If any of the foregoing risks are realized, our business, financial condition and results of operations could
be materially adversely affected.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 19; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>Because we have limited manufacturing experience, we depend on third-party
manufacturers to manufacture our product, product candidates and the materials for our product candidates. Often, especially early
in the development and commercialization process, we have only one source for manufacturing. If we cannot rely on existing third-party
manufacturers, we will be required to incur significant costs and potential delays in finding new third-party manufacturers.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have limited manufacturing experience and only a small scale manufacturing
facility. We currently rely upon a very limited number of third-party manufacturers to manufacture the materials required for our
product, product candidates and most of the preclinical and clinical quantities of our product candidates. We depend on these third-party
manufacturers to perform their obligations in a timely manner and in accordance with applicable governmental regulations. Our third-party
manufacturers, which may be the only manufacturer we have engaged for a particular product, may encounter difficulties with meeting
our requirements including but not limited to problems involving:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">inconsistent production yields;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">product liability claims or recalls of commercial product;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">difficulties in scaling production to commercial and validation sizes;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">interruption of the delivery of materials required for the manufacturing process;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">scheduling of plant time with other vendors or unexpected equipment failure;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">potential catastrophes that could strike their facilities or have an effect on infrastructure;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">potential impurities in our drug substance or products that could affect availability of product for our clinical trials or future commercialization;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">poor quality control and assurance or inadequate process controls; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">lack of compliance or cooperation with regulations and specifications or requests set forth by the FDA or other foreign regulatory agencies, particularly associated with peramivir, BCX7353, galidesivir and our early stage compounds.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These contract manufacturers may not be able to manufacture the materials
required for our product candidates at a cost or in quantities necessary to make them commercially viable. We also have no control
over whether third-party manufacturers breach their agreements with us or whether they may terminate or decline to renew agreements
with us. To date, our third-party manufacturers have met our manufacturing requirements, but they may not continue to do so. Furthermore,
changes in the manufacturing process or procedure, including a change in the location where the drug is manufactured or a change
of a third-party manufacturer, may require prior review and approval in accordance with the FDA&#8217;s cGMP and comparable foreign
requirements. This review may be costly and time-consuming and could delay or prevent the launch of a product. The FDA or similar
foreign regulatory agencies may at any time implement new standards, or change their interpretation and enforcement of existing
standards for manufacture, packaging or testing of products. If we or our contract manufacturers are unable to comply, we or they
may be subject to regulatory action, civil actions or penalties any of which could be costly to the Company and could result in
a delay or shortage of product.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we are unable to maintain current manufacturing or other contract
relationships, or enter into new agreements with additional manufacturers on commercially reasonable terms, or if there is poor
manufacturing performance or failure to comply with any regulatory agency on the part of any of our third-party manufacturers,
we may not be able to complete development of, seek timely approval of, or market, our product candidates.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our raw materials, drug substances, and product candidates are manufactured
by a limited group of suppliers, including some at a single facility. If any of these suppliers were unable to produce these items,
this could significantly impact our supply of product candidate material for further preclinical testing and clinical trials.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>We face intense competition, and if we are unable to compete effectively,
the demand for our products, if any, may be reduced.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The biotechnology and pharmaceutical industries are highly competitive
and subject to rapid and substantial technological change. There are many companies seeking to develop products for the same indications
that we currently target. Our competitors in the United States and elsewhere are numerous and include, among others, major multinational
pharmaceutical and chemical companies and specialized biotechnology firms. Most of these competitors have greater resources than
we do, including greater financial resources, larger research and development staffs and more experienced marketing and manufacturing
organizations. In addition, most of our competitors have greater experience than we do in conducting clinical trials and obtaining
FDA and other regulatory approvals. Accordingly, our competitors may succeed in obtaining FDA or other regulatory approvals of
product candidates more rapidly than we do. Companies that complete clinical trials, obtain required regulatory approvals, and
commence commercial sale of their drugs before we do may achieve a significant competitive advantage, including patent and FDA
exclusivity rights that would delay our ability to market products. We face, and will continue to face, competition in the licensing
of potential product candidates for desirable disease targets licensing of desirable product candidates, and development and marketing
of our product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical
companies. Competition may also arise from, among other things:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 20; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">other drug development technologies;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">methods of preventing or reducing the incidence of disease, including vaccines;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">new small molecule or other classes of therapeutic agents.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Developments by others may render our product candidates or technologies
obsolete or noncompetitive.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are performing research on or developing products for the treatment
of several rare disorders, including HAE, as well as developing broad spectrum antivirals for use as medical countermeasures. We
expect to encounter significant competition for any of the pharmaceutical products we plan to develop. Companies that complete
clinical trials, obtain required funding or government support, obtain required regulatory approvals and commence commercial sales
or stockpiling orders of their products before their competitors may achieve a significant competitive advantage. Such is the case
with the current neuraminidase inhibitors marketed by GSK and Roche for influenza; CINRYZE<sup>&#174;</sup>, KALBITOR<sup>&#174;</sup>
and FIRAZYR<sup>&#174;</sup>, marketed by Shire Pharmaceuticals, Inc. for HAE; and BERINERT<sup>&#174;</sup>, marketed by CSL for
HAE. Therapeutic products with potentially promising data to treat Ebola include Mapp Biopharmaceutical, Inc.&#8217;s ZMapp (antibody-based)
and Gilead Sciences, Inc.&#8217;s product currently under development (small molecule), both of which have been used in Ebola infected
patients. Further, several pharmaceutical and biotechnology firms, including major pharmaceutical companies and specialized structure-based
drug design companies, have announced efforts in the field of structure-based drug design and molecules in development in the fields
of HAE and in other therapeutic areas where we have discovery and development efforts ongoing. If one or more of our competitors&#8217;
products or programs are successful, the market for our products may be reduced or eliminated.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Compared to us, many of our competitors and potential competitors
have substantially greater:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">capital resources;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">research and development resources, including personnel and technology;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">regulatory experience;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">preclinical study and clinical testing experience;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">manufacturing and marketing experience;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">production facilities.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Any of these competitive factors could impede our funding efforts,
render technology and product candidates noncompetitive or eliminate or reduce demand for our product candidates.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"></p>



<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>We face risks related to our government-funded programs; if BARDA/HHS
or NIAID/HHS were to eliminate, reduce or delay funding from our contracts, this would have a significant negative impact on the
programs associated with such funding and could have a significant negative impact on our revenues and cash flows.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our projections of revenues and incoming cash flows are substantially
dependent upon BARDA/HHS and NIAID/HHS reimbursement for the costs related to our galidesivir program. If BARDA/HHS or NIAID/HHS
were to eliminate, reduce or delay the funding for these programs or disallow some of our incurred costs, we would have to obtain
additional funding for continued development or regulatory registration for these product candidates or significantly reduce or
stop the development effort.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In contracting with BARDA/HHS and NIAID/HHS, we are subject to various
U.S. Government contract requirements, including general clauses for a cost-reimbursement research and development contract, which
may limit our reimbursement or if we are found to be in violation could result in contract termination. If the U.S. Government
terminates any of its contracts with us for its convenience, or if we default by failing to perform in accordance with the contract
schedule and terms, significant negative impact on our cash flows and operations could result.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>Our government contracts with BARDA/HHS and NIAID/HHS have special contracting
requirements, which create additional risks of reduction or loss of funding.</i></b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 21; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have completed work under a contract with BARDA/HHS for the development
of our neuraminidase inhibitor, RAPIVAB. We also have entered into contracts with BARDA/HHS and NIAID/HHS for the development of
galidesivir as a treatment for diseases caused by RNA pathogens, including Marburg virus disease and Ebola virus disease. In contracting
with these government agencies, we are subject to various U.S. Government contract requirements, including general clauses for
a cost-reimbursement research and development contract, which may limit our reimbursement or, if we are found to be in violation,
could result in contract termination.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">U.S. Government contracts typically contain a number of extraordinary
provisions that would not typically be found in commercial contracts and which may create a disadvantage and additional risks to
us as compared to competitors that do not rely on U.S. Government contracts. These risks include the ability of the U.S. Government
to unilaterally:</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">terminate or reduce the scope of our contract with or without cause;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">interpret relevant regulations (federal acquisition regulation clauses);</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">require performance under circumstances which may not be favorable to us;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">require an in process review where the U.S. Government will review the project and its options under the contract;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">control the timing and amount of funding, which impacts the development progress of our programs; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">audit and object to our contract-related costs and fees, including allocated indirect costs.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>Our government contracts with BARDA/HHS and NIAID/HHS have termination
and audit provisions which create additional risks to us.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The U.S. Government may terminate its contracts with us either for
its convenience or if we default by failing to perform in accordance with the contract schedule and terms. Termination for convenience
provisions generally enable us to recover only our costs incurred or committed, and settlement expenses and profit on the work
completed prior to termination. Termination does not permit these recoveries under default provisions. In the event of termination
or upon expiration of a contract, the U.S. Government may dispute wind-down and termination costs and may question prior expenses
under the contract and deny payment of those expenses. Should we choose to challenge the U.S. Government for denying certain payments
under a contract, such a challenge could subject us to substantial additional expenses which we may or may not recover. Further,
if the U.S. Government terminates its contracts with us for its convenience, or if we default by failing to perform in accordance
with the contract schedule and terms, significant negative impact on our cash flows and operations could result.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As a U.S. Government contractor, we are required to comply with applicable
laws, regulations and standards relating to our accounting practices and are subject to periodic audits and reviews. As part of
any such audit or review, the U.S. Government may review the adequacy of, and our compliance with, our internal control systems
and policies, including those relating to our purchasing, property, estimating, compensation and management information systems.
Audits conducted by the U.S. Government for the completed BARDA/HHS peramivir contract have been performed and concluded through
fiscal 2009; all subsequent fiscal years are still open and auditable. Audits under the active BARDA/HHS and NIAID/HHS galidesivir
contracts may occur at the election of the U.S. Government and have been concluded through fiscal 2013. Based on the results of
its audits, the U.S. Government may adjust our contract-related costs and fees, including allocated indirect costs. This adjustment
could impact the amount of revenues reported on a historic basis and could impact our cash flows under the contracts prospectively.
In addition, in the event BARDA/HHS or NIAID/HHS determines that certain costs and fees were unallowable or determines that the
allocated indirect cost rate was higher than the actual indirect cost rate, BARDA/HHS or NIAID/HHS would be entitled to recoup
any overpayment from us as a result. In addition, if an audit or review uncovers any improper or illegal activity, we may be subject
to civil and criminal penalties and administrative sanctions, including termination of our contracts, forfeiture of profits, suspension
of payments, fines and suspension or prohibition from doing business with the U.S. Government. We could also suffer serious harm
to our reputation if allegations of impropriety were made against us. In addition, under U.S. Government purchasing regulations,
some of our costs may not be reimbursable or allowed under our contracts. Further, as a U.S. Government contractor, we are subject
to an increased risk of investigations, criminal prosecution, civil fraud, whistleblower lawsuits and other legal actions and liabilities
as compared to private sector commercial companies.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to reach milestones or to make annual minimum payments or
otherwise breach our obligations under our license agreements, our licensors may terminate our agreements with them and seek additional
remedies.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we are unable or fail to meet payment obligations, performance
milestones relating to the timing of regulatory filings, product supply obligations, post approval commitments for RAPIVAB, or
development and commercial diligence obligations; are unable or fail to make milestone payments or material data use payments in
accordance with applicable provisions; or fail to pay the minimum annual payments under our respective licenses, our licensors
may terminate the applicable license or seek other available remedies. As a result, our development of the respective product candidate
or commercialization of the product would cease.&nbsp;&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to obtain additional financing or acceptable partnership
arrangements, we may be unable to complete the development and commercialization of our product candidates or continue operations.</i></b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 22; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As our programs advance, our costs are likely to increase. Our current
and planned discovery activities, pre-clinical and clinical trials, the related development, manufacturing, regulatory approval
process requirements, and the additional personnel resources and testing required for supporting the development of our product
candidates will consume significant capital resources. Our expenses, revenues and cash utilization rate could vary significantly
depending on many factors, including: our ability to raise additional capital; the development progress of our collaborative agreements
for our product candidates; the amount of funding we receive from NIAID/HHS and BARDA/HHS for galidesivir or from other new partnerships
with third parties for the development of our product candidates, including BCX7353 and our other rare disease product candidates;
the commercial success of peramivir achieved by our partners; the amount or profitability of any orders for peramivir or galidesivir
by any government agency or other party; the progress and results of our current and proposed clinical trials for our most advanced
product candidates, including BCX7353 and our other rare disease product candidates; the progress made in the manufacture of our
lead products and the progression of our other programs.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We expect that we will be required to raise additional capital to
complete the development and commercialization of our current product candidates and we may seek to raise capital at any time.
Additional funding, whether through additional sales of securities, additional borrowings, or collaborative arrangements with partners,
including governmental agencies in general and from any BARDA/HHS or NIAID/HHS contract specifically, may not be available when
needed or on terms acceptable to us. The issuance of preferred or common stock or convertible securities, with terms and prices
significantly more favorable than those of the currently outstanding common stock, could have the effect of diluting or adversely
affecting the holdings or rights of our existing stockholders. Additional borrowings may subject us to more restrictive covenants
than are currently applicable to us under our September 23, 2016 Senior Credit Facility with an affiliate of MidCap Financial Services,
LLC (&#8220;MidCap&#8221;), as administrative agent (the &#8220;Senior Credit Facility&#8221;). In addition, collaborative arrangements
may require us to transfer certain material rights to such corporate partners. Insufficient funds or lack of an acceptable partnership
may require us to delay, scale-back or eliminate certain of our research and development programs.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">In order to continue future operations and continue our drug
development programs, we will be required to raise additional capital. In addition to seeking strategic partnerships,
transactions and government funding, we may decide to access the equity or debt markets, incur additional borrowings, or seek
other sources to meet liquidity needs. Our ability to raise additional capital may be limited and may greatly depend upon the
success of ongoing development related to our current drug development programs, including post approval studies for
RAPIVAB,&nbsp;the progress, timeline and ultimate outcome of&nbsp;our kallikrein inhibitors, including the BCX7353 program
(including, but not limited to, formulation progress, phase 3 trials, long-term human safety studies, and the timing of
carcinogenicity or other required studies), the progress of our other rare disease product candidates, funding for and
continued successful development of galidesivir, and the progress of our early discovery programs. In addition, constriction
and volatility in the equity and debt markets may restrict our future flexibility to raise capital when such needs arise.
Furthermore, we have exposure to many different industries, financing partners and counterparties, including commercial
banks, investment banks and partners (which include investors, licensing partners, and the U.S. Government) which may be
unstable or may become unstable in the current economic and political environment. Any such instability may impact these
parties&#8217; ability to fulfill contractual obligations to us or they might limit or place burdensome conditions upon
future transactions with us. Also, it is possible that suppliers may be negatively impacted. Any such unfavorable outcomes in
our current programs or unfavorable economic conditions could place severe downward pressure on the price of our common stock
and may decrease opportunities to raise capital in the capital or credit markets, and further could reduce the return
available on invested corporate cash, which, if severe and sustained, could have a material and adverse impact on our results
of operations and cash flows and limit our ability to continue development of our product candidates.</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><B><I>We may not be able to continue as a going concern if we do not obtain
additional capital.</I></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">We have sustained operating losses for the majority of our corporate
history and expect that our 2017 expenses will exceed our 2017 revenues. We expect to continue to incur operating losses and negative
cash flows until revenues reach a level sufficient to support ongoing operations.</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Our liquidity needs will be largely determined by the success of operations
in regards to the progression of our product candidates in the future. Our plans to alleviate the doubt regarding our ability to
continue as a going concern primarily include our ability to control the timing and spending on our research and development programs
and raising additional funds through equity financings.&nbsp; We also may consider other plans to fund operations including: (1)
securing or increasing U.S. Government funding of our programs, including obtaining procurement contracts; (2) out-licensing rights
to certain of our products or product candidates, pursuant to which the we would receive cash milestones; (3) raising additional
capital through debt financings or from other sources; (4) obtaining additional product candidate regulatory approvals, which would
generate revenue, milestones and cash flow; (5) reducing spending on one or more research and development programs by discontinuing
development; and/or (6) restructuring operations to change our overhead structure.</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">There can be no assurance that any of our plans will be successful
or that additional capital will be available to us on reasonable terms, or at all, when needed. If we are unable to obtain sufficient
additional capital, we may be forced to curtail operations, delay or stop ongoing clinical trials, cease operations altogether
or file for bankruptcy.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to successfully commercialize or establish collaborative
relationships to commercialize certain of our product candidates, or if any partner terminates or fails to perform its obligations
under agreements with us, potential revenues from commercialization of our product candidates could be reduced, delayed or eliminated.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our business strategy is to increase the asset value of our product
candidate portfolio. We believe this is best achieved by retaining full product rights or through collaborative arrangements with
third parties as appropriate. As needed, potential third-party relationships could include preclinical development, clinical development,
regulatory approval, marketing, sales and distribution of our product candidates.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Currently, we have established collaborative relationships with Mundipharma
for the development and commercialization of forodesine and with each of Shionogi and Green Cross for the development and commercialization
of peramivir in Japan, Taiwan and South Korea. Most recently we have established a collaborative relationship with Seqirus UK
Limited for RAPIVAB on a worldwide basis other than Israel, Japan, Korea and Taiwan. The process of establishing and implementing
collaborative relationships is difficult, time-consuming and involves significant uncertainty, including:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 89%"><font style="font-size: 10pt">our partners may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, including post approval clinical commitments, a change in business strategy, a change of control or other reasons;</font></td>
    <td style="width: 6%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">our contracts for collaborative arrangements may expire;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">our partners may choose to pursue alternative technologies, including those of our competitors;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we may have disputes with a partner that could lead to litigation or arbitration;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we do not have day to day control over the activities of our partners and have limited control over their decisions;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom"></td></tr></table>

<!-- Field: Page; Sequence: 23; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%">&nbsp;</td>
    <td style="width: 89%">&nbsp;</td>
    <td style="width: 6%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">our ability to generate future event payments and royalties from our partners depends upon their abilities to establish the safety and efficacy of our product candidates, obtain regulatory approvals and achieve market acceptance of products developed from our product candidates;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we or our partners may fail to properly initiate, maintain or defend our intellectual property rights, where applicable, or a party may utilize our proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our proprietary information or expose us to potential liability;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">we or our partners may not devote sufficient capital or resources towards our product candidates; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">we or our partners may not comply with applicable government regulatory requirements.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we or our partners fail to fulfill our responsibilities in a timely
manner, or at all, our commercialization efforts related to that collaboration could be reduced, delayed or terminated, or it may
be necessary for us to assume responsibility for activities that would otherwise have been the responsibility of our partner. If
we are unable to establish and maintain collaborative relationships on acceptable terms, we may have to delay or discontinue further
development of one or more of our product candidates, undertake commercialization activities at our own expense or find alternative
sources of funding. Any delay in the development or commercialization of our product candidates would severely affect our business,
because if our product candidates do not progress through the development process or reach the market in a timely manner, or at
all, we may not receive additional future event payments and may never receive milestone, product sales or royalty payments.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We do not have a great deal of experience in commercializing our products
or technologies, and our future revenue generation is uncertain.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We do not have a great deal of experience in commercializing our product
candidates or technologies. We currently have limited marketing and commercial capability, no direct or third-party sales force
and limited distribution capabilities. We may be unable to establish or sufficiently increase these capabilities for products we
currently, or plan to, commercialize. In addition, our revenue from collaborative agreements may be dependent upon the status of
our preclinical and clinical programs.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our ability to receive revenue from products we commercialize presents
several risks, including:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">we or our collaborators may fail to successfully complete clinical trials, or satisfy post-marketing commitments, sufficient to obtain and keep FDA marketing approval;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">many competitors are more experienced and have significantly more resources, and their products could reach the market faster, be more cost effective or have a better efficacy or tolerability profile than our product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we may fail to employ a comprehensive and effective intellectual property strategy, which could result in decreased commercial value of our Company and our products;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we may fail to employ a comprehensive and effective regulatory strategy, which could result in a delay or failure in commercialization of our products;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">our ability to successfully commercialize our products is affected by the competitive landscape, which cannot be fully known at this time;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">reimbursement is constantly changing, which could greatly affect usage of our products; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">future revenue from product sales would depend on our ability to successfully complete clinical studies, obtain regulatory approvals, and manufacture, market and commercialize our approved drugs.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Commercialization of peramivir by our partners is subject to the potential
commercialization risks described herein and numerous additional risks. Any potential revenue benefits to us in the form of milestone
payments, royalties or other consideration are highly speculative.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Commercialization success of peramivir is uncertain and is subject
to all the risks and uncertainties disclosed in our other risk factors relating to drug development and commercialization. In addition,
commercialization of peramivir products is subject to further risks and may be negatively impacted by a number of factors, including,
but not limited to, the following:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">peramivir may not prove to be adequately safe and effective for market approval in markets other than the United States, Japan, Korea and Taiwan;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%">&nbsp;</td>
    <td style="width: 90%">&nbsp;</td>
    <td style="width: 5%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">necessary funding for post-marketing commitments and further development of peramivir may not be available timely, at all, or in sufficient amounts;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom"></td></tr></table>

<!-- Field: Page; Sequence: 24; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%">&nbsp;</td>
    <td style="width: 90%">&nbsp;</td>
    <td style="width: 5%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">flu prevention or pandemic treatment concerns may not materialize at all, or in the near future;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">advances in flu vaccines or other antivirals, including competitive i.v. antivirals, could substantially replace potential demand for peramivir;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">a limited number of governmental entities are expected to be the primary potential stockpiling customers for peramivir and if we are not successful at marketing peramivir to these entities for any reason, we will not receive substantial revenues from stockpiling orders;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">government and third party payors may not provide sufficient coverage or reimbursement which would negatively impact the demand for peramivir;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">we may not be able to supply commercial material to our partners and our partners may not be able to maintain or establish sufficient and acceptable commercial manufacturing, either directly or through third-party manufacturers;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">the commercial demand and acceptance for peramivir by healthcare providers and by patients may not be sufficient to result in substantial revenues of peramivir to our partners and may result in little to no milestones or royalties to us;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">effectiveness of marketing and commercialization efforts for peramivir by our
    partners;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">market satisfaction with existing alternative therapies;</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">perceived efficacy relative to other available therapies;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">disease prevalence;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">cost of treatment;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">pricing and availability of alternative products;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">marketing and sales activities of competitors;</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">shifts in the medical community to new treatment paradigms or standards of care; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">relative convenience and ease of administration.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>We are subject to various federal and state laws related to RAPIVAB and
other products under development and, if we or our partners do not comply with these regulations, we could face substantial penalties.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our or our partners&#8217; activities related to RAPIVAB, or any of
our other products under development and following their regulatory approval, are subject to regulatory and law enforcement authorities
in addition to the FDA, including the Federal Trade Commission, the Department of Justice, and state and local governments. In
the case of our collaboration with SUL, although SUL is responsible for RAPIVAB marketing and commercialization efforts, we continue
to carry certain risks associated with RAPIVAB because we hold the RAPIVAB NDA. For example, we are responsible for reporting adverse
drug experiences, we have responsibility for certain post-approval studies, we may have responsibilities and costs related to a
recall or withdrawal of RAPIVAB from sale, we may incur liability associated with RAPIVAB manufacturing contracted by us or in
support of any of our partners, we are required to maintain records and provide data and reports to regulatory agencies related
to RAPIVAB (e.g. risk evaluation and mitigation strategies, track and trace requirements, adverse events), and we may incur certain
promotional regulatory and government pricing risks, all of which could have a material adverse impact on our operations and financial
condition. In addition, we are now subject to the federal physician sunshine act and certain similar legislation in various states.
We are subject to various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including both federal
and state anti-kickback laws. Although we seek to comply with these statutes, it is possible that our practices, or those of our
distributors, might be challenged under anti-kickback or similar laws. Violations of the physician sunshine act and similar state
legislation or the fraud and abuse laws may be punishable by civil or criminal sanctions, including fines and civil monetary penalties,
and future exclusion from participation in government healthcare programs.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have a number of outstanding post-marketing commitments to the
FDA that we retain, despite our partnership with SUL, which we may not complete successfully or on time for any number of reasons,
including but not limited to lack of funds to complete the studies and insufficient interest by appropriate sites, investigators
or study subjects. For example, as a condition of the approval of RAPIVAB, we are required to complete a pediatric patient study
of RAPIVAB and to submit the final results of this clinical trial to the FDA. Depending on the outcome of this clinical trial,
we may be unable to expand the indication for RAPIVAB or we may be required to include specific warnings or limitations on dosing
this product, which could negatively impact sales of RAPIVAB and negatively impact our relationship with our partner. We may be
subject to penalties if we fail to comply with post-approval legal and regulatory requirements and our products could be subject
to continual recordkeeping and reporting requirements, review and periodic inspections by the FDA and other regulatory bodies.
Regulatory approval of a product may be subject to limitations on the indicated uses for which the product may be marketed or to
the other restrictive conditions of approval that limit our ability to promote, sell or distribute a product. Furthermore, the
approval of RAPIVAB and any other future product candidates may be subject to requirements for costly post-marketing testing and
surveillance to monitor its safety or efficacy.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 25; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Advertising and promotion are subject to stringent FDA rules and oversight
and as the holder of the NDA we may be held responsible for any advertising and promotion conducted by our partner that is not
in compliance with the rules and regulations. In particular, the claims in all promotional materials and activities must be consistent
with the FDA approvals for approved products, and must be appropriately substantiated and fairly balanced with information on the
safety risks and limitations of the products. Adverse event information concerning approved products must be reviewed and as the
NDA holder of RAPIVAB we are required to make expedited and periodic adverse event reports to the FDA and other regulatory authorities.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, the research, manufacturing, distribution, sale and promotion
of products are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including
the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services, the U.S. Department
of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments. Until we can
successfully transfer the pricing responsibilities to our partner, we remain responsible for pricing and rebate programs. Pricing
and rebate programs must comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990, as amended,
and the Veterans Health Care Act of 1992, as amended. If products are made available to authorized users of the Federal Supply
Schedule of the General Services Administration, additional laws and requirements apply. All of these activities are also potentially
subject to federal and state consumer protection and unfair competition laws.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If our operations with respect to RAPIVAB or our other products that
are subject to healthcare laws and regulations are found to be in violation of any of the healthcare fraud and abuse laws described
above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties,
damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring
of our operations could adversely affect our ability to operate our business and our financial results. Although compliance programs
can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any
action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal
expenses and divert our management's attention from the operation of our business. Moreover, achieving and sustaining compliance
with all applicable federal and state fraud and abuse laws may be costly.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20.15pt"><b><i>We and our partners may be subject to new legislation, regulatory proposals
and healthcare payor initiatives that may increase our costs of compliance and adversely affect our or our partners&#8217; ability
to market our products, including RAPIVAB, obtain collaborators and raise capital.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Patient Protection and Affordable Care Act, or PPACA, made extensive
changes to the delivery of health care in the U.S. The PPACA includes numerous provisions that affect pharmaceutical companies,
some of which became effective immediately and others of which will be taking effect over the next several years. For example,
the PPACA seeks to expand health care coverage to the uninsured through private health insurance reforms and an expansion of Medicaid.
The PPACA will also impose substantial costs on pharmaceutical manufacturers, such as an increase in liability for rebates paid
to Medicaid, new drug discounts that must be offered to certain enrollees in the Medicare prescription drug benefit, an annual
fee imposed on all manufacturers of brand prescription drugs in the U.S., and an expansion of an existing program requiring pharmaceutical
discounts to certain types of hospitals and federally subsidized clinics. The PPACA also contains cost containment measures that
could reduce reimbursement levels for health care items and services generally, including pharmaceuticals. It also will require
reporting and public disclosure of payments and other transfers of value provided by pharmaceutical companies to physicians and
teaching hospitals. We cannot predict what effect the PPACA or other healthcare reform initiatives that may be adopted in the future
will have on our business. Further, it remains unclear whether there will be any changes made to provisions of the PPACA or other
health care laws through acts of Congress in the future. The continuing efforts of the government, insurance companies, managed
care organizations and other payors of health care services to contain or reduce costs of health care could result in decreased
net revenues from our pharmaceutical products and decrease potential returns from our development efforts. In addition, pharmaceutical
and device manufacturers will also be required to report and disclose investment interests held by physicians and their immediate
family members during the preceding calendar year. Failure to submit required information may result in civil monetary penalties
for payments, transfers of value or ownership or investment interests not reported in an annual submission. Compliance with the
PPACA and state laws with similar provisions is difficult and time consuming, and companies that do not comply with these state
laws face civil penalties. Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some
of our business activities could be subject to challenge under one or more of such laws. Such a challenge could have a material
adverse effect on our business, financial condition, results of operations and growth prospects.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, there have been a number of other legislative and regulatory
proposals aimed at changing the pharmaceutical industry. In particular, legislation has been enacted in certain states and proposed
at a federal level that requires development of an electronic pedigree to track and trace each prescription drug at the saleable
unit level through the distribution system. Compliance with these electronic pedigree requirements may increase our operational
expenses and impose significant administrative burdens. In addition, our compliance may be deemed insufficient and we could face
a material adverse effect on our business, financial condition, results of operations and growth prospects.&nbsp;As a result of
these and other new proposals, we may determine to change our current manner of operation, provide additional benefits or change
our contract arrangements, any of which could have a material adverse effect on our business, financial condition and results of
operations.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 26; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Managed care organizations are increasingly challenging the prices
charged for medical products and services and, in some cases, imposing restrictions on the coverage of particular drugs. Many managed
care organizations negotiate the price of medical services and products and develop formularies which establish pricing and reimbursement
levels. Exclusion of a product from a formulary can lead to its sharply reduced usage in the managed care organization&#8217;s
patient population. The process for obtaining coverage can be lengthy and costly, and we expect that it could take several months
before a particular payor initially reviews our product and makes a decision with respect to coverage. For example, third-party
payors may require cost-benefit analysis data from us in order to demonstrate the cost-effectiveness of RAPIVAB or any other product
we might bring to market. For any individual third-party payor, we may not be able to provide data sufficient to gain reimbursement
on a similar or preferred basis to competitive products, or at all which may have a material adverse effect on our business, financial
condition and results of operations. &nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>There are risks related to the potential government use or sale of peramivir
(RAPIVAB).</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">United States Government use or sale of RAPIVAB in emergency situations,
or otherwise, may result in the use of RAPIVAB outside of its approved use. To the extent that RAPIVAB is used as a treatment for
influenza by the U.S. Government or peramivir by any other government entity, there can be no assurance that it will prove to be
generally safe, well-tolerated and effective. Such government use of RAPIVAB/peramivir may create certain liabilities for us or
our partners in the case of government use outside of the U.S. There is no assurance that we or our manufacturers will be able
to fully meet the demand for peramivir in the event of additional orders. Further, we may not achieve a favorable price for additional
orders of RAPIVAB in the U.S. or peramivir in any other country. Our competitors may develop products that could compete with or
replace peramivir. We may face competition in markets where we have no existing intellectual property protection or are unable
to successfully enforce our intellectual property rights.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">There is no assurance that the non-U.S. partnerships that we have
entered into for peramivir will result in any order for peramivir in those countries. There is no assurance that peramivir will
be approved for any use or will achieve market approval in additional countries. In the event that any emergency use or market
approval is granted, there is no assurance that any government order or commercialization of peramivir in any countries will be
substantial or will be profitable to us. In addition, the sale of peramivir, emergency use or other use of peramivir in any country
may create certain liabilities for us and our partners.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20.15pt"><b><i>If we or our partners do not obtain and maintain governmental approvals
for our product candidates under development, we or our partners will not be able to sell these potential products, which would
significantly harm our business because we will receive no revenue.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We or our partners must obtain regulatory approval before marketing
or selling our future product candidates. If we or our partners are unable to receive regulatory approval and do not market or
sell our future product candidates, we will never receive any revenue from such product sales. In the United States, we or our
partners must obtain FDA approval for product candidates that we intend to commercialize. The process of preparing for and obtaining
FDA approval may be lengthy and expensive, and approval is never certain. Products distributed abroad are also subject to foreign
government regulation and export laws of the United States. Because of the risks and uncertainties in biopharmaceutical development,
our product candidates could take a significantly longer time to gain regulatory approval than we expect or may never gain approval.
If the FDA delays regulatory approval of our product candidates, our management&#8217;s credibility, our value and our operating
results may suffer. Even if the FDA or foreign regulatory agencies approve a product candidate, the approval may limit the indicated
uses for a product candidate and/or may require post-approval studies.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The FDA regulates, among other things, the record keeping and storage
of data pertaining to potential pharmaceutical products. We currently store most of our preclinical research data, our clinical
data and our manufacturing data at our facility. While we do store duplicate copies of most of our clinical data offsite and a
significant portion of our data is included in regular backups of our systems, we could lose important data if our facility incurs
damage, or if our vendor data systems fail, suffer damage or are destroyed. If we receive approval to market our potential products,
whether in the United States or internationally, we will continue to be subject to extensive regulatory requirements. These requirements
are wide ranging and govern, among other things:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">adverse drug experience reporting regulations;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">product promotion;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">product manufacturing, including good manufacturing practice requirements;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">product changes or modifications.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our failure to comply with existing or future regulatory requirements,
or our loss of, or changes to, previously obtained approvals, could have a material adverse effect on our business because we will
not receive product or royalty revenues if we or our partners do not receive approval of our products for marketing. &nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Royalties and milestone payments from Shionogi under our license agreement
with Shionogi (the &#8220;Shionogi Agreement&#8221;) will be required to be used by Royalty Sub to service its obligations under
its PhaRMA Notes, and generally will not be available to us for other purposes until Royalty Sub has repaid in full its obligations
under the PhaRMA Notes.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 27; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In March 2011, our wholly-owned subsidiary Royalty Sub issued $30.0
million in aggregate principal amount of PhaRMA Notes. The PhaRMA Notes are secured principally by (i) certain royalty and milestone
payments under the Shionogi Agreement, pursuant to which Shionogi licensed from us the rights to market peramivir in Japan and
Taiwan, (ii) rights to certain payments under a Japanese yen/U.S. dollar foreign currency hedge arrangement put into place by us
in connection with the issuance of the PhaRMA Notes and (iii) the pledge by us of our equity interest in Royalty Sub. Payments
from Shionogi to us under the Shionogi Agreement will generally not be available to us for other purposes until Royalty Sub has
repaid in full its obligations under the PhaRMA Notes. Accordingly, these funds will be required to be dedicated to Royalty Sub&#8217;s
debt service and not available to us for product development or other purposes. As of September 1, 2014, the payments from Shionogi
were insufficient for Royalty Sub to service its obligations under the PhaRMA Notes, resulting in an event of default with respect
to the PhaRMA Notes. As a result of this event of default, the holders of the PhaRMA Notes may be able to pursue acceleration of
the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub and may&nbsp;exercise
other remedies available to them under the indenture or other documents related to&nbsp;the PhaRMA Notes. In such event, we may
not realize the benefit of future royalty payments that might otherwise accrue to us following repayment of the PhaRMA Notes, we
may incur legal costs&nbsp;and we might otherwise be adversely affected.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Because an event of default has occurred under the PhaRMA Notes, the
holders of the PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the
PhaRMA Notes and our equity interest in Royalty Sub, in which case we may not realize the benefit of future royalty payments that
might otherwise accrue to us following repayment of the PhaRMA Notes and we could otherwise be adversely affected.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Royalty Sub&#8217;s ability to service its payment obligations in
respect of the PhaRMA Notes, and our ability to benefit from our equity interest in Royalty Sub, is subject to numerous risks.
Royalty Sub&#8217;s ability to service the PhaRMA Notes may be adversely affected by, among other things, changes in or any termination
of our relationship with Shionogi, reimbursement, regulatory, manufacturing and/or intellectual property issues, product returns,
product recalls, product liability claims and allegations of safety issues, as well as other factors. As Royalty Sub has been unable
to service its obligations under the PhaRMA Notes and an event of default has occurred under the PhaRMA Notes, the holders of the
PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and
our equity interest in Royalty Sub and may&nbsp;exercise other remedies available to them under the indenture&nbsp;or other documents
related to&nbsp;the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise
accrue to us following repayment of the PhaRMA Notes, we may incur legal costs&nbsp;and we might otherwise be adversely affected.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We may be required to pay significant premiums under the foreign currency
hedge arrangement entered into by us in connection with the issuance of the PhaRMA Notes. In addition, because our potential obligations
under the foreign currency hedge are marked to market, we may experience additional quarterly volatility in our operating results
and cash flows attributable to the foreign currency hedge arrangement.&nbsp;</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes,
we entered into a foreign currency hedge arrangement to hedge certain risks associated with changes in the value of the Japanese
yen relative to the U.S. dollar. Under the foreign currency hedge agreement, we may be required to pay an annual premium in the
amount of $2.0 million in each May continuing through May 2020. Such payment will be required if, in May of the relevant year,
the spot rate of exchange for Japanese yen-U.S. dollars (determined in accordance with the foreign currency hedge arrangement)
is such that the U.S. dollar is worth 100 yen or less. We will be required to mark-to-market our potential obligations under the
currency hedge and post cash collateral, which may cause us to experience additional quarterly volatility in our operating results
and cash flows as a result. Additionally, we may be required to pay significant premiums or a termination fee under the foreign
currency hedge agreement entered into by us in connection with the issuance of the PhaRMA Notes. We are required to maintain a
foreign currency hedge at 100 yen per dollar under the agreements governing the PhaRMA Notes.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.25in; background-color: white"><b><i>Our Senior Credit Facility
contains restrictions that limit our flexibility in operating our business. We may be required to make a prepayment or repay the
outstanding indebtedness earlier than we expect if a prepayment event or an event of default occurs, including a material adverse
change with respect to us, which could have a material adverse effect on our business.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0; background-color: white">The Senior Credit Facility contains various
covenants that limit our ability to engage in specified types of transactions. These covenants limit our ability to, among other
things:</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 10.35pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 95%; text-align: justify"><font style="font-size: 10pt">convey, sell, lease, license, transfer or otherwise dispose of certain parts of our business or property;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">change the nature of our business;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">liquidate or dissolve;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">enter into certain change in control or acquisition transactions;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">incur or assume certain debt;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">grant certain types of liens on our assets;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td></td></tr></table>

<!-- Field: Page; Sequence: 28; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%">&nbsp;</td>
    <td style="width: 95%">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">modify, liquidate or transfer assets in certain collateral accounts;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">pay dividends or make certain distributions to our stockholders;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">make certain investments;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">enter into material transactions with affiliates; and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">modify existing debt or collaboration arrangements.</font></td></tr>
</table>
<p style="font-size: 10pt; text-align: justify; text-indent: 27.65pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0; background-color: white">The restrictive covenants contained in the
Senior Credit Facility could cause us to be unable to pursue business opportunities that we or our stockholders may consider beneficial
without the lender&#8217;s permission or without repaying all Senior Credit Facility obligations.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">A breach of any of these covenants could result in an event of default
under the Senior Credit Facility. An event of default will also occur if, among other things, a material adverse change in our
business, operations or condition occurs, which could potentially include negative results in clinical trials, or a material impairment
of the prospect of our repayment of any portion of the amounts we owe under the Senior Credit Facility occurs. In the case of a
continuing event of default under the agreement, the lender could elect to declare all amounts outstanding to be immediately due
and payable, proceed against the collateral in which we granted to the lender a security interest under the Senior Credit Facility,
or otherwise exercise the rights of a secured creditor. Amounts outstanding under the Senior Credit Facility are secured by substantially
all of our assets and those of our subsidiaries, excluding certain specified assets but including proceeds from those assets.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to adequately protect or enforce our intellectual property
rights or secure rights to patents of others, the value of those rights would diminish.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our success will depend in part on our ability and the abilities of
our partners to obtain, protect and enforce viable intellectual property rights including but not limited to trade name, trademark
and patent protection for our Company and its products, methods, processes and other technologies we may license or develop, to
preserve our trade secrets, and to operate without infringing the proprietary rights of third parties both domestically and abroad.
The patent position of biotechnology and pharmaceutical companies is generally highly uncertain, involves complex legal and factual
questions and has recently been the subject of much litigation. Neither the United States Patent and Trademark Office (&#8220;USPTO&#8221;),
the Patent Cooperation Treaty offices, nor the courts of the United States and other jurisdictions have consistent policies nor
predictable rulings regarding the breadth of claims allowed or the degree of protection afforded under many biotechnology and pharmaceutical
patents. Further, we may not have worldwide patent protection for all of our product candidates and our intellectual property rights
may not be legally protected or enforceable in all countries throughout the world. In some jurisdictions, some of our product candidates
in certain programs, including our HAE program, may have short or no composition of matter patent life and we may therefore rely
on orphan drug exclusivity or data exclusivity. There can be no assurance that we will obtain orphan drug exclusivity or data exclusivity
in every jurisdiction. Further, in some jurisdictions, we may rely on formulation patents or method of use patents. Both the ability
to achieve issuance and the enforcement of formulation and method of use patents can be highly uncertain and can vary from jurisdiction
to jurisdiction, and such patents may therefore not adequately prevent competitors and potential infringers in some jurisdictions.
The validity, scope, enforceability and commercial value of the rights protected by such patents, therefore, is highly uncertain.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We also rely on trade secrets to protect technology in cases when
we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to protect. If we cannot maintain
the confidentiality of our technology and other confidential information in connection with our collaborators and advisors, our
ability to receive patent protection or protect our proprietary information may be imperiled.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>We may be involved in lawsuits to protect or enforce our patents, the
patents of our partners or our other intellectual property rights, which could be expensive, time consuming and unsuccessful</i></b>.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Competitors may infringe or otherwise violate our patents, the patents
of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to
file legal claims, which can be expensive and time-consuming and unsuccessful. An adverse result in any litigation or defense proceeding
could put one or more of our patents at risk. Our success depends in part on avoiding the infringement of other parties&#8217;
patents and other intellectual property rights as well as avoiding the breach of any licenses relating to our technologies and
products. In the United States, patent applications filed in recent years are confidential for 18 months, while older applications
are not published until the patent issues. As a result, avoiding patent infringement may be difficult and we may inadvertently
infringe third-party patents or proprietary rights. These third parties could bring claims against us, our partners or our licensors
that even if resolved in our favor, could cause us to incur substantial expenses and, if resolved against us, could additionally
cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, our partners or our licensors,
we or they could be forced to stop or delay research, development, manufacturing or sales of any infringing product in the country
or countries covered by the patent we infringe, unless we can obtain a license from the patent holder. Such a license may not be
available on acceptable terms, or at all, particularly if the third party is developing or marketing a product competitive with
the infringing product. Even if we, our partners or our licensors were able to obtain a license, the rights may be nonexclusive,
which would give our competitors access to the same intellectual property.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 29; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we or our partners are unable or fail to adequately initiate, protect,
defend or enforce our intellectual property rights in any area of commercial interest or in any part of the world where we wish
to seek regulatory approval for our products, methods, processes and other technologies, the value of the product candidates to
produce revenue would diminish. Additionally, if our products, methods, processes, and other technologies or our commercial use
of such products, processes, and other technologies, including but not limited to any trade name, trademark or commercial strategy
infringe the proprietary rights of other parties, we could incur substantial costs. The USPTO and the patent offices of other jurisdictions
have issued to us a number of patents for our various inventions and we have in-licensed several patents from various institutions.
We have filed additional patent applications and provisional patent applications with the USPTO. We have filed a number of corresponding
foreign patent applications and intend to file additional foreign and U.S. patent applications, as appropriate. We have also filed
certain trademark and trade name applications worldwide. We cannot assure you as to:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">the degree and range of protection any patents will afford against competitors with similar products;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">if and when patents will issue;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">if patents do issue we cannot be sure that we will be able to adequately defend such patents and whether or not we will be able to adequately enforce such patents;&nbsp;or</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">whether or not others will obtain patents claiming aspects similar to those covered by our patent applications.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">If the USPTO or other foreign patent office upholds patents issued
to others or if the USPTO grants patent applications filed by others, we may have to:</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">obtain licenses or redesign our products or processes to avoid infringement;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">stop using the subject matter claimed in those patents;&nbsp;or</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">pay damages.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">We may initiate, or others may bring against us, litigation or
administrative proceedings related to intellectual property rights, including proceedings before the USPTO or other foreign patent
office. Any judgment adverse to us in any litigation or other proceeding arising in connection with a patent or patent application
could materially and adversely affect our business, financial condition and results of operations. In addition, the costs of any
such proceeding may be substantial whether or not we are successful.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our success is also dependent upon the skills, knowledge and experience,
none of which is patentable, of our scientific and technical personnel. To help protect our rights, we require all employees, consultants,
advisors and partners to enter into confidentiality agreements that prohibit the disclosure of confidential information to anyone
outside of our company and require disclosure and assignment to us of their ideas, developments, discoveries and inventions. These
agreements may not provide adequate protection for our trade secrets, know-how or other proprietary information in the event of
any unauthorized use or disclosure or the lawful development by others of such information, and if any of our proprietary information
is disclosed, our business will suffer because our revenues depend upon our ability to license or commercialize our product candidates
and any such events would significantly impair the value of such product candidates.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; background-color: white"><b><i>Our failure to comply with data protection
laws and regulations could lead to government enforcement actions and significant penalties against us and adversely impact our
operating results.</i></b></p>

<p style="font-size: 10pt; text-indent: 10.35pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0; background-color: white">European Union (&#8220;EU&#8221;) Member
States, Switzerland and other countries have adopted data protection laws and regulation, which impose significant compliance obligations.&nbsp;For
example, the EU Data Protection Directive, as implemented into national laws by the EU Member States, imposes strict obligations
and restrictions on the ability to collect, analyze and transfer personal data, including health data from clinical trials and
adverse event reporting.&nbsp;Data protection authorities from the different EU Member States may interpret the EU Data Protection
Directive and national laws differently, which adds to the complexity of processing personal data in the European Union, and guidance
on implementation and compliance practices is often updated or otherwise revised.&nbsp;Our failure to comply with these laws and
regulations could lead to government enforcement actions and significant penalties against us and adversely impact our operating
results.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 10.35pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; background-color: white"><b><i>We are subject to periodic litigation, which
could result in losses or unexpected expenditure of time and resources.&nbsp;</i></b></p>

<p style="font-size: 10pt; text-indent: 10.35pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">From time to time, we may be called upon to defend ourselves against
lawsuits relating to our business.&nbsp;Due to the inherent uncertainties in litigation, we cannot accurately predict the ultimate
outcome of any such proceedings.&nbsp;An unfavorable outcome in any such proceedings could have an adverse impact on our business,
financial condition and results of operations.&nbsp;If our stock price is volatile, we may become involved in securities class
action lawsuits in the future.&nbsp;Any litigation in the future, regardless of its merits, could result in substantial costs and
a diversion of management&#8217;s attention and resources that are needed to successfully run our business.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We face an inherent risk of liability in the event that the use or misuse
of our products results in personal injury or death and our product liability insurance coverage may be insufficient.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 30; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If the use or misuse of peramivir or any other regulatory body-approved
products we or a partner may sell in the future harms people, we may be subject to costly and damaging product liability claims
brought against us by consumers, healthcare providers, pharmaceutical companies, third-party payors or others. The use of our product
candidates in clinical trials, including post marketing clinical studies, could also expose us to product liability claims. We
cannot predict all of the possible harms or side effects that may result from the use of our products or the testing of product
candidates and, therefore, the amount of insurance coverage we currently may not be adequate to cover all liabilities or defense
costs we might incur. A product liability claim or series of claims brought against us could give rise to a substantial liability
that could exceed our resources. Even if claims are not successful, the costs of defending such claims and potential adverse publicity
could be harmful to our business.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We face an inherent risk of product liability exposure related to
the testing of our product candidates in human clinical trials and will face even greater risks upon any commercialization by us
of our product candidates. We have product liability insurance covering our commercial sale of peramivir and our clinical trials.
Clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient
insurance or increase our existing coverage at a reasonable cost to protect us against losses that could have a material adverse
effect on our business. An individual may bring a product liability claim against us if one of our products or product candidates
causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any product liability claim brought
against us, with or without merit, could result in:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">liabilities that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">an increase of our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, or at all;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">withdrawal of clinical trial volunteers or patients;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">damage to our reputation and the reputation of our products, resulting in lower sales;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">regulatory investigations that could require costly recalls or product modifications;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">litigation costs;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">the diversion of management&#8217;s attention from managing our business.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Insurance coverage is increasingly more costly and difficult to obtain
or maintain.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">While we currently have insurance for our business, property, directors
and officers, and our products insurance is increasingly more costly and narrower in scope, and we may be required to assume more
risk in the future. If we are subject to claims or suffer a loss or damage in excess of our insurance coverage, we will be required
to bear any loss in excess of our insurance limits. If we are subject to claims or suffer a loss or damage that is outside of our
insurance coverage, we may incur significant uninsured costs associated with loss or damage that could have an adverse effect on
our operations and financial position. Furthermore, any claims made on our insurance policies may impact our ability to obtain
or maintain insurance coverage at reasonable costs or at all.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If our facility incurs damage or power is lost for a significant length
of time, our business will suffer.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We store clinical and stability samples at our facility that could
be damaged if our facility incurs physical damage or in the event of an extended power failure. We have backup power systems in
addition to backup generators to maintain power to all critical functions, but any loss of these samples could result in significant
delays in our drug development process.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, we store most of our preclinical and clinical data at
our facilities. Duplicate copies of most critical data are secured off-site. Any significant degradation or failure of our computer
systems could cause us to inaccurately calculate or lose our data. Loss of data could result in significant delays in our drug
development process and any system failure could harm our business and operations.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>A significant disruption in our information technology systems or a
cyber-security breach could adversely affect our business.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are increasingly dependent on information technology systems to
operate our business. Like other companies in our industry, our networks and infrastructure may be vulnerable to cyber-attacks
or intrusions, including by computer hackers, foreign governments, foreign companies or competitors, or may be breached by employee
error, malfeasance or other disruption. A breakdown, invasion, corruption, destruction or interruption of critical information
technology systems could negatively impact operations.&nbsp;If our systems are damaged, fail to function properly or otherwise
become unavailable, we may incur substantial costs to repair or replace them, and we may experience loss of critical data and interruptions
or delays in our ability to perform critical functions, which could adversely affect our business, financial condition or results
of operations. Any compromise of our data security could also result in a violation of applicable privacy and other laws, significant
legal and financial exposure, damage to our reputation, loss or misuse of the information and a loss of confidence in our data
security measures, which could harm our business. There can be no assurance that our efforts to protect our data and information
technology systems will prevent breakdowns or breaches in our systems, or those of third parties with which we do business, and
any such events could adversely affect our business.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i></i></b></p>

<!-- Field: Page; Sequence: 31; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to retain our existing key personnel or fail to attract and
retain additional key personnel, the development of our product candidates and commercialization of our products and the related
expansion of our business will be delayed or stopped.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are highly dependent upon our senior management and scientific
team, the unexpected loss of whose services might impede the achievement of our development and commercial objectives. Competition
for key personnel with the experience that we require is intense and is expected to continue to increase. Our inability to attract
and retain the required number of skilled and experienced management, commercial, operational and scientific personnel will harm
our business because we rely upon these personnel for many critical functions of our business.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If because of our use of hazardous materials, we violate any environmental
controls or regulations that apply to such materials, we may incur substantial costs and expenses in our remediation efforts.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our research and development involves the controlled use of hazardous
materials, chemicals and various radioactive compounds. We are subject to federal, state and local laws and regulations governing
the use, storage, handling and disposal of these materials and some waste products. Accidental contamination or injury from these
materials could occur. In the event of an accident, we could be liable for any damages that result and any liabilities could exceed
our resources. Compliance with environmental laws and regulations or a violation of such environmental laws and regulations could
require us to incur substantial unexpected costs, which would materially and adversely affect our results of operations. &nbsp;&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Risks relating to investing in our common stock</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Our existing principal stockholders hold a substantial amount of our
common stock and may be able to influence significant corporate decisions, which may conflict with the interest of other stockholders.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Several of our stockholders own greater than 5% of our outstanding
common stock. Our top ten stockholders own more than 50% of BioCryst and can individually, and as a group, influence our operations
based upon their concentrated ownership. These stockholders, if they act together, may be able to influence the outcome of matters
requiring approval of the stockholders, including the election of our directors and other corporate actions.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>Our stock price has been, and is likely to continue to be, highly volatile,
which could result in the value of an investment in our common stock to decline significantly.</i></b> &nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The market prices for securities of biotechnology companies in general
have been highly volatile and may continue to be highly volatile in the future. Moreover, our stock price has fluctuated frequently,
and these fluctuations are often not related to our financial results. For the twelve months ended December 31, 2016, the 52-week
range of the market price of our stock was from $1.63 to $10.24 per share. The following factors, in addition to other risk factors
described in this section, may have a significant impact on the market price of our common stock:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">announcements of technological innovations or new products by us or our competitors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">developments or disputes concerning patents or proprietary rights;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">additional dilution through sales of our common stock or other derivative securities;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">status of new or existing licensing or collaborative agreements and government contracts;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">announcements relating to the status of our programs;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">developments and announcements regarding new and virulent strains of influenza;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">we or our partners achieving or failing to achieve development milestones;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">publicity regarding actual or potential medical results relating to products under development by us or our competitors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">publicity regarding certain public health concerns for which we are or may be developing treatments;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">regulatory developments in both the United States and foreign countries;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 90%"><font style="font-size: 10pt">public concern as to the safety of pharmaceutical products;</font></td>
    <td style="width: 5%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">actual or anticipated fluctuations in our operating results;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom"></td></tr></table>

<!-- Field: Page; Sequence: 32; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%">&nbsp;</td>
    <td style="width: 90%">&nbsp;</td>
    <td style="width: 5%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">changes in financial estimates or recommendations by securities analysts;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">changes in the structure of healthcare payment systems, including developments in price control legislation;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">additions or departures of key personnel or members of our board of directors;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">purchases or sales of substantial amounts of our stock by existing stockholders, including officers or directors;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">economic and other external factors or other disasters or crises; and</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">period-to-period fluctuations in our financial results.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>Future sales and issuances of securities may dilute the ownership interests
of our current stockholders and cause our stock price to decline.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Future sales of our common stock by current stockholders into the
public market could cause the market price of our stock to fall. As of January&nbsp;31, 2017, there were 73,955,169 shares of our
common stock outstanding. We may from time to time issue securities in relation to a license arrangement, collaboration, merger
or acquisition. We may also sell, for our own account, shares of common stock or other equity securities, from time to time at
prices and on terms to be determined at the time of sale.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of January&nbsp;31, 2017, there were 11,835,438 stock options and restricted stock units outstanding,
2,750,318 shares available for issuance under our Amended and Restated Stock Incentive Plan, and 363,646 shares available for issuance
under our Employee Stock Purchase Plan. In addition, we could also make equity compensation grants outside of our Stock Incentive
Plan. The shares underlying existing stock options, restricted stock units and possible future stock options, stock appreciation
rights and stock awards have been registered pursuant to registration statements on Form S-8.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If some or all of such shares are sold or otherwise issued into the
public market over a short period of time, our current stockholders&#8217; ownership interests may be diluted and the value of
all publicly traded shares is likely to decline, as the market may not be able to absorb those shares at then-current market prices.
Additionally, such sales and issuances may make it more difficult for us to sell equity securities or equity-related securities
in the future at a time and price that our management deems acceptable, or at all.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We have anti-takeover provisions in our corporate charter documents
that may result in outcomes with which you do not agree.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our board of directors has the authority to issue up to 4,800,000
shares of undesignated preferred stock and to determine the rights, preferences, privileges and restrictions of those shares without
further vote or action by our stockholders. The rights of the holders of any preferred stock that may be issued in the future may
adversely affect the rights of the holders of common stock. The issuance of preferred stock could make it more difficult for third
parties to acquire a majority of our outstanding voting stock.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, our certificate of incorporation provides for staggered
terms for the members of the board of directors and supermajority approval of the removal of any member of the board of directors
and prevents our stockholders from acting by written consent. Our certificate also requires supermajority approval of any amendment
of these provisions. These provisions and other provisions of our by-laws and of Delaware law applicable to us could delay or make
more difficult a merger, tender offer or proxy contest involving us.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We have never paid dividends on our common stock and do not anticipate
doing so in the foreseeable future.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have never paid cash dividends on our stock. We currently intend
to retain all future earnings, if any, for use in the operation of our business. Accordingly, we do not anticipate paying cash
dividends on our common stock in the foreseeable future.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Information Regarding Forward-Looking Statements</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">This filing contains forward-looking statements within the meaning
of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#8220;safe harbor&#8221; created
in Section&nbsp;21E. All statements other than statements of historical facts contained in this filing are forward-looking statements.
These forward-looking statements can generally be identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221;
&#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221;
&#8220;predicts,&#8221; &#8220;potential,&#8221; the negative of these words or similar expressions. Statements that describe our
future plans, strategies, intentions, expectations, objectives, goals or prospects are also forward-looking statements. Discussions
containing these forward-looking statements are principally contained in &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and
&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; as well as any amendments
we make to those sections in filings with the SEC. These forward-looking statements include, but are not limited to, statements
about:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td>&nbsp;&nbsp;&nbsp;&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the preclinical development, clinical development, commercialization, or post-marketing studies of our product candidates and products, including our HAE program, peramivir, galidesivir, and early stage discovery programs;</font></td>
    </tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    </tr>
<tr>
    <td></td></tr></table>

<!-- Field: Page; Sequence: 33; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    </tr>
<tr>
    <td>&nbsp;&nbsp;&nbsp;&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the potential funding from our contracts with NIAID/HHS and BARDA/HHS for the development of galidesivir;</font></td>
    </tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    </tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the potential for government stockpiling orders of peramivir, additional regulatory approvals of peramivir or milestones royalties or profit from sales of peramivir by us or our partners;</font></td>
    </tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    </tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the potential use of peramivir as a treatment for H1N1, H5N1, and H7N9 or other strains of influenza;</font></td>
    </tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    </tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the implementation of our business model, strategic plans for our business, products, product candidates and technology;</font></td>
    </tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">our ability to establish and maintain collaborations or out-license rights to our drug candidates;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    </tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">plans, programs, progress and potential success of our collaborations, including SUL for peramivir, Mundipharma for forodesine and Shionogi and Green Cross for peramivir in their territories;</font></td>
    </tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    </tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Royalty Sub&#8217;s ability to service its payment obligations in respect of the PhaRMA Notes, and our ability to benefit from our equity interest in Royalty Sub;</font></td>
    </tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    </tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the foreign currency hedge agreement entered into by us in connection with the issuance by Royalty Sub of the PhaRMA Notes;</font></td>
    </tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    </tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</font></td>
    </tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">our ability to operate our business without infringing the intellectual property rights of others;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">estimates of our expenses, revenues, capital requirements, annual cash utilization, and our needs for additional financing;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&#8226;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">our ability to continue as a going concern;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the timing or likelihood of regulatory filings or regulatory agreements, deferrals, and approvals;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">our ability to raise additional capital to fund our operations or repay our recourse debt obligations;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">our ability to comply with the covenants as set forth in the agreements governing our debt obligations;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">our financial performance;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">competitive companies, technologies and our industry.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These statements relate to future events or to our future financial
performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance
or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking
statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those
listed under &#8220;Risk Factors.&#8221; Any forward-looking statement reflects our current views with respect to future events
and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry
and future growth. Except as required by law, we assume no obligation to update or revise these forward-looking statements for
any reason, even if new information becomes available in the future.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><font style="font-size: 10pt"><b><a name="a_003"></a>ITEM 1B.</b></font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt"><b> <i>UNRESOLVED STAFF COMMENTS</i></b></font></td>
</tr></table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">None.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><font style="font-size: 10pt"><b><a name="a_004"></a>ITEM 2.</b></font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt"><b> <i>PROPERTIES</i></b></font></td>
</tr></table>
<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We lease property in both Durham, North Carolina and Birmingham, Alabama.
Our headquarters, including our clinical and regulatory operations, are based in Durham, while our principal research facility
is located in Birmingham. We currently lease approximately 15,000 square feet in Durham through June 30, 2020 and lease approximately
32,000 square feet in Birmingham through October 31, 2026. We believe that our facilities are adequate for our current and planned
future operations.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><font style="font-size: 10pt"><b><a name="a_005"></a>ITEM 3.</b></font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt"><b> <i>LEGAL PROCEEDINGS</i></b></font></td>
</tr></table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">None.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 34; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><font style="font-size: 10pt"><b><a name="a_006"></a>ITEM 4.</b></font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt"><b> <i>MINE SAFETY DISCLOSURES</i></b></font></td>
</tr></table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Not applicable.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>PART&nbsp;II</b></p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><font style="font-size: 10pt"><b><a name="a_007"></a>ITEM 5.</b></font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt"><b> <i>MARKET FOR REGISTRANT&#8217;S COMMON EQUITY,
RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</i></b></font></td>
</tr></table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><u>Market Information</u></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our common stock trades on the NASDAQ Global Select Market under the
symbol BCRX. The following table sets forth the low and high sales prices of our common stock as reported by the NASDAQ Global
Select Market for each quarter in 2016 and 2015:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 85%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-size: 10pt; text-align: left">First quarter</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">1.63</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">10.24</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">7.85</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">12.71</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Second quarter</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2.49</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">4.03</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">8.50</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">16.43</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Third quarter</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2.82</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">5.80</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">10.26</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">16.83</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Fourth quarter</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">3.75</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">7.56</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">8.01</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">12.88</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The last sale price of the common stock on January&nbsp;31, 2017 as
reported by the NASDAQ Global Select Market was $6.30 per share.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><u>Holders</u></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of January&nbsp;31, 2017, there were approximately 182 holders
of record of our common stock.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><u>Dividends</u></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have never paid cash dividends and do not anticipate paying cash
dividends in the foreseeable future.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><u>Stock Performance Graph</u></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">This performance graph is not &#8220;soliciting material,&#8221; is
not deemed filed with the SEC and is not to be incorporated by reference in any filing by us under the Securities Act or the Exchange
Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. The
stock price performance shown on the graph is not necessarily indicative of future price performance.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 0.25in"><b>PERFORMANCE GRAPH FOR BIOCRYST</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Indexed Comparison Since 2011</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><img src="graph.jpg" alt=""></p>


<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Beginning<br> Investment<br> 12/31/11</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Investment<br> at 12/31/12</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Investment<br> at 12/31/13</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Investment<br> at 12/31/14</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Investment<br> at 12/31/15</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Investment<br> at 12/31/16</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; font-size: 10pt; text-align: left">BioCryst Pharmaceuticals, Inc.</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">100.00</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">57.49</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">307.69</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">492.31</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">417.81</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">256.28</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">NASDAQ Stock Market (U.S.)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">100.00</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">116.43</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">155.41</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">174.78</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">175.62</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">198.47</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">NASDAQ&nbsp;Pharmaceutical&nbsp;Stocks</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">100.00</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">114.32</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">155.11</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">188.95</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">199.22</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">197.05</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The above graph measures the change in a $100 investment in our common
stock based on its closing price of $2.47 on December&nbsp;31, 2011 and its year-end closing price thereafter. Our relative performance
is then compared with the CRSP Total Return Indexes for the NASDAQ Stock Market (U.S.) and NASDAQ Pharmaceutical Stocks.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>


<!-- Field: Page; Sequence: 35; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->
<p style="font-size: 10pt; margin: 0pt 0"><b>Recent Sales of Unregistered Securities: None.</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Issuer Purchases of Equity Securities</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">There were no repurchases of our common stock or shares surrendered
to satisfy tax obligations during the fourth quarter of 2016.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><font style="font-size: 10pt"><b><a name="a_008"></a>ITEM 6.</b></font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt"><b> <i>SELECTED FINANCIAL DATA</i></b></font></td>
</tr></table>
<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The selected Statement of Operations Data and Balance Sheet data with
respect to the years ended December&nbsp;31, 2016, 2015, 2014, 2013, and 2012 set forth below are derived from our consolidated
financial statements. The selected financial data set forth below should be read in conjunction with &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations&#8221; contained in Item&nbsp;7 below and our consolidated
financial statements and the notes thereto appended to this annual report.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended December&nbsp;31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center">(In thousands, except per share amounts)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Statement of Operations Data:</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 35%; font-size: 10pt; text-align: left">Total revenues</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">26,353</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">48,257</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">13,608</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">17,331</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">26,293</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Cost of product sold</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,297</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,368</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Research and development expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">61,008</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">72,758</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">51,796</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">41,943</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">49,160</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">General and administrative expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11,253</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">13,047</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,461</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,007</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,130</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Royalty expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">402</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">528</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">121</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">98</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">132</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Restructuring costs</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,759</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Loss from operations</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(48,607</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(39,444</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(45,771</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(30,717</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(33,888</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Net loss</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(55,144</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(43,019</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(45,189</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(30,108</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(39,081</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Basic and diluted net loss per share</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(0.75</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(0.59</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(0.68</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(0.55</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(0.79</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Weighted average shares outstanding</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">73,699</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">72,901</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">66,773</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">55,216</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">49,474</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table>



<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of December&nbsp;31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center">(In thousands)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Balance Sheet Data:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 35%; font-size: 10pt; text-align: left">Cash, cash equivalents and investments</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">65,122</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">100,858</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">114,038</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">40,788</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">37,058</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Receivables</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,768</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,243</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,490</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,115</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,562</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Inventory</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">500</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,612</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">683</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Total assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">89,847</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">122,359</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">134,238</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">45,791</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">53,925</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Long-term deferred revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,184</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,674</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,552</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,736</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,920</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Non-recourse notes payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">28,243</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">27,804</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">27,364</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">26,925</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">26,486</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Senior credit facility</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22,777</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Accumulated deficit</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(566,061</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(510,917</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(467,898</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(422,709</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(392,601</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total stockholders&#8217; equity (deficit)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,578</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">47,724</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">75,635</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,126</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(454</td><td style="font-size: 10pt; text-align: left">)</td></tr>
</table>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><font style="font-size: 10pt"><b><a name="a_009"></a>ITEM 7.</b></font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt"><b> <i>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS</i></b></font></td>
</tr></table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>This Annual Report on Form&nbsp;10-K contains certain statements
of a forward-looking nature relating to future events or the future financial performance of BioCryst. Such statements are only
predictions and the actual events or results may differ materially from the results discussed in the forward-looking statements.
Factors that could cause or contribute to such differences include those discussed below and elsewhere in this report, as well
as those discussed in other filings made by BioCryst with the Securities and Exchange Commission.</i></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i></i></p>

<!-- Field: Page; Sequence: 36; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>The following Management&#8217;s Discussion and Analysis (&#8220;MD&amp;A&#8221;)
is intended to help the reader understand our results of operations and financial condition. MD&amp;A is provided as a supplement
to, and should be read in conjunction with, our audited financial statements and the accompanying notes to the financial statements
and other disclosures included in this Annual Report on Form&nbsp;10-K (including the disclosures under &#8220;Item&nbsp;1A. Risk
Factors&#8221;).</i></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Cautionary Statement</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The discussion herein contains forward-looking statements within the
meaning of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#8220;safe harbor&#8221;
created in Section&nbsp;21E. Forward looking statements regarding our financial condition and our results of operations that are
based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted
within the United States (&#8220;U.S. GAAP&#8221;), as well as projections for the future. The preparation of these financial statements
requires our management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses,
and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis. Our estimates are based
on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The results
of our estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We operate in a highly competitive environment that involves a number
of risks, some of which are beyond our control. We are subject to risks common to biotechnology and biopharmaceutical companies,
including risks inherent in our drug discovery, drug development and commercialization efforts, clinical trials, uncertainty of
regulatory actions and marketing approvals, reliance on collaborative partners, enforcement of patent and proprietary rights, the
need for future capital, competition associated with products, potential competition associated with our product candidates and
retention of key employees. In order for any of our product candidates to be commercialized, it will be necessary for us, or our
collaborative partners, to conduct clinical trials, demonstrate efficacy and safety of the product candidate to the satisfaction
of regulatory authorities, obtain marketing approval, enter into manufacturing, distribution and marketing arrangements, and obtain
market acceptance and adequate reimbursement from government and private insurers. We cannot provide assurance that we will generate
significant revenues or achieve and sustain profitability in the future. In addition, we can provide no assurance that we will
have sufficient funding to meet our future capital requirements. Statements contained in Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations and elsewhere in this report which are not historical facts are, or may constitute,
forward-looking statements. Forward-looking statements involve known and unknown risks that could cause our actual results to differ
materially from expected results. The most significant known risks are discussed in the section entitled &#8220;Risk Factors.&#8221;
Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements.&nbsp;We caution you not to place undue reliance on any forward-looking statements.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our revenues are difficult to predict and depend on numerous factors,
including the prevalence and severity of influenza in regions for which peramivir has received regulatory approval, seasonality
of influenza, ongoing discussions with government agencies regarding future peramivir and/or galidesivir development and stockpiling
procurement, as well as entering into, or modifying, licensing agreements for our product candidates. Furthermore, revenues related
to our collaborative development activities are dependent upon the progress toward and the achievement of developmental milestones
by us or our collaborative partners.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our operating expenses are also difficult to predict and depend on
several factors, including research and development expenses (and whether these expenses are reimbursable under government contracts),
drug manufacturing, and clinical research activities, the ongoing requirements of our development programs, and the availability
of capital and direction from regulatory agencies, which are difficult to predict. Management may be able to control the timing
and level of research and development and general and administrative expenses, but many of these expenditures will occur irrespective
of our actions due to contractually committed activities and/or payments.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As a result of these factors, we believe that period to period comparisons
are not necessarily meaningful and you should not rely on them as an indication of future performance. Due to all of the foregoing
factors, it is possible that our operating results will be below the expectations of market analysts and investors. In such event,
the prevailing market price of our common stock could be materially adversely affected.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Overview</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are a biotechnology company that designs, optimizes and develops
novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. We focus on the treatment of rare diseases
in which significant unmet medical needs exist and align with our capabilities and expertise. We integrate the disciplines of biology,
crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process
known as structure-guided drug design.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>Critical Accounting Policies and Estimates</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The accompanying discussion and analysis of our financial condition
and results of operations are based upon our consolidated financial statements and the related disclosures, which have been prepared
in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments
that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities.
We evaluate our estimates, judgments and the policies underlying these estimates on a periodic basis, as situations change, and
regularly discuss financial events, policies, and issues with members of our audit committee and our independent registered public
accounting firm. We routinely evaluate our estimates and policies regarding revenue recognition, administration, inventory and
manufacturing, taxes, stock-based compensation, research and development, consulting and other expenses and any associated liabilities.</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<p style="font-size: 10pt; margin: 0pt 0"><B>Recent Corporate Highlights</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 9pt"><B><I>RAPIVAB/RAPIACTA/PERAMIFLU/ALPIVAB (peramivir injection)</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Peramivir (i.e., product sold or marketed under the RAPIVAB, RAPIACTA,
and PERAMIFLU trade names) is approved for commercial sale in the United States, Canada, Japan, Taiwan and Korea and has a pending
approval in the European Union. We receive royalty revenue from commercial and governmental stockpiling sales of the product from
our partners with the exception of U.S. Government stockpiling sales for which we remain directly responsible. In 2016, our Japanese
partner, Shionogi, fulfilled a relatively large stockpiling order to the Japanese government in advance of the 2016/2017 influenza
season for which we recorded $5.7 million of net royalties. Although this was not the first Japanese Government order, it represented
the largest sales volume in a fiscal year from RAPIACTA&#8217;s history of availability. Proceeds from these stockpiling sales
to the Japanese Government are available to us for general corporate use and are not dedicated to satisfying non-recourse obligations
under the PhaRMA Notes.</P>


<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 37; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><FONT STYLE="font-size: 10pt">On January 8, 2017, we announced that
Health Canada approved RAPIVAB<B><SUP>&#174; </SUP></B>for treatment of acute, uncomplicated influenza in Canada</FONT>. <FONT STYLE="font-size: 10pt">On
January 30, 2017, we announced that the European Medicines Agency (&#8220;EMA&#8221;) accepted our Marketing Authorization Application
(&#8220;MAA&#8221;) for treatment of symptoms typical of influenza in adults 18&nbsp;years and older. The acceptance of the MAA
begins the review process by the EMA under the centralized licensing procedure for all 28 member states of the European Union,
Norway and Iceland.</FONT></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0"><b><i>BCX7353</i></b> </p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">In August 2016, we announced that we had dosed the first subject
in the APeX-1 clinical trial of BCX7353 for the oral treatment of HAE. APeX-1 is a multi-part, Phase 2, randomized, double-blind,
placebo-controlled, dose ranging trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of
BCX7353 as a preventative treatment to eliminate or reduce the frequency of angioedema attacks in HAE patients. APEX-1 is being
conducted in several European countries, Australia and Canada. In part 1 of APeX-1, subjects with HAE were randomized in a 1:1
ratio to receive an oral dose of either 350 mg of BCX7353 once daily (&ldquo;QD&rdquo;) or placebo QD for 28 days. The primary
efficacy endpoints of APeX-1 are the number of angioedema attacks; attack rate per week, counts of attacks, proportion of subjects
with no attacks, and number of attack-free days. Efficacy analyses will be conducted for HAE attacks reported over the entire
dosing interval (Days 1 through 28) and during the dosing period in which plasma concentrations of BCX7353 should be at steady-state
conditions (Days 8 through 28). Secondary efficacy endpoints include severity and duration of angioedema attacks and measures
of health-related quality of life. Safety will be characterized through evaluation of adverse events and laboratory testing. Pharmacokinetics
and pharmacodynamic effects will be assessed through measurement of plasma drug levels and kallikrein inhibition. A total of approximately
36 subjects have been enrolled in part 1.</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0; background-color: white">On February 27, 2017, we reported statistically
significant and clinically meaningful reductions in attack frequency from an interim analysis of part 1 of our ongoing multi-part
APeX-1 clinical trial in HAE patients. In the interim analysis, twenty-eight subjects, randomized equally to receive BCX7353 350&nbsp;mg
QD or placebo for 28 days. The baseline attack rate was approximately 1/week and average C1 inhibitor levels were less than
20% of the normal mean, indicating a severely affected patient population. Baseline characteristics of trial participants were
generally well balanced between the two groups with the exception of prior androgen use, which was more common in the BCX7353 group
(11 of 14 compared with 6 of 14 on placebo). Compliance with study drug dosing in the trial was excellent and was greater than
98%.</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0; background-color: white">The pre-specified per-protocol (&ldquo;PP&rdquo;)
interim analysis included data on 24 subjects with confirmed Type 1 or Type 2 HAE and completing 28 days of treatment (11 on BCX7353
and 13 on placebo). The mean rate of independently-adjudicated angioedema attacks for the pre-defined effective dosing period (weeks
2 through 4) in BCX7353-treated subjects was 0.34/week compared to 0.92/week for placebo, a reduction of 0.57/week (63%), p&nbsp;=&nbsp;0.006.
In the intent-to-treat (&ldquo;ITT&rdquo;) population of 28 subjects, the rate of attack for the effective dosing period for BCX7353
and placebo groups was 0.44/week and 0.91/week, a reduction of 0.47/week (52%), p&nbsp;=&nbsp;0.035.</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0; background-color: white">A pre-planned analysis of peripheral and
abdominal attacks showed reductions of 88% and 24%, respectively, for BCX7353 compared with placebo (PP analysis, weeks 2 through
4). To understand this difference, patient diaries were reviewed and abdominal attacks (n&nbsp;=&nbsp;9, BCX7353 and n&nbsp;=&nbsp;14,
placebo) were subdivided into two groups: attacks with abdominal symptoms only and attacks with a combination of abdominal and
peripheral symptoms (mixed attacks). This post-hoc analysis showed that there were 2, 2 and 7 peripheral, mixed and abdominal-only
attacks on BCX7353 compared with 22, 12 and 2 attacks, respectively, for placebo. Based on this distribution, it is likely that
subjects recorded abdominal adverse events as HAE attack symptoms in their diary. Accordingly, this post-hoc analysis
indicated an 88% reduction in the number of attacks for subjects treated with BCX7353, as compared to the placebo arm, characterized
by either peripheral symptoms-only or a combination of peripheral and abdominal symptoms.</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Pharmacokinetic and pharmacodynamic analyses indicate steady state
BCX7353 plasma levels in HAE subjects were similar to those in healthy subjects administered the same dose in a previously completed
Phase 1 trial. Steady state trough drug levels (24 hours after dosing) were 11&nbsp;&ndash;&nbsp;32 times the 50% effective concentration
(EC<SUB>50</SUB>) for plasma kallikrein inhibition. These observed steady state drug levels greatly exceeded our proposed therapeutic
target range of 4&nbsp;&ndash;&nbsp;8 times the EC<SUB>50. </SUB>Daily oral dosing with BCX7353 strongly inhibited plasma kallikrein
throughout the 24-hour dosing interval and the degree of inhibition was similar to that seen with this dose in the healthy subject
Phase 1 trial.</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0; background-color: white">Oral BCX7353 350 mg QD for 28 days
was generally safe and well tolerated in subjects with HAE. There were no serious adverse events (AEs) and no related severe
AEs. Two subjects in the BCX7353 treatment group discontinued study drug before day 28, one due to an unrelated pre-existing
liver disorder, and one due to an adverse event of gastroenteritis associated with elevated liver enzymes. Treatment-emergent
adverse events occurring in at least two subjects overall, enumerated by treatment group (BCX7353 [n=14] and placebo [n=14]),
respectfully, were: common cold (3,&nbsp;4); diarrhea (4, 2); flatulence (2,&nbsp;0); and fatigue (2,&nbsp;0). No clinically
significant changes in hematology parameters, renal function tests, electrolytes, or urinalysis were observed. One subject
treated with BCX7353, with pre-existing colitis, hepatic steatosis (i.e., a fatty liver) and more than 20 years of prior
androgen use, had an elevation of alanine aminotransferase (ALT) &gt; 3 times the upper limit of normal at the end of
treatment, which resolved.</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Based upon this interim analysis, the efficacy, safety and
tolerability profile of BCX7353 observed strongly supports its continued development as a prophylactic treatment for HAE.
Furthermore, the steady state drug levels observed greatly exceeded our proposed therapeutic target range of
4&nbsp;&ndash;&nbsp;8 times the EC<SUB>50</SUB>, thereby supporting and prompting us to evaluate doses of BCX7353 lower than
the 350 QD tested in part 1 of the trial. Therefore, the APeX-1 trial has been amended to add a 62.5 mg QD dose level, and to
increase the number of subjects at the 125&nbsp;mg QD and 250&nbsp;mg&nbsp;QD dose levels, in order to more fully
characterize dose response. Specifically, part 2 of APeX-1 will enroll 14 additional subjects with HAE and they will be
randomized to 250mg of BCX7353 QD (n=6), 125mg of BCX7353 QD (n=6) or placebo (n=2) and part 3 of APeX-1 will enroll 20
additional subjects with HAE and they will be randomized to 250mg of BCX7353QD (n=6), 125mg of BCX7353 QD (n=6), 62.5mg of
BCX7353 QD (n=6) or placebo (n=2).</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>Avoralstat</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 20pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">On February 8, 2016, we announced results from OPuS-2. In the
OPuS-2 study, HAE patients with a historical attack frequency of greater than 0.45 attacks per week were randomized to treatment
with either 500 mg or 300 mg of avoralstat, or placebo, administered three times daily for 12 weeks. Treatment with 500 mg and
300 mg of avoralstat three times daily failed to demonstrate a statistically significantly lower mean attack rate versus placebo.
The mean (standard deviation) attack rates per week were 0.63 (0.57) on avoralstat 500mg and 0.71 (0.66) on avoralstat 300mg,
compared to 0.61 (0.41) on placebo. Statistically significant improvements in duration of attacks and in the Angioedema Quality
of Life total score were observed comparing the 500 mg three times a day avoralstat arm to placebo. Following the analysis of
OPuS-2 results, the decision was made to discontinue further development of the softgel avoralstat formulation in order to focus
development efforts on novel dosage forms of avoralstat to achieve meaningfully better drug exposure.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 38; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">In August 2016, we reported a clinical pharmacology study of several
avoralstat dosage formulations. Cohorts of healthy volunteers received single doses of avoralstat ranging from 200 mg to 2000 mg
in tablet or suspension formulations, with no clinically significant adverse events reported. While these formulations improved
total avoralstat exposure (AUC) up to approximately five-fold compared to a 500 mg dose given as soft gel capsules, the plasma
concentration-time profile has not met our objectives of twice-daily dosing with drug levels at or above the target range. For
that reason, we decided to stop further development of avoralstat.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 20pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><B><I>Galidesivir (formerly BCX4430)</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March 7, 2016, results from a preclinical study of our antiviral
galidesivir in interferon-receptor-deficient mice infected with Zika virus were presented at a World Health Organization conference
in Geneva, Switzerland. The primary goal of the study was to assess the effect of galidesivir treatment on survival through Day
28 in interferon-receptor-deficient mice infected with the Zika virus. Galidesivir was administered by i.m. injection twice a day
beginning four hours prior to virus challenge and continuing for eight days; two dose levels were tested. In the standard dose
galidesivir group, 7 of 8 mice survived through Day 28. In the low dose galidesivir group (n=8), and in control groups administered
vehicle placebo (n=8) or ribavirin at two dose levels (n=16), no animals survived to Day 28. Overall survival for the standard
dose level of galidesivir was superior to both the placebo and the ribavirin treatment control groups (p &lt; 0.0001). For both
dose levels of galidesivir, median survival was superior to both control groups (&gt;28 days for galidesivir standard dose and
23 days for low dose) compared to 14 to 17 days for controls.</P>


<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Additional studies of galidesivir in the same mouse model were
conducted at Utah State University. In one study, surviving mice that were previously treated with the standard dose of galidesivir
after initial Zika virus challenge, were re-challenged with the Zika virus on Day 28, without additional galidesivir treatment.
All the re-challenged mice survived through day 56 with no disease signs observed, indicating the development of effective immune
responses. A further experiment using the same AG129 mouse model tested the delayed treatment with galidesivir after viral challenge.
Groups of mice received galidesivir 150 mg/kg twice-daily by i.m. injection starting on days 1, 3, 5, or 7 post infection, or vehicle
(control group). All galidesivir treated groups showed a statistically significant survival benefit compared to vehicle controls.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">On October 29, 2016, galidesivir nonclinical
results from a Zika virus infection model were presented in a late-breaker scientific session at IDWeek by Dr. James B. Whitney,
PhD, Assistant Professor of Medicine, Harvard Medical School, and Principal Investigator in the Center for Virology and Vaccine
Research at Beth Israel Deaconess Medical Center in Boston. Three groups of five healthy rhesus macaques were inoculated with
a Puerto Rico strain of Zika virus and administered either galidesivir by i.m. injection 100 mg/kg BID loading dose followed by
25 mg/kg BID for nine days, galidesivir loading dose of 100 mg/kg BID, or vehicle control. Both galidesivir groups showed reduction
in the proportion of animals viremic and in the amount of virus shed of into cerebrospinal fluid, saliva and urine. Galidesivir
dosing in rhesus macaques was well-tolerated and offered significant protection against Zika virus infection. In a follow-on experiment,
the same animals were rechallenged with a Thai strain of Zika virus, 72 days after initial inoculation. All animals demonstrated
immune responses, and the initial treatments with galidesivir did not impair the generation of immunity.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><u>Results of Operations</u></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Year Ended December&nbsp;31, 2016 Compared to 2015</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Total 2016 revenues decreased to $26.4 million as compared to
2015 revenues of $48.3 million. The decrease in 2016 revenues, as compared to 2015, was primarily due to the RAPIVAB
out-licensing transaction to Seqirus, which resulted in the recognition of $21.8 million of collaborative revenue in 2015 and
a $4.0 million decrease in 2016 RAPIVAB product sales, as well as a reduction in collaboration revenue associated with lower
galidesivir development activity in 2016. All of these decreases were slightly offset by a $7.3 million increase in 2016
peramivir royalty revenue derived from BioCryst&rsquo;s commercial partners. A component of the peramivir royalty revenue was
$5.7 million of Japanese government stockpiling revenue that is available for general corporate use. Although these orders
provided a significant cash infusion, stockpiling royalty revenues may not recur on an annual basis as they are subject to
the Japanese government&rsquo;s appropriation and stockpiling process, which is difficult to predict. Revenues in 2016
included $2.3 million of peramivir product revenue from inventory sales to our commercial partners, $9.7 million of royalty
revenue from SUL, Shionogi and Green Cross associated with sales of peramivir in the United States, Japan, Korea and Taiwan,
$9.5 million of reimbursement of collaborative expenses from NIAID/HHS and BARDA/HHS related to the development of
galidesivir, $2.9 million of reimbursement of collaborative expenses from BARDA/HHS related to the development of RAPIVAB and
$1.8 million associated with collaborative revenue amortization from other corporate partnerships. The 2015 revenue consisted
of $5.7 million of RAPIVAB product revenue and $21.8 million of collaborative revenue related to the SUL Agreement, $2.4
million of royalty revenue from SUL, Shionogi and Green Cross associated with sales of peramivir in the United States, Japan
and Korea, $16.3 million of reimbursement of collaborative expenses from BARDA/HHS and NIAID/HHS related to the development
of peramivir and galidesivir, and $1.4 million associated with collaborative revenue amortization from other
corporate partnerships. In addition, we recorded approximately $0.6 million of RAPIVAB revenue under the
&ldquo;Sell-Through&rdquo; revenue recognition methodology, but going forward we will recognize all future commercial RAPIVAB
sales as royalty revenue under one of our partnership arrangements. With the expiration of BARDA/HHS peramivir contract,
unless we enter into new government contracts, all significant and future reimbursement of collaborative expenses will be
under the NIAID/HHS and BARDA/HHS galidesivir development contracts. Our RAPIVAB revenue will be difficult to predict because
of volatility in prevalence, timing and severity of influenza season to season.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Research and Development (&#8220;R&amp;D&#8221;)
expenses decreased to $61.0 million in 2016 from $72.8 million in 2015. The decrease in 2016 R&amp;D expenses, as compared to
2015, reflects lower spending on our HAE portfolio of compounds associated with the discontinuation of avoralstat
development.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following table summarizes our R&amp;D expenses for the periods
indicated (amounts are in thousands).</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 12pt"></p>

<table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 85%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">R&amp;D expenses by program:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 55%; font-size: 10pt; text-indent: 10pt">Avoralstat</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">13,433</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">27,769</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">19,005</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-indent: 10pt">BCX7353</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">21,410</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11,819</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: 10pt">Other 2nd generation HAE compounds</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,139</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,320</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11,681</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-indent: 10pt">Galidesivir</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,458</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">12,400</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">13,060</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: 10pt">Peramivir</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,552</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,690</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,898</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-indent: 10pt">Other research, preclinical and development costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,016</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,760</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,152</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: 10pt">Total R&amp;D expenses</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">61,008</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">72,758</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">51,796</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<!-- Field: Page; Sequence: 39; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">R&amp;D expenses include all direct and indirect expenses and are
allocated to specific programs at the point of development of a lead product candidate. Direct expenses are charged directly to
the program to which they relate and indirect expenses are allocated based upon internal direct labor hours dedicated to each respective
program. Direct expenses consist of compensation for R&amp;D personnel and costs of outside parties to conduct laboratory studies,
develop manufacturing processes, manufacture the product candidates, conduct and manage clinical trials, as well as other costs
related to our clinical and preclinical studies. Indirect R&amp;D expenses consist of lab supplies and services, facility expenses,
depreciation of development equipment and other overhead of our research and development efforts. R&amp;D expenses vary according
to the number of programs in clinical development and the stage of development of our clinical programs. Later stage clinical programs
tend to cost more than earlier stage programs due to the longer length of time of the clinical trials and the higher number of
patients enrolled in these clinical trials.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Selling, General and administrative (&#8220;SG&amp;A&#8221;) expenses
decreased to $11.3 million in 2016 compared to $13.0 million in 2015. The decrease of $1.7 million was primarily due to lower unrestricted
grants awarded to HAE patient advocacy groups, as well as a general reduction of administrative expenses in 2016.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest expense increased to $6.5 million in 2016 primarily associated
with our execution of a $23.0 million Senior Credit Facility with an affiliate of MidCap Financial Services, LLC (&ldquo;MidCap&rdquo;)
in September 2016 (the &ldquo;Senior Credit Facility&rdquo;), as compared to $5.2 million in 2015. In addition, a mark to market
loss of $1.7 million was recognized in 2016 related to the foreign currency hedge entered into in conjunction with the royalty
monetization transaction, compared to a mark to market loss of $0.6 million in 2015, both resulting from changes in the U.S. dollar/Japanese
yen exchange rate during the respective years. In addition, realized currency exchange gains of $0.8 million and $1.7 million
were recognized in 2016 and 2015, respectively, related to the exercise of a U.S. dollar/Japanese yen currency option under our
foreign currency hedge. Thus, a resulting net loss of $0.8 million is recognized on our foreign currency derivative for 2016 compared
to a net gain of $1.1 million for 2015. We entered into a foreign currency hedge agreement to hedge changes in the value of the
Japanese yen relative to the U.S. dollar. The currency hedge does not qualify for hedge accounting treatment and therefore mark
to market adjustments are recognized in our Consolidated Statements of Comprehensive Loss. Although we cannot predict the future
yen/dollar exchange rate, the applicable foreign currency rates moved such that we currently have no collateral posted; however,
it is possible that collateral will be required to be posted in the future. We are unable to predict future changes in the yen/dollar
exchange rate or increases/decreases in our hedge gains/losses associated with the currency hedge agreement.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Year Ended December&nbsp;31, 2015 Compared to 2014</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Total 2015 revenues increased to $48.3 million as compared to
2014 revenues of $13.6 million. The increase in 2015 was primarily due to recognizing revenue associated with the SUL
out-licensing transaction, RAPIVAB product revenue and increased collaboration revenue associated with galidesivir
development. The 2015 revenue consisted of $5.7 million of RAPIVAB product revenue and $21.8 million of collaborative revenue
related to the SUL Agreement, $2.4 million of royalty revenue from SUL, Shionogi and Green Cross associated with sales of
peramivir in the United States, Japan and Korea, $16.3 million of reimbursement of collaborative expenses from BARDA/HHS and
NIAID/HHS related to the development of peramivir and galidesivir, and $1.4 million associated with collaborative revenue
amortization from other corporate partnerships. In addition, we recorded approximately $0.6 million of RAPIVAB revenue under
the &#8220;Sell-Through&#8221; revenue recognition methodology, but going forward will recognize all future commercial
RAPIVAB sales as royalty revenue under one of our partnership arrangements. RAPIVAB was available for commercial sale in the
U.S. on December 26, 2014. The 2014 revenue consisted of $3.0 million of royalty revenue from Shionogi and Green Cross
associated with sales of peramivir in Japan and Korea, $9.4 million of reimbursement of collaborative expenses from BARDA/HHS
related to the development of peramivir, $1.2 million associated with collaborative revenue amortization from other corporate
partnerships and $33,000 of RAPIVAB revenue. With the expiration of BARDA/HHS peramivir contract, unless we enter into new
government contracts, all significant and future reimbursement of collaborative expenses will be under the NIAID/HHS and
BARDA/HHS galidesivir development contracts. Our RAPIVAB revenue will be difficult to predict because of volatility
in prevalence, timing and severity of influenza season to season.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">R&amp;D expenses increased to $72.8 million in 2015 from $51.8 million
in 2014. 2015 R&amp;D expenses, compared with 2014, reflect increased spending on our HAE programs and slightly higher spending
on our RAPIVAB program. In addition, our 2014 equity compensation expense allocated to R&amp;D increased due to the vesting of
two underlying milestones under previously issued performance-based stock options for the successful outcome of OPuS-1 and RAPIVAB
approval in the U.S.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">SG&amp;A expenses increased to $13.0 million in 2015 compared to $7.5
million in 2014. The increase of $5.5 million is primarily associated with increased marketing and medical affairs activities associated
with our HAE programs, as well as unrestricted grants awarded to the U.S. and international HAE patient advocacy groups.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest expense, related to the non-recourse notes issued in conjunction
with the peramivir royalty monetization transaction in March 2011, increased slightly to $5.2 million in 2015 as compared to $5.0
million in 2014. In addition, a mark to market loss of $0.6 million was recognized in 2015 related to the foreign currency hedge
entered into in conjunction with the royalty monetization transaction, compared to a mark to market gain of $5.5 million in 2014,
both resulting from changes in the U.S. dollar/Japanese yen exchange rate during the respective years. In addition, a realized
currency exchange gain of $1.7 million was recognized in 2015 related to the exercise of a U.S. dollar/Japanese yen currency option
under our foreign currency hedge. Thus, a resulting $1.1 million net gain is recognized on our foreign currency derivative for
2015.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 40; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Cash expenditures have exceeded revenues since our inception and
we expect our 2017 operating expenses to exceed our 2017 revenues. Our operations have principally been funded through public
offerings and private placements of equity securities; cash from collaborative and other research and development agreements,
including U.S. Government contracts for RAPIVAB and galidesivir; and to a lesser extent, the PhaRMA Notes financing and the Senior
Credit Facility. To date, we have been awarded a BARDA/HHS RAPIVAB development contract totaling $234.8 million, which expired
on June 30, 2014, a NIAID/HHS galidesivir development contract totaling $39.5 million, which is ongoing, and a BARDA/HHS galidesivir
development contract totaling $39.1 million, which is also ongoing. The total amount of NIAID/HHS and BARDA/HHS galidesivir funding
obligated under awarded options is $39.5&nbsp;million and $20.6 million, respectively. We may issue securities through private
placement transactions or registered public offerings pursuant to a registration statement filed with the SEC. In addition to
the above, we have received funding from other sources, including other collaborative and other research and development agreements;
government grants; equipment lease financing; facility leases; research grants; and interest income on our investments.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of December 31, 2016, we had net working capital of $12.6 million,
an increase of approximately $11.1 million from $1.5 million at December&nbsp;31, 2015. The increase in working capital was principally
due to proceeds from the Senior Credit Facility partially offset by our normal operating expenses associated with the development
of our product candidates. Our principal sources of liquidity at December 31, 2016 were approximately $22.1 million in cash and
cash equivalents and approximately $41.5 million in investments considered available-for-sale. We anticipate our cash and investments
will fund our operations into 2018.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We intend to contain costs and cash flow requirements by closely managing
our third party costs and headcount, leasing scientific equipment and facilities, contracting with other parties to conduct certain
research and development projects and using consultants. We expect to incur additional expenses, potentially resulting in significant
losses, as we continue to pursue our research and development activities and begin to build a commercial infrastructure. We may
incur additional expenses related to the filing, prosecution, maintenance, defense and enforcement of patent and other intellectual
property claims and additional regulatory costs as our clinical programs advance through later stages of development. The objective
of our investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient
to meet cash flow requirements. We place our excess cash with high credit quality financial institutions, commercial companies,
and government agencies in order to limit the amount of our credit exposure. We have not realized any significant losses on our
investments.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We plan to finance our needs principally from the following:</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">lease or loan financing and future public or private equity financing;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">our existing capital resources and interest earned on that capital;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">payments under existing and executing new contracts with the U.S. Government; and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">payments under collaborative and licensing agreements with corporate partners.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As our programs continue to advance, our costs will increase. Our
current and planned clinical trials, plus the related development, manufacturing, regulatory approval process requirements and
additional personnel resources and testing required for the continuing development of our product candidates will consume significant
capital resources and will increase our expenses. Our expenses, revenues and cash utilization rate could vary significantly depending
on many factors, including our ability to raise additional capital, the development progress of our collaborative agreements for
our product candidates, the amount and timing of funding we receive from existing U.S. Government contracts for galidesivir, the
amount of funding or assistance, if any, we receive from new U.S. Government contracts or other new partnerships with third parties
for the development and or commercialization of our product candidates, the progress and results of our current and proposed clinical
trials for our most advanced product candidates, the progress made in the manufacturing of our lead product candidates and the
progression of our other programs.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">With the funds available at December 31, 2016, we believe these resources
will be sufficient to fund our operations into 2018. We have sustained operating losses for the majority of our corporate history
and expect that our 2017 expenses will exceed our 2017 revenues. We expect to continue to incur operating losses and negative
cash flows until revenues reach a level sufficient to support ongoing operations. Accordingly, our planned operations raise doubt
about our ability to continue as a going concern. Our liquidity needs will be largely determined by the success of operations
in regards to the progression of our product candidates in the future. Our plans to alleviate the doubt of our going concern,
which are probable of effectively being implemented and mitigating these conditions, primarily include our ability to control
the timing and spending on our research and development programs and raising additional funds through equity financings. We also
may consider other plans to fund operations including: (1)&nbsp;securing or increasing U.S. Government funding of our programs,
including obtaining procurement contracts; (2)&nbsp;out-licensing rights to certain of our products or product candidates, pursuant
to which the we would receive cash milestones; (3)&nbsp;raising additional capital through debt financings or from other sources;
(4)&nbsp;obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow;
(5)&nbsp;reducing spending on one or more research and development programs by discontinuing development; and/or (6)&nbsp;restructuring
operations to change our overhead structure. We may issue securities, including common stock, preferred stock, depositary shares,
stock purchase contracts, warrants and units, through private placement transactions or registered public offerings, pursuant
to our registration statement on Form S-3 initially filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) on March
3, 2015. Our future liquidity needs, and ability to address those needs, will largely be determined by the success of our product
candidates and key development and regulatory events and our decisions in the future.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 41; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Our long-term capital requirements and the adequacy of our available
funds will depend upon many factors, including:</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">our ability to perform under our government contracts and receive reimbursement, and receive stockpiling procurement contracts;</font></td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the magnitude of work under our government contracts;</font></td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the progress and magnitude of our research, drug discovery and development programs;</font></td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">changes in existing collaborative relationships or government contracts;</font></td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">our ability to establish additional collaborative relationships with academic institutions, biotechnology or pharmaceutical companies and governmental agencies or other third parties;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">the extent to which our partners, including governmental agencies, will share in the costs associated with the development of our programs or run the development programs themselves;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 92%">&nbsp;</td>
    <td style="width: 0">&nbsp;</td>
    <td style="width: 39px">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">our ability to negotiate favorable development and marketing strategic alliances for certain product candidates or a decision to build or expand internal development and commercial capabilities;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">successful commercialization of marketed products by either us or a partner;</font></td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the scope and results of preclinical studies and clinical trials to identify and develop product candidates;</font></td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="3" style="vertical-align: top"><font style="font-size: 10pt">our ability to engage sites and enroll subjects in our clinical trials;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="3" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="3" style="vertical-align: top"><font style="font-size: 10pt">the scope of manufacturing of our product candidates to support our preclinical research and clinical trials;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="3" style="vertical-align: top"><font style="font-size: 10pt">increases in personnel and related costs to support the development and commercialization of our product candidates;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="3" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="3" style="vertical-align: top"><font style="font-size: 10pt">the scope of manufacturing of our drug substance and product candidates required for future NDA filings;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="3" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="3" style="vertical-align: top"><font style="font-size: 10pt">competitive and technological advances;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="3" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="3" style="vertical-align: top"><font style="font-size: 10pt">the time and costs involved in obtaining regulatory approvals;&nbsp;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="3" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="3" style="vertical-align: top"><font style="font-size: 10pt">post-approval commitments for RAPIVAB and other products that receive regulatory approval; and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="3" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="3" style="vertical-align: top"><font style="font-size: 10pt">the costs involved in all aspects of intellectual property strategy and protection including the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We expect that we will be required to raise additional capital to
complete the development and commercialization of our current product candidates and we may seek to raise capital in the future.
Additional funding, whether through additional sales of equity or debt securities, collaborative or other arrangements with corporate
partners or from other sources, including governmental agencies in general and existing government contracts specifically, may
not be available when needed or on terms acceptable to us. The issuance of preferred or common stock or convertible securities,
with terms and prices significantly more favorable than those of the currently outstanding common stock, could have the effect
of diluting or adversely affecting the holdings or rights of our existing stockholders. In addition, collaborative arrangements
may require us to transfer certain material rights to such corporate partners. Insufficient funds may require us to delay, scale
back or eliminate certain of our research and development programs. Our future working capital requirements, including the need
for additional working capital, will be largely determined by the advancement of our portfolio of product candidates as well as
rate of reimbursement by U.S. Government agencies of our galidesivir expenses and any future decisions regarding the future of
the RAPIVAB and galidesivir programs, including those relating to stockpiling procurement. More specifically, our working capital
requirements will be dependent on the number, magnitude, scope and timing of our development programs; regulatory approval of our
product candidates; obtaining funding from collaborative partners; the cost, timing and outcome of regulatory reviews, regulatory
investigations, and changes in regulatory requirements; the costs of obtaining patent protection for our product candidates; the
timing and terms of business development activities; the rate of technological advances relevant to our operations; the efficiency
of manufacturing processes developed on our behalf by third parties; and the level of required administrative support for our daily
operations.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 42; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The restrictive covenants contained in the Senior Credit Facility
could cause us to be unable to pursue business opportunities that we or our stockholders may consider beneficial without the lender&rsquo;s
permission or without repaying all Senior Credit Facility obligations. These covenants limit our ability to, among other things,
convey, sell, lease, license, transfer or otherwise dispose of certain parts of our business or property; change the nature of
our business; liquidate or dissolve; enter into certain change in control or acquisition transactions; incur or assume certain
debt; grant certain types of liens on our assets; modify, liquidate or transfer assets in certain collateral accounts; pay dividends
or make certain distributions to our stockholders; make certain investments; enter into material transactions with affiliates;
and modify existing debt or collaboration arrangements. A breach of any of these covenants could result in an event of default
under the Senior Credit Facility.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Financial Outlook for 2017</b></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based upon our development plans, expected operations and our awarded
government contracts, we expect 2017 operating cash usage to be in the range of $30 to $50 million, and expect our total 2017 operating
expenses to be in the range of $53 to $73 million. Our operating expense range excludes equity-based compensation expense due to
the difficulty in accurately projecting this expense as it is significantly impacted by the volatility and price of the Company&#8217;s
stock, as well as vesting of the Company&#8217;s outstanding performance-based stock options. Our operating cash forecast excludes
any impact of our royalty monetization, hedge collateral posted or returned, and any other non-routine cash outflows or inflows.
Our ability to remain within our operating expense and operating cash target ranges is subject to multiple factors, including unanticipated
or additional general development and administrative costs and other factors described under the Risk Factors located elsewhere
in this report.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">As of December&nbsp;31, 2016, we are not involved in any unconsolidated
entities or off&#8211;balance sheet arrangements.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Contractual Obligations</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In the table below, we set forth our enforceable and legally binding
obligations and future commitments and obligations related to all contracts that we are likely to continue regardless of the fact
that they are cancelable as of December&nbsp;31, 2016. Some of the amounts we include in this table are based on management&#8217;s
estimates and assumptions about these obligations, including their duration, the possibility of renewal, anticipated actions by
third parties, and other factors. Because these estimates and assumptions are necessarily subjective, the obligations we will actually
pay in future periods may vary from those reflected in the table.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Payments Due by Period<br> (In thousands)</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Contractual Obligations</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Less&nbsp;Than<br> 1&nbsp;Year</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">1-3&nbsp;Years</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">3-5&nbsp;Years</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">More&nbsp;Than<br> 5&nbsp;Years</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-size: 10pt; text-align: left">Operating lease obligations</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">6,151</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">871</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">1,660</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">1,131</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">2,489</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Purchase obligations(1)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">32,964</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">32,964</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Contingent license obligations</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,775</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">225</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">450</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">350</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">750</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Non-recourse notes payable(2)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">53,871</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11,621</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,400</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">33,850</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Senior credit facility</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">29,519</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,982</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">16,625</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,912</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.25pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">124,280</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">47,663</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">27,135</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">46,243</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,239</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 4%"><font style="font-size: 10pt">(1)</font></td>
    <td style="width: 96%"><font style="font-size: 10pt">Purchase obligations include commitments related to clinical development, manufacturing and research operations and other purchase commitments.</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">(2)</font></td>
    <td><font style="font-size: 10pt">Assumes the PhaRMA Notes will be repaid at maturity and the related interest costs will accrue and be paid annually through maturity. This assumption is based on the unpredictable nature of the royalty payments from Shionogi, which are designated for both principal and interest payments on the PhaRMA Notes.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 43; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the Currency Hedge Agreement, we have the right to purchase
dollars and sell yen at a rate of 100 yen per dollar for which we may be required to pay a premium in each year from 2017 through
2020. A payment of $2.0 million will be required if, during the relevant year, the dollar is worth 100 yen or less. As of December&nbsp;31,
2016, we have no hedge collateral posted against the Currency Hedge Agreement. Because the posting of additional collateral and
payment of annual premiums is contingent on the value of the yen relative to the dollar and other factors, such payments have been
excluded from the foregoing table.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">In addition to the above, we have committed to make potential future
&#8220;sublicense&#8221; payments to third-parties as part of in-licensing and development programs. Payments under these agreements
generally become due and payable only upon achievement of certain developmental, regulatory and/or commercial milestones. Because
the achievement of these milestones is neither probable nor reasonably estimable, such contingencies have not been recorded on
our balance sheet.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Critical Accounting Policies</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have established various accounting policies that govern the application
of U.S. GAAP, which were utilized in the preparation of our consolidated financial statements. Certain accounting policies involve
significant judgments and assumptions by management that have a material impact on the carrying value of certain assets and liabilities.
Management considers such accounting policies to be critical accounting policies. The judgments and assumptions used by management
are based on historical experience and other factors, which are believed to be reasonable under the circumstances. Because of the
nature of the judgments and assumptions made by management, actual results could differ from these judgments and estimates, which
could have a material impact on the carrying values of assets and liabilities and the results of operations.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">While our significant accounting policies are more fully described
in Note&nbsp;1 to our consolidated financial statements included in this Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31,
2016, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating
our reported financial results and affect the more significant judgments and estimates that we use in the preparation of our financial
statements.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Inventory</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Our inventories consist of peramivir finished goods and work in process,
which are valued at the lower of cost or market using the first-in, first-out (i.e., FIFO) method. Cost includes materials, labor,
overhead, shipping and handling costs. Our inventories are subject to expiration dating. We regularly evaluate the carrying value
of our inventories and provide valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition,
we may experience spoilage of our raw materials and supplies. Our determination that a valuation reserve might be required, in
addition to the quantification of such reserve, requires us to utilize significant judgment. In connection with the FDA approval
of RAPIVAB and other regulatory approvals, we began capitalizing costs associated with the production of peramivir inventories.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Accrued Expenses</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We enter into contractual agreements with third-party vendors who
provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts
are subject to milestone-based invoicing and services are completed over an extended period of time. We record liabilities under
these contractual commitments when an obligation has been incurred. This accrual process involves reviewing open contracts and
purchase orders, communicating with our applicable personnel to identify services that have been performed and estimating the level
of service performed and the associated cost when we have not yet been invoiced or otherwise notified of actual cost. The majority
of our service providers invoice us monthly in arrears for services performed. We make estimates of our accrued expenses as of
each balance sheet date based on the facts and circumstances known to us. We periodically confirm the accuracy of our estimates
with the service providers and make adjustments if necessary. Examples of estimated accrued expenses include:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 87%"><font style="font-size: 10pt">fees paid to Clinical Research Organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials;</font></td>
    <td style="width: 5%">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">fees paid to investigative sites in connection with clinical trials;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and product candidates;&nbsp;and</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">professional fees.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We base our expenses related to clinical trials on our estimates of
the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and
manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to
contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful
enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over
which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services
or the level of effort varies from our estimate, we will adjust the accrual accordingly. If we do not identify costs that we have
begun to incur or if we underestimate or overestimate the level of these costs, our actual expenses could differ from our estimates.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 44; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Revenue Recognition</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We recognize revenues from collaborative and other research and development
arrangements and product sales. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&nbsp;persuasive
evidence of an arrangement exists; (ii)&nbsp;delivery has occurred or services have been rendered; (iii)&nbsp;the seller&#8217;s
price to the buyer is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 23pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and
research and development fees are recognized as revenue when the earnings process is complete and we have no further continuing
performance obligations or we have completed the performance obligations under the terms of the agreement. Fees received under
licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by
management based on the terms of the agreement and the products licensed. In the event a license agreement contains multiple deliverables,
we evaluate whether the deliverables are separate or combined units of accounting. Revisions to revenue or profit estimates as
a result of changes in the estimated revenue period are recognized prospectively.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Under certain of our license agreements, we receive royalty payments
based upon our licensees&#8217; net sales of covered products. We recognize royalty revenues when we can reliably estimate such
amounts and collectability is reasonably assured. Royalty revenue paid by Shionogi on their product sales is subject to returns.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">For arrangements that involve the delivery of more than one element,
each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting.
This determination is based on whether the deliverable has &#8220;stand-alone value&#8221; to the customer. The consideration that
is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable.
The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective
evidence of fair value, (ii) third-party evidence of selling price (&#8220;TPE&#8221;) and (iii) best estimate of selling price
(&#8220;BESP&#8221;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold
by us on a stand-alone basis. In most cases we expect to use TPE or BESP for allocating consideration to each deliverable. The
consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the
consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the
use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another
performance obligation.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In June 2015, we entered into a License Agreement (the "SUL Agreement")
granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize
RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments,
and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii)
regulatory support to obtain Canadian and EU marketing approvals. We received an upfront payment of $33.7 million from SUL of which
$7.0 million was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21.8
million of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately
$3.7 million of the upfront payment was allocated to the sale of inventory and was recognized in the third quarter when the inventory
transfer was completed. Approximately $1.2 million of the revenue from the SUL Agreement will be recognized ratably over the expected
period of involvement in these regulatory support activities.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the achievement
of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured
at the inception of the SUL Agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying
these revenue recognition criteria are recorded as deferred revenue.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, we may receive up to $12.0 million
in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the
FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Canada for an adult indication
in Canada. We evaluated each event based payment under the provisions of ASU 2010-17, <i>Milestone Method of Revenue Recognition</i>,
and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the
milestone method of accounting. No event based payments were achieved during the periods presented.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related
to research and development costs are recorded as revenue in the income statement rather than as a reduction in expenses. Under
our contracts with BARDA/HHS and NIAID/HHS, revenue is recognized as reimbursable direct and indirect costs are incurred.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Product Sales</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">We recognize revenue for sales of RAPIVAB when title and substantially
all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our
specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is
persuasive evidence that an arrangement exists, title has passed, the price was fixed and determinable, and collectability is reasonably
assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United
States, prior to completion of the SUL transaction, we sold RAPIVAB to specialty distributors, who, in turn, sell to physician
offices, hospitals and federal, state and commercial health care organizations. With the completion of the SUL worldwide license
of RAPIVAB, SUL will be responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales and the sale of inventory
from us to peramivir commercial partners. With the completion of the SUL collaboration, all peramivir third-party sales (i.e.,
RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#8217;s partners, except for U.S. Government stockpiling sales, and
the Company will be reliant on these partners to generate sales and provide for sales discounts and rebates.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 45; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Sales deductions consist of statutory rebates to state Medicaid, Medicare
and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are
recorded as reductions to revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived
from historical experience adjusted to reflect known changes in the factors that impact such reserves.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We utilize data from external sources to help estimate gross-to-net
sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. External sourced data includes, but is not limited
to, information obtained from specialty distributors with respect to their inventory levels and sell-through to customers, and
information from third-party suppliers of market research data to the pharmaceutical industry.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">We have categorized and described more fully the following significant
sales deductions, all of which involve estimates and judgments, which we consider to be critical accounting estimates, and requires
us to use information from external sources.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Rebates and Chargebacks</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Statutory rebates to state Medicaid agencies and Medicare are based
on statutory discounts to RAPIVAB&#8217;s selling price.&nbsp;As it can take up to nine months or more for information to be received
on actual usage of RAPIVAB in Medicaid and other governmental programs, we maintain reserves for amounts payable under these programs
relating to RAPIVAB sales.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Chargebacks claimed by specialty distributors are based on the differentials
between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers
covered under federally qualified programs.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The amount of the reserve for rebates and chargebacks is based on
multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience,
changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory
or negotiated prices), changes in prescription demand patterns and utilization of our product through public benefit plans, and
the levels of RAPIVAB inventory in the distribution channel. We acquire prescription utilization data from third-party suppliers
of market research data to the pharmaceutical industry. We update our estimates and assumptions each period and record any necessary
adjustments to reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent
actual rebates and chargebacks differ from our estimates, additional reserves may be required or reserves may need to be reversed,
either of which would impact current period product revenue.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Discounts and Sales Incentives</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Discounts and other sales incentives primarily consist of Inventory
Management Agreement (&#8220;IMA&#8221;) fees. Per contractual agreements with our specialty distributors, we provide an IMA fee
based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in our individual contracts. We track sales
to our specialty distributors each period and accrue a liability relating to the unpaid portion of these fees by applying contractual
rates to such sales.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Product Returns</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We do not record a product return allowance as we do not offer the
ability to return goods once a bona fide shipment has been accepted by a specialty distributor.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Research and Development Expenses</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our research and development costs are charged to expense when incurred.
Advance payments for goods or services that will be used or rendered for future research and development activities are deferred
and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed.
Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs,
clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of
various administrative and facilities related costs. Most of our manufacturing and clinical and preclinical studies are performed
by third-party CROs. Costs for studies performed by CROs are accrued by us over the service periods specified in the contracts
and estimates are adjusted, if required, based upon our on-going review of the level of services actually performed.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 46; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, we have license agreements with third parties, such
as AECOM, IRL, and UAB, which require fees related to sublicense agreements or maintenance fees. We expense sublicense payments
as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized
over the related revenue recognition period. We expense maintenance payments as incurred.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments paid
to our academic partners upon receipt of consideration from various commercial partners, and other consideration to our academic
partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt
of such payments or modifications from our commercial partners and are being expensed in proportion to the related revenue being
recognized. We believe that this accounting treatment appropriately matches expenses with the associated revenue.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">We group our R&amp;D expenses into two major categories: direct
external expenses and indirect expenses. Direct expenses consist of compensation for R&amp;D personnel and costs of outside parties
to conduct laboratory studies, develop manufacturing processes and manufacture the product candidate, conduct and manage clinical
trials, as well as other costs related to our clinical and preclinical studies. These costs are accumulated and tracked by active
program. Indirect expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and other
overhead of our research and development efforts. These costs apply to work on non-active product candidates and our discovery
research efforts.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Stock-Based Compensation</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">All share-based payments, including grants of stock option awards
and restricted stock unit awards, are recognized in our Consolidated Statements of Comprehensive Loss based on their fair values.
Stock-based compensation cost is estimated at the grant date based on the fair value of the award and is recognized as expense
on a straight-line basis over the requisite service period of the award. Determining the appropriate fair value model and the related
assumptions for the model requires judgment, including estimating the life of an award, the stock price volatility, and the expected
term. We utilize the Black-Scholes option-pricing model to value our awards and recognize compensation expense on a straight-line
basis over the vesting periods. The estimation of share-based payment awards that will ultimately vest requires judgment, and to
the extent actual results or updated estimates differ from our current estimates, such amounts will be recorded as a cumulative
adjustment in the period estimates are revised. In addition, we have outstanding performance-based stock options for which no compensation
expense is recognized until &#8220;performance&#8221; has occurred. Significant management judgment is also required in determining
estimates of future stock price volatility and forfeitures to be used in the valuation of the options. Actual results, and future
changes in estimates, may differ substantially from our current estimates.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Foreign Currency Hedge</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with our issuance of the PhaRMA Notes, we entered into
a foreign Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to
the U.S.&nbsp;dollar. Under the Currency Hedge Agreement, we have the right to purchase dollars and sell yen at a rate of 100 yen
per dollar for which we may be required to pay a premium in each year from 2017 through 2020, provided the Currency Hedge Agreement
remains in effect. A payment of $2.0&nbsp;million will be required if, on May&nbsp;18 of the relevant year, the U.S. dollar is
worth 100 yen or less as determined in accordance with the Currency Hedge Agreement. In conjunction with establishing the Currency
Hedge Agreement, we will be required to post collateral to the counterparty, which may cause us to experience additional quarterly
volatility in our financial results. We will not be required at any time to post collateral exceeding the maximum premium payments
remaining payable under the Currency Hedge Agreement. As of December 31, 2016, the maximum amount of hedge collateral we may be required
to post is $7.8 million.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Currency Hedge Agreement does not qualify for hedge accounting
treatment and therefore mark to market adjustments will be recognized in our Consolidated Statements of Comprehensive Loss. Mark
to market adjustments are determined by quoted prices in markets that are not actively traded and for which significant inputs
are observable directly or indirectly, representing the Level 2 in the fair value hierarchy as defined by generally accepted accounting
principles (&#8220;U.S. GAAP&#8221;). The Company is also required to post collateral in connection with the mark to market adjustments
based on defined thresholds. As of December&nbsp;31, 2016, no collateral was posted under the agreement.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Tax</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We account for uncertain tax positions in accordance with U.S. GAAP.
Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities
and any valuation allowance recorded against net deferred tax assets. We have recorded a valuation allowance against all potential
tax assets, due to uncertainties in our ability to utilize deferred tax assets, primarily consisting of certain net operating losses
carried forward, before they expire. The valuation allowance is based on estimates of taxable income in each of the jurisdictions
in which we operate and the period over which our deferred tax assets will be recoverable.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Impact of Inflation</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We do not believe that our operating results have been materially
impacted by inflation during the past three years. However, we cannot be assured that our operating results will not be adversely
affected by inflation in the future. We will continually seek to mitigate the adverse effects of inflation on the services that
we use through improved operating efficiencies and cost containment initiatives.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 47; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b>Recent Accounting Pronouncements</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Note&nbsp;12 to the Consolidated Financial Statements included in
Item&nbsp;8 of this Annual Report on Form&nbsp;10-K discusses accounting pronouncements recently issued or proposed but not yet
required to be adopted.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><font style="font-size: 10pt"><b><a name="a_010"></a>ITEM 7A.</b></font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt"><b> <i>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK.</i></b></font></td>
</tr></table>
<p style="font-size: 10pt; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Interest Rate Risk</i></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are subject to interest rate risk on our investment portfolio and borrowings under our fixed-interest
rate PhaRMA Notes and our variable-interest rate Senior Credit Facility. The interest rate applicable to our borrowings under PhaRMA
Notes is fixed at 14% and the Senior Credit Facility bears a floating interest rate based on LIBOR. Increases in interest rates
could therefore increase the associated interest payments that we are required to make on the Senior Credit Facility. As of December
31, 2016, our Senior Credit Facility had an interest rate of 8.6%.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">We invest in marketable securities in accordance with our investment
policy. The primary objectives of our investment policy are to preserve capital, maintain proper liquidity to meet operating needs
and maximize yields. Our investment policy specifies credit quality standards for our investments and limits the amount of credit
exposure to any single issue, issuer or type of investment. We place our excess cash with high credit quality financial institutions,
commercial companies, and government agencies in order to limit the amount of credit exposure. Some of the securities we invest
in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment
to fluctuate.</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our investment exposure to market risk for changes in interest rates relates to the increase or decrease
in the amount of interest income we can earn on our portfolio, changes in the market value due to changes in interest rates and
other market factors as well as the increase or decrease in any realized gains and losses. Our investment portfolio includes only
marketable securities and instruments with active secondary or resale markets to help ensure portfolio liquidity. A hypothetical
100 basis point increase or decrease in interest rates along the entire interest rate yield curve would not significantly affect
the fair value of our interest sensitive financial instruments, including our borrowings, but may affect our future earnings and
cash flows. We generally have the ability to hold our fixed-income investments to maturity and therefore do not expect that our
operating results, financial position or cash flows will be materially impacted due to a sudden change in interest rates. However,
our future investment income may fall short of expectations due to changes in interest rates, or we may suffer losses in principal
if forced to sell securities which have declined in market value due to changes in interest rates or other factors, such as changes
in credit risk related to the securities&rsquo; issuers. To minimize this risk, we schedule our investments to have maturities
that coincide with our expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly,
we do not believe that we have material exposure to interest rate risk arising from our investments. Generally, our investments
are not collateralized. We have not realized any significant losses from our investments.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We do not use interest rate derivative instruments to manage exposure
to interest rate changes. We ensure the safety and preservation of invested principal funds by limiting default risk, market risk
and reinvestment risk. We reduce default risk by investing in investment grade securities.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Foreign Currency Risk</i></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The majority of our transactions occur in U.S. dollars and we do not
have significant operating subsidiaries or significant investments in foreign countries. Therefore, we are not subject to significant
foreign currency exchange risk in our normal operations.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes,
we entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative
to the U.S. dollar. Under the Currency Hedge Agreement, we are required to post collateral based on our potential obligations under
the Currency Hedge Agreement as determined by periodic mark-to-market adjustments. Provided the Currency Hedge Agreement remains
in effect, we may be required to pay an annual premium in the amount of $2.0&nbsp;million from May&nbsp;2017 through May&nbsp;2020.
Such payment will be required if, in May of the relevant year, the spot rate of exchange for Japanese yen-U.S. dollars (determined
in accordance with the Currency Hedge Agreement) is such that the U.S. dollar is worth 100 yen or less.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 48; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><font style="font-size: 10pt"><b><a name="a_011"></a>ITEM 8.</b></font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt"><b> <i>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</i></b></font></td>
</tr></table>
<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b><a name="a_023"></a>CONSOLIDATED BALANCE SHEETS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="balance-sheet"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: center">ASSETS</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; font-size: 10pt; text-align: left">Cash and cash equivalents</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">22,104</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">28,899</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Restricted cash</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,546</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,612</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">32,546</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22,664</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Receivables from collaborations</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,768</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,243</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Inventory</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">500</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,612</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Prepaid expenses and other current assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,438</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,674</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Deferred collaboration expense</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">85</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">90</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Total current assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">66,987</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">63,794</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,926</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">47,683</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Property and equipment, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,922</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,149</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Deferred collaboration expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">199</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">265</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other assets</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,813</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,468</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Total assets</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">89,847

</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">122,359</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Accounts payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">4,269</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">9,307</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Accrued expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10,836</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">16,237</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Interest payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,990</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,746</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred collaboration revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,022</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,163</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Non-recourse notes payable</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">28,243</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">27,804</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Total current liabilities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">54,360</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">62,257</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Deferred collaboration revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,184</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,674</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred rent</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">244</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">329</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Lease financing obligation</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,704</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,375</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Senior credit facility</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22,777</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Stockholders&#8217; equity:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Preferred stock, $0.001 par value; shares authorized&nbsp;&#8212;&nbsp;5,000; no shares outstanding</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 20pt">Common stock, $0.01&nbsp;par value; shares authorized&nbsp;&#8212;&nbsp;200,000; shares issued and outstanding&nbsp;&#8212;&nbsp;73,782 in 2016 and 73,355 in 2015</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">738</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">734</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Additional paid-in capital</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">566,913</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">558,113</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Accumulated other comprehensive loss</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(12</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(206</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(566,061</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(510,917</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Total stockholders&#8217; equity</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,578</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">47,724</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Total liabilities and stockholders&#8217; equity</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">89,847</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">122,359</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">See accompanying notes to consolidated financial statements.</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 49; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b><a name="a_024"></a>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="comprehensive-income"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December&nbsp;31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Revenues</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 61%; font-size: 10pt; text-align: left; text-indent: 10pt">Product sales, net</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">2,269</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">6,291</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">33</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Royalty revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,682</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,386</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,025</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Collaborative and other research and development</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">14,402</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">39,580</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,550</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Total revenues</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">26,353</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">48,257</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">13,608</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Cost of products sold</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,297</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,368</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Research and development</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">61,008</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">72,758</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">51,796</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Selling, general and administrative</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11,253</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">13,047</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,461</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Royalty</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">402</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">528</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">121</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Total operating expenses</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">74,960</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">87,701</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">59,379</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Loss from operations</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(48,607</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(39,444</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(45,771</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Interest and other income</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">793</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">535</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">93</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Interest expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(6,487</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(5,200</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(4,998</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">(Loss) gain on foreign currency derivative</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(843</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,090</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,487</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net loss</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(55,144</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(43,019</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(45,189</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Basic and diluted net loss per common share</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(0.75</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(0.59</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(0.68</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Weighted average shares outstanding</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">73,699</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">72,901</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">66,773</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Unrealized gain (loss) on available for sale investments</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">194</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(76</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(134</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Comprehensive loss</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(54,950</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(43,095</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(45,323</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">See accompanying notes to consolidated financial statements.</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 50; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 6pt"><a name="a_025"></a><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 6pt"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="cash-flows"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December&nbsp;31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Operating activities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="width: 61%; font-size: 10pt; text-align: left">Net loss</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(55,144</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(43,019</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(45,189</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Depreciation, amortization, and impairment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">483</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">180</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">177</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Loss on disposal of property and equipment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">17</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">27</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock-based compensation expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,487</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,705</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10,177</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Amortization of debt issuance costs</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">558</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">439</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">439</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Amortization of premium/discount on investments
</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">523</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">570</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">150</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Change in fair value of foreign currency derivative</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(811</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">564</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(5,487</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Changes in operating assets and liabilities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-indent: 10pt">Receivables</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2,525</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,247</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(7,375</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: 10pt">Inventory</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,112</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(929</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(683</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-indent: 10pt">Prepaid expenses and other assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,702</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">637</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2,093</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: 10pt">Deferred collaboration expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">71</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(102</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">59</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-indent: 10pt">Accounts payable and accrued expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(10,524</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">13,676</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,656</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: 10pt">Interest payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,244</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">717</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,162</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-indent: 10pt">Deferred revenue</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,631</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,199</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,429</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: 10pt">Net cash used in operating activities:</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(53,438</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(13,116</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(38,551</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Investing activities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Acquisition of property and equipment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(5,277</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(5,122</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(106</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Proceeds from sale of property and equipment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Change in restricted cash</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">66</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,462</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Purchases of investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(14,106</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(53,830</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(73,875</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Sales and maturities of investments</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">42,652</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">42,410</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">34,000</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: 10pt">Net cash provided (used) in investing activities:</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">23,339</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(18,004</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(39,980</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Financing activities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Sale of common stock, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">106,600</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 20pt">Net proceeds from common stock issued under stock-based compensation plans</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">317</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,479</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,307</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Proceeds from senior credit facility</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22,658</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Increase in lease financing obligation</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">329</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: 10pt">Net cash provided by financing activities:</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">23,304</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">5,479</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">111,907</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">(Decrease) increase in cash and cash equivalents</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(6,795</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(25,641</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">33,376</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Cash and cash equivalents at beginning of year</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">28,899</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">54,540</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,164</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.25pt">Cash and cash equivalents at end of year</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">22,104</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">28,899</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">54,540</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">See accompanying notes to consolidated financial statements.</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 51; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><a name="a_026"></a><b>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="stockholders-equity"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Common<br> Stock</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Additional<br> Paid-In<br> Capital</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated<br> Other<br> Comprehensive<br> (Loss) Income</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated<br> Deficit</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<br> Stockholders&#8217;<br> Equity&nbsp;(Deficit)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-size: 10pt; font-weight: bold">Balance at December&nbsp;31, 2013</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">591</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">420,988</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">4</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">(422,709</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">(1,126</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net loss</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(45,189</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(45,189</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Other comprehensive loss</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(134</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(134</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Exercise of stock options, 1,314 shares, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">13</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,984</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,997</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Employee stock purchase plan sales, 49&nbsp;shares, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">309</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">310</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Issuance of common stock, 11,500 shares, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">115</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">106,485</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">106,600</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Stock-based compensation expense</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,177</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,177</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">Balance at December&nbsp;31, 2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">720</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">542,943</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(130</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(467,898</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">75,635</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net loss</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(43,019</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(43,019</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Other comprehensive loss</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(76</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(76</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Exercise of stock options, 1,359 shares, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,110</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,124</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Employee stock purchase plan sales, 41&nbsp;shares, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">355</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">355</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Stock-based compensation expense</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">9,705</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">9,705</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">Balance at December&nbsp;31, 2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">734</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">558,113</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(206</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(510,917</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">47,724</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Net loss</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(55,144</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(55,144</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Other comprehensive income</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">194</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">194</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Exercise of stock options, 351 shares, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(15</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(12</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Employee stock purchase plan sales, 75&nbsp;shares, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">328</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">329</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Stock-based compensation expense</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,487</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,487</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">Balance at December&nbsp;31, 2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">738</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">566,913</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(12</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(566,061</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">1,578</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">See accompanying notes to consolidated financial statements.</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 52 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>BIOCRYST PHARMACEUTICALS, INC.<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><a name="a_027"></a></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note&nbsp;1&nbsp;&#8212; Significant Accounting Policies and Concentrations of Risk</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>The Company</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a biotechnology
company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of
diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its
capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina.
The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop
small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative
cash flows from operations since inception.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">With the funds available at December 31, 2016, the Company believes
these resources will be sufficient to fund its operations into 2018. The Company has sustained operating losses for the majority
of its corporate history and expects that its 2017 expenses will exceed its 2017 revenues. The Company expects to continue to incur
operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. Accordingly, its
planned operations raise doubt about its ability to continue as a going concern. The Company&#8217;s liquidity needs
will be largely determined by the success of operations in regards to the progression of its product candidates in the future.
The Company&#8217;s plans to alleviate the doubt of its going concern, which are probable of effectively being implemented and
mitigating these conditions, primarily include its ability to control the timing and spending on its research and development programs
and raising additional funds through equity financings. The Company also may consider other plans to fund operations including:
(1)&nbsp;securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (2)&nbsp;out-licensing
rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&nbsp;raising
additional capital through debt financings or from other sources; (4)&nbsp;obtaining additional product candidate regulatory approvals,
which would generate revenue, milestones and cash flow; (5)&nbsp;reducing spending on one or more research and development programs
by discontinuing development; and/or (6)&nbsp;restructuring operations to change its overhead structure. The Company may issue
securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private
placement transactions or registered public offerings, pursuant to its registration statement on Form S-3 initially filed with
the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 3, 2015. The Company&#8217;s future liquidity needs, and ability
to address those needs, will largely be determined by the success of its product candidates and key development and regulatory
events and its decisions in the future.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Basis of Presentation</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The consolidated financial statements include the accounts of the
Company and its wholly-owned subsidiaries, JPR Royalty Sub LLC (&ldquo;Royalty Sub&rdquo;) and MDCP, LLC (&ldquo;MDCP&rdquo;).
Both subsidiaries were formed to facilitate financing transactions for the Company. Royalty Sub was formed in connection with
a $30,000&nbsp;financing transaction the Company completed on March&nbsp;9, 2011. See Note 3, Royalty Monetization, for a further
description of this transaction. MDCP was formed in connection with a $23,000 Senior Credit Facility that the Company closed on
September 23, 2016. See Note 4, Senior Credit Facility, for a further description of this transaction. All intercompany transactions
and balances have been eliminated.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#8217;s consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). Such consolidated financial
statements reflect all adjustments that are, in management&#8217;s opinion, necessary to present fairly, in all material respects,
the Company&#8217;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than
normal recurring adjustments.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Reclassifications</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During the first quarter of 2016, the Company adopted Accounting Standards
Update No. 2015-03, <i>Interest &#8211; Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance
Costs</i>. Accordingly, debt issuance costs of $2,196 classified as other current assets as of December 31, 2015 have been reclassified
and netted against non-recourse notes payable to conform to the 2016 presentation.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Cash and Cash Equivalents</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally considers cash equivalents to be all cash held
in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities
of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to
the short-term nature of these items.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i></i></b></p>

<!-- Field: Page; Sequence: 53 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>BIOCRYST PHARMACEUTICALS, INC.<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Restricted Cash</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Restricted cash as of December 31, 2016 reflects $141 in royalty revenue
paid by Shionogi&nbsp;&amp; Co., Ltd. (&#8220;Shionogi&#8221;) designated for interest on the PhaRMA Notes (defined in Note 3)
and $1,405 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out
of its new Birmingham research facilities.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Investments</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company invests in high credit quality investments in accordance
with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#8217;s investment
policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow
requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government
agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable
debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments,
municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#8217;s
investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years
and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market
risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize
this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the
need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to
interest rate risk arising from its investments. Generally, the Company&#8217;s investments are not collateralized. The Company
has not realized any significant losses from its investments.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company classifies all of its investments as available-for-sale.
Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be
other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments
for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that
the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary
declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income
in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions
recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature
at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months
from the balance sheet date are classified as long-term. At December 31, 2016, the Company believes that the cost of its investments
is recoverable in all material respects.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following tables summarize the fair value of the Company&#8217;s
investments by type. The estimated fair values of the Company&#8217;s fixed income investments are classified as Level 2 in the
fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted
prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets
that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2016</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br> Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br> Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br> Unrealized<br> Gains</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br> Unrealized<br> Losses</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br> Fair Value</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Obligations of U.S. Government and its agencies</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">20,266</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">34</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">2</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(4</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">20,298</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Corporate debt securities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,179</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">26</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(8</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,199</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">14,962</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">17</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(11</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">14,975</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">41,407</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">77</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">11</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(23</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">41,472</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>


<p style="margin: 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2015</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br> Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br> Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br> Unrealized<br> Gains</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br> Unrealized<br> Losses</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br> Fair Value</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt; width: 35%">Obligations of U.S. Government and its agencies</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">26,557</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">88</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(99</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">26,546</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Corporate debt securities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">21,820</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">184</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(41</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">21,963</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,884</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(72</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,838</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,261</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">292</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(212</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 54 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>BIOCRYST PHARMACEUTICALS, INC.<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following table summarizes the scheduled maturity for the Company&#8217;s
investments at December&nbsp;31, 2016 and 2015.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><b><i></i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 67%; font-size: 10pt; text-align: left">Maturing in one year or less</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">32,546</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">22,664</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Maturing after one year through two years</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,926</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">28,395</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Maturing after two years</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,288</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">41,472</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Receivable from Collaborations</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from collaborations are recorded for amounts due to the
Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables
from Shionogi, Green Cross Corporation (&#8220;Green Cross&#8221;) and Seqirus UK Limited (&#8220;SUL&#8221;), and product sales
to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.
At December 31, 2016 and December&nbsp;31, 2015, the Company had the following receivables.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2016</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">3,495</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">3,495</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,451</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,451</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Green Cross Corporation</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">686</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">686</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Seqirus UK Limited</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">957</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">179</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,136</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,094</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,674</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">8,768</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>


<p style="margin: 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2015</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">5,536</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">5,536</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">469</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">469</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Seqirus UK Limited</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">210</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">28</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">238</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">679</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,564</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,243</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Monthly invoices are submitted to the U.S. Department of Health and
Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of
indirect costs based on rates stipulated in the underlying contract. The Company&#8217;s calculations of its indirect cost rates
are subject to audit by the U.S. Government.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Receivables from Product Sales</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"></p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from product sales are recorded for amounts due to the
Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established
at each reporting date.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Inventory</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At December 31, 2016 and December 31, 2015, the Company&#8217;s inventory
consisted primarily of peramivir work in process and is being manufactured for the Company&#8217;s partners. Inventory is stated
at the lower of cost, determined under the first-in, first-out (&#8220;FIFO&#8221;) method, or market. The Company expenses costs
related to the production of inventories as research and development expenses in the period incurred until such time it is believed
that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon
regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During 2014, in connection with the FDA approval of RAPIVAB, the Company
began capitalizing costs associated with the production of RAPIVAB inventories.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#8217;s inventory consisted of the following:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of December&nbsp;31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Work in process</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">500</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,612</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net inventories</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">500</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,612</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"></p>

<!-- Field: Page; Sequence: 55 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>BIOCRYST PHARMACEUTICALS, INC.<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Property and Equipment</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Property and equipment are recorded at cost. Depreciation is computed
using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of
three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures
are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the expected
lease term, whichever is less. Property consists of a leased building which did not meet the sale-leaseback criteria and is recorded
at its fair value, less depreciation. The building is being depreciated over a period equal to the expected term of the related
lease.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In accordance with U.S. GAAP, the Company periodically reviews its
property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets
may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from
the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover
the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed
of are reported at the lower of carrying amount or fair value less cost to sell.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Patents and Licenses</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company seeks patent protection on all internally developed processes
and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability
of such expenditures is uncertain.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Accrued Expenses</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally enters into contractual agreements with third-party
vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these
contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records
liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of
the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel
to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost
incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service
providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of
each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the
accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses
include:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 91%"><font style="font-size: 10pt">fees paid to Clinical Research Organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials;</font></td>
    <td style="width: 1%">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">fees paid to investigative sites in connection with clinical trials;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">fees paid to contract manufacturers in connection with the
    production of  the Company&rsquo;s raw materials, drug substance and drug products;&nbsp;and</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">professional fees.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company bases its expenses related to clinical trials on its estimates
of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and
manage clinical trials on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary
from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such
as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company
estimates the time period over which services will be performed and the level of effort expended in each period. If the actual
timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.
As of December 31, 2016 and December 31, 2015, the carrying value of accrued expenses approximates their fair value due to their
short-term settlement.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">Accrued expenses were comprised of the following:</p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 67%; font-size: 10pt; text-align: left">Compensation and benefits</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">425</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">424</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Development costs</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,427</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10,398</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Inventory</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">705</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">549</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Professional fees</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">242</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">242</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Duties and taxes</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">56</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">102</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">Other</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,981</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,522</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total accrued expenses</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">10,836</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">16,237</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 56 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>BIOCRYST PHARMACEUTICALS, INC.<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p></div>
    <!-- Field: /Page -->


<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Income Taxes</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The liability method is used in the Company&#8217;s accounting for
income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting
and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect
when the differences are expected to reverse.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Accumulated Other Comprehensive Loss</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Accumulated other comprehensive loss is comprised of unrealized gains
and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#8217; equity. Amounts reclassified
from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive
Loss. During 2016 and 2015, realized gains of $11 and $13, respectively, were reclassified out of accumulated other comprehensive
loss.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Revenue Recognition</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenues from collaborative and other research
and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable
and earned when all of the following criteria are met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery
has occurred or services have been rendered; (iii)&nbsp;the seller&#8217;s price to the buyer is fixed or determinable; and (iv)&nbsp;collectability
is reasonably assured.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and
research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing
performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received
under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined
by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result
of changes in the estimated revenue period are recognized prospectively.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Under certain of the Company&#8217;s license agreements, the Company
receives royalty payments based upon its licensees&#8217; net sales of covered products. The Company recognizes royalty revenues
when it can reliably estimate such amounts and collectability is reasonably assured.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For arrangements that involve the delivery of more than one
element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit
of accounting. This determination is based on whether the deliverable has &#8220;stand-alone value&#8221; to the customer.
The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative
selling price of each deliverable. The estimated selling price of each deliverable is determined using the following
hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price
(&#8220;TPE&#8221;) and (iii) best estimate of selling price (&#8220;BESP&#8221;). The BESP reflects the Company&rsquo;s best
estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In
most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration
allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the
consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires
the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or
another performance obligation.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In June 2015, the Company entered into a License Agreement (the &#8220;SUL
Agreement&#8221;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture
and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone
payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory
and (iii) regulatory support to obtain Canadian and European Union (&#8220;EU&#8221;) marketing approvals. The Company received
an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent upon EU marketing approval and will be
deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue
in 2015. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized in 2015,
when the inventory transfer was completed. Approximately $1,223 of the revenue from the SUL Agreement will be recognized over the
expected period of involvement in these regulatory support activities.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the
achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not
reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior
to satisfying these revenue recognition criteria are recorded as deferred revenue.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 57 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>BIOCRYST PHARMACEUTICALS, INC.<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company may receive up to
$12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i)
by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food
Branch of Health Canada (&#8220;Health Canada&#8221;) for an adult indication in Canada. The Company evaluated each event based
payment under the provisions of ASU 2010-17, <i>Milestone Method of Revenue Recognition</i>, and determined that each event based
payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event
based payments were achieved during the periods presented.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related
to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a
reduction in expenses. Under the Company&#8217;s contracts with the Biomedical Advanced Research and Development Authority within
the United States Department of Health and Human Services (&#8221;BARDA/HHS&#8221;) and the National Institute of Allergy and Infectious
Diseases (&#8220;NIAID/HHS&#8221;), revenue is recognized as reimbursable direct and indirect costs are incurred.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><i>Product Sales</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenue for sales of RAPIVAB when
title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on
the date of shipment from  the Company&rsquo;s specialty distributors, utilizing the Sell-Through revenue recognition
methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the
price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated
allowances, discounts, sales returns, chargebacks and rebates. In the United States, and prior to the SUL Agreement, the
Company sold RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and
commercial health care organizations.&nbsp;With the completion of the SUL worldwide license of RAPIVAB, SUL will be
responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales. With the completion of the SUL collaboration,
all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#8217;s partners, except for U.S.
Government stockpiling sales, and the Company will be reliant on these partners to generate sales.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Sales deductions consist of statutory rebates to state Medicaid, Medicare
and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are
recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived
from historical experience adjusted to reflect known changes in the factors that impact such reserves.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company utilizes data from external sources to help it estimate
gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes,
but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through
to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company accounts for these sales deductions in accordance with
authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has categorized and described more fully the following
significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting
estimates, and require it to use information from external sources.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 13.5pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><i></i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><i>Rebates and Chargebacks</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 13.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Statutory rebates to state Medicaid agencies and Medicare are based
on statutory discounts to RAPIVAB&#8217;s selling price.&nbsp;As it can take up to nine months or more for information to be received
on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under
these programs relating to RAPIVAB sales.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Chargebacks claimed by specialty distributors are based on the
differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid
by eligible customers covered under federally qualified programs.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The amount of the reserve for rebates and chargebacks is based
on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment
experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices
and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&#8217;s product through
public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization
data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions
each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within
nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&#8217;s estimates, additional
reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i></i></p>

<!-- Field: Page; Sequence: 58 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>BIOCRYST PHARMACEUTICALS, INC.<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Discounts and Sales Incentives</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Discounts and other sales incentives primarily consist of Inventory
Management Agreement (&#8220;IMA&#8221;) fees. Per contractual agreements with the Company&#8217;s specialty distributors, the
Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual
contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of
these fees by applying the contractual rates to such product sales.&nbsp;With the completion of the SUL collaboration, all peramivir
sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#8217;s partners, except for U.S. Government stockpiling
sales, and the Company will be reliant on these partners to generate sales and to provide for discounts and sales incentives.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Product Returns</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company does not record a product return allowance as it does
not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recorded the following revenues for the years ended December&nbsp;31:</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 13.5pt">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; font-size: 10pt; text-align: left">Product sales, net</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">2,269</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">6,291</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">33</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Royalty revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,682</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,386</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,025</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Collaborative and other research and development revenues:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">U.S. Department of Health and Human Services</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">12,449</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">16,337</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,366</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Green Cross Corporation</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">132</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Shionogi &amp; Co. Ltd.</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,184</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,184</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,184</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Seqirus UK Limited</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">769</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,927</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total collaborative and other research and development revenues</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">14,402</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">39,580</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,550</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total revenues</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">26,353</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">48,257</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">13,608</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Advertising</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company engages in very limited distribution and direct-response
advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred. The Company did not
incur advertising and product promotion expenses in 2016. Advertising and product promotion expenses were $103 and $290 for the
years ended December&nbsp;31, 2015 and 2014, respectively.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Research and Development Expenses</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#8217;s research and development costs are charged to
expense when incurred. Research and development expenses include all direct and indirect development costs related to the development
of the Company&#8217;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for
future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related
goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel
costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials
and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#8217;s
manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued
by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#8217;s
on-going review of the level of services actually performed.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, the Company has license agreements with third parties,
such as Albert Einstein College of Medicine of Yeshiva University (&#8220;AECOM&#8221;), Industrial Research, Ltd. (&#8220;IRL&#8221;),
and the University of Alabama at Birmingham (&#8220;UAB&#8221;), which require fees related to sublicense agreements or maintenance
fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which
case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments
as incurred.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license
payments, paid to the Company&#8217;s academic partners upon receipt of consideration from various commercial partners, and
other consideration paid to  the Company&rsquo;s academic partners for modification to existing license agreements. These
deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&#8217;s
commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that
this accounting treatment appropriately matches expenses with the associated revenue.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i></i></b></p>

<!-- Field: Page; Sequence: 59 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>BIOCRYST PHARMACEUTICALS, INC.<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Stock-Based Compensation</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">All share-based payments, including grants of stock option awards
and restricted stock unit awards, are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss based on
their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value
of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is
recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding
performance-based stock options for which no compensation expense is recognized until &#8220;performance&#8221; is deemed to have
occurred.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Interest Expense and Deferred Financing Costs</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest expense for the years ended December 31, 2016, 2015
and 2014 was $6,487, $5,200 and $4,998, respectively, and primarily relates to the issuance of the PhaRMA Notes (defined in
Note 3) and the Senior Credit Facility (defined in Note 4). Costs directly associated with the issuance of the PhaRMA Notes
and the Senior Credit Facility have been capitalized and are netted against the non-recourse notes payable and Senior Credit
Facility on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the PhaRMA
Notes and the Senior Credit Facility using the effective interest rate method. Amortization of deferred financing costs and
original issue discount included in interest expense was $558, $439 and $439 for each of the years ended December 31,
2016, 2015 and 2014, respectively.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><b><i>Lease Financing Obligation</i></b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on the terms of the lease agreement for the new research facility
in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the
owner of the building (for accounting purposes only) during the construction period, which ended in 2016. Accordingly, the Company
recorded an asset of $1,589 at December 31, 2015, representing the Company&rsquo;s leased portion of the building and recorded
a corresponding liability. Upon completion of leasehold improvement construction, the Company did not meet the sale-leaseback
criteria for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation.
The asset will be depreciated over the expected duration of the lease of 20.5 years, and rental payments will be treated as principal
and interest payments on the lease financing obligation liability. The underlying accounting for this transaction has no impact
on cash flows associated with the underlying lease or construction in process. Interest expense for the year ended December 31,
2016 includes $408 related to the lease financing obligation.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">At December 31, 2016 and 2015, the lease financing obligation balance
was $2,704 and $2,375, respectively and was recorded as a long term liability on the consolidated balance sheets. At December 31,
2016 the remaining future minimum payments under the lease financing obligation are $4,768.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Currency Hedge Agreement</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the
PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value
of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting
treatment; therefore mark to market adjustments are recognized in the Company&#8217;s Consolidated Statements of
Comprehensive Loss. Cumulative mark to market adjustments for the years ended December&nbsp;31, 2016, 2015 and 2014 resulted
in losses of $1,654 and $564 and a gain of $5,487, respectively. Mark to market adjustments are determined by a third party
pricing model which uses quoted prices in markets that are not actively traded and for which significant inputs are
observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. In addition,
realized currency exchange gains of $811 and $1,654 were recognized in 2016 and 2015, respectively, related to the exercise
of a U.S. dollar/Japanese yen currency option under  the Company&rsquo;s foreign currency hedge. The Company is also required
to post collateral in connection with the mark to market adjustments based on defined thresholds. As of December 31, 2016 and
December&nbsp;31, 2015, no hedge collateral was posted under the Currency Hedge Agreement.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Net Loss Per Share</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Net loss per share is based upon the weighted average number of common
shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented
herein because common equivalent shares from unexercised stock options, outstanding warrants, and common shares expected to be
issued under the Company&#8217;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share
for the years ended December&nbsp;31, 2016, 2015, and 2014 does not include 1,226, 3,524 and 3,991 respectively, of potential common
shares as their impact would be anti-dilutive.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Use of Estimates</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP
requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results
could differ from those estimates.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 60 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>BIOCRYST PHARMACEUTICALS, INC.<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><b><i>Significant Customers and Other Risks</i></b><i> &nbsp;</i></p>

<p style="font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><i>Significant Customers</i></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Prior to the SUL Agreement, the Company relied primarily on three
specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted
for greater than 90% of all RAPIVAB product sales and accounted for predominantly all of the Company&#8217;s outstanding receivables
from product sales. The loss of one or more of these specialty distributors as a customer could have negatively impacted the commercialization
of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the SUL collaboration
as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis. In addition,
in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#8217;s
partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Other than royalty revenues, the Company&#8217;s primary source
of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB and galidesivir (formerly BCX4430) development
expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS. The Company relies on BARDA/HHS and NIAID/HHS
to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses
represents a significant portion of the Company&#8217;s collaborative and other research and development revenues. The completion
(as with the June 30, 2014 BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS galidesivir
contracts could negatively impact the Company&#8217;s future Consolidated Statements of Comprehensive Loss and Cash Flows. The
Company recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty
payments, except for Japanese government stockpiling sales, goes directly to pay the interest, and then the principal, on the Company&#8217;s
non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded
by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#8217;s drug development activities are performed
by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly
impact the Company&#8217;s ability to complete its drug development activities.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><i>Risks from Third Party Manufacturing and Distribution Concentration</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The Company relies on single source manufacturers for active pharmaceutical
ingredient and finished drug product manufacturing of product candidates in development. Delays in the manufacture or distribution
of any product could adversely impact the commercial revenue and future procurement stockpiling of the Company&rsquo;s product
candidates in development.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><i>Credit Risk</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Cash equivalents and investments are financial instruments which
potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company
deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided
on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification
and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company
maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative
partner receivables discussed above, the majority of the Company&#8217;s receivables from collaborations are due from the U.S.
Government, for which there is no assumed credit risk.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><b><i>Going Concern</i></b></p>

<p style="font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#8217;s liquidity needs will be largely determined by
the success of operations in regards to the progression of its product candidates in the future. The Company&#8217;s plans to alleviate
the doubt of its going concern, which are probable of effectively being implemented and mitigating these conditions, primarily
include its ability to control the timing and spending on its research and development programs and raising additional funds through
equity financings. The Company also may consider other plans to fund operations including: (1)&nbsp;securing or increasing U.S.
Government funding of its programs, including obtaining procurement contracts; (2)&nbsp;out-licensing rights to certain of its
products or product candidates, pursuant to which the Company would receive cash milestones; (3)&nbsp;raising additional capital
through debt financings or from other sources; (4)&nbsp;obtaining additional product candidate regulatory approvals, which would
generate revenue, milestones and cash flow; (5)&nbsp;reducing spending on one or more research and development programs by discontinuing
development; and/or (6)&nbsp;restructuring operations to change its overhead structure. The Company may issue securities, including
common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions
or registered public offerings, pursuant to its registration statement on Form S-3 initially filed with the Securities and Exchange
Commission (&#8220;SEC&#8221;) on March 3, 2015. The Company&#8217;s future liquidity needs, and ability to address those needs,
will largely be determined by the success of its product candidates and key development and regulatory events and its decisions
in the future.</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 61 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>BIOCRYST PHARMACEUTICALS, INC.<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note&nbsp;2&nbsp;&#8212; Property and Equipment</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Property and equipment consisted of the following at December&nbsp;31:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 67%; font-size: 10pt; text-align: left">Furniture and fixtures</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">540</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">718</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Office equipment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">141</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,122</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Software</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,117</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,427</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Laboratory equipment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,252</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,004</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Leased equipment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">63</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Leasehold improvements</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,294</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,610</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Construction in progress</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,821</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">Building</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,495</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,589</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,839</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">19,354</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less accumulated depreciation and amortization</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4,917</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(14,205</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Property and equipment, net</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">9,922</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,149</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Depreciation and amortization expense for the years ended December&nbsp;31,
2016, 2015 and 2014 was $483, $180 and $177, respectively.</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 3&#8212; Royalty Monetization</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt"><i>Overview</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March&nbsp;9, 2011, the Company completed a $30,000&nbsp;financing
transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi
licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received
net proceeds of $22,691&nbsp;from the transaction after transaction costs of $4,309&nbsp;and the establishment of a $3,000&nbsp;interest
reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account
has been fully utilized with the September 2012 interest payment.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As part of the transaction, the Company entered into a purchase and
sale agreement dated as of March&nbsp;9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things,
(i)&nbsp;its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&nbsp;the
right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#8220;Currency
Hedge Agreement&#8221;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi
in Japanese yen and milestone payments will paid in U.S. dollars. The Company&#8217;s collaboration with Shionogi was not impacted
as a result of this transaction.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt"><i>Non-Recourse Notes Payable</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March&nbsp;9, 2011, Royalty Sub completed a private placement to
institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &#8220;PhaRMA
Notes&#8221;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March&nbsp;9, 2011 (the &#8220;Indenture&#8221;),
by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are
payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the
Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest
at 14%&nbsp;per annum, payable annually in arrears on September&nbsp;1st of each year. The Company remains entitled to receive
any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes. &nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Royalty Sub&#8217;s obligations to pay principal and interest on the
PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except
to the extent of the Company&#8217;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company
may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion
pay any interest shortfall on, the PhaRMA Notes.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 62 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>BIOCRYST PHARMACEUTICALS, INC.<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In September&nbsp;2013, Royalty Sub paid $1,844 of interest on the
PhaRMA Notes from royalty payments received from RAPIACTA <sup>&#174;</sup> sales from the preceding four calendar quarters. This
payment resulted in an obligation shortfall of approximately $2,356 associated with accrued interest due September&nbsp;3, 2013.
As stipulated under the PhaRMA Notes Indenture, if the amount available for payment on any Payment Date is insufficient to pay
all of the interest due on a Payment Date, the shortfall in interest will accrue interest at the interest rate applicable to the
PhaRMA Notes compounded annually. Accordingly, commencing in September&nbsp;2013, the Company began accruing interest at 14%&nbsp;per
annum on the interest shortfall of $2,356. In March, June and August of 2014, Royalty Sub paid additional interest of $446, $1,882
and $70, respectively, bringing the 2013 shortfall down to $222 as of September 30, 2014. Under the terms of the Indenture, Royalty
Sub&#8217;s inability to pay the full amount of interest payable in September&nbsp;2013 by the next succeeding Payment Date for
the PhaRMA Notes, which was September&nbsp;1, 2014, constituted an event of default. Accordingly, the PhaRMA Notes and related
accrued interest have been classified as current liabilities on the December 31, 2014 balance sheet. As a result of the event of
default under the PhaRMA Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the
collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under
the Indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments
that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to
the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the
Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In
addition, the Company may incur costs associated with liquidating the related Currency Hedge Agreement, which would no longer be
required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of
Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is not expected to have a significant impact
on the Company&#8217;s future results of operations or cash flows. As of December 31, 2016, the PhaRMA Notes remain in default.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Indenture does not contain any financial covenants. The Indenture
includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of
Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters
typical for indentures used in structured financings of this type.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of December&nbsp;31, 2016, the aggregate fair value of the PhaRMA
Notes was estimated to be approximately 50% of its carrying value of $30,000. The estimated fair value of the PhaRMA Notes is classified
as Level 2 in the fair value hierarchy as defined in U.S. GAAP.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The PhaRMA Notes are redeemable at the option of Royalty Sub at any
time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid
interest through the redemption date on the PhaRMA Notes being redeemed.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Foreign Currency Hedge</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes,
the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese
yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen
at a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from 2017 through 2020, provided
the Currency Hedge Agreement remains in effect. A payment of $1,950&nbsp;will be required if, on May&nbsp;18 of the relevant year,
the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Currency Hedge Agreement does not qualify for
hedge accounting treatment; therefore mark to market adjustments are recognized in the Company&#8217;s Consolidated Statement
of Comprehensive Loss. Cumulative mark to market adjustments in 2016, 2015 and 2014 resulted in losses of $1,654 and $564 and
a gain of $5,487, respectively. In addition, realized currency exchange gains of $811 and $1,654 were recognized in 2016
and 2015, respectively, related to the exercise of a U.S. dollar/Japanese yen currency option under  the Company&rsquo;s
foreign currency hedge. The Company is also required to post collateral in connection with the mark to market adjustments
based on defined thresholds. As of December&nbsp;31, 2016 and 2015, no collateral was posted under the Currency Hedge
Agreement. The Company will not be required at any time to post collateral exceeding the maximum premium payments remaining
payable under the Currency Hedge Agreement. As of December 31, 2016, the maximum amount of hedge collateral the Company may
be required to post is $7,800.</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 4 &#8212; Senior Credit Facility</b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">On September 23, 2016, the Company closed a $23,000 Senior Credit
Facility with an affiliate of MidCap Financial Services, LLC (&#8220;MidCap&#8221;), as administrative agent (the &#8220;Senior
Credit Facility&#8221;). The Senior Credit Facility was fully funded at closing and bears a variable interest rate of LIBOR (which
shall not be less than 0.5%) plus 8%. The Senior Credit Facility includes an interest-only payment period through fiscal 2017 and
scheduled monthly principal and interest payments for the subsequent 40 months. The Company has the option to repay the Senior
Credit Facility at any time prior to the scheduled principal repayment date subject to prepayment fees. Final payment of the Senior
Credit Facility is subject to a final payment fee equal to 5% of the principal funded under the Senior Credit Facility.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">As of December 31, 2016, the Company had borrowings of $23,000
under the Senior Credit Facility bearing an interest rate of 8.6%. The carrying amount of the debt approximates its fair value
based on prevailing interest rates as of the balance sheet date. Scheduled principal repayments of the Senior Credit Facility are
as follows:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 50%">
<tr style="vertical-align: bottom">
    <td colspan="5" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Principal Payments</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify; text-indent: 0pt">2017</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: justify; text-indent: 0pt; width: 72%">2018</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 25%; font-size: 10pt; text-align: right">6,900</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify; text-indent: 0pt">2019</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,900</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: justify; text-indent: 0pt">2020</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,900</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify; text-indent: 0pt">2021</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,300</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify; text-indent: 0pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">23,000</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 63 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>BIOCRYST PHARMACEUTICALS, INC.<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The debt agreement contains two provisions that if deemed probable
would create the recognition of an embedded feature; however, at this time we do not believe either provision is probable.</p></div><p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note&nbsp;5&nbsp;&#8212; Lease Obligations and Other Contingencies</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has the following minimum payments under operating lease
obligations that existed at December&nbsp;31, 2016:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 85%">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; font-size: 10pt; text-align: left">2017</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">871</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">2018</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">838</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">2019</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">822</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">2020</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">653</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">2021</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">478</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt; text-align: left">Thereafter</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,489</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total minimum payments</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,151</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The obligations in the preceding table are primarily related to the
Company&#8217;s leases for buildings in Birmingham, Alabama and Durham, North Carolina. The lease for the Company&#8217;s headquarters
in Durham, North Carolina expires June&nbsp;30, 2020. The lease for the Company&#8217;s research facility in Birmingham, Alabama
expires October 31, 2026. Rent expense for operating leases was $721, $664 and $633 in 2016, 2015, and 2014, respectively.</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>&nbsp;</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Lease Financing Obligation</i></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on the terms of the lease agreement for the new research facility
in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the
owner of the building (for accounting purposes only) during the construction period, which ended in 2016. Accordingly, the Company
recorded an asset of $1,589 at December 31, 2015, representing the Company&#8217;s leased portion of the building and recorded
a corresponding liability. Upon completion of leasehold improvement construction, the Company did not meet the sale-leaseback criteria
for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset
will be depreciated over the expected duration of the lease, and rental payments will be treated as principal and interest payments
on the lease financing obligation liability. The underlying accounting for this transaction has no impact on cash flows associated
with the underlying lease and or construction in process.</p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At December 31, 2016 and 2015, the lease financing obligation balance
was $2,704 and $2,375, respectively and was recorded as a long term liability on the consolidated balance sheets. The remaining
future minimum payments under the lease financing obligation are $4,768.</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note&nbsp;6&nbsp;&#8212; Stockholders&#8217; Equity</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Sales of Common Stock</i></b></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March 3, 2015, the Company filed a $150,000 shelf registration
statement on Form S-3 with the SEC. This shelf registration statement became effective upon filing and allows the Company to sell
securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time
to time at prices and on terms to be determined at the time of sale. On February 26, 2016, the Company filed a post-effective amendment
to this registration statement, which allowed for its use by the Company when declared effective by the SEC&#8217;s staff on April
18, 2016.</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note&nbsp;7&nbsp;&#8212; Stock-Based Compensation</b></p>

<p style="font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Stock Incentive Plan</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of December&nbsp;31, 2016, the Company had two stock-based employee
compensation plans, the Stock Incentive Plan (&#8220;Incentive Plan&#8221;) and the Employee Stock Purchase Plan (&#8220;ESPP&#8221;).
The Incentive Plan was amended and restated in April 2016 and approved by the Company&#8217;s stockholders in May 2016. The ESPP
was amended and restated in March 2014 and approved by the Company&#8217;s stockholders in May 2014. Stock-based compensation expense
of $8,487 ($8,340 of expense related to the Incentive Plan, $147 of expense related to the ESPP) was recognized during 2016, while
$9,705 ($9,485 of expense related to the Incentive Plan, $220 of expense related to the ESPP) was recognized during 2015, and $10,177
($9,963 of expense related to the Incentive Plan, $214 of expense related to the ESPP) was recognized during 2014.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 64 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>BIOCRYST PHARMACEUTICALS, INC.<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company accounts for stock-based compensation in accordance with
FASB authoritative guidance regarding share-based payments. Total stock-based compensation was allocated as follows:</p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 85%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December&nbsp;31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; text-align: left">Research and development</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">6,088</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">7,580</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">8,906</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,399</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,125</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,271</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total stock-based compensation expense</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">8,487</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">9,705</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">10,177</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company grants stock option awards and restricted stock unit awards
to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted
with an exercise price equal to the market price of the Company&#8217;s stock at the date of grant. Commencing March&nbsp;1, 2011,
stock option awards granted to employees generally vest 25% each year until fully vested after four years. In January 2013, the
Company made retention grants of stock option awards and restricted stock units. These awards vest 50% each year until fully vested
after two years. In August 2013 and December 2014, the Company issued 1,032 and 1,250 performance-based stock options, respectively.
These awards vest upon successful completion of specific development milestones. As of December 31, 2015, 75% of the August 2013
grants have vested based upon achievement of three milestones: (1) successful completion of the OPuS-1 clinical trial, for which
vesting occurred in the second quarter of 2014, (2) FDA approval of RAPIVAB for which vesting occurred in the fourth quarter of
2014, and (3) initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered
BCX7353 in healthy volunteers, for which vesting occurred in the second quarter of 2015. Thus, as of December&nbsp;31, 2016, 25%
of the August 2013 performance-based grants and 100% of the December 2014 performance-based grants remain unvested and no compensation
expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to
non-employee directors of the Company generally vest monthly over one year. All stock option awards have contractual terms of 5
to 10&nbsp;years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in
the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive
Plan. <b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Related activity under the Incentive Plan is as follows:</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 85%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Awards<br> Available</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options<br> Outstanding</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<br> Average<br> Exercise<br> Price</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt">Balance at December&nbsp;31, 2013</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">1,082</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">8,986</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">4.99</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Plan amendment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,750</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Restricted stock awards granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(593</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Restricted stock awards cancelled</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,965</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,965</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10.99</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards exercised</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,258</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4.78</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards cancelled</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">88</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(88</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">8.83</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Balance at December&nbsp;31, 2014</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,362</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,605</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6.21</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Restricted stock awards granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(163</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Restricted stock awards cancelled</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2,217</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,217</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11.52</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards exercised</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,118</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4.36</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards cancelled</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">33</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(33</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">9.87</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Balance at December&nbsp;31, 2015</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">16</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10,671</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7.50</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Plan amendment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,800</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Restricted stock awards granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(34</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Restricted stock awards cancelled</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2,248</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,248</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3.20</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards exercised</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(107</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2.63</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards cancelled</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">717</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(717</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">10.78</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance at December&nbsp;31, 2016</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,273</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">12,095</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">$</td><td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right">6.55</td><td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 65 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>BIOCRYST PHARMACEUTICALS, INC.<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For stock option awards granted under the Incentive Plan during 2016,
2015 and 2014, the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions
noted in the table below. The weighted average grant date fair value of these awards granted during 2016, 2015 and 2014 was $2.17,
$7.72 and $8.02, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using
a straight-line expense attribution method. The following explanations describe the assumptions used by the Company to value the
stock option awards granted during 2016, 2015, and 2014. The expected life is based on the average of the assumption that all outstanding
stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised
at the midpoint of the current date (if already vested) or at full vesting (if not yet vested) and the full contractual term. The
expected volatility represents the volatility over the most recent period corresponding with the expected life. The Company has
assumed no expected dividend yield, as dividends have never been paid to stockholders and will not be for the foreseeable future.
The weighted average risk-free interest rate is the implied yield currently available on zero-coupon government issues with a remaining
term equal to the expected term.</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Weighted Average Assumptions for Stock Option Awards Granted under the Incentive Plan</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 85%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; text-align: left">Expected Life</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">5.5</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">5.5</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">5.5</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected Volatility</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">82</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">81</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">87</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Expected Dividend Yield</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.0</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.0</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.0</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Risk-Free Interest Rate</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1.4</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1.6</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1.6</td><td style="font-size: 10pt; text-align: left">%</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The total intrinsic value of stock option awards exercised under the
Incentive Plan was $339 during 2016, $10,117 during 2015 and $8,522 during 2014. The intrinsic value represents the total proceeds
(fair market value at the date of exercise, less the exercise price, times the number of stock option awards exercised) received
by all individuals who exercised stock option awards during the period.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following table summarizes, at December&nbsp;31, 2016, by price
range: (1)&nbsp;for stock option awards outstanding under the Incentive Plan, the number of stock option awards outstanding, their
weighted average remaining life and their weighted average exercise price; and (2)&nbsp;for stock option awards exercisable under
the Plan, the number of stock option awards exercisable and their weighted average exercise price:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 10pt"><b>&nbsp;</b></font></td>
    <td style="font-size: 10pt; text-align: center"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: center"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="9" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><font style="font-size: 10pt">Outstanding</font></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><font style="font-size: 10pt">Exercisable</font></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2"><font style="font-size: 10pt"><b><u>Range</u></b></font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: center"><font style="font-size: 10pt">Number</font></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><font style="font-size: 10pt">Weighted
    <br>
    Average <br>
    Remaining <br>
    Life</font></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><font style="font-size: 10pt">Weighted
    <br>
    Average <br>
    Exercise <br>
    Price</font></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: center"><font style="font-size: 10pt">Number</font></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><font style="font-size: 10pt">Weighted
    <br>
    Average <br>
    Exercise <br>
    Price</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; width: 5%"><font style="font-size: 10pt">0</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; width: 3%"><font style="font-size: 10pt">to</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; width: 5%"><font style="font-size: 10pt">3</font></td><td style="width: 2%; font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><font style="font-size: 10pt">1,919</font></td><td style="width: 2%; font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="width: 14%; font-size: 10pt; text-align: right"><font style="font-size: 10pt">5.7</font></td><td style="width: 1%; font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="width: 2%; font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 14%; font-size: 10pt; text-align: right"><font style="font-size: 10pt">1.64</font></td><td style="width: 1%; font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="width: 2%; font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="width: 14%; font-size: 10pt; text-align: right"><font style="font-size: 10pt">1,510</font></td><td style="width: 1%; font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="width: 2%; font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 14%; font-size: 10pt; text-align: right"><font style="font-size: 10pt">1.53</font></td><td style="width: 1%; font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font-size: 10pt"><b>&nbsp;</b></font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">3</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">to</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">6</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">4,749</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">6.9</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">4.02</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">2,578</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">4.48</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><font style="font-size: 10pt"><b>&nbsp;</b></font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">6</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">to</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">9</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">1,153</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">3.5</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">7.10</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">1,118</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">7.11</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font-size: 10pt"><b>&nbsp;</b></font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">9</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">to</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">12</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">3,457</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">7.2</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">11.10</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">1,074</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">11.29</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><font style="font-size: 10pt"><b>&nbsp;</b></font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">12</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">to</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">15</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">722</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">8.0</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">12.39</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">195</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">12.73</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font-size: 10pt"><b>&nbsp;</b></font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"><font style="font-size: 10pt">15</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"><font style="font-size: 10pt">to</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"><font style="font-size: 10pt">18</font></td><td style="font-size: 10pt; padding-bottom: 1.1pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: right; padding-bottom: 1.1pt; border-bottom: Black 1pt solid"><font style="font-size: 10pt">95</font></td><td style="font-size: 10pt; padding-bottom: 1.1pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">8.5</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; padding-bottom: 1.1pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">15.39</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; padding-bottom: 1.1pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><font style="font-size: 10pt">24</font></td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; padding-bottom: 1.1pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">15.39</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"><font style="font-size: 10pt">0</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"><font style="font-size: 10pt">to</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"><font style="font-size: 10pt">18</font></td><td style="font-size: 10pt; padding-bottom: 2.25pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: right; padding-bottom: 2.25pt; border-bottom: Black 2.25pt double"><font style="font-size: 10pt">12,095</font></td><td style="font-size: 10pt; padding-bottom: 2.25pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">6.6</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; padding-bottom: 2.25pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">$</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">6.55</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; padding-bottom: 2.25pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><font style="font-size: 10pt">6,499</font></td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; padding-bottom: 2.25pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">$</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">5.66</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td></tr>
</table></div>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>



<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The weighted average remaining contractual life of stock option awards
exercisable under the Incentive Plan at December&nbsp;31, 2016 was 6.6 years.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The aggregate intrinsic value of stock option awards outstanding and
exercisable under the Incentive Plan at December&nbsp;31, 2016 was $20,002. The aggregate intrinsic value represents the value
(the period&#8217;s closing market price, less the exercise price, times the number of in-the-money stock option awards) that would
have been received by all stock option award holders under the Incentive Plan had they exercised their stock option awards at the
end of the year.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The total fair value of the stock option awards vested under the Incentive
Plan was $6,380 during 2016, $4,492 during 2015 and $2,844 during 2014.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of December&nbsp;31, 2016, the number of stock option awards vested
and expected to vest under the Incentive Plan is 11,013. The weighted average exercise price of these stock option awards is $6.53
and their weighted average remaining contractual life is 6.5&nbsp;years.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 66 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>BIOCRYST PHARMACEUTICALS, INC.<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following table summarizes the changes in the number and weighted-average
grant-date fair value of non-vested stock option awards during 2016:</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" nowrap style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Non-Vested<br> Stock Option<br> Awards</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" nowrap style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average<br> Grant-Date Fair<br> Value</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 67%; font-size: 10pt">Balance December&nbsp;31, 2015</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 13%; font-size: 10pt; text-align: right">4,863</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">6.40</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Stock option awards granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,248</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2.17</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Stock option awards vested</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,278</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4.99</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Stock option awards forfeited</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(235</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6.79</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance December&nbsp;31, 2016</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,598</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5.40</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of December&nbsp;31, 2016, there was approximately $14,541 of total
unrecognized compensation cost related to non-vested employee stock option awards and restricted stock units granted by the Company.
That cost is expected to be recognized as follows: $6,880 in 2017, $4,649 in 2018, $2,606 in 2019, and $406 in 2020.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Employee Stock Purchase Plan</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has reserved a total of 1,475&nbsp;shares of common stock
to be purchased under the ESPP, of which 422&nbsp;shares remain available for purchase at December&nbsp;31, 2016. Eligible employees
may authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price
during six-month purchase intervals. No more than 3 shares may be purchased by any one employee at the six-month purchase dates
and no employee may purchase stock having a fair market value at the commencement date of $25 or more in any one calendar year.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">There were 75, 41 and 49 shares of common stock purchased under the
ESPP in 2016, 2015, and 2014, respectively, at a weighted average price per share of $4.36, $8.65 and $6.29, respectively. Expense
of $147, $220 and $214 related to the ESPP was recognized during 2016, 2015, and 2014, respectively. Compensation expense for shares
purchased under the ESPP related to the purchase discount and the &#8220;look-back&#8221; option were determined using a Black-Scholes
option pricing model. The weighted average grant date fair values of shares granted under the ESPP during 2016, 2015, and 2014,
were $1.95, $4.93 and $4.41, respectively.</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note&nbsp;8&nbsp;&#8212; Income Taxes</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has incurred net losses since inception and, consequently,
has not recorded any U.S.&nbsp;Federal and state income tax expense or benefit. The differences between the Company&#8217;s effective
tax rate and the statutory tax rate in 2016, 2015, and 2014 are as follows:</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; font-size: 10pt; text-align: left">Income tax benefit at federal statutory rate (35%)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(19,300</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(15,057</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(15,816</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">State and local income taxes net of federal tax benefit</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,173</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(819</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,286</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Permanent items</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,057</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">560</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">258</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Rate change</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,080</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,012</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Expiration of attribute carryforwards</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">559</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">330</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">373</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Research and development tax credits</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(4,681</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(10,454</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(748</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Orphan drug credit</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,798</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,307</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Other</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">822</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(218</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(115</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,838</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20,339</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">17,312</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Income tax expense</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes the impact of a tax position in its financial
statements if it is more likely than not that the position will be sustained on audit based on the technical merits of the position.
The Company has concluded that it has an uncertain tax position pertaining to its research and development and orphan drug credit
carryforwards. The Company has established these credits based on information and calculations it believes are appropriate and
the best estimate of the underlying credit. Any changes to the Company&#8217;s unrecognized tax benefits are offset by an adjustment
to the valuation allowance and there would be no impact on the Company&#8217;s financial statements. The Company does not expect
its unrecognized tax benefits to change significantly over the next 12 months.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">A reconciliation of the beginning and ending amount of unrecognized
tax benefits is as follows:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt">Balance at January&nbsp;1,</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">3,085</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">472</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Additions to current period tax positions</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,170</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,616</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Additions to prior period tax positions</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Reductions to prior period tax provisions</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance at December&nbsp;31,</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,255</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,085</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 67 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>BIOCRYST PHARMACEUTICALS, INC.<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#8217;s ability to utilize the net operating loss and
tax credit carryforwards in the future may be subject to substantial restrictions in the event of past or future ownership changes
as defined in Section&nbsp;382 of the Internal Revenue Code of 1986, as amended and similar state tax law.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Significant components of the Company&#8217;s deferred tax assets
and liabilities are as follows:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred tax assets:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; font-size: 10pt; text-align: left; text-indent: 10pt">Net federal and state operating losses</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">158,618</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">142,836</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Research and development credits</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">53,231</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">48,551</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Fixed assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,054</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Deferred revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,484</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,240</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock-based compensation</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,952</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,605</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Other</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,849</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,590</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total deferred tax assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">227,134</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">207,876</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred tax liabilities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Fixed assets</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</td><TD STYLE="font-size: 10pt; text-align: right">(674</td><TD STYLE="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</td><TD STYLE="font-size: 10pt; text-align: right">&#8212;</td><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Foreign currency derivative</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,415</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,668</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total deferred tax liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,089</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,668</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(225,045</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(205,208</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net deferred tax assets</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The majority of the Company&#8217;s deferred tax assets relate to
net operating loss and research and development carryforwards that can only be realized if the Company is profitable in future
periods. It is uncertain whether the Company will realize any tax benefit related to these carryforwards. Accordingly, the Company
has provided a full valuation allowance against the net deferred tax assets due to uncertainties as to their ultimate realization.
The valuation allowance will remain at the full amount of the deferred tax assets until it is more likely than not that the related
tax benefits will be realized. The Company&#8217;s valuation allowance increased by $19,837 in 2016, $20,339 in 2015 and $17,312
in 2014.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of December&nbsp;31, 2016, the Company had federal operating loss
carryforwards of $431,983, state operating loss carryforwards of $403,237, and research and development and orphan drug credit
carryforwards of $57,487, which will expire at various dates from 2017 through 2035. The federal losses begin to expire in 2018,
the state losses begin to expire in 2017 and the research and development credit carryforwards begin to expire in 2018.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#8217;s federal and state operating loss carryforwards
include $15,655 of excess tax benefits related to a deduction from the exercise of stock options. The tax benefit of these deductions
has not been recognized in deferred tax assets. If utilized, the benefits from these deductions will be recorded as adjustments
to additional paid-in capital.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Tax years 2013-2015 remain open to examination by the major taxing
jurisdictions to which the Company is subject. Additionally, years prior to 2013 are also open to examination to the extent of
loss and credit carryforwards from those years. The Company recognizes interest and penalties accrued related to unrecognized tax
benefits as components of its income tax provision. However, there were no provisions or accruals for interest and penalties in
2016, 2015, and 2014.</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note&nbsp;9&nbsp;&#8212; Employee 401(k) Plan</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In January 1991, the Company adopted an employee retirement plan (&#8220;401(k)
Plan&#8221;) under Section&nbsp;401(k) of the Internal Revenue Code covering all employees. Employee contributions may be made
to the 401(k) Plan up to limits established by the Internal Revenue Service. Company matching contributions may be made at the
discretion of the Board of Directors. The Company made matching contributions of $504, $366 and $361, in 2016, 2015, and 2014,
respectively.</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note&nbsp;10&nbsp;&#8212; Collaborative and Other Research and Development Contracts</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>U.S.&nbsp;Department of Health and Human Services (&#8220;BARDA/HHS&#8221;).</i>
In January 2007, the U.S.&nbsp;Department of Health and Human Services (&#8220;BARDA/HHS&#8221;) awarded the Company a $102,661,
four-year contract for the advanced development of peramivir for the treatment of influenza. During 2009, peramivir clinical development
shifted to focus on intravenous delivery and the treatment of hospitalized patients. To support this focus, a September 2009 contract
modification was awarded to extend the i.v. peramivir program and to increase funding by $77,191. On February&nbsp;24, 2011, the
Company announced that BARDA/HHS had awarded it a $55,000 contract modification, intended to fund completion of the Phase 3 development
of i.v. peramivir for the treatment of patients hospitalized with influenza. That contract modification brought the total contract
award from BARDA/HHS to $234,852 and provided funding to support the filing of a NDA to seek regulatory approval for i.v. peramivir
in the U.S. In December 2013, BioCryst submitted an NDA filing for i.v. peramivir to the FDA and the NDA was approved in December
2014. The BARDA/HHS contract expired on June 30, 2014.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 68 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>BIOCRYST PHARMACEUTICALS, INC.<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March 31, 2015, the Company announced that BARDA/HHS had awarded
the Company a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens,
including filoviruses.&nbsp;This BARDA/HHS contract includes a base contract of $16,265 to support galidesivir drug manufacturing,
as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the
contract to $39,120. As of December 31, 2016, a total of $20,574 has been awarded under exercised options within this contract.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><I>National Institute of Allergy and Infectious Diseases (&ldquo;NIAID/HHS&rdquo;).
</I>In September 2013, NIAID/HHS contracted with the Company for the development of galidesivir as a treatment for Marburg virus
disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company. The goals of this
contract, including amendments, are to file IND applications for intravenous (&ldquo;i.v.&rdquo;) and intramuscular (&ldquo;i.m.&rdquo;)
galidesivir for the treatment of Marburg virus disease and other hemorrhagic fever virus diseases, including Ebola virus disease,
and to conduct an initial Phase 1 human clinical trial. As of December 31, 2016, the total NIAID/HHS contract amount to advance
the program through the completion of the Phase I clinical program is $39,477. As of December 31, 2016, all options have been
exercised under this contract.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee
contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contract provisions
that are related to the development of galidesivir plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments
of progress and the continuation of the contract is based on the Company&#8217;s performance, the timeliness and quality of deliverables,
and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable
by the government at any time for breach or without cause.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>Seqirus UK Limited (&#8220;SUL&#8221;).</i> On June 16, 2015, the
Company and Seqirus UK Limited ("SUL"), a limited company organized under the laws of the United Kingdom and a subsidiary
of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the "SUL Agreement")
granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the
treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies
together constituting the "Territory"). Peramivir is an intravenous treatment for acute uncomplicated influenza and is
currently approved for use in the United States, Canada, Japan, Taiwan and Korea. Peramivir is the first and only intravenous influenza
treatment in the world and was approved by the U.S. Food and Drug Administration in December 2014 for the treatment of acute uncomplicated
influenza in patients 18 years and older who have been symptomatic for no more than two days. The Company retains all rights and
associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to pursue
government stockpiling outside the U.S.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Pursuant to the SUL Agreement, RAPIVAB will be commercialized by CSL's
subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets.
SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization
of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company is responsible for
fulfilling all post-marketing approval commitments in connection with the FDA's approval of the NDA, and upon fulfillment will
transfer ownership of and financial responsibility for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and
the EU, the Company is also responsible for regulatory filings and interactions with the Health Canada and the European Medicines
Agency ("EMA") until marketing approval for RAPIVAB is obtained and assigned to SUL. In accordance with the SUL Agreement,
the Company and SUL formed a joint steering committee, composed of an equal number of representatives from each party, to oversee,
review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory and any additional development.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company received an upfront
payment of $33,740, and may receive up to $12,000 in additional milestone payments related to the successful achievement of regulatory
milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in
the EU and (iii) by Health Canada for an adult indication in Canada. The Company is also entitled under the SUL Agreement to receive
tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well
as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the
Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract
Year (defined as July 1 - June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the
Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events
impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire,
on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from
the date of the SUL Agreement (the "Royalty Term"). The Company developed peramivir under a license from UAB and will
owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from SUL.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i></i></p>

<!-- Field: Page; Sequence: 69 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>BIOCRYST PHARMACEUTICALS, INC.<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>Shionogi&nbsp;&amp; Co., Ltd. (&#8220;Shionogi&#8221;).</i> In
February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in
Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi
obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and
will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In
October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include
Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan and Taiwan.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>Green Cross Corporation (&#8220;Green Cross&#8221;).</i> In June
2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of
the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company
received a one-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale
of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross
will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products
in Korea.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>Mundipharma International Holdings Limited (&#8220;Mundipharma&#8221;).</i>
In February 2006, the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development
and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&#8220;PNP&#8221;) inhibitor, for use in oncology (the
&#8220;Original Agreement&#8221;). Under the terms of the Original Agreement, Mundipharma obtained rights to forodesine in markets
across Europe, Asia, and Australasia in exchange for a $10,000 up-front payment.</p>

<p style="font-size: 10pt; text-align: center; text-indent: 27pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company deferred revenue recognition of the $10,000 up-front payment
that was received from Mundipharma in February&nbsp;2006 because the Company was involved in the continued development of forodesine.
Amortization of this revenue commenced in February 2006 and was initially scheduled to end in October 2017, which is the date of
expiration for the last-to-expire patent covered by the agreement. The Company also deferred revenue recognition of a $5,000 payment
received from Mundipharma in connection with the initiation of a clinical trial in 2007. Amortization of this revenue commenced
in 2007 and was initially scheduled to end in October 2017. Under its agreement with AECOM/IRL, the Company paid sublicense payments
related to these upfront cash payments received from Mundipharma. Expense recognition of these sublicense payments was deferred
and recognized under the same term as the related deferred revenue.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On November&nbsp;11, 2011, the Company entered into the Amended and
Restated License and Development Agreement (the &#8220;Amended and Restated Agreement&#8221;) with Mundipharma, amending and restating
the Original Agreement. Under the terms of the Amended and Restated Agreement, Mundipharma obtained worldwide rights to forodesine.
Commencing on November&nbsp;11, 2011, Mundipharma controls the development and commercialization of forodesine and assumes all
future development and commercialization costs. The Amended and Restated Agreement provides for the possibility of future event
payments totaling $15,000 for achieving specified regulatory events for certain indications and tiered royalties ranging from mid
to high single-digit percentages of net product sales in each country where forodesine is sold by Mundipharma. These royalties
are subject to downward adjustments based on the then-existing patent coverage and/or the availability of generic compounds in
each country.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Amended and Restated Agreement is a multiple element arrangement
for accounting purposes, in which the Company is required to deliver to Mundipharma both the worldwide rights to forodesine in
the field of oncology and the transfer of product data and know-how to permit Mundipharma to develop and commercialize forodesine
(the &#8220;Knowledge Transfer&#8221;). The Company accounted for these elements as a combined unit of accounting as they do not
have stand-alone value to Mundipharma. The worldwide license rights were granted to Mundipharma on November&nbsp;11, 2011 and the
Knowledge Transfer was completed during the first quarter of 2012. Upon completion of the Knowledge Transfer, the remaining deferred
revenue and deferred expense was recognized in full.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>Albert Einstein College of Medicine of Yeshiva University and Industrial
Research, Ltd. (&#8220;AECOM&#8221; and &#8220;IRL&#8221; respectively).</i> In June 2000, the Company licensed a series of potent
inhibitors of PNP from AECOM and IRL, (collectively, the &#8220;Licensors&#8221;). The lead product candidates from this collaboration
are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or
any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement
to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially
reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed
product (which range in the aggregate from $1,400 to almost $4,000&nbsp;per indication) for future development of these inhibitors,
single digit royalties on net sales of any resulting product made by the Company, and to share approximately one quarter of future
payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which
can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement
may be terminated by the Company at any time by giving 60&nbsp;days advance notice or in the event of material uncured breach by
the Licensors.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 70 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>BIOCRYST PHARMACEUTICALS, INC.<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In May 2010, the Company amended the licensee agreement through which
the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from
research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed
to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees of the licensed
PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i)&nbsp;any milestone payments the Company
may receive in the future under its license agreement dated February&nbsp;1, 2006 with Mundipharma and (ii)&nbsp;royalties received
from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect.
The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In consideration for these modifications in 2010, the Company issued
to the Licensors shares of its common stock with an aggregate value of $5,911 and paid the Licensors $90 in cash. Additionally,
at the Company&#8217;s sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid
by it to the Licensors under the license agreement may be made either in cash, in shares of its common stock, or in a combination
of cash and shares.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On November&nbsp;17, 2011, the Company further amended its agreements
with the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined)
received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On June&nbsp;19, 2012, the Company further amended its agreements
with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to
exclusive worldwide license of galidesivir to BioCryst for any antiviral use.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At its sole option and subject to certain agreed upon conditions,
any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement may be made either in cash,
in shares of the Company&#8217;s common stock, or in a combination of cash and shares.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On January 6, 2014, the Carbohydrate Chemistry Research Team from
Callaghan Innovation Research Limited, formerly Industrial Research Limited, transferred to Victoria University of Wellington (&#8220;VUW&#8221;)
to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts
relating to that intellectual property were transferred to a wholly owned subsidiary of VUW, including the contracts to which BioCryst
is a party. The parties executed novation agreements in order to effectuate the transfer. Except for a substitution of parties,
the terms and conditions of the contracts are substantially the same</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>The University of Alabama at Birmingham (&#8220;UAB&#8221;).</i>
The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements,
UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain
rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company
has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other
third-party partners. The Company has completed the research under the UAB agreements. These two agreements have initial 25-year
terms, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company
upon three months&#8217; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other
parties&#8217; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall
resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements,
but when the Company licenses this technology, such as in the case of the Shionogi, Green Cross and SUL agreements, or commercializes
products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note&nbsp;11&nbsp;&#8212; Quarterly Financial Information (Unaudited)</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">First</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Second</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Third</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fourth</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">2016 Quarters</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 48%; font-size: 10pt; text-indent: 10pt">Revenues</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">4,820</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">4,787</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">7,763</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">8,983</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Net Loss</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(22,832</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(16,281</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(11,528</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(4,503</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Basic and diluted net loss per share</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.31</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.22</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.16</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.06</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">2015 Quarters</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: 10pt">Revenues</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">6,826</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">25,842</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">10,987</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">4,602</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Net (Loss) Income</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(15,164</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,901</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(14,621</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(18,135</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Basic net (loss) income per share</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.21</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.07</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.20</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.25</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Diluted net (loss) income per share</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.21</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.06</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.20</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.25</td><td style="font-size: 10pt; text-align: left">)</td></tr>
</table></div>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p></div><p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 71 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>BIOCRYST PHARMACEUTICALS, INC.<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note&nbsp;12&nbsp;&#8212; Recent Accounting Pronouncements</b> &nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In November 2016 the Financial Accounting Standards Board (&ldquo;FASB&rdquo;)
issued Accounting Standards Update 2016-18: <I>Statement of Cash Flows (Topic 230): Restricted Cash </I>(&ldquo;ASU 2016-18&rdquo;).
The new standard requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents
and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted
cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period
and end-of-period total amounts shown on the statement of cash flows. The standard is effective for annual periods beginning after
December&nbsp;15, 2017, and interim periods within those annual reporting periods. Early adoption is permitted. The Company is
currently evaluating the impact of this update on its consolidated financial statements.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In August 2016, the FASB issued Accounting Standards Update No. 2016-15:
<i>Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</i> (&#8220;ASU 2016-15&#8221;).
The amendments in this update clarify how entities should classify certain cash receipts and cash payments on the Consolidated
Statements of Cash Flows. The new guidance also clarifies how the predominance principle should be applied when cash receipts and
cash payments have aspects of more than one class of cash flows. ASU 2016-15 will be effective for annual periods beginning after
December 15, 2017, including interim periods within those annual reporting periods, but early adoption is permitted. The Company
is currently evaluating the impact of this update on its consolidated financial statements.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In March 2016, the FASB issued Accounting Standards Update No. 2016-09:
<i>Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</i> (&#8220;ASU 2016-09&#8221;).
The amendments in this update simplify several aspects of the accounting for employee share-based payment transactions, including
the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement
of cash flows. ASU 2016-09 will be effective for the Company in fiscal year 2017, but early adoption is permitted. The Company
is currently evaluating the impact of this update on its consolidated financial statements.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In February 2016, the FASB issued Accounting Standards Update No.
2016-02: <i>Leases (Topic 842)</i> (&#8220;ASU 2016-02&#8221;). The amendments in this update require lessees, among other things,
to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous
authoritative guidance. This update also introduces new disclosure requirements for leasing arrangements. ASU 2016-02 will be effective
for the Company in fiscal year 2019, but early adoption is permitted. The Company is currently evaluating the impact of this update
on its consolidated financial statements.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In January 2016, the FASB issued Accounting Standards Update No. 2016-01:
<i>Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</i>
(&#8220;ASU 2016-01&#8221;). The amendments in this update address certain aspects of recognition, measurement, presentation and
disclosure of financial instruments. In particular, the amendments in this update supersede, for public business entities, the
requirement to disclose the methods and significant assumptions used in calculating the fair value of financial instruments required
to be disclosed for financial instruments measured at amortized cost on the balance sheet. ASU 2016-01 will be effective for the
Company in fiscal year 2018, but early adoption is permitted. The Company does not expect this standard to have a material impact
on its consolidated financial statements.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In July 2015, the FASB issued Accounting Standards Update No. 2015-11:
<i>Inventory (Topic 330): Simplifying the Measurement of Inventory</i> (&#8220;ASU 2015-11&#8221;), which changes the measurement
principle for inventory from the lower of cost or market to the lower of cost and net realizable value. ASU 2015-11 defines net
realizable value as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion,
disposal, and transportation. The update does not apply to inventory that is measured using last-in, first-out or the retail inventory
method. The update applies to all other inventory, which includes inventory that is measured using first-in, first-out or average
cost methods. The amendments in ASU 2015-11 will be effective for the Company for fiscal years, and the interim periods within
those years, beginning after December 15, 2016. The amendments must be applied prospectively and early adoption is permitted. The
Company does not expect this standard to have a material impact on its consolidated financial statements.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In May 2014, the FASB issued Standards Update No. 2014-09: <i>Revenue
from Contracts with Customers (Topic 606)</i> (&#8220;ASU 2014-09&#8221;), which provides a single, comprehensive revenue recognition
model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers
promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled
in exchange for those goods or services. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty
of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets
recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective
date of this standard, which will now be effective January 1, 2018; however, early adoption is permitted any time after the original
effective date, January 1, 2017. The Company is not electing early adoption. Companies can transition to the new standard under
the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this standard
will have on its consolidated financial statements.</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;<b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 72; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b><a name="a_028"></a>Report of Independent Registered Public Accounting Firm</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">The Board of Directors and Stockholders</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have audited the consolidated balance sheets of BioCryst Pharmaceuticals,
Inc. as of December 31, 2016 and 2015, and the related consolidated statements of comprehensive loss, stockholders&#8217; equity
and cash flows for each of the three years in the period ended December&nbsp;31, 2016. These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We conducted our audits in accordance with the standards of the Public
Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles
used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe
that our audits provide a reasonable basis for our opinion.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In our opinion, the financial statements referred to above present
fairly, in all material respects, the consolidated financial position of BioCryst Pharmaceuticals, Inc. at December&nbsp;31, 2016
and 2015, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December&nbsp;31,
2016, in conformity with U.S.&nbsp;generally accepted accounting principles.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We also have audited, in accordance with the standards of the Public
Company Accounting Oversight Board (United States), BioCryst Pharmaceuticals, Inc.&#8217;s internal control over financial reporting
as of December&nbsp;31, 2016, based on criteria established in <i>Internal Control-Integrated Framework</i> issued by the Committee
of Sponsoring Organizations of the Treadway Commission (2013 Framework) and our report dated February 27, 2017 expressed an unqualified
opinion thereon.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 32%">&nbsp;</td>
    <td style="width: 36%">&nbsp;</td>
    <td style="width: 32%"><font style="font-size: 10pt">/s/&nbsp;Ernst&nbsp;&amp; Young LLP</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Raleigh, North Carolina</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">February 27, 2017</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 73; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0"><b><a name="a_029"></a>Report of Independent Registered Public Accounting
Firm</b></p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">The Board of Directors and Stockholders</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have audited BioCryst Pharmaceuticals, Inc.&#8217;s internal control
over financial reporting as of December&nbsp;31, 2016, based on criteria established in <i>Internal Control-Integrated Framework</i>
issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) (the COSO criteria). BioCryst Pharmaceuticals,
Inc.&#8217;s management is responsible for maintaining effective internal control over financial reporting, and for its assessment
of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal
Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial
reporting based on our audit.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We conducted our audit in accordance with the standards of the Public
Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit
included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists,
testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such
other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our
opinion.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">A company&#8217;s internal control over financial reporting is a process
designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial
reporting includes those policies and procedures that (1)&nbsp;pertain to the maintenance of records that, in reasonable detail,
accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&nbsp;provide reasonable assurance
that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted
accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations
of management and directors of the company; and (3)&nbsp;provide reasonable assurance regarding prevention or timely detection
of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial
statements.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Because of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject
to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies
or procedures may deteriorate.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In our opinion, BioCryst Pharmaceuticals, Inc. maintained, in all
material respects, effective internal control over financial reporting as of December&nbsp;31, 2016, based on the COSO criteria.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We also have audited, in accordance with the standards of the Public
Company Accounting Oversight Board (United States), the consolidated balance sheets of BioCryst Pharmaceuticals, Inc. as of December&nbsp;31,
2016 and 2015, and the related consolidated statements of comprehensive loss, stockholders&#8217; equity, and cash flows for each
of the three years in the period ended December&nbsp;31, 2016 of BioCryst Pharmaceuticals, Inc. and our report dated February 27,
2017 expressed an unqualified opinion thereon.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 32%">&nbsp;</td>
    <td style="width: 36%">&nbsp;</td>
    <td style="width: 32%"><font style="font-size: 10pt">/s/&nbsp;Ernst&nbsp;&amp; Young LLP</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Raleigh, North Carolina</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">February 27, 2017</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 74; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><font style="font-size: 10pt"><b><a name="a_012"></a>ITEM 9.</b></font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt"><b> <i>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
ON ACCOUNTING AND FINANCIAL DISCLOSURE</i></b></font></td>
</tr></table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">None.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><font style="font-size: 10pt"><b><a name="a_013"></a>ITEM 9A.</b></font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt"><b> <i>CONTROLS AND PROCEDURES</i></b></font></td>
</tr></table>
<p style="font-size: 10pt; margin: 0pt 0 0pt 4.5pt"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Evaluation of Disclosure Controls and Procedures</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 4.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We maintain a set of disclosure controls and procedures that are designed
to ensure that information relating to BioCryst Pharmaceuticals, Inc. required to be disclosed in our periodic filings under the
Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), is recorded, processed, summarized and reported in
a timely manner under the Exchange Act of 1934. We carried out an evaluation as required by paragraph (b)&nbsp;of Rule&nbsp;13a-15
or Rule&nbsp;15d-15 under the Exchange Act, under the supervision and with the participation of management, including our Chief
Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and
procedures (as defined in Rule&nbsp;13a-15(e) or Rule&nbsp;15d-15 under the Exchange Act). Based upon that evaluation, the Chief
Executive Officer and Chief Financial Officer concluded that, as of December&nbsp;31, 2016, our disclosure controls and procedures
are effective. We believe that our disclosure controls and procedures will ensure that information required to be disclosed in
the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported within the time periods
specified in the rules and forms of the Securities and Exchange Commission, and include controls and procedures designed to ensure
that information required to be disclosed by us in such reports is accumulated and communicated to our management, including our
Chairman and Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Management&#8217;s Report on Internal Control Over Financial Reporting</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 4.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Management of BioCryst Pharmaceuticals, Inc. is responsible for establishing
and maintaining adequate internal control over financial reporting and for the assessment of the effectiveness of internal control
over financial reporting. As defined by the Securities and Exchange Commission, internal control over financial reporting is a
process designed by, or under the supervision of our principal executive and principal financial officers and effected by our Board
of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of the financial statements in accordance with U.S.&nbsp;GAAP.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our internal control over financial reporting is supported by written
policies and procedures that (1)&nbsp;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect
our transactions and dispositions of our assets; (2)&nbsp;provide reasonable assurance that transactions are recorded as necessary
to permit preparation of the financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being
made only in accordance with authorizations of our management and directors; and (3)&nbsp;provide reasonable assurance regarding
prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect
on the financial statements.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Because of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject
to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies
or procedures may deteriorate.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the preparation of our annual financial statements,
management has undertaken an assessment of the effectiveness of our internal control over financial reporting as of December&nbsp;31,
2016, based on criteria established in Internal Control&nbsp;&#8212; Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission (2013 Framework) (the COSO Framework). Management&#8217;s assessment included an evaluation
of the design of our internal control over financial reporting and testing of the operational effectiveness of those controls.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on this assessment, management has concluded that as of December&nbsp;31,
2016, our internal control over financial reporting was effective. Management believes our internal control over financial reporting
will provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with U.S. GAAP.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Ernst&nbsp;&amp; Young LLP, the independent registered public accounting
firm that audited our financial statements included in this report, has issued an attestation report on the Company&#8217;s internal
control over financial reporting, a copy of which appears on page&nbsp;80 of this annual report.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Changes in Internal Control over Financial Reporting</b> &nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">There have been no changes in our internal control over financial
reporting that occurred during the quarter ended December&nbsp;31, 2016 that have materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 75; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><font style="font-size: 10pt"><b><a name="a_014"></a>ITEM 9B.</b></font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt"><b> <i>OTHER INFORMATION</i></b></font></td>
</tr></table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">None.&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>PART&nbsp;III</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><font style="font-size: 10pt"><b><a name="a_015"></a>ITEM 10.</b></font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt"><b> <i>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE
GOVERNANCE</i></b></font></td>
</tr></table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The information required by this item is set forth under the captions
<i>&#8220;Items to be Voted on&nbsp;&#8212; 1. Election of Directors,&#8221; &#8220;Executive Officers,&#8221; &#8220;Section&nbsp;16(a)
Beneficial Ownership Reporting Compliance&#8221;</i> and <i>&#8220;Corporate Governance&#8221;</i> in our definitive Proxy Statement
for the 2017 Annual Meeting of Stockholders and incorporated herein by reference.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><font style="font-size: 10pt"><b><a name="a_016"></a>ITEM 11.</b></font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt"><b> <i>EXECUTIVE COMPENSATION</i></b></font></td>
</tr></table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The information required by this item is set forth under the captions
<i>&#8220;Compensation Discussion and Analysis,&#8221; &#8220;Summary Compensation Table,&#8221; &#8220;Grants of Plan-Based Awards
in 2016,&#8221; &#8220;Outstanding Equity Awards at December&nbsp;31, 2016,&#8221; &#8220;2016 Option Exercises and Stock Vested,&#8221;
&#8220;Potential Payments Upon Termination or Change in Control,&#8221; &#8220;2016 Director Compensation,&#8221; &#8220;Compensation
Committee Interlocks and Insider Participation&#8221;</i> and <i>&#8220;Compensation Committee Report&#8221;</i> in our definitive
Proxy Statement for the 2017 Annual Meeting of Stockholders and incorporated herein by reference.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><font style="font-size: 10pt"><b><a name="a_017"></a>ITEM 12.</b></font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt"><b> <i>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</i></b></font></td>
</tr></table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The information required by this item is set forth under the captions
<i>&#8220;Equity Compensation Plan Information&#8221;</i> and <i>&#8220;Security Ownership of Certain Beneficial Owners and Management&#8221;</i>
in our definitive Proxy Statement for the 2017 Annual Meeting of Stockholders and incorporated herein by reference.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><font style="font-size: 10pt"><b><a name="a_018"></a>ITEM 13.</b></font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt"><b> <i>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS,
AND DIRECTOR INDEPENDENCE</i></b></font></td>
</tr></table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The information required by this item is set forth under the captions
<i>&#8220;Certain Relationships and Related Transactions&#8221;</i> and &#8220;Corporate <i>Governance&#8221;</i> in our definitive
Proxy Statement for the 2017 Annual Meeting of Stockholders and incorporated herein by reference.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><font style="font-size: 10pt"><b><a name="a_019"></a>ITEM 14.</b></font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt"><b> <i>PRINCIPAL ACCOUNTING FEES AND SERVICES</i></b></font></td>
</tr></table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The information required by this item is set forth under the caption
<i>&#8220;Ratification of Appointment of Independent Registered Public Accountants&#8221;</i> in our definitive Proxy Statement
for the 2017 Annual Meeting of Stockholders and incorporated herein by reference.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>PART&nbsp;IV</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><font style="font-size: 10pt"><b><a name="a_020"></a>ITEM 15.</b></font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="font-size: 10pt"><b> <i>EXHIBITS, FINANCIAL STATEMENT SCHEDULES</i></b></font></td>
</tr></table>
<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><i>&nbsp;</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><i>(a)&nbsp;Financial Statements</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">The following financial statements appear in Item&nbsp;8 of this Form&nbsp;10-K:</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Page&nbsp;in</b></font><br>
<font style="font-size: 10pt"><b>Form&nbsp;10-K</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 86%; text-decoration: underline"><a href="#a_023"><font style="font-size: 10pt"><u>Consolidated Balance Sheets at December&nbsp;31, 2016 and 2015</u></font></a></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 9%; text-decoration: underline; text-align: right"><a href="#a_023"><font style="font-size: 10pt"><u>49</u></font></a></td>
    <td style="width: 2%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-decoration: underline"><a href="#a_024"><font style="font-size: 10pt"><u>Consolidated Statements of Comprehensive Loss for the years ended December&nbsp;31, 2016, 2015 and 2014</u></font></a></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-decoration: underline; text-align: right"><a href="#a_024"><font style="font-size: 10pt"><u>50</u></font></a></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-decoration: underline"><a href="#a_025"><font style="font-size: 10pt"><u>Consolidated Statements of Cash Flows for the years ended December&nbsp;31, 2016, 2015 and 2014</u></font></a></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-decoration: underline; text-align: right"><a href="#a_025"><font style="font-size: 10pt"><u>51</u></font></a></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-decoration: underline"><a href="#a_026"><font style="font-size: 10pt"><u>Consolidated Statements of Stockholders&#8217; Equity for the years ended December&nbsp;31, 2016, 2015 and 2014</u></font></a></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-decoration: underline; text-align: right"><a href="#a_026"><font style="font-size: 10pt"><u>52</u></font></a></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-decoration: underline"><a href="#a_027"><font style="font-size: 10pt"><u>Notes to Consolidated Financial Statements</u></font></a></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-decoration: underline; text-align: right"><a href="#a_027"><font style="font-size: 10pt"><u>53</u></font></a></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-decoration: underline"><a href="#a_028"><font style="font-size: 10pt"><u>Report of Independent Registered Public Accounting Firm on Consolidated Financial Statements</u></font></a></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-decoration: underline; text-align: right"><a href="#a_028"><font style="font-size: 10pt"><u>73</u></font></a></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-decoration: underline"><a href="#a_029"><font style="font-size: 10pt"><u>Report of Independent Registered Public Accounting Firm on Internal Control</u></font></a></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-decoration: underline; text-align: right"><a href="#a_029"><font style="font-size: 10pt"><u>74</u></font></a></td>
    <td>&nbsp;</td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">No financial statement schedules are included because the information
is either provided in the consolidated financial statements or is not required under the related instructions or is inapplicable
and such schedules therefore have been omitted.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 12pt">(b)&nbsp; <i>Exhibits.</i> See Index of Exhibits.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 76; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b><a name="a_021"></a>SIGNATURES</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized on February 27, 2017.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" nowrap><font style="font-size: 10pt">BIOCRYST PHARMACEUTICALS, INC.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 32%">&nbsp;</td>
    <td style="width: 36%">&nbsp;</td>
    <td style="width: 4%"><font style="font-size: 10pt">By:&nbsp;</font></td>
    <td style="width: 28%; border-bottom: black 1pt solid"><font style="font-size: 10pt">/s/&nbsp;Jon P. Stonehouse</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Jon P. Stonehouse</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td nowrap><font style="font-size: 10pt"><i>Chief Executive Officer</i></font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on February
27, 2017:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 32%">&nbsp;</td>
    <td style="width: 36%">&nbsp;</td>
    <td style="width: 32%; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-decoration: underline; text-align: center"><font style="font-size: 10pt"><b><u>Signature</u></b></font></td>
    <td>&nbsp;</td>
    <td style="text-decoration: underline; text-align: center"><font style="font-size: 10pt"><b><u>Title(s)</u></b></font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">/s/&nbsp;Jon P. Stonehouse</font></td>
    <td>&nbsp;</td>
    <td nowrap style="text-align: center"><font style="font-size: 10pt">President, Chief Executive Officer and Director</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">(Jon P. Stonehouse)</font></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><font style="font-size: 10pt">(Principal Executive Officer)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid">
        <p style="font-size: 10pt; margin: 0pt 0.8pt 0pt 0">&nbsp;</p>
        <p style="font-size: 10pt; margin: 0pt 0.8pt 0pt 0">/s/&nbsp;Thomas R. Staab II</p></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><font style="font-size: 10pt">Senior Vice President, Chief Financial Officer and Treasurer</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">(Thomas R. Staab II)</font></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><font style="font-size: 10pt">(Principal Financial Officer and Principal Accounting Officer)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">/s/ George B. Abercrombie</font></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><font style="font-size: 10pt">Director</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">(George B. Abercrombie)</font></td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">/s/&nbsp;Fred E. Cohen</font></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><font style="font-size: 10pt">Director</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">(Fred E. Cohen, M.D., D. Phil)</font></td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">/s/ Stanley C. Erck</font></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><font style="font-size: 10pt">Director</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">(Stanley C. Erck)</font></td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">/s/ Nancy Hutson</font></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><font style="font-size: 10pt">Director</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">(Nancy Hutson, Ph.D.)</font></td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">/s/ Robert A. Ingram</font></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><font style="font-size: 10pt">Director</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">(Robert A. Ingram)</font></td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">/s/&nbsp;Kenneth B. Lee, Jr.</font></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><font style="font-size: 10pt">Director</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">(Kenneth B. Lee, Jr.)</font></td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">/s/&nbsp;Sanj K. Patel</font></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><font style="font-size: 10pt">Director</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">(Sanj K. Patel)</font></td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 77; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b><a name="a_022"></a>INDEX TO EXHIBITS</b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0.8pt 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 7%; text-decoration: underline"><font style="font-size: 10pt"><b><u>Number</u></b></font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 92%; text-decoration: underline"><font style="font-size: 10pt"><b><u>Description</u></b></font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">3.1</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed December 22, 2006.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">3.2</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed July 24, 2007.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">3.3</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed May 8, 2014.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">3.4</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Certificate of Increase of Authorized Number of Shares of Series B Junior Participating Preferred Stock. Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed November 4, 2008.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">3.5</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Certificate of Increase of Authorized Number of Shares of Series B Junior Participating Preferred Stock. Incorporated by reference to Exhibit 3.2 to the Company&#8217;s Form 8-K filed May 8, 2014.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">3.6</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amended and Restated Bylaws of Registrant effective October 29, 2008. Incorporated by reference to Exhibit 3.2 to the Company&#8217;s Form 8-K filed November 4, 2008.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">4.1</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Indenture, dated as of March 9, 2011 by and between JPR Royalty Sub LLC and U.S. Bank National Association, as trustee. Incorporated by reference to Exhibit 4.3 of the Company&#8217;s Form 10-Q filed May&nbsp;6, 2011.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.1&amp;</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amended and Restated Stock Incentive Plan dated March 29, 2012. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K, filed May 25, 2012.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.2&amp;</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amended and Restated Stock Incentive Plan dated March 8, 2014. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed May 5, 2014.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.3&amp;</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amended and Restated Stock Incentive Plan, dated April 4, 2016.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-8, filed May 23, 2016.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.4&amp;</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amended and Restated Employee Stock Purchase Plan dated March 29, 2012. Incorporated by reference to the Company&#8217;s Form 8-K, filed May 25, 2012.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.5&amp;</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amended and Restated Employee Stock Purchase Plan dated March 8, 2014. Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 8-K filed May 5, 2014.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.6&amp;</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Form of Notice of Grant of Non-Employee Director Automatic Stock Option and Stock Option Agreement. Incorporated by reference to Exhibit 10.4 of the Company&#8217;s Form 10-K filed March 4, 2008.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.7&amp;</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Form of Notice of Grant of Stock Option and Stock Option Agreement. Incorporated by reference to Exhibit 10.5 of the Company&#8217;s Form 10-K filed March 4, 2008.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.8&amp;</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Form of Notice of Grant of Stock Option and Stock Option Agreement.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.7 of the Company&#8217;s Form 10-K filed March 2, 2015.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.9&amp;</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Form of Notice of Grant of Restricted Stock Unit Award and Restricted Stock Unit Agreement.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.8 of the Company&#8217;s Form 10-K filed March 2, 2015.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.10&amp;</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Annual Incentive Plan. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K filed March 12, 2012.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.11&amp;</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Executive Relocation Policy. Incorporated by reference to Exhibit 10.2 of the Company&#8217;s Form&nbsp;10-K filed March 4, 2008.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.12&amp;</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amended and Restated Employment Letter Agreement dated February 14, 2007, by and between the Company and Jon P. Stonehouse. Incorporated by reference to Exhibit 10.12 to the Company&#8217;s Form 10-K for the year ended December 31, 2006, filed March 14, 2007.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td></td></tr></table>

<!-- Field: Page; Sequence: 78; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 92%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.13&amp;</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Thomas R. Staab II, dated May 23, 2011. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K filed May 25, 2011.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 7%"><font style="font-size: 10pt">10.14&amp;</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 92%"><font style="font-size: 10pt">Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and William P. Sheridan dated June 12, 2008. Incorporated by reference to Exhibit 10.27 of the Company&#8217;s Form 10-Q filed August 8, 2008.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.15&amp;</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Yarlagadda S. Babu dated April 27, 2012.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.16&amp;</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Alane P. Barnes dated August 8, 2013.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.17&amp;</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Lynne Powell dated December 30, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.16 of the Company&#8217;s Form 10-K filed March 2, 2015.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.18#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Agreement dated January 3, 2007, between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services, as amended by Amendment number 1 dated January 3, 2007 and Amendment number 2 dated May 11, 2007. Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Form 10-Q filed August 9, 2007. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.19</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #3 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services, dated October 2, 2007. Incorporated by reference to Exhibit 10.6 of the Company&#8217;s Form 10-K filed March 4, 2008.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.20</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #4 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated April 3, 2008. Incorporated by reference to Exhibit 10.29 of the Company&#8217;s Form 10-Q filed August 8, 2008.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.21</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #5 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated July 2, 2008. Incorporated by reference to Exhibit 10.30 of the Company&#8217;s Form 10-Q filed August 8, 2008.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.22</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #6 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated August&nbsp;18, 2008. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K filed November&nbsp;7, 2008.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.23</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #7 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated November&nbsp;17, 2008. Incorporated by reference to Exhibit 10.12 of the Company&#8217;s Form 10-K filed March&nbsp;6, 2009.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.24</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #8 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated March 13, 2009. Incorporated by reference to Exhibit&nbsp;10.13 of the Company&#8217;s Form 10-K filed March 9, 2010.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.25</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #9 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated September 18, 2009. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 10-Q filed November 6, 2009.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.26</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #10 to the Agreement between the Company and the U.S. Department of Health &amp; Human Services, dated October 15, 2009. Incorporated by reference to Exhibit 10.2 of the Company&#8217;s Form 10-Q filed November 6, 2009.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.27</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #11 to the Agreement between the Company and the U.S. Department of Health &amp; Human Services, dated February 23, 2011. Incorporated by reference to Exhibit 10.25 of the Company&#8217;s Form 10-K filed March 15, 2011.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.28</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Stop-Work Order from U.S. Department of Health and Human Services, dated March 26, 2013, relating to Agreement dated January 3, 2007 between the Company and the U.S. Department of Health and Human Services. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 10-Q filed May 9, 2013.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.29</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #13 to the Agreement between the Company and the U.S. Department of Health &amp; Human Services, dated February 15, 2012.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.30</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #14 to the Agreement between the Company and the U.S. Department of Health &amp; Human Services, dated June 4, 2013. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 10-Q filed June 5, 2013.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.31#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #15 to the Agreement between the Company and the U.S. Department of Health &amp; Human Services, dated September 5, 2013. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 10-Q filed November 8, 2013. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.32</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #16 to the Agreement between the Company and the U.S. Department of Health &amp; Human Services, dated December 17, 2013. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K filed December 23, 2013.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.33</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #17 to the Agreement between the Company and the U.S. Department of Health &amp; Human Services, dated February 21, 2014. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K filed February 26, 2014.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt"></p>

<!-- Field: Page; Sequence: 79; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">10.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></td>
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt">Order for Supplies or Services from the U.S. Department of Health &amp; Human Services, dated November 4, 2009. Incorporated by reference to Exhibit 10.16 of the Company&#8217;s Form 10-K filed March 9, 2010.</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">10.35</font></td>
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt">Amendment #18 to the Agreement between BioCryst Pharmaceuticals, Inc. and the U.S. Department of Health and Human Services, dated March 28, 2014. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed April 3, 2014.</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">10.36</font></td>
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt">Amendment #19 to the Agreement between BioCryst Pharmaceuticals, Inc. and the U.S. Department of Health and Human Services, dated April 29, 2014. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed May 2, 2014.</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">10.37</font></td>
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt">Amendment #20 to the Agreement to the Agreement between BioCryst Pharmaceuticals, Inc. and the U.S. Department of Health and Human Services, dated May 30, 2014. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed June 5, 2014.</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">10.38#</font></td>
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt">License, Development and Commercialization Agreement dated as of February 28, 2007, by and between the Company and Shionogi &amp; Co., Ltd. Incorporated by reference to Exhibit 10.4 to the Company&#8217;s Form 10-Q filed May 10, 2007. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">10.39#</font></td>
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt">First Amendment to License, Development and Commercialization Agreement, effective as of September 30, 2008, between the Company and Shionogi &amp; Co., Ltd. Incorporated by reference to Exhibit 10.19 to the Company&#8217;s Form 10-K filed March 6, 2009. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">10.40</font></td>
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt">Riverchase Business Park Warehouse Lease dated July 12, 2000 between RBP, LLC an Alabama Limited Liability Company and the Registrant for office/warehouse space. Incorporated by reference to Exhibit 10.8 to the Company&#8217;s Form 10-Q for the second quarter ending June 30, 2000 filed August 8, 2000.</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">10.41</font></td>
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt">Third Amendment to Lease Agreement dated August 7, 2007, by and between Riverchase Capital LLC, a Florida limited liability company, Stow Riverchase, LLC, a Florida limited liability company, as successor landlord to RBP, LLC and the Company. Incorporated by reference to Exhibit 10.4 of the Company&#8217;s Form 10-Q filed August 9, 2007.</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">10.42</font></td>
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt">Fourth Amendment to the Lease Agreement dated February 1, 2012, by and between Riverchase Capital LLC, a Florida limited liability company, Stow Riverchase, LLC, a Florida limited liability company, as successor landlord to RBP, LLC and the Company. Incorporated by reference to Exhibit 10.27 of the Company&#8217;s Form 10-K filed March 11, 2013.</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">10.43</font></td>
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt">Fifth Amendment to Lease Agreement dated January 15, 2015, by and between Riverchase Capital LLC, a Florida limited liability company, Stow Riverchase, LLC, a Florida limited liability company, as successor landlord to RBP, LLC and the Company.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.42 of the Company&#8217;s Form 10-K filed March 2, 2015.</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">10.44</font></td>
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt">Stock and Warrant Purchase Agreement dated as of August 6, 2007, by and among BioCryst Pharmaceuticals, Inc. and each of the Investors identified on the signature pages thereto. Incorporated by reference to Exhibit 4.1 of the Company&#8217;s Form 8-K filed August 7, 2007.</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">10.45</font></td>
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt">Stock Purchase Agreement, dated as of February&nbsp;17, 2005, by and among BioCryst Pharmaceuticals, Inc., Baker Bros. Investments, L.P., Baker Biotech Fund II, L.P., Baker Bros. Investments II, L.P., Baker Biotech Fund&nbsp;II (Z), L.P., Baker/Tisch Investments, L.P., Baker Biotech Fund III, L.P., Baker Biotech Fund&nbsp;I, L.P., Baker Biotech Fund&nbsp;III (Z), L.P. and 14159, L.P. Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Form 8-K filed February&nbsp;17, 2005.</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">10.46#</font></td>
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt">Development and License Agreement dated as of February 1, 2006, by and between BioCryst Pharmaceuticals, Inc. and Mundipharma International Holdings Limited. Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 8-K/A filed May 2, 2006. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">10.47#</font></td>
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt">Amended and Restated Development and License Agreement, dated as of November 11, 2011, by and between BioCryst Pharmaceuticals, Inc. and Mundipharma International Corporation Limited. Incorporated by reference to Exhibit 10.32 to the Company&#8217;s Form 10-K filed March 6, 2012. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">10.48#</font></td>
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt">License Agreement dated as of June 27, 2000, by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., as amended by the First Amendment Agreement dated as of July 26, 2002 and the Second Amendment Agreement dated as of April 15, 2005. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed November 30, 2005. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="3">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.49#</font></td>
    <td colspan="3">&nbsp;</td>
    <td><font style="font-size: 10pt">Third Amendment Agreement by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., dated as of December&nbsp;11, 2009. Incorporated by reference to Exhibit 10.33 to the Company&#8217;s Form 10-K filed March&nbsp;9, 2010. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
</table>


<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt"></p>

<!-- Field: Page; Sequence: 80; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.50#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Fourth Amendment Agreement by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., dated as of May 5, 2010. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q filed August 6, 2010. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.51#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Fifth Amendment Agreement by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., dated as of November 17, 2011. Incorporated by reference to Exhibit 10.36 to the Company&#8217;s Form 10-K filed March 6, 2012. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.52#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Sixth Amendment Agreement by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., dated as of June 19, 2012. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q filed August 8, 2012. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.53</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Novation Agreement among Albert Einstein College of Medicine of Yeshiva University, BioCryst Pharmaceuticals, Inc., Mundipharma International Corporation Limited, Callaghan Innovation Research Limited, and Victoria Link Limited, dated May 18, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.6 to the Company&#8217;s Form 10-Q filed August 7, 2015.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.54</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Novation Agreement among Albert Einstein College of Medicine of Yeshiva University, BioCryst Pharmaceuticals, Inc., Callaghan Innovation Research Limited, and Victoria Link Limited, dated June 24, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.7 to the Company&#8217;s Form 10-Q filed August 7, 2015.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.55</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Purchase and Sale Agreement, dated as of March 9, 2011 between BioCryst Pharmaceuticals, Inc. and JPR Royalty Sub LLC. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 10-Q filed May 6, 2011.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.56</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Pledge and Security Agreement, dated as of March 9, 2011 between BioCryst Pharmaceuticals, Inc. and U.S. Bank National Association, as trustee. Incorporated by reference to Exhibit 10.2 of the Company&#8217;s Form 10-Q filed May 6, 2011.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.57</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Confirmation of terms and conditions of ISDA Master Agreement, dated as of March 7, 2011, between Morgan Stanley Capital Services Inc. and BioCryst Pharmaceuticals, Inc. dated as of March 9, 2011. Incorporated by reference to Exhibit 10.3 of the Company&#8217;s Form 10-Q filed May 6, 2011.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.58#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Agreement, dated as of September&nbsp;12, 2013, between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases. Incorporated by reference to Exhibit 10.2 of the Company&#8217;s Form 10-Q filed November&nbsp;8, 2013. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.59#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #1 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated December 26, 2013.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.51 to the Company&#8217;s Form 10-K filed on March 10, 2014.&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.60#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #2 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated January 24, 2014.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.52 to the Company&#8217;s Form 10-K filed on March 10, 2014.&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.61#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #3 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 17, 2014. Incorporated by reference to Exhibit 10.5 to the Company&#8217;s Form 10-Q filed on August 8, 2014.&nbsp;&nbsp;&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.62#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #4 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 17, 2014. Incorporated by reference to Exhibit 10.6 to the Company&#8217;s Form 10-Q filed on August 8, 2014.&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.63#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #5 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated August 11, 2014. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q filed on November 7, 2014.&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.64#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #6 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated August 27, 2014.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 10-Q filed on November 7, 2014.&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.65#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #8 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated September 17, 2014.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Form 10-Q filed on November 7, 2014.&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
</table>


<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt"></p>

<!-- Field: Page; Sequence: 81; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt"></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.66#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #9 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated October 29, 2014.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.4 to the Company&#8217;s Form 10-Q filed on November 7, 2014.&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.67#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #10 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated February 13, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 10-Q filed on August 7, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.68#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #11 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated March 19, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Form 10-Q filed on August 7, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.69#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #12 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 12, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.4 to the Company&#8217;s Form 10-Q filed on August 7, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.70#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #13 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 17, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.5 to the Company&#8217;s Form 10-Q filed on August 7, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.71#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #14 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated September 16, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Form 10-Q filed on November 6, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.72</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #15 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated November 16, 2015. Incorporated by reference to Exhibit 10.70 to the Company&#8217;s Form 10-K filed on February 26, 2016.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.73#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #16 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated December 18, 2015. Incorporated by reference to Exhibit 10.71 to the Company&#8217;s Form 10-K filed on February 26, 2016. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">(10.74)</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #17 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated April 18, 2016. </font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.75#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #18 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 30, 2016. Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Form 10-Q filed on August 8, 2016. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.76#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #19 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated August 10, 2016. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q filed on November 8, 2016. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">(10.77)&#8224;</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #20 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National
    Institute of Allergy and Infectious Diseases, dated January 9, 2017. (Portions omitted pursuant to request for confidential
    treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.78#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, dated March 27, 2015. &nbsp;Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 10-Q filed on May 8, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.79#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #1 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response, dated June 2, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q filed on August 7, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.80#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #2 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response, dated July 8, 2015. &nbsp;Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q filed on November 6, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td></td></tr></table>

<!-- Field: Page; Sequence: 82; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 6%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.81#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #3 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response, dated August 25, 2015. &nbsp;Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 10-Q filed on November 6, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.82#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #4 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response, dated February 25, 2016. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q filed on May 9, 2016. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.83#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #5 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response, dated April 11, 2016. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q filed on August 8, 2016. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.84#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #6 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response, dated May 20, 2016. Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 10-Q filed on August 8, 2016. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.85#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Amendment #7 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response, dated September 26, 2016. Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 10-Q filed on November 8, 2016. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.86#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">License Agreement by and between BioCryst Pharmaceuticals, Inc. and Seqirus UK Limited, dated as of June 16, 2015. &nbsp;Incorporated by reference to Exhibit 10.8 to the Company&#8217;s Form 10-Q filed on May 8, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.87#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Credit and Security Agreement, dated as of September 23, 2016, by and among Midcap Financial Trust, as administrative agent, the Lenders listed on the Credit Facility Schedule attached thereto and otherwise party thereto from time to time, BioCryst Pharmaceuticals, Inc., and MDCP, LLC. Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Form 10-Q filed on November 8, 2016. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">(21)</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Subsidiaries of the Registrant.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">(23)</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Consent of Ernst &amp; Young, LLP, Independent Registered Public Accounting Firm.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">(31.1)</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">(31.2)</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">(32.1)</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Certification pursuant to 18&nbsp;U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">(32.2)</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Certification pursuant to 18&nbsp;U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">(101)</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Financial statements from the Annual Report on Form 10-K of BioCryst Pharmaceuticals, Inc. for the year ended December 31, 2016, formatted in XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Consolidated Statements of Cash Flows, (iv) Consolidated Statements of Stockholders&#8217; Equity and (v) Notes to Consolidated Financial Statements.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#8224;</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Confidential treatment requested.</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">#</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Confidential treatment granted.</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&amp;</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Management contracts.</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">(&nbsp;)</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Filed herewith.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0.8pt 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>



<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">83</p>

<!-- Field: Rule-Page --><div align="CENTER" style="margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></p>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.74
<SEQUENCE>2
<FILENAME>exh_1074.htm
<DESCRIPTION>EXHIBIT 10.74
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right; text-indent: 20pt"><B>Exhibit 10.74</B></P>

<P STYLE="margin: 0; text-align: right; text-indent: 20pt">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;<IMG SRC="exh1074_1.jpg" ALT=""></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.77
<SEQUENCE>3
<FILENAME>exh_1077.htm
<DESCRIPTION>EXHIBIT 10.77
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right; text-indent: 20pt"><B>Exhibit 10.77</B></P>

<P STYLE="margin: 0; text-align: right; text-indent: 20pt">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;<IMG SRC="exh1077_1.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;<IMG SRC="exh1077_2.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;<IMG SRC="exh1077_3.jpg" ALT=""></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>4
<FILENAME>exh_21.htm
<DESCRIPTION>EXHIBIT 21
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit 21</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 24pt"><B>Subsidiaries of the Registrant</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="vertical-align: top; width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 39%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Subsidiary</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 43%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Jurisdiction of</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Incorporation</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 9%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">JPR Royalty Sub LLC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">MDCP, LLC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>5
<FILENAME>exh_23.htm
<DESCRIPTION>EXHIBIT 23
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit 23</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Consent of Independent Registered Public Accounting Firm</B></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">We consent to the incorporation by reference in the following Registration Statements:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statements (Form&nbsp;S-8 Nos.&nbsp;333-120345, 333-39484 and 333-30751) pertaining to the BioCryst Pharmaceuticals, Inc. 1991 Stock Option Plan, as amended and restated as of March&nbsp;8, 2004;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statement (Form&nbsp;S-8 No.&nbsp;333-90582) pertaining to the BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statement (Form&nbsp;S-8 No.&nbsp;333-136703) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, which amended and restated the BioCryst Pharmaceuticals, Inc. 1991 Stock Option Plan as of May&nbsp;17, 2006;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statement (Form&nbsp;S-3 No.&nbsp;333-145638) pertaining to the registration of up to 8,140,000&nbsp;shares of common stock;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statement (Form&nbsp;S-8 No.&nbsp;333-145627) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan as amended and restated effective March 2007 and Employment Letter Agreement dated April&nbsp;2, 2007 between BioCryst Pharmaceuticals, Inc. and David McCullough;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statement (Form&nbsp;S-3 No.&nbsp;333-153084) for the registration of 3,335,408&nbsp;shares of BioCryst Pharmaceuticals, Inc. common stock and 3,159,895 warrants to purchase common stock of BioCryst Pharmaceuticals, Inc.;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statement (Form&nbsp;S-8 No.&nbsp;333-152570) pertaining to the BioCryst Pharmaceutical, Inc. Stock Incentive Plan, as amended and restated effective February&nbsp;28, 2008 and the BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan, as amended and restated effective February&nbsp;28, 2008;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statement (Form&nbsp;S-8 No.&nbsp;333-167830) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, as amended and restated effective March&nbsp;31, 2010 and the BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan, as amended and restated effective March&nbsp;31, 2010;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statement (Form&nbsp;S-8 No.&nbsp;333-176096) pertaining to the BioCryst Pharmaceutical, Inc. Stock Incentive Plan, as amended and restated effective February&nbsp;17, 2011;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statement (Form S-8 No. 333-187193) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan and Employee Stock Purchase Plan, each as amended and restated effective March 29, 2012;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Registration Statement (Form S-8 No. 333-195869) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan and Employee Stock Purchase Plan, each as amended and restated effective March 8, 2014;</FONT></TD></TR>

<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statement (Form S-3 No. 333-202466) for the registration of up to $150 million of BioCryst Pharmaceuticals, Inc. common stock, preferred stock, depositary shares, stock purchase contracts, warrants or units;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statement (Form S-8 No. 333- 211529) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan as amended and restated effective May 23, 2016.</FONT></TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">of our reports dated February 27, 2017 with respect to the consolidated financial statements
of BioCryst Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of BioCryst Pharmaceuticals,
Inc. included in this Annual Report (Form 10-K) of BioCryst Pharmaceuticals, Inc. for the year ended December&nbsp;31, 2016.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD>
    <TD STYLE="width: 32%"><FONT STYLE="font-size: 10pt">/s/&nbsp;Ernst&nbsp;&amp; Young LLP</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Raleigh, North Carolina</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">February 27, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>exh_311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit&nbsp;31.1</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 24pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 24pt"><B>CERTIFICATIONS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 24pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 12pt">I, Jon P. Stonehouse, certify that:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 12pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">1.&nbsp;I have reviewed this annual report on Form&nbsp;10-K
of BioCryst Pharmaceuticals, Inc.;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">2.&nbsp;Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">3.&nbsp;Based on my knowledge, the financial statements, and
other financial information included in this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">4.&nbsp;The registrant&rsquo;s other certifying officer(s)
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f) for
the registrant and have:</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">a)&nbsp;designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating
to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
the period in which this report is being prepared;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">b)&nbsp;designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">c)&nbsp;evaluated the effectiveness of the registrant&rsquo;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation;&nbsp;and</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">d)&nbsp;disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
the registrant&rsquo;s internal control over financial reporting;&nbsp;and</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">5.&nbsp;The registrant&rsquo;s other certifying officer(s)
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">a)&nbsp;all significant deficiencies and material weaknesses
in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information;&nbsp;and</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">b)&nbsp;any fraud, whether or not material, that involves
management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 39%">&nbsp;</TD>
    <TD STYLE="width: 41%">&nbsp;</TD>
    <TD STYLE="width: 20%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/&nbsp;Jon P. Stonehouse</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Jon P. Stonehouse</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in">Date: February 27, 2017</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>exh_312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit&nbsp;31.2</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 24pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 24pt"><B>CERTIFICATIONS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 24pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 12pt">I, Thomas R. Staab II, certify that:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 12pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">1.&nbsp;I have reviewed this annual report on Form&nbsp;10-K
of BioCryst Pharmaceuticals, Inc.;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">2.&nbsp;Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">3.&nbsp;Based on my knowledge, the financial statements, and
other financial information included in this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">4.&nbsp;The registrant&rsquo;s other certifying officer(s)
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f) for
the registrant and have:</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">a.&nbsp;designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating
to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
the period in which this report is being prepared;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">b.&nbsp;designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">c.&nbsp;evaluated the effectiveness of the registrant&rsquo;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation;&nbsp;and</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">d.&nbsp;disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
the registrant&rsquo;s internal control over financial reporting;&nbsp;and</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">5.&nbsp;The registrant&rsquo;s other certifying officer(s)
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">a.&nbsp;all significant deficiencies and material weaknesses
in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information;&nbsp;and</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">b.&nbsp;any fraud, whether or not material, that involves
management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 37%">&nbsp;</TD>
    <TD STYLE="width: 29%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/&nbsp;Thomas R. Staab II</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Thomas R. Staab II</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer and Treasurer</FONT><BR>
<FONT STYLE="font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in">Date: February 27, 2017</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>exh_321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit&nbsp;32.1</B></P>

<P STYLE="font-size: 10pt; text-align: right; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATION PURSUANT TO</B> &nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>18&nbsp;U.S.C. SECTION&nbsp;1350,</B> &nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>AS ADOPTED PURSUANT TO</B> &nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">In connection with the Annual Report of BioCryst Pharmaceuticals,
Inc. (the &ldquo;Company&rdquo;) on Form&nbsp;10-K for the period ending December&nbsp;31, 2016 as filed with the Securities and
Exchange Commission on the date hereof (the &ldquo;Report&rdquo;),&nbsp;I, Jon P. Stonehouse, Chief Executive Officer of the Company,
certify, pursuant to 18&nbsp;U.S.C. &sect;&nbsp;1350, as adopted pursuant to &sect;&nbsp;906 of the Sarbanes-Oxley Act of 2002,
that, to the best of my knowledge:</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">(1)&nbsp;The Report fully complies with the requirements
of section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934;&nbsp;and</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">(2)&nbsp;The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 78%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 22%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font-size: 10pt; margin: 0pt 0; border-bottom: black 1pt solid">/s/&nbsp;Jon P. Stonehouse</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP>
        <P STYLE="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">Jon P. Stonehouse</P>
        <P STYLE="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">Chief Executive Officer</P>
        <P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 2.4pt 0pt 0">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">February 27, 2017</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">This certification is furnished with this Report on Form&nbsp;10-K
pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed
filed by the Company for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;).
Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended,
or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>exh_322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit&nbsp;32.2</B></P>

<P STYLE="font-size: 10pt; text-align: right; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATION PURSUANT TO</B> &nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>18&nbsp;U.S.C. SECTION&nbsp;1350,</B> &nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>AS ADOPTED PURSUANT TO&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">In connection with the Annual Report of BioCryst Pharmaceuticals,
Inc. (the &ldquo;Company&rdquo;) on Form&nbsp;10-K for the period ending December&nbsp;31, 2016 as filed with the Securities and
Exchange Commission on the date hereof (the &ldquo;Report&rdquo;),&nbsp;I, Thomas R. Staab, II, Chief Financial Officer of the
Company, certify, pursuant to 18&nbsp;U.S.C. &sect;&nbsp;1350, as adopted pursuant to &sect;&nbsp;906 of the Sarbanes-Oxley Act
of 2002, that, to the best of my knowledge:</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">(1)&nbsp;The Report fully complies with the requirements
of section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934;&nbsp;and</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">(2)&nbsp;The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 23pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 70%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 30%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font-size: 10pt; margin: 0pt 0; border-bottom: black 1pt solid">/s/&nbsp;Thomas R. Staab II&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP>
        <P STYLE="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">Thomas R. Staab II&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">Chief Financial Officer and Treasurer&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 2.4pt 0pt 0">(Principal Financial Officer)</P>
        <P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 2.4pt 0pt 0">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">February 27, 2017</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">This certification is furnished with this Report on Form&nbsp;10-K
pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed
filed by the Company for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;).
Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended,
or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>10
<FILENAME>bcrx-20161231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 12:31AM UTC 2017-02-25--><xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.xbrl.org/2003/instance" xmlns:bcrx="http://www.biocryst.com/20161231" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:href="bcrx-20161231.xsd" xlink:type="simple"/>
  <bcrx:AccruedDevelopmentCosts contextRef="i_2016-12-31" decimals="-3" id="c13548524" unitRef="iso4217-usd">7427000</bcrx:AccruedDevelopmentCosts>
  <bcrx:AccruedDevelopmentCosts contextRef="i_2015-12-31" decimals="-3" id="c13548525" unitRef="iso4217-usd">10398000</bcrx:AccruedDevelopmentCosts>
  <bcrx:AccruedExpensesPolicyTextBlock contextRef="d_2016-01-01_2016-12-31" id="c13552331">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accrued Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company generally enters into contractual agreements with &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt;"&gt; &lt;tr&gt; &lt;td style="width: 5%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 2%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 91%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to Clinical Research Organizations (&amp;#x201c;CROs&amp;#x201d;) in connection with preclinical and toxicology studies and clinical trials;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to investigative sites in connection with clinical trials;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to contract manufacturers in connection with the production of the Company&amp;#x2019;s raw materials, drug substance and drug products;&amp;nbsp;and&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;professional fees.&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&amp;#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;Accrued expenses were comprised of the following:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 67%; font-size: 10pt; text-align: left"&gt;Compensation and benefits&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;425&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;424&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Development costs&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,427&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,398&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;Inventory&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;705&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;549&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Professional fees&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;242&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;242&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Duties and taxes&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;56&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;102&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Other&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,981&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,522&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total accrued expenses&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,836&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,237&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:AccruedExpensesPolicyTextBlock>
  <bcrx:AccruedInventoryExpense contextRef="i_2016-12-31" decimals="-3" id="c13548526" unitRef="iso4217-usd">705000</bcrx:AccruedInventoryExpense>
  <bcrx:AccruedInventoryExpense contextRef="i_2015-12-31" decimals="-3" id="c13548527" unitRef="iso4217-usd">549000</bcrx:AccruedInventoryExpense>
  <bcrx:AdvanceNoticePeriodForTerminationOfAgreement contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" id="c13549219">P60D</bcrx:AdvanceNoticePeriodForTerminationOfAgreement>
  <bcrx:AmortizationOfDiscountAndPremiumOnInvestments contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548022" unitRef="iso4217-usd">523000</bcrx:AmortizationOfDiscountAndPremiumOnInvestments>
  <bcrx:AmortizationOfDiscountAndPremiumOnInvestments contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548023" unitRef="iso4217-usd">570000</bcrx:AmortizationOfDiscountAndPremiumOnInvestments>
  <bcrx:AmortizationOfDiscountAndPremiumOnInvestments contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548024" unitRef="iso4217-usd">150000</bcrx:AmortizationOfDiscountAndPremiumOnInvestments>
  <bcrx:AnnualLicenseFeeMaximum contextRef="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="INF" id="c13549218" unitRef="iso4217-usd">500000</bcrx:AnnualLicenseFeeMaximum>
  <bcrx:AnnualLicenseFeeMinimum contextRef="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="INF" id="c13549217" unitRef="iso4217-usd">150000</bcrx:AnnualLicenseFeeMinimum>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2016-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c13548444" unitRef="iso4217-usd">34000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2016-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c13548449" unitRef="iso4217-usd">26000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2016-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c13548454" unitRef="iso4217-usd">17000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2016-12-31" decimals="-3" id="c13548459" unitRef="iso4217-usd">77000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c13548464" unitRef="iso4217-usd">88000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c13548469" unitRef="iso4217-usd">184000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c13548474" unitRef="iso4217-usd">20000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2015-12-31" decimals="-3" id="c13548479" unitRef="iso4217-usd">292000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue contextRef="i_2016-12-31" decimals="-3" id="c13548485" unitRef="iso4217-usd">8926000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue contextRef="i_2015-12-31" decimals="-3" id="c13548486" unitRef="iso4217-usd">28395000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock contextRef="d_2016-01-01_2016-12-31" id="c-18">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 67%; font-size: 10pt; text-align: left"&gt;Maturing in one year or less&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;32,546&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;22,664&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Maturing after one year through two years&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,926&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;28,395&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Maturing after two years&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19,288&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41,472&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;70,347&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</bcrx:AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears contextRef="i_2016-12-31" id="c13548487" unitRef="iso4217-usd" xs:nil="true"/>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears contextRef="i_2015-12-31" decimals="-3" id="c13548488" unitRef="iso4217-usd">19288000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears>
  <bcrx:AveragematurityForPortfolioInvestments contextRef="d_2016-01-01_2016-12-31_RangeAxis-MaximumMember" id="c13548432">P1Y180D</bcrx:AveragematurityForPortfolioInvestments>
  <bcrx:AveragematurityPeriodOfHighQualityMarketableSecurities contextRef="d_2016-01-01_2016-12-31_RangeAxis-MaximumMember" id="c13548297">P1Y180D</bcrx:AveragematurityPeriodOfHighQualityMarketableSecurities>
  <bcrx:CollaborativeAgreementAdditionalContractValue contextRef="d_2009-09-01_2009-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="INF" id="c13549149" unitRef="iso4217-usd">77191000</bcrx:CollaborativeAgreementAdditionalContractValue>
  <bcrx:CollaborativeAgreementAdditionalContractValue contextRef="d_2011-02-01_2011-02-24_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="INF" id="c13549152" unitRef="iso4217-usd">55000000</bcrx:CollaborativeAgreementAdditionalContractValue>
  <bcrx:CollaborativeAgreementAdjustedContractValue contextRef="d_2007-01-01_2011-02-24_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="INF" id="c13549154" unitRef="iso4217-usd">234852000</bcrx:CollaborativeAgreementAdjustedContractValue>
  <bcrx:CollaborativeAgreementContractValue contextRef="d_2007-01-01_2007-01-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="INF" id="c13549145" unitRef="iso4217-usd">102661000</bcrx:CollaborativeAgreementContractValue>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13547956" unitRef="iso4217-usd">14402000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13547957" unitRef="iso4217-usd">39580000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13547958" unitRef="iso4217-usd">10550000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-01-01_2016-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c13548536" unitRef="iso4217-usd">12449000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c13548537" unitRef="iso4217-usd">16337000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2014-01-01_2014-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c13548538" unitRef="iso4217-usd">9366000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-01-01_2016-12-31_CounterpartyNameAxis-GreenCrossCorporationMember" id="c13548552" unitRef="iso4217-usd" xs:nil="true"/>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-12-31_CounterpartyNameAxis-GreenCrossCorporationMember" decimals="-3" id="c13548553" unitRef="iso4217-usd">132000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2014-01-01_2014-12-31_CounterpartyNameAxis-GreenCrossCorporationMember" id="c13548554" unitRef="iso4217-usd" xs:nil="true"/>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-01-01_2016-12-31_CounterpartyNameAxis-ShionogiAndCoLtdMember" decimals="-3" id="c13548539" unitRef="iso4217-usd">1184000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-12-31_CounterpartyNameAxis-ShionogiAndCoLtdMember" decimals="-3" id="c13548540" unitRef="iso4217-usd">1184000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2014-01-01_2014-12-31_CounterpartyNameAxis-ShionogiAndCoLtdMember" decimals="-3" id="c13548541" unitRef="iso4217-usd">1184000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-01-01_2016-12-31_CounterpartyNameAxis-SeqirusUKLimitedMember" decimals="-3" id="c13548555" unitRef="iso4217-usd">769000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-12-31_CounterpartyNameAxis-SeqirusUKLimitedMember" decimals="-3" id="c13548556" unitRef="iso4217-usd">21927000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2014-01-01_2014-12-31_CounterpartyNameAxis-SeqirusUKLimitedMember" id="c13548557" unitRef="iso4217-usd" xs:nil="true"/>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548542" unitRef="iso4217-usd">14402000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548543" unitRef="iso4217-usd">39580000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548544" unitRef="iso4217-usd">10550000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:ConcentrationOfMarketRiskPolicyTextBlock contextRef="d_2016-01-01_2016-12-31" id="c13552343">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Significant Customers and Other Risks&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-style: italic;"&gt; &amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Significant Customers&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Prior to the SUL Agreement, the Company relied primarily on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; specialty distributors to purchase and supply the majority of RAPIVAB. These &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; pharmaceutical specialty distributors accounted for greater than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;90%&lt;/div&gt; of all RAPIVAB product sales and accounted for predominantly all of the Company&amp;#x2019;s outstanding receivables from product sales. The loss of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; or more of these specialty distributors as a customer could have negatively impacted the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis. In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&amp;#x2019;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Other than royalty revenues, the Company&amp;#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB and galidesivir (formerly &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;BCX4430)&lt;/div&gt; development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses represents a significant portion of the Company&amp;#x2019;s collaborative and other research and development revenues. The completion (as with the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt; BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts could negatively impact the Company&amp;#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. The Company recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments, except for Japanese government stockpiling sales, goes directly to pay the interest, and then the principal, on the Company&amp;#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&amp;#x2019;s drug development activities are performed by a limited group of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&amp;#x2019;s ability to complete its drug development activities.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Risks from Third Party Manufacturing and Distribution Concentration&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of the Company&amp;#x2019;s product candidates in development.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Credit Risk&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&lt;/div&gt; months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&amp;#x2019;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:ConcentrationOfMarketRiskPolicyTextBlock>
  <bcrx:CurrencyHedgeAgreementPolicyTextBlock contextRef="d_2016-01-01_2016-12-31" id="c13552340">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Currency Hedge Agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore mark to market adjustments are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark to market adjustments for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt; resulted in losses of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,654&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$564&lt;/div&gt; and a gain of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5,487,&lt;/div&gt; respectively. Mark to market adjustments are determined by a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; party pricing model which uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; in the fair value hierarchy as defined by U.S. GAAP. In addition, realized currency exchange gains of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$811&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,654&lt;/div&gt; were recognized in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; respectively, related to the exercise of a U.S. dollar/Japanese yen currency option under the Company&amp;#x2019;s foreign currency hedge. The Company is also required to post collateral in connection with the mark to market adjustments based on defined thresholds. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; no hedge collateral was posted under the Currency Hedge Agreement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:CurrencyHedgeAgreementPolicyTextBlock>
  <bcrx:DebtInstrumentFinalPaymentFeePercentage contextRef="d_2016-09-23_2016-09-23_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" decimals="3" id="c13548677" unitRef="xbrli-pure">0.05</bcrx:DebtInstrumentFinalPaymentFeePercentage>
  <bcrx:DebtInstrumentMinimumLibor contextRef="d_2016-09-23_2016-09-23_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" decimals="3" id="c13548673" unitRef="xbrli-pure">0.005</bcrx:DebtInstrumentMinimumLibor>
  <bcrx:DeferredCollaborationExpenseAssets contextRef="i_2016-12-31" decimals="-3" id="c13547891" unitRef="iso4217-usd">199000</bcrx:DeferredCollaborationExpenseAssets>
  <bcrx:DeferredCollaborationExpenseAssets contextRef="i_2015-12-31" decimals="-3" id="c13547892" unitRef="iso4217-usd">265000</bcrx:DeferredCollaborationExpenseAssets>
  <bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548035" unitRef="iso4217-usd">-71000</bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities>
  <bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548036" unitRef="iso4217-usd">102000</bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities>
  <bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548037" unitRef="iso4217-usd">-59000</bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities>
  <bcrx:DescriptionOfCompanyPolicyTextBlock contextRef="d_2016-01-01_2016-12-31" id="c13552321">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;The Company&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;BioCryst Pharmaceuticals, Inc. (the &amp;#x201c;Company&amp;#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1986&lt;/div&gt; and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;With the funds available at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the Company believes these resources will be sufficient to fund its operations into &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018.&lt;/div&gt; The Company has sustained operating losses for the majority of its corporate history and expects that its &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; expenses will exceed its &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. Accordingly, its planned operations raise doubt about its ability to continue as a going concern. The Company&amp;#x2019;s liquidity needs will be largely determined by the success of operations in regards to the progression of its product candidates in the future. The Company&amp;#x2019;s plans to alleviate the doubt of its going concern, which are probable of effectively being implemented and mitigating these conditions, primarily include its ability to control the timing and spending on its research and development programs and raising additional funds through equity financings. The Company also &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; consider other plans to fund operations including: &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1)&lt;/div&gt;&amp;nbsp;securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2)&lt;/div&gt;&amp;nbsp;out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3)&lt;/div&gt;&amp;nbsp;raising additional capital through debt financings or from other sources; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4)&lt;/div&gt;&amp;nbsp;obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(5)&lt;/div&gt;&amp;nbsp;reducing spending on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; or more research and development programs by discontinuing development; and/or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(6)&lt;/div&gt;&amp;nbsp;restructuring operations to change its overhead structure. The Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; issue securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions or registered public offerings, pursuant to its registration statement on Form S-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; initially filed with the Securities and Exchange Commission (&amp;#x201c;SEC&amp;#x201d;) on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015.&lt;/div&gt; The Company&amp;#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events and its decisions in the future.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:DescriptionOfCompanyPolicyTextBlock>
  <bcrx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13549083" unitRef="iso4217-usd">1798000</bcrx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount>
  <bcrx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13549084" unitRef="iso4217-usd">4307000</bcrx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount>
  <bcrx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount contextRef="d_2014-01-01_2014-12-31" id="c13549085" unitRef="iso4217-usd" xs:nil="true"/>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour contextRef="i_2016-12-31" decimals="-3" id="c13548839" unitRef="iso4217-usd">406000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree contextRef="i_2016-12-31" decimals="-3" id="c13548837" unitRef="iso4217-usd">2606000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo contextRef="i_2016-12-31" decimals="-3" id="c13548835" unitRef="iso4217-usd">4649000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo>
  <bcrx:EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear contextRef="i_2016-12-31" decimals="-3" id="c13548833" unitRef="iso4217-usd">6880000</bcrx:EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear>
  <bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts contextRef="d_2013-09-01_2016-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="INF" id="c13549173" unitRef="iso4217-usd">39477</bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts>
  <bcrx:GoingConcernPolicyPolicyTextBlock contextRef="d_2016-01-01_2016-12-31" id="c13552344">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Going Concern&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s liquidity needs will be largely determined by the success of operations in regards to the progression of its product candidates in the future. The Company&amp;#x2019;s plans to alleviate the doubt of its going concern, which are probable of effectively being implemented and mitigating these conditions, primarily include its ability to control the timing and spending on its research and development programs and raising additional funds through equity financings. The Company also &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; consider other plans to fund operations including: &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1)&lt;/div&gt;&amp;nbsp;securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2)&lt;/div&gt;&amp;nbsp;out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3)&lt;/div&gt;&amp;nbsp;raising additional capital through debt financings or from other sources; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4)&lt;/div&gt;&amp;nbsp;obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(5)&lt;/div&gt;&amp;nbsp;reducing spending on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; or more research and development programs by discontinuing development; and/or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(6)&lt;/div&gt;&amp;nbsp;restructuring operations to change its overhead structure. The Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; issue securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions or registered public offerings, pursuant to its registration statement on Form S-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; initially filed with the Securities and Exchange Commission (&amp;#x201c;SEC&amp;#x201d;) on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015.&lt;/div&gt; The Company&amp;#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events and its decisions in the future.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:GoingConcernPolicyPolicyTextBlock>
  <bcrx:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13549077" unitRef="iso4217-usd">559000</bcrx:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards>
  <bcrx:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13549078" unitRef="iso4217-usd">330000</bcrx:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards>
  <bcrx:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13549079" unitRef="iso4217-usd">373000</bcrx:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards>
  <bcrx:IncreaseDecreaseInFinancingLeaseObligations contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548079" unitRef="iso4217-usd">329000</bcrx:IncreaseDecreaseInFinancingLeaseObligations>
  <bcrx:IncreaseDecreaseInFinancingLeaseObligations contextRef="d_2015-01-01_2015-12-31" id="c13548080" unitRef="iso4217-usd" xs:nil="true"/>
  <bcrx:IncreaseDecreaseInFinancingLeaseObligations contextRef="d_2014-01-01_2014-12-31" id="c13548081" unitRef="iso4217-usd" xs:nil="true"/>
  <bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock contextRef="d_2016-01-01_2016-12-31" id="c13552337">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Interest Expense and Deferred Financing Costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Interest expense for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6,487,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5,200&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4,998,&lt;/div&gt; respectively, and primarily relates to the issuance of the PhaRMA Notes (defined in Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3)&lt;/div&gt; and the Senior Credit Facility (defined in Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4).&lt;/div&gt; Costs directly associated with the issuance of the PhaRMA Notes and the Senior Credit Facility have been capitalized and are netted against the non-recourse notes payable and Senior Credit Facility on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the PhaRMA Notes and the Senior Credit Facility using the effective interest rate method. Amortization of deferred financing costs and original issue discount included in interest expense was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$558,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$439&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$439&lt;/div&gt; for each of the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; respectively.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock>
  <bcrx:Interestreserve contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="-3" id="c13548602" unitRef="iso4217-usd">3000000</bcrx:Interestreserve>
  <bcrx:LeaseFinancingObligationNetOfCurrent contextRef="i_2016-12-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember" decimals="-3" id="c13548394" unitRef="iso4217-usd">2704000</bcrx:LeaseFinancingObligationNetOfCurrent>
  <bcrx:LeaseFinancingObligationNetOfCurrent contextRef="i_2015-12-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember" decimals="-3" id="c13548395" unitRef="iso4217-usd">2375000</bcrx:LeaseFinancingObligationNetOfCurrent>
  <bcrx:LeaseFinancingObligationNetOfCurrent contextRef="i_2016-12-31_BalanceSheetLocationAxis-LongTermLiabilitiesMember_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember" decimals="-3" id="c13548710" unitRef="iso4217-usd">2704000</bcrx:LeaseFinancingObligationNetOfCurrent>
  <bcrx:LeaseFinancingObligationNetOfCurrent contextRef="i_2015-12-31_BalanceSheetLocationAxis-LongTermLiabilitiesMember_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember" decimals="-3" id="c13548711" unitRef="iso4217-usd">2375000</bcrx:LeaseFinancingObligationNetOfCurrent>
  <bcrx:LeaseFinancingObligationNetOfCurrent contextRef="i_2016-12-31" decimals="-3" id="c13547914" unitRef="iso4217-usd">2704000</bcrx:LeaseFinancingObligationNetOfCurrent>
  <bcrx:LeaseFinancingObligationNetOfCurrent contextRef="i_2015-12-31" decimals="-3" id="c13547915" unitRef="iso4217-usd">2375000</bcrx:LeaseFinancingObligationNetOfCurrent>
  <bcrx:LongtermInvestmentMaturityMinimum contextRef="d_2016-01-01_2016-12-31_RangeAxis-MinimumMember" id="c13548300">P1Y</bcrx:LongtermInvestmentMaturityMinimum>
  <bcrx:MaturityPeriodOfHighQualityMarketablesecurities contextRef="d_2016-01-01_2016-12-31_RangeAxis-MaximumMember" id="c13548296">P3Y</bcrx:MaturityPeriodOfHighQualityMarketablesecurities>
  <bcrx:MaturityperiodOfShortTermInvestment contextRef="d_2016-01-01_2016-12-31_RangeAxis-MinimumMember" id="c13548298">P90D</bcrx:MaturityperiodOfShortTermInvestment>
  <bcrx:MaturityperiodOfShortTermInvestment contextRef="d_2016-01-01_2016-12-31_RangeAxis-MaximumMember" id="c13548299">P1Y</bcrx:MaturityperiodOfShortTermInvestment>
  <bcrx:MaximumAggregateOfferingPrice contextRef="i_2015-03-03" decimals="-7" id="c13548723" unitRef="iso4217-usd">150000000</bcrx:MaximumAggregateOfferingPrice>
  <bcrx:MaximumAmountOfCollateralRequiredToPost contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="-3" id="c13548667" unitRef="iso4217-usd">7800000</bcrx:MaximumAmountOfCollateralRequiredToPost>
  <bcrx:MilestonePaymentMaximum contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="-3" id="c13548349" unitRef="iso4217-usd">12000000</bcrx:MilestonePaymentMaximum>
  <bcrx:MilestonePaymentMaximum contextRef="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember" decimals="INF" id="c13549183" unitRef="iso4217-usd">12000000</bcrx:MilestonePaymentMaximum>
  <bcrx:MilestonePaymentMaximum contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="INF" id="c13549214" unitRef="iso4217-usd">4000000</bcrx:MilestonePaymentMaximum>
  <bcrx:MilestonePaymentMinimum contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="INF" id="c13549213" unitRef="iso4217-usd">1400000</bcrx:MilestonePaymentMinimum>
  <bcrx:NumberOfMajorCustomers contextRef="d_2016-01-01_2016-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueProductLineMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_ProductOrServiceAxis-RAPIVABMember" decimals="INF" id="c13548425" unitRef="xbrli-pure">3</bcrx:NumberOfMajorCustomers>
  <bcrx:PaymentsForModificationOfLicenseAgreement contextRef="d_2010-05-01_2010-05-31_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="INF" id="c13549228" unitRef="iso4217-usd">90000</bcrx:PaymentsForModificationOfLicenseAgreement>
  <bcrx:PercentageOfCarryingAmountInExcessOfFairValue1 contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="INF" id="c13548643" unitRef="xbrli-pure">0.5</bcrx:PercentageOfCarryingAmountInExcessOfFairValue1>
  <bcrx:PercentageOfCommonStockSharesBeginning contextRef="d_2016-01-01_2016-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="2" id="c13548846" unitRef="xbrli-pure">0.85</bcrx:PercentageOfCommonStockSharesBeginning>
  <bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum contextRef="d_2016-01-01_2016-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="2" id="c13548845" unitRef="xbrli-pure">0.15</bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum>
  <bcrx:PeriodOfAgreement contextRef="d_2015-01-01_2015-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember" id="c13549238">P25Y</bcrx:PeriodOfAgreement>
  <bcrx:PotentialMilestonePaymentsReceivable contextRef="i_2011-11-11_TypeOfArrangementAxis-MundipharmaMember" decimals="INF" id="c13549207" unitRef="iso4217-usd">15000000</bcrx:PotentialMilestonePaymentsReceivable>
  <bcrx:PrivatePlacementOfSeniorSecuredNotes contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="-3" id="c13548608" unitRef="iso4217-usd">30000000</bcrx:PrivatePlacementOfSeniorSecuredNotes>
  <bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts contextRef="d_2016-01-01_2016-12-31_TypeOfArrangementAxis-ASPRBARDAContractMember" decimals="INF" id="c13549167" unitRef="iso4217-usd">20574000</bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts>
  <bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts contextRef="d_2013-09-01_2013-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="INF" id="c13549169" unitRef="iso4217-usd">5000000</bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts>
  <bcrx:RequiredForeignCurrencyHedgePerDollar contextRef="i_2014-12-31_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="INF" id="c13548651" unitRef="iso4217-jpy">100</bcrx:RequiredForeignCurrencyHedgePerDollar>
  <bcrx:RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="-3" id="c13548600" unitRef="iso4217-usd">22691000</bcrx:RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet>
  <bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized contextRef="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember" decimals="-3" id="c13548266" unitRef="iso4217-usd">30000000</bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized>
  <bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized contextRef="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="-3" id="c13548599" unitRef="iso4217-usd">30000000</bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized>
  <bcrx:RoyaltyMonetizationTextBlock contextRef="d_2016-01-01_2016-12-31" id="s433703">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&amp;#x2014;&lt;/div&gt; Royalty Monetization&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 6pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Overview&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 6pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011,&lt;/div&gt; the Company completed a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$30,000&lt;/div&gt;&amp;nbsp;financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received net proceeds of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$22,691&lt;/div&gt;&amp;nbsp;from the transaction after transaction costs of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4,309&lt;/div&gt;&amp;nbsp;and the establishment of a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3,000&lt;/div&gt;&amp;nbsp;interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2012&lt;/div&gt; interest payment.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;As part of the transaction, the Company entered into a purchase and sale agreement dated as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011&lt;/div&gt; with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i)&amp;nbsp;its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&amp;nbsp;the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &amp;#x201c;Currency Hedge Agreement&amp;#x201d;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese yen and milestone payments will paid in U.S. dollars. The Company&amp;#x2019;s collaboration with Shionogi was not impacted as a result of this transaction.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 6pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Non-Recourse Notes Payable&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011,&lt;/div&gt; Royalty Sub completed a private placement to institutional investors of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$30,000&lt;/div&gt; in aggregate principal amount of its PhaRMA Senior Secured &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14.0%&lt;/div&gt; Notes due &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2020&lt;/div&gt; (the &amp;#x201c;PhaRMA Notes&amp;#x201d;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011&lt;/div&gt; (the &amp;#x201c;Indenture&amp;#x201d;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14%&lt;/div&gt;&amp;nbsp;per annum, payable annually in arrears on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1st&lt;/div&gt; of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes. &amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Royalty Sub&amp;#x2019;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&amp;#x2019;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may,&lt;/div&gt; but is not obligated to, make capital contributions to a capital account that &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; be used to redeem, or on up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; occasion pay any interest shortfall on, the PhaRMA Notes.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt;    &lt;div style="page-break-before: always; margin-top: 6pt"&gt;  &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2013,&lt;/div&gt; Royalty Sub paid &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,844&lt;/div&gt; of interest on the PhaRMA Notes from royalty payments received from RAPIACTA &lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;&amp;reg;&lt;/div&gt; sales from the preceding &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;four&lt;/div&gt; calendar quarters. This payment resulted in an obligation shortfall of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,356&lt;/div&gt; associated with accrued interest due &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2013.&lt;/div&gt; As stipulated under the PhaRMA Notes Indenture, if the amount available for payment on any Payment Date is insufficient to pay all of the interest due on a Payment Date, the shortfall in interest will accrue interest at the interest rate applicable to the PhaRMA Notes compounded annually. Accordingly, commencing in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2013,&lt;/div&gt; the Company began accruing interest at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14%&lt;/div&gt;&amp;nbsp;per annum on the interest shortfall of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,356.&lt;/div&gt; In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August&lt;/div&gt; of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; Royalty Sub paid additional interest of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$446,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,882&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$70,&lt;/div&gt; respectively, bringing the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2013&lt;/div&gt; shortfall down to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$222&lt;/div&gt; as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014.&lt;/div&gt; Under the terms of the Indenture, Royalty Sub&amp;#x2019;s inability to pay the full amount of interest payable in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2013&lt;/div&gt; by the next succeeding Payment Date for the PhaRMA Notes, which was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; constituted an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt; balance sheet. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; pursue acceleration of the PhaRMA Notes, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; incur costs associated with liquidating the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is not expected to have a significant impact on the Company&amp;#x2019;s future results of operations or cash flows. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the PhaRMA Notes remain in default.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Indenture does not contain any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the aggregate fair value of the PhaRMA Notes was estimated to be approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50%&lt;/div&gt; of its carrying value of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$30,000.&lt;/div&gt; The estimated fair value of the PhaRMA Notes is classified as Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; in the fair value hierarchy as defined in U.S. GAAP.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Foreign Currency Hedge&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;100&lt;/div&gt; yen per dollar for which the Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; be required to pay a premium in each year from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; through &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2020,&lt;/div&gt; provided the Currency Hedge Agreement remains in effect. A payment of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,950&lt;/div&gt;&amp;nbsp;will be required if, on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&lt;/div&gt; of the relevant year, the U.S. dollar is worth &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;100&lt;/div&gt; yen or less as determined in accordance with the Currency Hedge Agreement.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore mark to market adjustments are recognized in the Company&amp;#x2019;s Consolidated Statement of Comprehensive Loss. Cumulative mark to market adjustments in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt; resulted in losses of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,654&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$564&lt;/div&gt; and a gain of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5,487,&lt;/div&gt; respectively. In addition, realized currency exchange gains of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$811&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,654&lt;/div&gt; were recognized in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; respectively, related to the exercise of a U.S. dollar/Japanese yen currency option under the Company&amp;#x2019;s foreign currency hedge. The Company is also required to post collateral in connection with the mark to market adjustments based on defined thresholds. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; no collateral was posted under the Currency Hedge Agreement. The Company will not be required at any time to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreement. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the maximum amount of hedge collateral the Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; be required to post is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$7,800.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:RoyaltyMonetizationTextBlock>
  <bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock contextRef="d_2016-01-01_2016-12-31" id="c-19">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&amp;nbsp;31, 2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,495&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,495&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,451&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,451&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Green Cross Corporation&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;686&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;686&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;957&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;179&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,136&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,094&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,674&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,768&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&amp;nbsp;31, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,536&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,536&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;469&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;469&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;210&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;28&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;238&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;679&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,564&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,243&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock>
  <bcrx:ScheduleOfRevenuesFromCollaborationsTableTextBlock contextRef="d_2016-01-01_2016-12-31" id="c-22">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 61%; font-size: 10pt; text-align: left"&gt;Product sales, net&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,269&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,291&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;33&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Royalty revenue&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,682&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,386&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,025&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Collaborative and other research and development revenues:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,449&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,337&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,366&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Green Cross Corporation&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;132&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Shionogi &amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,184&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,184&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,184&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;769&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,927&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total collaborative and other research and development revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,402&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;39,580&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,550&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26,353&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;48,257&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,608&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</bcrx:ScheduleOfRevenuesFromCollaborationsTableTextBlock>
  <bcrx:ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount contextRef="i_2016-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c13548852" unitRef="iso4217-usd">25000</bcrx:ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount>
  <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_TitleOfIndividualAxis-NonEmployeeDirectorsMember" id="c13548784">P1Y</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate>
  <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548896" unitRef="xbrli-shares">1965000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable>
  <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548914" unitRef="xbrli-shares">2217000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable>
  <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548935" unitRef="xbrli-shares">2248000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable>
  <bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage contextRef="d_2016-01-01_2016-12-31_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="2" id="c13548780" unitRef="xbrli-pure">0.25</bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage>
  <bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage contextRef="d_2016-01-01_2016-12-31_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="2" id="c13548782" unitRef="xbrli-pure">1</bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage>
  <bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548902" unitRef="xbrli-shares">88000</bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable>
  <bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548920" unitRef="xbrli-shares">33000</bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable>
  <bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548941" unitRef="xbrli-shares">717000</bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable>
  <bcrx:StockIssuedDuringPeriodValueForModificationOfLicenseAgreement contextRef="d_2010-05-01_2010-05-31_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="INF" id="c13549227" unitRef="iso4217-usd">5911000</bcrx:StockIssuedDuringPeriodValueForModificationOfLicenseAgreement>
  <bcrx:TransactionCosts contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="-3" id="c13548601" unitRef="iso4217-usd">4309000</bcrx:TransactionCosts>
  <bcrx:UpfrontPaymentsReceivableAmount contextRef="d_2006-02-01_2006-02-28_TypeOfArrangementAxis-MundipharmaMember" decimals="INF" id="c13549194" unitRef="iso4217-usd">10000000</bcrx:UpfrontPaymentsReceivableAmount>
  <dei:AmendmentFlag contextRef="d_2016-01-01_2016-12-31" id="c-15">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="d_2016-01-01_2016-12-31" id="c-4">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="d_2016-01-01_2016-12-31" id="c-14">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="d_2016-01-01_2016-12-31" id="c-13">2016</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="d_2016-01-01_2016-12-31" id="c-12">2016-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="d_2016-01-01_2016-12-31" id="c-11">10-K</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="d_2016-01-01_2016-12-31" id="c-2">0000882796</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="i_2017-01-31" decimals="INF" id="c-9" unitRef="xbrli-shares">73955169</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="d_2016-01-01_2016-12-31" id="c-6">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="d_2016-01-01_2016-12-31" id="c-5">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityPublicFloat contextRef="i_2016-06-30" decimals="0" id="c-10" unitRef="iso4217-usd">206175247</dei:EntityPublicFloat>
  <dei:EntityRegistrantName contextRef="d_2016-01-01_2016-12-31" id="c-1">BIOCRYST PHARMACEUTICALS INC</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="d_2016-01-01_2016-12-31" id="c-7">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="d_2016-01-01_2016-12-31" id="c-8">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:TradingSymbol contextRef="d_2016-01-01_2016-12-31" id="c-3">bcrx</dei:TradingSymbol>
  <us-gaap:AccountsPayableCurrent contextRef="i_2016-12-31" decimals="-3" id="c13547898" unitRef="iso4217-usd">4269000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="i_2015-12-31" decimals="-3" id="c13547899" unitRef="iso4217-usd">9307000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2016-12-31" decimals="-3" id="c13547877" unitRef="iso4217-usd">8768000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2015-12-31" decimals="-3" id="c13547878" unitRef="iso4217-usd">6243000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="i_2016-12-31" decimals="-3" id="c13547900" unitRef="iso4217-usd">10836000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="i_2015-12-31" decimals="-3" id="c13547901" unitRef="iso4217-usd">16237000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="i_2016-12-31" decimals="-3" id="c13548528" unitRef="iso4217-usd">242000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="i_2015-12-31" decimals="-3" id="c13548529" unitRef="iso4217-usd">242000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="i_2016-12-31" decimals="-3" id="c13548588" unitRef="iso4217-usd">4917000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="i_2015-12-31" decimals="-3" id="c13548589" unitRef="iso4217-usd">14205000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="i_2016-12-31" decimals="-3" id="c13547941" unitRef="iso4217-usd">-12000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="i_2015-12-31" decimals="-3" id="c13547942" unitRef="iso4217-usd">-206000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AdditionalPaidInCapital contextRef="i_2016-12-31" decimals="-3" id="c13547939" unitRef="iso4217-usd">566913000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="i_2015-12-31" decimals="-3" id="c13547940" unitRef="iso4217-usd">558113000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c13548140" unitRef="iso4217-usd">10177000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548143" unitRef="iso4217-usd">10177000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c13548180" unitRef="iso4217-usd">9705000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548183" unitRef="iso4217-usd">9705000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c13548220" unitRef="iso4217-usd">8487000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548223" unitRef="iso4217-usd">8487000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdvertisingExpense contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548359" unitRef="iso4217-usd">103000</us-gaap:AdvertisingExpense>
  <us-gaap:AdvertisingExpense contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548360" unitRef="iso4217-usd">290000</us-gaap:AdvertisingExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548737" unitRef="iso4217-usd">8487000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2016-01-01_2016-12-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c13548738" unitRef="iso4217-usd">8340000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2016-01-01_2016-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c13548739" unitRef="iso4217-usd">147000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548741" unitRef="iso4217-usd">9705000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c13548742" unitRef="iso4217-usd">9485000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c13548743" unitRef="iso4217-usd">220000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548745" unitRef="iso4217-usd">10177000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2014-01-01_2014-12-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c13548746" unitRef="iso4217-usd">9963000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2014-01-01_2014-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c13548747" unitRef="iso4217-usd">214000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2016-01-01_2016-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="-3" id="c13548875" unitRef="iso4217-usd">6088000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="-3" id="c13548876" unitRef="iso4217-usd">7580000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2014-01-01_2014-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="-3" id="c13548877" unitRef="iso4217-usd">8906000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2016-01-01_2016-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" decimals="-3" id="c13548878" unitRef="iso4217-usd">2399000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" decimals="-3" id="c13548879" unitRef="iso4217-usd">2125000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2014-01-01_2014-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" decimals="-3" id="c13548880" unitRef="iso4217-usd">1271000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AmortizationOfFinancingCosts contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548376" unitRef="iso4217-usd">558000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548377" unitRef="iso4217-usd">439000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548378" unitRef="iso4217-usd">439000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548420" unitRef="xbrli-shares">1226000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548421" unitRef="xbrli-shares">3524000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548422" unitRef="xbrli-shares">3991000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="i_2016-12-31" decimals="-3" id="c13547895" unitRef="iso4217-usd">89847000</us-gaap:Assets>
  <us-gaap:Assets contextRef="i_2015-12-31" decimals="-3" id="c13547896" unitRef="iso4217-usd">122359000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="i_2016-12-31" decimals="-3" id="c13547885" unitRef="iso4217-usd">66987000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="i_2015-12-31" decimals="-3" id="c13547886" unitRef="iso4217-usd">63794000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2016-12-31" decimals="-3" id="c13548489" unitRef="iso4217-usd">41472000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2015-12-31" decimals="-3" id="c13548490" unitRef="iso4217-usd">70347000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2016-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c13548447" unitRef="iso4217-usd">20298000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2016-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c13548452" unitRef="iso4217-usd">6199000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2016-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c13548457" unitRef="iso4217-usd">14975000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c13548467" unitRef="iso4217-usd">26546000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c13548472" unitRef="iso4217-usd">21963000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c13548477" unitRef="iso4217-usd">21838000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2016-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c13548445" unitRef="iso4217-usd">2000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2016-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c13548450" unitRef="iso4217-usd">2000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2016-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c13548455" unitRef="iso4217-usd">7000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2016-12-31" decimals="-3" id="c13548460" unitRef="iso4217-usd">11000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" id="c13548465" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" id="c13548470" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c13548475" unitRef="iso4217-usd">6000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2015-12-31" decimals="-3" id="c13548480" unitRef="iso4217-usd">6000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2016-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c13548446" unitRef="iso4217-usd">4000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2016-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c13548451" unitRef="iso4217-usd">8000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2016-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c13548456" unitRef="iso4217-usd">11000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2016-12-31" decimals="-3" id="c13548461" unitRef="iso4217-usd">23000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c13548466" unitRef="iso4217-usd">99000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c13548471" unitRef="iso4217-usd">41000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c13548476" unitRef="iso4217-usd">72000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2015-12-31" decimals="-3" id="c13548481" unitRef="iso4217-usd">212000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2016-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c13548443" unitRef="iso4217-usd">20266000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2016-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c13548448" unitRef="iso4217-usd">6179000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2016-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c13548453" unitRef="iso4217-usd">14962000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2016-12-31" decimals="-3" id="c13548458" unitRef="iso4217-usd">41407000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c13548463" unitRef="iso4217-usd">26557000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c13548468" unitRef="iso4217-usd">21820000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c13548473" unitRef="iso4217-usd">21884000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2015-12-31" decimals="-3" id="c13548478" unitRef="iso4217-usd">70261000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="i_2016-12-31" decimals="-3" id="c13548483" unitRef="iso4217-usd">32546000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="i_2015-12-31" decimals="-3" id="c13548484" unitRef="iso4217-usd">22664000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="i_2016-12-31" decimals="-3" id="c13547875" unitRef="iso4217-usd">32546000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="i_2015-12-31" decimals="-3" id="c13547876" unitRef="iso4217-usd">22664000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="i_2016-12-31" decimals="-3" id="c13547887" unitRef="iso4217-usd">8926000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="i_2015-12-31" decimals="-3" id="c13547888" unitRef="iso4217-usd">47683000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="d_2016-01-01_2016-12-31" id="c-17">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31, 2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Estimated&lt;br /&gt; Fair Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Obligations of U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,266&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;34&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,298&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,179&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(8&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,199&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,962&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(11&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,975&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41,407&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;77&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(23&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41,472&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Estimated&lt;br /&gt; Fair Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt; width: 35%"&gt;Obligations of U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26,557&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;88&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(99&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26,546&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,820&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;184&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(41&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,963&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,884&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(72&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,838&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;70,261&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;292&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(212&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;70,347&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2016-01-01_2016-12-31" id="c13552322">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, JPR Royalty Sub LLC (&amp;#x201c;Royalty Sub&amp;#x201d;) and MDCP, LLC (&amp;#x201c;MDCP&amp;#x201d;). Both subsidiaries were formed to facilitate financing transactions for the Company. Royalty Sub was formed in connection with a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$30,000&lt;/div&gt;&amp;nbsp;financing transaction the Company completed on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011.&lt;/div&gt; See Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,&lt;/div&gt; Royalty Monetization, for a further description of this transaction. MDCP was formed in connection with a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$23,000&lt;/div&gt; Senior Credit Facility that the Company closed on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt; See Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,&lt;/div&gt; Senior Credit Facility, for a further description of this transaction. All intercompany transactions and balances have been eliminated.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#x201c;U.S. GAAP&amp;#x201d;). Such consolidated financial statements reflect all adjustments that are, in management&amp;#x2019;s opinion, necessary to present fairly, in all material respects, the Company&amp;#x2019;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="i_2016-12-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember" decimals="-3" id="c13548398" unitRef="iso4217-usd">4768000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2016-12-31" decimals="-3" id="c13547871" unitRef="iso4217-usd">22104000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2015-12-31" decimals="-3" id="c13547872" unitRef="iso4217-usd">28899000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2014-12-31" decimals="-3" id="c13548089" unitRef="iso4217-usd">54540000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2013-12-31" decimals="-3" id="c13548090" unitRef="iso4217-usd">21164000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548085" unitRef="iso4217-usd">-6795000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548086" unitRef="iso4217-usd">-25641000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548087" unitRef="iso4217-usd">33376000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2016-01-01_2016-12-31" id="c13552345">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="d_2016-01-01_2016-12-31" id="c13552324">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Restricted Cash&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Restricted cash as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; reflects &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$141&lt;/div&gt; in royalty revenue paid by Shionogi&amp;nbsp;&amp;amp; Co., Ltd. (&amp;#x201c;Shionogi&amp;#x201d;) designated for interest on the PhaRMA Notes (defined in Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3)&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,405&lt;/div&gt; the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="d_2016-01-01_2016-12-31" id="s433720">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;&amp;nbsp;&amp;#x2014; Collaborative and Other Research and Development Contracts&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;U.S.&amp;nbsp;Department of Health and Human Services (&amp;#x201c;BARDA/HHS&amp;#x201d;).&lt;/div&gt; In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2007,&lt;/div&gt; the U.S.&amp;nbsp;Department of Health and Human Services (&amp;#x201c;BARDA/HHS&amp;#x201d;) awarded the Company a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$102,661,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;four&lt;/div&gt;-year contract for the advanced development of peramivir for the treatment of influenza. During &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2009,&lt;/div&gt; peramivir clinical development shifted to focus on intravenous delivery and the treatment of hospitalized patients. To support this focus, a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2009&lt;/div&gt; contract modification was awarded to extend the i.v. peramivir program and to increase funding by &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$77,191.&lt;/div&gt; On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011,&lt;/div&gt; the Company announced that BARDA/HHS had awarded it a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$55,000&lt;/div&gt; contract modification, intended to fund completion of the Phase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; development of i.v. peramivir for the treatment of patients hospitalized with influenza. That contract modification brought the total contract award from BARDA/HHS to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$234,852&lt;/div&gt; and provided funding to support the filing of a NDA to seek regulatory approval for i.v. peramivir in the U.S. In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2013,&lt;/div&gt; BioCryst submitted an NDA filing for i.v. peramivir to the FDA and the NDA was approved in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014.&lt;/div&gt; The BARDA/HHS contract expired on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt;&lt;div style="page-break-before: always; margin-top: 6pt"&gt;&lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; the Company announced that BARDA/HHS had awarded the Company a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&amp;nbsp;This BARDA/HHS contract includes a base contract of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$16,265&lt;/div&gt; to support galidesivir drug manufacturing, as well as &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$22,855&lt;/div&gt; in additional development options that can be exercised by the government, bringing the potential value of the contract to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$39,120.&lt;/div&gt; As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; a total of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$20,574&lt;/div&gt; has been awarded under exercised options within this contract.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;National Institute of Allergy and Infectious Diseases (&amp;#x201c;NIAID/HHS&amp;#x201d;). &lt;/div&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2013,&lt;/div&gt; NIAID/HHS contracted with the Company for the development of galidesivir as a treatment for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5,000&lt;/div&gt; to the Company. The goals of this contract, including amendments, are to file IND applications for intravenous (&amp;#x201c;i.v.&amp;#x201d;) and intramuscular (&amp;#x201c;i.m.&amp;#x201d;) galidesivir for the treatment of Marburg virus disease and other hemorrhagic fever virus diseases, including Ebola virus disease, and to conduct an initial Phase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt; human clinical trial. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the total NIAID/HHS contract amount to advance the program through the completion of the Phase I clinical program is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$39,477.&lt;/div&gt; As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; all options have been exercised under this contract.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contract provisions that are related to the development of galidesivir plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress and the continuation of the contract is based on the Company&amp;#x2019;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Seqirus UK Limited (&amp;#x201c;SUL&amp;#x201d;).&lt;/div&gt; On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; the Company and Seqirus UK Limited (&amp;quot;SUL&amp;quot;), a limited company organized under the laws of the United Kingdom and a subsidiary of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the &amp;quot;SUL Agreement&amp;quot;) granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the &amp;quot;Territory&amp;quot;). Peramivir is an intravenous treatment for acute uncomplicated influenza and is currently approved for use in the United States, Canada, Japan, Taiwan and Korea. Peramivir is the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; and only intravenous influenza treatment in the world and was approved by the U.S. Food and Drug Administration in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt; for the treatment of acute uncomplicated influenza in patients &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&lt;/div&gt; years and older who have been symptomatic for no more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; days. The Company retains all rights and associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to pursue government stockpiling outside the U.S.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Pursuant to the SUL Agreement, RAPIVAB will be commercialized by CSL's subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets. SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing approval commitments in connection with the FDA's approval of the NDA, and upon fulfillment will transfer ownership of and financial responsibility for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and the EU, the Company is also responsible for regulatory filings and interactions with the Health Canada and the European Medicines Agency (&amp;quot;EMA&amp;quot;) until marketing approval for RAPIVAB is obtained and assigned to SUL. In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee, composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory and any additional development.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Under the terms of the SUL Agreement, the Company received an upfront payment of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$33,740,&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; receive up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$12,000&lt;/div&gt; in additional milestone payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Canada for an adult indication in Canada. The Company is also entitled under the SUL Agreement to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined as &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt; - &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30)&lt;/div&gt; and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire, on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;ten&lt;/div&gt; years from the date of the SUL Agreement (the &amp;quot;Royalty Term&amp;quot;). The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from SUL.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&lt;/div&gt;&lt;div style="page-break-before: always; margin-top: 6pt"&gt;&lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Shionogi&amp;nbsp;&amp;amp; Co., Ltd. (&amp;#x201c;Shionogi&amp;#x201d;).&lt;/div&gt; In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2007,&lt;/div&gt; the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2008,&lt;/div&gt; the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan and Taiwan.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Green Cross Corporation (&amp;#x201c;Green Cross&amp;#x201d;).&lt;/div&gt; In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2006,&lt;/div&gt; the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company received a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-time license fee of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$250.&lt;/div&gt; The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Mundipharma International Holdings Limited (&amp;#x201c;Mundipharma&amp;#x201d;).&lt;/div&gt; In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2006,&lt;/div&gt; the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&amp;#x201c;PNP&amp;#x201d;) inhibitor, for use in oncology (the &amp;#x201c;Original Agreement&amp;#x201d;). Under the terms of the Original Agreement, Mundipharma obtained rights to forodesine in markets across Europe, Asia, and Australasia in exchange for a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$10,000&lt;/div&gt; up-front payment.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company deferred revenue recognition of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$10,000&lt;/div&gt; up-front payment that was received from Mundipharma in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2006&lt;/div&gt; because the Company was involved in the continued development of forodesine. Amortization of this revenue commenced in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2006&lt;/div&gt; and was initially scheduled to end in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; which is the date of expiration for the last-to-expire patent covered by the agreement. The Company also deferred revenue recognition of a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5,000&lt;/div&gt; payment received from Mundipharma in connection with the initiation of a clinical trial in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2007.&lt;/div&gt; Amortization of this revenue commenced in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2007&lt;/div&gt; and was initially scheduled to end in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017.&lt;/div&gt; Under its agreement with AECOM/IRL, the Company paid sublicense payments related to these upfront cash payments received from Mundipharma. Expense recognition of these sublicense payments was deferred and recognized under the same term as the related deferred revenue.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; November&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011,&lt;/div&gt; the Company entered into the Amended and Restated License and Development Agreement (the &amp;#x201c;Amended and Restated Agreement&amp;#x201d;) with Mundipharma, amending and restating the Original Agreement. Under the terms of the Amended and Restated Agreement, Mundipharma obtained worldwide rights to forodesine. Commencing on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; November&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011,&lt;/div&gt; Mundipharma controls the development and commercialization of forodesine and assumes all future development and commercialization costs. The Amended and Restated Agreement provides for the possibility of future event payments totaling &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$15,000&lt;/div&gt; for achieving specified regulatory events for certain indications and tiered royalties ranging from mid to high single-digit percentages of net product sales in each country where forodesine is sold by Mundipharma. These royalties are subject to downward adjustments based on the then-existing patent coverage and/or the availability of generic compounds in each country.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Amended and Restated Agreement is a multiple element arrangement for accounting purposes, in which the Company is required to deliver to Mundipharma both the worldwide rights to forodesine in the field of oncology and the transfer of product data and know-how to permit Mundipharma to develop and commercialize forodesine (the &amp;#x201c;Knowledge Transfer&amp;#x201d;). The Company accounted for these elements as a combined unit of accounting as they do not have stand-alone value to Mundipharma. The worldwide license rights were granted to Mundipharma on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; November&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011&lt;/div&gt; and the Knowledge Transfer was completed during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2012.&lt;/div&gt; Upon completion of the Knowledge Transfer, the remaining deferred revenue and deferred expense was recognized in full.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (&amp;#x201c;AECOM&amp;#x201d; and &amp;#x201c;IRL&amp;#x201d; respectively).&lt;/div&gt; In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2000,&lt;/div&gt; the Company licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the &amp;#x201c;Licensors&amp;#x201d;). The lead product candidates from this collaboration are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed product (which range in the aggregate from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,400&lt;/div&gt; to almost &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4,000&lt;/div&gt;&amp;nbsp;per indication) for future development of these inhibitors, single digit royalties on net sales of any resulting product made by the Company, and to share approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; quarter of future payments received from other &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$150&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$500,&lt;/div&gt; that are creditable against actual royalties and other payments due to the Licensors. This agreement &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; be terminated by the Company at any time by giving &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;60&lt;/div&gt;&amp;nbsp;days advance notice or in the event of material uncured breach by the Licensors.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt;&lt;div style="page-break-before: always; margin-top: 6pt"&gt;&lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2010,&lt;/div&gt; the Company amended the licensee agreement through which the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-half in the percentage of future payments received from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party sub licensees of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i)&amp;nbsp;any milestone payments the Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; receive in the future under its license agreement dated &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2006&lt;/div&gt; with Mundipharma and (ii)&amp;nbsp;royalties received from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In consideration for these modifications in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2010,&lt;/div&gt; the Company issued to the Licensors shares of its common stock with an aggregate value of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5,911&lt;/div&gt; and paid the Licensors &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$90&lt;/div&gt; in cash. Additionally, at the Company&amp;#x2019;s sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by it to the Licensors under the license agreement &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; be made either in cash, in shares of its common stock, or in a combination of cash and shares.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; November&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011,&lt;/div&gt; the Company further amended its agreements with the Licensors whereby the Licensors agreed to accept a reduction of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-half in the percentage of Net Proceeds (as defined) received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2012,&lt;/div&gt; the Company further amended its agreements with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to exclusive worldwide license of galidesivir to BioCryst for any antiviral use.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;At its sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; be made either in cash, in shares of the Company&amp;#x2019;s common stock, or in a combination of cash and shares.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; the Carbohydrate Chemistry Research Team from Callaghan Innovation Research Limited, formerly Industrial Research Limited, transferred to Victoria University of Wellington (&amp;#x201c;VUW&amp;#x201d;) to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts relating to that intellectual property were transferred to a wholly owned subsidiary of VUW, including the contracts to which BioCryst is a party. The parties executed novation agreements in order to effectuate the transfer. Except for a substitution of parties, the terms and conditions of the contracts are substantially the same&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;The University of Alabama at Birmingham (&amp;#x201c;UAB&amp;#x201d;).&lt;/div&gt; The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party partners. The Company has completed the research under the UAB agreements. These &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; agreements have initial &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25&lt;/div&gt;-year terms, are automatically renewable for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt;-year terms throughout the life of the last patent and are terminable by the Company upon &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months&amp;#x2019; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties&amp;#x2019; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi, Green Cross and SUL agreements, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2016-01-01_2016-12-31" id="s433706">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt;&amp;nbsp;&amp;#x2014; Lease Obligations and Other Contingencies&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company has the following minimum payments under operating lease obligations that existed at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 87%; font-size: 10pt; text-align: left"&gt;2017&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;871&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;2018&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;838&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;2019&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;822&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;2020&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;653&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;2021&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;478&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: left"&gt;Thereafter&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,489&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total minimum payments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,151&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The obligations in the preceding table are primarily related to the Company&amp;#x2019;s leases for buildings in Birmingham, Alabama and Durham, North Carolina. The lease for the Company&amp;#x2019;s headquarters in Durham, North Carolina expires &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2020.&lt;/div&gt; The lease for the Company&amp;#x2019;s research facility in Birmingham, Alabama expires &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2026.&lt;/div&gt; Rent expense for operating leases was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$721,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$664&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$633&lt;/div&gt; in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; respectively.&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Lease Financing Obligation&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Based on the terms of the lease agreement for the new research facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the owner of the building (for accounting purposes only) during the construction period, which ended in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt; Accordingly, the Company recorded an asset of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,589&lt;/div&gt; at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; representing the Company&amp;#x2019;s leased portion of the building and recorded a corresponding liability. Upon completion of leasehold improvement construction, the Company did not meet the sale-leaseback criteria for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected duration of the lease, and rental payments will be treated as principal and interest payments on the lease financing obligation liability. The underlying accounting for this transaction has no impact on cash flows associated with the underlying lease and or construction in process.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; the lease financing obligation balance was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,704&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,375,&lt;/div&gt; respectively and was recorded as a long term liability on the consolidated balance sheets. The remaining future minimum payments under the lease financing obligation are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4,768.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2016-12-31" decimals="INF" id="c13547931" unitRef="iso4217-usd-per-xbrli-shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2015-12-31" decimals="INF" id="c13547932" unitRef="iso4217-usd-per-xbrli-shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2016-12-31" decimals="-3" id="c13547933" unitRef="xbrli-shares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2015-12-31" decimals="-3" id="c13547934" unitRef="xbrli-shares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="i_2016-12-31" decimals="-3" id="c13547935" unitRef="xbrli-shares">73782000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="i_2015-12-31" decimals="-3" id="c13547936" unitRef="xbrli-shares">73355000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2016-12-31" decimals="-3" id="c13547937" unitRef="xbrli-shares">73782000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2015-12-31" decimals="-3" id="c13547938" unitRef="xbrli-shares">73355000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="i_2016-12-31" decimals="-3" id="c13547929" unitRef="iso4217-usd">738000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="i_2015-12-31" decimals="-3" id="c13547930" unitRef="iso4217-usd">734000</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548002" unitRef="iso4217-usd">-54950000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548003" unitRef="iso4217-usd">-43095000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548004" unitRef="iso4217-usd">-45323000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="d_2016-01-01_2016-12-31" id="c13552333">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accumulated Other Comprehensive Loss&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&amp;#x2019; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; realized gains of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$11&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$13,&lt;/div&gt; respectively, were reclassified out of accumulated other comprehensive loss.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="d_2016-01-01_2016-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueProductLineMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-ThreeCustomersMember_ProductOrServiceAxis-RAPIVABMember" decimals="INF" id="c13548426" unitRef="xbrli-pure">0.9</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CostOfGoodsSold contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13547963" unitRef="iso4217-usd">2297000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13547964" unitRef="iso4217-usd">1368000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13547965" unitRef="iso4217-usd">1000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostsAndExpenses contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13547975" unitRef="iso4217-usd">74960000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13547976" unitRef="iso4217-usd">87701000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13547977" unitRef="iso4217-usd">59379000</us-gaap:CostsAndExpenses>
  <us-gaap:DebtDisclosureTextBlock contextRef="d_2016-01-01_2016-12-31" id="s433704">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt; &amp;#x2014; Senior Credit Facility&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the Company closed a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$23,000&lt;/div&gt; Senior Credit Facility with an affiliate of MidCap Financial Services, LLC (&amp;#x201c;MidCap&amp;#x201d;), as administrative agent (the &amp;#x201c;Senior Credit Facility&amp;#x201d;). The Senior Credit Facility was fully funded at closing and bears a variable interest rate of LIBOR (which shall not be less than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.5%)&lt;/div&gt; plus &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8%.&lt;/div&gt; The Senior Credit Facility includes an interest-only payment period through fiscal &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and scheduled monthly principal and interest payments for the subsequent &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt; months. The Company has the option to repay the Senior Credit Facility at any time prior to the scheduled principal repayment date subject to prepayment fees. Final payment of the Senior Credit Facility is subject to a final payment fee equal to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5%&lt;/div&gt; of the principal funded under the Senior Credit Facility.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the Company had borrowings of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$23,000&lt;/div&gt; under the Senior Credit Facility bearing an interest rate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.6%.&lt;/div&gt; The carrying amount of the debt approximates its fair value based on prevailing interest rates as of the balance sheet date. Scheduled principal repayments of the Senior Credit Facility are as follows:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="5" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Principal Payments&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: justify; text-indent: 0pt"&gt;2017&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: justify; text-indent: 0pt; width: 72%"&gt;2018&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 25%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,900&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: justify; text-indent: 0pt"&gt;2019&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,900&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: justify; text-indent: 0pt"&gt;2020&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,900&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: justify; text-indent: 0pt"&gt;2021&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,300&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: justify; text-indent: 0pt"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23,000&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="page-break-before: always; margin-top: 6pt"&gt;&lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The debt agreement contains &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; provisions that if deemed probable would create the recognition of an embedded feature; however, at this time we do not believe either provision is probable.&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="d_2016-09-23_2016-09-23_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember" decimals="3" id="c13548674" unitRef="xbrli-pure">0.08</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="INF" id="c13548609" unitRef="xbrli-pure">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="i_2013-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="INF" id="c13548624" unitRef="xbrli-pure">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentTerm contextRef="d_2016-09-23_2016-09-23_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" id="c13548676">P3Y120D</us-gaap:DebtInstrumentTerm>
  <us-gaap:DeferredCostsCurrent contextRef="i_2016-12-31" decimals="-3" id="c13547883" unitRef="iso4217-usd">85000</us-gaap:DeferredCostsCurrent>
  <us-gaap:DeferredCostsCurrent contextRef="i_2015-12-31" decimals="-3" id="c13547884" unitRef="iso4217-usd">90000</us-gaap:DeferredCostsCurrent>
  <us-gaap:DeferredIncomeTaxLiabilities contextRef="i_2016-12-31" decimals="-3" id="c13549125" unitRef="iso4217-usd">2089000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredIncomeTaxLiabilities contextRef="i_2015-12-31" decimals="-3" id="c13549126" unitRef="iso4217-usd">2668000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="i_2016-12-31" decimals="-3" id="c13547912" unitRef="iso4217-usd">244000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="i_2015-12-31" decimals="-3" id="c13547913" unitRef="iso4217-usd">329000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRevenue contextRef="i_2006-02-28_DeferredRevenueArrangementTypeAxis-UpfrontPaymentMember_TypeOfArrangementAxis-MundipharmaMember" decimals="INF" id="c13549199" unitRef="iso4217-usd">5000000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueAdditions contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_DeferredRevenueArrangementTypeAxis-RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="-3" id="c13548345" unitRef="iso4217-usd">3740000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:DeferredRevenueAdditions contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_DeferredRevenueArrangementTypeAxis-RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="-3" id="c13548347" unitRef="iso4217-usd">1223000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2016-12-31" decimals="-3" id="c13547904" unitRef="iso4217-usd">2022000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2015-12-31" decimals="-3" id="c13547905" unitRef="iso4217-usd">2163000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="i_2016-12-31" decimals="-3" id="c13547910" unitRef="iso4217-usd">8184000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="i_2015-12-31" decimals="-3" id="c13547911" unitRef="iso4217-usd">9674000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="i_2016-12-31" decimals="-3" id="c13549112" unitRef="iso4217-usd">3484000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="i_2015-12-31" decimals="-3" id="c13549113" unitRef="iso4217-usd">4240000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsGross contextRef="i_2016-12-31" decimals="-3" id="c13549118" unitRef="iso4217-usd">227134000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross contextRef="i_2015-12-31" decimals="-3" id="c13549119" unitRef="iso4217-usd">207876000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="i_2016-12-31" id="c13549129" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="i_2015-12-31" id="c13549130" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="i_2016-12-31" decimals="-3" id="c13549106" unitRef="iso4217-usd">158618000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="i_2015-12-31" decimals="-3" id="c13549107" unitRef="iso4217-usd">142836000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsOther contextRef="i_2016-12-31" decimals="-3" id="c13549116" unitRef="iso4217-usd">2849000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther contextRef="i_2015-12-31" decimals="-3" id="c13549117" unitRef="iso4217-usd">2590000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="i_2016-12-31" id="c13549110" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="i_2015-12-31" decimals="-3" id="c13549111" unitRef="iso4217-usd">1054000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="i_2016-12-31" decimals="-3" id="c13549108" unitRef="iso4217-usd">53231000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="i_2015-12-31" decimals="-3" id="c13549109" unitRef="iso4217-usd">48551000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="i_2016-12-31" decimals="-3" id="c13549114" unitRef="iso4217-usd">8952000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="i_2015-12-31" decimals="-3" id="c13549115" unitRef="iso4217-usd">8605000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="i_2016-12-31" decimals="-3" id="c13549127" unitRef="iso4217-usd">225045000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="i_2015-12-31" decimals="-3" id="c13549128" unitRef="iso4217-usd">205208000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="i_2016-12-31" decimals="-3" id="c13549121" unitRef="iso4217-usd">674000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="i_2015-12-31" id="c13549122" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains contextRef="i_2016-12-31" decimals="-3" id="c13549123" unitRef="iso4217-usd">1415000</us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains>
  <us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains contextRef="i_2015-12-31" decimals="-3" id="c13549124" unitRef="iso4217-usd">2668000</us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13549137" unitRef="iso4217-usd">504000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13549138" unitRef="iso4217-usd">366000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13549139" unitRef="iso4217-usd">361000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548567" unitRef="iso4217-usd">483000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548568" unitRef="iso4217-usd">180000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548569" unitRef="iso4217-usd">177000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DerivativeForwardExchangeRate1 contextRef="i_2015-09-30_CurrencyAxis-JPY_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="INF" id="c13548646" unitRef="xbrli-pure">100</us-gaap:DerivativeForwardExchangeRate1>
  <us-gaap:DerivativeGainOnDerivative contextRef="d_2014-01-01_2014-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="-3" id="c13548405" unitRef="iso4217-usd">5487000</us-gaap:DerivativeGainOnDerivative>
  <us-gaap:DerivativeGainOnDerivative contextRef="d_2016-01-01_2016-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="-3" id="c13548408" unitRef="iso4217-usd">811000</us-gaap:DerivativeGainOnDerivative>
  <us-gaap:DerivativeGainOnDerivative contextRef="d_2015-01-01_2015-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="-3" id="c13548409" unitRef="iso4217-usd">1654000</us-gaap:DerivativeGainOnDerivative>
  <us-gaap:DerivativeLossOnDerivative contextRef="d_2016-01-01_2016-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="-3" id="c13548403" unitRef="iso4217-usd">1654000</us-gaap:DerivativeLossOnDerivative>
  <us-gaap:DerivativeLossOnDerivative contextRef="d_2015-01-01_2015-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="-3" id="c13548404" unitRef="iso4217-usd">564000</us-gaap:DerivativeLossOnDerivative>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2016-01-01_2016-12-31" id="s433709">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&amp;nbsp;&amp;#x2014; Stock-Based Compensation&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock Incentive Plan&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the Company had &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; stock-based employee compensation plans, the Stock Incentive Plan (&amp;#x201c;Incentive Plan&amp;#x201d;) and the Employee Stock Purchase Plan (&amp;#x201c;ESPP&amp;#x201d;). The Incentive Plan was amended and restated in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and approved by the Company&amp;#x2019;s stockholders in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt; The ESPP was amended and restated in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt; and approved by the Company&amp;#x2019;s stockholders in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014.&lt;/div&gt; Stock-based compensation expense of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$8,487&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;($8,340&lt;/div&gt; of expense related to the Incentive Plan, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$147&lt;/div&gt; of expense related to the ESPP) was recognized during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; while &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$9,705&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;($9,485&lt;/div&gt; of expense related to the Incentive Plan, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$220&lt;/div&gt; of expense related to the ESPP) was recognized during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$10,177&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;($9,963&lt;/div&gt; of expense related to the Incentive Plan, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$214&lt;/div&gt; of expense related to the ESPP) was recognized during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014.&lt;/div&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&lt;/div&gt;&lt;div style="page-break-before: always; margin-top: 6pt"&gt;&lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company accounts for stock-based compensation in accordance with FASB authoritative guidance regarding share-based payments. Total stock-based compensation was allocated as follows:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year Ended December&amp;nbsp;31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 55%; font-size: 10pt; text-align: left"&gt;Research and development&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,088&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,580&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,906&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,399&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,125&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,271&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total stock-based compensation expense&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,487&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,705&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,177&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&amp;#x2019;s stock at the date of grant. Commencing &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011,&lt;/div&gt; stock option awards granted to employees generally vest &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25%&lt;/div&gt; each year until fully vested after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;four&lt;/div&gt; years. In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2013,&lt;/div&gt; the Company made retention grants of stock option awards and restricted stock units. These awards vest &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50%&lt;/div&gt; each year until fully vested after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; years. In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2013&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; the Company issued &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,032&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,250&lt;/div&gt; performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;75%&lt;/div&gt; of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2013&lt;/div&gt; grants have vested based upon achievement of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; milestones: &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1)&lt;/div&gt; successful completion of the OPuS-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt; clinical trial, for which vesting occurred in the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;second&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2)&lt;/div&gt; FDA approval of RAPIVAB for which vesting occurred in the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;fourth&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3)&lt;/div&gt; initiation of a Phase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt; clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;BCX7353&lt;/div&gt; in healthy volunteers, for which vesting occurred in the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;second&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015.&lt;/div&gt; Thus, as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25%&lt;/div&gt; of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2013&lt;/div&gt; performance-based grants and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;100%&lt;/div&gt; of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt; performance-based grants remain unvested and no compensation expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to non-employee directors of the Company generally vest monthly over &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; year. All stock option awards have contractual terms of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;&amp;nbsp;years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan. &lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Related activity under the Incentive Plan is as follows:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Awards&lt;br /&gt; Available&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Options&lt;br /&gt; Outstanding&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted&lt;br /&gt; Average&lt;br /&gt; Exercise&lt;br /&gt; Price&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 55%; font-size: 10pt"&gt;Balance at December&amp;nbsp;31, 2013&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,082&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,986&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.99&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Plan amendment&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,750&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Restricted stock awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(593&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Restricted stock awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Stock option awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,965&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,965&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10.99&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Stock option awards exercised&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,258&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.78&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Stock option awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;88&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(88&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.83&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;Balance at December&amp;nbsp;31, 2014&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,362&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,605&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.21&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Restricted stock awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(163&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Restricted stock awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Stock option awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,217&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,217&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11.52&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Stock option awards exercised&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,118&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.36&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Stock option awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;33&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(33&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9.87&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;Balance at December&amp;nbsp;31, 2015&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,671&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.50&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Plan amendment&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,800&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Restricted stock awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(34&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Restricted stock awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;22&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Stock option awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,248&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,248&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.20&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Stock option awards exercised&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(107&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.63&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Stock option awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;717&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(717&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10.78&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Balance at December&amp;nbsp;31, 2016&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,273&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,095&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.55&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;/div&gt;&lt;div style="page-break-before: always; margin-top: 6pt"&gt;&lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;For stock option awards granted under the Incentive Plan during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value of these awards granted during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.17,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$7.72&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$8.02,&lt;/div&gt; respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. The following explanations describe the assumptions used by the Company to value the stock option awards granted during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014.&lt;/div&gt; The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if not yet vested) and the full contractual term. The expected volatility represents the volatility over the most recent period corresponding with the expected life. The Company has assumed no expected dividend yield, as dividends have never been paid to stockholders and will not be for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;zero&lt;/div&gt;-coupon government issues with a remaining term equal to the expected term.&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted Average Assumptions for Stock Option Awards Granted under the Incentive Plan&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 55%; font-size: 10pt; text-align: left"&gt;Expected Life&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.5&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.5&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.5&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expected Volatility&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;82&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;81&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;87&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expected Dividend Yield&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.0&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.0&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.0&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Risk-Free Interest Rate&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.4&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.6&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.6&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The total intrinsic value of stock option awards exercised under the Incentive Plan was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$339&lt;/div&gt; during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$10,117&lt;/div&gt; during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$8,522&lt;/div&gt; during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014.&lt;/div&gt; The intrinsic value represents the total proceeds (fair market value at the date of exercise, less the exercise price, times the number of stock option awards exercised) received by all individuals who exercised stock option awards during the period.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The following table summarizes, at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; by price range: &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1)&lt;/div&gt;&amp;nbsp;for stock option awards outstanding under the Incentive Plan, the number of stock option awards outstanding, their weighted average remaining life and their weighted average exercise price; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2)&lt;/div&gt;&amp;nbsp;for stock option awards exercisable under the Plan, the number of stock option awards exercisable and their weighted average exercise price:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="9" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Outstanding&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Exercisable&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="2"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; text-decoration: underline;"&gt;Range&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Number&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Remaining &lt;br /&gt; Life&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Exercise &lt;br /&gt; Price&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Number&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Exercise &lt;br /&gt; Price&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 1%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; width: 5%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;0&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; width: 3%"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; width: 5%"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1,919&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;5.7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1.64&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1,510&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1.53&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;3&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;4,749&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6.9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;4.02&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;2,578&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;4.48&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1,153&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;3.5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;7.10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1,118&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;7.11&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;9&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;12&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;3,457&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;7.2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;11.10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1,074&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;11.29&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;12&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;15&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;722&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;8.0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;12.39&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;195&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;12.73&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;15&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right; padding-bottom: 1.1pt; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;95&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;8.5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;15.39&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;24&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;15.39&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;0&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right; padding-bottom: 2.25pt; border-bottom: Black 2.25pt double"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;12,095&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6.6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6.55&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6,499&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;5.66&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The weighted average remaining contractual life of stock option awards exercisable under the Incentive Plan at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.6&lt;/div&gt; years.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The aggregate intrinsic value of stock option awards outstanding and exercisable under the Incentive Plan at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$20,002.&lt;/div&gt; The aggregate intrinsic value represents the value (the period&amp;#x2019;s closing market price, less the exercise price, times the number of in-the-money stock option awards) that would have been received by all stock option award holders under the Incentive Plan had they exercised their stock option awards at the end of the year.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The total fair value of the stock option awards vested under the Incentive Plan was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6,380&lt;/div&gt; during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4,492&lt;/div&gt; during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,844&lt;/div&gt; during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the number of stock option awards vested and expected to vest under the Incentive Plan is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,013.&lt;/div&gt; The weighted average exercise price of these stock option awards is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6.53&lt;/div&gt; and their weighted average remaining contractual life is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.5&lt;/div&gt;&amp;nbsp;years.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt;&lt;div style="page-break-before: always; margin-top: 6pt"&gt;&lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The following table summarizes the changes in the number and weighted-average grant-date fair value of non-vested stock option awards during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Non-Vested&lt;br /&gt; Stock Option&lt;br /&gt; Awards&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted Average&lt;br /&gt; Grant-Date Fair&lt;br /&gt; Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 67%; font-size: 10pt"&gt;Balance December&amp;nbsp;31, 2015&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,863&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.40&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Stock option awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,248&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.17&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Stock option awards vested&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,278&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.99&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Stock option awards forfeited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(235&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.79&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Balance December&amp;nbsp;31, 2016&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,598&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.40&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; there was approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$14,541&lt;/div&gt; of total unrecognized compensation cost related to non-vested employee stock option awards and restricted stock units granted by the Company. That cost is expected to be recognized as follows: &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6,880&lt;/div&gt; in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4,649&lt;/div&gt; in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,606&lt;/div&gt; in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019,&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$406&lt;/div&gt; in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2020.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Employee Stock Purchase Plan&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company has reserved a total of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,475&lt;/div&gt;&amp;nbsp;shares of common stock to be purchased under the ESPP, of which &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;422&lt;/div&gt;&amp;nbsp;shares remain available for purchase at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt; Eligible employees &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; authorize up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15%&lt;/div&gt; of their salary to purchase common stock at the lower of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;85%&lt;/div&gt; of the beginning or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;85%&lt;/div&gt; of the ending price during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;six&lt;/div&gt;-month purchase intervals. No more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; shares &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; be purchased by any &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; employee at the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;six&lt;/div&gt;-month purchase dates and no employee &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; purchase stock having a fair market value at the commencement date of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$25&lt;/div&gt; or more in any &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; calendar year.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;There were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;75,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;49&lt;/div&gt; shares of common stock purchased under the ESPP in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; respectively, at a weighted average price per share of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4.36,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$8.65&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6.29,&lt;/div&gt; respectively. Expense of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$147,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$220&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$214&lt;/div&gt; related to the ESPP was recognized during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; respectively. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &amp;#x201c;look-back&amp;#x201d; option were determined using a Black-Scholes option pricing model. The weighted average grant date fair values of shares granted under the ESPP during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.95,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4.93&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4.41,&lt;/div&gt; respectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasic contextRef="d_2015-01-01_2015-03-31" decimals="INF" id="c13549265" unitRef="iso4217-usd-per-xbrli-shares">-0.21</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="d_2015-04-01_2015-06-30" decimals="INF" id="c13549266" unitRef="iso4217-usd-per-xbrli-shares">0.07</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="d_2015-07-01_2015-09-30" decimals="INF" id="c13549267" unitRef="iso4217-usd-per-xbrli-shares">-0.20</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="d_2015-10-01_2015-12-31" decimals="INF" id="c13549268" unitRef="iso4217-usd-per-xbrli-shares">-0.25</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c13547993" unitRef="iso4217-usd-per-xbrli-shares">-0.75</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c13547994" unitRef="iso4217-usd-per-xbrli-shares">-0.59</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c13547995" unitRef="iso4217-usd-per-xbrli-shares">-0.68</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2016-01-01_2016-03-31" decimals="INF" id="c13549252" unitRef="iso4217-usd-per-xbrli-shares">-0.31</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2016-04-01_2016-06-30" decimals="INF" id="c13549253" unitRef="iso4217-usd-per-xbrli-shares">-0.22</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2016-07-01_2016-09-30" decimals="INF" id="c13549254" unitRef="iso4217-usd-per-xbrli-shares">-0.16</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2016-10-01_2016-12-31" decimals="INF" id="c13549255" unitRef="iso4217-usd-per-xbrli-shares">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2015-01-01_2015-03-31" decimals="INF" id="c13549269" unitRef="iso4217-usd-per-xbrli-shares">-0.21</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2015-04-01_2015-06-30" decimals="INF" id="c13549270" unitRef="iso4217-usd-per-xbrli-shares">0.06</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2015-07-01_2015-09-30" decimals="INF" id="c13549271" unitRef="iso4217-usd-per-xbrli-shares">-0.20</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2015-10-01_2015-12-31" decimals="INF" id="c13549272" unitRef="iso4217-usd-per-xbrli-shares">-0.25</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2016-01-01_2016-12-31" id="c13552341">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Net Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, outstanding warrants, and common shares expected to be issued under the Company&amp;#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt; does not include &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,226,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,524&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,991&lt;/div&gt; respectively, of potential common shares as their impact would be anti-dilutive.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="d_2016-01-01_2016-12-31" decimals="2" id="c13549065" unitRef="xbrli-pure">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="d_2015-01-01_2015-12-31" decimals="2" id="c13549066" unitRef="xbrli-pure">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="d_2014-01-01_2014-12-31" decimals="2" id="c13549067" unitRef="xbrli-pure">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="i_2016-12-31" decimals="-3" id="c13548522" unitRef="iso4217-usd">425000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="i_2015-12-31" decimals="-3" id="c13548523" unitRef="iso4217-usd">424000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="i_2016-12-31" decimals="-3" id="c13548832" unitRef="iso4217-usd">14541000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13549054" unitRef="iso4217-usd">15655000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions>
  <us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased contextRef="d_2016-01-01_2016-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c13548860" unitRef="iso4217-usd-per-xbrli-shares">4.36</us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased>
  <us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c13548861" unitRef="iso4217-usd-per-xbrli-shares">8.65</us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased>
  <us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased contextRef="d_2014-01-01_2014-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c13548862" unitRef="iso4217-usd-per-xbrli-shares">6.29</us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased>
  <us-gaap:GainLossOnDispositionOfAssets1 contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548013" unitRef="iso4217-usd">-17000</us-gaap:GainLossOnDispositionOfAssets1>
  <us-gaap:GainLossOnDispositionOfAssets1 contextRef="d_2015-01-01_2015-12-31" id="c13548014" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:GainLossOnDispositionOfAssets1 contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548015" unitRef="iso4217-usd">-27000</us-gaap:GainLossOnDispositionOfAssets1>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13547987" unitRef="iso4217-usd">-843000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13547988" unitRef="iso4217-usd">1090000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13547989" unitRef="iso4217-usd">5487000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GovernmentContractReceivable contextRef="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember" decimals="INF" id="c13549162" unitRef="iso4217-usd">16265000</us-gaap:GovernmentContractReceivable>
  <us-gaap:GovernmentContractReceivable contextRef="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember" decimals="INF" id="c13549163" unitRef="iso4217-usd">22855000</us-gaap:GovernmentContractReceivable>
  <us-gaap:GovernmentContractReceivable contextRef="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember" decimals="INF" id="c13549164" unitRef="iso4217-usd">39120000</us-gaap:GovernmentContractReceivable>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2016-01-01_2016-12-31" id="s433715">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8&lt;/div&gt;&amp;nbsp;&amp;#x2014; Income Taxes&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company has incurred net losses since inception and, consequently, has not recorded any U.S.&amp;nbsp;Federal and state income tax expense or benefit. The differences between the Company&amp;#x2019;s effective tax rate and the statutory tax rate in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt; are as follows:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 61%; font-size: 10pt; text-align: left"&gt;Income tax benefit at federal statutory rate (35%)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(19,300&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(15,057&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(15,816&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;State and local income taxes net of federal tax benefit&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,173&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(819&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,286&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Permanent items&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,057&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;560&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;258&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Rate change&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,080&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,012&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;22&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expiration of attribute carryforwards&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;559&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;330&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;373&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Research and development tax credits&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4,681&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(10,454&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(748&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Orphan drug credit&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,798&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,307&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;Other&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;822&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(218&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(115&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19,838&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,339&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,312&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Income tax expense&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recognizes the impact of a tax position in its financial statements if it is more likely than not that the position will be sustained on audit based on the technical merits of the position. The Company has concluded that it has an uncertain tax position pertaining to its research and development and orphan drug credit carryforwards. The Company has established these credits based on information and calculations it believes are appropriate and the best estimate of the underlying credit. Any changes to the Company&amp;#x2019;s unrecognized tax benefits are offset by an adjustment to the valuation allowance and there would be no impact on the Company&amp;#x2019;s financial statements. The Company does not expect its unrecognized tax benefits to change significantly over the next &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt; months.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 70%; font-size: 10pt"&gt;Balance at January&amp;nbsp;1,&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,085&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;472&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Additions to current period tax positions&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,170&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,616&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Additions to prior period tax positions&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Reductions to prior period tax provisions&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Balance at December&amp;nbsp;31,&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,255&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,085&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&lt;/div&gt;&lt;div style="page-break-before: always; margin-top: 6pt"&gt;&lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s ability to utilize the net operating loss and tax credit carryforwards in the future &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; be subject to substantial restrictions in the event of past or future ownership changes as defined in Section&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;382&lt;/div&gt; of the Internal Revenue Code of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1986,&lt;/div&gt; as amended and similar state tax law.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Significant components of the Company&amp;#x2019;s deferred tax assets and liabilities are as follows:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Deferred tax assets:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 70%; font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Net federal and state operating losses&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;158,618&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;142,836&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Research and development credits&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;53,231&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;48,551&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Fixed assets&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,054&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Deferred revenue&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,484&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,240&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Stock-based compensation&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,952&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,605&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Other&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,849&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,590&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Total deferred tax assets&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;227,134&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;207,876&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Fixed assets&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(674&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Foreign currency derivative&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,415&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,668&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total deferred tax liabilities&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,089&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,668&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(225,045&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(205,208&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Net deferred tax assets&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The majority of the Company&amp;#x2019;s deferred tax assets relate to net operating loss and research and development carryforwards that can only be realized if the Company is profitable in future periods. It is uncertain whether the Company will realize any tax benefit related to these carryforwards. Accordingly, the Company has provided a full valuation allowance against the net deferred tax assets due to uncertainties as to their ultimate realization. The valuation allowance will remain at the full amount of the deferred tax assets until it is more likely than not that the related tax benefits will be realized. The Company&amp;#x2019;s valuation allowance increased by &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$19,837&lt;/div&gt; in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$20,339&lt;/div&gt; in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$17,312&lt;/div&gt; in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014.&lt;/div&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the Company had federal operating loss carryforwards of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$431,983,&lt;/div&gt; state operating loss carryforwards of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$403,237,&lt;/div&gt; and research and development and orphan drug credit carryforwards of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$57,487,&lt;/div&gt; which will expire at various dates from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; through &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2035.&lt;/div&gt; The federal losses begin to expire in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; the state losses begin to expire in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and the research and development credit carryforwards begin to expire in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s federal and state operating loss carryforwards include &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$15,655&lt;/div&gt; of excess tax benefits related to a deduction from the exercise of stock options. The tax benefit of these deductions has not been recognized in deferred tax assets. If utilized, the benefits from these deductions will be recorded as adjustments to additional paid-in capital.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Tax years &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2013&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt; remain open to examination by the major taxing jurisdictions to which the Company is subject. Additionally, years prior to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2013&lt;/div&gt; are also open to examination to the extent of loss and credit carryforwards from those years. The Company recognizes interest and penalties accrued related to unrecognized tax benefits as components of its income tax provision. However, there were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt;&lt;/div&gt; &lt;/div&gt;provisions or accruals for interest and penalties in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2016-01-01_2016-12-31" id="c13549092" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2015-01-01_2015-12-31" id="c13549093" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2014-01-01_2014-12-31" id="c13549094" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2016-01-01_2016-12-31" id="c13552332">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The liability method is used in the Company&amp;#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13549038" unitRef="iso4217-usd">19837000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13549040" unitRef="iso4217-usd">20339000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13549042" unitRef="iso4217-usd">17312000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13549074" unitRef="iso4217-usd">1080000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
  <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13549075" unitRef="iso4217-usd">1012000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
  <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13549076" unitRef="iso4217-usd">22000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13549062" unitRef="iso4217-usd">-19300000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13549063" unitRef="iso4217-usd">-15057000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13549064" unitRef="iso4217-usd">-15816000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13549071" unitRef="iso4217-usd">1057000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13549072" unitRef="iso4217-usd">560000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13549073" unitRef="iso4217-usd">258000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13549086" unitRef="iso4217-usd">822000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13549087" unitRef="iso4217-usd">-218000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13549088" unitRef="iso4217-usd">-115000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13549068" unitRef="iso4217-usd">-1173000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13549069" unitRef="iso4217-usd">-819000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13549070" unitRef="iso4217-usd">-1286000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13549080" unitRef="iso4217-usd">4681000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13549081" unitRef="iso4217-usd">10454000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13549082" unitRef="iso4217-usd">748000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548038" unitRef="iso4217-usd">-10524000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548039" unitRef="iso4217-usd">13676000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548040" unitRef="iso4217-usd">4656000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548044" unitRef="iso4217-usd">-1631000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548045" unitRef="iso4217-usd">1199000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548046" unitRef="iso4217-usd">4429000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDerivativeAssets contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13549487" unitRef="iso4217-usd">811000</us-gaap:IncreaseDecreaseInDerivativeAssets>
  <us-gaap:IncreaseDecreaseInDerivativeAssets contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13549488" unitRef="iso4217-usd">-564000</us-gaap:IncreaseDecreaseInDerivativeAssets>
  <us-gaap:IncreaseDecreaseInDerivativeAssets contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13549489" unitRef="iso4217-usd">5487000</us-gaap:IncreaseDecreaseInDerivativeAssets>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548041" unitRef="iso4217-usd">2244000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548042" unitRef="iso4217-usd">717000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548043" unitRef="iso4217-usd">2162000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:IncreaseDecreaseInInventories contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548029" unitRef="iso4217-usd">-1112000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548030" unitRef="iso4217-usd">929000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548031" unitRef="iso4217-usd">683000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548032" unitRef="iso4217-usd">-3702000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548033" unitRef="iso4217-usd">-637000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548034" unitRef="iso4217-usd">2093000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548026" unitRef="iso4217-usd">2525000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548027" unitRef="iso4217-usd">-3247000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548028" unitRef="iso4217-usd">7375000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548057" unitRef="iso4217-usd">-66000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548058" unitRef="iso4217-usd">1462000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548059" unitRef="iso4217-usd">-1000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="d_2016-01-01_2016-12-31" id="c13552330">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Patents and Licenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
  <us-gaap:InterestAndOtherIncome contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13547981" unitRef="iso4217-usd">793000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13547982" unitRef="iso4217-usd">535000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13547983" unitRef="iso4217-usd">93000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestExpense contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548371" unitRef="iso4217-usd">6487000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548372" unitRef="iso4217-usd">5200000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548373" unitRef="iso4217-usd">4998000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2016-01-01_2016-12-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember" decimals="-3" id="c13548390" unitRef="iso4217-usd">408000</us-gaap:InterestExpense>
  <us-gaap:InterestPaid contextRef="d_2013-09-01_2013-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="-3" id="c13548618" unitRef="iso4217-usd">1844000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid contextRef="d_2014-03-01_2014-03-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="-3" id="c13548627" unitRef="iso4217-usd">446000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid contextRef="d_2014-06-01_2014-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="-3" id="c13548628" unitRef="iso4217-usd">1882000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid contextRef="d_2014-08-01_2014-08-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="-3" id="c13548629" unitRef="iso4217-usd">70000</us-gaap:InterestPaid>
  <us-gaap:InterestPayableCurrent contextRef="i_2016-12-31" decimals="-3" id="c13547902" unitRef="iso4217-usd">8990000</us-gaap:InterestPayableCurrent>
  <us-gaap:InterestPayableCurrent contextRef="i_2015-12-31" decimals="-3" id="c13547903" unitRef="iso4217-usd">6746000</us-gaap:InterestPayableCurrent>
  <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="i_2013-09-03_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="-3" id="c13548620" unitRef="iso4217-usd">2356000</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="i_2014-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_StatementScenarioAxis-Shortfall2013Member" decimals="-3" id="c13548631" unitRef="iso4217-usd">222000</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:InventoryNet contextRef="i_2016-12-31" decimals="-3" id="c13547879" unitRef="iso4217-usd">500000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet contextRef="i_2015-12-31" decimals="-3" id="c13547880" unitRef="iso4217-usd">1612000</us-gaap:InventoryNet>
  <us-gaap:InventoryPolicyTextBlock contextRef="d_2016-01-01_2016-12-31" id="c13552328">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Inventory&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; the Company&amp;#x2019;s inventory consisted primarily of peramivir work in process and is being manufactured for the Company&amp;#x2019;s partners. Inventory is stated at the lower of cost, determined under the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt;-in, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt;-out (&amp;#x201c;FIFO&amp;#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;During &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; in connection with the FDA approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s inventory consisted of the following:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of December&amp;nbsp;31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Work in process&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;500&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,612&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Net inventories&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;500&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,612&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="i_2016-12-31" decimals="-3" id="c13548518" unitRef="iso4217-usd">500000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="i_2015-12-31" decimals="-3" id="c13548519" unitRef="iso4217-usd">1612000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InvestmentPolicyTextBlock contextRef="d_2016-01-01_2016-12-31" id="c13552325">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Investments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&amp;#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&amp;#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; years and requires an average portfolio maturity of no more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&lt;/div&gt; months. Some of the securities the Company invests in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; have market risk. This means that a change in prevailing interest rates &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&amp;#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months and which mature at or less than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt; months from the balance sheet date are classified as current. Investments with a maturity beyond &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt; months from the balance sheet date are classified as long-term. At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the Company believes that the cost of its investments is recoverable in all material respects.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The following tables summarize the fair value of the Company&amp;#x2019;s investments by type. The estimated fair values of the Company&amp;#x2019;s fixed income investments are classified as Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; inputs.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31, 2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Estimated&lt;br /&gt; Fair Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Obligations of U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,266&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;34&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,298&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,179&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(8&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,199&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,962&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(11&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,975&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41,407&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;77&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(23&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41,472&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Estimated&lt;br /&gt; Fair Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt; width: 35%"&gt;Obligations of U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26,557&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;88&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(99&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26,546&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,820&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;184&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(41&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,963&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,884&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(72&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,838&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;70,261&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;292&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(212&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;70,347&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;/div&gt;&lt;div style="page-break-before: always; margin-top: 6pt"&gt;&lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The following table summarizes the scheduled maturity for the Company&amp;#x2019;s investments at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 67%; font-size: 10pt; text-align: left"&gt;Maturing in one year or less&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;32,546&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;22,664&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Maturing after one year through two years&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,926&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;28,395&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Maturing after two years&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19,288&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41,472&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;70,347&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
  <us-gaap:LeasePolicyTextBlock contextRef="d_2016-01-01_2016-12-31" id="c13552339">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Lease Financing Obligation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Based on the terms of the lease agreement for the new research facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the owner of the building (for accounting purposes only) during the construction period, which ended in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt; Accordingly, the Company recorded an asset of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,589&lt;/div&gt; at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; representing the Company&amp;#x2019;s leased portion of the building and recorded a corresponding liability. Upon completion of leasehold improvement construction, the Company did not meet the sale-leaseback criteria for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected duration of the lease of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20.5&lt;/div&gt; years, and rental payments will be treated as principal and interest payments on the lease financing obligation liability. The underlying accounting for this transaction has no impact on cash flows associated with the underlying lease or construction in process. Interest expense for the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; includes &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$408&lt;/div&gt; related to the lease financing obligation.&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; the lease financing obligation balance was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,704&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,375,&lt;/div&gt; respectively and was recorded as a long term liability on the consolidated balance sheets. At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; the remaining future minimum payments under the lease financing obligation are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4,768.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LeasePolicyTextBlock>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2016-12-31" decimals="-3" id="c13547947" unitRef="iso4217-usd">89847000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2015-12-31" decimals="-3" id="c13547948" unitRef="iso4217-usd">122359000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="i_2016-12-31" decimals="-3" id="c13547908" unitRef="iso4217-usd">54360000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="i_2015-12-31" decimals="-3" id="c13547909" unitRef="iso4217-usd">62257000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LineOfCredit contextRef="i_2016-09-23_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" decimals="-3" id="c13548274" unitRef="iso4217-usd">23000000</us-gaap:LineOfCredit>
  <us-gaap:LineOfCredit contextRef="i_2016-09-30_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" decimals="-6" id="c13548680" unitRef="iso4217-usd">23000000</us-gaap:LineOfCredit>
  <us-gaap:LineOfCredit contextRef="i_2016-12-31" decimals="-3" id="c13547916" unitRef="iso4217-usd">22777000</us-gaap:LineOfCredit>
  <us-gaap:LineOfCredit contextRef="i_2015-12-31" id="c13547917" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="i_2016-09-30_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" decimals="3" id="c13548681" unitRef="xbrli-pure">0.086</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
  <us-gaap:LongTermDebt contextRef="i_2016-12-31" decimals="-5" id="c13548689" unitRef="iso4217-usd">23000000</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="i_2016-12-31" id="c13548684" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="i_2016-12-31" decimals="-5" id="c13548688" unitRef="iso4217-usd">2300000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="i_2016-12-31" decimals="-5" id="c13548687" unitRef="iso4217-usd">6900000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="i_2016-12-31" decimals="-5" id="c13548686" unitRef="iso4217-usd">6900000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="i_2016-12-31" decimals="-5" id="c13548685" unitRef="iso4217-usd">6900000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548082" unitRef="iso4217-usd">23304000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548083" unitRef="iso4217-usd">5479000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548084" unitRef="iso4217-usd">111907000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548066" unitRef="iso4217-usd">23339000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548067" unitRef="iso4217-usd">-18004000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548068" unitRef="iso4217-usd">-39980000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548047" unitRef="iso4217-usd">-53438000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548048" unitRef="iso4217-usd">-13116000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548049" unitRef="iso4217-usd">-38551000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetIncomeLoss contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c13548102" unitRef="iso4217-usd">-45189000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548103" unitRef="iso4217-usd">-45189000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c13548152" unitRef="iso4217-usd">-43019000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548153" unitRef="iso4217-usd">-43019000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c13548192" unitRef="iso4217-usd">-55144000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548193" unitRef="iso4217-usd">-55144000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c13549248" unitRef="iso4217-usd">-22832000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c13549249" unitRef="iso4217-usd">-16281000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2016-07-01_2016-09-30" decimals="-3" id="c13549250" unitRef="iso4217-usd">-11528000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2016-10-01_2016-12-31" decimals="-3" id="c13549251" unitRef="iso4217-usd">-4503000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c13549261" unitRef="iso4217-usd">-15164000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c13549262" unitRef="iso4217-usd">4901000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c13549263" unitRef="iso4217-usd">-14621000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2015-10-01_2015-12-31" decimals="-3" id="c13549264" unitRef="iso4217-usd">-18135000</us-gaap:NetIncomeLoss>
  <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="d_2016-01-01_2016-12-31" id="s433723">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt;&amp;nbsp;&amp;#x2014; Recent Accounting Pronouncements&lt;/div&gt; &amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; November&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued Accounting Standards Update &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18:&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Statement of Cash Flows (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;230):&lt;/div&gt; Restricted Cash &lt;/div&gt;(&amp;#x201c;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&amp;#x201d;).&lt;/div&gt; The new standard requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for annual periods beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; and interim periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the FASB issued Accounting Standards Update No. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15:&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Statement of Cash Flows (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;230):&lt;/div&gt; Classification of Certain Cash Receipts and Cash Payments&lt;/div&gt; (&amp;#x201c;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15&amp;#x201d;).&lt;/div&gt; The amendments in this update clarify how entities should classify certain cash receipts and cash payments on the Consolidated Statements of Cash Flows. The new guidance also clarifies how the predominance principle should be applied when cash receipts and cash payments have aspects of more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; class of cash flows. ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15&lt;/div&gt; will be effective for annual periods beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; including interim periods within those annual reporting periods, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the FASB issued Accounting Standards Update No. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09:&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Compensation - Stock Compensation (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718):&lt;/div&gt; Improvements to Employee Share-Based Payment Accounting&lt;/div&gt; (&amp;#x201c;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09&amp;#x201d;).&lt;/div&gt; The amendments in this update simplify several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09&lt;/div&gt; will be effective for the Company in fiscal year &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the FASB issued Accounting Standards Update No. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02:&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Leases (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842)&lt;/div&gt;&lt;/div&gt; (&amp;#x201c;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02&amp;#x201d;).&lt;/div&gt; The amendments in this update require lessees, among other things, to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous authoritative guidance. This update also introduces new disclosure requirements for leasing arrangements. ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02&lt;/div&gt; will be effective for the Company in fiscal year &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019,&lt;/div&gt; but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the FASB issued Accounting Standards Update No. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;01:&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Financial Instruments - Overall (Subtopic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;825&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10):&lt;/div&gt; Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/div&gt; (&amp;#x201c;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;01&amp;#x201d;).&lt;/div&gt; The amendments in this update address certain aspects of recognition, measurement, presentation and disclosure of financial instruments. In particular, the amendments in this update supersede, for public business entities, the requirement to disclose the methods and significant assumptions used in calculating the fair value of financial instruments required to be disclosed for financial instruments measured at amortized cost on the balance sheet. ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;01&lt;/div&gt; will be effective for the Company in fiscal year &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; but early adoption is permitted. The Company does not expect this standard to have a material impact on its consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; the FASB issued Accounting Standards Update No. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11:&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Inventory (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;330):&lt;/div&gt; Simplifying the Measurement of Inventory&lt;/div&gt; (&amp;#x201c;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&amp;#x201d;),&lt;/div&gt; which changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt; defines net realizable value as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The update does not apply to inventory that is measured using last-in, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt;-out or the retail inventory method. The update applies to all other inventory, which includes inventory that is measured using &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt;-in, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt;-out or average cost methods. The amendments in ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt; will be effective for the Company for fiscal years, and the interim periods within those years, beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt; The amendments must be applied prospectively and early adoption is permitted. The Company does not expect this standard to have a material impact on its consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; the FASB issued Standards Update No. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09:&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Revenue from Contracts with Customers (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;606)&lt;/div&gt;&lt;/div&gt; (&amp;#x201c;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09&amp;#x201d;),&lt;/div&gt; which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09&lt;/div&gt; also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; the FASB finalized a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; year delay in the effective date of this standard, which will now be effective &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018;&lt;/div&gt; however, early adoption is permitted any time after the original effective date, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017.&lt;/div&gt; The Company is not electing early adoption. Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
  <us-gaap:NotesPayableCurrent contextRef="i_2016-12-31" decimals="-3" id="c13547906" unitRef="iso4217-usd">28243000</us-gaap:NotesPayableCurrent>
  <us-gaap:NotesPayableCurrent contextRef="i_2015-12-31" decimals="-3" id="c13547907" unitRef="iso4217-usd">27804000</us-gaap:NotesPayableCurrent>
  <us-gaap:NotesPayableFairValueDisclosure contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" decimals="-3" id="c13548644" unitRef="iso4217-usd">30000000</us-gaap:NotesPayableFairValueDisclosure>
  <us-gaap:OperatingIncomeLoss contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13547978" unitRef="iso4217-usd">-48607000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13547979" unitRef="iso4217-usd">-39444000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13547980" unitRef="iso4217-usd">-45771000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="i_2016-12-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember" decimals="-3" id="c13548712" unitRef="iso4217-usd">4768000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="i_2016-12-31" decimals="-3" id="c13548719" unitRef="iso4217-usd">6151000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="i_2016-12-31" decimals="-3" id="c13548713" unitRef="iso4217-usd">871000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="i_2016-12-31" decimals="-3" id="c13548717" unitRef="iso4217-usd">478000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="i_2016-12-31" decimals="-3" id="c13548716" unitRef="iso4217-usd">653000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="i_2016-12-31" decimals="-3" id="c13548715" unitRef="iso4217-usd">822000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="i_2016-12-31" decimals="-3" id="c13548714" unitRef="iso4217-usd">838000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="i_2016-12-31" decimals="-3" id="c13548718" unitRef="iso4217-usd">2489000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548697" unitRef="iso4217-usd">721000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548698" unitRef="iso4217-usd">664000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548699" unitRef="iso4217-usd">633000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLossCarryforwards contextRef="i_2016-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" decimals="-3" id="c13549046" unitRef="iso4217-usd">431983000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="i_2016-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" decimals="-3" id="c13549047" unitRef="iso4217-usd">403237000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="i_2016-12-31" decimals="-3" id="c13548532" unitRef="iso4217-usd">1981000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="i_2015-12-31" decimals="-3" id="c13548533" unitRef="iso4217-usd">4522000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2016-12-31" decimals="-3" id="c13547893" unitRef="iso4217-usd">3813000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2015-12-31" decimals="-3" id="c13547894" unitRef="iso4217-usd">5468000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c13548106" unitRef="iso4217-usd">-134000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548108" unitRef="iso4217-usd">-134000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c13548156" unitRef="iso4217-usd">-76000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548158" unitRef="iso4217-usd">-76000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c13548196" unitRef="iso4217-usd">194000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548198" unitRef="iso4217-usd">194000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13547999" unitRef="iso4217-usd">194000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548000" unitRef="iso4217-usd">-76000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548001" unitRef="iso4217-usd">-134000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities contextRef="d_2015-01-01_2015-09-30_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="-3" id="c13548649" unitRef="iso4217-usd">1950000</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548060" unitRef="iso4217-usd">14106000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548061" unitRef="iso4217-usd">53830000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548062" unitRef="iso4217-usd">73875000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:PaymentsToAcquireProductiveAssets contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548051" unitRef="iso4217-usd">5277000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:PaymentsToAcquireProductiveAssets contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548052" unitRef="iso4217-usd">5122000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:PaymentsToAcquireProductiveAssets contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548053" unitRef="iso4217-usd">106000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="d_2016-01-01_2016-12-31" id="s433719">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9&lt;/div&gt;&amp;nbsp;&amp;#x2014; Employee &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;401(k)&lt;/div&gt; Plan&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1991,&lt;/div&gt; the Company adopted an employee retirement plan &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&amp;#x201c;401(k)&lt;/div&gt; Plan&amp;#x201d;) under Section&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;401(k)&lt;/div&gt; of the Internal Revenue Code covering all employees. Employee contributions &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; be made to the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;401(k)&lt;/div&gt; Plan up to limits established by the Internal Revenue Service. Company matching contributions &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; be made at the discretion of the Board of Directors. The Company made matching contributions of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$504,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$366&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$361,&lt;/div&gt; in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; respectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2016-12-31" decimals="INF" id="c13547921" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2015-12-31" decimals="INF" id="c13547922" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2016-12-31" decimals="-3" id="c13547923" unitRef="xbrli-shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2015-12-31" decimals="-3" id="c13547924" unitRef="xbrli-shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="i_2016-12-31" decimals="-3" id="c13547925" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="i_2015-12-31" decimals="-3" id="c13547926" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2016-12-31" decimals="-3" id="c13547927" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2015-12-31" decimals="-3" id="c13547928" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue contextRef="i_2016-12-31" id="c13547919" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PreferredStockValue contextRef="i_2015-12-31" id="c13547920" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i_2016-12-31" decimals="-3" id="c13547881" unitRef="iso4217-usd">1438000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i_2015-12-31" decimals="-3" id="c13547882" unitRef="iso4217-usd">2674000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PriorPeriodReclassificationAdjustment contextRef="d_2016-01-01_2016-03-31_CreationDateAxis-December312015Member_NewAccountingPronouncementEarlyAdoptionAxis-DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" decimals="-3" id="c13548285" unitRef="iso4217-usd">2196000</us-gaap:PriorPeriodReclassificationAdjustment>
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="d_2016-01-01_2016-12-31" id="c13552323">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Reclassifications&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;During the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the Company adopted Accounting Standards Update No. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;03,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Interest &amp;#x2013; Imputation of Interest (Subtopic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;835&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30):&lt;/div&gt; Simplifying the Presentation of Debt Issuance Costs&lt;/div&gt;. Accordingly, debt issuance costs of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,196&lt;/div&gt; classified as other current assets as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt; have been reclassified and netted against non-recourse notes payable to conform to the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; presentation.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2016-01-01_2016-12-31" id="c13548070" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2015-01-01_2015-12-31" id="c13548071" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548072" unitRef="iso4217-usd">106600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="-3" id="c13548341" unitRef="iso4217-usd">33740000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_StatementScenarioAxis-ContingentUponEuMarketingApprovalMember_TypeOfArrangementAxis-AgreementMember" decimals="-3" id="c13548342" unitRef="iso4217-usd">7000000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember" decimals="INF" id="c13549182" unitRef="iso4217-usd">33740000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2006-06-01_2006-06-30_TypeOfArrangementAxis-GreenCrossCorporationMember" decimals="INF" id="c13549192" unitRef="iso4217-usd">250000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromLinesOfCredit contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548076" unitRef="iso4217-usd">22658000</us-gaap:ProceedsFromLinesOfCredit>
  <us-gaap:ProceedsFromLinesOfCredit contextRef="d_2015-01-01_2015-12-31" id="c13548077" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProceedsFromLinesOfCredit contextRef="d_2014-01-01_2014-12-31" id="c13548078" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548063" unitRef="iso4217-usd">42652000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548064" unitRef="iso4217-usd">42410000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548065" unitRef="iso4217-usd">34000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleOfFurnitureAndFixtures contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548054" unitRef="iso4217-usd">4000</us-gaap:ProceedsFromSaleOfFurnitureAndFixtures>
  <us-gaap:ProceedsFromSaleOfFurnitureAndFixtures contextRef="d_2015-01-01_2015-12-31" id="c13548055" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProceedsFromSaleOfFurnitureAndFixtures contextRef="d_2014-01-01_2014-12-31" id="c13548056" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548073" unitRef="iso4217-usd">317000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548074" unitRef="iso4217-usd">5479000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548075" unitRef="iso4217-usd">5307000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2016-01-01_2016-12-31" id="s433701">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&amp;nbsp;&amp;#x2014; Property and Equipment&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Property and equipment consisted of the following at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 67%; font-size: 10pt; text-align: left"&gt;Furniture and fixtures&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;540&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Office equipment&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;141&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,122&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;Software&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,117&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,427&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Laboratory equipment&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,252&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,004&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Leased equipment&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;63&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Leasehold improvements&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,294&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,610&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Construction in progress&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,821&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Building&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,495&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,589&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,839&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19,354&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Less accumulated depreciation and amortization&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4,917&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(14,205&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Property and equipment, net&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,922&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,149&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Depreciation and amortization expense for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$483,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$180&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$177,&lt;/div&gt; respectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-12-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" decimals="-3" id="c13548384" unitRef="iso4217-usd">1589000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" decimals="-3" id="c13548704" unitRef="iso4217-usd">1589000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" decimals="-3" id="c13548570" unitRef="iso4217-usd">540000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" decimals="-3" id="c13548571" unitRef="iso4217-usd">718000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember" decimals="-3" id="c13548572" unitRef="iso4217-usd">141000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember" decimals="-3" id="c13548573" unitRef="iso4217-usd">1122000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember" decimals="-3" id="c13548574" unitRef="iso4217-usd">1117000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember" decimals="-3" id="c13548575" unitRef="iso4217-usd">1427000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember" decimals="-3" id="c13548576" unitRef="iso4217-usd">3252000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember" decimals="-3" id="c13548577" unitRef="iso4217-usd">6004000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-LeasedEquipmentMember" id="c13548578" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-LeasedEquipmentMember" decimals="-3" id="c13548579" unitRef="iso4217-usd">63000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" decimals="-3" id="c13548580" unitRef="iso4217-usd">8294000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" decimals="-3" id="c13548581" unitRef="iso4217-usd">5610000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember" id="c13548582" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember" decimals="-3" id="c13548583" unitRef="iso4217-usd">2821000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember" decimals="-3" id="c13548584" unitRef="iso4217-usd">1495000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember" decimals="-3" id="c13548585" unitRef="iso4217-usd">1589000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31" decimals="-3" id="c13548586" unitRef="iso4217-usd">14839000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-12-31" decimals="-3" id="c13548587" unitRef="iso4217-usd">19354000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2016-12-31" decimals="-3" id="c13548590" unitRef="iso4217-usd">9922000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2015-12-31" decimals="-3" id="c13548591" unitRef="iso4217-usd">5149000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2016-01-01_2016-12-31" id="c13552329">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Property and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; years. Laboratory equipment, office equipment, and software are depreciated over a life of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt; years. Furniture and fixtures are depreciated over a life of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;seven&lt;/div&gt; years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less. Property consists of a leased building which did not meet the sale-leaseback criteria and is recorded at its fair value, less depreciation. The building is being depreciated over a period equal to the expected term of the related lease.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2016-01-01_2016-12-31" id="c-23">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 67%; font-size: 10pt; text-align: left"&gt;Furniture and fixtures&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;540&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Office equipment&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;141&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,122&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;Software&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,117&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,427&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Laboratory equipment&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,252&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,004&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Leased equipment&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;63&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Leasehold improvements&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,294&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,610&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Construction in progress&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,821&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Building&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,495&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,589&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,839&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19,354&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Less accumulated depreciation and amortization&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4,917&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(14,205&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Property and equipment, net&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,922&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,149&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2016-01-01_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" id="c13548321">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2016-01-01_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" id="c13548322">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2016-01-01_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" id="c13548323">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2016-01-01_2016-12-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" id="c13548387">P20Y182D</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="d_2016-01-01_2016-12-31" id="s433721">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;&amp;nbsp;&amp;#x2014; Quarterly Financial Information (Unaudited)&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;First&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Second&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Third&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Fourth&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;2016 Quarters&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 48%; font-size: 10pt; text-indent: 10pt"&gt;Revenues&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,820&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,787&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,763&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,983&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Net Loss&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(22,832&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(16,281&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(11,528&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4,503&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Basic and diluted net loss per share&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.31&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.22&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.16&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.06&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;2015 Quarters&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-indent: 10pt"&gt;Revenues&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,826&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25,842&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,987&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,602&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Net (Loss) Income&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(15,164&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,901&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(14,621&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(18,135&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Basic net (loss) income per share&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.21&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.07&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.20&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.25&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Diluted net (loss) income per share&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.21&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.06&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.20&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.25&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" id="c13548491" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c13548492" unitRef="iso4217-usd">3495000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c13548493" unitRef="iso4217-usd">3495000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" decimals="-3" id="c13548494" unitRef="iso4217-usd">3451000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" id="c13548495" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" decimals="-3" id="c13548496" unitRef="iso4217-usd">3451000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember" decimals="-3" id="c13548497" unitRef="iso4217-usd">686000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember" id="c13548498" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember" decimals="-3" id="c13548499" unitRef="iso4217-usd">686000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c13548500" unitRef="iso4217-usd">957000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c13548501" unitRef="iso4217-usd">179000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c13548502" unitRef="iso4217-usd">1136000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember" decimals="-3" id="c13548503" unitRef="iso4217-usd">5094000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember" decimals="-3" id="c13548504" unitRef="iso4217-usd">3674000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31" decimals="-3" id="c13548505" unitRef="iso4217-usd">8768000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" id="c13548506" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c13548507" unitRef="iso4217-usd">5536000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c13548508" unitRef="iso4217-usd">5536000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" decimals="-3" id="c13548509" unitRef="iso4217-usd">469000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" id="c13548510" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" decimals="-3" id="c13548511" unitRef="iso4217-usd">469000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c13548512" unitRef="iso4217-usd">210000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c13548513" unitRef="iso4217-usd">28000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c13548514" unitRef="iso4217-usd">238000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember" decimals="-3" id="c13548515" unitRef="iso4217-usd">679000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember" decimals="-3" id="c13548516" unitRef="iso4217-usd">5564000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31" decimals="-3" id="c13548517" unitRef="iso4217-usd">6243000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesPolicyTextBlock contextRef="d_2016-01-01_2016-12-31" id="c13552327">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivable from Collaborations&lt;/div&gt;&lt;/div&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, Green Cross Corporation (&amp;#x201c;Green Cross&amp;#x201d;) and Seqirus UK Limited (&amp;#x201c;SUL&amp;#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; the Company had the following receivables.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&amp;nbsp;31, 2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,495&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,495&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,451&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,451&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Green Cross Corporation&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;686&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;686&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;957&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;179&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,136&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,094&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,674&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,768&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&amp;nbsp;31, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,536&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,536&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;469&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;469&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;210&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;28&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;238&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;679&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,564&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,243&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&amp;#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivables from Product Sales&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
  <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548335" unitRef="iso4217-usd">11000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
  <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548336" unitRef="iso4217-usd">13000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13547966" unitRef="iso4217-usd">61008000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13547967" unitRef="iso4217-usd">72758000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13547968" unitRef="iso4217-usd">51796000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2016-01-01_2016-12-31" id="c13552335">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Research and Development Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&amp;#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&amp;#x2019;s manufacturing and clinical and preclinical studies are performed by &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&amp;#x2019;s on-going review of the level of services actually performed.&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Additionally, the Company has license agreements with &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; parties, such as Albert Einstein College of Medicine of Yeshiva University (&amp;#x201c;AECOM&amp;#x201d;), Industrial Research, Ltd. (&amp;#x201c;IRL&amp;#x201d;), and the University of Alabama at Birmingham (&amp;#x201c;UAB&amp;#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Deferred collaboration expenses represent sub-license payments, paid to the Company&amp;#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&amp;#x2019;s academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&amp;#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2016-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember" decimals="-3" id="c13548293" unitRef="iso4217-usd">141000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2016-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember" decimals="-3" id="c13548295" unitRef="iso4217-usd">1405000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2016-12-31" decimals="-3" id="c13547873" unitRef="iso4217-usd">1546000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2015-12-31" decimals="-3" id="c13547874" unitRef="iso4217-usd">1612000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2016-12-31" decimals="-3" id="c13547943" unitRef="iso4217-usd">-566061000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2015-12-31" decimals="-3" id="c13547944" unitRef="iso4217-usd">-510917000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="d_2016-01-01_2016-12-31" id="c13552334">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Revenue Recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&amp;nbsp;persuasive evidence of an arrangement exists; (ii)&amp;nbsp;delivery has occurred or services have been rendered; (iii)&amp;nbsp;the seller&amp;#x2019;s price to the buyer is fixed or determinable; and (iv)&amp;nbsp;collectability is reasonably assured.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Collaborative and Other Research and Development Arrangements and Royalties&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Under certain of the Company&amp;#x2019;s license agreements, the Company receives royalty payments based upon its licensees&amp;#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;For arrangements that involve the delivery of more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &amp;#x201c;stand-alone value&amp;#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party evidence of selling price (&amp;#x201c;TPE&amp;#x201d;) and (iii) best estimate of selling price (&amp;#x201c;BESP&amp;#x201d;). The BESP reflects the Company&amp;#x2019;s best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; be an obligation to deliver services, a right or license to use an asset, or another performance obligation.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; the Company entered into a License Agreement (the &amp;#x201c;SUL Agreement&amp;#x201d;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&amp;#x201c;EU&amp;#x201d;) marketing approvals. The Company received an upfront payment of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$33,740&lt;/div&gt; from SUL, of which &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$7,000&lt;/div&gt; was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$21,777&lt;/div&gt; of the upfront payment was allocated to the license rights and recognized as revenue in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015.&lt;/div&gt; Approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3,740&lt;/div&gt; of the upfront payment was allocated to the pending sale of inventory and was recognized in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; when the inventory transfer was completed. Approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,223&lt;/div&gt; of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt;&lt;div style="page-break-before: always; margin-top: 6pt"&gt;&lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Under the terms of the SUL Agreement, the Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; receive up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$12,000&lt;/div&gt; in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food Branch of Health Canada (&amp;#x201c;Health Canada&amp;#x201d;) for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2010&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Milestone Method of Revenue Recognition&lt;/div&gt;, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&amp;#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&amp;#x201d;BARDA/HHS&amp;#x201d;) and the National Institute of Allergy and Infectious Diseases (&amp;#x201c;NIAID/HHS&amp;#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Product Sales&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from the Company&amp;#x2019;s specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, and prior to the SUL Agreement, the Company sold RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&amp;nbsp;With the completion of the SUL worldwide license of RAPIVAB, SUL will be responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales. With the completion of the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&amp;#x2019;s partners, except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party suppliers of market research data to the pharmaceutical industry.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources.&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Rebates and Chargebacks&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 13.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&amp;#x2019;s selling price.&amp;nbsp;As it can take up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&amp;#x2019;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months from point of sale. To the extent actual rebates and chargebacks differ from the Company&amp;#x2019;s estimates, additional reserves &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; be required or reserves &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; need to be reversed, either of which would impact current period product revenue.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&lt;/div&gt;&lt;div style="page-break-before: always; margin-top: 6pt"&gt;&lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Discounts and Sales Incentives&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Discounts and other sales incentives primarily consist of Inventory Management Agreement (&amp;#x201c;IMA&amp;#x201d;) fees. Per contractual agreements with the Company&amp;#x2019;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&amp;nbsp;With the completion of the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&amp;#x2019;s partners, except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales and to provide for discounts and sales incentives.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Product Returns&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recorded the following revenues for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 61%; font-size: 10pt; text-align: left"&gt;Product sales, net&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,269&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,291&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;33&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Royalty revenue&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,682&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,386&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,025&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Collaborative and other research and development revenues:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,449&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,337&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,366&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Green Cross Corporation&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;132&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Shionogi &amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,184&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,184&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,184&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;769&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,927&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total collaborative and other research and development revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,402&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;39,580&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,550&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26,353&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;48,257&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,608&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Advertising&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred. The Company did not incur advertising and product promotion expenses in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt; Advertising and product promotion expenses were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$103&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$290&lt;/div&gt; for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; respectively.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:Revenues contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="-3" id="c13548343" unitRef="iso4217-usd">21777000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548558" unitRef="iso4217-usd">26353000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548559" unitRef="iso4217-usd">48257000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548560" unitRef="iso4217-usd">13608000</us-gaap:Revenues>
  <us-gaap:RoyaltyExpense contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13547972" unitRef="iso4217-usd">402000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13547973" unitRef="iso4217-usd">528000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13547974" unitRef="iso4217-usd">121000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyRevenue contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548548" unitRef="iso4217-usd">9682000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548549" unitRef="iso4217-usd">2386000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548550" unitRef="iso4217-usd">3025000</us-gaap:RoyaltyRevenue>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548545" unitRef="iso4217-usd">2269000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548546" unitRef="iso4217-usd">6291000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548547" unitRef="iso4217-usd">33000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueNet contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13547959" unitRef="iso4217-usd">26353000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13547960" unitRef="iso4217-usd">48257000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13547961" unitRef="iso4217-usd">13608000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c13549244" unitRef="iso4217-usd">4820000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c13549245" unitRef="iso4217-usd">4787000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2016-07-01_2016-09-30" decimals="-3" id="c13549246" unitRef="iso4217-usd">7763000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2016-10-01_2016-12-31" decimals="-3" id="c13549247" unitRef="iso4217-usd">8983000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c13549257" unitRef="iso4217-usd">6826000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c13549258" unitRef="iso4217-usd">25842000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c13549259" unitRef="iso4217-usd">10987000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2015-10-01_2015-12-31" decimals="-3" id="c13549260" unitRef="iso4217-usd">4602000</us-gaap:SalesRevenueNet>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="d_2016-01-01_2016-12-31" id="c-21">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 67%; font-size: 10pt; text-align: left"&gt;Compensation and benefits&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;425&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;424&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Development costs&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,427&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,398&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;Inventory&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;705&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;549&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Professional fees&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;242&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;242&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Duties and taxes&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;56&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;102&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Other&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,981&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,522&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total accrued expenses&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,836&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,237&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2016-01-01_2016-12-31" id="c-33">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Deferred tax assets:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 70%; font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Net federal and state operating losses&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;158,618&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;142,836&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Research and development credits&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;53,231&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;48,551&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Fixed assets&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,054&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Deferred revenue&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,484&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,240&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Stock-based compensation&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,952&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,605&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Other&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,849&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,590&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Total deferred tax assets&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;227,134&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;207,876&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Fixed assets&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(674&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Foreign currency derivative&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,415&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,668&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total deferred tax liabilities&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,089&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,668&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(225,045&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(205,208&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Net deferred tax assets&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2016-01-01_2016-12-31" id="c-31">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 61%; font-size: 10pt; text-align: left"&gt;Income tax benefit at federal statutory rate (35%)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(19,300&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(15,057&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(15,816&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;State and local income taxes net of federal tax benefit&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,173&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(819&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,286&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Permanent items&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,057&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;560&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;258&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Rate change&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,080&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,012&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;22&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expiration of attribute carryforwards&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;559&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;330&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;373&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Research and development tax credits&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4,681&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(10,454&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(748&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Orphan drug credit&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,798&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,307&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;Other&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;822&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(218&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(115&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19,838&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,339&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,312&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Income tax expense&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2016-01-01_2016-12-31" id="c-26">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year Ended December&amp;nbsp;31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 55%; font-size: 10pt; text-align: left"&gt;Research and development&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,088&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,580&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,906&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,399&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,125&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,271&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total stock-based compensation expense&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,487&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,705&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,177&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="d_2016-01-01_2016-12-31" id="c-25">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 87%; font-size: 10pt; text-align: left"&gt;2017&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;871&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;2018&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;838&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;2019&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;822&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;2020&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;653&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;2021&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;478&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: left"&gt;Thereafter&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,489&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total minimum payments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,151&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="d_2016-01-01_2016-12-31" id="c-20">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of December&amp;nbsp;31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Work in process&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;500&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,612&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Net inventories&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;500&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,612&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="d_2016-01-01_2016-12-31" id="c-24">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="5" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Principal Payments&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: justify; text-indent: 0pt"&gt;2017&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: justify; text-indent: 0pt; width: 72%"&gt;2018&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 25%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,900&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: justify; text-indent: 0pt"&gt;2019&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,900&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: justify; text-indent: 0pt"&gt;2020&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,900&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: justify; text-indent: 0pt"&gt;2021&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,300&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: justify; text-indent: 0pt"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23,000&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="d_2016-01-01_2016-12-31" id="c-34">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;First&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Second&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Third&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Fourth&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;2016 Quarters&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 48%; font-size: 10pt; text-indent: 10pt"&gt;Revenues&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,820&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,787&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,763&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,983&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Net Loss&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(22,832&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(16,281&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(11,528&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4,503&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Basic and diluted net loss per share&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.31&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.22&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.16&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.06&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;2015 Quarters&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-indent: 10pt"&gt;Revenues&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,826&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25,842&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,987&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,602&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Net (Loss) Income&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(15,164&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,901&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(14,621&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(18,135&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Basic net (loss) income per share&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.21&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.07&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.20&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.25&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Diluted net (loss) income per share&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.21&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.06&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.20&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.25&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="d_2016-01-01_2016-12-31" id="c-27">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Awards&lt;br /&gt; Available&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Options&lt;br /&gt; Outstanding&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted&lt;br /&gt; Average&lt;br /&gt; Exercise&lt;br /&gt; Price&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 55%; font-size: 10pt"&gt;Balance at December&amp;nbsp;31, 2013&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,082&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,986&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.99&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Plan amendment&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,750&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Restricted stock awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(593&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Restricted stock awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Stock option awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,965&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,965&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10.99&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Stock option awards exercised&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,258&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.78&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Stock option awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;88&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(88&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.83&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;Balance at December&amp;nbsp;31, 2014&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,362&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,605&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.21&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Restricted stock awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(163&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Restricted stock awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Stock option awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,217&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,217&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11.52&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Stock option awards exercised&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,118&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.36&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Stock option awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;33&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(33&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9.87&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;Balance at December&amp;nbsp;31, 2015&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,671&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.50&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Plan amendment&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,800&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Restricted stock awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(34&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Restricted stock awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;22&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Stock option awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,248&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,248&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.20&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Stock option awards exercised&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(107&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.63&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Stock option awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;717&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(717&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10.78&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Balance at December&amp;nbsp;31, 2016&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,273&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,095&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.55&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2016-01-01_2016-12-31" id="c-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Non-Vested&lt;br /&gt; Stock Option&lt;br /&gt; Awards&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted Average&lt;br /&gt; Grant-Date Fair&lt;br /&gt; Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 67%; font-size: 10pt"&gt;Balance December&amp;nbsp;31, 2015&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,863&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.40&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Stock option awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,248&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.17&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Stock option awards vested&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,278&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.99&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Stock option awards forfeited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(235&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.79&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Balance December&amp;nbsp;31, 2016&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,598&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.40&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2016-01-01_2016-12-31" id="c-28">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 55%; font-size: 10pt; text-align: left"&gt;Expected Life&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.5&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.5&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.5&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expected Volatility&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;82&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;81&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;87&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expected Dividend Yield&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.0&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.0&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.0&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Risk-Free Interest Rate&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.4&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.6&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.6&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="d_2016-01-01_2016-12-31" id="c-32">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 70%; font-size: 10pt"&gt;Balance at January&amp;nbsp;1,&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,085&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;472&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Additions to current period tax positions&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,170&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,616&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Additions to prior period tax positions&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Reductions to prior period tax provisions&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Balance at December&amp;nbsp;31,&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,255&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,085&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13547969" unitRef="iso4217-usd">11253000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13547970" unitRef="iso4217-usd">13047000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13547971" unitRef="iso4217-usd">7461000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548016" unitRef="iso4217-usd">8487000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548017" unitRef="iso4217-usd">9705000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548018" unitRef="iso4217-usd">10177000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember" id="c13548753">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-StockOptionsAndRestrictedStockMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest50PercentEachYearUntilFullyVestedMember" id="c13548756">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="d_2014-01-01_2014-12-31" id="c13548893" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548911" unitRef="xbrli-shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548932" unitRef="xbrli-shares">22000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548890" unitRef="xbrli-shares">593000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548908" unitRef="xbrli-shares">163000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548929" unitRef="xbrli-shares">34000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2016-01-01_2016-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c13548872" unitRef="iso4217-usd-per-xbrli-shares">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c13548873" unitRef="iso4217-usd-per-xbrli-shares">4.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2014-01-01_2014-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c13548874" unitRef="iso4217-usd-per-xbrli-shares">4.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2016-01-01_2016-12-31" decimals="3" id="c13548953" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2015-01-01_2015-12-31" decimals="3" id="c13548954" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2014-01-01_2014-12-31" decimals="3" id="c13548955" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2016-01-01_2016-12-31" decimals="3" id="c13548950" unitRef="xbrli-pure">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2015-01-01_2015-12-31" decimals="3" id="c13548951" unitRef="xbrli-pure">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2014-01-01_2014-12-31" decimals="3" id="c13548952" unitRef="xbrli-pure">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2016-01-01_2016-12-31" decimals="3" id="c13548956" unitRef="xbrli-pure">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2015-01-01_2015-12-31" decimals="3" id="c13548957" unitRef="xbrli-pure">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2014-01-01_2014-12-31" decimals="3" id="c13548958" unitRef="xbrli-pure">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee contextRef="d_2016-01-01_2016-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c13548849" unitRef="xbrli-shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548887" unitRef="xbrli-shares">3750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548926" unitRef="xbrli-shares">3800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="i_2016-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c13548841" unitRef="xbrli-shares">1475000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2016-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c13548842" unitRef="xbrli-shares">422000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2013-12-31" decimals="-3" id="c13548884" unitRef="xbrli-shares">1082000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2014-12-31" decimals="-3" id="c13548905" unitRef="xbrli-shares">2362000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2015-12-31" decimals="-3" id="c13548923" unitRef="xbrli-shares">16000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2016-12-31" decimals="-3" id="c13548944" unitRef="xbrli-shares">2273000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2014-12-31" decimals="INF" id="c13548907" unitRef="iso4217-usd-per-xbrli-shares">6.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2015-12-31" decimals="INF" id="c13548925" unitRef="iso4217-usd-per-xbrli-shares">7.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2016-12-31" decimals="INF" id="c13548946" unitRef="iso4217-usd-per-xbrli-shares">6.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="d_2016-01-01_2016-12-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c13548801" unitRef="iso4217-usd">339000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c13548803" unitRef="iso4217-usd">10117000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="d_2014-01-01_2014-12-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c13548805" unitRef="iso4217-usd">8522000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548903" unitRef="xbrli-shares">88000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548921" unitRef="xbrli-shares">33000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548942" unitRef="xbrli-shares">717000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c13548904" unitRef="iso4217-usd-per-xbrli-shares">8.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c13548922" unitRef="iso4217-usd-per-xbrli-shares">9.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c13548943" unitRef="iso4217-usd-per-xbrli-shares">10.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13549021" unitRef="xbrli-shares">235000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548897" unitRef="xbrli-shares">1965000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548915" unitRef="xbrli-shares">2217000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548936" unitRef="xbrli-shares">2248000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2013-08-01_2013-08-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="INF" id="c13548759" unitRef="xbrli-shares">1032000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2014-01-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="INF" id="c13548760" unitRef="xbrli-shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13549017" unitRef="xbrli-shares">2248000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2016-01-01_2016-12-31_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c13548794" unitRef="iso4217-usd-per-xbrli-shares">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c13548795" unitRef="iso4217-usd-per-xbrli-shares">7.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2014-01-01_2014-12-31_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c13548796" unitRef="iso4217-usd-per-xbrli-shares">8.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c13549018" unitRef="iso4217-usd-per-xbrli-shares">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2013-12-31" decimals="-3" id="c13548885" unitRef="xbrli-shares">8986000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2014-12-31" decimals="-3" id="c13548906" unitRef="xbrli-shares">9605000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2015-12-31" decimals="-3" id="c13548924" unitRef="xbrli-shares">10671000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2016-12-31" decimals="-3" id="c13548945" unitRef="xbrli-shares">12095000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2013-12-31" decimals="INF" id="c13548886" unitRef="iso4217-usd-per-xbrli-shares">4.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="d_2016-01-01_2016-12-31" id="c-29">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="9" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Outstanding&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Exercisable&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="2"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; text-decoration: underline;"&gt;Range&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Number&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Remaining &lt;br /&gt; Life&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Exercise &lt;br /&gt; Price&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Number&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Exercise &lt;br /&gt; Price&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 1%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; width: 5%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;0&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; width: 3%"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; width: 5%"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1,919&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;5.7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1.64&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1,510&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1.53&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;3&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;4,749&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6.9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;4.02&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;2,578&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;4.48&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1,153&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;3.5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;7.10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1,118&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;7.11&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;9&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;12&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;3,457&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;7.2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;11.10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1,074&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;11.29&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;12&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;15&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;722&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;8.0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;12.39&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;195&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;12.73&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;15&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right; padding-bottom: 1.1pt; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;95&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;8.5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;15.39&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;24&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;15.39&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;0&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right; padding-bottom: 2.25pt; border-bottom: Black 2.25pt double"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;12,095&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6.6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6.55&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6,499&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;5.66&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="i_2016-12-31_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c13548825" unitRef="xbrli-shares">11013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="i_2016-12-31_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c13548826" unitRef="iso4217-usd-per-xbrli-shares">6.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c13548901" unitRef="iso4217-usd-per-xbrli-shares">4.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c13548919" unitRef="iso4217-usd-per-xbrli-shares">4.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c13548940" unitRef="iso4217-usd-per-xbrli-shares">2.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c13548898" unitRef="iso4217-usd-per-xbrli-shares">10.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c13548916" unitRef="iso4217-usd-per-xbrli-shares">11.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c13548937" unitRef="iso4217-usd-per-xbrli-shares">3.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2016-01-01_2016-12-31" id="c13552336">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock-Based Compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &amp;#x201c;performance&amp;#x201d; is deemed to have occurred.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member" decimals="INF" id="c13552365" unitRef="iso4217-usd-per-xbrli-shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member" decimals="INF" id="c13552372" unitRef="iso4217-usd-per-xbrli-shares">3</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member" decimals="INF" id="c13552379" unitRef="iso4217-usd-per-xbrli-shares">6</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member" decimals="INF" id="c13552386" unitRef="iso4217-usd-per-xbrli-shares">9</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member" decimals="INF" id="c13552393" unitRef="iso4217-usd-per-xbrli-shares">12</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member" decimals="INF" id="c13552400" unitRef="iso4217-usd-per-xbrli-shares">15</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c13552407" unitRef="iso4217-usd-per-xbrli-shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member" decimals="-3" id="c13552370" unitRef="xbrli-shares">1510000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member" decimals="-3" id="c13552377" unitRef="xbrli-shares">2578000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member" decimals="-3" id="c13552384" unitRef="xbrli-shares">1118000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member" decimals="-3" id="c13552391" unitRef="xbrli-shares">1074000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member" decimals="-3" id="c13552398" unitRef="xbrli-shares">195000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member" decimals="-3" id="c13552405" unitRef="xbrli-shares">24000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="i_2016-12-31" decimals="-3" id="c13552412" unitRef="xbrli-shares">6499000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member" decimals="-3" id="c13552367" unitRef="xbrli-shares">1919000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member" decimals="-3" id="c13552374" unitRef="xbrli-shares">4749000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member" decimals="-3" id="c13552381" unitRef="xbrli-shares">1153000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member" decimals="-3" id="c13552388" unitRef="xbrli-shares">3457000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member" decimals="-3" id="c13552395" unitRef="xbrli-shares">722000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member" decimals="-3" id="c13552402" unitRef="xbrli-shares">95000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="i_2016-12-31" decimals="-3" id="c13552409" unitRef="xbrli-shares">12095000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member" decimals="INF" id="c13552366" unitRef="iso4217-usd-per-xbrli-shares">3</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member" decimals="INF" id="c13552373" unitRef="iso4217-usd-per-xbrli-shares">6</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member" decimals="INF" id="c13552380" unitRef="iso4217-usd-per-xbrli-shares">9</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member" decimals="INF" id="c13552387" unitRef="iso4217-usd-per-xbrli-shares">12</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member" decimals="INF" id="c13552394" unitRef="iso4217-usd-per-xbrli-shares">15</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member" decimals="INF" id="c13552401" unitRef="iso4217-usd-per-xbrli-shares">18</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c13552408" unitRef="iso4217-usd-per-xbrli-shares">18</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember" decimals="2" id="c13548752" unitRef="xbrli-pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-StockOptionsAndRestrictedStockMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest50PercentEachYearUntilFullyVestedMember" decimals="2" id="c13548755" unitRef="xbrli-pure">0.5</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="d_2016-01-01_2016-12-31_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="2" id="c13548763" unitRef="xbrli-pure">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2016-01-01_2016-12-31" id="c13548947">P5Y182D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2015-01-01_2015-12-31" id="c13548948">P5Y182D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2014-01-01_2014-12-31" id="c13548949">P5Y182D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="i_2016-12-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c13548816" unitRef="iso4217-usd">20002000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MinimumMember" id="c13548785">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember" id="c13548786">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2016-01-01_2016-12-31_PlanNameAxis-IncentivePlanMember" id="c13548813">P6Y219D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2015-12-31" decimals="-3" id="c13549015" unitRef="xbrli-shares">4863000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2016-12-31" decimals="-3" id="c13549023" unitRef="xbrli-shares">5598000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c13549022" unitRef="iso4217-usd-per-xbrli-shares">6.79</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="i_2015-12-31" decimals="INF" id="c13549016" unitRef="iso4217-usd-per-xbrli-shares">6.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="i_2016-12-31" decimals="INF" id="c13549024" unitRef="iso4217-usd-per-xbrli-shares">5.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="d_2016-01-01_2016-12-31_PlanNameAxis-IncentivePlanMember" id="c13548827">P6Y182D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="d_2016-01-01_2016-12-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c13548817" unitRef="iso4217-usd">6380000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c13548819" unitRef="iso4217-usd">4492000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="d_2014-01-01_2014-12-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c13548821" unitRef="iso4217-usd">2844000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13549019" unitRef="xbrli-shares">1278000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c13549020" unitRef="iso4217-usd-per-xbrli-shares">4.99</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member" decimals="INF" id="c13552371" unitRef="iso4217-usd-per-xbrli-shares">1.53</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member" decimals="INF" id="c13552378" unitRef="iso4217-usd-per-xbrli-shares">4.48</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member" decimals="INF" id="c13552385" unitRef="iso4217-usd-per-xbrli-shares">7.11</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member" decimals="INF" id="c13552392" unitRef="iso4217-usd-per-xbrli-shares">11.29</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member" decimals="INF" id="c13552399" unitRef="iso4217-usd-per-xbrli-shares">12.73</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member" decimals="INF" id="c13552406" unitRef="iso4217-usd-per-xbrli-shares">15.39</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="i_2016-12-31" decimals="INF" id="c13552413" unitRef="iso4217-usd-per-xbrli-shares">5.66</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member" decimals="INF" id="c13552369" unitRef="iso4217-usd-per-xbrli-shares">1.64</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member" decimals="INF" id="c13552376" unitRef="iso4217-usd-per-xbrli-shares">4.02</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member" decimals="INF" id="c13552383" unitRef="iso4217-usd-per-xbrli-shares">7.10</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member" decimals="INF" id="c13552390" unitRef="iso4217-usd-per-xbrli-shares">11.10</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member" decimals="INF" id="c13552397" unitRef="iso4217-usd-per-xbrli-shares">12.39</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member" decimals="INF" id="c13552404" unitRef="iso4217-usd-per-xbrli-shares">15.39</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="i_2016-12-31" decimals="INF" id="c13552411" unitRef="iso4217-usd-per-xbrli-shares">6.55</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member" id="c13552368">P5Y255D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member" id="c13552375">P6Y328D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member" id="c13552382">P3Y182D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member" id="c13552389">P7Y73D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member" id="c13552396">P8Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member" id="c13552403">P8Y182D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2016-01-01_2016-12-31" id="c13552410">P6Y219D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2016-01-01_2016-12-31" id="s433692">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;&amp;nbsp;&amp;#x2014; Significant Accounting Policies and Concentrations of Risk&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;The Company&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;BioCryst Pharmaceuticals, Inc. (the &amp;#x201c;Company&amp;#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1986&lt;/div&gt; and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;With the funds available at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the Company believes these resources will be sufficient to fund its operations into &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018.&lt;/div&gt; The Company has sustained operating losses for the majority of its corporate history and expects that its &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; expenses will exceed its &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. Accordingly, its planned operations raise doubt about its ability to continue as a going concern. The Company&amp;#x2019;s liquidity needs will be largely determined by the success of operations in regards to the progression of its product candidates in the future. The Company&amp;#x2019;s plans to alleviate the doubt of its going concern, which are probable of effectively being implemented and mitigating these conditions, primarily include its ability to control the timing and spending on its research and development programs and raising additional funds through equity financings. The Company also &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; consider other plans to fund operations including: &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1)&lt;/div&gt;&amp;nbsp;securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2)&lt;/div&gt;&amp;nbsp;out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3)&lt;/div&gt;&amp;nbsp;raising additional capital through debt financings or from other sources; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4)&lt;/div&gt;&amp;nbsp;obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(5)&lt;/div&gt;&amp;nbsp;reducing spending on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; or more research and development programs by discontinuing development; and/or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(6)&lt;/div&gt;&amp;nbsp;restructuring operations to change its overhead structure. The Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; issue securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions or registered public offerings, pursuant to its registration statement on Form S-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; initially filed with the Securities and Exchange Commission (&amp;#x201c;SEC&amp;#x201d;) on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015.&lt;/div&gt; The Company&amp;#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events and its decisions in the future.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, JPR Royalty Sub LLC (&amp;#x201c;Royalty Sub&amp;#x201d;) and MDCP, LLC (&amp;#x201c;MDCP&amp;#x201d;). Both subsidiaries were formed to facilitate financing transactions for the Company. Royalty Sub was formed in connection with a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$30,000&lt;/div&gt;&amp;nbsp;financing transaction the Company completed on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011.&lt;/div&gt; See Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,&lt;/div&gt; Royalty Monetization, for a further description of this transaction. MDCP was formed in connection with a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$23,000&lt;/div&gt; Senior Credit Facility that the Company closed on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt; See Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,&lt;/div&gt; Senior Credit Facility, for a further description of this transaction. All intercompany transactions and balances have been eliminated.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#x201c;U.S. GAAP&amp;#x201d;). Such consolidated financial statements reflect all adjustments that are, in management&amp;#x2019;s opinion, necessary to present fairly, in all material respects, the Company&amp;#x2019;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Reclassifications&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;During the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the Company adopted Accounting Standards Update No. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;03,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Interest &amp;#x2013; Imputation of Interest (Subtopic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;835&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30):&lt;/div&gt; Simplifying the Presentation of Debt Issuance Costs&lt;/div&gt;. Accordingly, debt issuance costs of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,196&lt;/div&gt; classified as other current assets as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt; have been reclassified and netted against non-recourse notes payable to conform to the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; presentation.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&lt;/div&gt;    &lt;div style="page-break-before: always; margin-top: 6pt"&gt;  &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Restricted Cash&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Restricted cash as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; reflects &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$141&lt;/div&gt; in royalty revenue paid by Shionogi&amp;nbsp;&amp;amp; Co., Ltd. (&amp;#x201c;Shionogi&amp;#x201d;) designated for interest on the PhaRMA Notes (defined in Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3)&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,405&lt;/div&gt; the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Investments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&amp;#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&amp;#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; years and requires an average portfolio maturity of no more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&lt;/div&gt; months. Some of the securities the Company invests in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; have market risk. This means that a change in prevailing interest rates &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&amp;#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months and which mature at or less than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt; months from the balance sheet date are classified as current. Investments with a maturity beyond &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt; months from the balance sheet date are classified as long-term. At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the Company believes that the cost of its investments is recoverable in all material respects.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The following tables summarize the fair value of the Company&amp;#x2019;s investments by type. The estimated fair values of the Company&amp;#x2019;s fixed income investments are classified as Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; inputs.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31, 2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Estimated&lt;br /&gt; Fair Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Obligations of U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,266&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;34&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,298&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,179&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(8&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,199&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,962&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(11&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,975&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41,407&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;77&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(23&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41,472&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Estimated&lt;br /&gt; Fair Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt; width: 35%"&gt;Obligations of U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26,557&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;88&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(99&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26,546&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,820&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;184&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(41&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,963&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,884&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(72&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,838&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;70,261&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;292&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(212&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;70,347&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;/div&gt;  &lt;div style="page-break-before: always; margin-top: 6pt"&gt;  &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The following table summarizes the scheduled maturity for the Company&amp;#x2019;s investments at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 67%; font-size: 10pt; text-align: left"&gt;Maturing in one year or less&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;32,546&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;22,664&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Maturing after one year through two years&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,926&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;28,395&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Maturing after two years&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19,288&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41,472&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;70,347&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;&lt;/div&gt;  &lt;div&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivable from Collaborations&lt;/div&gt;&lt;/div&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, Green Cross Corporation (&amp;#x201c;Green Cross&amp;#x201d;) and Seqirus UK Limited (&amp;#x201c;SUL&amp;#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; the Company had the following receivables.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&amp;nbsp;31, 2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,495&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,495&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,451&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,451&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Green Cross Corporation&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;686&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;686&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;957&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;179&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,136&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,094&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,674&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,768&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&amp;nbsp;31, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,536&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,536&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;469&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;469&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;210&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;28&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;238&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;679&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,564&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,243&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&amp;#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivables from Product Sales&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Inventory&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; the Company&amp;#x2019;s inventory consisted primarily of peramivir work in process and is being manufactured for the Company&amp;#x2019;s partners. Inventory is stated at the lower of cost, determined under the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt;-in, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt;-out (&amp;#x201c;FIFO&amp;#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;During &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; in connection with the FDA approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s inventory consisted of the following:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of December&amp;nbsp;31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Work in process&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;500&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,612&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Net inventories&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;500&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,612&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;&lt;/div&gt;  &lt;div&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;    &lt;div style="page-break-before: always; margin-top: 6pt"&gt;  &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Property and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; years. Laboratory equipment, office equipment, and software are depreciated over a life of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt; years. Furniture and fixtures are depreciated over a life of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;seven&lt;/div&gt; years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less. Property consists of a leased building which did not meet the sale-leaseback criteria and is recorded at its fair value, less depreciation. The building is being depreciated over a period equal to the expected term of the related lease.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Patents and Licenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accrued Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company generally enters into contractual agreements with &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt;"&gt;  &lt;tr&gt; &lt;td style="width: 5%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 2%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 91%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to Clinical Research Organizations (&amp;#x201c;CROs&amp;#x201d;) in connection with preclinical and toxicology studies and clinical trials;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to investigative sites in connection with clinical trials;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to contract manufacturers in connection with the production of the Company&amp;#x2019;s raw materials, drug substance and drug products;&amp;nbsp;and&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;professional fees.&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&amp;#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;Accrued expenses were comprised of the following:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 67%; font-size: 10pt; text-align: left"&gt;Compensation and benefits&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;425&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;424&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Development costs&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,427&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,398&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;Inventory&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;705&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;549&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Professional fees&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;242&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;242&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Duties and taxes&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;56&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;102&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Other&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,981&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,522&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total accrued expenses&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,836&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,237&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;&lt;/div&gt;  &lt;div&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;&lt;/div&gt;    &lt;div style="page-break-before: always; margin-top: 6pt"&gt;  &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The liability method is used in the Company&amp;#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accumulated Other Comprehensive Loss&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&amp;#x2019; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; realized gains of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$11&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$13,&lt;/div&gt; respectively, were reclassified out of accumulated other comprehensive loss.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Revenue Recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&amp;nbsp;persuasive evidence of an arrangement exists; (ii)&amp;nbsp;delivery has occurred or services have been rendered; (iii)&amp;nbsp;the seller&amp;#x2019;s price to the buyer is fixed or determinable; and (iv)&amp;nbsp;collectability is reasonably assured.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Collaborative and Other Research and Development Arrangements and Royalties&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Under certain of the Company&amp;#x2019;s license agreements, the Company receives royalty payments based upon its licensees&amp;#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;For arrangements that involve the delivery of more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &amp;#x201c;stand-alone value&amp;#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party evidence of selling price (&amp;#x201c;TPE&amp;#x201d;) and (iii) best estimate of selling price (&amp;#x201c;BESP&amp;#x201d;). The BESP reflects the Company&amp;#x2019;s best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; be an obligation to deliver services, a right or license to use an asset, or another performance obligation.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; the Company entered into a License Agreement (the &amp;#x201c;SUL Agreement&amp;#x201d;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&amp;#x201c;EU&amp;#x201d;) marketing approvals. The Company received an upfront payment of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$33,740&lt;/div&gt; from SUL, of which &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$7,000&lt;/div&gt; was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$21,777&lt;/div&gt; of the upfront payment was allocated to the license rights and recognized as revenue in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015.&lt;/div&gt; Approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3,740&lt;/div&gt; of the upfront payment was allocated to the pending sale of inventory and was recognized in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; when the inventory transfer was completed. Approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,223&lt;/div&gt; of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt;  &lt;div style="page-break-before: always; margin-top: 6pt"&gt;  &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Under the terms of the SUL Agreement, the Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; receive up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$12,000&lt;/div&gt; in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food Branch of Health Canada (&amp;#x201c;Health Canada&amp;#x201d;) for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2010&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Milestone Method of Revenue Recognition&lt;/div&gt;, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&amp;#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&amp;#x201d;BARDA/HHS&amp;#x201d;) and the National Institute of Allergy and Infectious Diseases (&amp;#x201c;NIAID/HHS&amp;#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Product Sales&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from the Company&amp;#x2019;s specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, and prior to the SUL Agreement, the Company sold RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&amp;nbsp;With the completion of the SUL worldwide license of RAPIVAB, SUL will be responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales. With the completion of the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&amp;#x2019;s partners, except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party suppliers of market research data to the pharmaceutical industry.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources.&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Rebates and Chargebacks&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 13.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&amp;#x2019;s selling price.&amp;nbsp;As it can take up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&amp;#x2019;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months from point of sale. To the extent actual rebates and chargebacks differ from the Company&amp;#x2019;s estimates, additional reserves &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; be required or reserves &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; need to be reversed, either of which would impact current period product revenue.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&lt;/div&gt;  &lt;div style="page-break-before: always; margin-top: 6pt"&gt;  &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Discounts and Sales Incentives&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Discounts and other sales incentives primarily consist of Inventory Management Agreement (&amp;#x201c;IMA&amp;#x201d;) fees. Per contractual agreements with the Company&amp;#x2019;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&amp;nbsp;With the completion of the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&amp;#x2019;s partners, except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales and to provide for discounts and sales incentives.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Product Returns&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recorded the following revenues for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 61%; font-size: 10pt; text-align: left"&gt;Product sales, net&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,269&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,291&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;33&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Royalty revenue&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,682&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,386&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,025&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Collaborative and other research and development revenues:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,449&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,337&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,366&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Green Cross Corporation&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;132&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Shionogi &amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,184&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,184&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,184&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;769&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,927&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total collaborative and other research and development revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,402&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;39,580&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,550&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26,353&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;48,257&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,608&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Advertising&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred. The Company did not incur advertising and product promotion expenses in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt; Advertising and product promotion expenses were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$103&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$290&lt;/div&gt; for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; respectively.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Research and Development Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&amp;#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&amp;#x2019;s manufacturing and clinical and preclinical studies are performed by &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&amp;#x2019;s on-going review of the level of services actually performed.&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Additionally, the Company has license agreements with &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; parties, such as Albert Einstein College of Medicine of Yeshiva University (&amp;#x201c;AECOM&amp;#x201d;), Industrial Research, Ltd. (&amp;#x201c;IRL&amp;#x201d;), and the University of Alabama at Birmingham (&amp;#x201c;UAB&amp;#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Deferred collaboration expenses represent sub-license payments, paid to the Company&amp;#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&amp;#x2019;s academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&amp;#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&lt;/div&gt;    &lt;div style="page-break-before: always; margin-top: 6pt"&gt;  &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock-Based Compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &amp;#x201c;performance&amp;#x201d; is deemed to have occurred.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Interest Expense and Deferred Financing Costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Interest expense for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6,487,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5,200&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4,998,&lt;/div&gt; respectively, and primarily relates to the issuance of the PhaRMA Notes (defined in Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3)&lt;/div&gt; and the Senior Credit Facility (defined in Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4).&lt;/div&gt; Costs directly associated with the issuance of the PhaRMA Notes and the Senior Credit Facility have been capitalized and are netted against the non-recourse notes payable and Senior Credit Facility on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the PhaRMA Notes and the Senior Credit Facility using the effective interest rate method. Amortization of deferred financing costs and original issue discount included in interest expense was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$558,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$439&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$439&lt;/div&gt; for each of the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; respectively.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Lease Financing Obligation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Based on the terms of the lease agreement for the new research facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the owner of the building (for accounting purposes only) during the construction period, which ended in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt; Accordingly, the Company recorded an asset of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,589&lt;/div&gt; at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; representing the Company&amp;#x2019;s leased portion of the building and recorded a corresponding liability. Upon completion of leasehold improvement construction, the Company did not meet the sale-leaseback criteria for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected duration of the lease of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20.5&lt;/div&gt; years, and rental payments will be treated as principal and interest payments on the lease financing obligation liability. The underlying accounting for this transaction has no impact on cash flows associated with the underlying lease or construction in process. Interest expense for the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; includes &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$408&lt;/div&gt; related to the lease financing obligation.&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; the lease financing obligation balance was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,704&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,375,&lt;/div&gt; respectively and was recorded as a long term liability on the consolidated balance sheets. At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; the remaining future minimum payments under the lease financing obligation are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4,768.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Currency Hedge Agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore mark to market adjustments are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark to market adjustments for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt; resulted in losses of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,654&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$564&lt;/div&gt; and a gain of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5,487,&lt;/div&gt; respectively. Mark to market adjustments are determined by a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; party pricing model which uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; in the fair value hierarchy as defined by U.S. GAAP. In addition, realized currency exchange gains of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$811&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,654&lt;/div&gt; were recognized in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; respectively, related to the exercise of a U.S. dollar/Japanese yen currency option under the Company&amp;#x2019;s foreign currency hedge. The Company is also required to post collateral in connection with the mark to market adjustments based on defined thresholds. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; no hedge collateral was posted under the Currency Hedge Agreement.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Net Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, outstanding warrants, and common shares expected to be issued under the Company&amp;#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt; does not include &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,226,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,524&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,991&lt;/div&gt; respectively, of potential common shares as their impact would be anti-dilutive.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt;    &lt;div style="page-break-before: always; margin-top: 6pt"&gt;  &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Significant Customers and Other Risks&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-style: italic;"&gt; &amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Significant Customers&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Prior to the SUL Agreement, the Company relied primarily on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; specialty distributors to purchase and supply the majority of RAPIVAB. These &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; pharmaceutical specialty distributors accounted for greater than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;90%&lt;/div&gt; of all RAPIVAB product sales and accounted for predominantly all of the Company&amp;#x2019;s outstanding receivables from product sales. The loss of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; or more of these specialty distributors as a customer could have negatively impacted the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis. In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&amp;#x2019;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Other than royalty revenues, the Company&amp;#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB and galidesivir (formerly &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;BCX4430)&lt;/div&gt; development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses represents a significant portion of the Company&amp;#x2019;s collaborative and other research and development revenues. The completion (as with the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt; BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts could negatively impact the Company&amp;#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. The Company recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments, except for Japanese government stockpiling sales, goes directly to pay the interest, and then the principal, on the Company&amp;#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&amp;#x2019;s drug development activities are performed by a limited group of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&amp;#x2019;s ability to complete its drug development activities.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Risks from Third Party Manufacturing and Distribution Concentration&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of the Company&amp;#x2019;s product candidates in development.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Credit Risk&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&lt;/div&gt; months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&amp;#x2019;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Going Concern&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s liquidity needs will be largely determined by the success of operations in regards to the progression of its product candidates in the future. The Company&amp;#x2019;s plans to alleviate the doubt of its going concern, which are probable of effectively being implemented and mitigating these conditions, primarily include its ability to control the timing and spending on its research and development programs and raising additional funds through equity financings. The Company also &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; consider other plans to fund operations including: &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1)&lt;/div&gt;&amp;nbsp;securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2)&lt;/div&gt;&amp;nbsp;out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3)&lt;/div&gt;&amp;nbsp;raising additional capital through debt financings or from other sources; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4)&lt;/div&gt;&amp;nbsp;obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(5)&lt;/div&gt;&amp;nbsp;reducing spending on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; or more research and development programs by discontinuing development; and/or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(6)&lt;/div&gt;&amp;nbsp;restructuring operations to change its overhead structure. The Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may&lt;/div&gt; issue securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions or registered public offerings, pursuant to its registration statement on Form S-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; initially filed with the Securities and Exchange Commission (&amp;#x201c;SEC&amp;#x201d;) on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015.&lt;/div&gt; The Company&amp;#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events and its decisions in the future.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c13548124" unitRef="xbrli-shares">49000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c13548174" unitRef="xbrli-shares">41000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c13548214" unitRef="xbrli-shares">75000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="d_2016-01-01_2016-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c13548854" unitRef="xbrli-shares">75000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c13548855" unitRef="xbrli-shares">41000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="d_2014-01-01_2014-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c13548856" unitRef="xbrli-shares">49000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c13548134" unitRef="xbrli-shares">11500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c13548114" unitRef="xbrli-shares">1314000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c13548164" unitRef="xbrli-shares">1359000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c13548204" unitRef="xbrli-shares">351000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548900" unitRef="xbrli-shares">1258000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548918" unitRef="xbrli-shares">1118000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548939" unitRef="xbrli-shares">107000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c13548119" unitRef="iso4217-usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c13548120" unitRef="iso4217-usd">309000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548123" unitRef="iso4217-usd">310000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c13548169" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c13548170" unitRef="iso4217-usd">355000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548173" unitRef="iso4217-usd">355000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c13548209" unitRef="iso4217-usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c13548210" unitRef="iso4217-usd">328000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548213" unitRef="iso4217-usd">329000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c13548129" unitRef="iso4217-usd">115000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c13548130" unitRef="iso4217-usd">106485000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548133" unitRef="iso4217-usd">106600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c13548109" unitRef="iso4217-usd">13000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c13548110" unitRef="iso4217-usd">4984000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13548113" unitRef="iso4217-usd">4997000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c13548159" unitRef="iso4217-usd">14000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c13548160" unitRef="iso4217-usd">5110000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13548163" unitRef="iso4217-usd">5124000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c13548199" unitRef="iso4217-usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c13548200" unitRef="iso4217-usd">-15000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13548203" unitRef="iso4217-usd">-12000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockholdersEquity contextRef="i_2013-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c13548094" unitRef="iso4217-usd">591000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2013-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c13548095" unitRef="iso4217-usd">420988000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2013-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c13548096" unitRef="iso4217-usd">4000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2013-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c13548097" unitRef="iso4217-usd">-422709000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2013-12-31" decimals="-3" id="c13548098" unitRef="iso4217-usd">-1126000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c13548144" unitRef="iso4217-usd">720000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c13548145" unitRef="iso4217-usd">542943000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c13548146" unitRef="iso4217-usd">-130000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c13548147" unitRef="iso4217-usd">-467898000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31" decimals="-3" id="c13548148" unitRef="iso4217-usd">75635000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c13548184" unitRef="iso4217-usd">734000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c13548185" unitRef="iso4217-usd">558113000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c13548186" unitRef="iso4217-usd">-206000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c13548187" unitRef="iso4217-usd">-510917000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-12-31" decimals="-3" id="c13548188" unitRef="iso4217-usd">47724000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c13548224" unitRef="iso4217-usd">738000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c13548225" unitRef="iso4217-usd">566913000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2016-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c13548226" unitRef="iso4217-usd">-12000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c13548227" unitRef="iso4217-usd">-566061000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2016-12-31" decimals="-3" id="c13548228" unitRef="iso4217-usd">1578000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2016-01-01_2016-12-31" id="s433708">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&amp;nbsp;&amp;#x2014; Stockholders&amp;#x2019; Equity&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Sales of Common Stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; the Company filed a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$150,000&lt;/div&gt; shelf registration statement on Form S-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; with the SEC. This shelf registration statement became effective upon filing and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale. On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the Company filed a post-effective amendment to this registration statement, which allowed for its use by the Company when declared effective by the SEC&amp;#x2019;s staff on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:TaxCreditCarryforwardAmount contextRef="i_2016-12-31_TaxCreditCarryforwardAxis-ResearchMember" decimals="-3" id="c13549048" unitRef="iso4217-usd">57487000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxesPayableCurrent contextRef="i_2016-12-31" decimals="-3" id="c13548530" unitRef="iso4217-usd">56000</us-gaap:TaxesPayableCurrent>
  <us-gaap:TaxesPayableCurrent contextRef="i_2015-12-31" decimals="-3" id="c13548531" unitRef="iso4217-usd">102000</us-gaap:TaxesPayableCurrent>
  <us-gaap:UnrecognizedTaxBenefits contextRef="i_2015-12-31" decimals="-3" id="c13549095" unitRef="iso4217-usd">3085000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits contextRef="i_2014-12-31" decimals="-3" id="c13549096" unitRef="iso4217-usd">472000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits contextRef="i_2016-12-31" decimals="-3" id="c13549103" unitRef="iso4217-usd">4255000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="d_2016-01-01_2016-12-31" id="c13549101" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13549102" unitRef="iso4217-usd">3000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="i_2015-12-31" decimals="-3" id="c13549025" unitRef="iso4217-usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="i_2014-12-31" decimals="-3" id="c13549026" unitRef="iso4217-usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="i_2016-12-31" decimals="-3" id="c13549027" unitRef="iso4217-usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13549097" unitRef="iso4217-usd">1170000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13549098" unitRef="iso4217-usd">2616000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="d_2016-01-01_2016-12-31" id="c13549099" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="d_2015-01-01_2015-12-31" id="c13549100" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:UseOfEstimates contextRef="d_2016-01-01_2016-12-31" id="c13552342">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2016-01-01_2016-12-31" decimals="-3" id="c13547996" unitRef="xbrli-shares">73699000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c13547997" unitRef="xbrli-shares">72901000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c13547998" unitRef="xbrli-shares">66773000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended"/>
  <xbrli:unit id="xbrli-shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd-per-xbrli-shares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="iso4217-jpy">
    <xbrli:measure>iso4217:JPY</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2000-06-01</xbrli:startDate>
      <xbrli:endDate>2000-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2006-02-01_2006-02-28_TypeOfArrangementAxis-MundipharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:MundipharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2006-02-01</xbrli:startDate>
      <xbrli:endDate>2006-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2006-06-01_2006-06-30_TypeOfArrangementAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2006-06-01</xbrli:startDate>
      <xbrli:endDate>2006-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2007-01-01_2007-01-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2007-01-01</xbrli:startDate>
      <xbrli:endDate>2007-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2007-01-01_2011-02-24_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2007-01-01</xbrli:startDate>
      <xbrli:endDate>2011-02-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2009-09-01_2009-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-09-01</xbrli:startDate>
      <xbrli:endDate>2009-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2010-05-01_2010-05-31_TypeOfArrangementAxis-AECOMAndIRLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-05-01</xbrli:startDate>
      <xbrli:endDate>2010-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2011-02-01_2011-02-24_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-02-01</xbrli:startDate>
      <xbrli:endDate>2011-02-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-03-01</xbrli:startDate>
      <xbrli:endDate>2011-03-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-03-01</xbrli:startDate>
      <xbrli:endDate>2011-03-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-08-01_2013-08-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-08-01</xbrli:startDate>
      <xbrli:endDate>2013-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-09-01_2013-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-09-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-09-01_2013-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-09-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-09-01_2016-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-09-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_CounterpartyNameAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_CounterpartyNameAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_CounterpartyNameAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-03-01_2014-03-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-03-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-06-01_2014-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-06-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-08-01_2014-08-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-08-01</xbrli:startDate>
      <xbrli:endDate>2014-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_CounterpartyNameAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_CounterpartyNameAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_CounterpartyNameAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:UABMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_DeferredRevenueArrangementTypeAxis-RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_DeferredRevenueArrangementTypeAxis-RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_StatementScenarioAxis-ContingentUponEuMarketingApprovalMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">bcrx:ContingentUponEuMarketingApprovalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-16</xbrli:startDate>
      <xbrli:endDate>2015-06-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-07-01_2015-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-10-01_2015-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-10-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_CreationDateAxis-December312015Member_NewAccountingPronouncementEarlyAdoptionAxis-DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">bcrx:December312015Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:NewAccountingPronouncementEarlyAdoptionAxis">bcrx:DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:August2013Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:December2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_TitleOfIndividualAxis-NonEmployeeDirectorsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcrx:NonEmployeeDirectorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_AwardTypeAxis-StockOptionsAndRestrictedStockMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest50PercentEachYearUntilFullyVestedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:StockOptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest50PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueProductLineMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-ThreeCustomersMember_ProductOrServiceAxis-RAPIVABMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">bcrx:ThreeCustomersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueProductLineMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_ProductOrServiceAxis-RAPIVABMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_CounterpartyNameAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_CounterpartyNameAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_CounterpartyNameAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentOfficeEquipmentAndSoftwareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange01Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange02Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange03Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange04Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange05Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange06Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_TypeOfArrangementAxis-ASPRBARDAContractMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-01_2016-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-07-01_2016-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>
      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-09-23_2016-09-23_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-09-23</xbrli:startDate>
      <xbrli:endDate>2016-09-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-09-23_2016-09-23_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-09-23</xbrli:startDate>
      <xbrli:endDate>2016-09-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-10-01_2016-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-10-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2000-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2006-02-28_DeferredRevenueArrangementTypeAxis-UpfrontPaymentMember_TypeOfArrangementAxis-MundipharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:UpfrontPaymentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:MundipharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2006-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-11-11_TypeOfArrangementAxis-MundipharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:MundipharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-11-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-09-03_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_StatementScenarioAxis-Shortfall2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">bcrx:Shortfall2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-03">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AdditionalDevelopmentOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:BaseContractMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_CurrencyAxis-JPY_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_BalanceSheetLocationAxis-LongTermLiabilitiesMember_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bcrx:LongTermLiabilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-LeasedEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LeasedEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-09-23_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-09-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-09-30_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_BalanceSheetLocationAxis-LongTermLiabilitiesMember_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bcrx:LongTermLiabilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_InvestmentTypeAxis-CertificatesOfDepositMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-LeasedEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LeasedEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange01Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange02Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange03Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange04Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange05Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange06Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_TaxCreditCarryforwardAxis-ResearchMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-01-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>bcrx-20161231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 12:31AM UTC 2017-02-25--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:bcrx="http://www.biocryst.com/20161231" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biocryst.com/20161231">
  <xsd:import namespace="http://fasb.org/us-roles/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20161231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20161231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20161231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20161231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.biocryst.com/20161231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-" roleURI="http://www.biocryst.com/20161231/role/statement-consolidated-balance-sheets-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://www.biocryst.com/20161231/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-comprehensive-loss" roleURI="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-comprehensive-loss">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows" roleURI="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-stockholders-equity-deficit" roleURI="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-stockholders-equity-deficit">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Stockholders Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-stockholders-equity-deficit-parentheticals" roleURI="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-stockholders-equity-deficit-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Statement - Consolidated Statements of Stockholders Equity (Deficit) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentrations-of-risk" roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-property-and-equipment" roleURI="http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 2 - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-royalty-monetization" roleURI="http://www.biocryst.com/20161231/role/statement-note-3-royalty-monetization">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 3 - Royalty Monetization</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-senior-credit-facility" roleURI="http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 4 - Senior Credit Facility</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-lease-obligations-and-other-contingencies" roleURI="http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 5 - Lease Obligations and Other Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-stockholders-equity" roleURI="http://www.biocryst.com/20161231/role/statement-note-6-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 6 - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-sharebased-compensation" roleURI="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 7 - Share-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes" roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 8 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-employee-401-k-plan" roleURI="http://www.biocryst.com/20161231/role/statement-note-9-employee-401-k-plan">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 9 - Employee 401 (k) Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-collaborative-and-other-research-and-development-contracts" roleURI="http://www.biocryst.com/20161231/role/statement-note-10-collaborative-and-other-research-and-development-contracts">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 10 - Collaborative and Other Research and Development Contracts</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-quarterly-financial-information-unaudited" roleURI="http://www.biocryst.com/20161231/role/statement-note-11-quarterly-financial-information-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 11 - Quarterly Financial Information (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-recent-accounting-pronouncements" roleURI="http://www.biocryst.com/20161231/role/statement-note-12-recent-accounting-pronouncements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Document - Note 12 - Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.biocryst.com/20161231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-property-and-equipment-tables" roleURI="http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 2 - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-senior-credit-facility-tables" roleURI="http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 4 - Senior Credit Facility (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-lease-obligations-and-other-contingencies-tables" roleURI="http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 5 - Lease Obligations and Other Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-sharebased-compensation-tables" roleURI="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 7 - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-tables" roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 8 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-quarterly-financial-information-unaudited-tables" roleURI="http://www.biocryst.com/20161231/role/statement-note-11-quarterly-financial-information-unaudited-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 11 - Quarterly Financial Information (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentration-of-risk-fair-value-of-the-companys-investments-by-type-details" roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-fair-value-of-the-companys-investments-by-type-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 1 - Significant Accounting Policies and Concentration of Risk - Fair Value of the Company's Investments by Type (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentration-of-risk-scheduled-maturity-for-the-companys-investments-details" roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-scheduled-maturity-for-the-companys-investments-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 1 - Significant Accounting Policies and Concentration of Risk - Scheduled Maturity for the Company's Investments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-receivables-details" roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-receivables-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 1 - Significant Accounting Policies and Concentration of Risk - Summary of Receivables (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentration-of-risk-inventory-details" roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-inventory-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 1 - Significant Accounting Policies and Concentration of Risk - Inventory (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentration-of-risk-accrued-expenses-details" roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-accrued-expenses-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 1 - Significant Accounting Policies and Concentration of Risk - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-revenues-details" roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-revenues-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 1 - Significant Accounting Policies and Concentration of Risk - Summary of Revenues (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-property-and-equipment-details-textual" roleURI="http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 2 - Property and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-property-and-equipment-property-and-equipment-details" roleURI="http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment-property-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note 2 - Property and Equipment - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-royalty-monetization-details-textual" roleURI="http://www.biocryst.com/20161231/role/statement-note-3-royalty-monetization-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">036 - Disclosure - Note 3 - Royalty Monetization (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-senior-credit-facility-details-textual" roleURI="http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">037 - Disclosure - Note 4 - Senior Credit Facility (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" roleURI="http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">038 - Disclosure - Note 4 - Senior Credit Facility - Scheduled Principal Repayments of the Credit Facility (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-lease-obligations-and-other-contingencies-details-textual" roleURI="http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">039 - Disclosure - Note 5 - Lease Obligations and Other Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-lease-obligations-and-other-contingencies-minimum-payments-under-operating-lease-obligations-details" roleURI="http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies-minimum-payments-under-operating-lease-obligations-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">040 - Disclosure - Note 5 - Lease Obligations and Other Contingencies - Minimum Payments under Operating Lease Obligations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-stockholders-equity-details-textual" roleURI="http://www.biocryst.com/20161231/role/statement-note-6-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">041 - Disclosure - Note 6 - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-sharebased-compensation-details-textual" roleURI="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">042 - Disclosure - Note 7 - Share-Based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockbased-compensation-stockbased-compensation-allocation-details" roleURI="http://www.biocryst.com/20161231/role/statement-note-7-stockbased-compensation-stockbased-compensation-allocation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">043 - Disclosure - Note 7 - Stock-Based Compensation - Stock-based Compensation Allocation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-sharebased-compensation-stock-incentive-plan-activities-details" roleURI="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-stock-incentive-plan-activities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">044 - Disclosure - Note 7 - Share-Based Compensation - Stock Incentive Plan Activities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-sharebased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" roleURI="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">045 - Disclosure - Note 7 - Share-Based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-sharebased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" roleURI="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">046 - Disclosure - Note 7 - Share-Based Compensation - Number of Stock Option Awards Exercisable and their Weighted Average Exercise Price (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-sharebased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" roleURI="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">047 - Disclosure - Note 7 - Share-Based Compensation - Changes in the Number and Weighted-Average Grant-Date Fair Value (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-details-textual" roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">048 - Disclosure - Note 8 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">049 - Disclosure - Note 8 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">050 - Disclosure - Note 8 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">051 - Disclosure - Note 8 - Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-components-of-deferred-tax-assets-and-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">052 - Disclosure - Note 8 - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-employee-401-k-plan-details-textual" roleURI="http://www.biocryst.com/20161231/role/statement-note-9-employee-401-k-plan-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">053 - Disclosure - Note 9 - Employee 401 (k) Plan (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-collaborative-and-other-research-and-development-contracts-details-textual" roleURI="http://www.biocryst.com/20161231/role/statement-note-10-collaborative-and-other-research-and-development-contracts-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">054 - Disclosure - Note 10 - Collaborative and Other Research and Development Contracts (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" roleURI="http://www.biocryst.com/20161231/role/statement-note-11-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">055 - Disclosure - Note 11 - Quarterly Financial Information (Unaudited) - Schedule of Quarterly Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="bcrx_AECOMAndIRLMember" name="AECOMAndIRLMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ASPRBARDAContractMember" name="ASPRBARDAContractMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AccruedDevelopmentCosts" name="AccruedDevelopmentCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AccruedExpensesPolicyTextBlock" name="AccruedExpensesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AccruedInventoryExpense" name="AccruedInventoryExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_AdditionalDevelopmentOptionsMember" name="AdditionalDevelopmentOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" name="AdvanceNoticePeriodForTerminationOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AgreementMember" name="AgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" name="AmortizationOfDiscountAndPremiumOnInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AnnualLicenseFeeMaximum" name="AnnualLicenseFeeMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AnnualLicenseFeeMinimum" name="AnnualLicenseFeeMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_August2013Member" name="August2013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesAccruedInterest" name="AvailableForSaleSecuritiesAccruedInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" name="AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" name="AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AveragematurityForPortfolioInvestments" name="AveragematurityForPortfolioInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" name="AveragematurityPeriodOfHighQualityMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_BaseContractMember" name="BaseContractMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_BirminghamResearchFacilityMember" name="BirminghamResearchFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CSLLimitedMember" name="CSLLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CSLMember" name="CSLMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAgreementAdditionalContractValue" name="CollaborativeAgreementAdditionalContractValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAgreementAdjustedContractValue" name="CollaborativeAgreementAdjustedContractValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAgreementContractValue" name="CollaborativeAgreementContractValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAndOtherResearchAndDevelopment" name="CollaborativeAndOtherResearchAndDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" name="CollaborativeAndOtherResearchAndDevelopmentRevenues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CollateralForCreditMember" name="CollateralForCreditMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" name="ConcentrationOfMarketRiskPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ContingentUponEuMarketingApprovalMember" name="ContingentUponEuMarketingApprovalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CurrencyHedgeAgreementMember" name="CurrencyHedgeAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CurrencyHedgeAgreementPolicyTextBlock" name="CurrencyHedgeAgreementPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DebtInstrumentFinalPaymentFeePercentage" name="DebtInstrumentFinalPaymentFeePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DebtInstrumentMinimumLibor" name="DebtInstrumentMinimumLibor" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" name="DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_December2014Member" name="December2014Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_December312015Member" name="December312015Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DeferredCollaborationExpenseAssets" name="DeferredCollaborationExpenseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" name="DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DescriptionOfCompanyPolicyTextBlock" name="DescriptionOfCompanyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" name="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" name="EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ExercisePriceRange01Member" name="ExercisePriceRange01Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ExercisePriceRange02Member" name="ExercisePriceRange02Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ExercisePriceRange03Member" name="ExercisePriceRange03Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ExercisePriceRange04Member" name="ExercisePriceRange04Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ExercisePriceRange05Member" name="ExercisePriceRange05Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ExercisePriceRange06Member" name="ExercisePriceRange06Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" name="ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_GoingConcernPolicyPolicyTextBlock" name="GoingConcernPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_GreenCrossCorporationMember" name="GreenCrossCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_IncentivePlanMember" name="IncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" name="IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_IncreaseDecreaseInFinancingLeaseObligations" name="IncreaseDecreaseInFinancingLeaseObligations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" name="InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_Interestreserve" name="Interestreserve" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_JPRRoyaltySubLLCMember" name="JPRRoyaltySubLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" name="LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_LeaseFinancingObligationNetOfCurrent" name="LeaseFinancingObligationNetOfCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_LeasedEquipmentMember" name="LeasedEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_LongTermLiabilitiesMember" name="LongTermLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_LongtermInvestmentMaturityMinimum" name="LongtermInvestmentMaturityMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" name="MaturityPeriodOfHighQualityMarketablesecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaturityperiodOfShortTermInvestment" name="MaturityperiodOfShortTermInvestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaximumAggregateOfferingPrice" name="MaximumAggregateOfferingPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_MaximumAmountOfCollateralRequiredToPost" name="MaximumAmountOfCollateralRequiredToPost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_MidCapFinancialServicesLLCMember" name="MidCapFinancialServicesLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MilestonePaymentMaximum" name="MilestonePaymentMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MilestonePaymentMinimum" name="MilestonePaymentMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_MundipharmaMember" name="MundipharmaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NonEmployeeDirectorsMember" name="NonEmployeeDirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_NumberOfMajorCustomers" name="NumberOfMajorCustomers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PaymentsForModificationOfLicenseAgreement" name="PaymentsForModificationOfLicenseAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" name="PercentageOfCarryingAmountInExcessOfFairValue1" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_PercentageOfCommonStockSharesBeginning" name="PercentageOfCommonStockSharesBeginning" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" name="PercentageOfSalaryToPurchaseCommonStockMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PeriodOfAgreement" name="PeriodOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_PhaRMANotesMember" name="PhaRMANotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PotentialMilestonePaymentsReceivable" name="PotentialMilestonePaymentsReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_PrivatePlacementOfSeniorSecuredNotes" name="PrivatePlacementOfSeniorSecuredNotes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" name="ProceedsFromAwardsForResearchAndDevelopmentContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RAPIVABMember" name="RAPIVABMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" name="RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RequiredForeignCurrencyHedgePerDollar" name="RequiredForeignCurrencyHedgePerDollar" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" name="RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" name="RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" name="RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_RoyaltyMonetizationMember" name="RoyaltyMonetizationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyMonetizationTextBlock" name="RoyaltyMonetizationTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RoyaltyReceivableMember" name="RoyaltyReceivableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" name="ScheduleOfReceivablesFromCollaborationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" name="ScheduleOfRevenuesFromCollaborationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_SeniorCreditFacilityMember" name="SeniorCreditFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_SeqirusUKLimitedMember" name="SeqirusUKLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" name="ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" name="SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ShionogiAndCoLtdMember" name="ShionogiAndCoLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_Shortfall2013Member" name="Shortfall2013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" name="StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_StockOptionsAndRestrictedStockMember" name="StockOptionsAndRestrictedStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ThreeCustomersMember" name="ThreeCustomersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_TransactionCosts" name="TransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_UABMember" name="UABMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_USDepartmentOfHealthAndHumanServicesMember" name="USDepartmentOfHealthAndHumanServicesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_UpfrontPaymentMember" name="UpfrontPaymentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_UpfrontPaymentsReceivableAmount" name="UpfrontPaymentsReceivableAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_Vest25PercentEachYearUntilFullyVestedMember" name="Vest25PercentEachYearUntilFullyVestedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_Vest50PercentEachYearUntilFullyVestedMember" name="Vest50PercentEachYearUntilFullyVestedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" name="VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-accrued-expenses-details" name="statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-accrued-expenses-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-fair-value-of-the-companys-investments-by-type-details" name="statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-fair-value-of-the-companys-investments-by-type-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-inventory-details" name="statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-inventory-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-scheduled-maturity-for-the-companys-investments-details" name="statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-scheduled-maturity-for-the-companys-investments-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-receivables-details" name="statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-receivables-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-revenues-details" name="statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-revenues-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" name="statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-11-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" name="statement-statement-note-11-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-11-quarterly-financial-information-unaudited-tables" name="statement-statement-note-11-quarterly-financial-information-unaudited-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-2-property-and-equipment-property-and-equipment-details" name="statement-statement-note-2-property-and-equipment-property-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-2-property-and-equipment-tables" name="statement-statement-note-2-property-and-equipment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-4-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" name="statement-statement-note-4-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-4-senior-credit-facility-tables" name="statement-statement-note-4-senior-credit-facility-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-5-lease-obligations-and-other-contingencies-minimum-payments-under-operating-lease-obligations-details" name="statement-statement-note-5-lease-obligations-and-other-contingencies-minimum-payments-under-operating-lease-obligations-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-5-lease-obligations-and-other-contingencies-tables" name="statement-statement-note-5-lease-obligations-and-other-contingencies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-7-sharebased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" name="statement-statement-note-7-sharebased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-7-sharebased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" name="statement-statement-note-7-sharebased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-7-sharebased-compensation-stock-incentive-plan-activities-details" name="statement-statement-note-7-sharebased-compensation-stock-incentive-plan-activities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-7-sharebased-compensation-tables" name="statement-statement-note-7-sharebased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-7-sharebased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" name="statement-statement-note-7-sharebased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-7-stockbased-compensation-stockbased-compensation-allocation-details" name="statement-statement-note-7-stockbased-compensation-stockbased-compensation-allocation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-8-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" name="statement-statement-note-8-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" name="statement-statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" name="statement-statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-8-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" name="statement-statement-note-8-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-8-income-taxes-tables" name="statement-statement-note-8-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>bcrx-20161231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 12:32AM UTC 2017-02-25--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies-minimum-payments-under-operating-lease-obligations-details" xlink:href="bcrx-20161231.xsd#statement-note-5-lease-obligations-and-other-contingencies-minimum-payments-under-operating-lease-obligations-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies-minimum-payments-under-operating-lease-obligations-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:href="bcrx-20161231.xsd#statement-note-8-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-scheduled-maturity-for-the-companys-investments-details" xlink:href="bcrx-20161231.xsd#statement-note-1-significant-accounting-policies-and-concentration-of-risk-scheduled-maturity-for-the-companys-investments-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-scheduled-maturity-for-the-companys-investments-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment-property-and-equipment-details" xlink:href="bcrx-20161231.xsd#statement-note-2-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:href="bcrx-20161231.xsd#statement-note-4-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:href="bcrx-20161231.xsd#statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:label="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:label="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-consolidated-balance-sheets-" xlink:href="bcrx-20161231.xsd#statement-consolidated-balance-sheets-" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20161231/role/statement-consolidated-balance-sheets-" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DeferredCostsCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="bcrx_DeferredCollaborationExpenseAssets" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LineOfCredit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:href="bcrx-20161231.xsd#statement-consolidated-statements-of-comprehensive-loss" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SalesRevenueNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-cash-flows" xlink:href="bcrx-20161231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:label="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:label="us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="arc"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="arc"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-inventory-details" xlink:href="bcrx-20161231.xsd#statement-note-1-significant-accounting-policies-and-concentration-of-risk-inventory-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-inventory-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-accrued-expenses-details" xlink:href="bcrx-20161231.xsd#statement-note-1-significant-accounting-policies-and-concentration-of-risk-accrued-expenses-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AccruedDevelopmentCosts" xlink:label="bcrx_AccruedDevelopmentCosts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AccruedInventoryExpense" xlink:label="bcrx_AccruedInventoryExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="bcrx_AccruedInventoryExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="bcrx_AccruedDevelopmentCosts" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>bcrx-20161231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 12:32AM UTC 2017-02-25--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-12-recent-accounting-pronouncements" xlink:href="bcrx-20161231.xsd#statement-note-12-recent-accounting-pronouncements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-12-recent-accounting-pronouncements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-11-quarterly-financial-information-unaudited" xlink:href="bcrx-20161231.xsd#statement-note-11-quarterly-financial-information-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-11-quarterly-financial-information-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-document-and-entity-information" xlink:href="bcrx-20161231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="bcrx-20161231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-stockholders-equity-deficit-parentheticals" xlink:href="bcrx-20161231.xsd#statement-consolidated-statements-of-stockholders-equity-deficit-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-stockholders-equity-deficit-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:href="bcrx-20161231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:label="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_December312015Member" xlink:label="bcrx_December312015Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ThreeCustomersMember" xlink:label="bcrx_ThreeCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="us-gaap_CreationDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="us-gaap_DefaultFinancialStatementsDateMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:to="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreationDateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefaultFinancialStatementsDateMember" xlink:to="bcrx_December312015Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_DefaultFinancialStatementsDateMember-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueProductLineMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MajorCustomersAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="bcrx_ThreeCustomersMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment" xlink:href="bcrx-20161231.xsd#statement-note-2-property-and-equipment" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-3-royalty-monetization" xlink:href="bcrx-20161231.xsd#statement-note-3-royalty-monetization" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-3-royalty-monetization" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_Shortfall2013Member" xlink:label="bcrx_Shortfall2013Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_JPY" xlink:label="currency_JPY" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="bcrx_Shortfall2013Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_JPY" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bcrx_RoyaltyMonetizationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility" xlink:href="bcrx-20161231.xsd#statement-note-4-senior-credit-facility" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies" xlink:href="bcrx-20161231.xsd#statement-note-5-lease-obligations-and-other-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LongTermLiabilitiesMember" xlink:label="bcrx_LongTermLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="bcrx_LongTermLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-6-stockholders-equity" xlink:href="bcrx-20161231.xsd#statement-note-6-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-6-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation" xlink:href="bcrx-20161231.xsd#statement-note-7-sharebased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes" xlink:href="bcrx-20161231.xsd#statement-note-8-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-9-employee-401-k-plan" xlink:href="bcrx-20161231.xsd#statement-note-9-employee-401-k-plan" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-9-employee-401-k-plan" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-10-collaborative-and-other-research-and-development-contracts" xlink:href="bcrx-20161231.xsd#statement-note-10-collaborative-and-other-research-and-development-contracts" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-10-collaborative-and-other-research-and-development-contracts" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_UpfrontPaymentMember" xlink:label="bcrx_UpfrontPaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_UpfrontPaymentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-significant-accounting-policies-policies" xlink:href="bcrx-20161231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_GoingConcernPolicyPolicyTextBlock" xlink:label="bcrx_GoingConcernPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="us-gaap_LeasePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LeasePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_GoingConcernPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:href="bcrx-20161231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment-tables" xlink:href="bcrx-20161231.xsd#statement-note-2-property-and-equipment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility-tables" xlink:href="bcrx-20161231.xsd#statement-note-4-senior-credit-facility-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies-tables" xlink:href="bcrx-20161231.xsd#statement-note-5-lease-obligations-and-other-contingencies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-tables" xlink:href="bcrx-20161231.xsd#statement-note-7-sharebased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-tables" xlink:href="bcrx-20161231.xsd#statement-note-8-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-11-quarterly-financial-information-unaudited-tables" xlink:href="bcrx-20161231.xsd#statement-note-11-quarterly-financial-information-unaudited-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-11-quarterly-financial-information-unaudited-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:href="bcrx-20161231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AveragematurityForPortfolioInvestments" xlink:label="bcrx_AveragematurityForPortfolioInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:label="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_December312015Member" xlink:label="bcrx_December312015Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NumberOfMajorCustomers" xlink:label="bcrx_NumberOfMajorCustomers" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ThreeCustomersMember" xlink:label="bcrx_ThreeCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="us-gaap_CreationDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="us-gaap_DefaultFinancialStatementsDateMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:to="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreationDateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefaultFinancialStatementsDateMember" xlink:to="bcrx_December312015Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_DefaultFinancialStatementsDateMember-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueProductLineMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MajorCustomersAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="bcrx_ThreeCustomersMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCredit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PriorPeriodReclassificationAdjustment" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenueAdditions" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvertisingExpense" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NumberOfMajorCustomers" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityForPortfolioInvestments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment-details-textual" xlink:href="bcrx-20161231.xsd#statement-note-2-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-3-royalty-monetization-details-textual" xlink:href="bcrx-20161231.xsd#statement-note-3-royalty-monetization-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-3-royalty-monetization-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_Interestreserve" xlink:label="bcrx_Interestreserve" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_Shortfall2013Member" xlink:label="bcrx_Shortfall2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_JPY" xlink:label="currency_JPY" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="bcrx_Shortfall2013Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_JPY" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_TransactionCosts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_Interestreserve" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPaid" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeForwardExchangeRate1" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility-details-textual" xlink:href="bcrx-20161231.xsd#statement-note-4-senior-credit-facility-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DebtInstrumentFinalPaymentFeePercentage" xlink:label="bcrx_DebtInstrumentFinalPaymentFeePercentage" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DebtInstrumentMinimumLibor" xlink:label="bcrx_DebtInstrumentMinimumLibor" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCredit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentMinimumLibor" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentFinalPaymentFeePercentage" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies-details-textual" xlink:href="bcrx-20161231.xsd#statement-note-5-lease-obligations-and-other-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LongTermLiabilitiesMember" xlink:label="bcrx_LongTermLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="bcrx_LongTermLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-6-stockholders-equity-details-textual" xlink:href="bcrx-20161231.xsd#statement-note-6-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-6-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAggregateOfferingPrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-details-textual" xlink:href="bcrx-20161231.xsd#statement-note-7-sharebased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:label="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-details-textual" xlink:href="bcrx-20161231.xsd#statement-note-8-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:href="bcrx-20161231.xsd#statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-9-employee-401-k-plan-details-textual" xlink:href="bcrx-20161231.xsd#statement-note-9-employee-401-k-plan-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-9-employee-401-k-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-10-collaborative-and-other-research-and-development-contracts-details-textual" xlink:href="bcrx-20161231.xsd#statement-note-10-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-10-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CollaborativeAgreementAdditionalContractValue" xlink:label="bcrx_CollaborativeAgreementAdditionalContractValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CollaborativeAgreementAdjustedContractValue" xlink:label="bcrx_CollaborativeAgreementAdjustedContractValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CollaborativeAgreementContractValue" xlink:label="bcrx_CollaborativeAgreementContractValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PaymentsForModificationOfLicenseAgreement" xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PotentialMilestonePaymentsReceivable" xlink:label="bcrx_PotentialMilestonePaymentsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_UpfrontPaymentMember" xlink:label="bcrx_UpfrontPaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_UpfrontPaymentsReceivableAmount" xlink:label="bcrx_UpfrontPaymentsReceivableAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_UpfrontPaymentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementContractValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementAdditionalContractValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementAdjustedContractValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentContractReceivable" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_UpfrontPaymentsReceivableAmount" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenue" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PotentialMilestonePaymentsReceivable" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMinimum" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMinimum" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMaximum" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PaymentsForModificationOfLicenseAgreement" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PeriodOfAgreement" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies-minimum-payments-under-operating-lease-obligations-details" xlink:href="bcrx-20161231.xsd#statement-note-5-lease-obligations-and-other-contingencies-minimum-payments-under-operating-lease-obligations-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies-minimum-payments-under-operating-lease-obligations-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:href="bcrx-20161231.xsd#statement-note-8-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-stockholders-equity-deficit" xlink:href="bcrx-20161231.xsd#statement-consolidated-statements-of-stockholders-equity-deficit" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-stockholders-equity-deficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-scheduled-maturity-for-the-companys-investments-details" xlink:href="bcrx-20161231.xsd#statement-note-1-significant-accounting-policies-and-concentration-of-risk-scheduled-maturity-for-the-companys-investments-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-scheduled-maturity-for-the-companys-investments-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-revenues-details" xlink:href="bcrx-20161231.xsd#statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-revenues-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-revenues-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_SeqirusUKLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment-property-and-equipment-details" xlink:href="bcrx-20161231.xsd#statement-note-2-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LaboratoryEquipmentMember" xlink:label="bcrx_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LeasedEquipmentMember" xlink:label="bcrx_LeasedEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcrx_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcrx_LeasedEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:href="bcrx-20161231.xsd#statement-note-4-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-stock-incentive-plan-activities-details" xlink:href="bcrx-20161231.xsd#statement-note-7-sharebased-compensation-stock-incentive-plan-activities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-stock-incentive-plan-activities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:href="bcrx-20161231.xsd#statement-note-7-sharebased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:href="bcrx-20161231.xsd#statement-note-7-sharebased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:href="bcrx-20161231.xsd#statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:label="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:label="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:href="bcrx-20161231.xsd#statement-note-8-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-consolidated-balance-sheets-" xlink:href="bcrx-20161231.xsd#statement-consolidated-balance-sheets-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-consolidated-balance-sheets-" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCostsCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="bcrx_DeferredCollaborationExpenseAssets" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LineOfCredit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:href="bcrx-20161231.xsd#statement-consolidated-statements-of-comprehensive-loss" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestAndOtherIncome" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-cash-flows" xlink:href="bcrx-20161231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:label="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:label="us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:href="bcrx-20161231.xsd#statement-note-7-sharebased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ExercisePriceRange01Member" xlink:label="bcrx_ExercisePriceRange01Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ExercisePriceRange02Member" xlink:label="bcrx_ExercisePriceRange02Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ExercisePriceRange03Member" xlink:label="bcrx_ExercisePriceRange03Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ExercisePriceRange04Member" xlink:label="bcrx_ExercisePriceRange04Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ExercisePriceRange05Member" xlink:label="bcrx_ExercisePriceRange05Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ExercisePriceRange06Member" xlink:label="bcrx_ExercisePriceRange06Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bcrx_ExercisePriceRange01Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bcrx_ExercisePriceRange02Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bcrx_ExercisePriceRange03Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bcrx_ExercisePriceRange04Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bcrx_ExercisePriceRange05Member" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bcrx_ExercisePriceRange06Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:href="bcrx-20161231.xsd#statement-note-1-significant-accounting-policies-and-concentration-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-receivables-details" xlink:href="bcrx-20161231.xsd#statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-receivables-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-receivables-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_BilledRevenuesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_UnbilledRevenuesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_SeqirusUKLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-inventory-details" xlink:href="bcrx-20161231.xsd#statement-note-1-significant-accounting-policies-and-concentration-of-risk-inventory-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-inventory-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-accrued-expenses-details" xlink:href="bcrx-20161231.xsd#statement-note-1-significant-accounting-policies-and-concentration-of-risk-accrued-expenses-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AccruedDevelopmentCosts" xlink:label="bcrx_AccruedDevelopmentCosts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AccruedInventoryExpense" xlink:label="bcrx_AccruedInventoryExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AccruedDevelopmentCosts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AccruedInventoryExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxesPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-7-stockbased-compensation-stockbased-compensation-allocation-details" xlink:href="bcrx-20161231.xsd#statement-note-7-stockbased-compensation-stockbased-compensation-allocation-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-7-stockbased-compensation-stockbased-compensation-allocation-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-11-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:href="bcrx-20161231.xsd#statement-note-11-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-11-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>bcrx-20161231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 12:31AM UTC 2017-02-25--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DocumentAndEntityInformation" xlink:label="bcrx_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DocumentAndEntityInformation" xlink:to="bcrx_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:label="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Next Year</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share-based compensation nonvested awards compensation cost expected to be recognized next year.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:to="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpense</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DebtInstrumentMinimumLibor" xlink:label="bcrx_DebtInstrumentMinimumLibor" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtInstrumentMinimumLibor-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DebtInstrumentMinimumLibor</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentMinimumLibor-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Minimum LIBOR</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentMinimumLibor-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum LIBOR interest that will be added to the basis spread.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtInstrumentMinimumLibor" xlink:to="bcrx_DebtInstrumentMinimumLibor-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="bcrx_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AmortizationOfFinancingCosts</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-significant-accounting-policies-policies" xlink:label="bcrx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementsignificantaccountingpoliciespolicies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-significant-accounting-policies-policies" xlink:to="bcrx_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1significantaccountingpoliciesandconcentrationsofrisktables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-2-property-and-equipment-tables" xlink:label="bcrx_statement-statement-note-2-property-and-equipment-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-2-property-and-equipment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote2propertyandequipmenttables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-2-property-and-equipment-tables" xlink:to="bcrx_statement-statement-note-2-property-and-equipment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-4-senior-credit-facility-tables" xlink:label="bcrx_statement-statement-note-4-senior-credit-facility-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-4-senior-credit-facility-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote4seniorcreditfacilitytables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-4-senior-credit-facility-tables" xlink:to="bcrx_statement-statement-note-4-senior-credit-facility-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-5-lease-obligations-and-other-contingencies-tables" xlink:label="bcrx_statement-statement-note-5-lease-obligations-and-other-contingencies-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-5-lease-obligations-and-other-contingencies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote5leaseobligationsandothercontingenciestables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-5-lease-obligations-and-other-contingencies-tables" xlink:to="bcrx_statement-statement-note-5-lease-obligations-and-other-contingencies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-7-sharebased-compensation-tables" xlink:label="bcrx_statement-statement-note-7-sharebased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-7-sharebased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote7sharebasedcompensationtables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-7-sharebased-compensation-tables" xlink:to="bcrx_statement-statement-note-7-sharebased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-8-income-taxes-tables" xlink:label="bcrx_statement-statement-note-8-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-8-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote8incometaxestables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-8-income-taxes-tables" xlink:to="bcrx_statement-statement-note-8-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-11-quarterly-financial-information-unaudited-tables" xlink:label="bcrx_statement-statement-note-11-quarterly-financial-information-unaudited-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-11-quarterly-financial-information-unaudited-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote11quarterlyfinancialinformationunauditedtables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-11-quarterly-financial-information-unaudited-tables" xlink:to="bcrx_statement-statement-note-11-quarterly-financial-information-unaudited-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-fair-value-of-the-companys-investments-by-type-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1significantaccountingpoliciesandconcentrationofriskfairvalueofthecompanysinvestmentsbytypedetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-fair-value-of-the-companys-investments-by-type-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-scheduled-maturity-for-the-companys-investments-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-scheduled-maturity-for-the-companys-investments-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-scheduled-maturity-for-the-companys-investments-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1significantaccountingpoliciesandconcentrationofriskscheduledmaturityforthecompanysinvestmentsdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-scheduled-maturity-for-the-companys-investments-details" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-scheduled-maturity-for-the-companys-investments-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-receivables-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-receivables-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-receivables-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1significantaccountingpoliciesandconcentrationofrisksummaryofreceivablesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-receivables-details" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-receivables-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDeferredRevenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-inventory-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-inventory-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-inventory-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1significantaccountingpoliciesandconcentrationofriskinventorydetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-inventory-details" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-inventory-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-accrued-expenses-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-accrued-expenses-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-accrued-expenses-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1significantaccountingpoliciesandconcentrationofriskaccruedexpensesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-accrued-expenses-details" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-accrued-expenses-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-revenues-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-revenues-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-revenues-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1significantaccountingpoliciesandconcentrationofrisksummaryofrevenuesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-revenues-details" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-revenues-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-2-property-and-equipment-property-and-equipment-details" xlink:label="bcrx_statement-statement-note-2-property-and-equipment-property-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-2-property-and-equipment-property-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote2propertyandequipmentpropertyandequipmentdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-2-property-and-equipment-property-and-equipment-details" xlink:to="bcrx_statement-statement-note-2-property-and-equipment-property-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-4-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:label="bcrx_statement-statement-note-4-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-4-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote4seniorcreditfacilityscheduledprincipalrepaymentsofthecreditfacilitydetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-4-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:to="bcrx_statement-statement-note-4-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-5-lease-obligations-and-other-contingencies-minimum-payments-under-operating-lease-obligations-details" xlink:label="bcrx_statement-statement-note-5-lease-obligations-and-other-contingencies-minimum-payments-under-operating-lease-obligations-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-5-lease-obligations-and-other-contingencies-minimum-payments-under-operating-lease-obligations-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote5leaseobligationsandothercontingenciesminimumpaymentsunderoperatingleaseobligationsdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-5-lease-obligations-and-other-contingencies-minimum-payments-under-operating-lease-obligations-details" xlink:to="bcrx_statement-statement-note-5-lease-obligations-and-other-contingencies-minimum-payments-under-operating-lease-obligations-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-7-stockbased-compensation-stockbased-compensation-allocation-details" xlink:label="bcrx_statement-statement-note-7-stockbased-compensation-stockbased-compensation-allocation-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-7-stockbased-compensation-stockbased-compensation-allocation-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote7stockbasedcompensationstockbasedcompensationallocationdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-7-stockbased-compensation-stockbased-compensation-allocation-details" xlink:to="bcrx_statement-statement-note-7-stockbased-compensation-stockbased-compensation-allocation-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-7-sharebased-compensation-stock-incentive-plan-activities-details" xlink:label="bcrx_statement-statement-note-7-sharebased-compensation-stock-incentive-plan-activities-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-7-sharebased-compensation-stock-incentive-plan-activities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote7sharebasedcompensationstockincentiveplanactivitiesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-7-sharebased-compensation-stock-incentive-plan-activities-details" xlink:to="bcrx_statement-statement-note-7-sharebased-compensation-stock-incentive-plan-activities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-7-sharebased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:label="bcrx_statement-statement-note-7-sharebased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-7-sharebased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote7sharebasedcompensationweightedaverageassumptionsforstockoptionawardsgrantedtoemployeesanddirectorsundertheincentiveplandetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-7-sharebased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:to="bcrx_statement-statement-note-7-sharebased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-7-sharebased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:label="bcrx_statement-statement-note-7-sharebased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-7-sharebased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote7sharebasedcompensationnumberofstockoptionawardsexercisableandtheirweightedaverageexercisepricedetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-7-sharebased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:to="bcrx_statement-statement-note-7-sharebased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-7-sharebased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:label="bcrx_statement-statement-note-7-sharebased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-7-sharebased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote7sharebasedcompensationchangesinthenumberandweightedaveragegrantdatefairvaluedetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-7-sharebased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:to="bcrx_statement-statement-note-7-sharebased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:label="bcrx_statement-statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote8incometaxesdifferencesbetweenthecompanyseffectivetaxrateandthestatutorytaxratedetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:to="bcrx_statement-statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:label="bcrx_statement-statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote8incometaxesdifferencesbetweenthecompanyseffectivetaxrateandthestatutorytaxratedetailsparentheticals</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:to="bcrx_statement-statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInterestPayableNet</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-8-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:label="bcrx_statement-statement-note-8-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-8-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote8incometaxesreconciliationofbeginningandendingamountofunrecognizedtaxbenefitsdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-8-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:to="bcrx_statement-statement-note-8-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-8-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:label="bcrx_statement-statement-note-8-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-8-income-taxes-components-of-deferred-tax-assets-and-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote8incometaxescomponentsofdeferredtaxassetsandliabilitiesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-8-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:to="bcrx_statement-statement-note-8-income-taxes-components-of-deferred-tax-assets-and-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-11-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:label="bcrx_statement-statement-note-11-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-11-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote11quarterlyfinancialinformationunauditedscheduleofquarterlyinformationdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-11-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:to="bcrx_statement-statement-note-11-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NotesToFinancialStatements" xlink:label="bcrx_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NotesToFinancialStatements" xlink:to="bcrx_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="bcrx_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskPercentage1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConcentrationRiskPercentage1</link:label>
    <link:label xlink:label="us-gaap_ConcentrationRiskPercentage1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Revenues</link:label>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueProductLineMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Product Line [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueProductLineMember" xlink:to="us-gaap_SalesRevenueProductLineMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:label="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Orphan drug credit</link:label>
    <link:label xlink:label="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents orphan drug credit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:to="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDerivativeAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of foreign currency derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredIncomeTaxLiabilities</link:label>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsLiabilitiesNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsGross</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CustomerConcentrationRiskMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:label="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:type="locator"/>
    <link:label xlink:label="bcrx_IncreaseDecreaseInFinancingLeaseObligations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase in lease financing obligation</link:label>
    <link:label xlink:label="bcrx_IncreaseDecreaseInFinancingLeaseObligations-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the period for financing lease obligations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:to="bcrx_IncreaseDecreaseInFinancingLeaseObligations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsDeferredIncome</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestAndOtherIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and other income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SeqirusUKLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seqirus UK Limited [Member]</link:label>
    <link:label xlink:label="bcrx_SeqirusUKLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Seqirus UK Limited.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SeqirusUKLimitedMember" xlink:to="bcrx_SeqirusUKLimitedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueAdditions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredRevenueAdditions</link:label>
    <link:label xlink:label="us-gaap_DeferredRevenueAdditions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Additions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueAdditions" xlink:to="us-gaap_DeferredRevenueAdditions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInReceivables</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInReceivables-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SalesRevenueNet</link:label>
    <link:label xlink:label="us-gaap_SalesRevenueNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label xlink:label="us-gaap_SalesRevenueNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RoyaltyRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty revenue</link:label>
    <link:label xlink:label="us-gaap_RoyaltyRevenue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyRevenue" xlink:to="us-gaap_RoyaltyRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan sales, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan sales</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of stock options, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards exercised (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="us-gaap_LeasePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeasePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePolicyTextBlock" xlink:to="us-gaap_LeasePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net federal and state operating losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Stock option awards forfeited (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInventories</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock option awards granted (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AmortizationOfDiscountAndPremiumOnInvestments</link:label>
    <link:label xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of premium/discount on investments</link:label>
    <link:label xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of amortization expense attributable to the discount and premium on investments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Foreign currency derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:to="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Fixed assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_JPY" xlink:label="currency_JPY" xlink:type="locator"/>
    <link:label xlink:label="currency_JPY-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_JPY" xlink:to="currency_JPY-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueGoodsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product sales, net</link:label>
    <link:label xlink:label="us-gaap_SalesRevenueGoodsNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product sales, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred collaboration expense</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseAssets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred collaboration expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborationExpenseAssets" xlink:to="bcrx_DeferredCollaborationExpenseAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" xlink:type="locator"/>
    <link:label xlink:label="currency_AllCurrenciesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value; shares authorized &#8212; 200,000; shares issued and outstanding &#8212; 73,782 in 2016 and 73,355 in 2015</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative and other research and development</link:label>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative and other research and development during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CertificatesOfDepositMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, amortization, and impairment</link:label>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenuesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized</link:label>
    <link:label xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition Royalty and Milestone Revenue Recognized</link:label>
    <link:label xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue recognition royalty and milestone revenue recognized.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities</link:label>
    <link:label xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average Maturity Period of High Quality Marketable Securities</link:label>
    <link:label xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average maturity period of high quality marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:to="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaturityperiodOfShortTermInvestment</link:label>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Period of Short Term Investment</link:label>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maturity period of short term investment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityperiodOfShortTermInvestment" xlink:to="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StateAndLocalJurisdictionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value; shares authorized &#8212; 5,000; no shares outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred collaboration expense</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred collaboration expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CollaborativeAgreementContractValue" xlink:label="bcrx_CollaborativeAgreementContractValue" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAgreementContractValue</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Contract Value</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaborative agreement contract value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementContractValue" xlink:to="bcrx_CollaborativeAgreementContractValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AveragematurityForPortfolioInvestments" xlink:label="bcrx_AveragematurityForPortfolioInvestments" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AveragematurityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AveragematurityForPortfolioInvestments</link:label>
    <link:label xlink:label="bcrx_AveragematurityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average Maturity for Portfolio Investments</link:label>
    <link:label xlink:label="bcrx_AveragematurityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average maturity for portfolio investments during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AveragematurityForPortfolioInvestments" xlink:to="bcrx_AveragematurityForPortfolioInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefits</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPaid-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestPaid</link:label>
    <link:label xlink:label="us-gaap_InterestPaid-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Paid</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredCostsCurrent</link:label>
    <link:label xlink:label="us-gaap_DeferredCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred collaboration expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reductions to prior period tax provisions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions to current period tax positions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions to prior period tax positions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Department of Health and Human Services [Member]</link:label>
    <link:label xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">United States department of health and human services.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConstructionInProgressMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AECOMAndIRLMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AECOM and IRL [Member]</link:label>
    <link:label xlink:label="bcrx_AECOMAndIRLMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AECOM and IRL</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AECOMAndIRLMember" xlink:to="bcrx_AECOMAndIRLMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_UABMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UAB [Member]</link:label>
    <link:label xlink:label="bcrx_UABMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UAB</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UABMember" xlink:to="bcrx_UABMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CollaborativeAgreementAdditionalContractValue" xlink:label="bcrx_CollaborativeAgreementAdditionalContractValue" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAgreementAdditionalContractValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAgreementAdditionalContractValue</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementAdditionalContractValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Additional Contract Value</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementAdditionalContractValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative agreement additional contract value during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementAdditionalContractValue" xlink:to="bcrx_CollaborativeAgreementAdditionalContractValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CollaborativeAgreementAdjustedContractValue" xlink:label="bcrx_CollaborativeAgreementAdjustedContractValue" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAgreementAdjustedContractValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAgreementAdjustedContractValue</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementAdjustedContractValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Adjusted Contract Value</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementAdjustedContractValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaborative agreement adjusted contract value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementAdjustedContractValue" xlink:to="bcrx_CollaborativeAgreementAdjustedContractValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts</link:label>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from awards for Research and Development Contracts</link:label>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents proceeds from awards for research and development contracts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeForwardExchangeRate1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeForwardExchangeRate1</link:label>
    <link:label xlink:label="us-gaap_DerivativeForwardExchangeRate1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Forward Exchange Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeForwardExchangeRate1" xlink:to="us-gaap_DerivativeForwardExchangeRate1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net inventories</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeGainOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeGainOnDerivative</link:label>
    <link:label xlink:label="us-gaap_DerivativeGainOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Gain on Derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainOnDerivative" xlink:to="us-gaap_DerivativeGainOnDerivative-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BuildingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeLossOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeLossOnDerivative</link:label>
    <link:label xlink:label="us-gaap_DerivativeLossOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Loss on Derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLossOnDerivative" xlink:to="us-gaap_DerivativeLossOnDerivative-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts</link:label>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected Receivable From Awards for Research and Development Contracts</link:label>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents expected receivable from awards for research and development contracts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromLicenseFeesReceived</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from License Fees Received</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_BaseContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Contract [Member]</link:label>
    <link:label xlink:label="bcrx_BaseContractMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The base contract of ASPR/BARDA to support BCX4430 drug manufacturing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BaseContractMember" xlink:to="bcrx_BaseContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TaxCreditCarryforwardAmount</link:label>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Development Options [Member]</link:label>
    <link:label xlink:label="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The additional development options that can be exercised by the Government.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AdditionalDevelopmentOptionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ASPRBARDAContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ASPRBARDA Contract [Member]</link:label>
    <link:label xlink:label="bcrx_ASPRBARDAContractMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The potential value of the ASPR/BARDA Contract.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ASPRBARDAContractMember" xlink:to="bcrx_ASPRBARDAContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignExchangeContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignExchangeContractMember" xlink:to="us-gaap_ForeignExchangeContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_GreenCrossCorporationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Green Cross Corporation [Member]</link:label>
    <link:label xlink:label="bcrx_GreenCrossCorporationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Green Cross Corporation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_GreenCrossCorporationMember" xlink:to="bcrx_GreenCrossCorporationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MilestonePaymentMinimum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Minimum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents milestone payment minimum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentMinimum" xlink:to="bcrx_MilestonePaymentMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_TransactionCosts</link:label>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction Costs</link:label>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents transaction costs associated with royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TransactionCosts" xlink:to="bcrx_TransactionCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_Interestreserve" xlink:label="bcrx_Interestreserve" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Interestreserve-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_Interestreserve</link:label>
    <link:label xlink:label="bcrx_Interestreserve-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Reserve</link:label>
    <link:label xlink:label="bcrx_Interestreserve-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents interest reserve established as part of the royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Interestreserve" xlink:to="bcrx_Interestreserve-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MilestonePaymentMaximum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Maximum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents milestone payment maximum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentMaximum" xlink:to="bcrx_MilestonePaymentMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RequiredForeignCurrencyHedgePerDollar</link:label>
    <link:label xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Required Foreign Currency Hedge Per Dollar</link:label>
    <link:label xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Company is required to maintain a foreign currency hedge per dollar under the agreements governing the PhaRMA Notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:to="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ReceivablesNetCurrent</link:label>
    <link:label xlink:label="us-gaap_ReceivablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyMonetizationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Monetization [Member]</link:label>
    <link:label xlink:label="bcrx_RoyaltyMonetizationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the royalty monetization transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationMember" xlink:to="bcrx_RoyaltyMonetizationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">National Institute of Allergy and Infectious Diseases [Member]</link:label>
    <link:label xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents National Institute of Allergy and Infectious Diseases.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwards</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables from collaborations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentContractReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GovernmentContractReceivable</link:label>
    <link:label xlink:label="us-gaap_GovernmentContractReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Contract Receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentContractReceivable" xlink:to="us-gaap_GovernmentContractReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency Hedge Agreement [Member]</link:label>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyHedgeAgreementMember" xlink:to="bcrx_CurrencyHedgeAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaximumAggregateOfferingPrice</link:label>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Aggregate Offering Price</link:label>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumAggregateOfferingPrice" xlink:to="bcrx_MaximumAggregateOfferingPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AnnualLicenseFeeMinimum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual License Fee Minimum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represent minimum annual license fee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualLicenseFeeMinimum" xlink:to="bcrx_AnnualLicenseFeeMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Decrease) increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AnnualLicenseFeeMaximum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual License Fee Maximum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual maximum license fee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualLicenseFeeMaximum" xlink:to="bcrx_AnnualLicenseFeeMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestPayableCurrentAndNoncurrent</link:label>
    <link:label xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided (used) in investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Shar-based Payment Award, Awards Unvested, Percentage</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of performance awards that remain unvested.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:to="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AdvanceNoticePeriodForTerminationOfAgreement</link:label>
    <link:label xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advance Notice Period for Termination of Agreement</link:label>
    <link:label xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents advance notice period for termination of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum</link:label>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Salary to Purchase Common Stock, Maximum</link:label>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of salary to purchase common stock maximum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased</link:label>
    <link:label xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCommonStockSharesBeginning</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Common Stock Shares, Beginning</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of common stock shares beginning.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCommonStockSharesBeginning" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shar-based Compensation Arrangement by Shar-based Payment Award, Maximum Number of Shares Per Employee, Amount</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:to="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement</link:label>
    <link:label xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, for Modification of License Agreement</link:label>
    <link:label xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents stock issued during period value for modification of license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:to="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PaymentsForModificationOfLicenseAgreement" xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PaymentsForModificationOfLicenseAgreement</link:label>
    <link:label xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for Modification of License Agreement</link:label>
    <link:label xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents payments for modifications of license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PaymentsForModificationOfLicenseAgreement" xlink:to="bcrx_PaymentsForModificationOfLicenseAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal statutory rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationOtherAdjustments</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PeriodOfAgreement</link:label>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of Agreement</link:label>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents period of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PeriodOfAgreement" xlink:to="bcrx_PeriodOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rate change</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfGoodsSold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of products sold</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_IncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Plan [Member]</link:label>
    <link:label xlink:label="bcrx_IncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_IncentivePlanMember" xlink:to="bcrx_IncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeStockPurchasePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xlink:label="bcrx_EmployeeStockPurchasePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan, (ESPP).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeStockPurchasePlanMember" xlink:to="bcrx_EmployeeStockPurchasePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyMonetizationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Monetization [Text Block]</link:label>
    <link:label xlink:label="bcrx_RoyaltyMonetizationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationTextBlock" xlink:to="bcrx_RoyaltyMonetizationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from common stock issued under stock-based compensation plans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_StockOptionsAndRestrictedStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options and Restricted Stock [Member]</link:label>
    <link:label xlink:label="bcrx_StockOptionsAndRestrictedStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents stock options and restricted stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_StockOptionsAndRestrictedStockMember" xlink:to="bcrx_StockOptionsAndRestrictedStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable Number (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Weighted Average Remaining Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of common stock, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Number (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NonEmployeeDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-employee Directors [Member]</link:label>
    <link:label xlink:label="bcrx_NonEmployeeDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents non-employee directors of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NonEmployeeDirectorsMember" xlink:to="bcrx_NonEmployeeDirectorsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CostsAndExpenses</link:label>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upper Exercise Price Range (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards cancelled (in shares)</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award options forfeitures in period awards available.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on available for sale investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lower Exercise Price Range (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="us-gaap_CreationDateAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CreationDateAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Report Date [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_CreationDateAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefaultFinancialStatementsDateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Statement Filing Date [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefaultFinancialStatementsDateMember" xlink:to="us-gaap_DefaultFinancialStatementsDateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredRevenue</link:label>
    <link:label xlink:label="us-gaap_DeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturing after two years</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents debt maturities after two years.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Dividend Yield</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CurrencyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrencyAxis" xlink:to="us-gaap_CurrencyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-Free Interest Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebt</link:label>
    <link:label xlink:label="us-gaap_LongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet</link:label>
    <link:label xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition Royalty And Milestone Revenue Recognized, Net</link:label>
    <link:label xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents revenue recognition royalty and milestone revenue recognized, net.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PrivatePlacementOfSeniorSecuredNotes</link:label>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement of Senior Secured Notes</link:label>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents private placement of senior secured notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCredit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior credit facility</link:label>
    <link:label xlink:label="us-gaap_LineOfCredit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_LongtermInvestmentMaturityMinimum</link:label>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Investment Maturity, Minimum</link:label>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents long term investment maturity minimum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LongtermInvestmentMaturityMinimum" xlink:to="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax benefit at federal statutory rate (35%)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and local income taxes net of federal tax benefit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</link:label>
    <link:label xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaximumAmountOfCollateralRequiredToPost</link:label>
    <link:label xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Amount of Collateral Required to Post</link:label>
    <link:label xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maximum amount of collateral required to post.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:to="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock awards cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_JPRRoyaltySubLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JPR Royalty Sub LLC [Member]</link:label>
    <link:label xlink:label="bcrx_JPRRoyaltySubLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents JPR Royalty Sub LLC.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_JPRRoyaltySubLLCMember" xlink:to="bcrx_JPRRoyaltySubLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock awards granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Receivable [Member]</link:label>
    <link:label xlink:label="bcrx_RoyaltyReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents royalty receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyReceivableMember" xlink:to="bcrx_RoyaltyReceivableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PhaRMANotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PhaRMA Notes Member]</link:label>
    <link:label xlink:label="bcrx_PhaRMANotesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents PhaRMA notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PhaRMANotesMember" xlink:to="bcrx_PhaRMANotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollateralForCreditMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collateral for Credit [Member]</link:label>
    <link:label xlink:label="bcrx_CollateralForCreditMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted cash and cash equivalents required to maintain as collateral for a letter of credit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollateralForCreditMember" xlink:to="bcrx_CollateralForCreditMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RAPIVABMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RAPIVAB [Member]</link:label>
    <link:label xlink:label="bcrx_RAPIVABMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents RAPIVAB product.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RAPIVABMember" xlink:to="bcrx_RAPIVABMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComputerEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OfficeEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SoftwareDevelopmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software Development [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaturityPeriodOfHighQualityMarketablesecurities</link:label>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Period of High Quality Marketable Securities</link:label>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maturity period of high quality marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock option awards granted (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock option awards forfeited (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance December 31, 2016 (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CreditFacilityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock option awards vested (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Interest</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents available for sale securities accrued interest.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:to="bcrx_AvailableForSaleSecuritiesAccruedInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CreditFacilityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Non-vested stock option awards (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance December 31, 2016 (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Stock option awards vested (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnbilledRevenuesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Revenues [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledRevenuesMember" xlink:to="us-gaap_UnbilledRevenuesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards cancelled (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BilledRevenuesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billed Revenues [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BilledRevenuesMember" xlink:to="us-gaap_BilledRevenuesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billing Status, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesBillingStatusDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables Billing Status [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_ReceivablesBillingStatusDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards granted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards exercised (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MajorCustomersAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_MajorCustomersAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NameOfMajorCustomerDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="us-gaap_NameOfMajorCustomerDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities Fair Value [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of available for sale securities debt maturities fair value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:label="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs Reclassifed from Other Current Assets [Member]</link:label>
    <link:label xlink:label="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt issuance costs reclassified from other current assets to conform to the 2016 presentation as per the newly adopted Accounting Standards Update.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:to="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturing after one year through two years</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents available for sale securities debt maturities after one through two years fair value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options Outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_December312015Member" xlink:label="bcrx_December312015Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_December312015Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 31, 2015 [Member]</link:label>
    <link:label xlink:label="bcrx_December312015Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period reclassified.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_December312015Member" xlink:to="bcrx_December312015Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Receivables from Collaborations [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure representing receivables from collaborations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseArrangementTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="us-gaap_LeaseArrangementTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShionogiAndCoLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shionogi and Co. Ltd [Member]</link:label>
    <link:label xlink:label="bcrx_ShionogiAndCoLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shionogi &amp; Co. Ltd.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShionogiAndCoLtdMember" xlink:to="bcrx_ShionogiAndCoLtdMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CSLLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CSL Limited [Member</link:label>
    <link:label xlink:label="bcrx_CSLLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents CSL Limited which is a company organized under the laws of Australia.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CSLLimitedMember" xlink:to="bcrx_CSLLimitedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseArrangementTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Awards Available (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Awards Available (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesRentExpenseNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasesRentExpenseNet</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasesRentExpenseNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CorporateDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from Collaborations [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of schedule of revenues from collaborations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:to="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan amendment (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues</link:label>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and other research and development revenues</link:label>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaborative and other research and development.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromLinesOfCredit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from senior credit facility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardDateAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardDateDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per common share (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards granted (in shares)</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents share based compensation arrangement by share based payment award options grants in period awards available.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EarningsPerShareDiluted</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareDiluted-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted net (loss) income per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EarningsPerShareBasic</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic net (loss) income per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of Company [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The description of company policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents accrued expenses policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccruedExpensesPolicyTextBlock" xlink:to="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense and Deferred Financing Costs [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents interest expense and deferred financing costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency Hedge Agreement [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents currency hedge agreement policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration of Market Risk [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents concentration of market risk policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInRestrictedCash</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in restricted cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Principles, Early Adoption [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Hedge, Investing Activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeContractTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeInstrumentRiskAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRentCreditNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred collaboration revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentTypeCategorizationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MidCapFinancialServicesLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MidCap Financial Services, LLC [Member]</link:label>
    <link:label xlink:label="bcrx_MidCapFinancialServicesLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents MidCap Financial Services, LLC entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MidCapFinancialServicesLLCMember" xlink:to="bcrx_MidCapFinancialServicesLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DebtInstrumentFinalPaymentFeePercentage" xlink:label="bcrx_DebtInstrumentFinalPaymentFeePercentage" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtInstrumentFinalPaymentFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DebtInstrumentFinalPaymentFeePercentage</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentFinalPaymentFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Final Payment Fee, Percentage</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentFinalPaymentFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage fee of principal amount of debt at which final payment has been made.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtInstrumentFinalPaymentFeePercentage" xlink:to="bcrx_DebtInstrumentFinalPaymentFeePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SeniorCreditFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Credit Facility [Member]</link:label>
    <link:label xlink:label="bcrx_SeniorCreditFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents senior credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SeniorCreditFacilityMember" xlink:to="bcrx_SeniorCreditFacilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">(Loss) gain on foreign currency derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AccruedDevelopmentCosts" xlink:label="bcrx_AccruedDevelopmentCosts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AccruedDevelopmentCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AccruedDevelopmentCosts</link:label>
    <link:label xlink:label="bcrx_AccruedDevelopmentCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development costs</link:label>
    <link:label xlink:label="bcrx_AccruedDevelopmentCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents accrued development costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccruedDevelopmentCosts" xlink:to="bcrx_AccruedDevelopmentCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement [Member]</link:label>
    <link:label xlink:label="bcrx_AgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a License Agreement (the "Agreement") granting rights to develop, manufacture and commercialize RAPIVAB&#174;.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AgreementMember" xlink:to="bcrx_AgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AccruedInventoryExpense" xlink:label="bcrx_AccruedInventoryExpense" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AccruedInventoryExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AccruedInventoryExpense</link:label>
    <link:label xlink:label="bcrx_AccruedInventoryExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label xlink:label="bcrx_AccruedInventoryExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of accrued inventory expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccruedInventoryExpense" xlink:to="bcrx_AccruedInventoryExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Sale of Inventory to be Recognized When the Inventory Transfer Is Complete [Member]</link:label>
    <link:label xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred revenue from the sale of inventory to be recognized when the inventory transfer is complete.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CSLMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CSL [Member]</link:label>
    <link:label xlink:label="bcrx_CSLMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents CSL Limited (&#8220;CSL&#8221;) and its affiliates.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CSLMember" xlink:to="bcrx_CSLMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MundipharmaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mundipharma [Member]</link:label>
    <link:label xlink:label="bcrx_MundipharmaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Mundipharma.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MundipharmaMember" xlink:to="bcrx_MundipharmaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Support Revenue for Canadian and EU Marketing Approvals, Portion Recognized Ratably Over Expected Period of Involvement [Member]</link:label>
    <link:label xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred revenue from upfront payment allocated to the regulatory support for the Canadian and EU marketing approvals, portion to be recognized ratably over the expected period of involvement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCarryingAmountInExcessOfFairValue1</link:label>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Carrying Amount in Excess of Fair Value</link:label>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of carrying amount in excess of fair value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LeasedEquipmentMember" xlink:label="bcrx_LeasedEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LeasedEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leased Equipment [Member]</link:label>
    <link:label xlink:label="bcrx_LeasedEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to leased equipment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LeasedEquipmentMember" xlink:to="bcrx_LeasedEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LaboratoryEquipmentMember" xlink:label="bcrx_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label xlink:label="bcrx_LaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to laboratory equipment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LaboratoryEquipmentMember" xlink:to="bcrx_LaboratoryEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentTerm</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales and maturities of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest Upon Successful Completion of Specific Development Milestones [Member]</link:label>
    <link:label xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vesting upon successful completion of specific development milestones.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_December2014Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2014 [Member]</link:label>
    <link:label xlink:label="bcrx_December2014Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents award date of December 2014.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_December2014Member" xlink:to="bcrx_December2014Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_August2013Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">August 2013 [Member]</link:label>
    <link:label xlink:label="bcrx_August2013Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents award date of August 2013.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_August2013Member" xlink:to="bcrx_August2013Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest 25% Each Year Until Fully Vested [Member]</link:label>
    <link:label xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vest 25% each year until fully vested.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest 50% Each Year Until Fully Vested [Member]</link:label>
    <link:label xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vest 50% each year until fully vested.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NondesignatedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NondesignatedMember" xlink:to="us-gaap_NondesignatedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HedgingDesignationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HedgingDesignationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_HedgingDesignationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NotesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-recourse notes payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateStatedPercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TaxesPayableCurrent</link:label>
    <link:label xlink:label="us-gaap_TaxesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Duties and taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ContingentUponEuMarketingApprovalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent upon EU Marketing Approval [Member]</link:label>
    <link:label xlink:label="bcrx_ContingentUponEuMarketingApprovalMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information about the contingent proceed which is upon EU marketing approval.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ContingentUponEuMarketingApprovalMember" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeRelatedLiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation and benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:label="us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleOfFurnitureAndFixtures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:to="us-gaap_ProceedsFromSaleOfFurnitureAndFixtures-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherAccruedLiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableRateAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RoyaltyExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableRateDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireProductiveAssets</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisition of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedProfessionalFeesCurrent</link:label>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ExercisePriceRange01Member" xlink:label="bcrx_ExercisePriceRange01Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExercisePriceRange01Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 01 [Member]</link:label>
    <link:label xlink:label="bcrx_ExercisePriceRange01Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the first exercise range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExercisePriceRange01Member" xlink:to="bcrx_ExercisePriceRange01Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ExercisePriceRange03Member" xlink:label="bcrx_ExercisePriceRange03Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExercisePriceRange03Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 03 [Member]</link:label>
    <link:label xlink:label="bcrx_ExercisePriceRange03Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the third exercise range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExercisePriceRange03Member" xlink:to="bcrx_ExercisePriceRange03Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ExercisePriceRange02Member" xlink:label="bcrx_ExercisePriceRange02Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExercisePriceRange02Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 02 [Member]</link:label>
    <link:label xlink:label="bcrx_ExercisePriceRange02Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the second exercise range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExercisePriceRange02Member" xlink:to="bcrx_ExercisePriceRange02Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ExercisePriceRange05Member" xlink:label="bcrx_ExercisePriceRange05Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExercisePriceRange05Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 05 [Member]</link:label>
    <link:label xlink:label="bcrx_ExercisePriceRange05Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the fifth exercise range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExercisePriceRange05Member" xlink:to="bcrx_ExercisePriceRange05Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ExercisePriceRange04Member" xlink:label="bcrx_ExercisePriceRange04Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExercisePriceRange04Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 04 [Member]</link:label>
    <link:label xlink:label="bcrx_ExercisePriceRange04Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the fourth exercise range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExercisePriceRange04Member" xlink:to="bcrx_ExercisePriceRange04Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ExercisePriceRange06Member" xlink:label="bcrx_ExercisePriceRange06Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExercisePriceRange06Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 06 [Member]</link:label>
    <link:label xlink:label="bcrx_ExercisePriceRange06Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the sixth exercise range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExercisePriceRange06Member" xlink:to="bcrx_ExercisePriceRange06Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:label="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:type="locator"/>
    <link:label xlink:label="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiration of attribute carryforwards</link:label>
    <link:label xlink:label="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income tax reconciliation income tax expense benefit expiration of carryforwards.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:to="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_UpfrontPaymentMember" xlink:label="bcrx_UpfrontPaymentMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_UpfrontPaymentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment [Member]</link:label>
    <link:label xlink:label="bcrx_UpfrontPaymentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining upfront payment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UpfrontPaymentMember" xlink:to="bcrx_UpfrontPaymentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_UpfrontPaymentsReceivableAmount" xlink:label="bcrx_UpfrontPaymentsReceivableAmount" xlink:type="locator"/>
    <link:label xlink:label="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_UpfrontPaymentsReceivableAmount</link:label>
    <link:label xlink:label="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront Payments Receivable Amount</link:label>
    <link:label xlink:label="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents upfront payments receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UpfrontPaymentsReceivableAmount" xlink:to="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PotentialMilestonePaymentsReceivable" xlink:label="bcrx_PotentialMilestonePaymentsReceivable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PotentialMilestonePaymentsReceivable</link:label>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments Receivable</link:label>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents potential milestone payments receivable based on possibility of future event payments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PotentialMilestonePaymentsReceivable" xlink:to="bcrx_PotentialMilestonePaymentsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_Shortfall2013Member" xlink:label="bcrx_Shortfall2013Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Shortfall2013Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shortfall 2013 [Member]</link:label>
    <link:label xlink:label="bcrx_Shortfall2013Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the 2013 interest shortfall.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Shortfall2013Member" xlink:to="bcrx_Shortfall2013Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_GoingConcernPolicyPolicyTextBlock" xlink:label="bcrx_GoingConcernPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_GoingConcernPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Going Concern, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_GoingConcernPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for the entity's ability to continue as a going concern.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_GoingConcernPolicyPolicyTextBlock" xlink:to="bcrx_GoingConcernPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</link:label>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment, Office Equipment and Software [Member]</link:label>
    <link:label xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to laboratory equipment, office equipment and software.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_BirminghamResearchFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Birmingham Research Facility [Member]</link:label>
    <link:label xlink:label="bcrx_BirminghamResearchFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the Birmingham Research Facility.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BirminghamResearchFacilityMember" xlink:to="bcrx_BirminghamResearchFacilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdvertisingExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdvertisingExpense</link:label>
    <link:label xlink:label="us-gaap_AdvertisingExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PerformanceSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnDispositionOfAssets1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GainLossOnDispositionOfAssets1</link:label>
    <link:label xlink:label="us-gaap_GainLossOnDispositionOfAssets1-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NumberOfMajorCustomers" xlink:label="bcrx_NumberOfMajorCustomers" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NumberOfMajorCustomers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_NumberOfMajorCustomers</link:label>
    <link:label xlink:label="bcrx_NumberOfMajorCustomers-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Major Customers</link:label>
    <link:label xlink:label="bcrx_NumberOfMajorCustomers-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NumberOfMajorCustomers" xlink:to="bcrx_NumberOfMajorCustomers-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, First Vesting Period After Grant Date</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award first vesting period after grant date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NotesPayableFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NotesPayableFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_NotesPayableFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease financing obligation</link:label>
    <link:label xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Financing Obligation, Net of Current</link:label>
    <link:label xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Financing obligation as of the balance sheet date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ThreeCustomersMember" xlink:label="bcrx_ThreeCustomersMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ThreeCustomersMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Three Customers [Member]</link:label>
    <link:label xlink:label="bcrx_ThreeCustomersMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the three specialty distributors as customers.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ThreeCustomersMember" xlink:to="bcrx_ThreeCustomersMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LongTermLiabilitiesMember" xlink:label="bcrx_LongTermLiabilitiesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LongTermLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Liabilities [Member]</link:label>
    <link:label xlink:label="bcrx_LongTermLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents long term liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LongTermLiabilitiesMember" xlink:to="bcrx_LongTermLiabilitiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PriorPeriodReclassificationAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PriorPeriodReclassificationAdjustment</link:label>
    <link:label xlink:label="us-gaap_PriorPeriodReclassificationAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Period Reclassification Adjustment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustment" xlink:to="us-gaap_PriorPeriodReclassificationAdjustment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>bcrx-20161231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 12:31AM UTC 2017-02-25--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-12-recent-accounting-pronouncements" xlink:href="bcrx-20161231.xsd#statement-note-12-recent-accounting-pronouncements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-12-recent-accounting-pronouncements" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-11-quarterly-financial-information-unaudited" xlink:href="bcrx-20161231.xsd#statement-note-11-quarterly-financial-information-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-11-quarterly-financial-information-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-document-and-entity-information" xlink:href="bcrx-20161231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DocumentAndEntityInformation" xlink:label="bcrx_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_DocumentAndEntityInformation" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="bcrx-20161231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-stockholders-equity-deficit-parentheticals" xlink:href="bcrx-20161231.xsd#statement-consolidated-statements-of-stockholders-equity-deficit-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-stockholders-equity-deficit-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:href="bcrx-20161231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:label="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_December312015Member" xlink:label="bcrx_December312015Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ThreeCustomersMember" xlink:label="bcrx_ThreeCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="us-gaap_CreationDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreationDateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreationDateAxis" xlink:to="bcrx_December312015Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueProductLineMember" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MajorCustomersAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="bcrx_ThreeCustomersMember" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment" xlink:href="bcrx-20161231.xsd#statement-note-2-property-and-equipment" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-3-royalty-monetization" xlink:href="bcrx-20161231.xsd#statement-note-3-royalty-monetization" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-3-royalty-monetization" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_Shortfall2013Member" xlink:label="bcrx_Shortfall2013Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_JPY" xlink:label="currency_JPY" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="bcrx_Shortfall2013Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="currency_JPY" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bcrx_RoyaltyMonetizationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility" xlink:href="bcrx-20161231.xsd#statement-note-4-senior-credit-facility" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies" xlink:href="bcrx-20161231.xsd#statement-note-5-lease-obligations-and-other-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LongTermLiabilitiesMember" xlink:label="bcrx_LongTermLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="bcrx_LongTermLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-6-stockholders-equity" xlink:href="bcrx-20161231.xsd#statement-note-6-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-6-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation" xlink:href="bcrx-20161231.xsd#statement-note-7-sharebased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes" xlink:href="bcrx-20161231.xsd#statement-note-8-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-9-employee-401-k-plan" xlink:href="bcrx-20161231.xsd#statement-note-9-employee-401-k-plan" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-9-employee-401-k-plan" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-10-collaborative-and-other-research-and-development-contracts" xlink:href="bcrx-20161231.xsd#statement-note-10-collaborative-and-other-research-and-development-contracts" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-10-collaborative-and-other-research-and-development-contracts" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_UpfrontPaymentMember" xlink:label="bcrx_UpfrontPaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_UpfrontPaymentMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-significant-accounting-policies-policies" xlink:href="bcrx-20161231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_GoingConcernPolicyPolicyTextBlock" xlink:label="bcrx_GoingConcernPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-significant-accounting-policies-policies" xlink:label="bcrx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="us-gaap_LeasePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LeasePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_GoingConcernPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:href="bcrx-20161231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment-tables" xlink:href="bcrx-20161231.xsd#statement-note-2-property-and-equipment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-2-property-and-equipment-tables" xlink:label="bcrx_statement-statement-note-2-property-and-equipment-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-2-property-and-equipment-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility-tables" xlink:href="bcrx-20161231.xsd#statement-note-4-senior-credit-facility-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-4-senior-credit-facility-tables" xlink:label="bcrx_statement-statement-note-4-senior-credit-facility-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-4-senior-credit-facility-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies-tables" xlink:href="bcrx-20161231.xsd#statement-note-5-lease-obligations-and-other-contingencies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-5-lease-obligations-and-other-contingencies-tables" xlink:label="bcrx_statement-statement-note-5-lease-obligations-and-other-contingencies-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-5-lease-obligations-and-other-contingencies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-tables" xlink:href="bcrx-20161231.xsd#statement-note-7-sharebased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-7-sharebased-compensation-tables" xlink:label="bcrx_statement-statement-note-7-sharebased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-7-sharebased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-tables" xlink:href="bcrx-20161231.xsd#statement-note-8-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-8-income-taxes-tables" xlink:label="bcrx_statement-statement-note-8-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-8-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-11-quarterly-financial-information-unaudited-tables" xlink:href="bcrx-20161231.xsd#statement-note-11-quarterly-financial-information-unaudited-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-11-quarterly-financial-information-unaudited-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-11-quarterly-financial-information-unaudited-tables" xlink:label="bcrx_statement-statement-note-11-quarterly-financial-information-unaudited-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-11-quarterly-financial-information-unaudited-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:href="bcrx-20161231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AveragematurityForPortfolioInvestments" xlink:label="bcrx_AveragematurityForPortfolioInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:label="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_December312015Member" xlink:label="bcrx_December312015Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NumberOfMajorCustomers" xlink:label="bcrx_NumberOfMajorCustomers-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ThreeCustomersMember" xlink:label="bcrx_ThreeCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="us-gaap_CreationDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreationDateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreationDateAxis" xlink:to="bcrx_December312015Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueProductLineMember" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MajorCustomersAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="bcrx_ThreeCustomersMember" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCredit-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PriorPeriodReclassificationAdjustment-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityperiodOfShortTermInvestment-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LongtermInvestmentMaturityMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenueAdditions-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvertisingExpense-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NumberOfMajorCustomers-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityForPortfolioInvestments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment-details-textual" xlink:href="bcrx-20161231.xsd#statement-note-2-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-3-royalty-monetization-details-textual" xlink:href="bcrx-20161231.xsd#statement-note-3-royalty-monetization-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-3-royalty-monetization-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_Interestreserve" xlink:label="bcrx_Interestreserve-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_Shortfall2013Member" xlink:label="bcrx_Shortfall2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_JPY" xlink:label="currency_JPY" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="bcrx_Shortfall2013Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="currency_JPY" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_TransactionCosts-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_Interestreserve-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPaid-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeForwardExchangeRate1-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RequiredForeignCurrencyHedgePerDollar-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAmountOfCollateralRequiredToPost-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility-details-textual" xlink:href="bcrx-20161231.xsd#statement-note-4-senior-credit-facility-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DebtInstrumentFinalPaymentFeePercentage" xlink:label="bcrx_DebtInstrumentFinalPaymentFeePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DebtInstrumentMinimumLibor" xlink:label="bcrx_DebtInstrumentMinimumLibor-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCredit-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentMinimumLibor-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentFinalPaymentFeePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies-details-textual" xlink:href="bcrx-20161231.xsd#statement-note-5-lease-obligations-and-other-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LongTermLiabilitiesMember" xlink:label="bcrx_LongTermLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="bcrx_LongTermLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-6-stockholders-equity-details-textual" xlink:href="bcrx-20161231.xsd#statement-note-6-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-6-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAggregateOfferingPrice-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-details-textual" xlink:href="bcrx-20161231.xsd#statement-note-7-sharebased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:label="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-details-textual" xlink:href="bcrx-20161231.xsd#statement-note-8-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:href="bcrx-20161231.xsd#statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:label="bcrx_statement-statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-9-employee-401-k-plan-details-textual" xlink:href="bcrx-20161231.xsd#statement-note-9-employee-401-k-plan-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-9-employee-401-k-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-10-collaborative-and-other-research-and-development-contracts-details-textual" xlink:href="bcrx-20161231.xsd#statement-note-10-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-10-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CollaborativeAgreementAdditionalContractValue" xlink:label="bcrx_CollaborativeAgreementAdditionalContractValue-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CollaborativeAgreementAdjustedContractValue" xlink:label="bcrx_CollaborativeAgreementAdjustedContractValue-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CollaborativeAgreementContractValue" xlink:label="bcrx_CollaborativeAgreementContractValue-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PaymentsForModificationOfLicenseAgreement" xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_PotentialMilestonePaymentsReceivable" xlink:label="bcrx_PotentialMilestonePaymentsReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_UpfrontPaymentMember" xlink:label="bcrx_UpfrontPaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_UpfrontPaymentsReceivableAmount" xlink:label="bcrx_UpfrontPaymentsReceivableAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_UpfrontPaymentMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementContractValue-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementAdditionalContractValue-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementAdjustedContractValue-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentContractReceivable-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_UpfrontPaymentsReceivableAmount-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenue-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PotentialMilestonePaymentsReceivable-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PaymentsForModificationOfLicenseAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PeriodOfAgreement-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies-minimum-payments-under-operating-lease-obligations-details" xlink:href="bcrx-20161231.xsd#statement-note-5-lease-obligations-and-other-contingencies-minimum-payments-under-operating-lease-obligations-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies-minimum-payments-under-operating-lease-obligations-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-5-lease-obligations-and-other-contingencies-minimum-payments-under-operating-lease-obligations-details" xlink:label="bcrx_statement-statement-note-5-lease-obligations-and-other-contingencies-minimum-payments-under-operating-lease-obligations-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-5-lease-obligations-and-other-contingencies-minimum-payments-under-operating-lease-obligations-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:href="bcrx-20161231.xsd#statement-note-8-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-8-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:label="bcrx_statement-statement-note-8-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities-n9" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-8-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-n7" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains-n7" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities-n9" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n7" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-stockholders-equity-deficit" xlink:href="bcrx-20161231.xsd#statement-consolidated-statements-of-stockholders-equity-deficit" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-stockholders-equity-deficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-scheduled-maturity-for-the-companys-investments-details" xlink:href="bcrx-20161231.xsd#statement-note-1-significant-accounting-policies-and-concentration-of-risk-scheduled-maturity-for-the-companys-investments-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-scheduled-maturity-for-the-companys-investments-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-scheduled-maturity-for-the-companys-investments-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-scheduled-maturity-for-the-companys-investments-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-scheduled-maturity-for-the-companys-investments-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-revenues-details" xlink:href="bcrx-20161231.xsd#statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-revenues-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-revenues-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-revenues-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-revenues-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-revenues-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_SeqirusUKLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyRevenue-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment-property-and-equipment-details" xlink:href="bcrx-20161231.xsd#statement-note-2-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LaboratoryEquipmentMember" xlink:label="bcrx_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LeasedEquipmentMember" xlink:label="bcrx_LeasedEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-2-property-and-equipment-property-and-equipment-details" xlink:label="bcrx_statement-statement-note-2-property-and-equipment-property-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-2-property-and-equipment-property-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_SoftwareDevelopmentMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="bcrx_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="bcrx_LeasedEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ConstructionInProgressMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n7" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:href="bcrx-20161231.xsd#statement-note-4-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-4-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:label="bcrx_statement-statement-note-4-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-4-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-stock-incentive-plan-activities-details" xlink:href="bcrx-20161231.xsd#statement-note-7-sharebased-compensation-stock-incentive-plan-activities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-stock-incentive-plan-activities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-n8" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-7-sharebased-compensation-stock-incentive-plan-activities-details" xlink:label="bcrx_statement-statement-note-7-sharebased-compensation-stock-incentive-plan-activities-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-7-sharebased-compensation-stock-incentive-plan-activities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-5" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:href="bcrx-20161231.xsd#statement-note-7-sharebased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-7-sharebased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:label="bcrx_statement-statement-note-7-sharebased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-7-sharebased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:href="bcrx-20161231.xsd#statement-note-7-sharebased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-7-sharebased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:label="bcrx_statement-statement-note-7-sharebased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-7-sharebased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-n7" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n7" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-5" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:href="bcrx-20161231.xsd#statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:label="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:label="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:label="bcrx_statement-statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-n7" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:href="bcrx-20161231.xsd#statement-note-8-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-8-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:label="bcrx_statement-statement-note-8-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-8-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions-n7" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-consolidated-balance-sheets-" xlink:href="bcrx-20161231.xsd#statement-consolidated-balance-sheets-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-consolidated-balance-sheets-" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCostsCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="bcrx_DeferredCollaborationExpenseAssets" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LineOfCredit" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:href="bcrx-20161231.xsd#statement-consolidated-statements-of-comprehensive-loss" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueNet-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestAndOtherIncome" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestExpense-n7" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-cash-flows" xlink:href="bcrx-20161231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-n8" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:label="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:label="us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1-n7" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets-n7" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue-1" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets-n7" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash-n7" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-n7" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:href="bcrx-20161231.xsd#statement-note-7-sharebased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ExercisePriceRange01Member" xlink:label="bcrx_ExercisePriceRange01Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ExercisePriceRange02Member" xlink:label="bcrx_ExercisePriceRange02Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ExercisePriceRange03Member" xlink:label="bcrx_ExercisePriceRange03Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ExercisePriceRange04Member" xlink:label="bcrx_ExercisePriceRange04Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ExercisePriceRange05Member" xlink:label="bcrx_ExercisePriceRange05Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ExercisePriceRange06Member" xlink:label="bcrx_ExercisePriceRange06Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-7-sharebased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:label="bcrx_statement-statement-note-7-sharebased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-7-sharebased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="bcrx_ExercisePriceRange01Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="bcrx_ExercisePriceRange02Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="bcrx_ExercisePriceRange03Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="bcrx_ExercisePriceRange04Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="bcrx_ExercisePriceRange05Member" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="bcrx_ExercisePriceRange06Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:href="bcrx-20161231.xsd#statement-note-1-significant-accounting-policies-and-concentration-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n7" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-receivables-details" xlink:href="bcrx-20161231.xsd#statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-receivables-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-receivables-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-receivables-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-receivables-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-receivables-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_BilledRevenuesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_UnbilledRevenuesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_SeqirusUKLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesNetCurrent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-inventory-details" xlink:href="bcrx-20161231.xsd#statement-note-1-significant-accounting-policies-and-concentration-of-risk-inventory-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-inventory-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-inventory-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-inventory-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-inventory-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-accrued-expenses-details" xlink:href="bcrx-20161231.xsd#statement-note-1-significant-accounting-policies-and-concentration-of-risk-accrued-expenses-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AccruedDevelopmentCosts" xlink:label="bcrx_AccruedDevelopmentCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_AccruedInventoryExpense" xlink:label="bcrx_AccruedInventoryExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-accrued-expenses-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-accrued-expenses-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentration-of-risk-accrued-expenses-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AccruedDevelopmentCosts-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AccruedInventoryExpense-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxesPayableCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-7-stockbased-compensation-stockbased-compensation-allocation-details" xlink:href="bcrx-20161231.xsd#statement-note-7-stockbased-compensation-stockbased-compensation-allocation-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-7-stockbased-compensation-stockbased-compensation-allocation-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-7-stockbased-compensation-stockbased-compensation-allocation-details" xlink:label="bcrx_statement-statement-note-7-stockbased-compensation-stockbased-compensation-allocation-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-7-stockbased-compensation-stockbased-compensation-allocation-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20161231/role/statement-note-11-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:href="bcrx-20161231.xsd#statement-note-11-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20161231/role/statement-note-11-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20161231.xsd#bcrx_statement-statement-note-11-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:label="bcrx_statement-statement-note-11-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-11-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueNet-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted-2" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>graph.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graph.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_X0RC17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  $D^    G
M$  23X   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,3<Z,#(Z
M,C @,30Z,C@Z-30      Z !  ,    !__\  * "  0    !   #4J #  0
M   !   !7P         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   MM
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 "_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ 0@"@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MJI:_9_IO?^CQU4O #SXOP38['\F#[Z<MVUK7MQ>"65/W6_R0\,_1T?RO\/\
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MVL_X/^=2;UICF.<W#S):QSPUU#FDP6-8QN_:WU+?4]C/^,];TMB2F]M?^_\
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MI^JDE\JI)*?JI)?*J22G_]G_[1%&4&AO=&]S:&]P(#,N,  X0DE-!"4
M !                      .$))30/M       0 '@    !  $ >     $
M 3A"24T$)@      #@             _@   .$))300-       $    'CA"
M24T$&0      !    !XX0DE- _,       D           $ .$))300*
M   !   X0DE-)Q        H  0         ".$))30/U      !( "]F9@ !
M &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M   ! #4    ! "T    &       !.$))30/X      !P  #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M      0     .$))300:      ,_    !@             !7P   U(    %
M &< <@!A '  :     $                          0             #
M4@   5\                      0                         0
M 0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   5\     4F=H=&QO;F<   -2    !G-L:6-E<U9L3',    !3V)J8P
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M;VYG   #4@    -U<FQ415A4     0       &YU;&Q415A4     0
M $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E
M>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L
M:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T
M06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G
M0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M"71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG          QB
M;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"
M24T$*       #     $_\        #A"24T$$0       0$ .$))3004
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M_]D .$))300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0
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M(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_^X (4%D;V)E &1
M     0, $ ," P8               #_VP"$  $! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,# P,#
M P,! 0$! 0$! 0$! 0(" 0(" P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# __" !$( 5\#4@,!$0 "$0$#$0'_Q $S
M  $   <! 0$              0(#!@<("04$"@$!  $% 0$
M  $" P0%!@<($   !00 !0($! 8" 04!   ! @,&!P $!0@1$A<8"1,6,$!0
M8! A,10@(A4W&0IP02.0,D(D*"<1   & 0(# @8-!@D)!@,$"P$" P0%!@<
M$2$2"#$302*5U98W46%Q,A34-M9'E]<X"8&1D],5%A P0%"Q([1V%V"AP='A
M0E*2,_!RTB0G"B F&&*"HD,E<#14E*0UI;8H&1(  0,"! (%! H," @,!@,
M 1$" P $(3$2!4%187$B$P:!D:$R4&#PL<'1X2,4!Q! 0E)B<I+2,],5-C#Q
M<Y,TU#46('""LL)CHR20HD-3@\-49'24)3?B\D2$I+2%)A?_V@ , P$! A$#
M$0   /W\
M   HE,D(E<J@                          EHF0JUP
M       .?!Q2+/,5':X[!& 2XB                         !@CH-/ZN)
M8S%JM^                +G+_     -=30\V.,.FVQLP80,W$0
M              21%"W&!-UH^$/OWDN=]+D;#<UTEQXU_?;SGM\AZW*DKCZL
MF[.)                      81,VD0                      2IEHM_
M'<IY:^H^<7;C9_23S7NJUJJ@6?G6-#N_Y"Q+VLA>93U&WWPXGJ?9QLFN@KC,
M3U                    ,(F;2(                      /EF=9=OSO/
M[T+ANHWF?H^7,'9S@ $EM\%$XKW6DT=['F;:R\:I;N[%Z/HMP^*W_K7JZH
M                 ,(F;2(                    !!$EAYM<\J/5_,\L:
MK:]#/.NXK7:9ZI  $+:G<IGMS+>F2FU47===MSNE'>Z:-K&C#;7B^KV<T&YF
MR,?[+5V"9ZYBD            "4E)03DYA$S:1                    !)
M2IT6]2.MT6E/:\3U(\M]&R1JMG/E412     !3I4;-N-4_)51IUV.BUQZ/G9
MXC2WNN.[&^*>I[1Z'H:DIHK            &AAC<YX'OG2@W[-.S,0
M              !Y=O'YC^I\1EK29.]_%=O/,          "E$Z+]ER&O/1:
M3:;1[_<KA^EGBZJ      787\     :PG%LP 9D.GYT<,)F;"8
M        $(F2*J$-->QY34KJ>9ZM^6^@71BY]:[$0          04J:_FLL$
M[?2\_?0.0W)YGH]LN/Z>>],\4QJ@    2DP    !*0)2(*AA$S:1
M          ()@BT*L7D_ZEYQMAS/1[M\7V%2_3-             "C3'S6*M
M)^MY#6GL.<Z0>;>@9:P]G--,8)            #")FTB
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M                    "5,*JJ%FQI-Z-Q6 KUCISYOW%Q6[\]47?-60)
M  ?,2D"!4/I,(F;2(              !J'T7/ZM=AR_5KROT6M-49D
M                "2F+=OV>6WH_ Y%U>1T;\\[O[<N8I        PB9M(@
M            'SV9T*[OB[6S\/H_YKWU>[(2                       @
MA,4K=6'-MK^;GI7G^,MWK.X'@_L'LJP      !A$S:1            !+,D4
M(GFAZ-YUE76[+=_A>QFJ37)                         %&W:\ZU>XW>U
M^3]E?'/5?3FH       81,VD0            2'R6J>2_K_FNZW"]?LSS.]K
MWH)                                 M(PV74?>7\>T81,VD0
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M^^;5*9J*8U4*ZT);5U--.JW6FF$U13,F"W&Q5-4C-4:@       PB9M(@
M    02@1()HQ.A_7<E:&XU?1OR_T+ZLNB)Y-FO!FIO8=XM:G/V)[<?2LZ,<+
MO=._!M1VB^N[_O\ 5;JY=QU61=SS.1KN@O/)Q_I4T[LTYQJU-5-=A,EVO-NO
M15$H19^:JKT(N       ?(F2N:=-G[9JJTU                81,VD0
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MBV4W-M,JT,*=$O#L7JY],9<N?9Y5>Q>6=$O*/0,NZ[;1D
M                !=QD0     U[-(#VRYC9RF<U85/+CQ)NS[O;Q=U.DP3T
MVB^.W:K;&U)3<AC7,GXVRVMX_;93TVUGHJC2C=F>]%0A%,$P56!?P>1?K/F_
M8'RGTB\\7+FFH                                0(@      "$M,X0
MM3FZJF%^FE;HFIO)I^3%M0SHQ7D86L/9Z3&&RT\,>]3R$M=KT\B<]:;=;-\1
MO;JP\K5CI='HEW7$]B?'?4O2N5S52D
M           ,(F;2(    *-$_/@U^;FXV"MYK=8.LU5F;+4\5_=O&OV _%WU
M+]EU,J                                          &$3-I$    $"
M$U0QZ9,BQ4B[+:27HJIFBH
M  2E,JD081,VD0
M   >4<*CNL>H4C5,S(        2DP       )28                 E)@
M      #VR\@     > <*#M(92*9AXR 1       !8!?Q$       HEB&00
M     6474?6       "PB_0       "R3+0     ($I.8_-"3/9CXVX,B
M   @:T&"CW#T#8<RT     "4T1/-,@F.3H 5P     4SGD7*7<>\;0
M'GG/4R"5CY3=T      PX:AF2"[S*IE,      U_/Q\F_)H"?J,-_P
M$#GL?GC,.G9(Z+F[X     ('"4X:FXALN?HG+C     !2/S@'*LWR,#'[%SZ
M      >$?E4/(+%.IQW+      -3#\M)>IY!W;.J      !\I(3$P/I
M *)("F53Z      0/F($24K%8     %,E*!4)BN      2'S$A4*I6
M)#YB!,5"N
M
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MDI0(D02DAI>;D'UD2) B2D2 (D2   (D"(
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M+.6*MDMCURE @<>/UX!6YC")2V5O=7J_MS ,A!SO+*NI0;<$R$233'Z"<#B
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MKE"N4*Y2UREKE+7*%<I:X%K@6CD,-<O"O62H5.8Q[@RER.,R1Z4MU$/I7 >
M?G5]>IV5K9DO';?6UM:VZ'Q. C7*:N%<!&N UP&A 2@ "-" A0" F$API0Y$
M2G43(3]S;T"Z(T:ZMBC_ %?%T3*8Y0?W]E7]0LZ_J"(B-ZI07BW ;VX$/W=W
M7[N[K][=5^\NA!%6Y43R!<F!42W]P0BB_J__ &*$EV%'&YX":Y"@57$?_N@
M*9$:-=7I#)FRJPVS<>]X?&1%,#@I#7F63@O"4M6I;R.'U;!A+!PMMR-+8&SR
M4QOT]K=OSZ24>-9C/6>#M+3!YIWWJ9+-(GQ><"UZQ:YTZ$P 'JEI3,MT#$R>
M+6,*]R-)W.7I7]_<))XQ000BMV.)J+14^</AP:V6&@:N5H&MEN(X!SA2;)>=
MZ7IV]Z".WL%=.WV:DHND98G2J2Z"*9+&AB>3@!"()25+T<E.NCDIU=1+(*)F
M9JE'F:9\M:IK8]QCKJZK<J<"8\I^B;$LEKECP39I$L-=;0J.8UZL%%'Y$%LH
M,M,9 0V4O\8DKL=+"P#.TLE#+R4^LZHNX<\J*E\O<TBF5,4"WR2R:::=VJLH
MJM]'_*A35*&=SJ&-M\3@E\W<@024/#C7+<44JE< H2J (AR#&47N23L_=:]Y
MVRQ2=[9J*!<^I1+DYE[)KO7)&QL'3%F#+:T2E:".ON=M0)#[%*"<:PWBC+MS
M7VV$IM7[1.V=&M%DHO+$'V!BS VP!"?;S'A<[(2:N:+]HL?C\+,6S!W"H.Q\
MX#7<?.%=Q\X4,]3 -*3E+2P=:Y2KK7*5#-4IB'6>4ZZSRG031*8#UJE2KF5Y
M(NU.I\B5U/D2E)8?UNNR=O6SBFU-<R%DS.$44 %!$]%.H6E/_( )$$ (D  1
M(IA.4:YA !&X&BH(!0EH/4"A$XT)#C0@8: /R_Z^B#^5!^=<!H$P/6;=B-HM
MAVV<UX!2%)P'\ 34,!<7?&%6R6M  .8?4X"NJJ!FVN?&W4>91LY*V_>8ZX4Q
M[ISF+I.89810R+Y>^4$]WE;LJ:=O;@8I34('* %LEA_;VM KP OJ#7JJIT)3
MJ&_!5%)>D$[6T+\<%UT:_<@:DT;"R'D4Y_J1ETBJ<R11,@"HK(G!,@$*"&%R
M-VGEFL]+@<;$MUA"K(-4P^ICD@#**6YE<_F%C?UW+B4N/MB@F@DA7'\_LA4Q
MB)G,1,JBOH@DN5>^ P#0 !JY*Y3T(&#\0(<XIV.25.5LN0Q0:[E$2L]S#5O'
M+@73&-,V4 9B(TQ;9GL]PX;9^-KF1KZ]CBRO%7?A;(UY(.?,%U(CQ<>2 +RY
MLT[&W2#T"@)[2T4%.V3)10(F',>OYJ#C]E%X\<1<8\,C,<B,V/9XE1WM/-2'
M:/!OY 4+NV,4UP4: Z%&67+25^X$1-FW2 J9=T*D+?N(M!EG,4%,LX3)G7NE
M*"W,H 61!']@C10''5B\QF<-E>)[D]Q?EQY+B\OL_?XO#66'MN7B/VB \!%)
M,P71;BYOKM"ROU+AIX2X)<QMB[HWM/(V9 ))MN<7 [L<4)!P1*1>6#N"H9G'
MW)B'YR\#\ ]:C>L4>8YOPY"UP#AS& ,EDK;'6B9<@[UL=8H8RT#@(?:?'\A,
M/'@4:],@4>W25%,?2 X&-0^LA7IIW!5VZW%@N67A+LBT;6'$F#=V.2$C\M2>
M[<W94E)6("K=[-FX!+)6*P>LASY%T83%JV6'O7U=H%);IAS#]Q / >"9Z634
M.>X:UM>@K'V) ;AE'LT<5'6?NG8@FD@3AQ/]Q /"A,8:'\P&V0,/(6N0O,":
M8*"0@C_ZV@F H"M:T5ZX0V7,(< *KR?QAPHY;GE9;:5>KG#35Q(V&9M+[$9;
M@(?.<*X4)1 $UR*B!!$/K-VB7((C'V-!:XBNX2<AHZP"*^/M4K-#^,0*8F%S
M>1;EPQ-BLBJ]PFZ)#VC@V$=*^6S.35S66^<5*!TE+=3]O;V5P44T1*'UH!$H
MB &-S&XF,8WP. <1,8P& #&,0AQYC?/B8P@  '_#'__:  @! 0 !!0#[N%8@
M"%T4PC>D"C7I  %>8_U83<!%3@/T[R8+;/VVGD<.3;>;/#D7>M_LJ!->O*_L
MQL)K_P""#<*4=YO&G=*JHIW\XN/'YX9,?8#U-?E=37Y74U^5U-?E=37Y74U^
M5U-?E=37Y74U^5U-?E=37Y74U^5U-?E=37Y74U^5U-?E=37Y74U^5U-?E=37
MY74U^5U-?E=37Y74U^5U-?E=37Y74U^5U-?E=37Y74U^5U-?E=37Y74U^5U-
M?E=37Y74U^5U-?E=37Y74U^5U-?E=37Y74U^5U-?E=37Y74U^5U-?E=37Y74
MU^5U-?E=37Y74U^5L#NKA-:F9#&V]AL$R>IK\KJ:_*ZFORNIK\KJ:_*ZFORN
MIK\KJ:_*ZFORNIK\KJ:_*ZFORNIK\KJ:_*ZFORNIK\KJ:_*ZFORNIK\KJ:_*
MZFORNIK\KJ:_*ZFORNIK\KJ:_*ZFORNIK\KJ:_*ZFORNIK\KJ:_*ZFORNIK\
MIK.UR.!7X>Q<%(SVRH8\6%G VL<^Z.1OL(UK/Q4:Y-;7O4O6&*M,-?J=H :>
M2_I]0, \#*%*2?-CHAUL:6QT [7^1]?7KQJ;9Z^LY.?/)A"X-+RM:SW&28DJ
MQO)^+(<U%5'F+^8?3G9_?L/T^G&-RAZ@<5\E9VZ4M;]9Y\/2!O'UC,&[4$E4
MRF*/ R2I@=+ :SWQ[\\5&I;FOC:I>0"'![P=WH@",O*-IJ_[IO/!JNRP4O;=
M(2JD,7U2T!RC]*=G]^P_3Z==G B>Q>V4,:O-H(YVT\A2T2PM&4(- I.4?X1
MIBKI)&&2X+AN7;+/>*77U"^3BCR?PP)/(9-L1!%7D/T\EU:RR]ID4B*"8?I#
ML_OV'Z?2Q&A$:R&3M\9:2-OA(TWNS7#01DQ<YBH(&+Z9./\ %RA1D$C4!"@
M)$"BVR)3<A:E+4?66:"77BZ;3+NCH^62%!0\H7L):+MS-:YI2(K<B2U/<#7-
M^7&@'YSG*->LEP+<(F ;A  !0@FIV?W[#]/I7J$X&62YMG-R89U;QUE &U.^
M=S&T9LV)6QRB% ' /BFX\3@8Q2%'D7M$[M.6M M39C53\<$GQ24)"\J<'CLW
MYAI0P]QJ=LRTMJXD(H0QN8OS?D6VPS&EFJNGFS\TY[36%?-[G)BTFCCS?6\Y
M:_\ C$WCPGD:TON;I&T3=$_0@K-?<= ):[D( KN0@"NY" *[D( KN0@"NY"
M*[D( KN0@"NY" *[D( KN0@"NY" *[D( KN0@"NY" *[D( KN0@"NY" *[D(
M KN0@"NY" *[D( KN0@"NY" *[D( KN0@"NY" *[D( KN0@"NY" *[D( KN0
M@"NY" *[D( KN0@"NY" *[D( KN0@"NY" *[D( KN0@"AV0U_P"%ULYKS86,
MN>2#/S6YM:(<TS@/)DV/@$"=R$ 5W(0!7<A %=R$ 5W(0!7<A %=R$ 5W(0!
M7<A %=R$ 5W(0!7<A %=R$ 5W(0!7<A %=R$ 5W(0!7<A %=R$ 5W(0!7<A
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M[>HTKMZC2NWJ-*[>HTKMZC2A@&-"A/BNLVMD?0UJ,]]SG-#?CNUL@^X#7F-
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M5ULO*ZV7E=;+RNMEY76R\KK9>5ULO*ZV7E=;+RNMEY76R\IHO]=UK?#V&@'
M[#LMM>**-&KHDSO%M#S4U40\8VLF#@7677"*M1X.SF'L\WB[CQ[0RUWXQM:(
M=8D</#QX:6O<]UXG=><8H;2';ME*%Q'ES929=KM^V,I_E.8;<,U/)IH\[;EI
MS5#+W3*JD<A3@-<"!7$I@(4 "N4M<A!H2I@,@OUF1BST<;,'E SC#936CMJ%
M .' /L+@'R/#\W44>O7 1 ""%*HF.8R0F*5(X5<6JRU#8G.5S0%$+V0=GB^T
MA=BAO%2R6Z)-3O(.Q#'S'EU8)C[P;9,TV/\ +5K;8&9WD-TK?0-N1F"\2#=I
M!4N;K:U0N6/H*EW?]X8S&6>*M  ?M9V?W[#]/A'2 0%'@%]:6MW3SU:UBD <
M_P"*'2+.'R/C5=+5M8<T5VI=&X"%L9-, _/[6=G]^P_3X0@ @!"A1DR&K]NC
M7(4*%),1_:V_J<A0^TSG*0 N$1*4P&#\'9_?L/T^Y,W<J6>)\3^]>U^\KB3O
MB)A2RZ-N1TRY%!YOZTPX6NM<-5UKAJNM<-5UKAJNM<-5UKAJNM<-5UKAJNM<
M-5UKAJNM<-5UKAJNM<-5UKAJNM<-5UKAJNM40F$)KAH:ZUPU76N&JZUPU76N
M&JZUPU76N&JZUPU76N&JZUPU76N&JZUPU76N&JZUPU76N&JZUPU0S5#XT$UP
MW76N&JZUPU76N&JZUPU76N&JZUPU76N&JZUPU76N&JZUPU76N&JZUPU76N&J
MZUPU76N&JZUPU0S5#W*,U0V%=:X:KK7#5=:X:KK7#5=:X:KK7#5=:X:KK7#5
M=:X:KK7#5=:X:KK7#5=:X:KK7#5=:X:KK7#5#-<0<>M<-UUKAJNM<-5UKAJN
MM<-5UKAJNM<-5UKAJNM<-5UKAJNM<-5UKAJNM<-5UKAJNM<-5UKAJNM<-5@9
M!9+J5^(ZK'(Y-N:Q^,*9$MNHLB%FQ"U*4235#-Q3A;Z1"LUH<OLUH5[-:%>S
M6A7LUH5[-:%>S6A7LUH5[-:%>S6A7LUH5[-:%>S6A7LUH5[-:%>S6A7LUH4V
M8JP>%<0,YH"'LUH5[-:%>S6A7LUH5[-:%>S6A7LUH5[-:%>S6A7LUH5[-:%>
MS6A7LUH5[-:%>S6A1V<TN>+8EP;-9'LUH5[-:%>S6A7LUH5[-:%>S6A7LUH5
M[-:%>S6A7LUH5[-:%>S6A7LUH5[-:%>S6A7LUH5(T7X!U,#'L9IVMA[-:%>S
M6A7LUH5[-:%>S6A7LUH5[-:%>S6A7LUH5[-:%>S6A7LUH5[-:%>S6A7LUH5[
M-:%.V*<#G'![-:%>S6A7LUH5[-:%>S6A7LUH5[-:%>S6A7LUH5[-:%>S6A7L
MUH5[-:%>S6A7LUH5[-:%>S6A5K'*..E7X@E U>FG0  !*$DM.)6'&WEBTHE#
M7ME;L:XO6'[;R5Z7K:>13([6F"-_B#^FRNT,=:J1Y@?)EJ&\X)D_R.:81!J=
MLIOQ VJ<10C,D<;"1A\0_P#[=R?(3K;HMC9M\DNGL#+SUO!K'K&]=DO))JSJ
M3+2(B8WQ%?\ V7ODVU.Q.V3(\@^K,C3RQ=WM99*V@RNV$*-_:;XN5OK;&8Z"
M_)UJ7L#,.O>]>N.T=S 6^6K>SV%T_P!XV9N0I\6>)M9FOD<1UY1=.Y2UL[^M
M3+35VWV^UZ/JY$4@I2BUOB[-; 1OJ[!\[Q7$>XOC;U#:>;A#7>+Y$9N/_P!/
MGQ9/-KO'QV?$-PY?(GNE'>E<%8>#=?F&V]DX9D[5S_4(VYWRUHC_ ,=/CDMM
M9\?IA\0P\ \T6SNJ>#C?R8:UOA_2/YDLEB8;S7F(D!W3 @V?ZC_2_B+\/2ES
M;'Q_;"^4+2O1[9UI[P:^RLRKO_9Z@1L[XI?[*UN10@?$<U_B\5@<3*&IODQF
M?PS0A*36VK\4CT@1TLGQ,ZS1# ;B^+NQM?&^ENOV3B*$'QJPRXR?>LW^O!DL
M,])9\<'AA?6Y<C^//XHVW$XV?, 6O _[>@MB!<?$&O1 *"W-1;?EHEGR'20%
M(_Q! # 6V.2OVG"B6PD +, 321!+XJR8+)^D(E+9 !1MS<R2/I#\4Y .![3U
M"_L$A$UNH($1 A_BG()P-:<QALP$XVO&D$ 0#_FHRG*4;WE%;?S71'8XJPF)
MNUY*HMT-<.N^_NNVQV S'D[@O PS;>9R%5Y8EWRVZ\1;&C)V>,^)R3/ZB="(
MA2^030/.TQX^"88/_L 1>1./WXC(+#W"\E.N6B3YQ>V.,RVTD?;3PO*$\21Y
M5=7XZ>;B\J,<M_=2 =CHDV>CG6S:2&-MH]1WOC%Q92'YJC&?HSCKRIZQ2S>M
MB3F,],P%X;ANUY!8<T'L1NN4[!\I\"//>>Z\HD&'W]/="2MA)VP&M\):M[,1
M_MYKVMF+6VM&+(+2DUD;8^4'7S49B'\@^']C[1;J0UJ54%[(,C87$1'.T>3;
MBOPXUZ@\/5#A'LQ-&3,D-P0H,_R8ZZ.S<C7#:W#;&LJ!-OH"V2UJAWRC03/F
M%A;S::O3-'.PNT<.:N0&^9BC*,HM/Y"8@PN)VXVG:^G$!L[S1:J.QGZA;:1?
MNQK86X$2FN1"C7HA070BK^X#U"Y IC$N%#5=2HQ+20-;MAVIM##07B8F<GD#
MAMI;Y2SO!#$3;"Q)MO"4R1V-X $=3H.UVQHKO'#GD.UJ&Z IOG9$8>+DMAJ^
M(77%(5_#=)W<J7Q!ZTF#SULIOL]C)ZH[#;(POK;-\2R1K6X&C-\X>1FUFOQR
M;>Z/>'O:K+99D)" ITIQ$9@BK S3'>QWB+B-L0*OH;NMR19X=H)RT:[.L_6?
M+[)Z9M*>/&C-C\D"8M2-_-KB/G%O/J_A6I_LEZ>8^3M)H)TXD!Y:.^5#QA3?
M&OB;U9\&^JLV:I:&P+;RO$<TZB0!M+"NLL2X/R>)ZN>49CQUB]!O'5,$=/24
M=^<?E9.DV*KC",3_ &2LOG=BLIM%XU8ROKK_ %[?$-*.&CR/V-K#Y-9TTT\,
M+=9+4\8NO^NVRFTG^N%KC=8G8"%=P7CKWY!B>/'<#:)C:SZ=64CF\^GX<:F"
M'V],S>EW3!F,I@PQK/*MW(MCHA$UA<R9KK$WD=?6OLY3LQ])=2IN=^ATH:DX
MIZZ8;DZ.W#B<_B9NVKD<G"K5PVR>_G@3\FVRD6^2W13RU6W3[P[ZJ:J0&AXA
M?"[?S;$6V&)SNPE_.VL$1W^9_P!7Q_8&?,TRWP_7U-T$ZK);R/+3WR+PUN&\
M-JO(1 FX#"PEW$+.5\Z.IB^WQO"CO%'5_B0\:3EV$=7DA\GD>1_)>Q3I8.RT
MS;H20W?(\MY(=7V^ZR;F^$!^XN!-3/&AA)<0W>^>$A34**0T"9  I"$ 2$,/
M   0 P"'&A*!@  *%" #0$(6C((G 4R&#D)0   4A"!P !$ '\ *4H^DD">S
M>I\);<L6+F+?1ZU! ! 2$$!* UP#B( (<*$ $.'"N <1 !#E* "4HTWX7C]E
MR@)0-7*7C>%,:HEAM@0O@?QX!0I)&KTR#7*  ( 8"D(4H  !P :$ $#$(8JZ
M954Y<T?AZ4)JLTA3 2$$P@ A7 .- 4H#REY@*4H@4H5RA7 *Y2T( ( 4I0X!
M7 .' /P$I3???__:  @! @(&/P#_ !4NCTX  KUT^/1@!G[:CMVUPE\A:N10
M(<23D.A<S@.B;;=UMW-D+DQ"9DH0>(Z1QP]L^HBB8(@9. R'GZJ$6QVCC&/T
MKGM(8P(JESD#1R12> *4-DV_<?I]VYW>2W"-!BD> '1-?VGEC"$ UN0DHUH)
M  WK81/8!XU2!P$Q;@'&,Z0X.1=)+CBA+5IK/#6\S6;WHC+H@M!(XO<(QYW(
MN527MJ^QW*S10;:XB5@X!S&O<2XC$8Y+1;?VTL3@40PN<5Y89^2@;9LG>?A:
MD]-#Z0QJ')/A2NR<: )Q]KV) HJ" .82FLA(<YV0!5>I,_(M'=O'-T=LVF-"
M8W!+R4*&CN;=YC?*-1 ?H*M9J>J-2H]B\,VPV[9(PBQ@-EEX+(YJ'$9MU.4E
M2X\-(7Y:)UD.X<4/#K3EQI)+@D= T^\:=+MEU<1O<.T63O8HY$# CCBM=TZW
ML;IN.-U;P7#ORI(RX^4\>JA^UO#)LRXA9+<!0@ST-[H$= J:3PSXZB;=HKF;
MB66<:+@(GR2N#W+FT-73VE.5,?9VD=]$5[5F_P"D-_V8.?!%J2UOMNN()V%"
MV2-["#R(<!6F29C7=) ]^E:=?XO:]Z@X]D\C@?,<:]4^;VM(J$8CK'"G6AM>
MZMRX-+W*&@%5)*! .A30A\'3Q;KXFB:1+)(=44$CAE$KI0] 04+01BJ8&I+S
M==PDNKT$\>S%S:&M(:T<@B='^'V$6F=_$XZ"K44$'I0BFMVS>I[5PP1I)]!*
M=/33+#?[:VN[2,:070QM<X ('%S8\'',G$G'$YT8MWVJ>RNB1VXG"088D)K
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M!V'RRL!)S)E=(>LJT)P6G7'A_P 2VM[%]X"0\=! !4\,2T+RKO#X>D%F2CI
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M0Q;NR+==N4I;S OCC:<=+ XN#=)R3#/"KJ^V*YBV_<,2+0E&.7/2XEK !P:
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M^BHMOVVW6$-[Q\Q_1,:H"$@J'8Z@"U" 44X5^SO#S'G>V_I+DZ$U#@P 8ID
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MX)TKQRI7EB^0_!3"Y[&NZ 0<^HCT4Z.XW-[(W8$@8@<P<**>()_.*U2;K<N
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MD=1(0!$Q4#^X^VD\W/N%/^V-,_9_@/:(90$U-[YQ7GVY2%\E-:9H880W ,:
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M1(@XEQ*G$ *<?Q:MCMOU'[]>/:W&6."[D82I.LEMFYK0AQ*Y!504YP^HW=<
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MP-"=F:1G//2['SUK.[W)')[C(/,]:9$RQVRZB7MNN+6"1XZ&&2.32H5=&D%
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MXVVUJC*>0QG_ (K2G413Y/#TUGNEL,W6DCY0'<6%8VHX!"F2$8XTYTG@V_(
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M$"EV 1 3& !$  =]@[-& I##R* F8.8G,&^P";E*8P@4AA$#<W+MRB/9L(D
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M[:]?=WRUY?P+]M>ON[Y:\OX%^VO7W=\M>7\"_;7K[N^6O+^!?MKU]W?+7E_
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M^#O$+);4"JTK'[I'QRLL>5)R0T>V38N1$4'BR!5"#Q130#@)BJ'*;QS<@EW
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M_!AS^X.:_P"W8FT'N!_1_-?-OPW -P 1XF'8/![(Z3#O";F$=@W =]NT0V\
M:2&[3;B6NTNB4:EB^II)S5\M;M0_<-BQ\.D83,6!W9BIJ/'7(W()N!A-XHMK
M5U;/)3 _3V!T7M>Z8J3+*(VFWM .1=JYRM9D0173%4I2F,U I3E$Q@!% P <
M8BCXZJ,12ZC#-1290<"S;,F"9Q$H&<."I@*[N17 H"JNJ<ZBAN)CF'LWV\'^
M?V->Q_'#L CV;=G'LT.Z9A'V!VX^UVZV$@\/]WAX0]W2K9TT(X:JD,FHV<))
M+MU"&WYBJ)+<Y%"G#M 0VTL[MN!Z<C,KBH(6:I-$Z78TE53\YW7[6K1HU99T
M)Q$>=8B^YN(^SH%.E3K+S=BMJW#9I2+X[0R?044^<ROP9K'2HHN& *CL4ZQ>
M^-VB!0T*-WPSAWJLKC8O,><Q58EZ#<W1>'*!(28:ILU%B$W%0"LAYCAL4X@.
MH"I8RQ!9,-WJ!GH^2R;&9AC&+A\1FR[MR-2BHMJL#@8V=:G(9>24!JH")P^#
ME#?O#0N5:RQDH SEPM#V&O2:*XGB;*R2(:2CFDD=)-E,,DS* JD[:B)%4S )
M^4W, ;@;P"'8(;[#Q$-P#<./;V:[?Y7>^H2%K(3YJS9,;5V6E9)%VZJN.J[?
M,BURD6'+MY1C5T)!Q1L50LXO-2*"!B&63; F91$ACK)QV>>K. @#KH8VQ)>J
ME=,7$343ZB(&]=/.+LGNINK4 LB_/5;FID6U3=9"&3=B@X>17PMN9!HX3(E^
M'7GW_#:BU7,_XEO6Y:>ES%%06&>FJOBVH,L[9+I!,DV:-">835X?4^E5.,._
M:,Y*$2?S4H445&37Q"] <S0:?3ZIU!]<75S>NCM>M3LD\M-3Q#9<.O;.WR=D
M=Q6HV:KUDN=?3:1D,[CXC]H12R25I9_"'H"D4R^'NK&*KJ5*D[RA8H6[49"3
M":2J-\H]AE:C:(5*4.U;.';,S^)^&-#*E*L#1TF"GC@8-'67.":*9%%553B!
M4TDDB"HJJH<P@1---,!,81$   UBJ43RYC8T?&4C,;60>#=( K9FY=2.+"-T
M'"PON1%54S94"E-L(BF8/!KE-F?&1#%X&(I=J\F<HAP$#IJ2!3D,'A 0 0UZ
MZ<7^G-;\XZ]=.+_3FM^<=>NG%_IS6_..O73B_P!.:WYQUZZ<7^G-;\XZ]=.+
M_3FM^<=>NG%_IS6_..O73B_TYK?G'7KIQ?Z<UOSCKUTXO].:WYQUZZ<7^G-;
M\XZ]=.+_ $YK?G'7KIQ?Z<UOSCKUTXO].:WYQUZZ<7^G-;\XZ]=.+_3FM^<=
M>NG%_IS6_..O73B_TYK?G'7KIQ?Z<UOSCKUTXO\ 3FM^<=>NG%_IS6_..O73
MB_TYK?G'7KIQ?Z<UOSCKUTXO].:WYQUZZ<7^G-;\XZ]=.+_3FM^<=>NG%_IS
M6_..O73B_P!.:WYQUZZ<7^G-;\XZ]=.+_3FM^<=>NG%_IS6_..O73B_TYK?G
M'7KIQ?Z<UOSCKUTXO].:WYQUZZ<7^G-;\XZ]=.+_ $YK?G'7KIQ?Z<UOSCKU
MTXO].:WYQUZZ<7^G-;\XZ]=.+_3FM^<=>NG%_IS6_..A_P#6G%_IS6_..EGC
MS..*VS1!,%EW3N^5ILD1$3E*!CJ+2*9"@??8FX@!Q$ #<1TOB'HRE*A7V)%%
MF]LZG\NO6=6Q[6V2:X-'R]!8S_<+6B1:B4Q2J&;J<JFW*@(""H.\B67/5'S-
MU S8?"K)FC(EUK4I9 ?+)@#@M5(^?N?W;8F(/(04U#N.ZV+W@$V(! '-6,-P
M*7F$;S6Q$1V#?<?VB&XB/AUZZ<7^G-;\XZ]=.+_3FM^<=>NG%_IS6_..O73B
M_P!.:WYQUZZ<7^G-;\XZ]=.+_3FM^<=>NG%_IS6_..O73B_TYK?G'7KIQ?Z<
MUOSCKUTXO].:WYQUZZ<7^G-;\XZ]=.+_ $YK?G'7KIQ?Z<UOSCKUTXO].:WY
MQUZZ<7^G-;\XZ]=.+_3FM^<=>NG%_IS6_..O73B_TYK?G'7KIQ?Z<UOSCKUT
MXO\ 3FM^<=>NG%_IS6_..O73B_TYK?G'0?\ K5B\!V$-_P!^*V.W8.^PR(EW
M 0X;ZJD_<,TXYK=MK,G%]_;*[<JHG,S]3;//A$I3I115X")V<BD  @X$IUF2
MH<Y.<H"F+FZ=!O5CC->L++.).;Z7\O9*AIBBSB@\JCA.E6-X_&3K$BZ5( $
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M^8>'$V_A[=;E3( [@.X% .)=]AX!VAS#^?\ @PY_<'-?]NQ-H/<#^C^9MA,
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MC4I>,DV6$I-2ADC*R4[8Y%&.8H%#B5),ZOCNW:X?])!$JBJH^*4HFV#3JO\
M2%'2N ^GU906<YU/7:-79VFTM43"11'%=>5 '":3M,3%*[*'.4>43+H&YDM+
M_N)$K2MTG.[6MV3[5RRU_MCHYBK.3R4TYYG+5LNXW.+9$2)<P[G Y]SC[\.W
M?_IAOO[8@(;Z..X#SFYN!0+MP -AV[>S^8M@$"\0'<2@;L\&PZ >8.S80$H"
M ^T/$.&X=FI>K76"A[569U &TK ST:WDXM\AR["FX:NP5(?8W$@\!(.PE$!
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MU695_P #L"4:$CF3#(%ZS2V>VZ/L..%FMDFH*N5:7J+VC3"4J[EI%E$-@CQ
MCDY5VQE,:=2."K"-LQ5E6 /.52;69.XM]W#=Z\B96-DHI\B5W%RT-/QKED\;
MJ&-W3AL8"F,  (^,(% 1VW$=@W$0  W'AN(CK#H@!A *#FO?8IA$-W^)0#<
M 1#B.@]P/YA#M$1'AL CQV$?!V=FIW+SBMRUK?,EV<% 0C$BJ<6K8)Q8&\4O
M99$H"6*@DW12@HJ(&.<1!),IEE$Q+$=-DIF><J,-EFY2,O8;Q0:3^U;I6JU(
MH=X_K5>>Q[[>MTANX!,A'H@!H]-4Y#+JI!N/["Q74D(]W(% ;1;Y<2RMZMKW
MBH=_8K(XYG;KO5@Y@03,FV1$WBI%$1$.  ':/9X1'<?SC_-79KL#V?8$1TC9
M9N*?TG*<64IZYF+'CLU9R'!O$"&^"+C,,03&5:H#M_4N@.7;@ AOOHD9U'U>
M0ZHL M1(5EU XVC.7)-6BTS@DFMDRCMDP"4*W3,7O7C8 *([G.J8VX:0N>([
MM"W6".5$'"D6[ [V(<K$,?\ 9\Y&G,#Z'D""4Q11<$(;<H\NX .C"4!'B(#M
MN/$!$!#AV" AL/L#_P#  "(!N.P>V(;[@'LB&P\/XRZ8YR[A:V9MP_?YJO5K
M*;*@GGB7K&%1.^6DQSQ5DJO%S-N>S>'YJ*:2[9*)0-(E40!1$#\@HJXNQ5U^
M4SJ&O^&\F+5O!./\P83QYD^K91-TWGPU09O&.2<H5O"7P'+-2A6=H:O:BUF8
M]D[4D&#%@\DT@92#H^OPF,K=3#O(V07_ $'_ (H++*TK5I:(4G<L5#H*;6(E
M0QY:[]6:BC(2]RO..Z[ -)!1I'L5I=K!RQB*MC.&CG?\(7-F2X#):"G3=^)G
MGGJ:SSA^.:25PEL885ZC):8C:I;E*!5$9NPR;NJI5>)>.HZ-:O)&+/<)$ZB)
M03=BE@7#^=8N9K65'\MDG(UFH<TJW7>8Z'(UZG;1$4U?X(X=MV;B-@'#99PW
MY^9N[=*I& #E$ ,DKS\ATU4C<ASI'Y%B"FIR*I&(LD82&'8Q#%,4>(" ZQ9%
M@6\_!9*EYA=N3?XO9?\ A(*-'^+Q3(V=#>Q<LT3B\-SD1.0IN4H" @4  !$,
M@ (AOLGF;,J1 ]HB9+^!"%]@ X!KZ0_KJS1\_P#7TA_75FCY_P"OI#^NK-'S
M_P!?2']=6:/G_KZ0_KJS1\_]?2']=6:/G_KZ0_KJS1\_]?2']=6:/G_KZ0_K
MJS1\_P#7TA_75FCY_P"OI#^NK-'S_P!?2']=6:/G_KZ0_KJS1\_]?2']=6:/
MG_KZ0_KJS1\_]?2']=6:/G_KZ0_KJS1\_P#7TA_75FCY_P"OI#^NK-'S_P!?
M2']=6:/G_KZ0_KJS1\_]?2']=6:/G_KZ0_KJS1\_]?2']=6:/G_KZ0_KJS1\
M_P#7TA_75FCY_P"OI#^NK-'S_P!?2']=6:/G_KZ0_KJS1\_]?2']=6:/G_KZ
M0_KJS1\_];BGD;;QOIJS*'O1$/#D+P[:D,DY3F\@0<&R 4F;7_&K,:TQ/RQR
M'^!0%?BRY%*XE9=^H7E3(F E(/C',4H"8$,V=341;Z!@%-1)YB;I=F<BY&GG
MLTPV458W3)[N?LS]TS?2"9TU$FS?X,N)-RF$B7!6R2-.K]B3E[+*R3Q:8"]W
M6(DXZ&?+ X;TZ/>5J=@UC5F,5W[I-P*ZQP'^N45, &#LR%[?_K5FC[0-?2']
M=6:/G_KZ0_KJS1\_]?2']=6:/G_KZ0_KJS1\_P#7TA_75FCY_P"OI#^NK-'S
M_P!?2']=6:/G_KZ0_KJS1\_]?2']=6:/G_KZ0_KJS1\_]?2']=6:/G_KZ0_K
MJS1\_P#7TA_75FCY_P"OI#^NK-'S_P!?2']=6:/G_KZ0_KJS1\_]?2']=6:/
MG_KZ0_KJS1\_]?2']=6:/G_KZ0_KJS1\_P#7TA_75FCY_P"OI#^NK-'S_P!?
M2']=6:/G_KZ0_KJS1\_]?2']=6:/G_KZ0_KJS1\_]?2']=6:/G_KZ0_KJS1\
M_P#7TA_75FCY_P"OI#^NK-'S_P!?2']=6:/G_KZ0_KJS1\_]?2']=6:/G_KZ
M0_KJS1\_]?2']=6:/G_KZ0_KJS1\_P#7TA_75FCY_P"OI#^NK-'S_P!?2']=
M6:/G_KZ0_KJS1\_]?2']=6:/G_KZ0_KJS1\_]?2']=6:/G_KLR%]=6:-_P#_
M #_0[!D+?80]=6:=N(>UD#0D!.]' R9B'(MF;-"B9BG#E.7E-?S% IB#MV:<
M7CICN%GZ7<JBDZ5=S](LUL3@+:=54')F5TCTII.6=,WSD !PLV=HJB'C"50=
MP&/QSU^XQR'CP[U<D57^HBA9=SE/87N3GFY$5915M>5'--D7X" ]TH4./,84
MD2;@6-L=5F+A9("7;INHR:@L]9;E8I\V4V JS608Y&7:KDWW 1*8=A =]"4"
MY%X  [CFG,X .^VVW_J#N/;KWN1/KJS/]H&GRT#^\@'D4TDG/[<N]WMQ>1 W
M,F#=*WV.>09&W[3(E3,;PB/\8(\QRFW.8IBB4#)G. E%1,>7<IP*(AOV["(#
MPT( LL)S=WS*B) 4/W8[%$XE(4##W8 41$.P/9XZ3/SJ\Z7+R'Y@YO% P%$X
M\O\ 6"4IQ .;?M]GCHZ@&5[PVP=YSCW@%+N!4P/[X2  [;"(^SVZ[P#G$W,!
MN(EV[% $NP% .014$=O /$-A$?X,.?W!S7_;L3:#W _H_F!G)6@CFR7BT+N(
MO&N*ZT07MUO]@46[ENRB6*(JK$8 NH N'1B<B*8#R\Y]B#&=5O7*#28R @)7
M^),$)@+FA80BU%"*Q_>L5R&1EK:EW95#'6 3H*CNL!EBE*CRDWY0#AN(FVVX
M!Q'<>S0?SAQ$0[0W =AX]O$..I.M6N!B;)7IILHSEX2;8-9.+DVJI 341?,7
MB2K=R0Q2AMS%$2[ (" @&SS(/X?F23T-)9Z:1G^F[(;Y[.X8M:H'%1RE!*+*
M+/*7(N4PY 53$0\;<%4]-L-]1]/E>E_/!.5F-4R"H1*HVM<P%Y'=#O1@3B)9
MD\4*(H)K&1,H \J8JG 0#O$]Q(;E$IMO%.4Q"G*HF;B10ARF 0$HB&WM[AH/
M<_D6'/[@YK_MV)M![@?T?RX  _+N!PV >(F  $ X>$-]]1.,,:0;[,'4O>R)
MM<?8?@3*.#D4=HF30L-S79@HI"5QNH(J&YC)+JE3$Q>5(#J@OU(=4%@1R[U2
M7!,JKJ9<ID=53%S%9-15.GXXCS$!NQ1BR"*2CQ( *?<W<E(03G4$>4-QX]GA
MW#^<N.NP-#RI$#< #8"@ ; (B ;!P[1'2U*R[0X.ZP+@5.Z))-Q(_C%E2CS/
M8:8;"E)P[TH@ @HW53$P@ &W#AI_.X&M[CJ<Z<89L[E)'">4YI-EDN@0+-)1
M9RK0[XZ$B4NQ9-DSG^"N2 ( F $24,81U68"3HTU5<(S4+&L)*\SJA3V6OW1
MZY[M=V_C8U=RU7J#)4IF:ADC"YW*+HO.',U(QE(I\A)QDBU2?,9%DY2>,'K)
MT@DY9.V;EN8S=PU=H+ =-4HB!B]@_P APY_<'-?]NQ-H/<#^C^5@4>T0W[!_
MIT(CX/:$?;\ :$#;F Y?>E*81$!#LX!P'P<?#I+I>Z0X9KD_J<E$ED)M^805
MHV#HIT5-)Q9;S()IJ,3RC I@%)F<YN[/L94AS=V@K+W2R3#K*74%?#*2&4<R
MV/G=3<Y(.A!5S$01WXN74+5FZH\J2)3]XH4A3'$H<J9 V#P!PW#A[6MQ#P?S
MJ3;?@<!X#MV /Y].6$@S;/V#UNNS?,'J*#MJ^9N2&2=-7+=P4R*Z#E PD,0X
M"4P&'?1,B%D@2P&8I[$MAHHJE6"W&?BH-<2?E***>-50.+E1 #B\$Y0;E$J.
MYA91D8R;1L9&M6[".CF2*+5DQ9,T0;M6K1LW*1%%LBB4"D(4  H   '\APY_
M<'-?]NQ-H/<#^C^5[\-]NT=O].A PD NQQYQ4 H% A=SB;F -@+X1#< VXB&
MIKI8Z&7C<KF(5"-S9U*G!1U3<:1X_P!2^B::^;AW$Y;5.51)-1)0I3+@(('$
M$U5T#4Z@-73Z6E%BRUUOD]R/+??;&J)S.YVQR1P%1<RJQSBBW*;NFY3B!>(B
M81 P[B(>#?;?;P )C"!0]L1T'^0DW<+Q8(BJ56NL5I*;L,^_:Q4/&,$3%!1V
M]>NU2)() 90B9/&$ZJAP*0HF$ TGU,0^<<7&P : 96ISER3MT+7J1"U]_%1\
ML@[LTM8'L<%7> RE&ZBC22(S>("N5-1$#[ :/S<RR[C%YAJ4CF,S'969W6N.
M,?2,7(N@:L'<;;6\@Z@I!)^X$J+<4W ]\N/=E\<0*".4K%DBCPV-G+6/D6^0
M7ME@T::YCY@"#$.F=A4?%C7C>4*LG\&,D=07 F 2 )=^6,FX*48S<',L6TC$
M2\0Z;2,1*QSY CQG(L))D9PR>LW+90ID5D5CI*E-N CP_@PY_<'-?]NQ-H/<
M#^C^4CKMX^X'^O3Z8F9!E%Q,6R5?R4C(N46;)@R;$45<.W;E<Z:3=NBD01,<
MQM@ -3>)>FZ4F<9=*$!)GB,M=1I&RK2:R:!# F]H^*D5#MU18+%, .7( )%$
M3\ZJB0"1!Q"8TQ966M;J\$0Q>[0/WC^2D13(5S,STARE<3$W(;\RSA43[ !4
MR<J9"$*(@ AN  /C#MPWVX;\.W7^W^2]NNW_ .'AKCK@.WY-];[[^URZ_P!@
M_P"K7^P?]6O]G^S7^S_9KC_JUX/SZ[0_/K@(</RZ3^'/$&15UVK5 [A5-$JK
MMXL#=HT2,KL!W#I<P%(7M$>S7:(?_=UQ, ^UP#_/KP?\VO!_S:[ _(.X_FUV
M#^;_ &:[!_-_LUV#^4->#\X:\'^;78'_ &_)KL#_ +?DT&P\ON% V_\ JUOO
M^<-O]&O>#^8?_#HHB'*'-L(B'@V'LW*&XZ576?-DFZ"9G"ZSA5NU3;H);F54
M645W(1$I??&,( 4..X:[PUYIY1,4#;_O-7]BEX<=_P!I<FP^SOMI%RW71<ME
MR=XBNV436062$-RJIK)B*:A3?\1!,0? /\6ZQ#.9B5P3<+SE[#),$9#<P\A8
MZRTZC*=D&*R-A.$NE<9F%M/4R>NM0;MY!H^,DS72/R]X5;N &0RSG/INIM,M
MN+[#BRDYIH][L,-9*%F+J-QKTSX-Q5BBWU*2O!FN/W[^_P"+BU5D03((IPTT
MDX*Y$[MHN[-^"7B?'>5Z9DVB2/XWM$S+U-1V(KFROF-<495S/+3-FQ9B:M2$
M*]?1<91:&T4=L"E$&J3^7,21*W14?I$U^ *K:DS?_3\C^,YU0_LDS@987R44
MM-Y1#"(NQ='^ A#FG@R(#,=NY%#X!\''B/-TOCDH51;C)9>_PR%X*HO_ /"8
M<L6\*2#D%P[TJ8I@Y^"@/B_ >XY/ZOE#1O@@)BMW:H)]]S=UWHD'N15Y-C]T
M"FW/R^-R[[<=M8N,H;# 2P4K,!HK^JOZC46?[0Q>5Z1YLIWO?B4R E$"B'BF
M[/#XI\&\O@YB7X1V]L>\XCKWV#/T=^_6:]]@S]'?OUFO?8,_1W[]9KWV#/T=
M^_6:]]@S]'?OUFO?8,_1W[]9KWV#/T=^_6:]]@S]'?OUFO?8,_1W[]9KWV#/
MT=^_6:]]@S]'?OUFO?8,_1W[]9KWV#/T=^_6:]]@S]'?OUFO?8,_1W[]9KWV
M#/T=^_6:]]@S]'?OUFO?8,_1W[]9KWV#/T=^_6:]]@S]'?OUFO?8,_1W[]9K
MWV#/T=^_6:]]@S]'?OUFMN?!F_L<E^_6:'<^"P#;CN2_=GZ34[>L@6CITJE6
MKK([Z5FYE:_-F31( W*41%0RCAPN8>5%!(IUEU! A"B80#3:5DDHC%/2#"S2
M2C6 4/<H1[U+E9NSB"[TK<[>TP=%41VW(KR%,80[L%%0[UM!TRG0'3Q5ZQ7H
M]O&PL#"L+^RC8UBV  20;HIG I1Y0W.8PF.H<1,8QA$1T \V"]P#8![N_;@'
ML!_6=FO?8,_1W[]9KWV#/T=^_6:]]@S]'?OUFO?8,_1W[]9KWV#/T=^_6:]]
M@S]'?OUFO?8,_1W[]9KWV#/T=^_6:]]@S]'?OUFO?8,_1W[]9KWV#/T=^_6:
MXGP9_P E^_6:_P"I@O\ Y+]^LU[_  7_ ,E^_6:XGP7_ ,E^_6:WY\&;?]R_
M?K->_P %_P#)?OUFO^I@O_DOWZS7%7!?;M[R_=OL?]3AK@I@O_DOWZS7_5P5
MV;[\M^VV]G?O-M>*M@D1#M "WT1_-WN^K#?+2[P:C#5Q@H_=@DED [EP<GBM
M&3-(JO,X>O7)@333 !$YC &H6VPK_!"\'/1C*6CW1POQ=VKU$BJ0+"9;9-=/
MGY%"B.Y5 $H\0UNYF>GEN'LKN[HB'YU')= +FY=,;<!WV%:<M*0<.WB=^7LT
M<SC(_2HB"1!44%2SV(H$(':8V\EP+H@.LM])2 J?],I[39.8^P;CR@$@(F'8
M-]&*XS;TC <FXF33L=M67#;MY$47*BAQ]G8- "N:.E_F4 3$% ^370;!X#%;
M(* !QV[!$!'0]YEWI^4 !VY6U;S@\.''8#<C:$5,0O#V-@T ,KQB62,/C$,P
MH6=U"' .T"BI"-^8P^#CH@M4J[)?U@)K&C\99A6*ES!N7G$_="D)P =MPXZ5
M3CL?.)!;<>Y[G%F3TTG !V&(JYDT! OMB4- :+P0YD$@VW,:E9$;<3;@ <IE
M5U!W';L(;_3HP1W2>9\H4R9RIF87MB44C&V[SO%HU0 ,';RB&DQ_^D)B3O!$
MO*O,V5L8A0$?&/\ "XTA2"/L".E0'I.KA2DVY>]O?P3GV'L#X6FD C[@Z(4>
MEVDH'4+N5=?*L0"*!O!WR1'!G7Y +[HAHHEPSB&($I3%[IU?%W*BH\!,NF9
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M#X)*/G+4.4>("!> \>W148*A4V'11Y.X+&UJ);&*)>;8><K3O-R[\! =] 0
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MLF9H7L.+H3#][?2"5JQ_?:;56UKH5;812249')O(I@R0*V= H"JJO3YTG/\
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M$J)$B()DYSF+XQSGYE5#F,8YS&$3"' .S79_D%OL&X\!';MV[/Y#V!MM[/\
MLUAW< ^06;!X"/\ ^^XE]K0;;#P#M'_9KCM^01_U:((;>+N ^,)> [>P [Z
M. [!MQ$0]WB ;ZXF+[6P![/_ '=%XD, &WY3&$H=@AQY2#OL.N104Q(("!R"
M'>$4*8-A*8IPV$-O9 0TNUN>*\:VANOWAE235-@7QE#J;[F.96.$VYP'QA =
MQT5R? %5KC],PJ)/Z3*VBE*MUC>^50;UJ7CF &]@#(F+[6EG&(>I;JMQ&\4$
M12"#RT_E8UIN.Y2(,GK9LX[HFX^*=P<!W_.0F,_Q #6E@@/,FPS/BJN6%5R
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M#S;%$I"@!B@(%Y@YA+NH $V 0'<.(=O\!E%E"))D(=0ZBA@(0B:91.HH<YA
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MA4SS9,'9797JK=,MQGL>YFLR,9/0D)6;75J^%CM$6D]LD9#A+D@8]/E<ND"
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M.Y0(.P@'@ = 83JB8I")IGYQYR%3#Q=A[!V-XVP@(<X%';<H#HH Y5 "[\3
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MJC.G9=PSD6QPB,'9\<2458D11C2F),0[E91)^D90OPQ;J&ZKND"OS>1^KO\
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M8*D=-1,/(<IA_#;K5/4L36T=(TMBN:S?6+90[I4G])FZ?T>9,PW/TJQDM43
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ML+1(\0P7*89$O>"59M=U[=%YHR+C"1H&;^H#&>=LBQUKQID.G.>HC+]693&
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M*9[=DN7BIVYS/PN5>2*"D[*0L#6XQR+!%X#5L"31+D;I% PJF 53" @ @/:
MAN ^[H"B0HE 0,!1*&P&*8#E$ VV 0, "'MZX@ ]@\0 >P=P_,(\-;[!N(
MCX1 -]@W]@-Q_/H0$ $!W 0$-P$!#80$!]D-![7$/:\'#\@ZY1 ! 0V$!#@(
M=FVW9MMK_-K?;B'8/A#?M_/MH0$ $! 0$!#<! 0V$! >T!#0  !L7WH;!L78
M-@V]CAK<2E'COQ .T. #[NVK[E.GU\]:L^421CK)1H1TNP@KW8(-K%QL/;K%
M H"$<[NL7 1J3 94I4WCJ-23;+F<%0;@AL8 $/8$ '^G0FY0W'8!'8-QY=Q+
MN/;XHB.WL;Z4(D*Z)SD$!6;E$#^,7QA(<2F**X$('(&VP#MOOV:D82A0'[,4
ML=GE;O=)QXJM)V>]WNP T+8;S=+"[#X?9K/+$:(I'>.1YDVJ"2"14VZ**1/X
M=M@VT/,FF;FX&W(4=P'B.^X<=;\A-P$1 >4.T=P$>SM$!'6VP; &VVP;;>QM
M[&MC  AN [" "&X" @.P^$!#7(4A2D  *!2E "@4"@4 Y0#;8"@ >X&@
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>exh1074_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh1074_1.jpg
M_]C_X  02D9)1@ ! @$"6 )8  #_X1?G17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  6XV    G
M$ !;C8   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,3<Z,#(Z
M,C(@,3@Z-30Z-38      Z !  ,    !  $  * "  0    !   "P* #  0
M   !   #CP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $  !:Q
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M24WDEEV9/6WY'I544U-82UUILWM)+6O;[?3JM_._,4&9772^H^A4]KR0]HM
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M[S=YIV[J_P!Q0'6<DN ;@@@_G>I$:[?SZ6N^DY5,NVE^18ZS&Q+0&[;'V5W
MG9[=O\Q8RQFOL>Q_\W[U#U,5C7N;B8<P=T5W20=S#_VGW)*;IZW>!/V*9U:
MXZ^'^!]KOZZ<]7RR(. )$Z&R/H_RC5L5.C[&2ZJO$P&6 0X.WL:=L?1L?C[/
MSE;IP\")?7T^M[C]%K0\:?1=NW5?]0DIFWJ>8YK7LPJ]K@3)O:TC^26O8URF
M[J.<.,.MVI$C(9!T'N]S6_2^BH-P^FM)@8()F?T3>_\ UU-]AZ27%Q&#N(VD
M^FV2(X_G$E,_VKF=\6H'P^TLGF/W4F]4R7?2QJFZD?TBLZ?<C"VD  9&*
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ML)$B=SVAKGV[W?2V?0_PB2FW4ZMYM;7=D4,:_96VN'!@:&N]K=MGT_\ A/\
MK:-CT[L@-.9E/]I)J>-C?W?YQE5;MS7?\(F9T[JC2".I$;CNMBBL3HT>S]SZ
M/_"(K,+J >[U.H6.8?H!M=37#^LYU=C7_P"8Q)3>0>__ %S^")M/[Q_#^Y"C
MS/\ .<Z>'P24_P#_T/54DDDE*30 20.>4Z22E))))*4DDDDI22222E))))*4
MDDDDI2% G^W_  14+O\ V_X)*?_9_^T<@E!H;W1O<VAO<" S+C  .$))300E
M       0                     #A"24T#[0      $ )8     0 ! E@
M   !  $X0DE-!"8       X             /X   #A"24T$#0      !
M !XX0DE-!!D       0    >.$))30/S       )           ! #A"24T$
M"@       0  .$))32<0       *  $          CA"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-! @      !     !   "0    D      .$))
M300>       $     #A"24T$&@     #10    8              X\   +
M    " !E '@ : !? #$ ,  W #0    !                          $
M             L    ./                      $
M        $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   ./     %)G:'1L;VYG   "P     9S;&EC97-6;$QS
M     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M      =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/
M<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54
M>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
MCP    !29VAT;&]N9P   L     #=7)L5$585     $       !N=6QL5$58
M5     $       !-<V=E5$585     $       9A;'1486=415A4     0
M    #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M    "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U
M;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F
M875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M    3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N
M9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L
M;VYG       X0DE-!"@       P    !/_         X0DE-!!0       0
M   !.$))300,     !;-     0   'P   "@   !=   Z(   !:Q !@  ?_8
M_^  $$I&248  0(  $@ 2   _^T #$%D;V)E7T--  '_[@ .061O8F4 9(
M   !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.
M#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1" "@ 'P# 2(  A$! Q$!_]T !  (_\0!/P   04! 0$! 0$
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ME<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$
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M_]D .$))300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0
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M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M                ]M8  0    #3+4A0("
M                                     !%C<')T   !4    #-D97-C
M   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G
M6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q
M (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $
M#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A
M8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M             !)S4D="($E%0S8Q.38V+3(N,0
M                                            6%E:(        /-1
M  $    !%LQ865H@                     %A96B        !OH@  ./4
M  .06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E
M<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:
M                          !D97-C         "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)
M14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                            9&5S8P         L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                             '9I97<      !.D_@ 47RX $,\4  /M
MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                         H\    "<VEG(     !#4E0@8W5R=@
M  0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C
M &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -
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MUTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\
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MD92H"E)B=">X*7GPH7)3-+1VI\&"HK)#1%3$I;5&IA(!  (! @0#! L!
M     1$" R$2 &!1(C&!!*#007'P8:&QP3)"4H(3(P7_V@ , P$! A$#$0
M /[^ ?)]'"<QQG(                                       1*2T
M                                         0F38
M                     ?A^@     $,$S@
M                 $5DJ
M _#]  !"!-X                                     /P_0    0<3B
M                                           0@3>        ?!]G5
M.T                         :0>;9MY)!U#]-,(T/18E8   A<F@    \
MORKX!^'R#[.,ZA]G2.Z=T^#Z    /D_3Y/H_3@.,XSG/@^3E/P'X?H   !@3
M/   XCZ.,_3KGR8<[A7XV @,GPZ1M1B3>RV1ZY   BDE8
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M<I"!M)+I[ GR2B7,  !#I,0   !6 VTPQT#/F'-/(.+8G.9PQ!F38#H$F@
MHZ380$6=*R$V Z1&I=P  IH;<2T:<9<R1]'</HQYSG3.V:>2F=,VX  'GT79
M,$8 RYFS'&H&CDG&:,<2N    0V3(    4&/&4B\FH@4O<;<;P>R9W
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MV,B7X .P<9)A=H  %>"PX    !Y<'BN1P6D)H*YD-&VF<+\%<3K%=21#^K<
M        IL2V3<                    5O+(     'G$>=IJ1.1OI"A&A(
MI;\IR3B4:+,EIBF99TJZ1.2\2X3H>;9,9W#('HV7?   *;$NDV'\QQ-0(Z,R
M2L>[H                *X%CP    "FIXL%RR0#S:+S&UD/F8) /HJ^:.>C
M)9$VP_#6#%F))7-(,<=TR!*1*P  !38EDG A@T0G8A(R1OI)0
M     *WED     #SG*7DVEASR\-D+2D+D)&CGZ;D7()H/1@         IL2Z
M38                    5W+$     %&CQ=-./0THJ68+&GF.66+ZE)S7C^
MA8          IL2T3>                    0<3B     >*)YZ$*DE%JR!
MB,S;R+R[!7\Z1[9GHL         "FQ+I-@                   ! !/X
M  !YSGFB9DEXC ]&3R5/84\CS+F@GH&5V)C/:0         IL2Z38   <0.4
M    Q9E           5\+!@   'DJ0X4(*Z%AB!C;C92&R?2%B3ROI:<VXAD
MLD2"6!*T$[G$:,;P1:2>1Z0&6U-*-]+6GR#]-1,N9@ZISGV8P'V<Y]'&=<X2
MH9J9J1H9>$ID:F9@PQLAESL'>-.-G.D:V;\3*6H ):+Z   @\G     @8SY5
M,U@F8TXRYB#&F1,F2V0P90PQ()'AO!M1"1OQ@R.":2-S9#LG2+$E;"1"UP
M      /%4^#1"VA9\@8VLQICR4S7#<B*SL$A&EG 2$=HLX    "MI9(  XC[
M/H&",Z                       #RY/1<KJ=PM:     #IG<     !7@L.
M    1N=PQQP&IDH$3FXF$)(,(:@2,<Q&9CS8S'&8,X<IV#%G:/@WX
M    'FF>EA6P\ARVAU".S<C0#-&&,T;"94[@.$Y  ?1,)?4  %=BQ(   !X'
MGC068,T5^+-G6/3L\-"42EA*YKQL184P)Z2E&S-%'CTT+/GFB0\>^QZQ@
MXCE       /-,]+"JQXPGJ44A.D:N0R62(U,>6)/3(L&       5Y+#    %
M=#R9)?)1*7&J$HFI'1+'$7F6+KE4"5"-B3R$S$E^3SM)./9X
M \SCTQ*HF>+(            %>2PP   !34\TB2"RY1<C4]("D)*AF#9R+20
M36B2#13#$V'5-\*IF]GL2             >$)94K:9XG,  ^SX/TYSX.,R!P
MG8!W#[!*A=0  %<B>#*@   \QB@I'IH9CSO%XC6RL)ZZGEP6#(//20]+@
M             =0\V3TK*I'EN7$*DD+FO%FB)#*&^G?(E-P(E)\.H5>.Z7&)
M9/5HY0  5Z+"@   %7R&#;#MF1(G-Z)C*:EBS)DL%%RWY.X    /D^CY/H
M        'FH>E94$Z1II^'4.F9XV,PIWC:"+#T+       (')X
M       /D^@          >99YT'K490H:?9NQ-)"1GC63C)\-4/44
M@DG8                            'F,6J(J/%<W<Q!$!K)(Y"1-A"19X
MVD] @<AQGV? !,1>T  $%DZ    %$2,@<1TCY /PX#\ .8^CL'<   .,PQRG
MZ<8 !V#L'P=@SA]G(=H^0<@  .,@@]CBG1W#>##'V:P8\QA*Q%Q)!D"P@
M   ! )/P   !Y_GF"3F>Y8         !0DH>8PTHN05Q*HG]$18
M\TCTM*/%FB1S^8@J89,LH4L/Z CPG/;<\KC'']51MH     ! !/X   !Y)$&
M@' <Y\GP<9P' <AP&5.8&OGV:B:P=PSII!O!$QF#NF9.^80UDV(UXV$U\F<U
M<TX[1BS;31S/FO$BFD&<.<Z17@E4&N$I'*:\3F=<_3JG$=0[Q\G8.F9,^SO'
MV9 LR>I8  *_%@0           #SI-+,V>6IA#TP*"F8-A,B:46-+4'DX?)<
M\IT>C)6\DLH"<!-9IA$Y;D_3&%ABF);T@@PI8HK<2<88TXSQ/9[/@
M   KR6".0   'C 4L/38SI\&0 ,>9,ZYQF6/PR)C#L'4,48\S!^FMG>.^=4V
MHUDRQJAM!E@8<&4.(P1K9V3;#K&%,H8 U,V<V<_#Z/P^CE//<UP]*3.'7,*<
MIEC6#R&+Q%KS\.,_#$'Z94E8N$  "OY8     \O2JQ>T\^312Q!B",S2B0"0
M#2C)D;DRE@"EIUCB)K-B--(X,F3@14;.9$]?#P7)N-()1(./@L$4N+&D'DUD
MP%=3527#930")SV#+?@ 'E ::;L5F(@.R7D/68T<\=S;#J$9FP$3$<E]SUS
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MU@   'F20 =XQIH1^FYDJE=#LG=-^,8:P2 :(:X9TL"028\ZQL9N) YEB<S
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M&&)0*_F]&),<9\F0ZQB"L)M9%I;TB8W V$B8D4C,E0T,]:B2#]/D^@ #C/L
MX3E. '.?A^'Z?9\ _3Z .,Z9\G0!^     E\NN  "%":P   "LYHYYY'R1(2
M81&7+*QEBBI9\FBEDC&'4)K-=)"(9,8;B;J>RH         .$Y@   #\/T
M         $(DW           '$<H                              !!
MY.  /@^P=8[!^@       ZQV0                             "%R:
M  #R&(9!QGR<I^GX<1]G0.(^#Y.P=P[    .,^3\.$^3].J#L'X=TY3D,F8X
MR0.4 'P?IQ@ZQ\G9.J8H^#Y,<?I]'9.,R!^G(?A]GR?I^@%F3U&  !#Q,(
M        !XZE@SR;,P6B*BDSE-CT[*YE:R1C:B^AYB%GS>##GZ4;)"-G*]$X
MD@DX%#C[+DD8$WE4C\,>1N7J.(K$;&0:; ;^5#/=D]/0         0L32
M        1R;0><QM)MA&1V#33?24""33RV)&9L) 1:@X"$222-#/&FDT&/)$
M,T:P1<8LD B,^38CA/DG\IN2>;H;X<A-)C250         0:3D  #I'=
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M8,L:V=P^3)F*/L[9B#JFU&%.X:^=@V$X3>     "%R:     #RR/4T
M                               A8ET[@    /+T]0@       ?)\GR
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MZ1GCX-X/TYC@.P?IPGZ?)V#J@'T?(   .P#\/DS1P'6.(XSC!.1=L  $(DW
M    'F4;<>@1_/J;F"+S=B"BR9B"RA4 TLS!MI:<KZ9PU<U(E<SQNA&Q!A/Q
MTRVI#AK1 QKQ:(RAA#V0  .$Y@                0@3>     >9)Z;
M                                 $'DX    %"R.#SH)'+@GEZ8 G$^
MSD-B,L= S!&1*IE3=36S4S(FF%R3/ '$<ASGZ<AR'8.,[1R@   ^#[  !UCE
M.@?1TS\/@'X #Z/DYSX.0YCN',"6RV   (0)O    !XSDN$ZFZ$$FNG4-.-\
M-Q(!+)%8CD(\+$'3)*(B)(.B7M-R /P'Z                #X/L
MAPF,    QYXEDV'J"?SMFL&P%GSS>+#&?(M+)G7*O'H(><9,!Z8%XC\/P
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M9D/EQ"%S5"%2\1*)3TRAMI')OI,Q*A3$U(]DCSU) (R)+(3+B%A3S%)>+3$
MD2&3+ E9B'B9R;":R 2FYV"8"[)0PE(TLQ)()M9JAI1+AO15X[I)Y[>DF
M $4$K@  ZQV#]*]FO$:&[G,18;080D(KD3 2T3L=0[!\G.<ICS('R?A\'(<1
M]G*<1^':,*9<K668.0X#6S(&6.,Y3\/L^3D.$^B,S%$RG$?A\%;2R)^'Z?)\
MG.<1R'&#B!%Q*AD0    1$2Z    4/*G&$/0TI*9,S)BS'FUFAEM2[H
M    !Q'*                     "(R7
M                "&B90   "!BIA&9(YC#)%NR "SAA#7B0C $'DPF2-/,N
M8<S9\'1!O!5TM61*=PYCZ-R*]$_FNF!-H(@)6,.8@W,T<SYG3128BNA&Y;\X
MR/23RIA#9Z5F"-1-?,H;*:J9HA8FXB0W@SA]$9F,,P7!-@  !#!,X   !6 @
M,JD3R=0KN>N!Y[&1(M->+"%#R\Y6,E@KP3P0:7>(6-#+#$C%/"P!#9IIDSA+
M4'X8DB0D\M^00;\:T5/( +&$8FZ'2)N*_F*+?E(BYA#Q[3GDB:V<Q!)MQKQG
MB>RKI;L\XBXAI!@B92(S:2'CWD)   !"1-H   !Y=GF"1J73-9-M+&'GV;80
M>9<W(G,V IT2&8 ^2-B[!H!6,[!Z+F2/, ]2BJ9$)DSN%[#SD*VGNF>>Q")<
M0V0I<>BQ2<BHO<0F6]*'&5-B(W+CF^E12%3&DUG1+^'G&2D<I7,ATL86X*&$
M[GV5E+,'H$>K(  !!Y.    !5TUXKH8HV8P1V39#2S)GT69*V'T9,PY5PO(0
M^=@SQBRX)Y[EP34R*S*G 261T;Z9XC0A4MB9LJ&8HWLWPQAHQ5HF8S)))+I#
MYEC4#7"TAPD=&%-?.Z;"9PS17DZINI9HAXH\7S)H+>@   $(DW    %(S %3
MS?#7R<2)"T!$Y+Q%!(960QY=XT\U<^S$D:FZG?+6$$&>- ,2?!CR>"*2,">C
MX- ,J;^0P9L[QPFX&0-0+.%3")BQ!#1)9TS4"?SF(E(2)N.(E0CPV$BXW,A4
MNP5A.F;47P-R    (1)N                          !Q'*
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M0(<)&,^<)&1*A\GT?I\GZ?H/T_#13X-^     (V,F;J?!A#/F ,\#]
M          !"9-@        !PG,#J';
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MYT'HN >%9#)ZGE'37SU**PE=#Z)Q/+$]0C$E=3T=)-)@- ,J<9JAWR<3*
M     @ G\     %<#S&*Q'6-=/Z4RDY:TF@PAX)FW&SG3*5E;"Y!,)3LMV7_
M #^9<]^CUT!3PJT:(>SAX6DTGK@><QZ,@'@@8$FHC0L$4H)/-!,X=@O.4A+"
M'&50)X)2(.,$3@4V-Y/;XE@^@ #Y/T_0   0&3X=4[0  !YKE;28"#CJ&RG9
M-7-E-4.F:$0B9T]$S<3Y!VCX/PW$QQDSNFE%=21#K'$:X8T^S %L2D)94^S4
M#5#724#5CI'$24<P(@-J)R-R/LQ!C#K@  @HXS<C033C;S6C\,J6S)J+4@
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MB*R1#K$2%'3T0*RD_%RB*L2Z-'<@?2QUI:._[U(G)X-6*#%ZB:S:#[,X:\1
M6/+2@   KN6(     (B/"8M*5)//(]@2I(('/:\DDQ)Y+$K$C%I#>S'F]FU@
MVLL85Z-6+7   UH\XB$2QQ?(@$_#@/PU,K>24=$WDA@V\X#C-O("-NBZ.[2\
M[=3O&;+*&4.D4*/0,V0       KP6'   !^'AP=,\GST*)2*HG@D4X+GGJZ4
ML*]$-E^23R3CB)".T5:/8$D< $9'P2@   "L!9X_0?)] @<\Q3<#-&^FWD0F
M&-E-),>9XD\]'3'GZ?)USOE92T1PG,<9VSZ/D[9]EH2ZY\GT?A^@A<M 9$
M 'DJ4O*F%\"?C.$,GA4>UIM!<$]!3PM/5HGL         'C*2F<QZ@@
M '\TA-Y7 V,KT6C-@(W-3)T+*'E$6S/0TKL5(-D/Z/P   "!2>@   #Q_*(%
M&#T])E*?'4(0)U-W))-9)4*BG]0P      !U#ME6#SX(H,D2>1N#2CW6)+
M   . _GG-Y.D;J<1"1:@]B  ?)]  ^#[    *_%@0    "BI4L]CRO1Y(']
M9#1YOGL*"KY2(]?0        #IG<    !UCL@  X3^>XD0K87E*1EQ#7C%'N
M>        "O!8<     $#'FD6%/2$ HB56/PFD]+P
M#KG8/@XSG         !6\L@        ?)]
M        %<BQH .B=X   ^3Z
M!"I-0     /DXSF                                    (8)G
M     .,Y                                "%":P?!]@
M                          ^#[   (5)J
M                   (/)P
M    /D^@"%B:0                                          "*25@
M                                          "%":P
M                             "#B<0
M    #\!^@          @XG$__]H " $"  $% /\ Z".[=_AE_I?/V^&7^EN>
M>....>_;C]++U\Z<]OC_ $ISC^.3_P",U__:  @! P !!0#_ .@CL&OT[Z7]
M+I.'C)H<\<]>?Z5PX,NQW[]-3!EYWD[9YV>NOQU_I3'O_H:O_P 9K__:  @!
M 0 !!0#^'?M^3KYCU\&'MYCQ8L/7^CSNLJK>#O\ 2\C_ /8G^B.?..>>>/>R
M'XP]@K_2YNS:^ 4_TAUXYXX]J2'Y>0G_ $9^7CX^ZDE_LE_2\C^.G(5_ \8^
MO7OYAW]'8VOYF3"$VA(.'M;]' 8N/':;'C0 RS9)"Y 6W+9G!QG<*\[VVGLM
M@V@Q]>#G6KG(D-IIBDL)I8P>W(;'TS!OW,NK98^0P+7_ &%X>>?]A>'GG_87
MAYYQ]PQ#SGGG[AF'O'?)]PS#WIT_["\._.WW#4/NN/']Q'$3OUS_ '#L0</?
M']Q1%#)L8_N%8RY>V3[@:-V/+U^X(CCWY_[ D=?/^P)'7S_L"1U\_P"P)'7S
M_L"1U\_[ D=?/^P)'7S_ + D=?/^P)'7SM]P-';CS_L"QU^.3[@:.W3IU^X%
MCMVZ]ON!(\<=,/W!$?<O3K]P9'[OUZ_<%@OMYT^X""F37[?<"!7IK]?N!0WV
MZ9+_ $0]._>_X0].?7^$GG-_XCX\]?X2>>O\)//7^$GGK_"3SU_A)YZ_PD\]
M?X2>>O\ "3SU_A)YV^XHCYT=7K_"3SU_A)YZ_P )//7^$GGK_"3SU_A)YE^X
M$#N#KW^X"#^+SI]P0&<GG?[@4.8^./N$0CVZ_P#85!GZ2S]QS&)M)^Y]P9'I
M2U-BU&M3]DSK@Z_F-H,Z=U6#.4%>WZO9?3\=KU<W7S0NH@^ANS2MYKTQ9QS=
ME"P4:49+BP]*8Y>T;M?KM"_^5\]>.>?>R0T7GN3[DIG/3J:;E#]GZBNO4"V=
MK;6;>I;RWV@/PM*5>1I"CRQ!3+TE&G8*KOE2'%HVZ3*Z6S)QLC+^-F'3!GC4
MH-2V-LC@S^J6Y]>->H]]$$&W$4LX98XQLP>\@?'@/;2-]4D*YK8",PHSH\T4
M^7/MF3O^F-_=YLV+7Q)UNXF)4$]>\<"NU9C?;8ZI0E>'%S[-G"CQ:ON&\DT3
M/]QL >T%W9:\ZF_,=LW2,MR'1LVBF!P3'-=@^1IRA3K\PZ0E*3]D31B8.=NS
M]8<I9$=UHID(6B[9\S@7,[0L=+^]&_>N6>VH"2M8^P8W(<G[+RW'23+UO-80
M?<Y)MQ7PNX@;< 'S^$6/> TMTD@ZY3O))"]<5$=*:W+QV*07,'[JW0:Q&!K>
MMF4;BD)9..(D Z6=A98C =GO>"U@4Y7+:Z]AH\8(6CL&P+<)URJ"U=3-<CB<
M4HSS/+7'TMNUF1!6)&*OW"(";XXD+:^7([C&25S!*BR6"Y;+'4*QW?$YE;;F
M&2[5I#B\G,%>6W4Q?/\ _7?WEF^/MECE_!'<[:<.SY8\4'Z+D#^",XV\X^/9
MRX^V7'_"0F3KB$/NY/BEY'('CNHMT 4R,2@D:@PD1BJ')<73(UJJ&*UC+%RA
M/9 C2+WV^; )8T?=4)'<<W3'4F-S_MM>#ZPW;,"S7^[,LQ!A]O\  X5OF9L5
M565[:!M+^_#A;8=(/>/;\[T[.8D'AM0;DTGQ"7:F'<J0LL#JBTK$$ I5Z%8T
MFHST@->09'=]7;Z)Q=4*E WIR9>]0K'(YMC_ $Y*,7=)%H]ZL/EGT<-\</&.
MM0Z''>(,=JAER([WF%5QQ.<=D6N8J%5&D+2R/Y5%Q2JV?1 )0IK[#X:G 3J:
MTUSZ 1JB&0<G"<X"[+RFD[*\B!VDK'JI,0 (3O.FI#VZ^YY4MC>Q&21=I@<\
MHHUBNM M! O20K]<TAS5_#'M<=[A_>6:?'Z=?X039"RR#CY:9UZY$/\ A78R
M51C+ON#I^U^5GN;%PP)N,4KH70[BD 2,6X.Z#JP'./G41*A^BL.4)#(H3*.Z
M-^P9)3D=4@H=LOSL: OSHZY\&+B1E?M'Y&C^^N PE;>0PQEU>Y9W8O#%%AL&
MXA2F=OI5PO\ .M5T,.G..K.&>/MQ5C#+KQCJTAGBS8JO(;8<\^X 1J%D&(Z1
M6C.YR[*K9CQ'4I+[O'K;65%3%BC'5QZXZ&SX;*J#MV/>J\X5:KN;F06[1!Q5
MA0TP=LE7D+\VOO5'0%4]C)3U7GEZ[M/5>:CMS9JO@X)X71,C;6\8S1,QD09B
MG))]-.'C-3G0T(B(:0S&?%,E:S+V(3N]L[ZU"?586XT8PH8-U>\+G0#,&O6T
MWEL?*<-W41#9]#0GD<-Q% 1T&"8#/@G$DKQ(@9 D^*/HZ5U_DUZ?*[M7S:I\
MKNV^OHXUT^=Z<JZLG'HW5T>21K0AX.I,#R#\"7G I#)D-40@OY3AFP6\/(OQ
M1/[B<XGAN.HP1:&\$CJ7CR+(3C$LNO=I(8914WK2FYG*2GW3Z@*(8P5>EE:P
M5-P0UM7BIB!W7;$]?T50@]_:/O7\PI]S*_>B2@#\8J\>3N+>D1(E:R+W!</
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M]E/)5=[M#91X#!-VPZR7^VG6AMD9+#\?KP8F5FKJ^H,MOY76*7NW@4DN%O\
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M7W( ;5::/<6+66JC>ZIGYU0ZV+!$!""5UD@\B82W/:B%!_*=YW3B-A<H]M0
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M(<HS>&(K@4^XJDIHPV&2EM#&*2]M@E?K)>84U@A&Y9&$O&)"2,;E9[ZA<[&
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MD;-F?P,2E-S+$ *EZ<#*DD2'E*:4;*F/("4K+D2H2GM'66T3#]/,KD)(F!.
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MQTNO.D4"[-DDT73R%K@(X/TDULH^2=T[%I92&XCT-HZGNP\]C\O7\WN)+_\
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MT;R0DMK.SVUC:$+'7RF[D<I*YW2S0/(5JN]/1YLLR++$=-A[)'1&#LGBRHK
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M5^3V_C/ERNJP1Q)0%Z]./\\NG2/N=8^WBQ;Q.56UGMZ?3X?&(UTZ>S-__]H
M" $# @8_ /<$=ZO.T;7I:H:Q EUL^=0\^6/^C2^3:^HVXL?2V2K_ &0O\2D_
MNR5G3AK82PPCXCT>5JX\.-M=0 ZN@>;Q;#?U&3)CI9C9 ;M"R69#4B0M(#/$
M^L]#9R0]Y=;+UN&PN_6-7Y\8;X$[ADUTAC452?'\S/C/*M<.#&US:C:3]4BA
M$[MO:,]M=VV&R^S-_P#_V@ ( 0$!!C\ _8$W0QN@@'0A1,;XB ?  ^/0.OQ_
M<#]@YD4$4C*G.HH9-,A#***#W'.<2E 3G.;XB(_$1_8$J*::11,)Q*F0I $Y
MOWQA H  F-]\?I'_ %H:+-P;]Q%R\76'[R/D&A_+<M'2)2F361/\>TY1_P!;
M&I__ (GRG_[!?]9/T=?[0??_ +7QZ!X 1 2B( (@/3J _N#T$0ZA_:^[:&1=
M(5TSP0D%N!"*>I,=XT(FU$BGX,2N5!!,>[H4 -\1 /B'^M>[*.EO3H#$E2.M
MYADA(*[QJBGVJ$$#$.910 *(#UZB'^M'H)A,/4?B( 'P$1$ Z!T#ZH?#]O>^
MX1 /1Q7Q* &'K]H(GM^ B7Z3?V_]9O=T#NZ=O7[_ $ 1$ _V $?N=[_^9(G_
M *0Q'^MB\@H8Q2>EB>XQ" H8 ^T,1^](8Z8&'_\ 2#^PCJ  ]Z@$ P]QA 0)
MW=O0HCVAT[A^@ Z_?_8=LD'C1=['^G]>T1<(J.F7JTQ6:^K;D.95MZE(HF3[
MP+WE#J'4/]5+_JMT<.6E/S2EVB_6ITR:*OWC>N4^$?6":7:L4 %9XX2C8]0Q
M$B_6.8  /I\;+1M)J.K5'0<:J$)8W5+5C:;+R%_G9U&)DT<YS.1A+H_@K5?(
MZKV:*G'S8KI)NR@WJCU5<J#"2,SUWD!<X>_TFM8M)TN+ME?DX^OR-K=N;](%
MC:Z2O,(6QOFDP95<BYE.Q<"E1:+*%,<J9A!U7)78U4)AHLR1.U2S;6WI''S6
MU+T:%<1KQC0W+&686"Z-5(F-<M5%F\E(E%NV.JK]7P]-9]YBH8D>)/4J.JAH
MHI@D:03BS.T5$:@J1VP0?N$4UG"0G00%P@*AR@NB)Z+=X['M2L,5?:1LMW8#
M'2&5L$H9EA[QVE<$+,[L6CPC>&;#'1ZSI*2,)HDO<@W5=$=NFR"C>LV.,M^2
M"E Q%EM$YJCBBUJNT*'LGXQ&=8=7273NCYM#C,V/'K;%F+U4,Q=P1C.P0;NV
M*SBS7NQM=$A:?6JG VWY\]CJB1K.(WNL.;]E4/!%"Y"H[FM.SMH>98)G!))F
M@'D2"C1UU0"]+1U?GZ_]@]#G,[>?.UJT];S;F&CX662L-=DZI8;+$R-?DX^>
M0$@F73=MW!%FSI!!P@JD7]O=4U%T6Q#MHH#+KD4.BD'S^)'N.1(BBA@^'WBB
M/7[D7&]+R?E]=;*:JPMO^<8AQ>TS7:46/G7$FV:,C6RJ1[B*"90-%',NU PJ
M(D.F)OWW0/\ -Y]Q[\PW<?\ DCQ_F\^X]^8;N/\ R1X_S>?<>_,-W'_DCP8/
MR=_<?  Z=##P-W#H;J #U+TB1'X"/3X@'Q#]SP4GY.WN0B42F$50X';=V%$/
MH(8!BP4[C?>Z%$/W1#P)B\=?<A6, EZ)I\#MM YNXQ2B("K%I)]" /</4P?
M!Z=1Z /^;U[CWYANY?\ (_@QPXZ>Y$<P%,8$2\#MM!0XAUZ$*)HPJ(&/T^'4
MX!\?B(>#B;C)[EJ0E5%,I5.".NB90@)@<%B>4DH4$A,/9T,)3]P?O>WH82 A
MQG]REX9;M QFO [8BB!NXA"D/ZIJU.<P <1#M WP*/3X] $K;\DSW/RK&4%'
ML'@EIQC@KU$H)>4FY.L*@G#M[0*(]P^$R)\./=04.J82)$)P'U,YE#E$P&(F
M4K@1.8HE$! .O00'PFD;AI[JG50B1Q,/M_Z\4$RJ'33,)RG[%1!%10"F$I3
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M=:Q8).Y3\=>E$4E5SSK)]&,T)$%C)(BU(8?&U\H]-Y%5J<Y3Z3QKJ/$J@7.
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M1,$S'. L]QY#QYA%3M 04,PUAL94H=OU2F$2DZCV@'4>I/\ YQ$_^##H'_B
MY*#U^L8WX0!V#HJ/4WTFZ_#H'T  >$P-A$Z'ED["BGOW))(3!U$W50R6OD,L
M?J/[XXF-T^'7IX_F)L7YPG)C^F/QQMJ]$QVZO:U8\6YF7FT9>WY/;Q6835+)
ME-8R-_G,+9+%8=;]%"M8^7LCHS=VLY:M6:ZX+KF%-,0\/N7,CQ47A+W"X9?]
M.L>6J<HN518B NF?0MD>S5 ?VAYI#1X9HQFZXJP4EDF2C1P0HO&?J6IT5%<P
MKNS>V-8J+6-(PZ3WN(D&/,7EP:S6&@MJ#M][AYNIPMIFZS'>KMY<6780$',/
M8F=L3AT=6+;NT&XJ*H^IX-9_/7$(.K7]RSK/.SEK-5E;/K]Q+T'E57$XR2;6
M()9W=81OG:D!)LS,TT5!FH>214!*03:%OE)J_!G*6SK'%:4%_B=SYB\PZ+,*
MVVS'T*ST^5JM)F).<E$R4Y#/V2CDCDI9 DX+Y!J8BD.99QQ,Y/WS@@WDJIR2
M@9:^VMOF?,?EK;W6-Y$OA;S9XK5IE@]M,')VN#HH-/(NK.+26=QD2"THS]:5
MLHT' *=9N'C>MP7(1OR0AJ))U/F1RHL=VH5HXE2U8K%V-IU7?WJ%2KU/O$Q.
M*?9EXB[47(B:-(Y1!643*WN5 R?@E.Z;"0+F8SIJ8>6_)>OV^UZT;2\1QBCM
MHRNJ:H=D.93N\;6T@E9)9T1Z0U1L+E!HNFR0\^7Q:U<=]OMNBU2QPU/NLYFN
MP;G.4?[2+RERK%NF(I20Y1-+8G6*Q=\\F8]?UD>E(+*I(>D0>%>-%'%(<)\1
M;NEF#)9O,7!]K>U\@HZ]TJP*I,[?FEPJ=2C-KNS6483&=0MJE6;Y%PA(-'T2
MFT.#5558R$93LTXD;7;;2UNU'2UBJO=_VGUE9H*$Q<&>L244VK/)Z>):+IEC
M6FR@IM$C"PEW*)T8IW(*_@S$J%/X_7>8E&O**N9 VD*[R3Y5FIJD1H6FV6JY
MQ*P\PKL /9'1S9928ZZS$<DS(RCH01'UICMC$(FR;Y5>T&:+MF_2:H\E>4::
M";Z/6,X8NR)$V<"%<LUS"=(X!W$,(B AX?OPRB\@^E'B,A)//RD^4/J7[]NY
M2>(/'BWXY_,<.D7:!%2G.(F*H4# /4 'Q6-$S6CW*&M=-2G$*TZE-SWRXQ<6
ME9&:["<33K%UTZQ5=P60;N3]WG,U.U7M5+VJD(<O[:Q@+LC#J]JG]^'(*A$/
M^>-?^N8@ (F#[W_I^Y0ENYB0N1R]"K=VKZU0'6J3#W\C;27RBS.L%HE<D(.Q
M2S^^NA.J1FG$M%9(Z8*B0O84XAE%\RS\66E9*U-'6G&YR!C8.8K,(\K))&N,
M)6ED,T,G7)RK?WY'=4"-WL:H"[8P)'!5,!K:7&+CNWKJC]&1- IXQFZ,*I*)
MJ1:K=\:+)6RL3OR+0;$Y%!3%0#LD! >J*8E"0+B_'7,HF6&.S$'#+-,ZJC*1
M#4YZMU".HG]Y0;))TC?;$$3'A']#$D'";5,2'%-,"^@@./&#P,<WG2V7T</D
MV?Q;)*S$CI6()8#-V4 @@6=)$V!\U!V(>H!N^73[^Q90#/Y'\ECC>,K+#*J2
M<@.(YF,E)FFS/C3:C]Z-9%V\-+'E7(NA4,85Q<J>9W>8;J[:Z@/'2&E\PN&:
MT\XW&#I*#FH:#MM>89MF%5C'4I'?WG==!II&D,Q8-#^O<PIF[<4_1G2*:8Q)
M]8^(LAN$3IHN9RCR-2I+FV1^KQ%QJE)&:?D>UXQF]JC+VYA([YD90%49(S-/
MS@5\H/# J/&G 2%B;%(V^* ,>ST0B[7+BP&4LL;W5X?03LA\K:^<[2[%U ;)
M 8P@F3I<.SC?@Q/QA,'\7?\ LR'/R_;B,E9\EJE8VX=M>#[3,).T)EDG"+WS
MTUWX X.!E?K^%[C#XEDL7;7,\QM*]GC\ZJ+.P*6>,BGL%'6,TPWB$Y#YZQA)
M)RS2>>9Z@C9PHD!P(H8!;LFO'3"FS-HSJL<U:(9)0$6K:/HL\XM5)8MVZ=?*
MDBSIUH=JR44D4 )'OU3N&X)K&$XJ6&O8GDL%/JVY[H"DW$9U4(V7->Y*.DH>
M1N@R+.'1>?:I_$S+QJM(=_JU6[M=,R@D54 R$J.;4$91M6H&F-I(:?7O7MZ?
M5I=.P5BJ(._EWJ$JU7)Y$CU@Q*8&K-V4%DB$4 #>'T]3,HS:I3DG8)*V2,Q6
MJ/68*4?VF89N(Z6LCQ_&1C5TYG9-@[50<.SG%=9)4Y#F$IS /[;W O\ R3\I
M_P#N.O/C,[0-,J8V:0H^8S+^Q#78<9U[,0=$:PD)*NY?T?S!S)0\,^7:-5SJ
M&5;M5CI)F*0YBBACNMCB*^[W26HM4>(6C+V\\NXLU];J-\SI=PT16GR-5@[=
M=6C0"0,-,2K:1DDC) T04*JEWSP6#.,IFV<[96<U9PF:?49)M,W"*:_*(^6G
M@>QRR4C98YFIZ5%=QWND4C>64P%'M\1P;W!Y%0I39JG+5\I"8FO:I*Z9[E[2
MMIS+.RITFAV-V;.Z PD(HJYY0$XB-1.W 3)E G2R361FR*R-&&D1C*PS-3B:
MX9F[U"-J5=M$(["4:L4F\[96=-L<:Z9OD%'!RLUT_*5Z (%:Y[(T?&H5]NT_
M*5@U5)1ZHDEI5AKU=G=/E(J?8MH<6DR\C*]$/Y@Q9 #=I4SJA]<P=U%BM B\
M.HT;I]MS_'<YAIBO4Z.0O%NDK.I-9Q0:K$_+P^=O4;4Z5DF#1NDH1FX%5Z )
M]JBP6S+\N8X%==*PJ6F7LQ 1N>U\K^IRA+J\8VJ;J;]]6FK&7)':5#KM9B1@
MEW:+*PMS(/%4WQ>P/VO.\!^@>&G* !^]\!Q&\!]/CBS)O8"%?2T-Q\Q5O&2[
MV-CWTHP(TSVOF0!G)JM?4H^4HH8Q13$@=QA,  (CXEG%NS#/+4XG@C2SB]DI
M5;G%IDL*1=.'++*R<:Z/(A$D=*E; L)_(!0P$[>X>N82KG'Z&REL5L#ZT9)+
MUZ 9U66SF:EB/DIQS3Y2L$B'\&WL2$FY2DVR"A6LFBX53=)K$4,421)L2R(T
M4D[GGZ<8.;4T8]-_:FX-+0](S&%],1W9&I02?J 7O>)AVK"</AX12C,GS2.2
M;KP+ENFPHE79IH.:JDHC5W")&\4F5)>MHJF(P.4 ,S*801$@"/B-5;Y3FR"L
M,RF8V(41HM72/%1UB%X:P1\:<D64S%E.FD7 O$DNU-T*ZGF ;O-U392.;T)^
MR1CX6)2:/:?7G35**K9TU:[&)MUXXZ1(^!51(9DB  FU,4!2 H@'B2FY_.:'
M.3,PP9Q<O+S%0K\G)RL9'.6[R/CI)^]CUW3Y@Q=M$E4453F3243(8H 8H"!G
MDID^:23PX3('=/Z)5GCDP6)0%K !EW$4HJ8)U8H'>=1_OHP=5.X?$N5ME^=M
MRV!J#&>*A2:TD$VR!5FN#.7!.,*$DU!:.;G\M;O)W()CTZD+T9J,\AR]H>.E
M%IN/.VH%40.QF7"K5PXEV9DHD@M91==B@<[@G:J8Z)!$PB0H@^<3>79U,KRD
MDI,R:\K2:U(+2,NJW*S5E7RCN,6.[DE6A 2,NH)E3)@!1-VAT\4F]2&/T0MO
MSFMSE+IT_&P36$D(BC68Y%;%0#*0I8\LGG\XX2(L[@G8+Q"[@A5CMQ5*4X/)
M52KUT\I(/6,D_DCPL:9^^D8Q@M%QK]X\,V%PY>Q\8X4;(*G,91) YDRB!#"
MIMJ52:C3VR+=5FBWJU;AJ^@DT7?+R:[5-*)9-$TVZTDZ5<'(  4RZAE!#O,(
MC^VX.0\NP92L3*XUSFC92+DFJ#Z.DHY]%\=VSU@_9.B*MGC)XV5,FJDH4R:A
M#"4P" B'B9@F]+J:$)8V+>+L,.C7(=**GHQI"-:TUCIF/(S*TE&+:N,4(]-%
M<ATR,D2(  )$*4&CH<IS874?'5F'8.1HU7%=E$TMZC)TZ+:+#%^8VCJG)-DW
M$8@02I,%TRJ(%(8H"!V3;!,7;LU/M+YC1#+:.DV/]LWD9(7#O03@BI&^UC^%
M9KR?4/[_ %FB)U^\R1!+%2+#(,N92$%7Y:IP;YIG]3;/(:JSZ[QU.UJ*=(Q)
M%XZOS3F0<*.V2)B-G)UU#*$,)S"-58,*!26+&BMWS2D,F=5@FS2G-9-DI&R3
M:JMD6!$:\WD(Y8[=<C0J)54#"0X"41#Q*61OEF<(6*<<UIY-3R-'K*4U+O*8
MYCGM/=RDH2+*^D'-4>1#16-454.9BJU1,@)#)D$L'I#G/XM6WUZSRUSCY(7$
MB"2EHEW"SXTU*1P/0C9MW$2;MR]B@>)+DB'[QPZ9%0<+J*FD+S;LKB1MDE0-
M.SA><KSV6I[Y*%V+Y870IMDM5'\,=AH4VC$(I)V=$26%BEYA&CQ JZP*0=-C
M<@S5.LUNLMJ;"Q"]*KKQJRJS2.DHE*#*#R.7.I'GCIIZDHF<3 J1ZX[^[SU>
M\)QCEF<LIHLA&RP3#2D5EM*!*PR1T(B3"01C".PD(I%0Q&RW?YB!3"!!* CX
MKV@1F<5&*MM382$=796)A647\J2DHU&%<.&S-@DW8?,DX)(T>@[,D9TUCW#A
MJBHF@Y<)J_<;)\R,J5CZRI^I,B4#*@G]LJ_\4RB!@$W7I][[E1H#-J?5;U+T
MG7JQHCF#D]@TWCIH#)"&AK-$M[3AG(;* =V7(==J[Z>2<M7BK%_'2D7Z^*=$
M22?BNEQ]OF]:!7]5KD&CGS>1<(;9%5RY<>*_ []JFA:37D+,AQ:=3>\V78,F
MO,;"VJP0KC-7%WE6+H)]-PS636"JKZ)IU(V^R02UWQMC#M=DD,N0A,CS^@9E
ME'#';&]KMN [D9EL6;UVH6.6L2L7%LI]*:NCMQ$39%"*>? W-O5L6T2^.=WW
M+9-A<VB[V!-[L:COW$,-Y$<>74_+2%,>,Y"T4#CU6;=$-CO&AF\0^F%63<3-
M7JZQ):K3$A4+<]2T'&Y?8:ZYY#58U>YM$H:>Z(V70[3'SG"R4K%+MLA.Z3"V
M)$]YCM-E7SR-.T=OP*SC7A>/^X6J>J$OKN<[YF[JZ:0[U2^7R_R?%.J>W:GQ
MVD<:-=)>F512WI?E#IHRZB#F.C6LJS8MI-P!'R23=/EUD=BHM;<:U"^Y=DG,
M#'=@TJ%E'4 YS61T_CUHRTIGEX=5Z75C+G6,HS"9H"[.-[56Q8UN@N=)D_34
M-[B]R/6VVI:!R+R+-N(/#:M5MN]D)/+ZO9F,.A*W*?D3Q:+:E)-^05Q<VRP2
M!53MT8.FQ+A5?S6B**3%H[>*2#IJS:MW+]4A4E7SA% B:SQ1(@B1-1RH43B4
M/@ FZ!]U]P+_ ,D_*?\ [CKSXRC_ *M:+_T7B_$QK.-S] RN#N>AX?:);<*E
MMFOTZ=_%_FS*NQMMSW;>((5>UX#R>N"D?$O4:?<GLC79JO)2+4I5$S0K51U"
MTN2LF?3J,+8*\30,U3Y"-HNG\BK'$YEHU"4Y(S\F_P"#UAK="T-M.7)*3(A(
MU2ZVMZV47!>V%?,HUT'"F.HD@ROB>!<6MEX]Z<[D>:'(KBS>[!/:=5\%K[2X
MDV'&\SO-TT2%15RN06E8V718A++N6[A83*D$I6]/DY[BQKDJ["_5JOW*=+:,
MW2X\V.TU#B#!UGEUC%)K>=SL(RVBCAQYEH]K",E(/RF3B.!M.-TE)-LHA5@D
M^.F<RU8OFDVZU\F:S:M(?;#S>D)UER-E:RORTIWV+BJ\M2K:ZU6+K-X@49.5
MEI"ONI5)C/-V"3**4XENC4K'JIJF![SQ>UQ8Q$S2D9GU>S?1\_N.O4;([<%.
M93;=C+PU3&/8@5C#H2J;5J5VFV( %2MDI9K- %R2)SF]Y[%&B]AU;3Y[>Y^U
M[D_U&IZ_=*7H,-'5C!)S/*4\6KQH6M.Y9I*KR3A8[A-NS8HA^UYWB/T!PTY/
MB/T_1^)&\?N?'QQF52[/+4X^XRHGY0K"GV'SFMF)Y8N/[X$G:/P\SZ_3]]\>
MO]B\#/\ JGYN?_@/'3^Q; #IR#--Q+4=BFOU, ^JD;[6&#%$HD36-YCEZY32
M+T*/UCA]RIMUDO<%Y'\<8[5K75,>SW)<OK_#U[ 2U]DT7J_S1E*;UA=LF&@)
MQC-R_E%7U@2CTT6P$1*1=1)!?.I&W^Y[[@LRTTG38++89.F8_P"W].NVL]--
M;%9&ZLDQ7XGQK\T<I 5IPV[F23QV+@""F@H=0I/"MI8>Y/[FUAB76)73DG%H
M0N9^ULZ<.L6H32QGL-KKKE#$#L=!9-7%3<I.SP:LA\C?.6K"7^7O'*""DAD%
MO]P?W,HVZQL&I92QHTGVJ0//Q+6K1MKD0JS=WBC24L3V(CI=,SQ!DV77;E15
M5.0&I!<>+]IBON1^Y_&'I,SQQ/;J/8,\]MF"LL-7N3J=>0P>^-'DSQT99X7.
MK\ZEB-UG2,Z;T;Q!\D_2;*-7)4\YHE!]RGW1U[+IE3SW6\^;RN5^WW#QMJQG
M3J;:;8ALS5NZXNE6<Y;39&)/7IM<Z(.8NR.HUB#907;1126:#[K'/9,LP4X+
M+I5_@NF\8]YE3=8=R'#/OBQ**OU?+^@"E#[P>&*9?=-YR*@P2*DF=Q4>"2RC
MD"H W\R0.?AGU>K&*'<)C_$5![OI\,T#^[3[B30K(7@D4CFO"%DNX]:Y,Z.#
MU9/AH)G8-S'[$.[^"2 "!\ \)'#W;_<;4%)LX; 58O"-4ARN2N"F65*;AGT4
M<H@X$4U!^)!(00_>AX_6[^Y1_'\)_P!#+Q^MW]RC^/X3_H9^/UN_N4?Q_"?]
M#/Q^MW]RC^/X3_H9^#>9[N'N3+"(E$HF=\*R=H!W=P "?#4O7OZA]/T=/"?G
M>[/[DCD"D3*H!I'ADEYIRK"=1011X<D$@JI#Y?0O0"@'4 [OCX)T]UKW(B@
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MW"2<Z]CIV5F;76V+Y>5?IN90ZS</[XZ'4 XI@8HJ%*4YB 8.\I#B<I#"7KW
M4YDS  _0(E']S[M:LNTZMLK=0[I%J0]CK[\[E%)ZT,HDX140>,5VDC&24>]0
M2<LWC59!VR=HIKH*IK)D.5O-V2J6ZRS@I5PLY-V#6-4E96\.Z1(3LOG<OH;U
MW<5%;Y.YC,69\\K#V5%TYKSI8%6!T#II"2$L45FD['V.NU\E3B;*UUW:$K.W
MJ:%+1SIC55;,&A?/WE9B:,D:,8QZSE1FP;.7/ITTCNG)U>;5"V3+>6<=/V3W
M!.4FDUU>G<*N6VH5BP4.YV&&>U:T05VS3%[939J+F6Z*@I':OU3 *9@.!?AU
M0(7..<"P+*"F91+VZ.=YDVQ03.IYSD3<>2"1(1+V@)0,/<(!T^_X[?Q>\V^G
M:!N__1T\\>SJ(B'9U_)VZ]X '7Z.G3[_ (72_%ASG,5%(BI5R^W-SK%!P8ZA
MB"BW./'T#&63 O<8! H 4?IZ_#PW <PYSI N"HF,K[<_.H"MO*[N@.>WC\82
M"L)?J= -UZAUZ>!.?-^<+404,3RW/MT<[B*"!>GX0H)\>52BF;K\!Z]?@/P\
M$:DRCG>Z(?L_OUM[<?.DS(G?UZ@=53 $E"^7T^M]3X>$CACW/E3S#* )$_;@
MYRB=+RS 4#*@."@!2J]>I>@CU /CT\'3'(.>Q2$\[M7-[<7.7R5O) 1_!"&"
M"<?-^ $ZE#N$0_M]"E3Q7G\(F!00 WMQ\WD_@D4#'ZBIA9  0 P= 'XF^]U\
M=J6+<_3#];X&]N3FXGT[2B8W7S<,)T^J'_I^]XZ)XKS]$?.*W^/MR<W"?A3E
M4.4O4^&%#M$J1OK_ +P!#IUZB #S2JC+'.<3"0GN)O(R%;O+!P&Y@5Z 9.)3
M([?%H.YNQS&.,X2"AV[ET4SEZ[71:M$ ,LLH1(ASEX_:$,6Z:78./^!P+F=8
M3TVS=/("FTUZ]@*Y(@PE$V<G7V<C=9%RHS4*HU=.E$UEBJJ-VQDIZ1U;.R7!
M]9%(,\F[=VBZ,')$Z]6;A3HYG$N(>QQRU>C%*SH$VT=M(\S5K()RKD72:QE3
M")&TEC$?+I!-0]E<&F[5?9M>3M%;>Y^^JMKG'<O:7KNP6JG*Y36TX62?'</8
M9K"M6[)5!ND"7BU4%#'@DJ->*K-4FW4VT7W3;G5[%6IZJT.D/V$M V^YSD6\
M43JN6UMFU<'2%RQ)!,C-E$CH$.$<]K><R#%2(6O[V(16T;4)-C$S&I-[NSOU
MDBHZ5NCUC&6NQL]*GT595!-.1(E+N")K$*< "2K#O-I52OS694W&IF()J.NM
MV$OF.>UVRU*DU"5;MKXBG(Q]:K=RE6;518#N")2"_503*&-XND:VQ\T;#Z'"
MKUNZ5^&T/5(2LS]><R]UL*\&ZK,1>&5?2B%;#H\_("V2;)H@_F7CD"@NX4.9
M:EI9TLUAW6GUS9WSUC=]#86V4U.G,(J*J-VE[\RMB%ZEYJK1<#'MHX[F25(R
M;Q[1)$I"-D"IP$IF6?QU*5JN1UW"*ZQ@I"<:P4-D]4D'4K7J@PK8RAZ^W;QL
MB^76*Y!MZXYUE.]8W>;JTN4,SFYM:.S&/RZ.A;*];R< SBT*94LWE)A&-%HF
MFE+3F>T"$A5$TO+CVS!B<C5L@+MX9<[1?CU4W*"T %8=^KE+:\5D(0L9-P2;
M:4<.K$LXE5T:]8G<8FY<'5<IQ:A61% :I(I)V*NY]DT-7(6TYXKDTPP0E+*]
M3-FJ\C9Y96E1IY.;?+04 :0N,@?R&)FP "J9 Z$;MBI(6!UQSK0S:$.2O_-$
M+'?F;QS#$O1].]!)+,[8@:62/H)BS!Q=><91^BBJ81%!'LCJ ..Q;6CQ4GHT
MPSJ498KG$5T)'6*D[H5]<.(B*LC-D]^<4I^O%I$6(H2/8K'29E;E.8!1;2.!
M5>2;MEWSAFA)RELD48\\E.S]D?)QB3VPKDC&KB8M$@H*#<$D03='1 H(]J80
M'(%_44S7^!G'%L!8'"QXV3N7V?B*M%6A^R<&7(F_@X2&2*DBU%LT<.TFSUVD
MX>1\<NT_;_C'O-)+,VMS1%<NGW"<_9XJ)O&;*23Z93H.D5J'F6%;TFGLI:6>
M.&T=.M)!JV4?.A2(0'3@%&*+S(7S\K*-DX$YGVI; Y5EZO+TF'S1Y2[.LI?A
M5MU$_%Q M8!*"E!>1",,0[1-N5%=<BJ\UA&1Z;(,HKE3Q#U"UTC.#;5M<RVJ
M]>YXY?OFIRU!R=F^OKYL9-ZK,3KYI7HM$RP>8(D$B9"E!8<6Y^BD951$IR^W
M%S?,(J) 43AY9<*%4I>A@$#"4"FZ_ 1\?S+^X!_5N\Y/Z!_%;L]^R/W/K#>:
MI+<B5(F^#[>G,*&LYZ7RF>3[S8<FEE*[Q=AXN>S.7-9WI&;)XU7<QX+"9%R"
MIE%#QNWN\P]SECMD'R.A^1L!K\7[;W*1KHT(I"4<V;-L0C[0;B0M(!QY<499
M>-<5Q0RAUT'*PF=BJH*GC^9?W /ZMWG)_0/X_F7]P#^K=YR?T#^/YE_< _JW
M><G] _@"AC_/A?J<Q>Y#VX><QR!V@0>\1-@A?J&[^@#^Z4?W/'0,<Y]J?64+
MU3]M_G*8.A#=H'^.#%^HI])1^^'[GB&S2K9KRYK4Y.-Y5PSE]8X6<I\=HR(0
M\:XE'*4GH.F9/5Z9$.7#9J<K9-T^2.[7[440.J<I!_;/#+N'+9/\8>&E!5JB
M1=453[EG)$$1347;%!!RL8J:IN[J1(YC 4X@!#?<^'4/Q@O5IS;5*_R5L-_@
M[;%#.C10E:'Q@Y#6>IU3<V\*DLF^Q'0[U'Q<!.MW0 0Y)),4!!X5MXQ*KQF4
M\I,8:ZMRBT6=T[+]!QE]<$JQ4-IYZ;!4K<FUNR^.:@2=BL-S9_$.&KL+/0J]
M$QB\2_;C86;\S)M7?-L_)V":%Q[(65@WYYQ)M.L[%>.2U6XL-#T_CW;*78\X
MLS@U?MO()S*5N=LR<0BJ4\"W:GF6+B2)(*36C6PVS(J:38^7U2?T"I<9:E-0
M/%EOCO); *)DMLB+3'Y;;+3*5N?SJY6IP]GI:.O17L.R^;1<)(&CU4G?,71.
M1M8U^,T@G"VO4V /8\]NU":62W43D![BL-6I6M0$E0,M:/KS/9>2EO9!S'5J
M </DWC!<\:Q!9!LGG5FH-CVT'$=5:-QW9YG9.*AM.<49M!^TYG.W'WV749TM
M[MEVMP<KR/H9PJ\>2# ZQW,<:*?2*:: YG.O;%RP>V^\9G:Z/746F+R,?55W
M]-T+D\R_'_1I&.PO*/E%A@XM_36\;-S=;ICR<:/D7!H! J:9PL> T^3Y>2NB
M?BT=/X34:[Q9N,9?W?'IO[5M?ND;9E+[)Y0VKC+1Y/FM&S<(HB"Z-R,^;+,D
MT4UO3&'<UHFPW2-@8"2FVT297BWJ$DM4LGC]MS6&Q[7(V=A>$-GK\(KM&%KR
M<M*.T%-:7CG$BJ[&J0Z40Y9H\'=':N.0^/6'2Z[(+<C]$J'&.-U'<ZO<8[#;
MG)Y9%R6'QM T5C6X79=TCH=I(K$K2'I6CQ-H;Y"H\%1G[G6L7"-V]'FGNUSP
M9Q$UMA OBR]2-!8]Q=F)2G8^A1HZ$L,SFU'O=IMD8!6+]TDH2.>!ZDSH[]TO
MJ<K4YUM)0=U6X\P%HWG*..6R,<_IU=B<]Y:S5<@:U0#53GI,O9F8TUW7XRQ2
MT; O2'%>+9.3PX/"/DTLPFJ+R&^R$TPR9CJE2I_'N]5>-J$Q!Q'&/15K52)!
MCAS9_%0-QN1;:FBK*:7-OGD>5[%R5:B!9%45;:2TTOF#/(U.4X;9!I5-U/&
MGH#1W5N]RKF#2^12#AU9,[CK U8Y#AMLCYH9ZM.&9$&"L:]>O7L6@U3#^P^=
MG_DVY/?]R5W\<?5"@8"GQ'*#@!RF(8 -0X$0 Q#@4Y#=!^(" " _3_J4[$2%
M4#\96"!VG[NT.[>\S*!_J&(;N3$>X/CTZA\0$.H?=.-=CP3.HS7'-LWN1B]8
MS8S-\[NENPZD8/M.QZ8QR$&3IL0^P-8;-O5P+5R"C:4=-_0& AG1%D\YBX:A
M0&]UG9.0FA4BFZ50[6]@647G%SY7ZM@'%Z5?0$32;NQCV<TUI;(TQ)VB5J8.
M2J+FATIA\W=QZ#)[<<"KM]V&:X^YCR2D\UKU\CLRHE1RICQ>@>0NS6* O\_"
M6>7LME<Q]LB"0=>>L&Q3/WRB"\HW9-59 UEN <8C,<TFG>YP''FW3FWQ$=):
MY;,$W')<1L<99Z@US^3F:"WL<CLD<[A&\5]KK%*F9NV;6(6=BR3><I;M"4MM
MGE9R;BC5-%KE3EFDA*3\)LD;K'-K)]*;N74U&TF>G:>>7XW1JL6E)0<%)%24
M4*[;-'"BC9#-[K?.)<MH#*<S^GU0+G1-(A(B?TWD\[]OZB\ZY:JU;(I.LF4@
M:!+5RPO(M&3^=OGR<JBD@UC7P*@8M?L.;XSFT!75*'(.9&%4T!_:)AIMU=M'
M)V#?YS=FUEH.>VZH4^1C\);NW /X2#N,2+@4746@JH!26346O'VOK<D8 %\[
M6KSG0 4SLNG-/;FIO/1];4UF]?"8>4ULQMP1(1P>6Y.HAW"Z*4_4MQPP_'+0
M*)7ZXYV6LQ.MKA<96H2^A\<[M!YML-8?RLGF%2I*#8;A*./LXO$3\\ZD8]@J
MK)LX5P=)F;C-E>%9/7,7DN3VW8K)YYHUKT*!O#^7XFVRZ[% 6&T2E+7H?H*/
MK<N;%UTR5]5:62:,9=(Y'YGR+ILTJG'J+=UTN$U)K3\KWN<DJ/?I!W!;]R%J
M]IM6'"CH\5$+YU5H&J+UVLQDVQDWR+YXIID:JW3$&A^^!@-+PZ7WO17L%F6K
M7<^-5J[,4*-C]FQ'B3*61:!B*=GVG-+'<4-4VN<70;S\A4X9*,:HH+3!'*C=
M)6*F6?#:%2@)!>FV5PYD>3<?'R;/(=2YE+<'\NNI8Q;&NQ]:IO4XB2E)6!16
M,E#5Y%LH,@X?O","<DK_ !672%6@>(V)#;>0"MJO=?@DZ!R(KZFJCJ/&"5DY
M]C"0+&;R]AFJ#R0L3MVUC09V!@L=)$ACB6^*5CA.68M&-UCD5I.PLG>XV.B5
M^"S#CMF?'#7IB8J+C4./%)O5HM-HJ/(]BWCHY]7(-FK(QRAROSQCA"1&"I;/
M.83/.,5NXU\D=0RQ\[M;&SZ1HLKB?*>A<>'%END A Q!\E.S=GES(PB;V>([
M:OVRJSMN[;N&*)07X_4S57E;;Y[$W+4WVL%S-O\ ;[D9NW)?&<)KL3FK/-+%
MZ^#@YK$V"=GD32[,R+*1%PR0>K)&0.5QR!P*\:G(9UEEEEM8VVF,I^"K;_:F
M.$1')=M2&!OQ'U##JUG[BL7"/KK!ZM<%K,B\*1R^B#L3&E5)BB;'C69Y/GV2
MQ>"2&O)Y1L=>Y"V@TQ>-MT>MV)E +)TVMBO7Y[.:.4R3&495BU1;P_>=H=%T
MV5!C3]3XY0E*N,IA-KY.LVM4WAC?ZREBY.-T_P B\Y6?6H<VK":%]L3&J243
M-1A6QV4,=!-\T?2S-PF?Q>,JGL3+BPQN;Q>I9P>:ODC.V31*@,E$0M@GXZ,<
M9U5ZE,5R,D[ P+Z^LSUG38J.B,YHL/)]&(\8=RU7<ZCJS;F'BUNTT*E 9!2J
M1:\">T^V9PNE+P#Y!_*Q=SSQ]%W$]=DC33$KI"2=L%V[HASG0,[I,3P_F'N^
MO-)M,)5L>2NFDR[YSF53HMIOSJZV)Q3>.ULLK20FV-7,TB'4+"V"B2JBYG;>
MU'8,GSAO;*C4>)5BM:/XNK)9<V33NUF^T\O=J<GQ_/:Z!>8Z QVRU)E8:^IO
M1$7D)2IZ_7%J[A56BD&#V0CFR]*0J/%&?OD(WH>7SFYS-(O<])LLSNVM.-0B
MH&JPUCFLCKN>K159G<O7;3[JZSE E8\[DZ)(I9ZP?-$9G1;%GK3)[G5;]*T&
MWYTE.6V8D*U)-(&LVJ/2FVM^S7(KK!2;ROVUFJ9J_@6Q#E,#AFL\8+M7B_[?
MG9_Y-N3W_<E=_& ?]2>5?]!8']CW1LDIWV/D9JG5'/(S@&[=UEHHI&:K#8EE
M&G\C8FW&!%\WN#>@4+54;VD1T@'DQ<8\25[D"@8BN25?E%6N-T% S',B:D=!
M_%'E]U3/#8?6N!CFC04_&WH[5F$*U?<B[&\DW#1RQ>JHHI)BY1*F"@>V+JF7
MM=)I]ZY;N["^U6&XV9#G&SZ-+1%3XX:CI[AYD5%W>5A*^ZKL_.TIM*-RJN59
M0T,N1)MZM<Y?-D;7-<P,6XLJ89PWIO+!_?;-F6;VBL;?!:#JW(:*K5EV^.)/
MV!EG--I>=8G%L;W#T>21E(BY3,BT3DT#,F[,[>;T>?TN4XJSO,+DO@!W0XCD
MTYDZM4SNAZ+:,YB,5?Y#.3_+VW;.]EJ4W2]'+5!>)?MQ?I@L1<K$[C$*-05K
M(;B*Z/E6/;"_G^/>S04HRW3E%'6&9RIS8[W9J)#P.-.,P=15/BI6MV5S$33Y
M33FZH-!%BD"O^H3HZ9S$-^,O R]Q1$INT^^9F0X=0^/0Q#" _P!H?NG'-W'<
M=)_DKK=NVF5JV(5&L3.:UB9KER)B6NV6SV]M:]4L]2K5?(VRNO3[%10KOU+A
M-^+<A# J;I1H>A>U_01V7/TG5YL,3=[9PRX_36'ZXSY.Z_#6"J>3I6P5B N&
MCU+=JC89Q"0K"LRU2+.%>L78%EC KI7 5/A;FJP8XC6M 82\[G%:>Y7;KO1H
M&NL[C1:)-^J>.I"QX-3=EK+&=B3II,FT5:T(\B:K=%T@A2.-E=]ON!Y8:A<8
M#:]O)GE68Y'1X[/ZA8=&H%@U;2Y6\:-9*A%U:T:7KB,&M'%CE1DY:=C?4BHU
M18+/$4,@XX<)9&/_ !IY30HB]5^"HE7R6*B/M1(<B[=,8WI3AXV<5UFMF:]6
MT!W8UC.U8AO,R#@B+AUY[]TUF,IN,'QV6@ZC U>^3^2OLK<76)1EK3DN?<?&
ML#3V,%4;!7-4T6*S"[URDO(>JJ34PP:/F+%5NEYJ!!Q[D\>@8<RQYM(3E)R*
MUQ>76BU3CRS6N>M<I<*LVHT169O1YN^DL$98%YYF_BEYF,5;2IGY6X)/NWE+
M'9[Q1PF0S3B/CF?TR[<AI6G03BFV#.-(X\*'-"U)R^CEG\S0XSCJZ1BEI@%3
M).X<J;1$5&2+4YHKG,.15WA_<=,GK=D$P6YY,[+R 25J,7&V67"U15 B[M:4
M(6=RVNP-UEY<XBW& 6824TX(8@')8JCBC/C>UVB4VJOWY\[J>4OXTUJV?[8V
MG-("\5&[)TYM5KF^C[_H$[$EE(-^\8LI:5DDSJIKJO.NMX_=PRESG^KZ?6']
MC\ZEJW:O[?J$J_4BYNVVRJ5RN3L[&%SRQY.Q8R5FLC1E%L58]D/K2)I(F",R
M>:XCX9 3V-Z$>4EIBUY]F\?G><D@8_<*PK;(6[*LRUBQFKM8X'-C2<*U4,LQ
M;1[#N145AGA6/%'5ICD&;/:3C=R>*4;(JIBKJ&AFLKFFH9MR'G+#882S<?I+
M8..\46V7:N3<]9V3RHLINOS""SMZLQ53<%Y68KCV@L^1\GH6OZWHW+28NM':
MLVFLW+7+%9L_N3MX@VS^DYC?J0BGG[JG@M7FSV)%. 4;.5EG@.5%9VL9_P 7
M\.J$!:*M<*19XN"SBLL6UDJ.A1=9A+Y7K "4>!YJ+N</2XAK*)N15!\A%M2+
M=Y4$@+<=KS# LDS_ %W06CN/NVD5"AUV N5G82#R,DI%C+ST:P;R#IE(RD,U
M=N4A/Y;AXB5=0#+=3BZA&> 9"VAWSRG2#R+1H%:38.GV>VFQ7BBO%VI8\$57
M50N-NE)2..8!,T?R#A=,2J*G,*E]0XLX(G<5L[#)%K!^*RG&?K9I]C$\X&E+
M&/$F35@%,[1)7SHF*('@R%8&ZM !$*/)T?BE@U4DLV*X+1G\%FM8CGE;,ZM3
M>\++,7+>/(L+D;@T3DBJJ"=4CPOFE,!A$1_%2IPTXUJ9K]NGFF#15,>HYZN:
M^2$0I7GUG-#FAA9FD7=<5-&*")1(:-'T@E]. )>+9HN/X-DV8WN]L&45<+91
M:)7:Q.V&-CS(J-V,E(1#!JNLV%9LFJJ3J +K)$45[U"%,%PC<^XG<>J:RT!)
MDWNZ%>R6DQ@6II'6%K;8^/G3MH<BDC&,K2R1D4FJ@F;D?)%7 @*% WBQT5SP
M_P".*]-MUY3TNR5A7(*.>$E[XBWE&:-H=1QH86WS1!C.OVZ9BE*5-N_=)% $
MW*Y5+;8);B+QPD)R]Q"T!;Y9UC=!5D)^$<-8=FXBW[HT%YQF3A"O1_F)E$I3
MG8-CFZG;I&)G,R?BIQ[5E<AK1Z;F#]?(J,NYHM546E7)J_6E%H0XQD4#N>?K
M%1)T(5=^Y5* *.%C'_%]A.64/(:.,H[FS53.ZO$5."4F'Z35N[E%HZ&:M&ZS
M]9JQ01%4X"<$&Z28"":9"E_;\[?_ ";<GO\ N2N_CCV54P'5+A^3E4. = .H
M%"@ .8 ^\!C?']B3L%KQ#)K+/34C8YB7F9W/JK*RLI*W#-$<9MDE(/WT4NZ=
MOK-D3=.KR"JAC'>5\A8]43M2@D$:WTGBEQUO[>'L-@ML6A<\:SZS(,+/;&E?
M86FP-49FOO$TI>R,:G%HOW !YCQ*.;$5$Y4$P+2I-U3ZPXD,V6=KYX]6@HP[
MJBK/Z^]J;U6H+&;"I7#NZM).(Y06@H][%=1 ?P1S%&I/+EQ>P"TNJ':[->:6
MM/Y'194U7N%TLJETN%C@_6P:P1TM:;DH,Q(K)@4SR5Z/%>]P *!+\@*KQOPR
MN;I/2$U+36QPN5TB-TZ4E;(BHWL4F]O+2$2LJ\A/-UCIO%S.15=)G,50QBF$
M!N-;=9A0'->T.V!?;["+U&"5BKI> <0CLMPM+ [$S:=LY'5:CE"OW)5'15&#
M<P' 44Q+_J$[$GT_C+P,/WH&^ [YF8&^ @(?O1'_ &/I^Z8-I>A\QHGA-,91
MMBUHS749B(S^QMYNWSN1ZCG<C2TZWHK*2AYM61HUUEW0)HHG=(@T\\O0B1Q\
M5/DQQWYAL= 2T"EK*VG6+9B?%OD\RV>X2>T:ALEJUEC-VJBO*_3+#,W?29!D
MNSK*$9'L&D<T9D;IF9%[8+5L-TVR5'FU7+GN.I/.5<ZQC)B9U+0-W@+\QN37
M4*8Z9R%'5HS^<MD8\^7Q\8AZ8M7B4DA C4"C \H8?E7(<2-&Q_*K52+_ +>I
M!9M.9_-8]*NX.U69OHM6U%D[J#).MV&M$EH:6*NU5AEEG29Q<-';ELKD;FL^
MX!76L9OT+6J)E4H]U/()J6V:S4[.N9V-76PM7SMHW3L%YNEQYT6&0GP0;-D&
M]I29,4F[85O1GTC$&O.FU'R/C9>X+9/Q/O6.&V6I8!R#.QJ6G2^B[@A/UUZM
M=X.>BXMS*)5FS*(1D=%V1^=(>T8Y:/Q'\7G*XN.1/&>P6WES2>7%)I> Q]+8
MHW>FZJMHUY<45C34,-/F4YFFR3QD3ILNC9L9L_,\<.$E'#C8^,\5S!3J&3\K
M,*R'6)-[+:+2S3LKQ)P+(\"PZ\6.&L1TVI7^=:KG]<8L9^<*0$R'MRH,11[F
MI$S\O>*_N%LN&U"L]Q>4F$G,\E*+;J_%: YS17.MA@ZO3M0@[58(K3K/FT'5
M';L@MC/8,E-C9 $ 8F=IN,9V%[[GM?SGBJGFE@GN(6I:'=L,?SE)U";Y+Y[R
MV:2E.M-@K"=4W^AW-NUGEI-U./'CA-@Y:D;="@9R#+&\\]RIW;]9CJ]6-PF5
MXF4XXSVE_8"5-<;RIK5)E(.JLY3+;-,H;6:496JLK,/EL?*-S>0HQ>(%-E-3
ML_/].6@^3B-KM^<9]]O\H1F=K-H=IYMGB;51K.FR4G74<H;G?9HJ,7;>8E)O
MH^-\I11R59-?;[1JO(W9-<U_D3@6X<>-5U6:A\TK#V8J&PT;#,UCG\;4Z=4(
M>JPLOGM,P.+29G1;]K]X^?.7H+&52*AN6JUS8=#NGXZ3B"U*DH>@4RF1)CW&
MT75>RS$%G%7JL7>M0<.K0:.5M4D@:8<0[-LV746.11=7^P^=G_DVY/?]R5W\
M8!_U)Y5_T%@?]2G(.G"K9'\8^$]RR)>]0#!NV;"F0"]Q.I55>A#?'X%,/^Q]
MTXI)4;1+GDC7*MUM.B6[2LVFJO#Z'581[QPW;-XQ>I%N53N]=E'+ZW7Z-;NF
MSF-7(=@HN(]O;U\8\Q4B89W:JC9*DM$<J6G(ZUH!E-\KG*[5-JY0\G7>(J]L
M=>+![@M!O#%"0K %79P<BDO%.#(PS9DJ> JV@5>,IE&A:0$1HU2+RNTN]+;Q
MRCIG%WD]1#\SG\AZUD6$;ZYM.ETZ0)#*B1X0\$20E&I'#)J \Q<^B*-F>LL;
MY&\>+3BV1;YI%BON=6O0ZMQ^RJ#W=:\RT\QNDA#S5^V6I2<H:34;/"/)I9.5
M7()E%A\4[/9OB?4;UB&I\B-7W;D"$GR0S;\JAU2;7M]1U:A\>M4Y"2U,DY2X
MTQ/0(-Y=K::NN!<R?9%P+1^FV;O'#OW!LRR"[YSQORKD]R!H&WKUR(H2=IB.
M1,7&<;("L:#GFJ1U=N.82]4:7S?(P)B9DTY!TYF$6_E/$W#-PX;*W_@=I-0@
MG&M4S@;7^.4%H17#*&S/4KQ9N.#JI.XF+8E=S;R+AZ#-J(0<A(+'41E#)F>I
M)HE4.T0MKNQUG#M6S_.\&USAWQPHM@T>Y4=LWXG5G6>/FP<?ZTO;J A#W7.]
M4,ZBK2T83\:LM]G)6MU]XH59 #)! \K7.5LMPF(F0VNB0.![)NV9/>1\#FNI
MTWCJSB[]=^3M>SF+I.KZ5!7+!EXHIIA20EFV?RK9L,V^<L 8J93QMEH#&\YF
M+I.Y95^2];P0TC1\SJ.&.;>UGMSSW'0<LTI)9I8*.V7J8+F08*/6TFY>$1:'
M,1!+17UWK58L_%&WZ/RTOES-<-*=:%0-0R_DC$P;*AX'5N+D_!*U#&9C*%8X
MD;+V&-%$9^KQC>-66>-'@L8SV_L-GL6Q28P#!,NX^)<@#T33HK/[WH.E8GJ;
M^\9C19B=7S2=F9SCAQ]F 1MT77HYW$J3EF,#=55".(Z2?_V+SL_\FW)[_N2N
M_CCZ"A@.H&(90!SE+V <X4.! Q@)U-V@8WQZ=1Z?ZE+1<*D*S\]^QI]V FFI
MVL8C9*#+RJPD5^H)6\4Q64'[X 7J'QZ?=..,;5M$?8_B\_H.G#M^EM7_ "$A
MVL8^@\2NTOC-9EYOB]:J3K\<SMVD(HIM2MI5HQ<S#=B@X*]%1*,?Z1R*IEO]
MP/*K-F/!OB]<.0%+G=_Y$WF3=:9RV?TP=]"N9HJNWSZ/NG%CC359^03-4:O$
MN4+792NDF;1Y'(I!(MJ?I?*"4J]?UR!8^T "]YY%2S3D/ NN<HUO7&&K2DPY
M73W"JP.*I)1T4[T)Q*IM\^45F45QZ#)$7L#B&T?C#H#+BC R.,YHAO')B4LZ
MNGPF]:P1*:QRN<.V]SP76=AOE581C=&"OA'$8GWL&T@!6*SHWBO!@V=:-H;2
MG^WMLNH#GK'DUR6XSN&&@,M3S=A'S-35XWR<=7])W" AI!P:/KLW(,FKXB1T
M6SD@J"<)>-R6=EN4<Y3\3G&D)FTYQ8O<)9+'E])X<TO3:9[AMAL+-..FWRVP
M;2\<,%\_+Z=RHL[/!M4T9B->J>-E)2>0^A;W@5BXX+4*1Y:TOCCHV8,3:@WJ
MW,N9QFHY_GWK?L]5I*^W1-K V#4ZTT,V0E(:OQ((HN7)I%KK--,O%46HT=%A
M1G<=-Y!H>EZ1AF+PUPP6J,.:;B/;9VN.@L)K-[S,VMR,U8G47*&2 C%L*D7*
M(*9[ $VFQW,DGRB4KV<Q-RXWVEVMSH@-HYP<DZ],SI+Y.^H0XSQL)2:W6F=2
MB3K,VJ<?)I>F1<(.HP6WN,6G7)=HMI57XK6&T9FOF5-O]'T#--BN/'[19VWX
MV7S<[H;8EKR&\1C!O&LV;B7M,0X6\F7='<BU56XTTGV\]GY!H8%L<)QVSGE+
MJ.W5_?.0E?S[>GT1HEOG5,L><K'T@ZC;98ZE3'3"U?+5U*W$KN(E1=L1^LF1
M6BTW-LM?VJYCQ?I?,'Y_-97?[.A5,0;TAYD>GYQ,.YA:>LUDUJF<@GK.WHLE
M57\ZZJI%$P07(0_B8M^Y6"N7B9AM=O\ 3J9I59KUBKK/2<[A31"]>M;Q*7S?
M*X"8E$WDB\C5I*MQ1:X_^7E6:G\PRZ:7]B<[/_)MR>_[DKOXP#_J3RK_ *"P
M/^I0N@$A2DT[!$UC* 80*V<;SFK=T)0(!C"H#94W9\/W_3K\/NG&R-R1L(R^
MX;G)YI-2;#C]HG*2S0L#$8IK.I*.ZOA^57[/+K:G[F2SYLV<.$'AT(Q@NNY6
M3$$R^*55YSB_?K?O9\D"7UQOGD/-LJ/E>U3?XUV-+SR[0=A3<V>AD^;9=V7)
M*5>D<45:2(U6/(';.U4;EIG+KBE:*?E,6YH4#%7S,K%2K FSTVV\!\QYDDR)
MS67%X?6"P2,N:;F&S6=;%;Q+,',6S<=ZP/':>#U>T<7-NS,=5TRRY?=+;H*T
M13,ZSN8A9BHQ<6\A+M=D*I&:6G8VMU:/VC-H#*4=MF[Q)DU>OF_HE+SHMCXF
M6&O9#,X_Q<U?C/%V#2\MA;]KM2Y#NN2TPSOLNZ0NDXC$-75'Q%HNTJ4?%2=L
M:.EUS.$#M.]PTN_/W$JNV&7<</'')[+*;J;1RBU![+Y>GH50KU^9U^7:N4T2
M*O4$)$K)\40 #^4M^]/XI%!R^@8O59I?C?B9=<L=M@KK<F6;<V[GS#XT\;=F
MR)K Q-YJ02]5Q> VQ9^NV4D4)%P]<QY3.4T@4!;E?QRW17/+)H7%RWY>S+IF
M4UJP4BGWRH[%G#/0:N#^BV6X:'(4V]5POJ6\FS+.R+=9L=D\2%$KKR$[+//<
M+X2ZSIV>W/-\ASC:V]"TF69<2;QK?*',L:XMQ6^:6]N$/5]IU:4SG6[->35&
M'8P<Q0E4R-D) J,\E(N*QEKW/LLMS;/-!M&';W*TVAZ TI\_JK+<N4>)4Q)I
MJDGH;RM\<Y72W^'UM6JUV?96A2>D;6HP&29@W;NG6C/H9SQM9Z3F</@UEE(^
M7XY\HXBVW'2.1.6:/.4+A9CW'>7N<??M.V1OL^?'K[^VH332';UXZTR,8!6;
MLB%,G>*MNXSM=V97RBX'JN#Z32]!UMXAR>U=[!UNKY3 W&C:ED\3!PU$LWSI
MU:)M9&71)7HAR]02*+<2*[:D3(,S/Y5&Y>K<:*K;JS<\HK>H6_A[M<1BEVGV
M.U)7K55[#4D%1>SDY&O*75W[!!PQ9PSBP=KYZC[=RU;98+8"\M<?XMZ/;,/K
M-6TBQ; ,!ID.-@Y*;5(6-&TLJ=Q_PW"J\_8*P+J;0L2MOFE%(1-=N^4:>;_8
M?.S_ ,FW)[_N2N_C /\ J3RK_H+ _<%EP257%%%14$$"E,NL*9#'!)$IC$*9
M53IT* B "(_2'A%84E4!5235%!<"E71%0@&%)8I#J$*JF(]# !C  A\!'[E&
MJ-2][<)$I9,"I+++ P.S>%**":*:AS'"0%#N$0 "I=PB(=/['/YR:ZJ:>FX&
ML9-LEYRI_3[UFBY2@GW% Q!,F'?UZE G7J AU ?N.<70WN0\I>,52VO0*%A5
M RS'L)XN:/52://(2'I'*D_JN!Z!;4G]F%H<_I5)151PJF"4>T44ZI^*M>-D
M]YSFK!4:UZ+4<S<W)KQOX!24)2I6YNEFL/8KNY;\5R+5NCMWB $DIA1)5E$H
M'%R],W:)K.$H/\I?W4N?-R=YSDMUYIUBA-.-?#=CJ-7HV?6AUB%JO%9=97Q_
MAWKF<,WMSY,D2RE7#R4A3NE$6RWEF*%2SFN>XQR>LUTI430:A59#.>.GM]0^
M<2I[/0+%L-!@ESS6-TJC[%>$*C?I"4C%Y%I/S:$C/JD9+?-'*B?B5XS:;[BG
M*BWL:CAM^Y@N<B3XO<+=6D)#/\@RZ!XO6*RMB6#C=+2MJN,5ALL6!CHD7#F2
M>0$:Y%FBHLU P5&7C_<)YNSM/S$]3U)COHX'PSTG/5(:ZW?,)>J:EH]HD,DL
MUKU.I1NA3%8?)#:X^<3JK]FF\.WCPCUEF^H46R\]N5A]"KV:U7E';:[G?'[B
M$M/LZ1$Z#,8W ?9*1:XA"MJE%P\CNDJR4JD2[C(L:_87:2C)1BY\D^K\9UO<
M7]PFL89\DA<[Y#9S.\6N#CW.<DK[=Y7N*T=1+?#KX5+2=1J#6/KT*R,>MI+P
M(PSI"9%R9FNX?^)5TOSKYD.4MCV70J=:#.^,?MS4$9W9[M)Y7K5V!_:D\HK4
M*YT&UV?':M('8QDDI84Y:N-$O2H+"DFXKN0\=_<PYYTEIJ7(JUY3&A!\9/;;
M<'T#7*X]@*Y?9NRVJ?Q:4MEIO-80.U^;0DRY7T2.AX]9=:%381K@[??96V<Y
M^;IHS3-1TW/]:T-MAW";\7FP;-%Z72+'M,="_:3+X2.A]#S_ $%Q&R\A94F$
M,HU>P3QU%2*AXA\#7"[+!\R^9TI,TG%JWM[>0J_%;V_+@RQ_!IG0K1#5O:=L
M33PY_7]28DMUJL<RQFSDO-@:I#.3K<Q43/'@YA0+QR_YST!D^)#:?C:]MX_\
M/:L Q^HY#9BX_:XB]0F4@]JM7UG.:(\J-(CI:5C&< LT+5Q:PKA\W8.*)<-(
MY\^YC$U+C;<<\0H4Q<>,WMN-DLMT>WX >:SQ>/7DL85=GL]APG2%B,$UQ=NE
MRR9V@=\FH5(=QL,3[CO,&/Y 6S&L\TG0V$+QPX8C:K?6^7.J1%"K] KU-L7%
M1K#U'1]?U9] #9XIHQ@7+N0F(I_/' RI'!*?H&G\@?<XR'5\6RBMQ]-MTA@W
M!6"7J.1<>;G YOF\)$,Z'F;V%N=7KNFWN(A:\U19S"<B_FT'*95V9UWB=.XO
M3/NE^Z'6-IMUL4S:5I\CBWMO/I6@W8LY M5(2Q)UC )][,';LKG"RJ\K6D9^
M(95N42DW+M&/;OEVC[,YSW8O<AGIA1._P#&9KF+>WH]IDOHN;U&&T&T9+"2T
MSQFA44=(2K=JCQ;&6*A%.';@8\C[US5VW0ONW5KWHN;%]H67PMTG[6ZSS/>!
M5ZE434RO!8[!!,V-:XE2"DS.I1*":K-HW,H+H'*2B J)N$U#M)*S^^[S&QV8
M>.'2GV-U:%]N2&L!4V4!"6U%>.DJ]QFL],LL5*4.UP=@05AY602/$6&+<*&(
M+]N0\3F-)]^#EU<+Y.N+&#&NU&K<$[ Y*:KP$#:K#ZU6(X?O&42VB8:V1ISF
M<J(D [U% !%8P)^)ROW'W^>2]5G*_)I04_&R;'V^XL\+*J"J?TKX%N)A4F2J
M3A$6JQCF B+H2M5!*N<B9CPTA_\ $,\C5IEG&LYGY%!QG 2Q6QW'3$F6N1SA
MI U[B))SLH5W-@+5$B#=0XNRG( =Y3@%_P"1L1[UO.C0<LSF+<3=@G,XJ' 6
MU)),&D?&RSDR+M'B:A$E;-8B9;/G#Q=R@R9L#"Z<+)-R'4*I9KC[Y/.?/)*-
M<3L58J1=J5P7:WV"LD)%M)=_5G->KG$&QI2U@CVCD>Q"(7D2OEDUT&YU5FKA
M-(E^/[^G*@M*<W5WG#2T(-. K^'<7B*.BE*U]H]:<1%DGCQJJX3\P4^Y-(%4
M^I^AR".-,LP]\?FQO:NU:M'Y36&F-POMX6D6T@O6I^XREAGW!>+;4L;4H"L5
MIV[>.4O/<>6F/D(+"10"75&R^X5[PS!KGKZ^M+%*K9O[5R$&<^:+9^RNC=M-
M*Y<1@@ZK\WJU<B7J3@Z#F/F9=-@\2;O$7:+> VU#W<O<?1B;7,5.GUNF.LVX
M(HZ!-Z#>Y-C$4ZCQ4.IQ.+%2$W8'LPT,V<(OE(<[$_S#UOR[N=ET.=U'WD.?
M>173,(.[S]LQN^1'MLDU9LQHYUS*GCH:M<<;% 2Y[)%(-Y2,*A)',I$3#!XN
M#=%PF;Q2HFD>\+S]>OK92;5:7T&6#]O)^[I\U1"9:2\9[;WD#Q:F4XZ^U-QL
M$,#QLV]6S(8ZA2N3"4O?^M?]P+_!'!G]##P?I[L/N ?$/P?6$X,CV&[>G4W_
M (,@\P.[X]/A\/AXZ![L/N  IV@'?\DX,B3OZ?$WE_D9]>T1^/3N_P#3X'N]
MV#W 1'N,("$-P9* %$PB4O3\C(?B4O0!'[XAU\7G,[[[I'N 6&C:34+)0KK
M+,N$[1&:J5NA'M=L<0+N/X<M'[$LG#2*R)E6RJ*Z??W$.4X 8(&K5[W4N?\
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M['[A1^T #\,PX/*@/3O^)@/PR$!$>_XC_:#]SP A[LWN'_ SHW06G" 2B+L
M _4!X9#U*AT_ A]"7WO )#[M?N,(  ]>]JGPC;J_3U^*A>&?40__ #> >?Z6
M_P!QXQ@.)_3G_(C,S$1*)>T6WY&0$$@=>O3]WX^-CXIN/=5YX%S[/N).#[S%
M2S>&X9(VTURU[5.0.>3\=)2ZG$9:)>5UK!Y$Q7CVZ+)NX:O%G"AUU2G(0DKQ
MOQ#W%.;=F?U).X*3UYU'1.(M,AEY[/ZM@=DL5<C&52]NJ^2#GTL1R(K9_,='
M0(NN+SM3Z) =7=.3#CW&N?>>Z'@\KR[J#VB.K#PTOM>-H?%R?T.D2";V==\$
MZ1+SE9?VJE*&%(S1DJ=MT IB")3A$RNS^[Q[D]7OM9X>5#EIJX5F'X,#70.M
MCV5ZE<JE2HPW%9_;SNP;[##%AVKQL1G*+/R,&3]Z_9OD6\IRPF_>+]Q8^*Q&
M0M=E"PQ[/A$Z=2]'/6?M3#+0C$O#=,\K.V6/?HI,FQ#"L_>+((DZG,0!N[AW
M[L_NER;^JUKBI:Z9 L:?[?QI;;:WS2<0".-262?,^+S*/L*3:1GT49]:16BR
MUU+JN[$C,Z*ZM;FE_<H]V^K5F^J7&L560E:W[62[)SH=4J#:XHYQ+V>JX]/L
M<\O=XCWZ#. 2LAH=FZF'+1B9PF[>LDG$&:[>X;[R>7L;%>[;08J;N&:>VY9H
MQ=SGVU0W'C6;6H_HV"6TC>J8IIUB8?:(5A(\+"N!EFK9U&-W;EO<<BK/N:>[
M/<[%5I+3HZ.DH:A^UG"Q%^/BMC&K:4MF[:_Y+3+';VD5,(K>4HA']7;%$\@V
M*M']KHV7RV4^X=[PVHU;8I>E5.C6ZH99[73:-<WVS4.UWN2SZ;AKSD=-NE3O
MM2CZ).(3L3*131Q%2,0NT$#J';^=HK:S^Z9[K%D@,QO$KE%@O5.RGVW%J@YV
M* R)MO=@RF,=6; JO)C9H7'ESS:SQRU;0)P;+,DI!22*#,V#V&Z>[=[F5;A]
M_@]/MU=D'U(]LEPP@:/C\FDSO-R?2T5A4E"WB,C8=7YZ5I2G-JF#UI-65]'Z
M-!94E9PZ.]R'W<ZWI5LH%@U*/KUJRCVS&/I*+&T>LZ!6IF0?-<2?-DOQA0UK
M;MXE$@J+H22#IK*$CE&J_;+ZS5_<']Y&Y42IU_/)K19VNY#[79B9A):;F\1K
MU5J%O1E,EB_/L*^=6F$D7:D4:3C(\TXQ:.'9'JIVZ7(O9=8]S?W:<9H_&"T,
MZ-HSF\Y%[:\Q)O[NNU@9![4Z=$Y?A6BO+#+PD7:(]X\'M1;ILW(K$5.FW=&0
MLN=3WN)>[^HSJ=TQ:GS6E1N7^UB]SANWY#7![2\?NI7X94G9E*/<'\8Z<IN_
ME0+H,6YE5T$^I"GSUM8O=8]UZEL]6AZ!:J#.VO&?;K8U^9HNS5^]3F#7^3EF
MW'IXA2ZAMSW.)6'AW,]\L/&S16S6=)$"_8&<T:N73W4O=.K5FTO$*)OM!AI;
M,/;:;&ME4ND^P@I2M1<V; _LF71,W:OOG$[#+2"3D\&@Z>QGS))B\%"P153]
MV+W,:?-0E(R_56<-H>7>WW%2%GQ_;&UF=Y+JE?""XPV-L-9O"=,E2)M7JC.<
MCUF*B4BP9J"F4_ZX+GI_D+P3_1"\?K@N>G^0O!/]$+Q^N"YZ?Y"\$_T0O$)>
M;Q[C7+'D%6HMK,-WV4ZG5.*<929]22C'+%F[DWN8<=<_NJ+B#=+$=MO2RK<A
METBE6*JD)DS?MI3RF;9\JI:<P022=JL$DD%'.HTQN22(,D4S51U$&5!V@GT\
MU59$I$OPIB?<J;$[%67-F8T*WLKS646T_8('T=A8MW#1%RL>!DHX[U'T[HX>
M6J)RE-VG)VJ%*8*+6[VC,62*H%CA;3'H/YI\8)Z3A8.6KH)70B:A$+A$2\5.
M.DY%B^(LS?\ G"*R9N@=*A&1% GJ_P#B^3BHVCRT%?KFQLE7IT+1F^>1V9QM
MF^<J3Q\K0KK4IOLXNX6B32'5\* O!%;Q'W&BY_;\ZEHID_CHY*@ZMH]6BV+*
M6C)Z%ETF<7'61-FT6DHFSOT#N$BD<ID7ZI*)F31,G)Z#?*I/.;]*3A9D]YA+
MQ;JM<634<[?9:ZJ,99JW+Q<TPSR2I\HZ(YKQ%@AEWSA1^9L+X?4A/VTV6O&)
M;=9'EMNE.AKQ>8/-+K.R5Y@=/E5[7F\1865,FF4OHU88S3UDJS%B\?(F,NBH
M19<BEGM>CU*R25MN$Q)2<];8J_7&LVIU'2M9JE4=4LMCKLQ&3*>=$CJ7'+(P
M +?*FTBB+Y) CPYEQDI1_3[E-&L:[*0O#&=U?2Y>*TN;8:.MK:,]I\:^M*S;
M09(^@G2?*%E0=-5$FC5F9$6+9!LG%JU:KZ#$JQB\Z^,+79M621E9BSQ;Z L-
MEFF25M3825NFJZ_^7NI@Z7S-PT;-"*+F%FT,B>R+56YS,PZN5$O4NYL&I:%.
M!8YW+7M9DLS<VE&0L*R-F=4*0I\>I&/GQ5Y1$$3)&='16724L$[:*//J*6&Z
MR>E+1<9H-YA:_$:)8;!3K1;KQ68*+GFL96K-=9JAQJLNY9)HF?='15/JR,D#
MN,T><K<@ULK//39)*A7;+8:Q"7+*OG"E@1SB^5N!DF$#<*:SF7"ZR+)ZW532
M*\=H!_>SQVBM-5)_G4S9:M8LZ_$[-URX:'H%LAI'(&E,>T&MY<X8S]D?HC1Z
M17))P$&R  "+?+*/D3%?',X&R0ELSZ6L%?N%LSRZV>N2E^OCN FI_+<F2PVF
M+/8E6QF:'9,<O;HQJ[0"@V?&03<N4U7:95PCEIVAVJ<GXLCXB-XF-8U21T9X
M9P?.7,6M.Z&[N"MRLSFGRV15F1@%))Z[/!24(V=,A07()S>?HE;L]]<K9'<<
M1D'5MT;0)AQ*T.^72'T:QI/E%[('6Q#>J]'RD?+I E)PSE@W".7:)HID+$:4
M^HULD-/A9,UA::<[U?3QT)2VGMT!<SW-U;4+:A,+VT\A5X]B+X505- -@A1Z
MQ!U&)[,KHM%#04[1:3VUS'627FCPK&2+JEBV1HI&03&19Q#)TC>;0[67=)HE
M=R#;RFSM1=NBDF28R>HP=HKU-G9>LV*21BM'T1E-*V.GRD3+P%@3L[>SIV-O
M+M'%>CDE%4W1?5,8]LS7!1FB1 )^N,<4,UAK(>)7?LD=$U(@-'</9<UMS=[7
M5@NOJ*F\=3V.UA5XI%G9B^)"MDG'F)%$@UZ]9+6K/GE@KUFT2R%/ Z+?5XV6
M)K$C'SN@5N9AINQ2\2[JEBLL)&R1F)44R(/(Y 4!2)YI%9YI;<SEI^.LLMH\
MU*Q,EIVJ.8D7NJV0MVN"<=&J706<''*WLOS]BS8D;M(J=$7[)-!UT5" <YAF
MRV;W^A2:=FR[2&UMOULGJ-=8^PQ]PK]H4:VZWRK"[?9^WQI9)O'3I9",%PNZ
M R D>.RK1F#P["Z!ED#)5:7K57+H=RC"5J0JT(UB$U8B2@9B(ERHSSE-Q(2J
M"SA9O(OWS@ZQ#$.5,K:9;8J]:NF<I&S31NTUC:&D.UDX>P2EEBW3> :Z&E!(
MG82$TZ32 K< (R7.T  :F%$<OS$^4R*5)QEO/M,XAV>HZZP&!:66=IMGE&B\
M@QOC>3GF83^>0;MLC(K.TF2L6@+<J0$Z"VV#*\<1H]^8A*BPDX.ZZ*C$QZTS
M7']0=.V%15MRU.9/4*K)+1K19)@11BR,"+84B% H5^2A*;=DU:P2JHPK62VO
M:)Z*:MZ;>X'3X=J:&G;])1+EN[T6L,9R6*JB?Y_*H ZE/6+"8XK5>X1\W,Q_
MV^C-0BW3BX6T)RK7N#F&L] S]*L))LLW3%(*2:%,S0C%VK1NB91 B0(*JIG>
M25]R)Y:9)_).99U)2>F:R,FL]DX%K6[(*DHVO+>14;76)8-B3Z!E3(SQVC=1
M^5P=NB9.1L65P+^'2^0OJI4H1[.3,Y&4"L3\PPM%RB*LK//Y2413NUMBVCZ1
M,LX5ZECF#9$J3=FBF']A<AG?(+><:PUK;_;SX=M:HMKFDU?.BV=W"\@.::\N
MA7E+9,1+&74BD)% [DB J+HE73$P 0W49+7GWN'8-2M L;1X=W9,K]P5MDKI
MW\X@ZK5)A^8N=Z]7$G*\W"YS7D'7G%435&OL5.P%$>\W(_"N//-WBI\HDLCY
M*6I*.D^7]+T6Y6_0M5A+K8[5/25@M^C3]GLEJO5ZGW#E7N74.X>NQ*D0.XI/
M'#S1M"SMG9;RIQ)XD0[B8F)":65) 4.D4:Y0U.]":1"/2IJUQCVTE*0P(A'3
M+YFV5D$7)FS?RZ_AL=69IQD=4L=6LM<H$W>;Q8J[$J4IW&R%7KR#.>L,CYU$
MB)"(;KIUY8587S$PZM1 .GAE&JXHJX2AP;(UIVYT;4G,Q38]F_JDDTA*3.KW
M12:J%=;.*+#%3CHYPW9)MXU% J0( 9,SJA.LXF[30W=.G\_6H^@:EJ^BU *=
M9!C%'\$A7;S=;!%-6K5Y#-73 R21%8QXW3<-#(+%*<)E[*9S9YU>><7Y20+8
M]AV2R-2,]8M4C>-8A(IA.WV085^N:G;Y-20L4?'IM6DRX(B+I-0K=N5*6<5[
M/;K7 G(!U5)5E7=TW:#BGM8>.85ZO7EH>,TAK%C#"]KC!8&X(@F"C0@]/WW=
M"6& SU>!FX/5Z9N24G#7"[1CF5UJ@Y4GB->O%F]'8DDK5,&RQ,8A_P#,"N4I
M5$YE7I%W ^=XNEGO6?S3M_H$RZM5I90VDZ75Z^]O,A0HW*I+1FE9K5MBJ_#Z
M/)Y?%(UYQ/,VS>45B>] 5^BJHGJ;_7:":\-*>V9-6%7E[):?L')EC9LMDCW%
MGH#69;TRTR#6< RX.7[%=P8JRR)SF07724AK3%U_3HZS0-=D*:PL3'?MS:3H
MTN0K-7I8TUU,(:$G(O*PPJ=,C6#1HHH9-HDBH9+M5=.U%Y6G1M6OL+3[%5Z;
M4[35H+:MAA82W,,\@(^HTF1MC2-N[8;'9:[3(AE#)2CLRK]:+8-$%U52LVOD
MSI;!1G=G96G5KAMUFA;5;+;9ZW8--O.>#E<[8YBL3LT_KT@5.C]K1@S4;&8Q
M2A0<,T4'(>=X2CVU-MZ[5%IQLCRED]=UF94/'\1'S^2X]L'*\M='J[UI0G\F
MX5,1<R@2PJB$EZPO0H.(M3,'DW .Z,IE3NKVJ]WZW59WD):;:Z#$8\[KUELL
MI%NLJJM8O4RE#0*B9HZ)6DEG#5--QV*EKK>X9NVMD74*_C%<JD!99JPSE?K;
M7C[9W-OR62A8:2E7#&/LM7F7J_=*ID"1?M%U6CM9=JH=$RTSE,/:H5ZM6X"D
M",KHE]MB*="IC19AGE 11M=BF2)4K-&3UVG78TO1M$!(/#(%*=TN93[DYZ#T
M$VG<?R%^/01,??\ ,2%*'[HG,;H ??$>G[998J*K@R*2BI6Z )BNN9,@G!%$
M%5$DA55$.TO<<I>H_$0#X^"'$ATQ.0IA3/V]Y!, ")#]ACD[R]>@]!$.OT"/
M[-?9V&Q04$[MDV2LU5K,RS",<V6R*1LE,IU^OH/7""LS-GAX9X[!HV!1<6S1
M97L[$CF+_JARI&<@HF9%O[?/"9-N:5C6<B1!-;?N<"BR:17B2P)^:= AC=H?
M'L#K] >/\1ZA\?C_ (M0O^\O'*-TG3JDV.AQSW!0K@E>AT3H],QM &4!4K,H
MI]"=>H]0^'CAGUZ]?R4N._7K]/7\4-/Z]>OQZ]?NJ3U@N1RU6%0J:I , "9%
M4Z"Q#%.4IR*(KI&(8I@ Q3%$! !#[JW$H@ CKW' @]0 WU5.1>5)G#H8!#J)
M##\?I#Z0^/W*.N6SW/-Z!7(J;;#$VK3[%6*K"1MD<,I!LT&.G+6\8,&<VO'*
MNDT_*5*N9 RI2]2B</%0EZKHU#LT3H(ORT*4K]OK\U'7<8MJZ>R85![&R+EM
M91CF3%=9?T1EO)21.<_0I#"%LS:EZWF5OT6A&[;S0:O?:K/W6F&\TJ';;*M$
MRKN<KIO/.!.CQ!'ZX@'TCXL>316QY7)ZI3HT\S;LTC]"J+W0*M#IE2.I*V.F
MMI=6QP<:0BY!%=TV22 #E$3?$/%@"F\EN/\ ;1J<#(VFU!6=DSJ>&LUB'2,O
M+V.P!%6-W\F@8I HG<O'/EMT" (G.4/%-]=>*>R_&*N5MGWJ[-"M_MTY/#N+
M$1O3?.>D^TZYJ^S5? 1EYYA9I'6Z>64Q@LUUC^4''=_3:5.L*M<;:RVO-759
MJ5FE%%D8RN6:>0LQXJ!G9%9LH1!FZ52<+&3,!"")1Z33;']FRC5W-;*Q/8F^
M:Z)4+TO $DQ<A&FFDJO,2BD660%FMY K@F"OE'[>O:;I8(6D<AL-N4S4XJ3G
M;3$U76J#89.M0D(;MF9BP,(B?>.H:*B#!T=.')$T6X_OS%\4X$;E551T1 [G
M/P3L,0H-Z;)PQ[&HXIP%>"-G0)7DS/Q.R\\H,BBN(^4 F\7.VO-1SII5,XF)
M&O:%9W-VK2%>H<_$*-4I:#N<TK)DC:O,1:KY$KAL^5060,L0#E*)R];/?JUR
M)PNPT6E+1S>Y72#UN@2U2J3B873:Q*%GL;"P.(>!6E'*I$VQ72R1EU# 4@&$
M0#Q5Z9(W>HL+A>&<G(4NJ/;)#-;+;X^$;)O9E]5X)=ZG*6!G$,UB*NE6B2Q&
MZ1@,H)2B ^+,VK-OJ]B<TJ;<UFY-X*?B9=>I61DU;OGE?LR4>[<*0,VT9/$E
ME6CH$ETTE2',0"F*(WBV4[D3A5MJN8J"CI5EK.N4">K^>JE\SN2O$S%V!U'5
M-0/)/U*_4;C]4?W!\2;:B\F^/=U<0GR(9EO4MHSBQK1'VHG&=9K7S-*'LCP[
M#[1621;Q['S0)ZM\NF@EWJG*07RNP[ECV3IQC>#=R2FE:92J(2/:V=[*1M:<
MOCVB;BBM&]AD8-ZW8G4[2NUF:Y$A.9)0"D8YCR&PW1WJLZG5DV=#UJ@V]TI9
ME8B4L"5=(WK\_(JGG58&#>OBM #U!F;-=8">6DH8MIRBD[3DUPU*C J:[9M5
MM&I]@OU/*BLDV6-::=$S+NQ5\J3A8B9A=MD>TYP*/Q$ \7]VKI-!2:Y090FI
M.5+C72-\U.E%)SJI+^L:1!.G&3A%B/#!(BV$&I@5'\&(&\/]'TO0J/GF>139
ML\D[Y>+9 U.FQS1ZHDDR=/K///V$(T;O%5R%2.HN4JACE HB(AUB;[EUZIVD
MT:?2.O!W.@V:%N%4F4$U3HJ+15AKSV1B)!)-9,Q#&16.!3E$!^(#X7JTSJ.=
M1%G:V&H5)S7).[5IA.MK7H*#MS0:PO$.Y-*01L-X;1ZZD.R,F#F3(@H9L10"
M&$+PYL&BT2";YDP8RNDN)BW5^,1SV+DV)Y.-DKPJ]D$"5-A(1J1G""S\6Z:J
M!14*(E 1\,;_ ([I%"UBB2BKE"-NN:W"O7JIR"[)44'B+*Q5B0E(ATLT7 2*
ME(L8R9PZ& !_LGE?_P#4_P#A#_W]<Y?V.5I!^ 'XV;H0?P8K? V7VD!_!%36
M,K]/[T"&$WT=!^CQQ=B9;A;QFCX*&XT\>D8B:N/N54&AR,E7WV60B=7FY:OS
MN!&5KKFR,XA=9-J9PX*4R*Q"+*^2<_AQ/3WMN8E!U=DQ/(O[7,>Y!1XVO1[4
M%$R)+/)%YQW2300<E5 Q%1_!=! #&*(@ Q\[">WMQ]EH27?N(N'F(SW+*')1
M<Q(-2NSN&<7(1_'=RT?.T"1[@3I)G%4@(*"8H=ANC<K?B%P\>*.U44&R3;W8
M,=,HX5=*^F9IH%5PM(%CO'IBH)%((F.J<I0#]R34H/MT8+?FL0X*TD7E-]S3
M,; V9.CMR.$6SPS#!E3LG"Y##V$6*F8>T1Z=O0PNVKG@=Q>159),G+DJ_NOX
M0W.@TDD@7C':Z+C'DUD&TDW,"B!SE*"I! 2]0\/8V#]O?CG,2$;&O)J0917N
MF8O)/&,&P03<.IMXU8XLX<-8E!-=,5%U"E33!0ICB4H]?"7?P7XL$!5J1UU/
M[L&%E[2'*10.O7'/KE%NH54#E[DQ(8![OB'B1L$9[=W'F2@H9./6F9EC[I6+
MNHF'0EW'I85>4DD<7.R8I3+@!(U,H<H+G^J7J;X>)#YI[86/1ORGT/S3YA[F
M&4,_EOS,RA(WYAZC#T_1_,#HG!#S.WSA(($Z]!\,Y*-]JG,Y".D&K=\P?L?<
M?S-VR?,G:1'#5XS=-\)40<M7*"A3IJ$,8AR& 0$0'P8?]$_G@" E "_Z1?.N
MI@'KU$!#!>T )T^/40^GX=?  ;VH,\( ]>IC>XOG0@'0!$.H$P4QOB(=/H^_
MX$B7M,YRD03J*"1/W%<V(45%E#++*"4F"@ G55.8QA^DQA$1^(^/U3N>_P!8
MOG'] WC]4[GO]8OG'] WC]4[GO\ 6+YQ_0-X_5.Y[_6+YQ_0-X-U]I[/P,';
MV 'N*YP)3?'ZW<;\1 "3H'T= 'J/[GB'K6Y\ JE@^8NX^67F-/B^8U+UV0AI
M%I&'<14>E0(7+*R_E$I>4*#85RODP;D-YIB" "3]NV_ZX>-G_P!$=E/W+A/)
MSD_F5-K4/[B^+2UDOFU9')[KD%&BFF2;^7[1:3E<5+0#FW55-\L@W4;B_9$\
M]PD85B=OQPQOQ]91/VTGN<7NY6+CQNF<9!9N/7'K0;9H?M5OT<_TS&,:M[ 7
M&,Y=$Z8LA!D)ZJ1BY6?BI"40?/#/E1+[260\"\<G,VY\\=KM6W7*]VOC-JH>
MH83166#WR!Y51',R^2M3B"3#S5-,?,@1:2[UXM;Y\[>4C0722]2'"##77&/1
M+%[HN-,[^YY OHW,+G3-]P;;_P 4&BH<E.0')O5WK*K)6G,-(LTBY*U3F)6;
MC[LK,QGH&4B9J0&OL@WGE13..L;@=XQEJWR:\<?N) 9SJ[S<-+XSS52A>//.
MW1)VQ6F6MU+T[-;9,G,[:Q\;%V*WQ";>3;-R&9>=[J>:Z4WY#\@,6]O+)-*X
MJ\ \AS=!FPUG-,'Y5\?XC:M6BL&L<VZ;_;#8H>M7MGGE3E73E1VRK];1C$SF
M]8Y1,_R)+/>-'-7(*QP[B8E7D77N$]@XP2N7A3]+IPT_C1R]QB:*[P*];NN=
M5>:C'3&)C;)6CPDH!V+1K)@)^,-@@<HJ>>7NY9\[4OLM&4.(I]QLQX^_7<T,
M%S=MXF-G)9>.:O# W*_,<Z!%1 H% P@.5\D+G#<7<WIV#\=N<^B5&*R+CY<:
MGS/V*9T'&>2.2M:#R"U6:GRD>U\&]Y4?R,:TB%#3$@PCRF*B#<H^/9VY%[]J
MS/D'GV(<5]@M=$Q*C<2YW/[C0KM'>W78X;/*-8;3":/H$I;9:=D)-G52)KQ4
M,=>4<F<F,B'X!'FEQMWG"(.NS?N!\2Z7MSR2SZ^V[D6PT7G%D&ZT*5Y)7"YL
M$LUI#6AV+8:/JK.47KB1Y9D=E3'";:45!,P!S8Q+D?G^5_C"W?*^!N9Y6]X/
M\7)3"^.VN<;I3W$L)<[;8[9#1-AO]C/R/Q^?D>JZ$A,^6PJ3Q-_'F,5>1%MQ
M#YJ<@<8V-^\]MBA<C. 3>/:TN[O7&C6_BUPNWUWI^B0<,RBW1Y9CR0UFP4J*
M@I,A#(N5FHH(JF_"&\<B\1M64D9W[W,>&-LTS0G^#7_0=3MFG<P\ST=[MW)Z
M-L1G&;YXED.C;]Q<UBPU.#BF3Z7;/G-*:,T)-5T*(K<T4O;FXO6$MTK?MYRM
M#O&P9;Q]O^:YS0ZJEL&2/8'C5H>>.("HET#8.V.?2GR<(:3FJ_%Q#Y!99F21
M%-QN[3/M6Q?DM-9=H7!;=[=6.(GM3;5PYOD/CN)<U\2T[7+*O(3LQ=?QW(Q=
M0@C/0K4.7UZ)F"JI$E3E["\L^2=!J;/;N)T#P-P'%H_0[_CUA-F=JVJIZYR,
MU*:A*=&Z#5F+F^/*'7K?&'D',<T5+'/7@,P4!T"B9/\ X>5IDN5)YQK\A]II
M.VV"%H UI[!:4[]LCEA7:E;M26&OMY-L[87B?9I$=3':=-=<$C"8R@%-PK:1
MG"S7YGFIP:P;1K;R4&KX;IM'UKC/=:CQYMA^1=DW.XJ1$,VU!]ONB(N8Z%BU
M7]C/<Y>?:2K%LN5#U2'*>Z\AL6K!O]*;[=G-6$UYUCEMU'7+M/\ ,.3IVT<G
MLJFMJJ2V/5>*SB;:9_H]BS9@WC7\ZU4) QC(KHOEM_/X^-J=H.RQ,'QJW3"+
M7<MVC>(F@Z)G/&F\,,OT>+HURW_C]N.:P)]?PN;>HOX20<Q+9P:KRCV/E5GD
M;Y"3LERIDQ4LVHMCVSDUO%GR>_Y!C&Q8+E'-"*I=%R23O/)+/<8T]6:=Y,S=
M#.(13YN1XG#SLE$.I2*.Y3=*G#DYEDS":O 5/9>?OM#PJFFY]$S[*:J+"#XK
M<G_ENE4ZS-HIPS8O,TT,S!PN^(H*#5<4DG9B)J=I^0&B<[>/N@RD-AG/GVTV
M'/.)J.96;0*)MF<X%QHW&C.>0%7S^MPLQ)Z7@KW796BW]]$-(Z15C6::A7#4
MX,3 .XWWC%A]JR/+][WJBT^N:^SSR^TO+N5>QML?>R=@MN:YPZAF):K U:LT
MOY7)W!6&A82RRC,2E>OG"9#F^X)@NDFL"2R:Z0*$*<$UT3=R2I , ]JB9OB4
M?I ?[ Y7_P#U/_A#_P!_7.7]CF,L3IWH\5N0JI.XI3E[D\DMYR]2' Q#AU#Z
M! 0'[_CBSN55N%7BWKOC7PQ7/2[/(3C:*E9"LT#CRZNEI5ME>K7VWK4F_JV(
MPD!%QC)TI$-@7>RIDRO7*J:DIPAL%KH=GMJ/%%7B_#W]U$RK2KS"'XG&F8-[
MC8JP)'[MB*3PRSDT>BN[[D4DBBX\PYS$/<(?;<NS.=B>0=&Y8TC.<UJ$A%XO
M7=IH%;R7'FD;(P,I'R4A*4RZX;2[*C9%F/RB0E)NXN3#VMD1*XJULJ1N/<$Q
MK?)CDCM9(IE&VBK^IIVOL:W&Y[0'RU7KS9:2AL[1CGAG<88Z47)H+^D*1NFH
MHH'(I*JZ;G43IUUXP:QQZJ3#%Z^^IJERC=7Y#VW=[-8+I89Y\P;_ &ZAJ[;G
MM3J*Q4TDH(CYX\%T'K/*:N;U7[1QDAZL]UR/V?\ %HQBM,KT#"WJ%S"XYPW=
M5>6C6[RSP>:VA[9F$],T$CT8;YE#'*T=MR2BYFW.[Y38.+</IO*6C[1 9U>8
M*LW<$,TG=5E)F!KP0D,K'M8_/:#FF/I5V%+"0Z3H; XK3!5VY23;))A>(*CQ
M_'"&A'\[PDK% 3/$S57M=3P;B%3'KQ[5&F@5VD/IR$T'4MD?*/Y.?9)><M B
M5FOYQDDQ#.=LOFG9.UIZ6B<4;5M&'YM#VRLY=>6?#QY=;-E<@QKSU%^5\_-=
M;,1^ZBY95VP5=KR,@LLX?N&BK#6=O0:X[H,_<>;%!Y9_8$7<U&N;/5^,''-A
MG/$;(G$W*Q;*,8'B-RBV]NLKY4XHBS4=-6I3&5[AX_85:;<M?;/D>/9[GMCN
M2HJ=ECGJK6(V(F)1BFLDBLVB'$@U4%D@<H'09^4F;J)1$?N[;S!.4GXX.-W4
M2% YNOY1F5=O0ICD#H)N@#\?@'Q^/T?<KMO&GFE7D-5FS5G U&L,5)F]:7>I
MURG$TC+\ZKC8#/;+?;[8W*$?&,D"F,=9;O/V(IJ*$X)5:L99B4;=>:7%K+N4
MBL#R#Y?UOCXQH$+KDU5*]3J'!3DEE5R1TNZRDO-222"9$8A!48@P=Y3N$B!<
MV%YX[KTOBA&Z!RVQ:D<GG^I1"LC:]@X546[7W8F$YDQZNT7JF?OV&56]I!3A
M)R16>/*VN5PR:D<-3J637 I>)46,C2T11A Y3R@A>1EGB3W*K_:E6"UF+B\W
MSQ;++?"M'38@L%?F*;DYUA27$$#":KV8F4\%JK3;# :I:EZ4S]R6$M7*V+A<
MR@[W+K,EN,B''B*FE+4\^Q?>YC_FY0CV*YW)UCE0,0W#SE1$<8YASJ7*+E!$
M\:['QX6TU!-[C_2QMHRV:+)W5"C.AL-6K\%9:R_1'Y3'@Z^U+!)11L)^X:^Q
MM?&7+(S +I[@]Z]O*I7:K\JFUBY /M#K&VV[#(J^.N-$CC-:5/3'UCJAG\B5
ME9WCV+A53/A36104\1FACE7!JLUA[1M@T%?,X7W((B[\L&<+E%.T*S.&*G'-
MIQVB)'[0N7%'(5XT&6 (Z/=G>F44(W.F;,+1N^)X93<VU?BWJW*EI+\;.8L)
MRJT+*J=CV.MMPM#'?LJ9Y%F,SF K558\8B[%T^;DLX(Q2O8LZ1,.'67E1PDA
ML-R_E36+R[PV5KO(%/2+S5-&K>1W/<JAD7(NHK9;36%!L^EYS0951HZ@)*T,
MHZ7;?+G1@4435-P]I%TQ#CU!1?-#/;%>:=^3WS.BN2NE8\:!RP-<!OR'RYKC
M6=.\XAG,*'RI:1)(/DV-D7;1ZQ .Y(<.1&1L,MX[6*-XV8]C>Q3#'4N8D3A>
MU;4TU92_J+TGC7DTSDEH9:G?H1K03I-H\TXP/*2DBR9)B15P01YU0-%Q)^WN
M?$>SURG4VH6BS'@9C4[/<.+>6<C*_ V9NM7%%,NERRNHHUM^@8)?T;AHHX[C
M]?(+Q%W_ #+'UM#LG)S&=QWF?S!Y=3UM_CE XP8)<=6Y"J6N73J<VJK+YSI-
M>89ZJ@JS9E/8YA$ISIF(*)^+.<\FN,E&R*"YKYA+WOCSHN1;Y);9!K6NN9TW
MUV;RK38BS8QB\Y3+,.:B[DF3YDG,1;M2-<MQ634!(5=-XIYEA617*S9+!9#/
M-J-JO*.NX'R Y3(ZHS"5?M^$^8W&CNJKLWXOX\JK9^N^LT*BXGVZT404U2 L
M;W)N1AL?0?G]O_8=ERIG3?MR9E^-0,FH.<7,DJYL!ZLY2I:L^XOPM#) UDTV
M8-?,%53O$I.:FS9/Q=QJ_9AP9W"YXMIZ-YY%7#/[[9UZ_1\.M\38J/#0N WV
MON$'H[&=-VV?2;,S=.+[DE%S. (GG/'/6Z+[=V/:M9,$L&]VFS;MSZM60X@C
M&--?=YE7J9GE\M'&%*:NUP?QI4)5\BO$QA&13J)$,X I53Y1JF28GE?(7:M5
M=9]&L:YDV^%DN.<4VN[KJ_U!7D"ZSXLQ,XS58(!D%)&.JCN2?E%-%JQ.94#E
M@KAE7#Z#T70:9D/*7?\ DQ3$N1<9&U*CY/Q*VJQX3;Y3$=*;YI,1^ZRVHVNF
M33FF%.SK[!ZQBU1>NF2AB$'/9.,XRP4UQD-O<%PTJ7*U_>XT=3K^^;#B55V?
MT4/DBU*5.RR"7!_#U:2ET;.F_/8"@ QRC-#S_P"S.6J93 )T. /!XBH=0ZE,
MINW.14H" #U#J0P#\?V.9G_E1Y$_]T-P\<5D^XY^SC?AQ.]0>Y0_;F-7+W'-
MT#N.;IU$?OC_ &4V$Q"J!^.#C<'8<3@41'D9E0 /5,Y#=2B/4/CTZA\>H?#[
MEGR>KJ:'&V/')FS6[(;3G>L:AEDK2+W9*G(4XUK(YS*WU!W+/&4-)KHI%<*G
M!-%PN0@D!=7NRKAA0>8U?2X^NN(F>\0.2;34,-4T[1)NM526>R]KOO'70I/2
M&<_E-BNZ4R[CV\385;A7*PT0CCQ#)LHQZ+6!DERU90?&.!T?EION Y]!8TSD
M-<R_>.75'OE-GYNQ:'>KG<:)H%&RIYK%KEZ[$+U-MZMY-BE*JO$&Q"J;'OO)
M?9<UV'<-8S_#L9,]QC&G6%9Q%Y?QZ0O9J6X7IS^^:*^D+_8I;295W+//F"4>
M@EZ5E'LVK9OT4JF1CM/!:QYE U[3:.I<&7 F;@N3<C7=(C+RQ,N?<4N1S]-"
MT-3W'L7?_)A2=-$3(G1 %3&\+'9<ED!;M,1X9T6JP*N8*_9FJZ]@-HXB/]^V
MQA&)W=)<\MR5J?#&J1B[7SB&BC LL99V8YP/I>HOLSQ*^\B- Y%<FMP3Y%#B
ME.AM?BHC?]CN6F1-)-?7"4S<7)*+!6A&%(Y+()$<(M.XB*"9_)+6\+6VS@O/
M9?!YCI^4.KM"\#)RM\FY.!T.H7>N%F%=O-R3E0):$'=L34>N?E(HOFJ*C<44
MP6$Y<&I6?V&I46);<+WW!'G&QI.7Q%3C^9^/2.1!24;9+(0\F@>F[-4;X16<
MA+*N::=H-)62CW(.2.4UD,CKO+3FK4-LR_C!"70<"CZAQZ/F=]M^E6#'KIA]
M1U[DK9U]3N$+=;'G%(T"5,U8UB+JL?(2[D'[@H"DFW+PAOW'NU47,K[Q_P '
MKG&CE,\JV2Q<!7>9N5PM#C8U)]<8:%F6"\!IE<U"$0LL'8%G$J[:D>2+!SZM
M!Z8R?)C3:3N''*GT'EMA&68-ID/KO$%+?-+I$-F[+2HPUEQB[R>PTZ J5CDV
MNEKK)&>0LBBUD&+5R)%!2 @Z;;L/Y79&\X\[+HF#V_0Z'L?'^Y:#N4C$8_@.
M.\>9=@RVZ+WJHPH6*XU;(D7II-W5W@-Y)XHH9!4@"F;W!9UKM+UU7.66.<@L
M6X]T=Q2VQ87B/6.6,C9=&Y'$A%4ITKB\)Z1O5A+9/*_X**R:,D(\@F(0JI>,
MFB<K.4U)VR-X89W-4?CEGN0X$^PRM1L]8\[:9),:=I4C8-@V*<O5M+FY'<:Q
M;ME(B-9#)NU_)54.EY.TUD.5503XY\B$:B6TYIM?'=CNE^X]R<!$P\!/6?A5
MI[_1ZHWPZP6N.A4GR9WT-/IPEE$\PQ JQQ1#E%D5)Y;PE+X9\UM;A-?Y#9?-
M8:M<=T+).*YG57UFKYENPZI!P]>@-DB\T9^K<2E5F)&'5=NSLUNY1,4O</P]
M'8THI;GER G-P+9U: G*)9BC-5#$:BI5CP:MJ;%N'8WQT5/6>HC1ZR/0$BB@
M!E*QROR+7N/M2E8CCDXX[RM(Y#<4W')2O.HY;33:46U0!F^VY,:NS(.>UF<!
M3=E40[AZ@(AVU_C%6N3M$QK1'AZE$:SIF>87/U^C7K-XETX4N.757-J[MM?N
M&65C08HK>)=+Q-R^:,XH7*35TFJN59&E0-&Y08?B=I4XQ:?P;UY7*>(SJ"S&
M:XFWV?:2E8KV/YG(;[,*9/I^4QP/FT1-.9:?C7!Y5=5U&'[4B%JTG ;\@UX<
M5+D52N8$;QL/F"2M^/R&S_%8#&JX=SN1KGY*^5IN*TSM2T/]FBR*EA2^$B#0
M10_LSE=(\G-TI.,!>>#7")G2@NLBX9)V E<UCF@ZL0QB:#%T*AHKYNU%<>XH
M%*N4>@_$0 1YUX0 #UZ",](=!Z#T'H/RKH/0?'*RG57FQB$Y:+9QLW2MUR%9
M3STSV8G9S+[3&1$6S(>-(4[N0?N4T4BB(=QS@'W_ !QUJ]BYM8A%6"M8-D$)
M/13F=?>JBI:*SZN1\DP>%3C#D2<,GJ1DE Z_54*(?3X_S[,'_P /O_\ DKQ_
MGV8/_A]__P E>/\ /LP?_#[_ /Y*\?Y]F#_X??\ _)7C_/LP?_#[_P#Y*\**
M!SLP7M2[!/UL;PIOKF["]A#1@'5'J/Q[0'M#XCT#X^/\^S!_\/O_ /DKQT#G
M9@W7H(_&P/@#H4!,/Q&+ .O0/_3X26#G9@78N=8B?_.=P"G<W*4ZGF)#'^:B
M7M.':8Y2@<>H%$1 ?'8GSKP7NZ /U[&[2#H8Y"!]96-(7]\<.OQ^ =1'X (@
M8H\[,&ZE$2CTL#X0Z@/0>@A%B AU#Z0^ ^%I!/G;Q[!NW\SS 5N1$'0^44IS
M^4P7:IOG'P,'3RTS=P_ .H@/A1);G9Q_$Z1$#G\BUJ.R=K@O<EV*M62R:@]/
MWP%$1(/P-T'P9^GSLX]>G*!Q$%+D1%R()G!,W:Q5;$>G'N'X "8B(?$.H?'P
MS05YV\>14?=OD"C=4G*0=PE*'J5VS=5!ET$X=?.,GT#XCT !\"G^7CQL[BD,
MH8?QC1780I1* @=7N\HA^AP'M$0,)?CTZ (^"B'/'C6(' !((:1#B!P$.X!(
M('^L E^(=/O?'QU+SQXU&#J(=2Z3#F#J41*8.I3B'4I@$!_<$/$=D^%\K,5U
M729>/E9:,I-+N<=-6)[&0;47LN_0CFQA6.UCFI1.J?IVE#]NW5<*IHHEV+C4
M!E%5")D 3\D<G3('><0*!CG,!2A]\P@ ?$?#AS"2K"6;M'KB.<KQSI%VDW?M
M!*5TR540.<J;EN8P <@CW%$?B'W'A'G&';;:./\ +\C><E!PVYZ+2JQFMKMC
M+/Y3&=XO<LQ@H_6*5?Z>W>/)B@1_5PK&+*IIE,!!#N'K7.%=ZWHNS2.7>Y;Q
M<QF?W9WG^<5>TZOQZY-<.>06Z-<STNNU*N1])A-*HMRSAL*\K7F4*=]%*1RO
MIVYEW +[%AM V7D!4:)"<X^.&.1+;BK@>2[EO$10KC[:^G<C+=7*52[UG5W;
M6922U.M1\K(KNVKI['Q0+>0=)#ZGCB;>G]DY$\GLJT_W*.0N&52$+BO':K<Q
M-GP;,^'VE6"3JVKY+7E:/2LQN>;<GJ3*BJB*E4L9J_!D,_:)&6\ASS!4-KLS
MQ#U;2_<_B^&'&:9Y!YO0%K'Q%S>$XY8+KNHW2ZYW4V%^87-&J-7\^\ SQS-%
M,ZL<8FHLDB*:*?LO;75+C!PG&G?LAO:G/:C+0M<4B8*^%U[&>);VPKVJ5B$+
M/28_(N2&HMC*B5TQ;*1B_<\1.44^WG[:-HM9)G-6.SYW<^*-7"N5Z#6HO&K8
M:,]O&51SYW$P$-+S<E8*6:.EEUY-5ZX [WH14$^A"_+K.XCYKVYJ-Q6X[RW)
MENG%1A;#@EIY$[MO&>U+D^:3:PY[%*YO6)/+X^%MS91X9K$Q<F6530_O9R<:
M'G4IS1M/&R:H'$MAR*L^J9EG.#3=\VF_;7R>Y4T#(EG[:\9Y;*&AB.74# FA
M7[2%C(]]8'4H0%9! J?X6I:&GS6X[9)/ITRA6+=.;M"BZ_8,BC*##*LU]CT;
M$&MT>VBBQ\O8HUDY2@59T)J*C'#ON40=F233/@VMQ_,G>\UW?9]KLW&WB947
MN!\:JQ*<GHO0=>MAN.&]<B:5H.$6>5RZ69<>H%6XVF/A25Y U?BUS Q9/W )
M)Y-4*M[@6V:DWJ6-VOECR.QZ;R#BS#9T?#<0IK*J.(.,D(;$VFCQ-FY)[@*:
M;$A;,/RF.2G%D#&*Q:I#5,ZE>9S*4O'-'V[LBYX5/0#XMD2TAQGM%GUC.(S1
M\>P*M-6-8KMNB[)F^G)Q5%&\*SSMO98LKQ\Y>H++- LYMYF;I)ZYDF_[9C%G
M9:Q4*G1=TK\-4;6>2S*,WRMYTV;98WUQ]D=A@).2<53S*Z]2D$'#10X*F'_4
M-QZ]1HH8SMP9KZ1!9$J;$3_WHDX%9=<5G94P_"'+V$,8?@0 #X\Y>X1-_P""
MWV_B^4)"F3$!T[G2(F$PIB8#?  Z=P (?>'IU#^ 1_BB?W/CF8)44BB'%'D3
M\2ID ?CD%P ?B =?B ^,XA,);Z6^HA.)_M]2E9D*UDD)9EZW*R>1\A$M#8T:
M3DZ.[C[:6;OM6RMA9&[M>35@H&<>O$ACT^]VUW"K<A,>NM3QN])U6;XK2K7,
MK.M$5Q"GK63-]6JVD6!I5R%J$K;;+4$KA!?/%R$<0DZFFBN;L2!7DM7N-E*O
MUTQVPPO'Q#,;9!Y,PFY?#[% SE0D-R"BB:CS!M)8[%0K(X8,UEFE@2J<_%N7
M:O8@'I!Q<EGG>95:I,Y#IRG)Y]GW%NK6NSYAMGV)Y)+2>78]&O<%L+6XXLSL
MM5I7I)0R3]!<7;/NFA"4?%;K-[+9^2.9W=OD.]W2\0T/AM/0HM?T*BY-Q>M&
M?4[)9=[QKT2'O+JT:#/:+&,8E2=7"0*R,FC)K'9LCN=!LVF+\EW_ "#;5@:1
MG>*R7'R);8S*C;:'D\/D>T3=WC\GAW439$K]8WTO<T1DQ)#*!,,G$2V913=4
MJ5AD[ES(S+1H3A!I,];J/0^.^:6&GN>8^/W>JXO%1E)=RO&RV3$]7-K6CYF[
MQS$DDN9Y'/V[EL=)@D#<*FSS^>TN&NK[2='2TB U;C^W>X#46%8Y,Q-:XVUF
MO6B!RJ/LTW0=^XW(23JZS;.4>.JPY5;S:BL6NA\E=X9+JPG("DZ=8<=Y:W:4
MC8S,\[TN[&Y50%[BAXK\;ME+7<Q>5&&Q2:KLA),W5D8(0K>53C&RR\PP*KY[
MFX:/IDQI[R[6/DY3:?,-8K-*_*ZSC/&IAR1GJAJFA9OF26$5-[,6%+&56;N.
M!1G=06CFY)EL1RY.LP-?8S-[QR;FY^)G5XK'IUYQ=JPQMSXU&X^6>YN.05\8
M)8PZ(VY%0&]MTH!O5>D.M,,F<>A]GDBR[F11S-ML.D\DL@AK-M^\TC36&38_
MD%PRN"H&5<>JQ8<]U'/)N7XZWFVPU(VG7_4KQC:PR#F23;OAA! 'S)97P1_H
MN.[#>.3S'6Z%J$C#V? (^*4><5*11,]OVPTZ%GH*BT"I2>L:Q-,+!6X2LGBF
MUH@7S\[8HR!6;.3>:IIS+2.6M"W-CH<P5/":_P 9J>ZHU=ICSDBRJV<I9]*6
M3CU:;':&#[CE)EF))1!Y+O?6E5<NSQAVJL>-V0J4UMDE$LV%%)QE&/Q6KS,?
ML,_$[0OC^KL^24@QRXJ>=-7675%"]LGC9*J,0"U.G+,'(QZ,8C#&TMUS"K-^
M;5#?++%MH#B=1+6I;9]OC^-S'&F$N#\W'"&K#)M=-?7MS.6B%$JH]KR >@D9
M,4$&<\YOIZ"VVQ]KSOD:]JM4H$;DM584J/SI$NL$<D3OMQX@2%3B:HE(QU?1
MA)]>;L:4RS #OG44#@'!L*G\#)I-CC;;QGS7\=%.>\?$<HN%=TBS:73:K*[!
M24-%IUGCJ1;J,8\B:UY[,/)=56I.EGL7_?46BK(MXWDDTTITC8<0SV=OC6_8
MVC0HC*N5SJ?T574L@RV6@J9!,['DT)5(A@HUE'KN;0,<&9D9ETO)&0)YA$42
MJ=O;WE3(4_:/Q[>X"@;MZ_>_;L4R*MT#?CEXTJ JY_@B^3R0RA80[NI034.5
M,2IF$>A5! 1Z@'3[EG]9U\^B,"Y7I\/L6>V3*M5T+&[Q4]!@H"S5=A.PUWS.
MPUFS,E @+A(MCD(Y AR.1ZAU !"4X_$S:S(5:8UJ-Y O[PEKVO'WE;D!"@U+
M"[F;D,YO#C:CZK#),446LN:<,N@S3!F7HSZM_%&D:E5+;)VNB[7:.1J6AWW4
M=(T;2+?N%RRF<Q&PZ/H]ZNMHF['?YIUEUA<1"*4FNX9,6I42M4$?(1[$^0L;
M2YF)T1+=E^3"9(JZVZ/IZ>YR.+6+C[8M%2HS:8)5&\Y<LNLJK*;%-J1.7<H-
MWCHJKM$JWB<Y4UO/7+?;[!/:?:'UJ>VZXRK)*R;) Y15=&G8VKR4ZZJ\5*V&
ML8C68XRS=FF=!G'"FD) <.?.W-2X8LK*)<CH?9H366/XP-':QLTUY!V[++]L
M+B(CFML195&2NMUQ:MRJSJ)(R70?L#+MS(J.71EJ;:,*<VK% AKWCMHO$13K
M5:S1FG53 ^.MBXV95EED9/["M'DHM>ILE'+J-?3K$>/(9LX5*9V!'2>I:A9Z
M&PL5MVG%:]QWTX\V[DI.$MN.5B5T&:BJ3(5AV\5KH,?7ZC."NJFU(X=$>BFJ
MH<B:128_EU=SW2<TKF'9_9,?HLAD?(CD!F%T5Q>XV1[;K9C-QO\ 3-*B+IH.
M7SUAD5G*L1-OG[=$YS>G\GN-UI/$VUYTXB./F<N<V<TC.<XN=ZR:/KGXH';"
M1S5K'R>9V2J3I8^I2D2T>-FYG1D1>-$%SE.JD0P8R]4::-=I?C_?[MI^4V+6
M=LV38K17+MH-*LF=V68<6?4+U;)ZP%4IMODF31M(N';6-([.9HFB<"F"Z[.G
M7$UM&T*@4O+K9//7LB_2D:#G\M>)VKUI*'>NW$+',6<OH\RNMZ9NB=X=Y_?!
ME021!/3<ZB\AL:]7TZ.H\&JE,[+M$_+YK6,NN2NCY94<%L<S?WM@P&J9CH:Y
MYV 84]S#-XR3$JR10\M("*YMCT+,1T-(V6>O%HF[7;[9H=]OM]M2Z;FT7W0]
M#ODS8KI>+E8%D$_4R$D^<+BDBDB02(HI)D^Y 7M$2B4PB?J'0H@)>TO3KW")
M@$?C] =/V!.<Q2$*'4QC"!2E#]T3"(  ?V/SF_\ )E[??_>7SL_8YONA452!
MMQ!Y*N/-0!(RZ7DXQ=%/,1!8BB(JD[>I0.4Q>H?$!#QE6OW5I8$*/E'$[-[M
M;$8*+=VRP1E5JN4P4I.N6\7$-P>S:T-$M%5E2MD144(B82$$>A?$+CCV*V5O
M>)VT8)3&S8V16PT6ULO)6JSUTRB,D9HC8T<R/)5VIRRS]0RGE1 QBY'ID#@0
MIXBGU1AL,K89*W6ZF/HU+(K@1Q5I"G[#.\?74I;4E&9582JR^VU:4K3"6.4T
M>O(QZPF5(AV+'JE\I'XW-!B[7(:]7$H;/\9T"YW:OW_#+&QJ&CY;;:'7H9_<
M*YI<39Y1LT1B'#(J[SSR+H=[8?/\9/+QR.\6:L[-%Q+VHW"J<:MSL%2;2TR2
MV"THUDG8^BJ,Z]IB*]&E6[JN+B$RR<M!2<-TCF3 V6.C/-8KT;JERFLV3F;A
MA.O5*#S/2X2WS6?GSK=)F>I[&-Q6YR=WKKR,8,K$HP,]<ID\H3)KMSJU::@[
M):B(7/8:'B, VD,]NC.07MFK51*^95+OVAH8YX2A:72';>4A9]Z+>+>(.DD@
M6*Z,* 7M.>?:="R^>WE&CRU8F,9TZ(MDL"M*L>EGNM0KDI66<I;\W:YM39F?
M6G(]-=DE%13A4Q@$$RJ6.(;62U6-]$O&$56"U*A6RS(:_..[)#4^0@,0=Q$8
MY::O-U>T6!FRF&\0=P>,.MYB_8B114CX\1+7B[+-<3S'D$QC\[RK2K[+6;,]
MCMKRCYW(TR(JM6E)*WR\Y96"B"D=').'T>4 4>)MTQ XJVFIK;!:8N&A3V30
MDX3"=6<2N/UX+S;\[0E]>A5ZNWEJ"@]LE FA12>(@Z/&QB\CY01Y0<C]WA4#
MF;@FIM?&H%2N3%*FJF7D9E9SH%[A #++%+VIE#XF4$ #XC_J()%"E.0P=#$.
M4#%,'[@E, @(?V/SU!8&H(H\//;U39^4H<SHZ1K_ ,Y55C.B=3))E!P<P$_>
MF$ $>@AT'QBC$.5@TGACR]KJN/3$R2CYR]L' _:)^RU2MTWD=/3+K-K&M9<@
MG2JN&+.-LJZ,:6P'<&6=BV3*BCS/A'<],6E>.X2\CHYS9;":+4G9]1OA=S05
MF)@T+%PT,:2D3%%5;TK-LV\PP^6BF3H0"\>ZO8&-36TSB*SQN,L\]7U)YI7F
M5QR%"E&F7M9CI*J&DU8V/D3*@T3<L2'5(!.Y,O4 )8HVX9%"Y4^U[AUK-CR%
MID%A4C9=UQ:S?1:#-Q)9573^Q(-*6TA5ZFX5:+#$?+6Z9R2 G55\8D]+K67-
M P7>[YM65W"EX]8Z1K&60^D\G+[R$T3(*3=VFJR)9;+-5K-U3I%DA9]K*13J
M-8$DDFB;XQ2I!L.)\BZ[DW(>9Q;2LJO-D:Y1*SV36>UW"T5MQ4MX+EQ-,@)=
MCK] SN)<UM-]]H%"234[$SLJB<8U;^.-$''Z_F$9=.+>?["AGKZ&QNPL\S2V
MF[59;.<RTQYGDKK5AL,G&9?G=CL+=RQ?65W(V"2ESO5I% _>4V-9I>.3^%67
M-Z+.W^T:1%1_&&_0]@TRYZ:_D@M>H&G7O*2<;--55C;-/OFTC*,YN.:VJ>5E
MTX\/0QC1I37CO98"6M\#N7$.]SDNE07[&)E\PX;YHTS&D4QC"C;W)HRY7%D@
MO(2<R*ZK1NZ>F208&203[M6VICKN>4?8].N5EEG*54SN[*Y:G'7;"-"X[W&V
M2M0L>K3;]_J\U3+I&O%'[1Y'1QUJG%M%&AT?/6/COXJ=JA(V*XEV6Z6GBE#6
MZA2-@"-=ZS=H>WZI'[7*-;C&O;ZR?M&KV-B5(P(5Q'IO"N%#KJ($(9C(Y=J4
M*A]F."M*XFTY>?IC^1?M+_1+'=[=&Z_,J?:OT[^)E+!=E5G4 0B9B@B $?=I
MNTMA><=MDI\51=7SW!ZUKT)?\T?6>?:7[#L_C\O4U3-)2,ND%%LGVDTV*:A+
M14RSDFR4PW"235.*SIHO]W@1.5,P&W#C,F *E2,4#J<C\J33.7S0$H*D4, D
M$/K@8 $O0W3_ %;]PUWY90 O%7V[&?G><<3CTLW-EQY?D"02%(7S>O>!PZB(
M@)?AW#LL%K.-4S1(7D(QH<9L\5;V;B<C] C<O=*/L]CYIH^=*H%95%^LHX9)
M(%1(DX4.J =YS&'F!2ZA%H0U6IG![D'6JS"HG77:Q,# 8/;HV'BD#/%7"YVC
M"/:IHD!0YQ\L@ (CX842=O/NCS$G6<]XX6*)5K_N=\L(J$L;/0\5W?6;.^8D
M>; W2K37/J%Q8M"I&(B=%^[*R9MRI>>)DM:I"^A^YWET]EO9(H-Y#W2.9\TQ
MM]8<:?L&/*S\"\=WRFR3Q!O<\/E2*JM6SV-307:%];ZT7C)G<,8T[1/<MJN?
MU'78G$/QXLO=?Y<S<6C>+3QCE>5D:M9:0?1XB9@:P?+ZS(I.'R*TD9I)MR%%
M$&ROK"X[I>(*>YG?J%K.=[A=_*L?O"<I:!9:?)<=)V0C-AI<_&%O-H7+/U]B
MR:NVY@>%2?%<]A!+V]RE:O,XT]T6 H"^026_W>8:^[AS#7GJCEK"T9!5)><8
MT_0YZ@R]LDXM/9(QX+-%1L1\V9O?EBK]3T!7[K#ZCJ?N;7Y%GNU6X\6_4I7W
M6.3N>YW2MLM-#K^DM,XE)R0N%B0C5YJHV"/;1#N1!FPEK$LYAD7:3Y "GPZU
MUV%]W>1/R0LTO6LA@5/=0Y9L'4K'057+*+7NP$?1R3ZH421?6.K(HV%ZD6N&
M7M4>L9\FT*[.C<\JI<W[K>GR-#U[C'@LO(1WNY;G64'6T\H:_'6^'HJ#:6FW
M9WGV"KTZPD)MXU45;-(5P+PQ@!%4@(W30;C[K>>9;'<IJ[Q/G;U_I5^33])M
M;)'67N5V*]LXYX\CT+GFM1D8N1<.IFOO7[%1&.% IRO%445>,.TQ>K^[U#Q/
M+?D^\X]XG6'ON7<A&]YEJ<SE-%4<;?=(*0NK,:S%-*5E4U85X9 7;]O%I-P4
M$%U5"(7JHP'(?W9*!,4&L-K68)GW)^23_P"T%?<[IR&PE.4.V);FDE .SVCC
MS*&]'(M6+XB"I"JMTU$U.O\ GE>Z+_6+\FOY:>/\\KW1?ZQ?DU_+3P41YC>Z
M";H !T-[B_)WH;H?NZF[;N7XB'U?]C^W\? ?^,GW11Z?N^XOR:^/^STN@?3X
M 0YC^Z$3H'3H3W%^3G01[C#W#W78WQZ#T^'0.@!X_P \KW1?ZQ?DU_+3Q_GE
M>Z+_ %B_)K^6GC_/*]T7^L7Y-?RT\1VF0O(_G-I#^.C)>+)5-TYB[9LF<NTY
MEL#55W(42\623KSV28E+WM'!TA5:J?63$!$?V\"02I& FV\:G'18ZI"AZ;D5
MEK@#%%(0,*I#)@) 'ZAC@ &^J(_<K#DFO[[#4O1*I\L^T%:=U+1))>.^<Q+*
M<C>][!T^4BUO514BBL'E+G[04Z&Z& 0#_.FKW^0FM?R \?YTU>_R$UK^0'CR
M?RHX7N[4S=P9WL0H]%%!3 /4!G8M^\HAU.7N[B%Z&, %$!\>7^4ZU[A05<?S
M3;MV=B7?W%%3\5_E@N;RQ[$NOFGZAVE'N+U;G-R=;B#DI3)@3(]Y5,4#_ /4
M$3RXYVA@^^"H$$OW^G@Q0Y/->I%C(")LEW<A1.0BAQ,0QLO JB/1(>BA1%,1
M$H 81,4!*\_*>:BD8X$["Y+NYG8"/40$S N7B^(3X?OA3 O]OP=3\IUOVIB8
M# &1[R)Q[ $1[$PR[S% 'I\!* @;[W7P CR;#ZP=0Z8SR"'X=1#X@&4")1ZA
M] ]!Z?'Q_G-__D8Y"?T3^/\ .;__ ",<A/Z)_'^<W_\ D8Y"?T3^"H->2:SE
M<_7L1;XER'75-T^(]J:62F.;H'T] \%56Y(N4DC"<I55<1Y$)IF,F5,ZA2J'
MR4"&,F14HF !Z@!@$?I#PHFRY#R3Q1'KYR;3">1SDZ702@/FD0R(YD^@G /C
MT^D/'\^]@_-]Y+?T.^/Y][!^;[R6_H=\?S[V#\WWDM_0[X_GWL'YOO);^AWQ
M_/O8/S?>2W]#OC^?>P?F^\EOZ'? C^/>P_ !'X<?.2XC\/W #'1$1_M!\?")
MPW2S@"Q>XH'XZ\GDCD#L[^BZ:F,D.U/T^':H!#=WU>G7X>%',KOUHBV:)T4U
M7\EQKY4L(Y-5THB@T24D'6(I,B+/7;A-N@05.Y9RH1$@&5,4@B0^UZ!W%^ ]
MO%3EZ< 'IUZ=Q,&,7J'7X_'X#\/!EOQVWWM*H5(2CQ7Y= J)C%,<!*@.$ N=
M, )\3@42%$0 1 1 !_GKT'\U'E__ $"^/YZ]!_-1Y?\ ] OC^>O0?S4>7_\
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M>6$R8" >4Y9=#" _$ [1= OPX]K?H<O]Y"7D#M2?IS"8H=77]Z.!>  "(]"
MA\ ^GK\!;>OX5>V0Z*02^L]'R3U]B+@ ;-2&]**\#(>D[G9%U [P6Z)J$)\3
M)F45,:0X3>V6Z;BLX,1)GR8UU@L5N9%N5JD9PO7)$AUD7!53*'!,I52'(4")
MB03J. )P:]MLIS%'TIC\JM4.5$WE  "X*%&3%R4%^INA12^I]7KU^MX8Q/,S
MB]PYRG$3U^=7D+?BN\WC0+PC94$4!KS%M7)ZJ1#!2-?+BH5PH*W<D4 $.H_
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M=0UW#<^VGE9SQVIM-TDF/SE@XOTS?>+F.8C4'EUAK$[L,8TLFLZ;1)JV3#&
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MYDIR**Y>D8)+$,L*93 D4P";H AX_P 6]X_/5YL?I#>/\6]X_/5YL?I#>/\
M%O>/SU>;'Z0WA]#MXW:%Y>,;LG4E%H\X>9ZDE'M9(7(1SE\R)R*,Z:(/Q9+
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M?CZ39'T]7"1BEAA&?*CDJZEX$DT@LYASS,:AMQWL626;-U%&PKD3!<A#&)W
M41#^:V^?G*\H_P"F?P/3++W\2F+\>2G*$WP, @/3NV8>AN@_ 0^(#\0^/B=J
M$75IF2MM7;QCNS5=ARQY(/+%76LT196&<SL(WW%22B&\LDW4,V.X23*N5,PD
M$P%'HQJZU(L:%EDF#V;C:\MRFY*$G9")B%V;22E6,4IMH2#N,C7,HW3<+)IF
M124<)%.(&.0!G&D10)R4=PKX\)86K3DGR(DW$%*N&+*8^6R*!=C<*0LM\LE6
MSE-,X)+D;.$E"="'((RR4!29B<>5Z64C)YHRY.<B)LT+,HD!16)F6)=G>$CW
MJ:9P,9JN0A@ 0$2?1X,0<DL  8>HB3;]^3.'Q >A%$]2*HF'P^@H@'T_NCXL
M"CBGF12JAVZ=I._Y(;BH2M*.6;59J2>.]U]0L*=RS,DJ0''E"H"GF!U%03&>
MSM@SAS!0L:@+B1EYG>=PC(E@V*8 %P]?/M409-4@,8 $ZABA\0#KX<0M+B86
MWRC5DI(.HZM<G=?L4JVC_/3:G?K(QNQ/7R#0CE<B?FB $*<Q2@("(!XB8%]G
M:K.<GB2"D%#.]ZVUO+32<2BDXE5(F.6U4CR2)&(+D.X%$AP1(<HGZ (#X_FB
MF_\ MIWG^D[Q_-%-_P#;3O/])WB*">SX\(,[+LZ]"!+[WMD:,Q/R!5CL(.*!
MYJJ(R$N^(W4%%LCWK*@F82E'M'HM5"9\<UH;Q#>P+ULN][8:?0@7;QS'-9M:
M'#51D4XAS(,UD$W)DP1.LD<@&$Q3 !DEL>EUDC_5.FIL^[J)GZ& >ABFTX2F
MZ&+]_P"^'AT0,8E (^.HH]+^./=>UVHLF5%4[D/QF]%CJ)$ IA-U$2@ #\/"
M9YC)6\&QE95E#(GD]MV>-:R,W9WS6(C8E([O4$4G4I8)-PBU0;E$RKI=0B1"
MF,8I1GVM*H=4O9J?,K5JTMZKR"U6S&JUA1024<0%@2B-8>C"3*+8Y#':N027
M*02B)>@AXM4O(TFN?9>ARDJUNTH\Y"ZP$%3)F,;)N9MM:GRNL@PKLG'M)$BC
MHCLZ*J*:Y3'  . C%RU>RI>0A9*/;R,-)PVW[<[BY"*DT47K1]&/66HJ-';"
M0;G35352,9-4@E,41 0'P9,<",)#" F)^-?;NTPE.<Y1$/QD]!$#J&$/[9A_
M=\1YIO%XJ&++2K&"BS2NS;%'EDIN34%*-AX\7>GH@\E9!4HE0;I]RRQ@Z$*(
M^.GY/X=>G7I^-;;>O3]WI^,GZ/%9J4]EU=AIVX.I!"G5J7W76XZ7M+V,9F?R
MB-:B'FJ(O9QS'L.JS@K5-4R*/4YP OQ\35X2KN9%J52DR1=CMY.2NAA7*U,E
M7113CIN?#7_ED/)@Z63("+A5-7S#E#IU$/#ZP4K-ZQH$>UE7D%(S55WO6+2R
M:SD2"2,A#/9"'U9\W0E8T#D*LW.<%D>I0,4.H>"J!@)N\HE,4_XU]N[@$G3L
M$!_&3U 2]H=/W.G@3&X_B)C")C".K;<(B81ZB(C^,GXB(CX\G\0)O*\SS?+_
M !K[=V>;V=GF=OXR>G?V?#K]/3P!R8 )3%^@Q=7VX!#J @/00TGJ'P'P"'X@
MC>250RQ4OQK[=Y8*G(1,R@%_&3T YB)E 1^D0 /W/"C4N#K%;*]/,0#6MO!)
M3H5,H=Z?XRNTW0J) ^/_ ,B'[@>/R=>,GMJUOD).?B1B-JO,];^=>P8+'Q$=
M8+_9*;6X1NT<L=)5LKEU)U!XZ65[VQ6Q2$Z%.8P"% XP<E?;(J_'"0T[(-AU
M_/[=G?N!;-NC-XCC=BR6M6N%EX=M!YBO".78[$P4;N"N'!5")*E$@?3XE&*>
M5#-.8!\E%S3-+<-KD'$+)F:1L\A'2B!-155C7QF#YF\*BJ!%!1615 .TY##_
M #13?_;3O/\ 2=X,4,@G/+.=50Z0;9OGD',L4P+"= -1\DY51.)C )1 3CWB
M'=\?#BE,L[%"R-(M&R.ZJQW[;F\\UA922=MT)]Q"M=73DD(N2E63A(CHR8)+
M+)JD PF X>)J#C*"]D9:LN&#2QQD=R'W=S+0#I\P3DHYM-MVNMG?Q3A_&.DW
M"1' )F70.10 ,7M-X,8<FLP"<AR"!-VY#$(4#J J8R:9-6*FDH!B] .4 ,4O
M4H"!1$/%HN+G(;BZ1K5>EK X:(\@^1J7J4(&+7?G;HICK0MDCN$VG:(]G0QA
M[C=1$>N;[70_98*I2=CSRHZ/3AFO>.UV)EUJ?>JY%6BM.G\6:$<!#2;J'F$C
M*)E.*R"A3E,;J!1-G?*:S838\78VZ LCZU5JT\O.0EFBL_?5FUSE.LC%]=G^
MHP<-(-XV7K:P$D ;-DQ*/<3H ]1*?\5=V$2'14 #<C>31RB9#KV 8AMB$AR#
MU^N4P"53_; /@%3Y9=@-WF, $Y'<FTDNXYS*" (I[&1'M[CCT+V]"AT
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MA<K.-6?YM-6?;+-=8M*U3V;J7I/S8ZNR*?K4(\[]!_U.V.;RECF+>\NE^0)
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MS*_T6K730J]1H&S5/16\*PE<QHG&RV6-\GD<CQ0E9S.DI1#E:C'M))Y'-8M
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MQ6):<L;>:TF,;1$%/N7EFL+V3?SZS*+BF#-NN1RNS(Q;()-3>G33*'[:D_\
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MX+A)S<5$HJ"  H<"<=S"1 G7ZR@_4+]\0\";[2;T/3[Q>%'-HYAZB ? I>/
MF'Z?O>"A]I-Z'N$0ZAPHYLB4O0.OUS!QX[2 /WNH_$?@'@?^<>]_ H&_S)^;
M74>O7ZH?^'CXG#I\2_2'4/W?!C_/^00@5 '':7@_S@,<0$3!Y)4R\=1.9T';
M\4@#S/H^'Q#P _:+? Z]?@;A-S;*/P !^(#QX 0Z]>G^S\/! ">Y")^810X"
MXX/<X6X%!-7RA*H9;CH0$U#B'<0INACD^L "7X^#$">Y")=I"'[G'![G"W((
M'*4P%*=;CH0ACE WUB@/<40$!#X#X OVCWKXE,;N_(GYM=@=HE#M$_Y/':!Q
M[^H%Z]1 !$/H'H</M'O9?+/V")^$W-L@'^J4_<F8W'@ 53Z&Z=Q>H=P"'T@/
M@3_:+?5.G4>U'A+S<64'H43?!-/CN8X_1T^ ?$>@?2/@#?:/?"=?]JKPFYMI
M'#_9(?CP4P?^KQ_C+O'YE7-C]'GPF'VBWTWF'[ %/A+S<4*0>TQ^Y8Q..X@B
MG]7IW&Z%[A .O40\'4&Q[X<$R&.)$N$W-M54P$*)A*FDGQW,HH<0#X%* B(_
M /!3?:3>B]Q2F I^%'-HAR@8H& #D-QX Q#AU^)1 ! ?@/Q\?XR[Q^95S8_1
MY\?XR[Q^95S8_1Y\?XR[Q^95S8_1Y\&5"U;H*9!4 Z@<+>:PD(*)C%5 YOR>
MNTHIF((&Z_0(?'PJ@I=]I(L@IY*R)^&O-$JJ2OED6\M0@\? ,0_E*%-T$.O:
M(#]_PLU5O.T).6X]KANIPUYHD61,"0KB55(W'T#D'R"B?H(?O0Z_1X I=(UT
MPC\  .'W,P1'_8_\/_Q\!UTC70ZE P=>'W,SXE'Z!#_P_P#T#T\?SDZY^9]S
M,_1_\?SDZY^9]S,_1_\ '\Y.N?F?<S/T?_'\Y.N?F?<S/T?_ !_.3KGYGW,S
M]'_Q_.3KGYGW,S]'_P ?SDZY^9]S,_1_\?SDZY^9]S,_1_\ '\Y.N?F?<S/T
M?_'\Y.N?F?<S/T?_  VR_([EH$W='D3*S;=A8N//(W.(PT;"D1/(JGM&EY-4
M*JBND5P3L0.]*NMU$$B'$!Z?MJ3_ -=>'_\ >E5ON6$K4!?0$8IUIEI9Z8-#
MJ;.W'2HQL'V)S&OI9D[A)<R)6&G-JX=EY8H^>_%)!7S&ZBR9H0NT1FZM-!B7
M=D=/G>_9_#TS1'E9EKC:G5'8SX4R"KU+G[57ZB@T82BT5'LB*N4 7!N";E!9
M=Y#:M1^0.8X7;]KD]0;7/'Z5&SNL4/!=!QRR1V+XTK$MJ3,O$K70=EIQ'EV\
MIC).&8ST:15V:*&0.C"/KA9>83>69<DKA4N3T74,RH2\5$\7TK!:SXYH'',8
M"FRSRR6B5@XVI%L)*VI.2J"$S/\ JF[=VS9@AID-HDAR J6]R<3EV@4B;HE#
MHUJAZS7D>)\['VJ/:%BJE*426NRG)\&+J9J2ZYG9UU1!AVP9#*%A7.EVGD+3
MEY&T<D(FVQ^*1>>6C'U(K)L-J<OCE\H)I&ES]RJ%=W[3W$@NWA)MQ(2C,Y_E
M F1.U%TO7'U,)K=WFWM!S^7M!;A5\]HNGYOK$7QEHRNW5UK%6J!AZAK-3NFA
MV"=D*>HCY3:%N]=+&NCN(21;E1UZGX!!:ZWUV[[/8Z+QIT[<45OGE8SF,HT5
M;%=6TMC8L?K\C3H9Y,0LK!QD=,PS]XM+O&_:X49*HJ)6Z^T*K\BZ16[TC7+O
M6J?&4BL-]FX\7XM(QU'0<:>UV>KKY'8LJG)NRV![ 3#4AW41)0+]JNNNU=1G
MDWV-H=;N$MO,WR%U(G'FS:'"56-N"'&B@OY'1Z4[VMC 0+BMPELTJ#J2].C$
MEV#.25).1JS\K62]8HE(VS-=%VW%Z#H?)_1Z'3*)I^;5\)',,\ELIMMJSS6K
MFJWR>558YG0;\\B8@8@',JI8G*().I)BW*X<FFJ]OGY3I\G=[-=EG-XSG/<_
M5U53(*S'<EHFB3=28$@#/:O,7?14,]]=7%V$J5M7R-'Q)%1%[8B1[ZWM;9HS
M/226JI4I?)&U<H[%G)V:<X]4*P35YC;:7-Y6LUC+Z/LB%BCS'2=2K29DWJ**
MBC"):(NUK=*TRF;5:9V#Y'TC5W378\]K-*E[1Q;H&0<?'6H8S0J_ 1LU",]*
MU[7)ZZI1;8S\Z;$(Y8B$EZ$D>NK;WV(7'E1:IEAMW(2E4J(OE=RI*JS&71?%
M28L&+7]=20HU=$B\EO[YNR;JOG+9JO(-R(/6B<<"BA[VMETGR!F\%1=RD-0Z
MYJD)3JAKMJS&;:<?(A]=T+@Y@HD]-UK)M1?WF8B6$PW*-LI;1PQ40*L:$=!K
M5CS:L[WH68U?9H5]!4"9B:8GBEKXZ)\26KVXQ]6F7$2G>3:,;E3Y2$,9HY6<
M]5%P72/#E$Z?&-AO=GY"M9RA7;D#3>34MD,=2CY3ID!ES"<TG#=#IY7M#92A
MXW6"SL;6W8&09*O'4:NU!LT*'JE=D8[;1)"MZO-\DLIB\SNM<@2S,;6>/W*&
MW4%WZ6"CC1K(TYJ/&>)MTU656KIHJW5F8F/6<+/4'"RJEFTV L\SJ=LBW6(X
MUE-;UN,?)46+M^CWJ*N/)_0=4=U6RUIWIT%QQI5Q;TUB]8>F-\YH\BFCZER]
M=KK9CGD]P_HL/KVEU'0[W$5@T2]DXUW&TADY9S=7369[0DY:SU.GSPJJSM0P
MLYEC92>D*F,<95]+6V/XH4NKMW!(-S(4.]Q;N8D81K/+Y1!1+:ENJCJI4Y:1
MJ:EPL\K:C.#. <H58B4<DGZXBA(V,V?+K?DU&BJ:U:R-'8J0?XOPK4<TW-O/
M:1-.FM\N9Y&:M%[^Q#*O]A(URJW2ERD0<MHY5\K_ &(LH9PJHFJ"0)MS%0!)
MN*8& XI&(B1<PK"(";S#G !#ZO0.H?<C")NH#T[2] #MZ!\?C](]1_LFC]A2
MFZ[=AH&[CB3H0=3JW<8.A#]QBA] ?#K^Z']D+)^6J7RC$+WG)VIJ=Y"GZHFZ
M_7*7NZ"/WC (?ZP*+U W0=PPTO4IRDZ==1K  )@,8H'*)N@= ZC\>H!\/VH$
M*)A .O03G,H;XB(_$YQ,8?B/WQ_97:'6<H$<)&2,LS<*-7293AT$R#E$2K(*
M=/H,40,7Z0$!\  ?0 = ZB(_1_;'XC_8*X.P;"!5A!LHW%4!4;BFF8#+I*%Z
M(K%5$Q>A3J%,4H&Z@)A*7_5VD$4#KV;1BRQ ["*"*B&E5Q8@@4Y3=.P2=PF#
MH)0#KU^'W*^916O:>]P[?8*FR3%C&;!CE)SF6S6\(/(6,EC2-6D)J_PLFNV9
MKR!V:WFMDQ*Y;* '4  1_4?>ZW_V<9)_2IX_4?>ZW_V<9)_2IX.*/L=^ZNHJ
M ?4(KGF3(IF'J'P.J33US$#I]\"&_P!CP(']CKW52E\P0 2Y]DYS>5Y0"!Q*
M.F$ %!6ZE[>O0"AW=W4>T#=WL>^ZT =?J],YR4>I>@?$P#J1>T>O7X?'X??^
M\'ZC[W6_^SC)/Z5/ ]OL>^ZT(]!Z .<Y( "/W@$0U,P@ C]_H/@ 4]CGW52D
MZ?$Q,_R<Y@'I] %-IB8"'=\.O7Z/C_:\'%+V//=8.J!#"F13.\E33.H #V%.
MH74%3)D,;X"8"F$ ^/0?H\ (>QA[I/F^E3.)!IN7 F#T3F!5N"OV[$PM2)@
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MN7$1:,ZW+2L8LVU2$.\D*_*6&!O% ;P%=1<0=@CU'",]$3+%Z@@0!5;IZ%D
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M,"B8 5T*#3%00,8H>6D!^XX]>H% >@"/P%0.PY>PX% QNWM4 2$/WI]#"(D
M3]OQ ![BC][H(_<+;5<P]L:Z;5085^@VK.J1O*_C-1&-S9*1S)TM(MJA=+,R
MM,$1N^75:BD\2(H8R J% 2'*(_J=="_/<X??RP\<+:MM7MX7#C;1'GN6^W^N
M[U&6Y+<=M28Q\@QY(4Q[%Q1ZIG=BDK4JI-/4"-R+H)"1 QNY403 P^(&R0^7
M9W%6*K,Y>/K$]&TFM,9FN1]@D'TM/,8&4:QB3Z'9S<K)N7+Q)N=,CEPX544
MQU#B/AZI(8GD;X\E+6B>D3O,WISH[^<O$<6'NLT],O#',ZEKA$D*UE7*G<M(
M-@!)P90@=OB&F:EBN2U>8KAGIZ]*UW.*="24">11]/('AGT9#-7,89\@'8L*
M!B"J3X&ZAX>620QC)WUBD;"UMTA//,ZJ#J:?6MBDHW96=W*+PYWSFPLT%3D2
M>G4%RF0P@4X (^$*JE@>+)U=K-DLK6MIY91B0+:QIQY(E.?0ARP01Z,VG%)E
M:E=E3!<&Y03 W8 !X:2%XQS/9M[%SLS+Q)K;2JA87K*3?K(-GMB9+.V$AZ"1
MGV\8V455(<KE1--(%A Q *68H<)D&70U&L*J"\_3(J@5./JDXLU*U*V6F*ZT
MB48B35;E8( F99$XD!$G3IV%Z"Q?X;CSUD*D*J+-WF=*<M14KD4M UU06ZT(
M=(3P,&X49,AZ=6K0YD4NU,PE&-!]AF.O AV2\9$ ZS*E. BHYT[>2#F/C06A
M#^A9.'\@X7422[4SK+J'$!,<PB:*5R7,U8LS^(E#1JE#JQV!I.OPR=<@)$S,
MT4+<7\'7D2,&:W;YC9D4$$Q*D %\1%05Q[+5*G7W+]Y UA3/JD>NPCN5;N6D
MHZB(4T0,;&N9)H\62<'12(99-4Y3B(&, E6C,=RN.6)6WM-*JPSVI,U2T^2]
M9\QJA5&\0F<M;?\ S%QY[$!]*KYZG<0>\W6.(;#,=,2'BE(&)*;,J4)8N#6.
M_55AHXHPG1E%*J2KHQFZ7:B8SE41+U4/UCJ8WS+/4*?#R[6P1-41IE<2K47/
M,70/F4W'01(TL6REV;T/.2<I)%635^N4P&^/B>FYG*LVEIFTGB5+/+R=&K#^
M3L:D NT=02D\_=1:KJ7/"N8]!1H+@Z@ME$$S)]HD*(6%^QQS*V;ZVLY>.M;Q
MIGM1;N[-'SZWJ)UC87",01::9S;CZ[M)R*A')_K* 8?CX5KJV19@K7EVT&S7
M@5:#55(99I6!?#6FJL6>)%BHVKPR;D6)!3$K07"OE 3S#]:^"]"I:P5-[$25
M6!6K0:@5J1@(\8F"?U_O8C\F>PD686S15MY9VS<?+3$I/AXG926HU/E).T0B
M5:LLC(UF%>O[%7$#F40K\Z\<LE7$O"(J',8C1P91 IA$0+U'PYB(.J5R#BWD
M6TA',?"PL=$M%H=@T58,(LZ$>V;IC'L&*QT4$>G8BF82D H"(>,SMQ<SKY9_
M( 7-0WI2NP+'/58!K5T)J5;>I]+:K%%P+0&["2E2/7\>558S95(ZZQE'U/G,
MQJ)8"28)Q3IM!Q2-5>#%)S(V \4WEZO\GF&4:ZESJ+.$$'":3D5EBJE.594I
MYFI0]'A%*[8IU2RST9.)K6E*8F149F:NI%6SKS#EVG#H1K5M&H'.+>+8LVS5
MF1!LV023\YIFM :K"\:R JMJ=74%!?L>_P!$^[THXIO6-/,-Y2O7O3[A[1#K
MX$D;1*;'D$B*8E8U>$:%%-M"N:VW3$J#%,.Q"NO%F! ^@K)4Z =$C&*(7HV<
M0HV0DM7IQ!<%9,L:SE*JZ7DH1S'UXK\*[&E;SBI)-5)NU22=S#5I(."JO631
M=!Q"6:$B+%"NQ1,[B)V-9R\6Z,W63<MQ<1\@BX:+B@X2*H3N(/:<H&#H( /A
MTZE,GS22<O7SF3>N)"B59XN\DGI6Y'DBZ6<Q2BCA\[(T2!58XBHH"9 ,(]H=
M*[#26>T>0B*@X([J<4^J<"[C:N[23.DFZKK%>/4:PCA-)0Q2G;%2,!3" #T$
M?#:2B<QSR+D6;16/9R$=2ZVR>M6#ALZ9KLFSIM&I+H,UVCU9(Z13 0R2QRB
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M=LYD%H.*-!0BSU=%F15TK#PAA9M3*"86[0113[4Q[?#RML,KSAE79&*?P,A
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M);- NT@E*6BQN;?I#!>6?HL6D:FX59P]RCHQN8K%BDGT103+T)UZ=1$1,?\
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MB)D#"F/4@B'AL@SR[.FB+-!PU:(M:36FZ35J[3<).FS9-*,(1!NY2=JE4(4
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M<<_UHU\/ #V^&$5-R$TJW>H>X\S;!+3<@",=/J1BP\*DFLD_?.U ;O3 <5E
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M?)Q1W4<U;-G2,:QTN/;ZYEF;RFBX!8./UO+7G5ZLYM=H<_,:+=$JIJUHDH&
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M;_?OC_'>H?Y2PW^_?")%;[2TSN%/);D4M,&0RZO:8_E(E,^ 55.PHCVEZCT
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MB7\"FEY!2]"UP Z@G\.[]\(_$1Z_'PJ!O;MX;""P(@I_X>LR#J#< !( $*Z
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MDXOS)5E+@](+%9%[ZE"R*.+/ZF-#6+%*7.:K&_7O/6/(G,+#S;PW<\LB"P4
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M\0N)](IMKPC ['K< :VYEIO*B:ND++RU6;F6AY&-C=)B52I.S=%B.1%,?J&
M.-.HU_CERDS+/,@XJ\OZE<;AN^'VC)H,MGU2_<4']+@HAW8NT)>2DF.;RZQB
M) /E)MNIA^L'B3O=:F8MO4T>=Q]^J3"RZ[,6"E!D#V(XE0T_ VJA.H L_ 3H
M.\?MDW7'%6FV"T+)/TVC@CN+FIEJG>=UPJX-\T^=/,*BJ%I!MAN*;O/8BNXO
MR>SW6YUKDR;5Q472LO8];J#PC$!*$O\ 9<RSA1!9)KYF*\D5:%F]X=X#<8.^
M-N-SW9+G*1+:U0'"+1,-TC3Z/=B9E=)D9O8]<DH.7<1B,*J]<%B2R:P*2[UR
M@%-L5LJRU&M,]5*[-66E.)%O,.*?/RD0S?3-67EVB2#646K\BNHT,Y2(1-<R
M(G*4 , ?L:'E6_\ &;EWFL)Q]Y7<V]#X_P!CSGAE,;_%[W8=YY8WK98J<V=?
MRDH&V<,5(%6'1D<U2<IFO#U,)*05;#&0X#S3T+?,"N>!Z%R!Y>[#HC+,+LWF
M:R\=14MC&+TEM,PB\RRC)]I4[--U)X>.7=-F[U!N(%73(NF</&"WK7YZORT'
M0^(%*Q34?F.C/M(=2VD5/,\CJ(67+YA>JU2WQ;2PV&GR[F?86)U,1+HYVTK'
MIL)1]+%4RFVQR48HWEM&V^P[+%FY=[? R%/LDIR?9ZOQYW*H2K>K6E2X.\^Q
M1D-/?55HI4>J)Q:(R9X]T^\U]G\Y7J;*['C6?\:[[H4TGK>QIYMRL*6R\Z<U
MTG09J]RV3MZY4-7NE8V2K3<[6DR6 4HV/9LE7 ))QX)\?JWNXUV=S^JRO#MU
MKRE?Y/:T=:40P[@WI_';2UHQ!I7JE*SQK#MUDK=N3:N'#1M)DAE3N^UP)0<2
M.?V%KEM\F[-7],S_ &:JVWE/K5EIN[72Q<>[QCU)Y>$3F,F;16;V>%LTXWFG
MM3^7S#E\Y=*OUYI:1BHH1XU360.,NK^LYIP7USC#8KQ)7>R0#RG7"YN>-5@;
M/:A/0])>STK6+2QQVRU%X[1+$R4>PM8OT2&.F=OXW/%V;MY5)O4N1;S6<SSN
MHZA%.6O'O-GMZI5K:YI5IN[9]9\]MU>B9:NR$LM4)2#/4GK>8<0'>DP!-R2
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ML1T+--:Y/RSR7A&[R =<A;)8X9_)()MEY$PPH/'IEGRQQ\6F7RR.RK M$N,
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M^DQX_6:9%_5ZU_\ 28\?K-,B_J]:_P#I,>/UFF1?U>M?_28\?K-,B_J]:_\
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M[2IN5PEIK&>0+"\\:HOCYLCU_*VDD7D.H6NYW2X,'M$3/#PLXU8NF3J'%"+
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MTT5"+G4Z[(2J0L$H]TW-Q8-E<?&/E<FA((^A(V"7O".?/[GS'VC.N..0UES
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M,UXN.6:'(U2.U59-E&QTV*OJ&29D#I"D8C-?ZZ0"'1,_Q+T'X^"&79M5C)K
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M<+19K!)MH6!K]=V[-9N:FY=X$D+2,B(R-LKEY)/W/R9V!$D2'.8S94 #JF8
MT3=*#9:1K<!GBX13]O7-3S.N1KBT'<PC="IN[S=[37J'6IQT6Q,E$4Y20:><
M5VW[.X7" *6>H9CM64:+:J2FHK<:W1M"J=LG*JFC+2,"L>Q1<%+/WL,5";B'
M3,_J")]CINHD;H<ABA%XW3M*J:Z5NH%?NN7: _NE+C:MK\G,Z;J&4OJ#FS)W
M/I6BQ7.NV/*7RCIL5B0%6CEJLV%=-7N"WVZNZSG,Y5L_5<(WFQ15RK[Z%J"C
M5@E*K?:23;OU&D,3Y4X3=%,N<A5&RA%2B9,Q3#9JVER/R+U]/JE+NEA<*W>"
M0B&$%H,Y:*W4E!F5GA(M>0EINFR+<&::IW2:J':HF43% ;Z#/D+DY&N:76#S
MVX2SZZP4?!1]MLE0@[W"QB$X]>H14B1]5[$U<E7;JJ-^AC@)^J9P*RI$+RMX
MYS%RD;1'TF.JL5M&=2-@?W&6FI"MQE691#.Q+/W4^_L<4YCTFB9#+G?(G0 O
MFAV>)4ESY2\?*BK!S+RO2Z-FV"@P3AA-Q[)Y)/HMPWE)YJL5XT81KE90G:(E
M3;JF'X)G[=A3IFF5&;2P*RK5+7G[>99%BZ-,M:G$79XG-R:JQ&+5FRKLRDLL
MY,H#=,4UBF.!D5 +A[3*7T#R*N?(K2+)F>2T[.-'SJ/&T3M#K<O;M ;)6JUV
M.(J3&5K4/#&0(P<O$'#J6=M&0>69QYA)B--NF2A(5]U?V,\Q'0*MZR&?90T9
M/]18RC8)05F+S-V$DV7GDE *I$(N$CNP2*H01L\Y9>3N UN%I<LP@;;+6'7:
M'!QM<FI4\JE&14P]E)UHW8/Y%:!?IH)*&*=55@Y(4!.W6*1O(UB5B8&ROYW5
MV,90']OIL[;9.K95K-SR)?1H]M4IR<9OJ';)NDN',5)(+*M7#90@>9YI5$R5
M[1;/4K;;H>?U_%,<%"H!7Q=0LMNFI57(ZQ8I@+!.P9?LW&6BXLO7"T]6](DI
MW)ME  PECH.VUFU6Y5EEEUY Z6K5E8!(<OX]9O:Z'2[WK4NVGY:)7L+&NS>C
M1YCQL4#J35:(NE2)"9%--;BYALK6K3+S'*VRZ55Z5:8;[/J5.O/\RRJQZY*?
M:E1W.M9TI9BNUEPFQ,Q8O$S+AT6.B42B:AW5SFEJU F@;7D>$1D+4)FGPLBT
MM^W76*SFA/'KF[3M=ATX)6Y3S)N]6!SYC1!85P34*F8/&4ZX:VQ^7L]@LMJH
MU1JVIS59K=ED+U2=(D\ALE8BO3SDC!V@Z>BQ9HYB]B'CZ/E3N6AF:RP.V_?+
M5A+D?B2MC@S2Y9:"3TVH'EF(P$;9IB:\^/++"Z (J*I,TY7$"B":$,_.;H5F
MY%*T0EZVK#<]AV5SI-'SVT6/?<;]+K$U=\_IU^8,JQ$,[DO.QTJ5G=F1$8^0
M0;OGS==N^;)*,G;9=4TA8>6''2 9$FI:N&<S>RY]$IA.P49&S<S%=9"P-Q%Y
M%P<RS?+D#XIL7:+@W1%4AS05D9<D,.>5RS6>9I<!8&NI4MQ"2UMKL@PB9VN,
MI9&9.P5F8B5EF;9PW!3S$G#QNF8 .ND!Z@Z@.3V)W-I>-/K&.0#RAZ-5+LS4
MT&XU^9M5=A'[NLRLDWB@DJ]7WCLB[@R: HH&'N^]XG-)B->SN3H-9F4J[8+@
MQML*ZK\-8')8<[2"D9-%V=LUF7Q+#'F;M3&!=P5^V,F4P+I"?;<Z/J&>4V6Q
MQRE+-'5FT_.4V>F90IC&?;HKNU!,SLSE21R-E2=$;*.990$T&PMUS*B1,G=X
M?GKE8F=MJ[/CU=N0R%WRZV9Y)5R0A<VW?+<%T"IME'=G;O4[33I_56CM\FLD
MF0J35PW3%1ZF9N6,S?3=_P 8S[0YJ.&8AZ'<],IM;N<K$@WEG?S..J\O,M)M
MXP,V@7IRK)H&3,5HMT$?+/TK</%[]CKZ6N$,^L-7C6^C5)1].PD82S*2,E&M
M0E?.<MF*=*FC+"!?P80S\3=/1.?*Y Z/&6&#K69\>-CMN16729RXTU>BRY:C
M4*-<G=YC;5$3C^#:55S'WMNF47:Z+I%9%0BZ21P[?%4K-/VS+;/8;RTDGM.A
M(&\5V4E+*A##/!+_ "9BSD%G#]>+&JRGJ$B%%5'Y8[[RAZ9?LJW&5[6+WH>\
M7F I$K3,_J4<V9JV:6TZTVBJ9S68VQ6->)JQ)&ROJ#/"HNN]191PL4".UDCO
MV95(I?4..VG8_FGY55IX>W;:;]H."Q^9YIK%*274L!KC+(Z<L]:UHPMS@Q>I
MMU$W@I*?P?:7OJ],@-<S>;MEWJC*]4RN15TKTA,6RFR49\ZCK/6V#605<3<(
M_A>KU%PV*HFJS 5RB*0"?Q>X"<WG(8F>S!K'O=%@W^AU5O,4IK+2C.#C%[+%
MJ2@/H@CZ<D&[)+SDR][QPD@'X50A#/8N1Y18'\[84AWI*U=9ZQ1Y*RJ4-G1W
MVEJ6II78^;<S+V&5SV,<32*Z*!R+QB)G*8F2 3^(Z29\K^/[9:0I-;T,\#*:
MS1HVUQ53MK* ?P4G/55W.)ST'ZM&T1X>6Y034*H[3*( )@#Q)2-_Y'9#$!%1
MM&F7<<WO-?EISY/I4W4*]1Y=O!1+Y[+.XJQ2-_A!0<I(F1]/*-7!C @LFH:W
MJVODO@E72H#^*B[PM8M<H<(A4I&<>O(R'96!>3GFJ44YDY..<M4"+"05'+99
M(.JB2A2S>N35WJ=K$F36G8,\H]<O-';VK9Z[6JA(75%#+?GUAB8BS.;'#1QS
M1ITW/DO!$ 2.?KXS6[QO('%OE&L2+6NT@Y=4HKLL[<E4X7UU'BW#.=6;R5LA
MGMA9-';) QUV[IV@D<I3K)%,SHK#.+WGBR^/Z7K[R8O+^E%BXECE/)&_<9[;
M7)!6 LTUY4NPM.?.9 RX",<,<Y1$CA10%B)6B]U;E%Q\L]*I$C%Q%RM=;V+/
MYZO565G&:DA#1MAEHFP/&4.^E8]$Z[=)P=,ZR"9U" )"&$'@QFT9-J.B!;\W
MSZ(R6B:]F3JY/;CK=C@ZO0V<RFZM"+2G0,B_L359Q+2AF[%JS,*QCCU(4\=H
M.@;WB.1I>IC(&VPN@[?CS-S0+^\@SSK_ #:S3L3>9:GJ6^$;M7(+IL9%V@J5
MHLJ@JJB05/$)4Z9RRXUVVTV698UVN5RL[EF4].S\_*(/',;"0L5%V=T^E9:0
M;QZYT6Z!%%52HG$I1[1Z6)WMVYYQ07=7AF,_+5V7L\6%N)%24M$P;!TTJ2+A
M6Q/RNI6=9I%!%L<0%TF8>A#@;Q67DYHE.M,:]WK-L#T:5J^B9L>.PB6TYU98
M^&M^RN)>W1?V0I[*4JKMJZ6,"CA)PF<OE=J*YDJ="U^*'4J5?+MQ5I-<U3+-
M)Q>YU957EG,7J*H]FD8>+T52ZQE,CDZ8DY&44C/2RS>324BS/"-GYFD%#V35
M<PS#1IFK4ZWJYS8]BR.P/V<5I%RMU)S5-I;*'=K30;-(W^3IKDT8VB91ZNX*
M=,H%\PX$\!.T^Q0EIA!?RL6$O7Y-G,1AI*"DW<+-L"OF"R[8SR(F&"[1TF!N
M]!RBHD<"G(8H?ML;35-\3[/6Q11%,IP<+(5ZVN@*)AZ"CZ<B!EP, @(BB!?B
M!A*/W'D%QI@KA%Y^_P!VRVUY8>ZS%:=7!E6HZZ1JL',2P5EI8*LK,.VT2\6%
MND+]NGZCL$XF(!B&XEZ;@[O(,>U_BM-:1/(1L;E"C3$]%>[;F09UKB\[2JK9
MZU98Z6EEVS.4CY()=T[069 B[]:14YRYKH%@Y#0\1<\BR*U,\XN\5EBZUNI/
M*&Q<AHCE&QWV 2D[^]KBU.A=*A CS4F192"$A6'3AFXDC+>4Z3YM3W*QYC.K
MSO-.N!5)JT9SCK[.;IF]>G..-8XUZ%!4BXVN_:C8(Z*MM8JB3](B*S<S5TZ6
M35%VF"8EH%NT?D#FENT+!L(G^.^)/'F!JO<_F*AH4[DRNSV+><\EM*>H7^?U
MRB9$UK;IE&O86)C&DG(KHHJJ+H$:80RKVA8)-TS%WG+^3AL-U/";;HV'5=MR
MU>4LSC/,FJ[O:(F6H64Y/'TPI(6,]8[4\^3>F148MSH-4+2?0[K1[[(S3>@@
MVL=<S!#/+'*25<SFMUBU2][>,K)-,[.[G+9%NWD8"3=D$/#K-XW^^A;>J5S$
MC'=\]?:QC_-?E!S J\A*X]..LBL;?E=^/1"]9A><]5U%:=?MZ\RY RQ(J8:3
M;5P0[)J8Z'0[@JG!?"$M :2N;<.\<U?'GKZU4I.=T"UM=-PQSC"5IHMB7GPC
M<MGJN+]609#Z&8(BF5%HEY9$@5''&MUU*@*WO+]8J%BM%NP_!V&+M=HR&JY0
MUR*>R74&2]\OD_-FUR(KL [M+LTL,>*L"S:QD;'-$2IC:23O(N'JL;>;]RYL
MMEL>7YU9ZIH"M)Y6W[2M!F,I=!)ZM8\TM]5A)C0$E4%YNN/)&/D8SYA$KQCA
MZZ UNXVL]8QZ"T:Z:CG6GV#1Z#QQ&B9Y,R6?V7+'JH268M=8D[<E/7BN9:@T
MDIQC<F<TP>.Q<PSF+*SCT6JF<2_*6@+Q#J7B0>V:G\?9JIW]O3X_CGR9XW&B
M(B<D=QMOHY<\!R4=22;QR5XB+N(025;K)K*F#GKD6@;SEEDNW-ZG-ZBK;*AQ
MZD*'2<Z%MQ:HG%CYPEGBNQ6D]@64KU!:RP-DY.,;H/CF23 K<$R)W_U?)RB5
M=[?++L%Y-/4/!)2,FH2X:'3.+4-5G"8S&PS4?.U^JVWB?"R4E'/D5$I]E*/V
M)Q:@9-P67NURWZDR[C2[_A.X;+"5O!OL'6U]NXW7[1M(SV4QZ,A-.56SK/;9
M8;]VW.+DW%CE[$5)ZX&70>S#YP-<Q.U(4R&X[9_PZX&Y'/[A3,W@*A=-2T'B
M-N^J:HU7RU&/U:8L6(V5ZSDJ\$],NX^7&2!9V1BNW41(<O&+3[7M%)O4UQJ=
MXK7&S!_B1D([0<EX\<?]PX]9BSGXYQID@QC=:/!;Y*24O9D$56;EY&1B+:+:
MMVYR*3B-EY@0ZC.VQ&@56U+U7C^\@)Q]6]2XR67B[=GT6]D=ML,/7[>]J;Z-
MD&AFD<G78YVV<MVT,FP70:-;OQUEM8R."TR^:GF&NN]0S+C97<ES8^CY7>\D
MN%1D7^,0-\4?V)>Q.\>C$IU9Y:E9.1.Y6*W=-&R;)HTH-IE-=R"\5_->1LAM
M<*2<XIUM#4+559V3VJT2V?ZAKC?0U):]/HFX;K*NH&359H-8U-L@9Q'/WQU7
MQJKZ#DKEYUJLMCJL*Y4XV++M%39/S)V/F(R178*;D=NZ9VFQZ^X@G;?N\H[!
MB140.HJ=,-RX4%W9BBMK\R61A;&E2K1.53(*\+>@QZ%1HE3N.LV.^KU5DG1%
MEHQK(VYRG"'?^BCQ;Q3!BP1'9YK5J#9TG41RG92E;JN-R=%6>2/*'DX7DU(O
MBS;G5;< (4N8ZP[5-5HJHZ8]JAU4CE[1@4UN3]2E*W4EL,BJNT6P&586EE1\
M,Y:ZARMB(9W9VVZG05LUCEM3<PSR6:,&*1$&39RFR\T@D'8N-,EHN2:(\U#/
M:CD(W97C'4Z3'3V<YQ7E*=3FFT0%*NC"?UJZ*U=51A+39)^%,)>Q2*;0ZI#&
M44A6/,%9XVFZUBL%<B:!D<QH\C-HXKH?(JVU^%;WJ1VB(TQ*MIUGD8[ABNG4
MR\MKL89HYDIV1*YDVSW.:\IR<HEU8YXU9P)(34N*-=TFAV.J3O&7!>,^FL)N
M@VG57T*I-R<-QPKDM67A3 VKSH[]L[9S#%V+=-!9IR5H#$S6,E8IN9EQRD&2
MA$)3W#HCW"S.158[FT$)!&VPR5<\U,$Q.Q_OP>CD +XKD3$<@LN,6CDU:M52
MR/\ B36&VA2V;W[$N06(5F&UN^5G3JY-ZO=J+"<BI1T2:<BR9NUV*)BQC9PZ
MDG3OE/Q9NNYO)NE\EZC380L_3J+]B;90K! \=<MP.?L#5\^N=P96-C-FR.,E
MVT<NW03:@JX9N%7R2OF%S7D%);73WMXC.3NE<I-BC8;()B%JE_M]^XQ0G$IM
M#T2*5UJ34S&.B\TA"2#M=PI874I8CF<J&30$&P2?)%76=)K;I[L>7;4IF4 Z
M:-:,A8(.BCE>XM%&""C===ERES& K<+:A5$1]/6TSH 51T\,KFSN0WV$G0QV
MR9 UH0VO'TI-=WB.+<H9WE7$470R)Z3',;K=W5KDF<0I:O(9IHQ;5=;Y:9\_
M<N!VR[Y7RS@$X7D7L$WL>HTJ?P%Q/Q24Y.[C/:,[3SIXZV@JU#1<Y;8U:8JV
M3(YB>]LA.(,4) [XKV)R^#OD9G3B-V/!]<//RE.=7A%PI@VOTW:8>!+$-;=2
MSHIS]EHC%JZ<B[.*3!1<$T_-,FHG"U_D=;*#<,PB=-7ML7#QV1M8'56^9)!G
MLLM@3+5#7.270H=WM=(.YN;E",2=V"(61C4P8^G!XIQ'V2S[76',AQ7U[>=%
M1BVV.F9IW.L:[3KSF%:HQ':6CB-8<Y_FUV%LI*E3?&F)1DD\.V;IG4:#F&':
MKK^=V*0J^RY9K.EV&<P=:1J.JL\FT9IHD11E\V;:O&-Z_ V,\2SC)8YI-^=9
MB"YD2HK*D.CBSI#DW%7;-,7JCW$JG4-2X\TK4Y='BZSTV$U3,L^A[=9K8YC(
M;6<=DX%"*@K^G#JN%85%MZZ-=RC-O*E=U^4Y )H5?$\.X_YMQVW^4Q6BOF,Y
M6Z90>>&*6?/KQF$9L:<W8+G6LKY=-W!+8J,.QEI]L==2,.D11!>@62U;W$7*
MK4XD0VD*XVQE>M6&::QG ZM<#C+1]T2U>6^R\RO4:PC/$>-HXZC>1.=%, 1[
M1+!9J_Y/9@M*P>2[_A)K?"\0J)2[%9ZCKW&IOQF@)J\DI.EU]2Y:E1LZ$7#N
M9>J*)RJXID19QC0#H*SFUI\AJ#(RMRN]DL%TJ5JXLUB]4Q6NRK7#W4%'4>*N
MVD3X9]>*K:L.:O&UC:^>H9I)+-S,_.:Q[QIE3>$Y15\[[((7BE 5IT?CR12/
MD&/&&J\HZ*8]D@I#8I)C,+Z#6.5LUZDIA(@T?1[-4R;I(5VZMXXD.=9A+)$6
MS5JOHT*6?I>B/:-FT+55<]6CJ!F+$V\?CKHD7$O:%\Q@)"-T%"2I\D[)\C59
M,6+%@C/L&_-'UTK-N[!(C?K+Q]BK%H17\WP8@^#!'$A(N-/;UB5])58%.P&
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MQ7E9F="R&CL<^L6'5O5L2-3<G9<AH9U4=SSN(V-.,W&X3T/R)F.MFC[!$#'
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MF[<+#0-<AVL%Q[XW:_1=!D7[2AUV/>E<;/>+E0F:*JZ;-RUBO3G3<S" O%-
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M+(B4A.0/'\LIICN#Y.S1[-K]X^U4?"Z/8;.6$J]>:V<9FJ5^O0?VC)'4V/\
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M46VP%LA(^,:W7W?+OQV]/7*;'Z6UA<UT/.,:LC2>6DW32357K<:S2>-3)?\
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M2E#J8XJ&'H  '43B(C_;^/@2B4H@(=H@( ("'Q#H(#\!#H/@"@4  H
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MEB8I3B3H(@ CT\=3<_.'90_=-R,R<H?^D1M0!X'_ .F!\-.H%[Q#\I+(^H$
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M\?\ $L3_ (.9_N=/_N/[GCX0T3_@YG_N/]KQ_P 31/T=/^+F?T?N?P/T>/\
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M32<-<*QH&,52IV-Y4,XA-<O#9"6T_1*0A"-(+.["@_0DI,6<0_%!TD1V0Z
MK:0NG(#'Z9+9_"U&;T6$G-&J9'E&;W4B(0?SI5"45:'07<K>3ZA ZK<#E$1.
M!?CXNT;C^LY[J#W-IM*MWY&@VV$M@5"P+%<F)"3ZL(\>HQTKT9J]4%# H7RS
M=0#I^UN3-[5X%TTT1%1O?&R\6S50N*"T"WJRJ5D2.D))DBM:9HL# N!^K-(B
M0_4*!0DYZD42K5*7F*[3:A)O:[#,HA1W5<[8O(RAUQ0C%)%((2G1\BX1C6Q2
M@BR374*D4H'-U\26I-ZI!):-,56*HTI=R1S<+,^IL'*2DY#5=S+]GK%(*,F9
MMXZ0;";RDW#I50"@90PCX85RK0L778"+3.E'0T*Q;1L:S(JLHY6!NS:)I()B
MNY6.JH(%ZJ*',<PB8PB/W;C^/5O]38GQO+59^H64'\2VPE_O-SYJ98U9(#"H
M940/YB)#H@'54!#[KKF[XG4*C>M<P.D6;6Z=5+E".)R/L:-.B'4Q:(!@A'N&
M,RC/RM7:.BQHLG3-=:0*@@9=-%54?&,<AL^.[-1]PRZB:O5"R*2"$DA!7VM1
MMFCF<HW;.7K=M*LFTD5%RD194J:Y#E Y@#N$]ETW<,@SJN)KN6JD_>M*IE2A
M2.F9C$=MC2D_-1[$KAJ<@@H3O[B" @( /BMMLGY*8%ISFXC,%J+;/MASVY.;
M2:O"<)\M<;UVQ2*TV,(*9O6 V*KZ;M'S.WIXHJ?)^#MFHT#/W!I2-Q1YH%R@
M,7L5A]6DZ;V#1<]JLS!PVGNH_P!.F1JVL 2,<V IA3;E,JL93W=/;GXV\!\4
MIU0:;OA3FD<@-OR[,<5DO;KRV?ILB,E>\&H-4BXO8+5/:(_K3F3H 0CAE#+D
M(A(2SE(KI9%6LU9:=EK,YK=>A8)>PV!T5Y8)Y6(C6T>I-SKHI2 YEY4[<5W*
MG:4#K*&-T#K^Q :_E.G3?%[F3G%=>53&^6='KD-;[52*O+SD;.V.CV.B6E7[
M%Z9G-I<1P%>P\ND<A1.95LJW7ZJ"5IR>X97CF?Q\@(,JDKRVX7-:P_U5LLP(
MW(]E=!X>O)UM.BS5!8SE=]6))PBW105-\O( % W,&-Q[F=A=<N2&?K6W/*O=
M;?'XWLD#N^63</K]$KS#-=%-3](A-!D;C54&K-5NP\X7:PG0.IT$PY!;ZG$;
ME9_*PEK=>0VMM,+TMEAN,W6FY?'V_2:Q:]4L,##0=AFVTLB^9-B5SYZ#AXV.
MD)B&#PXU&M^X+Q=8U%HX>-'(WG4(++[0DY8I)+K(C0=+5J5\,<Z2Q11[8T?4
M"/1+O'X>$Y_ -PRO8XP\% V94^=7FNVIW'P-I2=+5R3F(R)?N9.$;39&*_IO
M6(H"J*"@% 13. 62%S?5<WT&9ISPT?;XFD7FL6R3JL@595N9C9&$#*/W4&\*
MN@<@I.B)' Y#!TZ@(>/>EP6Q6)I7,9M+/C7SZI))N491=7J#?2<_GZ9N]A<N
MGR[5C!QI[3GS85E#"5L@T8$$QB 7XDVG-=CRW0,>4;2;TNK4R_U6S9P+.%56
M0F'0W:&E7E;*WB5VZA')Q<@5 Q# <2B ^#3USYM<4:_$%5,CZU]R RSL,J15
M)%5---&T*K*F146("G:4?+[@$W0/CXB*VTN55=6*P5]2VP, WL,2M-S=51.R
M36LT1%)NS/Y&OHJ23<IGB*9VY3.$P$X"<O6:X_L>-%XU.]4ZKUF]6N9O>AU+
MCEG<W5K0+(K5GB%IO4?./]TNS([T".X^(CB,V9TEB+/B*-W!$G>V5S?<2FLD
MB^J4[ID+K6?S>=P#Y(B)G<?+WN)L+NILW;(ZY2J%.[#M$P?>$.K*\Y/H-(T^
ME21UDXZWY[:X*Z5=^JW,!'"3.?KC^2BG*C<X]%"D5,)!^ @ _L<IJ3BQB%V"
MX<==IJV6F4=+,0#0;!G%DB:>)7K==LLR5^?NV_8L50@I'Z&[@Z=?'%?CM!;=
MCN)ZYQ_Q>BY-M''C2[7!Y+J>?;+48U.#U9K8*'>W=?L2[V7TEI*/57R:"J;Y
M=T943^8H8H9]PH_)PX\<=(;F]RHQSC;5]S_TB.9:G%VJLO[V%K?HNJQD5)5O
MU2H=Y@ZHTCYR7.108YE->D\A=9VD'BDZ5RAY:<3Z9G[)0&=^P/'./=B-4G#A
M_,.(:JQE9Y!:AKD?;&B[])W&I*'<5SJXDS*)MT2$6132JG(&DU>1ODCP:Y7\
M9.;\S0(QD:3<7*CX%HC:2T*//'?%-XWAJ1,OY@X' 2IA&>:'0Q"F#/\ 9\GL
M\;=,UU&HP5YH]IB50683=;L<>A)Q;U+Z%$53-G  JBH!5D%2F34*50ABA['/
M)+.A-%[BZY@V7C//*Q95V;VY\=]+RZVV#28NQNVQ3)RD)24*\J\:-')3D27D
MUE4A3,)SAX:']0=#LY5<!3="HE7(X_\ '5QT#TRZ1BB)D%NOUNT2&  Z@8/V
MF@4^:YOSEHW:_.M]C^2Z#Z5R9M(:SFNB1^*(:1F+VNQ%:AJM2IG/*OQVJ1#2
M->1:3\0BU<N7O_WYW)9G4*#[@D_:;3(T+4,YIU7BZ[GKMY/-IYCS5C; Y4*:
MG^<A,041S/MSA!)0Z0*LVL4\,15L(J.\?NF8[5=<IUW+./*'%V1TZ'K5&L+Z
M^Y(G]G7R+>=KMGA)"OL+5 6:NA+0L@T233CWCUVFJW=M'!FWB:LD%R;UK#<2
MH5>G'=6JQ&V;3<-GUEL%.X^TUU<SV"U4F>MMUG7U@XY5>4;Q[Y=VD\F57*0(
M+ \*B2M'J'*ZP)UK>V>]1.4RK:L\>VDS>*KR2Q';&<W Q=BC,X@K#JDM6JCJ
MMIGHI[,JRTDV:(%(L)VK9<JMNP#E+:H+;HJZ1>DYU.&8P*56:RF*VXLO6H6E
MS?R1*&2?2R&?OB,WS]LV8"JJ8PE*)B^>KE$'=^9>O.D>-M_RN=XY76;I^7+O
MJ#,UPKW,*HA=6$12VC769.P52[K5QV\D4T.])UZHI47GF.C9GG%,Y/:G05:M
M8[!I631[F$SB6?L%Z\CPYA$/4R4S45XZ88UN7XW5!0$')$S/%I=VET,D9!-M
M36LMRMV>TTBBS.IUJ=AV->R^-;S$Z^V;D'-:$1D[/1"R%,GA>[=8ZZ^>Q8HJ
M.&3"/,0P"W4,YBI6;Y<ZU/W4]6RROWFUR6>XBV3OTCBF_P!>Y!9Q8W];K]"@
MH*$DH^P01V3_ - FB,J@\677,+L2K!@53J?-7**<[B,L@*U8H/D%?LFQ^0EL
MQQS,JWB<)-.XIWCE[C-(QIXV<&4T*"<IQC"0=C&%*X0*!"%TF#I_,V#HFM\A
M,MK7%[E'2<UE,\DI?5XBF5ZWV>/CX*.G0G9/-=1:Y_H%@].]:'<NRUN3*N"!
MSM&+U"YL<\Y.33;.%KAR,KB%3HM;S"6@Z"I>^/['AK8<S8RJ;%^^05QFGTY-
MJU1=*F?H3;94)$5R@+<ELKDOSY<.(/).3,=)UF%L\+QEO\)A?(/0D'IM)SBX
M5:XYY/IW+\=3F^OG3"KVLKL(M6:3/$IE'TIBQ=<R/?*KJ="V';=AM&8V(DW0
M ;6.R6R<M5[M%!I+BG(1</:U*>$+,&\MJDJ[09QRX*@!6I^R5K=DY+8C S\%
M,6"OSD/+Z358^0A)NI),'%KBIALZDTE(M_5VDLT7DDEP3,P;NT%5P3362,=W
MJ]NOM0K>81\.SL3[1)JQ14?2&5=D ;&96!U:7#HD(W@G*;Q(Y7AE@;"FH!^_
MM'KX=0]QW;*:S*,AIQ73&;O->CW"1]#2<K4 @IN7Y!,I>4V:WR<H=328HJ V
M!02& *K!Y_LN9768O5.7T2E1=6NM?G7]NS]K)+PSB]5IK&OW"TY349=N9J:4
M; JQ!QT3\WO,4!-E-BVS*X#3".Z\P/0IN]UJ*MJ;ZW]GV19J0+^20D2.K690
M"1:8I@:04 2-P4,4P C,S')3#XJ(<3-QKJ$I(Z;4&<>M/YTFFMH<*D[<2R:!
MY2@(*^9.( ;S8A,ISNRHE(<2R+B0Y!XXR2B(&J6J3%SH=71.PK-\(*M'L+I$
M\D"R4)<4B'/%NA+Y$@1)0R!E 24$L18Z[*QT]7[!%L)N"G(=ZVDHB9AI5HD_
MC)6+D6:BS1_'2+)<BR"R1S)JI'*8HB40'^P>*JB:2BA&V\SZKA0B9CD;I'XU
M<A6Y5%CE 2I)G<+D3 3" "<Y2_2(!]U<)<)W?'9CMZD[$D;/.4#32'^7MJP8
M'03JQV>5N6=I<6%,?(%F3S"-3=#@J(?5\2T;M'"'B/R[J[VNR:4Q(\*MTL&=
M6]P@Y8JLWL1^+?E$TBF*RSAN[.=%5G//C&.W @MA!;\'B'#_ #]*-Q[F'&T2
M.H=UJ;B]QU.N),)5U"?//9U7--"(O%<S[7[%B+MO'IRAFSII%O5E0(9)0A%$
MPUB]>V1QJXXY5"<<HK.8W/=(U>(YO:S9=H"_(VTVKN+/::0XJM#=1=<</HIX
MO$O!=3!UT .0C5BU*7E_R+XWKUEW[E<MRMEN:_$75Z?4:]DILT<T&7;R.1<6
MH5LWE4:^WH3^IM'$1,+J+,&LU*/R/GQ.ULD0N=672J6.<:+8*-4YN^YZ,M&S
MWV&N<I L'MHJ 3D,[?Q,R6MS:Z[,';9=5!P"/F$.8I@'QM7N$5S6'#:L[_QA
MH6(Z3AHUM,&\KH.8VAJZI6K?:Q.4)WC$T@KB((Q48&5*+E10'/88$2[+OU4J
MIXW6-_:9XPU:TJS]EDBV)EE4*_K]&:M(.4F'M=K*$1&2:X*%BFC('JJ@K.O.
M6Z'#Q8&M5D&,39W,)*H5N5E&9Y&-C)Y9@NG#R$C'IJH*/V+*0,FHLB4Y!53*
M)0,'7KXJW'?D/[8?-WDSRIJRSV&L^[9O?\!M?'G;[ [DWBZFG1FLVS2*!^*N
MI6==P5PWK[JMLB5EF<K,$0*WZ>$_<[YTYUQ4R2]P6.SN1YAQYP>)6T:>3C['
M+Q4@2Z<D-ZL4'7&^FZ14XN'+'1:43$DC(]!41;N/J""O/[V_[WL;>'R+E!N7
M+*?P>4R5L^CYC"L(Y%OB3T+0UFDDUBV;Z0K-CDY55XS1,9@[:/#-P6[%#=CO
M5]VWZ@\B+_7.+\3Q7Q*5C^&N$XY&Y'4JW(MY>HW D-"&M:-KOE,>M@3B72RC
M5!DS570*B(.%## 1?MC[#7\VV*<XR[9Q0Y/3>T+6^&C.5M%W+ULI):):+?E8
M*6:@[3G%K>&=U:6:LI)NQ9%3CSHF:)&(K@W)N1XI<"N5TGA_'J7PFKU?A?HM
M2X+3D@>U)P,?:+ON[VUX%&,.0MD4B(5)-B1[)Q\<R=@J_1:INU#"I@O+;EI'
MXE@F.3N?/L2YA\1<HU6\Z/(:[@>?V)/:,.S[2M*5IE+K>A%D=W54-9XIA&Q4
M<2O) S!]*D<K)E0<<?<[I:O"/F2232YM<;Y"&I*F+9KO&64Z2LO'#F'5,>FU
M6%;MCX;Q!QT-;:FBV4B;*)(YW(M'!6RQR<I<SV%/C/C5(UOV]+UP<6T3BZM;
M9BV<@]!TJ[R]REN7.RU6^5*$2KF@P!7OI6D.UE9!FT0=KL6*S6.;LDT:GR9Y
M2<U[)6>:V.T_-\MXS:/P]A5J)F& Y9G45(Q$]6B9SK*NB0^P)\@%I$\C>$;0
MU=-U%2-VD>#9NT2.:(XZDY+76IVN+LU+M,MJL]5(.R-M//5'SA_(U#8<XH[[
M(X"V9O<E7 !)0;!Q#M52H(%^)$S$4FYBS\8$?<JXR[15*U,V["^-6JU/VTZA
MC'("BN9.-C[S#88RTZN9O>:Q-4B8,U;.WT])6-D]%V910Z;GJ:L<><L]L:#X
M0X A-3-JFT9GEM5=:L3>;G&YADY=9K6&.BR=OM$BXC6:*GK)UNW3:=@$< 5
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M;'5@HV"YI^V5,/[.V2?U]K&<6>8KU:7B5EZTU2GF1&_()05:V9S<XA/YE_\
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M(#OS.'^Z 8B/FF!0S8"\U1!14$.@E _:'?U 1Z?'Q_G(<*_S.=K_ $VO&@Z
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M:I23>3DC^:\=,4B,!^<_C=E,ZAI7CMM/&.W1<+38.?EI?..0%AS*4TI:'F;
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MJT=*/7$24$7C0CEP4V;W3,-9F:W&9_=RZ.CG3FK-Y3/&EKD<#T_$KBC08(;
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MQZN(8W @CN?(5Q")0M@9I5XAG_#+98R7B9>%;+JH.FJ%<=OW*JZ;EL5<[-%
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M;Q[I8'Z;8KL%7#!HD@<W?U.BF4@]2E  ^[\3_P#KANW_ -#EMWW$1 .H@ ]
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MDI7+L_NL$[@)D;&=)AZQ%Q(L$(]B!70^4J5:R2-_]C;G18AL4Y?K*FS?\YN
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M41 0$.@AX;,6+9NS9,VZ+5FS:HIMVK5JW3*BW;-FZ)2)(-T$B 4A"@!2E
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MW\6Z '$ 7*E ,Q7,) #H?R0,40Z_1W?ZV,-,'3L*WU$#]0()NIJ[%=G01^N
M? >O3Z?O_P"MC!__ )FU;_HY$?ZP!Z=!'H/0!'H'7[W40 1 .O@.O0!Z!U !
:ZAU^_P!!$ $0Z_V/@_\ \S:M_P!'(C]C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>exh1077_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh1077_1.jpg
M_]C_X  02D9)1@ ! @$!D &0  #_X19L17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  /0D    G
M$  ]"0   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,3<Z,#(Z
M,C(@,3@Z-3<Z-#D      Z !  ,    !__\  * "  0    !   "P* #  0
M   !   #CP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $  !4V
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 #_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M^U+@R74.#R)#!7D.!_=_2_9?9_4]%-^TLR8&*"9@3ZX&@W.]WV+_ #/WT?\
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M^C%<]>F/Y[-U_P" M_\ >9 L=T1SW7-L=47-:SV5&(</5;M8^E[?H_2_T?\
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M*:_2<UE7]M:.+U7%OK;;Z]3J[!+',)VD?O;W;5=#8 ',")/)3&NMQES02>9
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MINI)))*?_]#U5))))2DDDDE*22224I))))2DDDDE*22224I))))2DDDDE/\
M_]G_[1J,4&AO=&]S:&]P(#,N,  X0DE-!"4      !
M    .$))30/M       0 9     !  $!D     $  3A"24T$)@      #@
M           _@   .$))300-       $    'CA"24T$&0      !    !XX
M0DE- _,       D           $ .$))300*       !   X0DE-)Q
M  H  0         ".$))30/T       2 #4    ! "T    &       !.$))
M30/W       <  #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  -'    !@             #CP   L     ) &4 > !H #$ ,  W #< 7P Q
M     0                         !              +    #CP
M               !                         !     !        ;G5L
M;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #CP    !2
M9VAT;&]N9P   L     &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L
M:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M    !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T
M960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   X\     4F=H=&QO;F<   +
M W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0
M   !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O
M;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M#T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T
M   /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E
M;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T
M;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E
M=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M     3_P        .$))3001       ! 0 X0DE-!!0       0    !.$))
M300,     !52     0   'P   "@   !=   Z(   !4V !@  ?_8_^  $$I&
M248  0(  $@ 2   _^T #$%D;V)E7T--  /_[@ .061O8F4 9(     !_]L
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M:&M :UHAK1H !V"=)1>]E;'6/(:Q@+G./  Y*2FME9&90'V,I9;6V(AUF\S
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M+7.W!S!$.K9M_H>3N]UW^C_1J'37Y5X>\X;+@2 !8P4M U]U;W4!U_N_1O\
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M0ES-V1[/;2QB?]G9'MTM@/:\@-J ):=[1M]?:UOT_P#/13?C3'[:U/'NQO\
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M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "
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M9#TB=R(_/O_N "%!9&]B90!D       # ! #  $"                _]L
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MZ>.-XIL7VUOP      "&I9K 8ME(  #$<N
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M%[;MR+&,:YAKCN)HOTYBZ-\WUPI_K:GO+=N=714 ',3IWIKN4Y;]2.5G5,
M!B'"O1G&,0P;82DPW)=@,:BW/I/ZFX_;O3*_'124=1(HF"+I&J[QT%QBWWCY
MYQ;/ZD7NO\+Y[?N04-UQ:7IJFJ@_+%=Z32>;XMJ-?-PL)D_.86D6 -R*GJJ
M !S:V1C&3M))]VJQ]X93AF>XU+WV'*[?K4.TW3#K[D>Q<]_GZ<;.E&MV 9AC
M=5E^+VC"9(H<HV(V!!PEZ8Z'?FU.NDHZY8;D?EV"DL   YR<O<NGF-)R['@
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MLNIOQX_MN\KE[>P       ?S2;DX_0^>R6D-BWMY]Y7W1])$   Y.]8@
M    /YS8SVEC&9<UQ2".A^E&;=<90   <L>IP        '\W>PEVR:/=<:C3
MS?+',VV-ZH_65   Y8]3@       !&NA=L_E[EJ+,MW9T&VY_.8<V;01M8?Z
M7/?ZH[?Z4U#CF55'CXY7^?OS77[GST.R&^^OK<_U47.I95=/WWR.N7'Z
M .7VAV,2K$\XPE'+8[.HG]Z24(#F?8+4?>?3[%-DM;]B(&]9LUB[4;(TECH_
MRV4?E3V^G_%'9+,Y_P#/NAQ';KD/E?IC6R.4ZN2)=[E#LJS9VQL&4W+HB
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ME:?[MQ?LGI%AEMN\<QCN3;9DUYV.PS4O>+5_:O4F'9?[E[]@?C]_/GRI?NO
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M!$^7[(>L61I(5]NT'8U)T3SG%4>W^-_3'KAUC]\HM_Q5VJFO5=A%;Z[?]=
M   &H4J\^)!K_C#[G;<Y1%/L18A>=_M,KO%%IH)8RK$;KB&:^TPZYUN4V&,I
MUP+SB')HMN_6":0       XLS[S+E;4_<F(-^-%MA<*U*S>1)%SC12OJ8@VJ
MC2Z;J:G8S .7XSA\ZY78IQC_  [H;S;_ *;<Y     (3U1\OY_/Z#N/.L&V^
M)8=F<,WW/\EC*W2O'%RH)A@;I?K?:)FB++]A]5;'F<?8MGF#9_ABMS?&)1DO
M6:=(=N]3;9*Q;'-D,:Q#XON4VC$\]O&>2S1TM?-FZ8  -?\ 3J^QCUJQ?#[C
M64/E:[?>O''?W/XJ\\]OL89C"$23W8*&5:/ K;ZX[G>,3;"E\N690+*%+$-#
M7U631?+^O^:V*;M<L*EG&\[O$'R/?>D@   #E3U6             !!.M/GH
M+TY\/6Z72JNOK[5OM]^]5]5]75>OW=:KX\_M]^M0/T        >/G^_R2?U4
M\9(;T_F>4]1+-;O;9O6KYDG&(<_=H,%A/"Z_86'<A]+IMKS?V6U[D/!:#:+$
M).C;QD+,+!*^'V_/,[C'$)&C7;3#J*S2Y%^RN%P)*\!T.:23TVWH   .7/4;
MB-JGO)B&B$V7J5M9=H<&Q_%HCRG;R*<4S.^8+^?T*?/E25UKJ[;YU-+Y>=CI
M*[";K\>>0Q/XWF,Z;]SC#_NJML@Q%(F(U,HQ%3WF3-G0  -==5:_B;VNT/U8
MVG@C-H]]9)V B?'\@QR9(SL]ZLE)G%;'F5Y[Z8+*D<7Z%9ECW?NU*_Q^/;,\
M8HZVLM-/55GSY9#0X[EE;C.3^6/5&0?%LK)KVS   .(/;G7V",POL?VO-<"R
M7!EPII?P>Q_EHOUMSV!;Q][6ZIU_QA.+[G:C]2\M     LMZ  !K7J!E7/3H
M)DU[HOG)*WW\JRX5'O55]33U-VO5947GZJOSTK?0^?KY^@!35'Z      >+^
M4S^I[C5SXEBSY!.VODAV?5+9N,9CBFT8[G7;[%*;[MN*_/E:_P _?/RN5'\J
MGY\::LM5#<+=X76U?"C]+[^55SIO*YV7U]:;T\Z+9K=H  #^;'IM^ZV15G&=
MT$;Y!8YPQ"-)?MGUUBS;ZP?.0          0'J-2:^7V ;-L-IW-%;X9ED4.
MRG M-N'+/M0J^J_%14>;VO%/3TU924WU04=;Z?5KI/VX8W0>E?46+(ZNC]LO
M^ZB]WS\];[^?LIRD  "#.:-TT PBT[X11:NHT"QO\85E'2#<%Q-V'CF/I_Z7
M\^/YQ/Z1[5 WC07O9?5#.[?A\M7_ !BS6>;M;]I8XH>G/USTQ^]9%AN8_'UB
MLM:GV[:N::']H*6D^)1FL  &K>I^1VRP>_Q^4U^L-+266LRRM^.?D_9M9:.<
M-7=*>E..Z<;$UWQE<.X]LSCF=8/5?M;=*'/HEEJ._BJP:5,VRJU5D>2SKCM7
M;LLW_P#T   #SX!=]?Y_;WN%H%L!;+?M]K'MAJ-X97'$A^UGD+&+3FF([1?,
M,^6ZVG>V>38WGFH6W^DT4[12Y$\C1CG<&3-<X_Q+.=9=C[3K]?<HM-DR&AK?
M&JB61;MYU&SFV0  /+3.=M1LMPNT3E@6MVYFJ^[&ONO4WPIF&0Y%<HXL-YO&
M6>T47>Y8%JED]5437>+%^R[I1519M_IIGFF72&S_ )J[E>2>>04,8SOC5GL%
M-MUJAKGN=V5V!   -;>-<.;-; \])#D7%L%K.B/3<              _/T
M          .8<QQ?GD9;]0?L/D\72E!\XC!\XAN9&%9KYX7F^)9;A^8X[\9*
M         XW>\>99KCU3YF0O)UVUBFW"?/.=N=/K7O+&VM?U>XDV_P!!]AKO
M+&K6[.HUY_H@R8
M                     C_A=U&BBAC+XV+^X_GO5>\[=QG:+]ZW3"LW^<7D
M["[UXU>/RWJKLMIS(^Y>9@       !@W(O<K4F4(5NEBGJ,/N9M?9BC[$[/.
MGQ@6OS-MC\NYFS?>X^VUP:=-0);W]V'        #Q_FKCG;[3'9"#XICW9.0
M=DN;>Y&KU@EK8^1N=.,V:7-^NUP          C/^:"?\_C&Q67:W5_*)BHJW
M2W=6-+)\]9]V5/37$   \+!DP      %)^?E+;?BMLWAK%M+1>MGR>&\^D*Z
M           &K6HU7(\98WG]%ETH0==)-M]9"DY4.,2#X?&31/*&'3S!==*=
M-'&P$?Y'A<WV.1H^OE5>8^D?"\PCW'[=/'IBD0;$^H    !S.Y&5<AZ<[*6#
M[P"<\IQ>C^/JLR:48ZR&!9;^\+H[=.&M$R?%ZUTRC*XXPV5(%@'=C!\%S3"8
M-RV;<FNMSB"ZVZP[O[\^OEY5%71>'O\ 5#[7.IV9VB  !#O.7;;FKCD^QA.V
M9:TR]:(YUUW6N.AVU.)8?O#TY  MW\MO0*YZC6[8[4#;"S4V%YUK+AVQG[@4
MLQE*6J??CA9N3Y1I,/;]^?'[X4?O7@       "S\RNIKBG"VUVK\H=!M*<,O
M>/;.:IXG-W86I/S&<GM%WMES    -<.:<KS_ ,R-X;WL+LV -8N5G66"I$N6
M&1MM7XU-RF8QGG3T\<4-=]P(;E^GP_&Z#;+G/=^ANF>RMRJ8YV]@:)-O=Y0
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MCP;,OKK#NT  '\\WA>91A/(W4#;\ -%.;V?P!*DNZG=\I:_&-9';ZKZP20@
M       M-V  #GASDGC7KXS/*HZZN[B@            &.7_ /,;NOU7>@#!
MLS]@                           !X>X             !^?H
M                                   !Y>H     _/SZ
M       'Q]@
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M^=S&O.P[M"'=YSY;>"\W'W>>-J3<F&5B2MG'G1RV+G/VL7RP.PO:]HN((O\
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M07"R>Z WJ%;XB=D#5&-2!498H;ZG4]A8K&310X8(K(Z!FFJ:X@<TH+P\4S.
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MS30T9/.HA]G<HV1E4E<ZW/=AK+<; -(T7WL0+)"G<;K:5EY7N!/1#Z-E=C'
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M.5:5"<JLDMFLKCI*6G3RK5)RUL34JEUXH:FJ5AOSK"4%@+RB&6N>K=V+K2?
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MJ\D3NE09!:(D:A^T4Q+/:D2U5VKRFPAMAM?@!C_Q7HRWX<[JK1.-#!97K&L
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M0X;%EG9$?A[G+&4 >6!6D]+0# N##)4D_P!GN..7S/5JV>Y:\,_F?#Q;-?J
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MYON'Y&ZTL/K55O0E5N2FII.51H]*OQ(IFK6351EUEUTQWN:,<Q['_+^V?O\
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MEW4%.R3Z)D%&[]*MI2C%9-*3%,&+CVC"FJ8"C]4Z9;Z'1EXC1'S>,S^51ML
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MZ6>):3D\%SCHYVW*3IIS_P!IOGV&;K,+Z7&U+:G3DU,@7#1NLXAUS/VA)M-
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M/D ?;$P'\>NW%\^!+_U?MX_4/H?/R-<0$^X!_>]18NCY$Q"J !?=N1/4/H.
MCX\^/T'[_10#Y&>'Q$WD2^GJ7%#?8H"(B(A=!  #Q^H_;S]$CX?Y">*9)ZH
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M$ #^@ ^@]WXX>*1\ (!Z>;\J3\ )2E^PIU@OCP4H>/ZOZ/K_ -3?XJ^WV_\
M-QRP?T_W_P"6O(C]>?\ DX.+/[7J\?[.F7^GSX*']G^7/3Z?X0^WZ?7D/C@X
MN ?/G[<[YB'_ !O7]O\ O=^P>?Z/ZOM^GV^CJJ_'+QZ!CG,H;V<*HC4GJ,
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M0P'%7LE<$&K6VR#O+J0X>V=JQE(:<9-K"Z5@SKS+9K-5R.>)IN3*$(Z8-E0
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MN(^*R7F[]EM\LTTM"/W4$^N^\0<9"WZ CB6P'4(!HB'=N%F9#*>IVX6 !3'
MJM(:@):-RK>^%Y;(9=BTDT=)L] Y=S*YY[L=$T>70>,(9"-Z-);S#((1S?\
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M,-/J;D8I!VX>'FWZK)VW9%*5=26A<JJ_53?%8*1T%U0-4E/E5^11FYO674N
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M9\I,,DH*8D9QW1U 7;H 0@D.5(\SA\L\,58P^HWN*G$#!_")2^0$?'RB_*R
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M5 B8AY\B83CY_B,(> !F1_U1\D3E5@H91LZ+\A/43-<HG,D)RJECM!9MG)#
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MJ@Z]L#>?Z//GZ*4?D+Y0\G(4Y0#8*J/\)@\@(^'H^D?'Z@/@0_I^A('R+<B
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MDM'RR$0F_9*IJ_Q%,FH40-]P^_\ FU9EJCBVK7S/K5U5\D_6ZL!GUWSQEM6
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MK!0&C'K67V&2YIB83U<]1= <O]9J>&LIYQ$W9S49!1:89LD4%W3,YAD^F$>
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MOUF#Y$"K"@8%F'^!PO43E. >HIB 8A3D,8 *<HBB[<ZWHY$%R@8AB\J]:JB
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M. ^I),2A6Y#G+(G%?+A)N8"0W\EQ"4:3G92683RN*IM$&Z2*>;K3$8W<J10
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M-5.4/QL+.:BL^C6#E6<5144+&$1.=P*1$U/3<<WR;"?C-UC0,X31<Z+4J/\
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M-PO#?R[5;99K*\52<IHF4;-B$*5M_%X)T5HG-705EP2]Z#T7D_3_ #0[99[
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M4D9<OK1*H'\\>2"J7[E\_P!H/T^CBX[TXR0!,!$XJ]/8FF! *5,XB<378/2
M$5*/W_H,']8?2;8O??%HN%5Q:I(AU'B'NJ.0$@"@0G\\>HRP"J7R4/N'J#^O
MZ1.3N'D Y'"9UFYR]+8P8BZ2::JJBB)@N@E4(1) YA$/( 4AA_0!\/7C/M7D
MITTC2$4D73;H_'5VS BCM!@F=ZNE<C)-2*/G22!14$H"LH4@?Q& !\'[MXU(
M/DP>#=/XD4?)!])@^]X#[E-]A_J'Z(]B>R>5)1FHK[";N.Z&R-ZV47\''V2+
MMK>JD=7PF;^$!\_PC_5]>HG4_.)R@8Y1$FWYD8 ,0?2<OD+.(>HAOL(?T#]
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M\H==,BA%2)K&/'"*I"*IE, &\@!B@/Z@'TT$V:4-#\1PDN7\:G5I+W2)>O\
MU1Q_W*-[K)43^3I_8#" ?U?7WRK-Q_7_ /@>L?T_K_\ >O\ I^O9-D&7F1]!
MD_:-0*F*?MF.50R?H&)$OH,H0#"'CP(@ _J'T/\ X@\6^X^1_P#%91ON/]8_
M]PON/T'_ (A,7^WV#_Q6T?[!_4'_ '"^OM@F+!_HRVC!_P!B"^O/^ F+^1^P
MC_A;1_(A_5_[@OH%%N9>?%E ^P**XQG"AP^WI^QCUL3?V1\?Z/KC^X9%SMAA
M[%3N5_E@U&$HJ.(5"9A+[?LTYKH<SG4?+TF%B63F[.&=B<@+=BEZG:A552H"
M0QS'"D5V7^,_GZZVB1Q33Y&X+L>0:R]3B-^OV/7S2^':1&/*F55A9H.^H8?.
MGO"S%OZ:^^ML#&*K,UTW"BN)NG/.?$VPY!H=4Y,O]\UR+^-%7.DJQ"77HFIY
M1U"VEHBUQ<H_BTZ/7T7[]-R\01/&-'#8[A)<S155:!IN#<F_'M1,RUKI#K//
M\UO=T^+2N3+.%H&/8/1M:Q6]V8DK+TI=2'T!_:W4<NY<M6#A53T_C% X*(CG
MO2<_P3Q#CU=TOIQAF5E>4SXY:EL=QP'&,_JUNHNA7J9I;.D2,E93Z)TEG2J<
M,_\ VO\ "AJ=9HUPX067(LH290:_'KQ[:_VJRKTRVQ#3XEVD<G0J0RO&05S)
M=TK(C7)21NH]&5BQSDTXK@*K.*BV4*FN1)2 DPD6&4ZY\8G&D-BC.;*P3T1[
M\:#?,#:=3P#IG^7KVPC+)29HM&D[,2@Y]*K1TH_0&$;3JR;E$YWC0K8R3S@S
MC5PF<R!S$4YCQ7P)FRR*Z _:D@/]TLW(8/\ ?('TP(]^/;BER6,]?[>57F#%
MC T%0Y%%#)?]Y8>#&.F4?(^1^WT7U_'/Q";T$ A/5R[BP^D@")@*7_O,^P>3
M"/\ U?HH!\=/$I *H53PES%C:(&,0#E*"@)4\@*D #C_  F\E_WOT^B*J_'Y
MQV"J8F$JJ'/&6M51]12D'UJ-:RB=4/04  #"( 'Z?J/TB+O@#DDXH-U6J7MX
M7G[;PBL0Q%"F_&A$?682F'P8WDP?T"'U^0C\??*Z#@#-SD<-\EK+=PDHU H-
MU$5T&B:J"J?I 0,02F$0\B/GZ65;\0<_(+.%%%55D:4W26,HJDFB<X+$6*J0
MQDDBE_A$/L4/Z@^FX*\7XH4&Q3E2_&@GC,3 HF5(PKBSD4!=&])0\"KZQ*;R
M(>!$1^@74XTS7W 2,B'MRE[03]!O7Y_N4+<FB)_[P?!_3Z@^W@?L'AN=/CK.
MT%&QDS(JM9F_M5BF2(F0@BLVN"2JGV3 1]0CZC_Q#Y,(B(I,^3:FT3,(F,FU
MN6J-TS&$3&$QB(WPA1,)C"(CX_41_K^A)_LLP)2&2,B*:>@:^DG[9@$HA[:>
MA%(!@ ?L;QZB_P! A]' .88_P?U>?_&CMP^/64"B!!'2Q%("@'DH%\ 4?N'@
M1$?HZ1>:3%34]8&*7:.@RAZ5?/NIAZ=7#TI*_P#'('@I_ >0'P'A),N!S94T
M"D*@F7?NE (@5,"@F5$H;!Z4@3 H 7T^/'@/'T8/\"K&GZS&.<6_0O3+43'.
M*(F,8S;8TC"8?8*'G]?3Y+^AC /RWY)E4"\K5"J?1/-G[##OIJUV)RW++\:8
MS+OSJ3EVFK#9)8SB4>+*>^X>*@8# 0GI3(4H?7+:+4J F_Y2;X[5%5' I 1%
M%+JS.%#J%!4Q2G5,8H$* >3>3_8/Z0^I6;DG;&/CH>-?2K]_)OFT7&LF4>U5
M=NG<A)O#%:1S%L@B8ZJZH@FBF43F'T@/U.ONV<UB6]HMO^#C[*<QS7,KIGTR
MS+K\E?DV;B*TJPW[6,1Z.PYK$TP3,=(J5B9+23WRD>L-4'#=S]:AJF2\Q[A;
M"UK.X25H$M?1H5$J-FU6X<H-NRJQFT\W&[25W@S,\757<RCL(PZ2$BS,Q(8Q
MUVJRJN<U;*.B+S>G.L5W#ZO$U6HTY*-NND3.W*<\/(J'L]GOU=JL0SBM*1,(
MKRSY@1Q$ +U#W 3633Q>)I7'_2CXN@MW-WGJG--L99WYSAKO(NA= A->H1FN
MV.:+(1;>?YPGF+Z/DIAA+G032.S:.3NVI3W"D9_5-QTF0@%6T35G]1J54&+T
MVXNKKDU!2IE24G;U"O(B37L.T0Y6SJPHPD8_1;R*C5RM^"H!L&KDIBTT\SK4
MH?67]VTA:X5)J>A3>;X;HVV-*/&U1J]DY2UV67C,T?IKN@.SA6:8$$KQPJH"
M1;Q9+]CT7B4Y7HO'KM"5-*P7B3G7.=[MG;?1Z'+3\?>,QS=5LLI&*J-ROHL9
M:%DEFZXM77]RH0NR<^L^5*G8[!3GF5QE#F(O>W[N%1D-NZ1SO ,@;=!2\=C4
MA7\7EM+@[J^O$5"Q[ZU3P5F!<&<LVZJR'JYRI*'+$W$SF\9YV?+J30ZO4EJ1
M'ZQQ?HSO*[?E%6E7D7&6>P-[%9V KI3\K#5^.:QKMJH .%S.F[3<$M.RV"Q[
M5N>^@+?@F@4^MW69NT$I)P$#5;4PFX9];J'EEY+%NXNWI-2KR-<CVTDNR5>Q
M:KZ*<,WJ_P#G,NQY-N61T3:AE*^O!3^X4ZSWG/"Q+>8:+65A)P=/LM5G?RY&
M$*LBV<)N3%06,4QDS!]RM_VKHSXJD#)+IF6]W NE2?DH?E(&5*83Z<_!(?Q4
MSE*!0 ?*G@3>0 _T0T=T'\2ZC1%NHF8KG%^G&AWJYP<>ARH0EMD18^P)DQ A
M5%0/X'R(?\8R9]<^(!LFNY-X<HYYU@\6CVRS@#C[;5659I2!V3?R0A3*(^Z/
MW,8!^X>T6_?#ZD[!Z53\S^2>P%DSLA? 8S;\(9Y+VE$V!/3ZO=.)SJ"'\'I
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M"Y)M9J)*T_<(H"UFZRB2CUJHX$ITO<*L7TAY)ZC"4LV_4^#KH5!C6U5D9_\
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M#VT2D0ORAV[-L;Y[>467)*A1+:;1*K:94^79?4[&N:HU5LYCH6MND2*,6B!
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MZ@ ?N)?O^GT<"=F<I'%(H'4 O1&0B*91*!P,H 7#R0/0/G[^/M]_HB0]H<G
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M^Z$ \>2??^U]_I$X?*/\E)1;HMB)%"]<Q>@5&QU5 7<$_P!E7T.S+B<H* H
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M:711-T]865HPF"PZJ;UNT<I+(BH5P?++]!.#,]OE6\(_O.(2%FG&.$HPA+5
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M8WW::_4W<MFT'F^J7"N42<LU.KMJ;GF=);T./KC&ARZMD0:PL_(_MS654.4
M(D<3)DT&0JDU8;+.4JS:=FX(OZ3?(.J-M3SR984=E6;Q:4ZK*J9]#6_5IIA6
MF$H_9^TL_=%,F0Z1DSJ6?3YV#;UW08/+)32WE00C=AGZ+0D8[$X32TT=AT>&
MQUV:J0LC:EI.%8RD9&S3.3_!(9F*[A<K4%8^9=:B6^DOILW8YQ&Y/='EHMMB
M)N,GSZ5]0A4C6T/;*W(WF"D%F3I!V"CB-9J']HKGTM305AOUFG8^4G48Q1DP
MS[*M]TB+D'EFE:DG4JM"R+7'865D= ?5W2:S(/X$\<C)1A)@ONI"BD=?ZSZZ
MW'2Y:.JFFY57=KK$^SS;3IR-2S6XI%_DJPV1Q!4^2+4#720.6/B6<I^(]D)0
MQ6:*)G!BICC,Q=+W:Z*CO]-O>@9<PO.0:_3YZ9J>;P<A9;5*2M=L-&CIRI"A
M 1BKQLA+MV+A^W$AVR:I54Q-B^E7C:4JU1^A:?-WO(+!(4C1/Q+A6("$/87[
MUN1M4UW#!RI%$]QJT=$0=OC&(1NFJ=1,#1<$TU.T!8IG3(S'X^L.L0W=E:%=
M"DI>UU]6%4KCO-49ELTK\_1IAE,R*J)(R$=1ZR;]PW, ><QDLOLLKI2%^V.G
M9G-E7J&FY^K0JM9'U#:RFJV(MPSMF2-J<*RU2MOVAY(T6WL+&5(>*<NSE]LW
M.6.8PZL&BJ]!-;W(FL2M1T&BHY]%U2GW6V0+RRQE\H\ L5:^DSR6)&,U%FL@
MNT;ED$4%X]0KCZU'FS2K,[S?0<\OE!H\2M/UZWK5:\GT2I9)/PDE$W5E6%:1
M&F;SFQ1<0]9NI,KI@LHBX<E1;.FZAZR_T_;X.K,K=G#77(9VI W.50+G,E#3
MT_!VB:4@ZW)EJ[2TQE5E30J4G^&XFU8MXBP3<+-5TT_Y2S?H"JSL\EFUFUR3
M9NXRU5HE;H-+GI.M6V6N+RU0$(RI+ZN2T*[*\C)=1E*-T6YUSM@0#W?JB43(
M4;1JD),Y?KVXZ3?V,!9:M#9)DF*C5D;?/3,#:*XPN$[8U37F'>L(1JP*\D81
M\E(-!72<,2/-1N>D:S'X?5<\NU*K<;)Z:RL$.O=:WI% S&_T>\0\6: *_082
MC+3VR+QF8AWD+^.=:0*V0.100Y]MYGL="QE)I-IN6QN%@1HU4DM/2M4EG<(4
M@M3.[4PDZU1Y25EY>)%W'5B-23=RIVK(5W3;1F6G_N_/:6>6FGTE20TMW$.F
M%@M-OOVY4%.,AUZD[GP!M!.<'DG\F_7]J/CXQTBY<+I)%5.2.=TK:\QO,A*7
MFLT%K$1]\KL2N$U.O8 7K=9Q-NV3="0AJ[.A)?@G$'CTJ0MFJ:KHY$AH)L\Z
M7RBV#JEI<4K-TXNRMS+W:S()D7)&5UNN5%>0&1:J NP6*7\>1;^5FIUD@$X7
M//4>KL#"YYY^YA=8!?3ZHU=UPT&2S&GDY$[J21;)JP!J5,)OR%4,9BM%.TUP
M34;JE)6,OC=UHDHO:)%]76EU:62#3SI&YEB<5GJ[2"7%Y)-8R:LUZA=]KZ\.
ME%B_2<B==(ZB2Z(I#ERS?:LYNC#4]%-GC"1I6A9_+M*R+2!FK%.7>W*+VIC^
MUY]56$.49223]\&0/6RADQ14%4KF=RV^53081H>,3<3%/G8ZP1B9YJ!BK3$E
M%]&.'+?S(UN=9/T?XO[QH[25#R4Y1'_/1_I_WOU_ZWTQMQ+G5AJLA.HUB/LI
MIR,+ N["ZL7\G-H5I+G<@P7DW=L_[EI(D4%15^(-R 940*-;QNT:YFE>UJX-
MD'M4S2;NU;C+W8VCQ200:.86J/9%&<DD'BT4Z31.D@8JQVZA""8Q# 'D"E ?
MT\@4 'P(^H0^P?TF^_\ I^A*"28 ;SY#T%\#ZC"<WD/'@?4<1$?ZQ'S]/[3>
M+#6:;5V3ABG*6&T2D9 031U+R3.'C2/I247:L45Y.7D$&J *' RSE9-,OJ.<
MI14?VMY7(>*5=Q[%5U.*QS-FJ]G)J,AHQJ=1Z)$E',K8))FV1)]S+.UTB% 5
M#D 4W ,&0+I&7,DL#5#W4S.BE3="FI[?K(9P0H IX$/6   ^?J6J@K4^<FJT
M@T+.UOW(63E*^VLD<X38!+0_E=W%(3\0@J5'WDTRNFQ#@7U$ ?J"K>X9;#72
M(K=N97J'13D)^K.6]F8PKRM)O5Y.F2]=E9%HZK<@M'.V3E99B]8*"W<(JH^"
M?2YI"-I=<A7$JRDG(O&<'$1:\VU%M^W/UQ73;M%)5N,>C[*IO*Q/8)Z1#T%\
M)NFM:KJ2I7\G,).$(:-(H$G.H&;S,HFLFV P/YELH)'*X#[C@AA YC /UB]]
MGJ32&^J98RNS;%U"+IPCR,93D3!1]O"&K#%XQC+"1A%1+#T'79NQB0(0[<6Y
MCB8T"XEX'*6T3FEI_*JZ\C%U%&.S^ZO%3)?D0*KE K:JVETO,F+ZVXH.SG="
M'D15_B@ZXYR[.G%>K";Q*MP2])K2T-7DI%=-S()P<6I&&8Q*;YRD118&Y$P5
M.4#&\B #]0[^(RS)ZHM#V!U-5]Y&T>H0:L5:K V;0[V6AW#6+:F8V";9H(M5
M5T!*Y<ID(D8QB@4OU.V$,-QX)^T+&<6:<#,Z4$Q8ES34=93+3LF$)^;+K&L<
M0TD!,X.H(O6J*_GW4R&*L=K@6*-SN&D3'N#M\LHJ)EV$ TDV$$Q6,G!%%5I"
ML9IXBT2-Y(V2=K$3 I53@9\0N'81&RMX=KK21"YIG[.0M[]O R<4Z5?%"%3<
MV!VA6)%XV4,I[QRL%UDQ\)'. N9-7G;"U9)X1--Y(*9'GYWKM-*0F9=(CEV:
MO"X7(G*V.0=% QA '#YPH'\:RAC4"H7#':4K2\WV&N[Q!4F'@HVO4^0TRJ5B
M4J$!-VJM0K5E$6QO'P<I[0-7Z2[93\9M[A# W2 LU'3&#8O)1EB2E4;"PDLO
MHSQA.H3EK:7V<2F6KJ"4;R:4Q>8]":=E7*<'$L@F\4]3@A5 <5)EEF8H5QW;
M"Z"ZK+:DU5*$<7I"2;R@7=:&2C"L%+8G+MD7'[F*0O <ID4]SUE*(%QJ2YXQ
M!YD9)1:<3R]?*J,;/TIQPW<,UIM"G_L05]O,J,W:J0NB-RN/:5.3U^DQ@%+1
MZU@>.P.@H,KC&H7B)S:GQ]N0C]$EU;!?6*-B:Q"4NFUNDZNH\E$P6 KYRH=1
M8#F,81K:D9S#@49_)24BG4SM<GHS?^6&\K3Z_0)-*$$D(4(M!Y1:G%Q"I4O0
M4T;&M6XA[3=(I+1&93SAAV;1=\JAZ#<8JDYI3ZS%VVFJNYZ07JM@C8F*:,9J
M%</+-)*JMETU$U3/5Q, ^LWD:NER+STE73.5GIX5/*J>2-5D5T)MN>56:EBP
M26F 3LK\2/#@9TF=VH<BA3F]7UD-6E>8,3DJ[@:$JUQJ%?T" >1^=-9U;\J:
M:UILX:*)LVTL]#\ARF(&(NY %C@94 /]5")@^3<%CH_/YBNV"EH)9M6CC69R
MI6:TW&MRT2NLQ4<-I"'LUWF7B*H']8*2CH!$2K*%&'U&X97"GM#?4HC7[<HP
M:L$&FJVJNYO<,OKC33TG#)VM9*Q"P-V>.$XTBC9JM(%36<%6 52*N)Q]R1@S
MZ3=772=$<N'V=P#PCBZ[#!)UK3; LV<M%6BCNYPR14GA13]H3A[I"%6_O/J;
M83W-..O&]DFDK#-B6EQ#)Q(3B5LJ]\-)J/&*+5X1VZN%)B9%R8AR_E.&"1EO
M6 " ZRWA.=,ICF>[2$5)Z['-ZLQ"+O;R!LKNYPQIF+,4T=[,3<9%U+-T44DD
M4I-TNZ*0%UU3GT2!4Q.ADBM:&H'TAJVB2LQMZN?V-Y;Z*XEG+11!V9S4+7(.
M)*-534(HS?+J+IB54YC#FU_K?/685^YY!'IQ6;6&&K;6,D*K&(5^OU9I'LSL
M_93=,F$%4XM!LFY*N1J,>W42 BJ)#E4>MN=*@DZ7MFEWETH64MPB^L^O,(R,
MODA(D-8Q)(HR",&R49-5P4:0SMF@YC4FCE%-4L.G)\Q9NX;P,#<:O&,0;RZ$
M:E7KY56E)L,0XC&TJC'R+(*PR(VCRN4U?V;R=2/_ !55%%#3&@/.>XA6Z35C
M-;74\G=M-;O&=E&YR&A%FH%)M=DFM7D$;A+.'B:D:FT%(5C)D]*(^W]0]I8X
M8P:RL YJTA$((7724X)E+4RPQ%GKLZ%7+<@K2]@:R5=C4E9!5H=X[CXQFP<*
M*L6C=NGG];L^,IRM?R_(T<)ID(>_:BVBF.4,RE&'J4JP979LUM25:<D*ZAW<
ML5](0SXA73%=NY*54,=L5_S5[,SF!55Q2<FE&NC:E7WE6K#IE',%HQ56M7:'
M&R 9O$MA!:6_.<$52!4IP5$3CD667/!&[Z@X37Y.K996XO1-9J[2MP,Q((2T
ME'+KU6^0KVQIN91N5QZI55\<BQCF(8HJ*>IEHBN33P76/O+C1VEC:[1NC"02
MMSVU:9=91Z)X_2FJ:D?-V/8K(K(1QBFCI!*3,W<H*MTD$DJDV)B\RFC2BP3>
M#!+9]U144BZM&Y?$UBO3KA+2R.+35JXTQ>L"QBY,[N/;+1*:I$0547.JREL^
M@]9S"_0E(&A5C4Z?T)N3C0JU$IH3,;'RC.8MN@6=K+VN"KEB?0L;+2K>0?QT
M$X_;&ZJ;!-)N3192<:2$--;.O!,M:DA?3%F;3M59-,^BK(QI]7LLT^I&9W6X
M5[)JS&N;5$Q:<V@SAT/:5*L +%):-;RE.>E H,5F;A.)MMXIT._J%;_F\::Q
MDH"G62"A)%YGZN@3BE>>K('>P2DLY,R51,H(_5ONT!FDTK*7^.O\;>(F?U36
MK52+:GI[NYN+N]L.=66\2M"EYF8::%,L ?+QIW;:+?'9(*)-0*D5:S5JL70\
MF[R#0<*D1GM5TFRHRV9Z63/F5B@I0D[9WYWRS:OY16XB.=',+F-BH9LW;G3*
M4PFK,(%"T"-?TY5BO7+I ;GL];T")7:UJ@4AXX87& O,;,,7<_1,RAX.160.
MFL\BD%&YS"5=;UFLM]IUC--+L*]!/W4#H=Y@D92IP5'O>8.Z<_C6,\6*4K=N
MS;2IF#G$B($6E6#A,%E15:M%4':493[S$O96>EY:>F8S5K^UEK%$V)[K#FR4
M>77"<,@>AV%IMEA9/(U%)$BS-RBF)@%JV,E>KW7,SD*Q:='T2$U6VR4!<;0P
M+)WF W>3Z,831V/[FI'D$NCS#@/9*D"!(DY8],A&J::9>9=PQ33+OE5-YPCX
M%DRRULXE;2C825*I4S.JZR6GK'8G;/\ ;#9Q2T(1R:0C)621;.':L<\CW+UT
MLKH#:U/-@F8[3IN8L-MC'&@@BT<R\S=.GM 4=LE6D*WD(TS"U];6ITT!%<H(
MF2COU_$'WK/')77?$(RZ'9.K1%C?*Z\C9:6(XYR=SDV9I(T9XFS?V];ENKA(
MD;@BS*G^61H@T*JF"!9-75>EW2SJ&;5ZSMI2\9_.QE[A:[GXY;FT?=(J=RJ3
MCIE+*:$!8Z),5)%202)ZILTNH=0YX?'J9=M'N=+K#.%BJD73IV-L\Y7(2$KD
M/ HPK6?:0D/(R+%RZC%I$WYQG2B#I\LBV,@P3:,FW^>SL(WE'\&O,0\G%(34
M4H"4I$+2#)=HG*1JH@()/X\ZP*HF'^RH0!^GU9&ZUY]6[7QE0^&5L\=6!Z>9
MJTK56V192WZ0D)X]O5ICNL5E#,973HQK&L"V<SRU.(T6J$@=R]-7-NA=&;P]
M)J%6PLDC1*TE>&>EV=W@6\O^@!AX)ZAL&?Y++N[^NFA!L36IDY:0#A49-)4C
ME-%5&5QRW[C;&O5MWFHNVN)S:+W:+8QB:]4KO62TS$KU8<AN458$X*=Q"BQM
M?NCVKSP.I.;DIB5*]=K/55%[+1Z]W4G4Y5S[$[%2%<W3J*M:))59*C:C!58;
M0TC]$>/B1^6Z!:8=A%OT'"JT]#1!%)A9:33 5;K3)_H&QP?.T5'M9&)D['K.
MNZ7!6J+MECZ=E%\0@\KL=Y<M%Z[36=UH;J3L5B64E5I.K,0CP,D50R$9JEVZ
MS/9K%#:/N4O'64FA[ZXF65$T7=^8M'A(^)A9JVO*U7',WGF)RU?GX2.3:UQ(
M9!([1$X+.3$YBBX?:-;Z0Y^BI'%Y_7'K[I35( \?.5=E@M4TXZ4C9],=S#N,
MM4O2[+;'T0]C)&'?1$JO"M"M'+D5 U#8,4W"E8_:[19*)9*#(-+#>J_;FT=2
M^8]?Q*>/-.JVP623<O[+J35!H\01=N86+6<O&JR3\R*!X*V&[DTMG)0QJ_((
M0*?3?4DA7$!KU-Y6KS"HKH*3K&)LL:$AG>E.'<S(Q)WLFM;VKIRT%=(Q6^2<
MA7_9:3:]XI=]D+5:-4N=IT&R(RD:8=;90;(M\DZV^MD^^:P%[CHR<%S#M&ED
M@DI2)!"-:R)%&O.Y>9.BX7$JMGN6:/3-.3@[]JF5M)RR6G-I6GUR8@J1GC.4
M@GK"O3SMM(QXNW*+N!49$,T.J(F*;GC;]?Z+@]GRC (_?8FD+6[7-@N>ELJ_
MJR=_BV-1&&M<8\K=HFH9H_@3/[:_DQG'"#,T<8AVS5H;ZW@AAS-1CI'R 9-V
M#FMF+=[K#3&++Y]@>)Y'*VI>C1]+?TW6+N^=Y_-@-9G52UQ^PFBJN79'1  F
M;CC+A/CCH!KLY[;:X-79)=LJWI>?SF@L*Y$FO5!J<VVG(O2/P8"2?Q+R,% (
MY\JU<E!= 0'-JYJ&U,=GREIN/-.I6.LW/I*]RTK4Y3-],Y[U2]6,KM]DC=+3
MJTT>YW96$/5G9XYLDM(,WZ:Z9P411G[USKT?9LMH)M6YO-&5-ALR<#%/,IK5
M*OH:ZNWKDCC6@0\!*+ZD_K+UZQ,F\5L\%%OF1'T89V @PH\+KJK_ #MW(K2E
MELK#J^PL]#:1U@NN=,+M6::K:<ALBC)=Q6:C,S4 [5D4R0(V12.2#U-BKJQ[
M%7:Y.^0[30+1,Q5VG-\A9#2*?6+;+A F3JTW8\C65K<I"YFW1:",>) <*K/C
M"83NU3*.J#U^OM\K2<[YW9TZ5LSY!)WC5UTR)K.""E=4[@YJ$'!VR1>RRMJ3
MC'5?=?N;XRL@I8V38[>*\M9*;Z?<T^9@=)=6)FP)JL+-5FQ/&UWP(DE,2[$N
M)23U3'[758;0'T723+E7AOW5FQ.[$"IJL\MB.H;-==DV2K=@X-I.PQM:ML/<
MKQ9\*@M@H,OH\#&2= J&:1\O68N1:R$\S@$F+MXXIS9.'<G=/%%2!GCQ6FN(
MMS/]X]W]$/;73U9*4I<%RIK>:NV)*7=9\&4-#1]HTK;GE3G$JV4SM07D0K(%
M!3\!99.TOH:[V)C0%-UMC^.E8K5<9DHL:JWOT=.Y_<&M E,@//0V,-,$:+U>
M8IJ3V1LDA>E"R:9BL_<?+<TQV[6S3*[!:K4(77]GHVN9-76MCS+.HRG9%)NY
MDNCT_,HG,HBYZWMU8LU?;YLO*#;*Q2[7^Y.FS1Y')@CM%&56/8N2;7=\C%E4
M8^Y8_!U:QY'":ARU:5X"+C)Z"=WUE<X^*JNIHWA&:57@K1%3<,S8E-Z%DVO\
M[<JR4[7J=AV<YA,<R0K*Y9/&5BGWVK83VCFEKHU,IMUKTNRA&%T=7C/V,N[D
M")$78@7\9VW_  !%/L9S9G#68Z?DM:8CS7!1DI@C-&-ST+C7$;6MG\PY;I4]
M2 >T)1XM H791K-IR9%T71FR?XC@T/9&=EJ\9>F3\[64HEEFN97M.E_QJADD
M"QD3NZ]2?W=I6W-OE;I,N03E E#MV#,A42B";1Q%383EPLYWD37X:STJQSW$
MD?*QD)(OGMFNDG4)2 @$H@-;A((J=<A7DB_>5\TJ8KIVU69B=RGSC1J[-S"+
M;/*75(>ST&V67EVXQAD*_)<H1[^#L5Q-#I7.5E9QD\UE\X>LY=?^Z;,RI.4E
MA9H*7=B>3M#*\S&./ZZSCF,SQK5)UEI\U2N@7<C9JK9Z6J)HUM7[]%4-C!*&
MD6ZHQ,H99XD9X1ZJSQR6FZKT9&TZ/[T2I^U14_&1M5ODED\#I&D4FG3@-<J]
M#A]@"VJIT]X9^"8/7]#24?2?N%.[5/Q/D?2C36OY^SRK:? 6$\K)UV=K\7S)
M"X!DT&6.UFW9E*2^872Y)]:,01H;]^[7NKZJ-WSMZGZUI-4-9U9%]>HE6X:_
MI%;R.AW4:M>X+<)F_P#><WH68Y#2TZUJ6LVEY:[WR]+R;9I/2]9K*5+0CVL>
M"_XI%3ML&KW)32(UT6.-3K+:+O/1.,UVLV?78^NJ-(V9>1=@GX"?JXSTVF#M
MHE#(KQC950J3I,[<#B36'L-5=+I=1V2<QNR1%XM[CE.U:C2ESO\ FVDZL%WS
MMI>IW'XI6IY-%6IQ!-J<<&,A847SR3;KJ.&!%9E:EM:M2]':Q.<J-8^ZUS!E
MJTZ4<%PRO3:L-)P<M;')Y]0+9?YZU(.T/P6+BJQS2#,JW?B19I<T:+(I6W4W
MG);*_I1$'E&GU+(*>QFNHGNDTRDUF2V?,(64?(2<C1V-LM9A!ZWB9,[MBTDA
MC$TTZ#6M4K\U6K?TYT)8+3<J18(O/[0UCZ!"9CRYDB\%B\(PTMW+MJ0AJ7\T
M! H0IU9]5H"5DG6R+9=V<\G;[]3JO2*Y)5ZA4O-(J_5+/7C>!TF,J$(NG7UM
M&E=>;M9HUT<LY-_*N+$_(H9HP<QD6N><7C@=9!,<CTZ*N$#+\H2&F7YQ(XXE
M(N7^O_XA8%#1]<BHJS:I07D)*N<LO-TL;6OKK?D+O:R@R4=)BJ8JC1*+Q4TQ
M(GO&<UB;=N.=:NG4FL'+4>4F6EUJAHCJ^1G96'MUB09L+<W>&2)0'2RPH/Y-
M $Q".PR&92<3#8';.&(KH-C5,I6GKSFK2^1G)FCZ35IRWWW6+I,6^9F:]HMQ
M&<CBD<R4'7&"3D[P%3)B[Z:RKF.D6AC6AQ4K7'[54J#$.5I5>Q5Z 5F+E :M
M-W:,81^PUJWDE(9K75D&9 B5T95,ZBZ93IYYGG)T_I\KG65Y5A5MJ\T^=25M
M:S^K5O2M*2U")UBP3VA1U]O,58<\>0"(U^6EUFBB"PN4S*+L_41CF&V\]S50
MQ.V-N@;Q-7<E4M+^*AG">CSK?)$%[G/7F=K=:1D*+&1Q21#!RY>G=/#J##,V
MQCNFIH:E<VM,^@5.BK5"K6#5.:K/YB</<Z-@]%I3XS5KT!"LY->/@+;>K"^?
M,G;T7#2KMC 1NB\()]!;H\MTQO+UBJUY>(8N\-TN0CINS1W.5MT^22B;&36Z
M]#O6^CZA#L:VB1F>5&LNW8M'WER*!ENAIV#Q*]-%WEGS:%>4C2>>M@E,IS#^
M6-(&A6"LX_,_XE5J T=)U0;<C9):VU]PXCIL6!54FR(-G*0WR$-R91H1Y46Z
M$>R<N.?-ZLA+ Z0R._W"&LT*K%Z5%5:1B]0T:HI5TK1K-/5Z>=RBK+^"O&/Y
M-DUF6H4V_P"BB=0WNE2]7LG.NBSBV1Y'*](S55K,NSR7.W\%==U@L^QU]%O$
MY2ONA&;;^IX)SBDX >@7NY\E)YM8JGE#Z^8;04ZS?JP%SN;*=TZ#/F,UH]M=
MN*W(2)UJK!J).V[2.]YK.%=$0,W(!QI!+-P[+1K6?PE]I=VLT/RYV!*-,XF4
M]G&DNCFILC'P=SO#NF41)R_?4]BDWL<VLQ,ZB5EH]PW4'IBJ[WG%UG6[XVF;
M7AIK?2;[0RG>J3[-FGC49=+>XE(2*IBKQ\W4K3%ZW;RL;&KJE5%\5JLHE):!
M+<L0Z<+7,ME;[,S5QY[ZMR.ONDXJI:I8- G2O;F@X<5>#Y^NE&AJ7+Q\DE^X
MW>2LS:5KYR1X(I.F&':'B.<0$ QHTSL%LO\ "K7JL/V65NK1H^99>LOG%W!2
MV5"ZZK;J&G8H^,EO08M,? L8?RDQ <2S ^=VO!Z$Z[7DZ9I4[3\NT-6;B\CJ
MF<]2R(9W?[9>Z7*U"+F$]%Q^FN7UFAR_R].Q5WCF;!PF8ZJBV],(C%K+L--S
MN[[#G$-DD)DVFP$8>I5QZO,X]>8*_$J+^"LEVMS-TDA*_P#=8[0L8""C5F"[
M@!+C'6#WFV%>[)HEHML)/4**AMZ6I;%G6V.LRU/=,(M]EL=L\0;=5\\B("NJ
M2L BU83MO8&=*K-BD_)UW5)B$N$_GU:N>F-J?S\KGD_7:+#$A>B$\3S5/0+N
MPY[LUQ<U&8SF;))NU8J3.J]G#L9!NJ+ KAJ.U]>36 URMV^GZ#:(#/<>E[!=
MV;W^3:MJS'+'%BU"4M-%H[JN2;Q)G)V J230L>2+%F07ACJ**ER4N;XI)1E:
MHMUU"D;W1)Y]98AG>+J9?H*I9IDM;MTGBKM9CL$Y)XS$RU;B"*,R39[8W:.E
M4$4BN%:%7['R5(8F;0;%E;-2V5JTWR6FZJE;M/Y!:.&3IM>>:C5X#1]0W^50
MG$Q274(O#.D6:R2B9WC: <7SD*K7P]BO$3&J(XA:KVF%<HS3G+&=>L,DBG;J
M4[=7>\6"W:3+1D'$- 9D.6K2J1UU3L5G'UT];-1>471[IF-KZ2OE&RW(IM6;
MTNQ9-0[=-MJ+$T*G+9[09ZYTIXR8(PL-:'3!!U-SGOM54/<0!9=EDYL)H%/K
M,?E$YJ%LT&-VJ?M)7B);,PKM7;YG!.,:KB%UA'3N0,SEI!S(10QDK'/FI$'/
MLD45E8R")72:T?DJU=OL;&]3619D:P@VK3T,-KE%1HTS$V/,ZO7:0YS6UVMW
M9(VPL;:Y J#/\Y1,$LSR?([%792@3M$Y/FY/+IB$IKA\^FMIZ=L&079-8/7_
M (T6$&^?I(OT&]482+N!7;?N<DW/%>\3ZG=!G,1L^''K-KD,VF:Y;I5:0E$M
M0HHC ;366?OUNN&D(3--,9OZXC-))BSG5XU=TT &HHG5_P R?)LE00>J-'*;
M-85") DZ.B<C9055&KTB?H6$H^H45@#^DA_[(U^TSW25HTR5J&9NZS-53&=Q
MLBMLL=FM_2,FO.2JT;9<)?#<ILN,69DHE86[R'&I!".48JON4E4&I%$9WM*+
M6SI",@4?P8W;]"+<9R0K>=6QK IO)Y?%B?MC-*[2D4A/O&!6+JSH1HR*J+=P
ML=J9"PN^LFI+[9:KAT#>9RL;I8(]VS2SW;.IK=.QU6&WX7=ZJV:O*9K%(*_=
MC" ^GD*PYBU5$$CMW7U':_QYI$!F<^;,<ZR^SR[:T15&ODS68;;#WZT0D%;)
MC(M9CX%LI&+D7*HY8R*;@B+E@#=#\T[H"A5^CIHKR8UZ@3MYD'O4\].GFZ=5
M[ST/.S!:\IH. :"G6*]8OYRK3N2@D&J;N29'5C@DVP1S597"LVI^R3=QZ593
MD1*](6J1U>*K=LLK:8KEO6LD1EFNKY+*QE>B:GJ,K"O6";NLBJ^K$2M&**D5
M<"L;>:9K'1MDO_9U]G;7*UFX4N[P%'J\'%PEU]_/J[F$G&9I6B9Q'V*A1K9O
M+?E,I%R1^Z<F%T8HD,2][5(;M2@U)H3H#.LUL%=O-&A+/4\<UO>>7;F-<RB4
MD^=;!6JBP4SC()0K UHC;.^C94QB']:;HBZ&GP;G7MSID/F\GHZ,@-A9T>G4
MZVVJF%VZ&S&.KMBNO(C,LM!7>Q1M!</CUI1:'<5O\R2,L@[>FCE8B>T+JYK(
M-ZNX=MT:TA9\J79WME7TYV7ISBU,1PI0T2>RRI(>/L*#6:5<"U2>"W?>%@$:
M-8>,MWJ5)RJ4K$5%:=6+\A!K%K<Q&6&0KCF?HC<]%G)"0DIVBZA(3RX/WAFI
M)K/(-HFB1"4D% DVF?N*9/5.FS'1EIPMH>S8XQO&6-]QOR%AG*IFUIG,A>M*
MK-N::629Q3F12F(]G+R_J?&<,4BIH:C:=VN"TMCNP0UDO=IK#N;RZ;;16[GK
MW-T!"6"KGIM%J,\S)88^NW,T\D<P0XR!&RC!FT0.0HS;:+EX%TRATKR^2SC)
MG?,U,=6=W>=#D+=:9ZCR]GS)2#C=<>M7S]Q&N)\R=>"3D"'?-UA,LHAK2N*Y
MS47DGO&BI:O8IZYV_*G\6VO9<+YJHUBLMO;L9.#_ &I>X7&LV)TO'UJ*%B#E
MLNX3(W(X;)JZL3.*A>*=!:'>]RVQ!'3&G&NBWN4N-XM4X]>HW5[$;%7JW79]
MRT"#-665<:+P!&Y)(S\J!TVC5S\>"N-YZFXL<S)T-YW7%?O>*RZ-<8-D<P<W
MZ#>35E/4&;U-VQ6M:23^IH(*_N:#7V4 05* 7*5YOE4U<86T'G6O5.!CZ1AE
MJEFM$L%?MI]JN;9&\W2D33Q[6M'B*ZTD22$@W3;5.:DW<6WD)%JW22N-9JL;
M(P$+L-R8:#HVI2\9@N@.):<O75CR OVA6JRR^O I"WK.N64H]>"KD+4W<(]9
M)(E64&0:J-5SR+Z(JK@8G0YA(]?L.>X)5V4^P_G:K5A2%3D(C:K#+*9-#5]_
M)SD18"!'V::9,O#I@Q<"BU<TQ3HJ@V*J<YR=2G)!8MPIG.D3>FKU7^;@;L]5
M=YCNEI6K=VB9AI#HQ+:LQ<Q$2\(Z4=R*T6^(=H2>J6GU>9G>8UMTUUS#W:P1
M^)H-D<7D+1T>^KA%WU9MK*](25=;,LP:51!*'7.[B)&8-,&_+03.AK.KXSG>
MC7!"K6N1H5.B+DAF!,,OF#7=?&W50BZPX::E%V1A-9]<&=HEYB7>0C>7(V=G
M9@X<M4FB)1OT)0[9*]?_ .):Q65.M.2Y)3;>\S'_ !"70]B4HM;W?3,]A)O^
M12B1J])/._R' (+N63!-=<6E(L&G\_7F(@:W(:"RE*G4;"SHC>.B+C<Z)!6&
MF28YYO ):5$URFUYI.5.T).49 )![*('*#= Q7$38U,RT*N3["]1D*YG$LGR
M\J4155]@S<NAU*O5.-W^TPVA92[AHM<\;9I9.NVQU#%562*Q,5;\IQ=KMSC(
M.9^HQK9>M9>ZI4;1J_=I^#@>O91:TJ3<'J,=*QSU=9#-8XL%,$5B99PZ$GH;
M' 9%O'U[>:0X;<V/(>QMV,_*\]-LQL3H45M!=UBU6&8:;;>"5N9<,8"$;.84
MT8 "O*F.!TP I$]9K53P1C'9Q4-JO#B@3+[GQ],-[UD%/DKFQK-7"=2W-FT:
MR.DL8Z%=)3J'Y9FJ;]5069%?5',^_=4UG/M%;;ZXB86TX3FUKS-Q!U"(N+##
M&<>;.,VJJFJST?=:S!ZA$*I+RS.6C"6/WRNQ1057$HL9QYS;2"##2C&+F*5(
M<V:;%R%N0@I? H>PR<3=9'>X0D(A;FM]N$C&JGKRI&J-7]*B)O<-XKECEN3J
MG9 5SF2D;-4V'.]^K]D=WV<B]O=,:^QCICHQVFR0S"0I%;:/P<*?C6TTV4S%
MVP1706 *S#95(:95Z>\NDJRG]FYCVT^H:BF[U?:[ G#N9N3WEDO36AZ>SK4?
M"E<L9(T4PDD2',^.S4]ZZN0Y=JR!HU>3:Q-:8<J;S^]M).=?SE<B8&/N\OKI
M:I=&>>R9&;YS9&D86(GV:1U$D&S55)T;F1##\W8:<E;,VBK/M1YO"M+:*'GC
MZAS73',4R=L;S'(8Y,O:;IMOL)HR;;RSADVK"Q3B8$%Q%H6J<D0%4:MUZ?'2
M2M_YMWID#V6DZ/FDC<?VT)C6:2H6#JMYLT]'@_, HNV\(11 5"JF.6)B[)S;
M:;_*VOHB7>W.>T[!NES3..UC4M7W"SPF91T?"#)O;_7T:-&5N+K<ZR*R@::G
M(LT;*L0@JN4:A1NO.=39=0[=SW6M#5M]1PK?HW^3MHMNDP]-8XO<'LT\MT6Q
M=1,9)F<+/T_6R.DBL\<KQS='T+8-7^;IS1ZY:[GUIB-,N<UFR<TD[C\NL+BP
M-;>ZM4] 4N^R%-I")@:FD)G\#VV/A,5%4B&,;ZTN'I\#N=SQ:-Y:WGEK-+E#
MYF_O&@R?:&-X8?4JKU',,&>7MG!(:V:##2](BWI8LM>EK$S8KMTCI/T2)[YG
M$C-=7K=)4[I^MW6I3\?A=@DY)IR;2-6YJ-HOIG4,J<U&Q0TSFTY9R))L4W\Z
M^]#X[0/<:'%'"M.S&X],.>6I*Q6^U;>Z3RZ4=0=3PNP]?2><T"PQN0OL#/HE
MX_?: U78C^#-Q4U5H%=K;3-9)FV.DYZ4NKVPZ%L?5+7#82]5"J;'!6.$5?[.
MKF%L<5NNV%M+<S<[HP,M,6^):1KZ&:S-N(UCVS-4'K,' $4QRF8%K^[W.EZ0
M]PB$L^EZ9ET?CDM7MUM&$]92VV9DO-NN4K9%5*K4JUT2A2*X+UYXWA['(DA%
MY!-)^9%'ERX8KL,\*SG6J-S7JL,_SF!M"%T1Z-5ALCAN@IW]AILB^K\QSG:G
MI;N=DP)&U^6:HO&#X4$#H+-M5SR@:GLSW?\ .]%[#J%JS9' 8&52J?)V)91=
M++SSU?#RZV3KQ-CT35[#5*D98R:[V'L;Z[249&0;=1D@6.8V7DK8;U:,"FY_
M2[:-C6PIG:XRL8OC]8X:0OFB1]:4QAO?=/KE,F+WICB0@6#^.GII9D\3C7Q3
MQ)&OUFS[F>F3^@R#2.?],:^ZKU<A+"JTY0QAW6)K3XR*BK//5<'MNT]I8FL-
M$HQIWL^@19T[91[I5KZ Z'V'+.E9]YT-3]VE*C2>))'':M#5!7(I#JO'J1B%
MA/=IS*YRXU1GIN#6]M+N;A(/)"&=!;%E&S5!2&$C=A=LJD+?I=D@>=-]?],9
MNRQ*IU_7^>-ZB=JKU+AG<)4Y$TS"3<%S98;22 LD2NZF_P"9*6W&QQKM\Y0,
M>04EZO-)VC18#.^RM1Z2P&/RYBJEST_Y;V2!#,LOJ,\YK<=/O7G0N<14E7([
M^8#NG]A6D"VF'_$9-19&I-X[$DJ]S[G#?L>G\ZV5]>Z_5(1>PTYYF/2O1#B]
M2LD+-G"5&)G<LG<CAE%FQU"-;!'32!50.OZB[JK5^D\ZKV95[IS&Z10@G(2A
M?S$G@6KS'%[J?O@4.:JD7<X9AGU)V>W2!;7-/740JHT19.(\KIN8RFG/7NIU
MQE7<RJ?0-AYQO\;FE:B%/D,4R+;F%.34IZ5Z.UJ;$T+55TF)HNN*MG5S>NS2
MT,Y;1I"E^HCG>YYI1)N.==/= 5+4-6N]#93>1V? HFH]2VOFR'K<!.,7=5M&
MDO+?@CN/L0 <4X\M(=/A0 DU'>EMU-18/GG4+'I/-]LVOK1+*ZWE+S9XE6DX
M/S"6KZ<D_P N?K)Z@KB]GU*6E):D6#V;3$4%%5 #J/6S-.0VZF7W;LLN>>97
M5\?L9Z35<G2@IQJ;>ZK/V^%CG=V0T2>$5*,A!III*F8"$TR=@N8J!O0(Z+3K
MIU3S_5:+ =V6'B>2U-_S^E$-,Y) \W5?HN*O;YT[U^3K[.QWF;D5:<SCYLA(
MM$SE)Q^4H\!!J[Y&Z592.<472=IW^CY'9)=Q"0)Z7>*C,VG1Z>WTC,V6M:1E
M%<@HO4H.IL+G7_WFQILV\._(B=XX()79LRC+S8LCI50TK/L-MIJ(C#T]O,1]
MMT/E]GJ5ER>%<3N]P^SNK@A;U'$PR?!09."-6&BJ(NSJBD^-W_6T5<!9P.!4
MK?YC 'EVJ<C"-KO<,30Y]E H478D]P4::I<VL?J4K_-D,LTH[N"9C#R+,TDU
M<//QDZ,RW?EO)!I,'GMAD(;2JQ6I>S;.&A[AI%%>PD(MFW35UI-?4I-/H[9@
M1S 35G!W;I1$'1&;<GX2^"O8*>Y6;:]O!]9;5FF6#.C-(EY,53FR[Z?15H\U
M%Z\TB;1H%HT&MD9&?S2,#.ILV<DFK$HJHI*GP"8B*%E5=HW0%@U*$K[U]6DY
M.5JZ."9E@K+;IJSM;9T/BL0WJ^?=*6Z\04FX:/'LHUBJZD=&,>.14]Q&+L$;
MR_:#7:#[-I#JQY'%S$=ME%@N,.NIG'*.K?7$C<;PG-Y-J$78E)2/4$T.+*P+
M+IH-W2*YU6_:V39Q3JE4F>#X]:MDYZTC3J==Y:F] Q'/#Z2KW6L7!/(JSTZ&
ML2M&N;N$BF#F$E'2;$7RJLD0JJ0M/IQODQE7,$FU<0SGL^]9E$P>D0.7SR,L
MHIT57B1E>1N+AZA<WNGK13Z<,Y?.8=^Z*^<BV4%R"'ULU ?8I3K7*Y[=]#S:
MPWY*%M+'%9EM7OCRN_701S>=2T)K<(VZS=@@VT8HP.V(W9PZBJJ;]=R"8A P
M<;0(K)JG37S:"H67H5V=K-EIU0>5>MV5L6ZM;)J6ORTU,6.9G7TNSFU9<5)V
M'?,WRJ*:ZZWJ_P R=I+,B229VZOJ8'(V4*\\$$Q6WH>&*T$5C !0]P0)Y'^(
M0#[_ %R)T0AFEJT:UP^/7EAL>#56QX]2JIF&B-.><YRRH(, E=15JUELFD6&
MO/%K7;HUV[.^.@S6.Q2!(0/T%=IS*BV;'NFG.1R5TQFIZ] LIVK43E;J"E_M
M>5(K6C0!J+F4ZJY:D;,K._LP,HE=XBWBY(Z N57 0N^4_F":K'/_ .%A,A3:
M':'&:62:SB[J;KT7==@L=-5/OD4KSS ,HV\UV>>14#&S;>711-#D9 8#D3Z_
MEL>Q748.YZ'J?:%PB])B]IJ5=J>DXEIG&,?FF;8X6JI:J*TU-V?IE!K98W]R
M9P"-4,Q<O0>M'+HZ;JC6JE\N:5$T^-K.TUR9@Y)[7*=FDXQN=1W-\&JYG%P'
M5.B/,*TN!D[G%U9>L33B6K.A)/DY5-C7G$61RSJF6Z+S'H-HTJ1@GRLQI3W1
M5'416^=XOXYG>-Q&+5"X1NZ13*J:^WWIT,4M&/TI"$?34DO<"+.#)?F-.C,*
MCYJUNM!T*1QJ$IG6J=]CXH\YFG.>+K6*CV&T1(O'SZJ:]HUUCH&DVYK&-CQL
MJ]2F9E-RT:NVR!-@W^J<\]"4C=-)X^Q>\.J0TWRZ/5*[U!==:49[+2(:&A]]
MC:3(R-*RN)%FHWCW;*%&-,C^ N1ROZR1\AB62]#5*X0618I7N:]3B+9/YMDN
M-Z?'=J= V[5K[?,SU#J;4I:1IZ?/5DADG];F5;1_,+(Q(]FV:@**+'OK=JG'
MZJQI2<]R;'T2'IMWTZO7G1\>1@\?9=F0V'MZSL3"BE<V['XZS0B#1Q6&=C/;
M 0>1<LV<@@K]8OJV*Y=V%6.;,RU"_:C3J<MI&BPVQTS#U=UX\E6E/KN9RFP5
MH):W3J,)ISZ+I]^932,?0Y9['%;,7ZD<S1WG1\CJ/5DWHUYX=Z0M%6DJ)M^^
MPU0:]'1D;E%*Q.NP-4A-@K=0JMH-7?WE5O%MXULTD%#NW3A3\PJ9QF[%=*MO
MUMQ-WT9(6JPIXO(]405=F:E5N"<5@:I'TFH9]T3!WJ!<O-6&Q,&#D9-&LC;S
M'?22?H34,=MN%:J74SGF2%QW!(NU1&=R>F31I*UV*J]9Q-P@(7+8N]!E<^S_
M "I*C!;Y@C!Y.PCQI$+QJGH)(N4L(JG5%<^2).DS&<R*>XN\>LW:,U?4>D)#
M%LCA<M<S\K,Z/:M=:C$RJU\&:=5%PAEY[8M$NWY031!5'J2&E'7>[R<E.I8>
M)H-I_F7K#\W_ &?H7M#G&3G;0V=O[5$\YMXF1QF(F3QS.E17[JXC%)M-Q[<>
MNFV-ENA7W4^ZRL+[UMS[4&.%5C<.LXW0L[S"0ZKOD)T-JNE2R-VC[C"5BYX$
M^B$THY14(2K1<2$BT,F_DE3%EJ35YCJ>0;5+/^,XGB2P9V\UFTT6S6: U1W&
M=)N.N+#$@M1IJ=F:NDQ&==7,Z;=6H&7<PY@FA<&^H>\RULZE3T?0-QPN2VR/
MFK-MEWZ7J7+L+LL%#;4XI-/T$MAM%%UF2S3]P7>LJTV$5(A('$4D:5%%51!^
MSM'847S]4*CN]VH4_I5LZ,H4Y(Y1!= N9C(8MS4FIDCZ'NTQ"GDX>/C-#3/+
MO<\"+>/VII#P/UQH&GW/K>5AM"YUI=^U>/>6WM*Y-JIHR>B<ML9.(LDO7LZM
M%LB=NG:"QN:S^I6APRI;:1=NA2_&:$4$'[>?DNVTKS*S>1:%!U"2IFP.W-RH
M$?D6YQ^AQ4#NL9EDM9\8VN[Z0E%&CZ?8H!_5XVP0$(B[%:"L[E^G=I+GO0-O
MS+.\\XHHNBRZ,>%P=U&QW=2;Z+;Z)G-!JM?I4_6- WRR5U"K(-2LY=B[KRI6
MC]L5T<_XZU.C5D>THS4:_:>JOR(56HVO4).%SJ0PG&I?-)Q.Z369P5=W>P@S
M=6BRU-K.M&CF.N3P:JY8N'L6FV5B(?F?0^S)WFJNZUI$S6M0_P ,[-H.AM<:
MC*[PY-V&:LL+HV43MOWV)I5NM^H(5^$4<1D]8V:#]LP=.S0[-(REUY:V#HZ4
MF[3S!TIK6:Y-'5RN.<2#:\@KN#JX;GE@7?98NZB6.GKO;.JZBYF;;/IEPX<)
M-UF_XB ->QH2-UKJ!YB]4Q_"M"QG6M K#F&V9;:#4Z\6[=J)!-K]EJ,M-5-T
M:%JRCIJG&G)%OYN2B(S\46X(,JQ(35QWR\4>5R7XA]/LUCNU)2B;+4;MNV\3
M;?KB@5ZHU/F=9.XQS&@ @G9(R1?1<K2HE0C@[Q)0"B7J"^6BS[5%= 0&/8G.
M4M^G"V-U)M](L,A)$GV\97[!RI2VE-LCRSJ?M$S7FK2[,HB-9MWA% !P<5>B
M(ZW7_<L@BZG*=G2F3HXYFLAL\5)[GGM+YH=\Y8K#7:2P6OO[MG4LI9[3(,(Y
M6";*VY^=VR"54"**F.RJ1LYN$%U+6G76%UGJ%'9"PLD/GS <-H=AQ&N4)^;+
M)Z$M%&B]*L+-K!N16GGD@\=R#5PN[%DX19W6+17T67[_ +3LFH\NYNQN.61+
M2S9?IEJNUH3SF1ML@UK=!QW3:_D&2'1GPO3%K$TNX(QB:A/;.[,A]1+.KUS9
M:3F=[SWX\X/2"-,XBX_3N5NB+?KUR@.B9DCJPT$86Q<[R%?RB9A+0_<(2BL*
MZD(J:CEF\:^.*6T6#_&G8]<0'XZ#;)(V.Y8Q3:VZPOKQE'W!H3.*),5C)Z%#
M6*5DHZ/)*2-5E6$_(0CMB@*JQ4)$C8^L5[)9B]=+6R;:XG<><=*?9!7JH]L;
MBAX7*;[VAFYGD74LQS&RUZN)Y\TK;&5;HIO6$[H9(P!D'\0= ="V^/Z:W>ZX
M /%./]E9%S2AE&6L8JU6O<;CI615+GI=9+&3ZRBN:Q%J J"M/-Y6-G'QE7RJ
M,<HH@G+6:SZ#&XQVKAW1K3F_I"4;,:/5!?3=!T 'EM-3+1=:KK6%95)[)BZ;
M26KLS9DW=2;/)9!@J_176263T[6JWTO:X[#:I:.,J'>IG5LMYVS&?H%EVBI<
M/S$]&U2J3U)F)NB6MTZUJ\N;0%P3L$!7V?XY&CH%8Y7W+LULG<\-DMERJOU&
MPT6J/,ZPJUN.G\=4PR5OVC;<TLL74G-8M+F'T1_(UQE+TE2.J3!WGZRCYBL2
M4%$FPZ4KU7*1E+S%?X_J.ZDX[*N:9.K'T7HVB<1R>E0+6*&EGO[6;8VC8;8L
MJZ45?Q#5E_J2147;,%DXIC>.WG5"C'?4*F?W:^W.H\C+-:!F+0.U?;E'<% T
MJ.D,T9N_\(Z804;RV;2\@9R9PP4!NN</KX_MXN6/OK)":C [(?J7/:=GEJ:V
MQ_4HJS53/,;W?+ZH*-EMM=97&T6> F1K[U1P9"LVA8ZZONQGN#R*&ES%0O\
M7G>@3E3[GUK.*>WC:-G,KNVM:QBO+-7I(R,J5S&Q]9OE68#-2;M)VJ:%,W>.
MTTOSR>GOB;UO6<[D9KB6D;7D$?)5VCUI!/2MKJ<!.[?6M^EX9FZ=#4JNTR"X
M4R%+5_<$JLZSG5%E#)@T'ZYZJ^E:SF]2LMTM^U-;XI-9[F-3UF"I]=P7!-*R
MZ9T"GWO7*-ET$VN=KOL](P3N!EGJ5FHAHH6I1G?SD$:@CJ.A9-$YT?LY+(='
MMK"KQC/+H3&K+@'46ET"R5[65KRL6(/:+7F%9C5&MMC8"SU^4,\C9*.,9[&N
M#Z=6M7WS%,PWZ7E<=9XQ&2.;)(S;9E+<\4+H72';O+'F@,)F;*]J\G,'CW#A
MPS:1B:*1UQ<"F=-7B+I"VWW*YVY=3:1APV&17S%U78*I9YL.7S-ZF*XV@$=.
M5(^ME-?1"J:,D:1;MU42 5=KZBG4-V/N%VS:BY_KO,?+&!Z$QK3F'EW65W;3
M-7K%PM;:]YW>9*X0[>_8AH<"G .(%,7,<\BGRSZ,D'9UVQU28K4=*M.-9\K.
MO.B&&O)3%2KT';,I-CG6&:974E=OHUIZ3A'>42-OR"\G<R,;$OK<X92*K.5:
M&=Q1U4 _F:P/,<GJJCE.J[!78NJ4M@B34F5-ZGZ9RG-J+7IZ;Z*:6D9W>\ZQ
MV":U>1KM9MS=:T3/Y"S4D<LW1^LSOM6Z&^/K3JEJ=ZXIS-@]HU T:=E:I=>N
M+U!U-^ZL3)ET*6,_DNM,987U>_UM*3FT_P"%P5M[7K<=$DD(KGQ]8^78[5[H
MJA&U.[-HGI]'.>M+US4OAV.-W&H/Y. T]I'YR9XY>^[/J$F+;"-QB"(E,+[0
MZAI^85A\^Q++NV-?>1.>T^RNI+H2G<[[,RS+*;5A;J2N$K'P,U,.T)B!LU?>
M_NK]C9F*!VS@(Z0:JGQ"IUZL\\:I,[]4N;=,JLUDN<Z#J$33VW1&?=,V%;&W
M-5C=BAW=VTZJ2^,QR[=ZWE8D\S N91Q^T-3M" IS)E4'FO/ULD^I:BURZL3D
M)!VMI"TGK6(4B;GJ<S:VKRYQ+UYSLI@\-:YZ.(U MA&0K"4>NLJI)-1)S_88
M^C\^)4[JIC%WBOIC(V9.S<\42-["P3F&6KW0:R5@_#?VB7K^VB]82B*,&PB[
M+#NH-5F\3)^XC \M+YGS;;LIT;5(NI3UJ3-884)V$M&W]89#'S$C:99U,YL2
MU0,5S"BJVBY(PNKO).5F$*!#MP$O03MMBO/]QRK#]KT?F*L9[H,NO_B,ZT[-
M>7)7>FVF2=+58GAVF3E<,#18,&J8205Q4; 1V5L'X1B34KS5@$C.0G+=^ZF:
M6@,4W[/+W'TB!C=_KT#&V2?M52ET<@;V!OBOLM)>:>I0TXRD&C>.75(_053Y
M-L&I\B\S7%+JR75T%U5Y*IZ/#_@SMEL'(M"*M*ET_$F<?4+-/CT<X,2Z6D8V
MK2K*$8IIR8_NS4$[)M-&YPP"<L6"0AY+-(6:I=9K4)6SR]J8A--X&9AZI*OZ
M:F[=RB[M48]N45GG\2@>HYCA6=IL/%F'9GC8]W="\Y1%BS7,D'^UTR!P&C=,
MP^C[A(0%7I[5FT(1?"!4<KQ#Y^JE4WKT%B^XS$B]TV6TY?6;]EW+ETK\5=[)
M;,$@[#%X+<[WH#J!MZLJ$[$.D\_E<\FXY.;O:P?C+5^*7;2KX0;JIK?5U1S/
MG>?96:^V6B/'$+AG.I:9=)IK=C<NMV<_L;R5C:-%EF4[!V75%R^7C]8S.9 X
M>5P<I$H.15JA)2<S>).S9)5Z>?G)T9LRJFGOZ631WTFS3K2\?7,>M%LOL*QL
MKMQ[4:]E7A =D5!-55.M\GXEA1-SD;+L<!S(RS*T9Y,U?!"UZ//ME<>V']P+
M0;=!R&/U"X<T6>K*.F40[8,).',8Y"LDB+GZ;A[AR0I#M*)-Z2K*:;?N:WT[
M 7[=L[8]49#IJ>D2=)SS07E=6<YQSE/-HV6D!=S4_5EGC8K(B3<[9?16?(50
MJ%)IF>ZQ8<[O<)2<H4Q^%2U&NQ,!_,(DKBU7J"DDHC&NV*)9$6GI<))$*4YB
M)E /\RGAKA$CV$(:4&"(NJD@B>9_!7_:R++KMW:"*1GWH QSI*$*'W$A@^PU
M_P#G>YTRC6R+K;-O,%K2G,TO$V6SE?ZM+/WS]21SF:681JC#^4HI,&0(& P.
MG'M%]1_;=R)[+7F;4-.GY=M7RH\X.*)_(9M0SQO6ZLD^&MFT5U!DR=[..7*R
MJS2;"2:*I X-Y8G<6:::Z"M"):-JB-_T9BQEN=+U)O9:6SO!*':7E<+?(-2
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M0L[&WVQ_0H!I.7,["?T%5M7I1^W4/$P[QRX?KF*V:+(EIM)G.(M#W.QHG;L
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MMM*>:FPO=:IC[,&5\8<EK55Q9W]5M*%G@$%U&YIUNU?QS8A9IDJQ-JF9:?\
M(1\DF>1.=6GHBLQ&COZ3\;]FK&CS?-N-4_=-$@*_'P7+BMOKKQ7/[PS=Q!I%
MBDWD'2*[ %4W/XZ;G&;%3.]?DB2P[7^>YOI5MO\ ,0/Q.LZG1<WH[>G-]7-H
M=;?X4G=XV2QFS7%"#GTT&CAV:5;O?QD'#9M[Y\P[;B_EG[TFZ'J4=9G]#H"V
M,_'0&E/9>C05VL&DUN0C0YF"O0DKFU9SNPO; LM*D91S.)<F.N/\!5'MMU+Y
M9>P^?*LE<7.>1<UJV+\'/9"8T2FYRCH^W4O]II?+,^M#EPIL<\58)AT<L,:5
M073:N5B%245 I_GGW6.]Z)0F6\A-<V\H1S1G&##6>=</9%S*\=LFB";5K3Y)
M!T#A1(S*19*,%@(]$K<8.&_Y?K=HJ6GXN)L$1!6'G7C)S+_RY8*]&7.$FWSQ
M+E5XS2AW5.GXZ3.[67*DU92+4[DR(KIE'8:AG/RM=L1Q<9D(UFI/V;GC@9HR
MO5?D[SJ-$B+M5A9\^K3B43)6G%Y]L"<LU8/!2;E/[(I*D.+!VW^77IXGXBZ:
MJS=SS_Q.Y:O$DB+ 1%1$O/S<G@ZB@>X)@.!RE\> -X.4D:O\NNGR14QBU"GL
M/&7&$VF+F+<D>)O#-SYHU3,[_*234(<1]21TRF*/J #  G^8*_. #\?R5;B;
MD< ."!Q.<#BA5D3?ZV ^E7TB4?2'\'H'[_13N/EOM3HB1GGH2-Q+R\B15-RF
M8B/Y9DHXIUEH\Q_6B9,42B8I?=(H & RHLOE:,IZT%2IEG.&<%?D2<'<%424
M],/8:X)VR+8QD_;$?68P$,*G\)RJD!I\LM9%/W/6H$E\?&0NU?2<2&.BW.PU
M6'321(;UE2]9%3D3$H&,H8HG,@Y0^7R)CVR;)9NLP:?'MAQD5G1TB@D^,H]T
M-ZX Z2R1!]L#@02'5#]3)F2:N0^7&JN$VOM&.P=_'?D8LWYDR&*<K\S/76;T
M47!A Q@161.40_@,4!'Z9JI_+G146S98AEFR?QSY7X?HE9)HG3='5V=8Y3*/
M .J(HF1\ (%#P ?<S,WR:X:X,471$95?X\(LLL=-RW5*FHZ*WZ@0AS.(]RMZ
MD?;:)IB5),%2J_WGN*R:_P G. R;$R!D$JZ\^.MBC%$$&1D4GGY4?U(SG1>"
M\$%C@+L4!\"4$P*/@#IH?)KS;'JJLY5 SA'X[BN10</9(J\<]9).>I1(1>(C
MFY42%7_(25]]852*&!(Z:(-/DQYI?)IL'4><);X\A(X766<L5$)Y9>,Z@:(C
M*-&R"Q"(IHI,S>\(G3,(%,16>5^0CG:Q-R+P462#JOQQ34O)J/9BTQ4,WD 8
MM^JE'A8IJVDC+2J_NB1DR1.X  *B<3H,S]U\/+2B[E#]PF%.&M%*=DS%=/\
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MNR#L&OE4['H7IN*;J.TR_<J2+GF65420<F'^'RH84@#[B?S]EU#X-\<B;A-
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M]&@JS4LQIE=@HG0:R@@VKEY8143#-&3:WP+9JDFSDBD!XV32(5-0I2% %X"
MY[Q:"@W4S1;$XAX;,Z=%QB\_E\VI9<WFE6+&'0;'E:#8E3/H9<2^[&NS"JW,
MF?\ B^IAW<^<<8M+R?D;M+S+V=SRL2+V1EM'<U9]>Y5R\<QQW)Y*U/Z-"N'B
M_K!55S$,U1-[C9$Q",H_G7'FK-.7R6>*T3H5=%K^\X-!I5K%I(6YV)DC.\M@
M42M8,P@/[>F ^UZ1$1&\0=:Y0P^&A-)J\W2+W"LJ'#$B+/3;&I559FK2<69
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M3Y&.1P*(F#PKLU20/_ 82CY26?)J  B7["(>#!]P\@(#]?\ JC/(?_EKIO\
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MM,U4;"\(N'3V+"F9J!1,*X&_G3Q[?I*(^?\ >^E%%^\>-DB)!ZE#'Z:Q< (
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M+$YP])CC'M!,8/ !X,;V?(AX* ??^@/HXC"1 BI_VP1C6?E3[E'^,?9\F^Y
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M+E,==SW/[2"K&B7-B2FW2.NL14IE=I*PT@])!SH($<D>MU!,.89?B7,7+[W
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M*8J0HE9D\)4:/\ W;$,F;QX]WU (^/3X$J37YHOEM103)&IH(_X]5U4B)(=
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M1H"!L#Q+HC@!LZU'EW)[K%3&ZVU[A]PK.DZJC+P+R8T+/7<;:)>V6NQ]'W.
M1N[YQ9(J$6C98A%'AQD$DS?6&<S0N0EP3>,\^.N^0%FE4[1G]?7MG8$70@PS
M-J'?;11)>8<3T,EF%MNS=E8$GJJ$4C84'*#E!TAZ$[==<+Y#N//]0<Y-P'B]
MKQV./AZEGT"4QCL7)MIM=QC:5(W><R.88\MXI2Y> @)27*J_L9IE:-:)+1R:
M8J\+5K4^'+WKL3R7KGR3!M+^OL,2M%*VAMTHC8W=6U/,Z;:-)CH2K4?<;#=A
M=KU$Z$<WIYR.&:K=)@U0<.**^V?"=+T)E3>-^>ZE&TJ'A>:M3S^;N%>['Z6V
MNO<LV32=.;S]BK5>YTS#7:K#M[="&BT&A81<S%T](T9ME9#8=!PR4;91K$IW
MS3:4^BZG2:7:>>5]$[2MW0,&KIR=9=%E]7S#H//U81]7I5\L_=4B8CG469NS
M))G.*.A8_0;/7\BTSY=WVQ[OC>@MD8P]-)G&^)6?+.W,'JU@>+5Z-;3-;C/Q
M+5&)%1"QQSAI)@V_<6:WO_'X[EN3->B]VX:B.HK#W+LL!$P1IWJ-M(Y9I$2X
MK&>W%.SLG/2MBZFV^8K][8LWSC\2.=1('EEXV12004A,'YO6F<J)4\YE>G76
MA6-A=8V*D-LHCUH\YKS>)GJ!86"RUOINFQY;7)1CD'T:J,3'$70=(K'('#G4
MY>8MCJ5\M2/'=CV3)-JPE[9<]JD0PCK?(WZ\4C;CL(.V<E[5S+-VV>9R-?D)
M5&*T5@+8A8AZH[*J;Y*F%-Y'VV_[3MO._$F>\A;?4,QLM2@Z'T;1W?0#A/9(
M?I\S6!@\U:84]OE7E)R11FT7+U@Q4C$$)!1-5E]=^VB?YFZ.T"6O.X[PRJ#'
M.>,ARO0[56;GQ#D>'Z)T/C/8MXK=;3SEVK<X2ZG80#)P^6M4G+$7;1KLKD'(
MX#9-WYMMVS<4TSICIYI=W6<<9:'0'NT7.TX=SI6N=>R^@.!(:LNY<7U>>5FY
MTIXYB*@G%_O9VUJ;P[%)V+Q++M0YNXSUJBX!F4?\=EZ84:#S-[%;=$Y9E^Z]
M,6+6(3'M#?34I$5.UUIQJ5&=6RBN7*4O8<X7>P#4&ZD4HT:0Y93 ]7K&>37<
M7S16IU/O^0-!VF.BLIU>AQC+#)=UE,7'0DZ6'T"=(16L"*D>=-\V*HB=!0A5
MB0^E]0X5N1;A#X=\2$<,7=>?;SM5WL.HT#(#U32YJ-Z$439-:?9L^NTE&REU
M>GD#I&09NF[XKHP*%)\9Y\QQC7<'T&E#U#;^Z[C9<JO675.ZX=-V#9(;,<<T
M-6UQU7C-/TAYH4U 3-:]*$A(5V'BEW0'9,WB:+S;0R)CLF#ZPX^4GH+2L)VW
M_"[78[.H6"C_ ([<PE:Z2\2Y:\UJ%GY?U3HV'DV=BC!<#%V%^NZ!LJG+"BM]
M/#O^;-'R[<+MUG5-2L.$P$)8KC=\ZL$O\BT',W<( U1BWTPZIL1F:3]5O(H)
MD:'J @83E:'^OEVF,WR/8$VU0^.W-'?/DC0([;Y%2:Z*OD1VHC?$,^/6UUG&
ME7:8_G"K'F&C89,2+_M2K@A%FC0Z&77+E6HZM*:USWN-[Z'1)E.'[3C5'U5Y
MF?(S*YAST[@IR5GX28:ZS 5)6H2BZ(M8R3LLXP] *RS5PDG\A]FZ(#13W.\[
MQC5P:_S@UM*5*KS&R\N9'9I3,<5>V!LW8R.9Y!;9V2KA5&0G TJP>G7,*YS"
M/ ,7B^.:?:ZK5>T?YHT^I*W^U9CIQTS?)BS<YFE>&%F@%[P_R(<VE7S^136*
M9FBU,T>R!%HQFH5;^;Z2\D7T#_,%PJX.)2O6&KNQF*);9NCV1((FT1<-+_B-
M['7G2;=S['XSY I'+919LJDJ?_<&'J>V4EO>*_ 3R-FB8]>8L4)^'-H,GL<F
M\*ZK4O"O52_A2*Q#)**'1.!_)B")2B!E3\^(@<_]L4M.V= IO!Q.'DB.BID$
M0$W@/M]B^"_V0 /HI_\ 9\()BF]1?7J>UJ !OO\ <"J:08OZ"(?I^@^/T^OC
MZD=KQ*XZ):NDM0T*"VG5S;WN=;;85F,OT-I>38U?M4E8'2XZ.80]GU\:E28<
MCW\5%Z(NU2*G&-6(+5K"4;48^,*5FLU)#=8]:L6RJ:#9%!JKZX_<T0<IG:HI
ME$3"8%2E#U>K[?5XSJ+P$UGHU<Y?LW34?)SGR-_(3%WJ9KU=TO*\>-5DZ^ST
M"4B&EJLF@:81.-*W<KD%L@0H*"Y< W3VBG/>=[LWB\QNENA6\W(_(7\A,<]B
MZ=6->ZBRA]==$I<=J$]=HV(AC\X(2$ZI%1TJ\K3"?.\79*LXQPNKUC!YGE>F
MOJ3R$IGD;H*=O^57OJF:EHDGH>),-81E,DJ<+?;HO8(=I&RS1EZCJE=RLBSD
M%44_,<!5Z7ERD'V6PD]&ZBZCP-6SR'R3_(M&US+VN0FN51Q"U[FTL.D14[F-
MEZ=UNNA782 =H$<&<E7,T4>*-@2/7:Q$TKIK,K^?)?\ %30(#;_EB^0RLL\_
M/4L9=[5H$*E9*??[?_B!%2E)FZ]-5.4@22",M6Y!W(.T6CJ,6C#= ;))5?J9
MNEE&X5#!LZBH'Y:/D3& O=OOW4%DY2@):^V:XVVNMZG06%I:QLQ)2L8WF?PF
M3Q9(J2KIH*:MPS&/K_9S":H\'LIY-\S^7KNA6BS.E80SZ\3DXJL6"Q1KYA+Y
MU;)/CAVDT=_D)65RK,E40@G*4;+>U9(IE#=CL9K-&MD<[$M!_,!V]9:K'/(/
M,<7V*-3I-XBJ'/P<A'SU0WM@1RXL:=228V)DO& *H"@J>O=9GFN]J^\DND8#
M +/GY_EIZ+!O!)3:4&Z=VN*N-P7I+MHZC$IY(A(VRP]:!THF=PDY&+782+O)
M^E)BY?)*]LNH7G9LP2QRJ_)9U.G88'1\IS/9=#+3)E/3D\XMS*W2+C'5X96)
M<PS5\C*/DBM4)(IVHN:] /K]\BU<;2C#&TX:UU[Y0.B95*U677M[S+!#1%>9
M7[/ZRS?-LNE]19GN;&4)%W:JR! 9RM>:E7;/%NA:ZZUKY5EO]GVVNZK./V_R
M&Z<:"LDB71;A0(TU?M4AB;JK1Q) U.%ZDTEI=A(.DUE",FSWV%C?59N9=M^6
MNX6]YU!L7)]CSNC]UVF?FRZABE6T.U3;&@/&N?KJZ8E98S-W*<61LQ8+&DER
MM7?X9DG7L8KH4[T7\NR<=M4!%6*+:,.\4E9",0LZN]*4Z$6_,JQF8SMBCL#>
M@)G)F,8Q?235%T_21*Y=HZ;ECSHSY<X>0S.X;94W));NB&96%^SQ+%]WV3^9
MAJ$EFC@3UC1&& .DH&38NY)@]3D2&,[*X:RC!I:0ANI?F1L\QGM3Y)MEHK%6
MZIHUDF)B.Z:?(QEOBLI%YF!TM2MW.\[+1K&R1@+,GZSMV=LT*=P@*!V5)RKI
M/Y+;/2[%D&C[?1--@_D%R^3AKK1Z9H-VRJJ/8!L[PI(%6>EW6II%8.%GOI;Q
M\@D[6-Z"')].+3H&^?,+0V%=B[;>[V^B.T^?;FRIN84/HTG+,Y:V2$ECL.]M
MDZCLK)\G^R?@>E:"8JO"N%%U6C%>'T"9^1/Y4;5,:)>H:IT&@LMAP2,G;7<9
M)"6M2T2T1OO/U?A:E"PE7K4E,2QGJC)JRAXIR D'_M"T+8;K\FWR<XS891E&
MR4;G4\_P^ZVJ5@YC^7VT([;EI?&EE<*6%0UC;J2<$<$[#!B1P:29-4$%%"^F
M"^6KY+K:LM-U*$27;CS_  ,$R;72=LC:,O*\K.<.*OY3+6U;SFS2Q;/%,9:$
M=QT4X.BNH;V3#GJ5G^<?OVG*:?#5*VTIJX;\Z2I)*O7ER(4U:35'A^0"M)SY
M2"H@24,R<*-&ZRYB^PDNH53,HSYFN[W< G5V#UCHPT?D6;AI>VR"L>[KV90$
M2EPR^N=ENUFB/R'#(44%/SU6;EB@"KLADBPM,J7S8]LW]]/.*XP5E*9E'%UB
M@X-Y9)O,X6I0;XI.*TY!Y,V177(U912.;O2QK,BSF5,R20 QM(2R+Y8>WK+4
MZ&G#H-;RE1^%EJQ:']C>6!DY-7RJ<?LGZB=4E:A(,E_>0!!<5$U&ZATRE,-I
MH%M[A^33,V=$TUWC%BM-\S7XGY^FDMTKA4IT35TR3$#GH22![-DL,9VP<'8*
M_BOG!$'I$%?40-WT$GR<=P4*GX5CZ.^Z"\N?._QM2$A&4M_F^;Z7%PT- 4_/
M+#;3R[NLZ9&E2,NR09.Y,CI%)Q_<AZZQDNG=Z=X4#7;HGE[RL9G9N=OB[>V6
MQ-MMWNL8'35J\S@(:93FRL+A;$W+U%DLX590K)ZN8IE&PI"VEHWY?NP)Z!E-
MFZ2PAE;X?E'A5]2O\6>:F]=DK)6U[$?+HB*B(;1G+U".ILL[60A)%])-VR[Q
ML=XU!Q'Z)8?D?[,2J%EM%@S2C6R;Y;^,:#A[#/U;9*[B-MEB5Z:N52GV4'1]
M'L'[&^L$I^!"K.&3ATDJ=J+07?3FIK?(_P!B56K<BS&?Q.L#>>+N$"3C9W>G
MQ6+Q5S78F5:R-;KM02ED960F[ C78-"O)%F&[V1B2JO/K5I2,^0?LM\SQR!3
MT"\,V?&WQPS-MBZ/"Y]FVO2]D3AV^N(OIBEJ577X)->1:L?QWRKPK:,6,L4#
M#5*OJOR)]15FVV/'%]?-46O"_#TC;H>OQ\K:8IZP?5M'3'$O9[<S7KJIG+:M
M)3+9)J=NN=0A#'4"A8),_(1T1#[-/V"V5)YE=B^.+DV9L:%QJY63W^4W?\H=
M"^S+.;$SL\0Z82, O,0;.'D&[J2>LT49!VA4K)+_ "86ZE*VH]AC:U4[7\:W
M/;"W7.0K.Z4WG:;"NQ9NK#DL,G#ZO="1J[.+57743C'SI-'\=-)5:]YMHGRR
M6>!L.<3^IU1V$E\660)5RWV_&\ZH.P6"GUJP);\BQ>V*V9?JT5+P3999@>81
M240:B#U)1NI*X=(]]:!?;ZTT.A9L6+I'Q5Y9,UQ2Y:+F[W5Z?7HN?/UC $6-
M-TF#E'1C+N!% T6[*H9/TI>["V*Q?+-4*-$O:WK=C2EM4^,FEMV2S#GK,V6I
MZZG/+Y[U?,MH&TPU'FDY4T*N9C*F(S4]MIZ $%8BYW+Y9<^ID!+<I-NU"*V3
MXN6449OB+QU7(1BS<1H]./I@FCR,Y;HULWKB95I5R_=$:HIG6.5'ZYXJ$W\M
MV7,+AU#!V:R8O767QN0!I.YQE&SE72YXOX;WHM=6*<N:\!!317,FJN\4*V1_
MO!$ RZM4OY6ZX[D-=FU8>E)6?XGQJK5_*-5,@:_LRSV<Z@KI91=5#=JN_43B
M?S7(-WZWV1,T=I-X#.#_ "RX/+WJT=&ZMRK$463^,>?AI0^P8K2IW1-'9K^U
MU0T495.!HL7^[$G%5 C'395G[*JAW1"*46W/?E5SS_#O0*%(:'&:4S^)"^O,
M^@*Q$;'_ ($.9&]V1IU&[+25%]9!&$_[H)HH(B]2<+'1;^XNDAT6S^2>O+9D
M>[Y3GJ")?B.LCN?E+9LT="3N?QS2&B^MGKWV9EA;(Q-P85"&8&=(@X!(5 ,-
MNZ#J'RBYEKF24.M9C:[))YU\2^BVH6M<V*'FI"HS:L1#=4-[,D6)/#N49QNH
M1!S!OFPM7J22WE,6W\Q?(+G$8_<W.5H+B,D_AQZ#;6*%N-:F\JK<U7IZN'[#
M:24(J[M._P!-BF;ARD5HNZE" 58Q$W*R-,D9CY.N9V"EYS>'V)BR3^)?H*6G
M:QE;ZW15"#0=!@X7KJ2=42G+6R82;*RDD5!@BF1P[(J=BV7<I5:)5^4WD%"4
MLU2D=)KT59/BPZ9JL[<J+#Y,\VH'\##2O6;!X^4M.9P[V=A&Z)0>SD>QD/P$
MEEF"Z2=G<R'=7']=C:;9&%)LTQI'Q%_(W16E:M*V>?XM.V=L=2_0+"+AT&V7
MB6P+N3+%;,XEPV<+&*1RD8UYI-E[A^,YW=Z!:<CHMFJ$!Q'UI-V:(N&ZH*.\
MFKR59K?6D]-6"6N<<W5=H(L4U108H*N%_:0244+<&<!V'\=\K_AUFS?6]#L-
MDX6[MS&J4O-EX*P3K:ZSUIN.[,ZI'1T@R@7:J22[])0R48^$GN&:KD3JU!BN
MK/C:<7:[R<)%5ZNRG)7R#U-\S=6X] 9TI*X)3UR3_D5U<I+3X$L(E-FC GB3
M3 6*BOY)!&!FFW0_QG6=E9+$QKL1"US#_D#:6QVYDZ#):3$NBUI6.F[0C 3E
M)K\G-,9E:+2B'<9'NE$'"H-7!R7G8V?2GQ/$S?&']3B=EM<KF_;5;9UAS>9.
M.C:C+N6,_,,96$J=D4EFXM)8Z+^*50$[D'8MTU#D@\?CM'^+"0T26O$GGP0\
MC-]EUA$;I&6"UU(:-(R3C+9> J-SE[)G=@1A&4C( YLH1QS1B*Z8>Z:V8-<K
M=\3=;U2F4V=O<W5YO0>UH]9"MPF=R>E.7S:2-S^K79=ZSIL2[G%8Q@_=2*D5
M'O#)I?ZLNJE%4+0;Q\5$);Y^GYQ<H:MA>NZWLHZ@]8<BPSF8]$3R_+%!I>9,
M0:1B!P3<+/"F;AZEP$@-J/1YKXKI^<GY6\U>EUX^^=>5F9M%KR^$D930XN)7
MM')T>PERU;]ADU'1F7O@DC&NP]1CM7/M4O3H"O\ Q-25!T7.[/K5"MSKMGH^
M$@K=F%&<Q#6Z7^(=2'&/K-6:Z:RQ0K+B02B,F@4@G]1#J1D-4,=^*JS3<W0X
M/4X>)A.[N@7TC(9I97R\?7KZWCTN+#/356;>L7"#5X)"HJKHG( ^I,X H <I
M_'J4X.C>V8_;&_>@S+T$$I?!>(S&_) XF 3#X*/@/X0^A(UXWX$DDQ3$Y5T>
MZML;%*81,!4#).^(DCB<  !$P#Z?O]OT^@]SB7@OT?\ &]'>VQ>H?L/CT^KB
M'P'W_K_H^O\ 7>(>&U/NGX_$[ZUA/P'J)[WGWN'5/(B3U>G^H1#SY#S]24-T
MGR]SUD&9MZVN]C;QEG55JVBP2%G_ #&I&D"I39WG')2-(XS%1919\:0$4U$B
M%(BH"HF2_P RC)/E[&\UV^^JV>-9RU3U'9I3#H)G4UF[T9.<8VR*R_6%GLNR
M=D;E(Q/'HD5244/[X&3*DJ\]SX]^13%09O%FGXWR'7!47[M,@ S9@#CBEF#7
M\E4WDRA_)2$(/ZB(!]((&^/;G%9(7P(N'B/R!21$",2N@;*/$DUN0@='.HD<
M'*:8I@/LE,4WI5]*9N<PLM,JS]&=8ZRUF8=_&M;!'*-6O1VLR[:$66F&9EIB
M+AY=8ZC87*8#[O\ ?>@BAA^F,3$L6<7%1C-M'QL9'-D64?',&:)&[-BQ9MB)
M-VC-HW3*FDDF4I$R% I0   /H)6UT*F6:4"-1A@DK!5X29D B&TRQL;:*![(
ML7+D(YO88QL_30]7M$>MTEP*"J9#!(R#O"\==OYB62GI=^ZS*E.'LK.H.7KQ
M&:DW:T(=P_ETGDBX5*Y5,=<%7"AP-ZCF$37"[8]EEQMIH ]4-:;5GU3L-C-5
MU55EE:T:<EXEY)C *+.5#F9^[^,)E#")/)A\R@L<LSEF,Y8(VV30M*166PR]
MIAIE:Q1%EE!1C"#(6"*L#A1\V>J^MR@\.98ARJ&$PQD%9<<RNPP<*A&MH:&G
M,]J4M$Q+>&C'\)#H1D<_B'#-@C$PLJZ9MBI$(5!JY52(!4U#E&X1L!BV30<=
MH90)H#"'SFGQC*\D*J\<%)<6K*'00LY07D'!P!Z5</6NH/ZG-Y2B''/V(N(E
M%K$LD8M;*:(K'),X%S/O8)HFR/ F;$;0KRV2JK1,"^ENK)NS)@4SA83P*!>:
M\"*A5CNU*PB&.YV"5;4D'1'K]2!3"N^B'4?/4RK+"W!,552@8WDP /U)P;O"
M\<=0LT\KLC,P[C,J4M%2TA4*ZA4*F_DXY2$,S?O:O4FJ47'*JD.HRCDB-D1(
MB4"!&T:P89D$Y1X9[(2D/2YC-J=)U.*EI5L[924Q&5Y[#+Q,?+OV3]P@LZ12
M(NHBNH0QA*<P#/QZ?.&(HM+37_Y6LB3?,J>W_?8'WX]U^!+*(1":KX/RXAFM
M[BAC*^\S04]7K12,1A&/.;,+?Q\7#Q4 P92&5TF0;-XB"*^)",P1>PJY#EB"
MRCK\4Q@,=#\M<2&**ROKHT#7\NS^#A<QFW]FSF*B:A QS"BV25;3K*6L%2:M
M&"25?FY9I:)--V[:@DNY)(N@5,<%U?7-$/S'ACA&Q24]+S#5[F52?LWCVT0%
MJJUD'\)[%KM&[6>KU[G6;MND0C=PA-R!3D-^<Z]US"->8L.2B'3MN]5CAS6J
MJ-"K-8BRP*!&Z*L:<C-J2%NDTU%!'T(&0F9 @D$'KKW:K*J8CE(R=%E)6;I;
M\M JY'E2F)VZ1.CS4I7'"<856%D)708%E-N%FXIJ+2S1%T8173*<&5HIF8T&
MI6&-J*E CIBLU.#@G\?1U;"ZMJM09.(MBU.TK2EI>K2(LD_2W%ZL=;T>X<QA
MIT0^YYR9Y%4"7L4[3XYU3(=PRA)*W7HFHV=1!JJW.BNUGM*23L+ILL"C9:;1
M2>F3%RDDH2IUC2JA'6FM4Z3E9&-K\HBD^AWB4]0KAF4[#33%ZFY2EX&:I=ZD
MF;ELKY*H"Q3>0.0HA-VXN5U^XVB1T.&T:!L-ZAZ_.S.>OJO%P\148#/I)*%8
M/*_7*TSA2"D43KOGJRRZS]R\56.<479(6T46I'HA<UG,TSJ1@JS3;;27EDNL
M[9ZW:'/\MOKI(0UOC=%FX5TV)+HI,H:4=HQI6"CEPLHGI.C<[YG;+PC"P]<1
ML$E!A^4E!0"3="(BDT&ZR#(K-BU:(HE*"7W;HII&\IID*50\MS7FSA8\V6R@
M[2CG;!\C8$W,@Z0F6LA'/F;YG)-%9=X""R2A#H)O'":8E365(=HSK>;Q626*
M!.[<46]Y;&P<)9\UD9*V3%TE9F@M):(GJC!3$C/6)\L=<8M4Q3+)F(!3-68M
MY^LY>R?%2LLTVDI.3F#QZLF,7 Q#&IT"GM1C(Z*8LZEFE!AH^"AFJ2!3%9L_
M?<G<OW#QXYF+C9<_5>V6P::SV*9EF]QOD6O(:/'XT]Y[8V-PG$VABW,+3&9)
MQ IM (#$C=8RH(@Y'W_J^U&A90]:4_3Z3*9U>:;8].UV_4V=ITW"5ZLRT2:I
M7^^V>N1ZDA6:E%QJKIHU0>F81S9O[OM(ID*9G8*!=;"X&%IU?3L%@WOH.<N3
M2+SW1VNN4=..N\KJ3NW1KNKZ)'MI)HZ0>INB':HIBH9!%-(MK4_P%@'C.\YR
MTRBW0$K.W&8J,_1F>?UG+$HR0ITI8W=65D%*'3(E@M) S"3<!'-UE7!UTRJ@
MK.S6665.3"WK7^*5@]JW.L-JC=GMMC+_ #%GSZ,KFD1<5G4K9KY",IN8-!H1
MY9B7:)/'I5W! 4^M1AZUGT[%%V1M0&5]ET]4UMQ:WK/+IM]9Z&SAKD\O+FUU
M-E7[/*O)(C>*>,D%GSURLL10SA83VRGU/)Y>O5:\5:6IEFKD9K>SHP#^ GZS
M1:9.((01M"/#Q3Z8J>:0<<Y>LT&[U5HP*F*OI46!2]SVG4)*VR6E8K)<\W%1
M[.V9LVDLBEI5_./:PA'QTRRCXIT>7DEER2K1)"81.8/;=$ A +!WX^>66<TN
MLSQ;3 ZO:M?V6U:NPLHST+875@+H]@O\C;CR\DXKS-B\6%WY?02/[0X!6+.H
MT/'0RN8N3,(J&DH*/3->M .JV9R^^1W3\BX3=*6@[HLLYW6);SXO0/\ EE43
M_&*H#(3-AU\MTQ>#LR6\V=Y==60EY6RNFMIM[UOCS<]E_$-- VA)ML7 :>9L
MXCB-%6BL(DH@*:BK@RSO9Y&G+NM*>Z91=?7LBEDLPF_G[-,QL^/4B71B_P!W
M_9FS6"H%TE6A6*;<K%95ZHY614<^E8L-GTME4Q9:E7;'7[9!15GU#4Y\L7/U
M<\<:%D&R\C<EG!ET4HM)!<RACF?-?6@Z%9%0Y#1E6OV2P]^KT3@$?S(TB+P\
ME;8P-D$/-5FRPL,Z;3KY\B\GH6QTZ,D&<VJ!YIL^9IN$W150]?UG<U)U28;S
MN11&2P&4S\9;[.PF\SAL8=RKBK,J%*)28NZN28:3*[&PBU,0;+&^VUDQ=(HH
ME3I\]GE>T*HGH2]9<U*(C-5O"M?K[FNR&5RKQQ!0\C+/FM=<W:3Q2LN+&K&_
MAJSCB/46=&.J^D3N[YH[NGWB*O\ I4W;INW7&O:?=HB>>C>@V<EHBF3Q&5-^
MRPLFAOED1,@S*AZ456:8& L;'@VL3R5KM])6K6>23GLQC-+MD/E;Z)E[?5M$
MD:N6CQCYK%M*<\T.F,)U6)0]N/5DOR#G2,1\^(X:X3"NM2CLZC]#R32HR-:W
MH4'<=.XC"0T%0$47Z<455PV:-Z\R5>+N/>DI)=JF9TZ5 A2AO>:0,#9JU%=-
MJYE([5-5^RK1EFN=FRN JE;A;FZD$6PM6UMGX^F,CSCM)N3]X="NX<%,NX64
M/9+Y;7.D,K-;M&LFF65_"2U-(,],627P^?&$G"S-$FQGJ;!S7/%8<1\4^%RU
M0_&73,51%RLF:B.TK%I[$U2QI#G6RM6EEAS1>NX0A/*6(,ITR%>5EW#JU,7K
MMVB0L$A!.6T>]79-UD69BH$D*YH;_8]/CY'.B94=>]7UC(3;&EP%;@JKE32#
MLD968BPUV8Q"*A5#5F58.F\K^5)/G,HXDUW1U/J^)WRS; _C-$VYWT+.PK6S
M51FQ::@7G:L\U5::@'):,>9@PSVH5%A*P7L.RK-;"C^4JHNB/XWU_B_"[%T'
M7MT<6!I>YG9FD[F<A;+3I\-?9BX5+2;/"S.5R- D9^E5JU3E,BF:<,A"M:9.
M.X\&(F!NX;]0.K_=]3TUGUYS_F'.FQQ5MF:PT0D*AF5-T"E)ST,_I]1JLU#W
M&WLM+E74JY3="V!ZH11FW:%(4@,M6L70/2%GWB)LT-?(;;IB1Q\EMCM!JB.2
M0=,N'[!%8_&9X^=5R@8U&5P63B&5C'\>Y>.7;=:542D4,,=K=";M-W?!'F8-
MZK?[!"8!,RCNDXK3M IN59^\KS_%5Z4WBZ835;#*H2;>-3L"T[)"]7?JF0:D
M0U[%JUIVFO:+N$IF=BT"*M;>A6]M*6G/;VWM,I-"C/4YV4[32:S%QU;G(E45
M(7]L8^\R:,WKEXY<5U',=5UFN5NN:-1]F+3K*^A;[$6'5\:L5ULF 6*USDW&
M)7Z2AL@7M#!JC'-YEF,RQK,6G(KN%0?+O=<F]:NE_>HZY$0+5RQKSF%K+ZBV
M.LY78\NA+[G-LB8E"W5>Y1R5C/(IN2/#D%4AFBB:D>Y>-7!--)JUWBI-*2X3
M<(1+>)J*\0G%<%WK0=$HD*)%8<'1D[]8='>_O:X*%62;I(ILA;"4QC#7Y_9-
M-F"QVP7[9ZG-1,92*E9:Q8]4N3FRZ6S0GHBOF?.H^^5F6DZE)CY167J\JY;@
M8CE0SLW.O/C'6K]#5CF?%'N1T*2BXVL-WKF0:V[&;O2KQ-L!CCP[QU4)S$HX
MHQ94"1D@T>.VZZ?M* 4M2WND['>7MSK>=6;'WS"U-FTM69[*9>.H;J!H9H=L
MZCD8.,J.D5%_:VSAE[;U>4L<@FNLHV,FD3_.N:"'.)Q$^U*!Y  ])%NAM:63
M3  *7P"2:@$#SY'P7[B(_<?^A2M6GHG6Z5CE9M]I2I5=L-[EDX.%D;2O$2T\
MC#!)N"_A-7*D/!.UP%<Z:?H0-_%Y\ *WY/<'.!TFQ$#N'C'2H*4CD <M5WJ(
M*R<8N\CTS"V;F$2BJ!B#Z2F #'* M8YIV_SH#Y\* -&KS1H:,6<"Y(U40!,L
MDJT$3* \3  _7U")?[13 '.]!T?L+F7/;K#-]16E:M=]KH%-FF));:=+G&1E
MHVU3T4\\+QKTBOK*04Q\CZ1$ ^DP:]T<@+"JX2:I@7I#'P%1RN155%$@&N >
MI15- YBA_24@C^@?2:B_>G&J*:JYFR:BG36+D(HX(B#@Z1#&N@%,<J!@./\
M[*/GZ*9'O+C50IP3$I@Z<Q7P/N^X*?W&Z@'DP(F^WZAX^_TL5AW!R"]%N8I%
MP:=*XRX%$QD#NBE5]JZ'] F;)F4#S_Q"B;] 'Z2(AV3RHN==T#%$B/0V1*&6
M>BW*[!FD4EO,*CH6IP5]L/)_;$#>/ ^?I1DGU]R\=ZDN5LJT)O\ E!G2;DXE
M C=1N%L%4BYA.  00 P^0^WUZTNI><U2>L$_6GMV9G+ZQ$2@3U%LXAZQ, AX
M_7R'THHSZ>YX=IHJ&15.UVK-G!$E2%$QTE#)64Y2*%* B)1\" !]%3+TQS\9
M0QCD*F79LY$YC))F54*4H63U"9-(HF,'Z@4!$?M]>2=$X6</X1\EUN@&#P8@
MJ%'R%@'^TF F#^L \_I]"/\ M!8CX /(C_BO0_ !]Q\C_P!WOT\!]%$F_8H8
M#  E$NJ44P& 2%4 2B$\/D!(8#?Z! ?H!0W;&UP$A5 %'3Z2IY3.!A(</1.&
M\D.!1\#^@^!^C^WM62J>V!#']&CTXWH!3[IB?TS(^D% #^'S^O\ 1]&*7:,F
M,8@>HQ2Z-3Q,4OV#R8 F!$ \F#]?Z_I<4M6S90&O@'(IWFL'!OY$Q0]_TR@^
MSY,40_B\?<!^E&[;2:"X72*<RJ"%QKJJR94P,*AE$TY$QR%(!!\B(!X\#_5]
M>K^?:7Z?4H3S_-,'X]:) 46)Y_.\>I),?48/U*7[C]OHX'N]0(*1UTU /984
MHIJ-DP5<D. O0]!VZ0^HX#]R%^X^ ^A!.Z5-00,H40)8X<X@9)--54H@5X/@
MR:2Q#&#^@I@$?L(?7NC-1/M>H"^Y^XL_;]1O1X+Z_>]/J'W2_;S_ ,8/ZP^O
M>3D&2B0"("JFZ0.F'I/Z#>3E.)0])_L/W^P_;Z4=2$DP8M4?^W.7CQNU;I!Z
MRI^5%EU")D#W#E+Y$0_B$ _4?HQ"R\88Q3&*8H/VHF*8H")BF+[OD#% !\A_
M1X^A.:3CP( B G%XW GDH@!OXQ4]/\(F !_J$0^A\2<>/C]?#QN/C^S^H I_
M[.'_  A_7]"))!B<"B &$CI P%$QBD*!A!00*)CF  \_J(@'UX(Y0./GT^"*
MD-Y'R0O@/!A\CZE"A_I,']8?7V$!^_C[??P/CSX'Q^GV^OZ?^ ?_ %OK^G[_
M .\/_K?7]/\ \R;_ -;_ '5 CA!%<A3>LI5DR*E*;P)?4!3E, &])A#S^O@?
MHZ!&;4B*@^3HE;I%2./CQY.F! (8?']8?151:MA4()1*I["7K*)1 Q1*?T^H
M!*8 $/'Z"'U\9<!GM'N-WYEDJ:X=:\R3PR.O^>E:S?8._,=$=O+P7,;&ZKUF
M@LK.C)N&R\_%"<&;=-FB\?O0;.8V51H]=_&?-64FR+)4UI'/D4UV@F:&<QLI
M%M9&,>I-'0D,BNDDX0]1DSE(;U%"UM^7J3:EJ)"\S0]\@8.H<V8Q>Z3([2OT
M9EV?'HRDK+X+H-K.I+9+.3TN]:L3N7#!!B+\Y ;HE05D*5N6*3\1S^-UN#;\
M-SR55E<^$Z6K]=P+6OQFD2''-<5L^>R>0T_-'BD_(359=&!RW%$[]9ZX9DV=
MW4^&([/;!<]D9Z9RA&U_@JK:&1[R(EA^M0$%3M9=GY<V62IFL+;7G$!.24'-
M1C&>:)7%K&D69L_6\87BT17+$8]G*6YVG1M$P*5X<R5WGCK%\:U+ IK*Z/E6
MIN<E)*6;9NDL!=V]E^VH6&R+&L"A@0+#_MB::KJK;#S-26F?/,W:ST:NSXFR
M* A*O;+WC5@U,]?;2Z?+,FQE0RN8?Q]8&17NC<59R/*Q<Q3Y=TH=/.UM]XSJ
M]0EO\&IRFWHE+^/?&;KFFG;-;N9-.OW/NF4F*K^13^@T6^/M-:P%=M%=FQ4A
MXJY).H\K0D<_8K%D:-*\49J\E,UMW2T@7=R_'/D=GG-/KD;DFD3?,U#A:XGA
M4U3&4BVU'.W]=N;]I ,@4;2< :-.8)47'U<YE_PK0190.*:2-59NOCMS%4]S
MU*,UCL.E9 L> /R8ZE;9$6NGT*@2KMT16G-HH9TKY:,%K*(,4[%-/?C_ ,,9
MWFF\KWR568(_&]F$4YKG2=;F>MV]5IO[6MSY;R[2Z%IG&=I/7E7F:]67(R0R
ML><S*29,R-/YQY!YKBHAYWDTPRP=6V+XWLX@)&C\P.\+C]#D]HE<DLE*+%2!
M";NF?.268(PE>72$C_\ %#P5<Q\^J7$W$]STDFE/Z$\A[?\ &;3JYG%4JL-8
M\"KG/VV6*P*TUV_9U+KW^=909-$L@=>MMGJR# C9W5I;\B^7MYQ5R77'4ISA
MUOOM>QC4/C:P-._4JTYCUI1,"QG&K)8F%:C8:7<:'7;,]?.71UE/W!9HD_:N
M"Q@G4-@C6U?$OR-:]!,VU*F='045P;2*\\J>R6NQ[)5N.: @5_4CI$<SLUCJ
MS"ZR$3^Y0K9:58OFBR<:]9&6YEMT?D7QU:[EVCVN\CJ9XCXGZ/ ST%'Y/QY9
MNFM&IL<H]C(47<])W:IDJ<:#5@9[!)2J3*2_.G&JH'94YQ\<7!5YUY'0I_*M
M2RVN_'/CPS5%>0FJXG3,LL323EDZC6E$>J*Q?;'(0CB6>H1:8QK)5IX;,ID5
M[9=83XS_ (^;39*G4H!Y8,_+\:$@VEJ>VF^$X#9[?H4I)'CH9TC6*+U9^7GR
M\5((-G4H$@5FFX1D(YPHME&26'XW.!U<"TE"<B;;H3'A_/TTJKH4C%[A,TK-
MO\3:J\N5%EK5:8/.(9\B^(S2K3UJX?-4Y(),&#%QKU)OWQY?';'_ ,L\\=(;
M%2XNN</TE-XNMDEQG*G%R>@LY-^E=ZT2PLC1SEF8\0[KEN8N%$XV6;2D=(,/
MK)VEN^+OX_>:*O(4O(*?T!T3JW%46IF^"[[+.]%9:UH#*.F@I4+9^>)67J59
M@*@_=R38ZTG8#"X<K)M 1<YG8'7QG?&VA;[S9JA7M7S*2Y4NC*R\\1.A9ARK
M:GN]7_\ .O;-)KEKF\ZPZJ1(Z40K\DD^7BS(N%U6<JV/B^C3/Q\_&]2:MO%I
MVV$JK*5YN#UR<;G72&38S)+Q#U+JVNQ"_P"\0N@GD4RV :XH1S79 RB2,:8K
MOZC.>97A_P"-.Z1DG+-XB;C*=B,C(VNJB[XSS_IS_&R<<P^L:GE\WDD+N%H3
MI+QLF[(W<OGD<,=*.UDE2_6C(W#@;XQ3R&<W;K;/Z=.)<\WFD0.\VODN[YA1
MS<UYFL&I62P->@.CG=\?.ZH=):6-'H0;I K"7]3L[/K#,6GQ_< L<ZRZGA+9
M[):'EEKAEKQJ+HG'MPEL\6L+?8(VKZO;HUEODH]E:\1*O.8J.BX][[SILJ[3
M;7!:=X;^,B3R2D;'R)B%QUR'S%!A336GHF>P1&QN#6MOT9=8]*8HL/>)DIHI
M-&1B$5H$BPV%<J7XRNEU7-N;OBHAL[?[O6LDS/7YFBO'U9AX*UL<EO\ ![;I
M$W ;S#25KAXXER1AEH]6,I\:XM\G E:V$YEU$4]9R*0Y5^+B0LN0\PY!N\!>
M,ZAM7>UP9';;;JCG/G35\I<PGXZGM&^2N+ X_'*@909MF+5T?V3NG%-O2/!7
M#QE+WS#R+NM>D8>(UE6I0M-Z3MNM45W2M.N9M>:S;&P5E3(TCL)!-M)'?.!.
MB=) Q/?(\ZD;<,X]<^C)?0'$'E.497:ML)%2DB&6QG0MF2?*US>-%F22-3QU
M"P3;U\#QDH\*P2%1FS4<@C]7>P9+RGROOU57TYZ&1EQ_6NE(S3V>#5NQ\V3K
M!U=8ISN;Z-_G;7:ONJ4;4Y05:^U;VZ,1:FCGI'1TV=>4R+E+*;_G$G8]&LM(
MSB)Z*Z1#H;7\ZHVJ\QT^CR^:*J]#U^J0^A:]4^FG=U@XI_$J+2J:#*+5*FX=
M?GHYG58S%<J<Y_?KWGL#6;?#]0?(37WM;I&E7J?KV;2U]SB+Z2EM K*UL7>H
M(+RJ45),X2<EF#2:*S2> [:\U0VU\X9HRS?8]8V#++%:J5V_\B,"&90V#]JP
M_%4I;IRU6G?W]5K]?F+A83340K( V9+>A*(%P21D6AAT.9YGY]>"- ZLYXR&
M%=:!\@7?=49Z=D_45TH.1<V]-9VI4="F235%N=VL]D2]X#^@(JON/8.X.Y.1
M)_&J\ZVF'FY$=.L&62=3^57Y$8#/K30.7])W_*.NK3..4]5B9QDGA2^)U5R@
MT015,[2T&,+Z4U"J@;EZP5_.-\C=DZNT^_T.GQ-M^4/Y/:'C](_POPBY;D8=
M0M$WK#RX5V;GX2M*QT6V)'G2>@\3D2',U*8@V"H3>3=635C@*!U=9ZI7*!\E
M/R>2LMH6T<^]%9ES7DV*9=8[)H+*F:G+;#;]7;M5W]<6E6\&Z1.15)4I#& L
MG7<ZZVLL-9J9EMLRBQF^6+N6$I=BC+1S(MO^@4*U6F2UMY"9]K&.IKP*,FF^
M,+!>MS)I1,WNQ,LQ2NV?%IW4UTMV;T;4)BTK9W\L/R7C%.9G-X^U1\!1_P!^
ML;>,J=,F[C+P0L$7UF>0T4^471/%.Y)02$-B70DBY[Q>2.CR6FR%XJD%\COR
M4_NV:YG@MR<4S9K!(5V;NE,T5U>*@]&+B"5=] 13Y*RS*+=ZJBR;/) FM*Y3
M=_D[U#2,O@M$&3H[?N?Y%D(N'M]&-9(E"NWZSP^W3J5383%S@VL85VBD]4\R
MS19))5)03%Q*]S6V?*:VBMLSJ:TNH)P_9GR)2$E$5JN5?0[8(S[,VUE6C'DS
M!9+9EHI 2*JR",*X53#V@(<T(^:[7\M%IFY9/!96<@8SO#Y#13H\3M:</9F\
M+9Y.LW^XH1VIQ.)_NMS2JWMG>/6$0?W%&J2I7 3;:;[?^5>.-!R+5)VI_ML_
M(U(HC7Y&)A)^-OX&A-%DQ99W*0MA;.FDN[!LV<H&$Z0G* "-&K52Z@^8@ TF
MVYW2*NXE^G_D89Q#NW[0\,RJ$"XMTM<C0[&1DX9HE+BF=Z7V85=%\3^Z6*<V
MD<]1?:7R75[0*,TVZ=;C$]R=<V*#?9IAUO=T:[:4%U6DW=0B3-;K!R;!"-<N
MUW2B;<K@B:K=PV4$TK&=]_,17&)@DF\^Y)T#V4T5H,C6K;$UN;@;R2PQTF-%
MGD7=NA55V\D5!8C&4C3E$AGR95Y5G:OE/^6Z&EHYI8)YNPC>K>K;2WEJC&SB
MK"$F8R;@L_6A7TQ9H11I*(P:"ZLP1N]2#V#BHD96^1<)\B/RQ7O6\_KU6<?X
M5LNE=&92<G,W]_0U8VFS=MMN/S-<K5QK,5I\',3K!P89VO03]%R\:E14(0\-
MI&G_ "-_+GS;/R,P_@9/*BZW9M)?5VP%G'<%%52RRC?D>1<P^IS L'CK^5!%
M.2(A&/7#9!>/;&=GBJ9M7S-_*)3K5*PY[*WAO\:JW97S:$",MDNS>3:=3Y<G
MD:^A,L:#.'C2/_QE)8\0\39@N=LJ0DC'1GSG?(+7I*$EV43-E>+Y#(.F;^1A
MGT]^WNF=FXA=E;&BHF-<.I(Y2!^T)-%OS3-P35 LMZ/GQ^1%%Q"/V<=*L7M:
MYRCIR.EWMN"A-*RK 2' C:7_ )F>VUT@U3C/QC29O=25*E["I%#M+";YQOD>
M6?OD!<Q]78EXPGY!VFX:6.3C/7*07%[^IL3/(*MJR+D'4B@,(T52/*@Q$P@%
M=Q.H?/5UO+:]=I56,JU$E6_$4W;)63&")+@G$,U>,4B2<6I#"5ZV>(*J1SM
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M7'$CXQ?4C[W\0(]D_8  ?2/Z^#_P_K] ,A\5OR.Q!_=.0Y%8/D-]Z4BB'I7
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M"A#*B54OD#@8!$!5,IQAFP^\H*BA"S&@)I"<3 ?[()W$J)"E, >D * %\
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M$+>[!88/.= U:W2E'S^)@ZO7JU5;'HB<7#SJ-ITYTO6IE_3J"N_,^?.RP)"
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M+ZO) \"8H?J8 $1)N=E-X*0WH#GCIOW1 XD*4")#C?NG.)E #TE 3 8?'CR
MA])J#M-R]"B15O(<U=3F]I,RQ$/+D"XH)FAB*G #E5 AB!Y$P  "( 9SNDRA
MY.8OH5POHDBQ0(DDN*IT#9,"Z;84U@$JIB@D80, &$2& "?D].-VYSN%FI4E
MLCWE)Q^0W="R71,W/EQ5R'1=E%,P"4/!P\#]_HZ*O6D "B:Y6PE)G&TJ^MP9
M<[8$4#)9L<KA05DQ#PF)OL'G]/O]']76M<*)$VZH%/GNR$.N#I5-! C0A\Y*
M=ZN9=4I!31 ZA3_8Q0$!\)%8]<TQV98X)ID;U/3U3F4\^GVP(2C"8%"F#P)1
M#R40$!\>/HL@[ZWI35F8WI!=S6-*0)_;21]1O=I)3%3%=<B7K$ +[IP)Y]8@
M7Z:@;MG+B_G!Y9>N-OA >%_*69>IJ)J@ ." ];J(B)/( JF<@_Q%, .2,NZ,
M#*HR.T2>)/[0M$K-%GX*BR1<HRS!DJ@N[(D)DB& #G()3  E.01 YN_N7BD,
M)RE.;4Z^!#&35_'4*4XK@4QDW ^V8 'R53^$?O\ ;Z*5Q\B')C<QTR*D*XV.
MIH&.DH BFJ0%GQ!,DH >2F#^$P?H/TFW2^1/D4%5%442%6VRE-BB=P'E$!4<
MR:29"G+_ !>H1 H%_B$?'W^CKE^1+BD$4S)E444Z9QY(B8JD*HD!Q5MQ/1[I
M# )?/CU!^GGP/T I_(IQ(H B<H&)T_C)RB8A!4.7R6XB'J @>?'Z_7XK3Y$.
M)5W'LK.?9+U!BX'%!NF*JRP :YE]2::0>H1#[>/IR,=W[Q<\!F"HNA1Z?Q00
M0! ZB:HG$;L'CT'2, _^TC]?P]T<=#]R%^W36*^0,H'J3*(?SMY QRAY /U$
M/H2#W5QQZR_VB_[3F)^H/])?YW\A^GT=9+N'C]5%-1-)19/IC%3I$56*H=%,
MYRW82E45(D82@/W,!1$/T'Z5$O87+1@0,)%A#H+)1!(P>L1*J(6X03, )&^P
M^!_A'^H?H2F[#Y9*8/U >@LE 0_I^X#;O(?8?H")]A\LG.8WI A.@LE,83?<
M?2!2VX1$W@/T^I@,@V#+=5&O&9EGPS;0*G>1@S2(+FCRS'\L2TI^V&?%:JBB
M"_H]T$S>GSZ1\?YEOEPCY]Q592M8WI<S#V-FJW1?PLVPITPXA)&-,[(JW/)M
MY8B(MB'(H"B_H)Z#>?2,"VV7H*-O5STBG\QPU6B?\7D]A4<Z;:<0L^A7AM(J
M1^-YN.9Z%8']:G57]67<OT&3.OD<-P;$6,5;C&!J.TW++*M>JEW<_P!*BJL[
MK3-M/QV:<D76]429D7]D@YQ*&>U#16$>XCEB DDX>*%0< X2,*!_CGR[2KNO
M4$JIT#%X-V5N$A5JK!-NO75LYPT;6<NM&,+J0SN#B*2>D,ZY:;E(QJ;'\"=G
M8Z';JE*+E)3CK;]KZ$*UYYZQOW.N=;'T&JPRF0O."(NPW.8T_1(]"MY+5J1B
ME.TN>@J-0?5;2V%:L2<D\>G,Q7.B0C!KC&_;'>UX^^_(E7<5LU(I>'2MHW_%
M\)KV>3F5=!3,%.Y3:%=0@L=ME@L+.24I,:@:_5RJ.A8,W$DN@<W+E;H7R93[
M2D=1\H[!TR(YM2<"F\O8.,A-R_"U9*@M;MFL];HO/+.>V7>2DB34F:3? 4Z"
M;EFI%'*'7(3B4CA^6;CQ7MO2OQ8Z5+U^C'D)N0YCKDU_-)'L?/&L["TNMBAY
M"O:#!1\NQ9.4JR^6:&;^^@HJ&N9KHVB3_-&E<U?'_:N@;W)Y9E^;V7%>AK T
M+.NLSVK![SJM'NK]OG^BPRB)Y6).LJ]K<M$/(Q5,#>A\KSLGJ^Q5[9+!O'+E
M1Z-=R,\^SNGZ96I%S4,48V""K^;9U2:W$VO-%+?<)-VK/&.@XA'+EE&*E>?D
M).$M4YT?=2M.#Z#FO(->WO*-5D*[F4DEM>DSMKT2%O#B6>;'7)^NS^;<\QE1
M@E9NN07[?-O#6HBR\BV1!J7ZM\6[QB,O$O0)W4,_=/T-1CJE)SENQ;:.=<*F
MYVXTT]3L+G(JAJTOT"VGZ>JJ[FG#^&:$]U%([M$02@JGSW0;/-V/1,9QJDT9
M3H%"N3LC?+ST+UGSO=[:I87&<2S*3R.!LW-!7$=(M8\';MK)D%1!-<Q6Q+Q
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M8R\OTI))Y[13&;L5%U4E4P(NFDKZ2BR4F?CM^4*16AW!)-A^Y\ Z'(*1;\"
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MC;)QM0:DY9PD]:[O3V,RFVL6<1S-PVL4OE4JJV,@=4RS)HD\\ W7;*JJ@_\
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M5T><4R"W8)B]=3T%6)B":#9='KM_E;M8Q:)^8DC%DC* W?2"38O_ $+_ &
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M_P R179-KD<X(21E'X..4^7K-S9G.F3L7WLVG#Y/A=NU)#"\_P 0TK;]8O\
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M*C-5M%(*/BJR+A)XD9(Q$0.8JA1*(>H!#Z1CV]ABEW#A/UH&1=IJM5C"Y7:
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M$EI*,$AP]']^D3R<0*'D3% 21YM.T]NK[*2[MP^Y5ZQCHZ((I(L8M4L])O\
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M0Z_,N_F*[<KM$4@9C(M:UFW+NWLX6,O:$G4U<E6C$8P:XM++J.SJOVD4FQ?
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M6N+2"*GO2A55O378*-Z5:: >W:0TFIBZTV;I- DL\KYYVTKQ;Z+"+HE'1G:
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M'L[4X"FHJD9(4W.>I* X$Z)_2GX]PP%$0 0 1^GA5]NBF:C#T@\0?U>^1[E
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MG8M&+VXLH&?6D0<+R?XKBJQMPG&]EML?7(-A:+&U9)1;6P61I&-F\W--HU
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MM)J*GV,']Y6X8_V,4Q#!_$R'[&(<0'^L!$/Z?I(ZE I*AT/^T&/58(YD? &
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>exh1077_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh1077_2.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_X1<217AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  %?D    G
M$  5^0   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,3<Z,#(Z
M,C(@,3@Z-3<Z,S4      Z !  ,    !  $  * "  0    !   "P* #  0
M   !   #CP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $  !7<
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M=K*]C=K&;/124Z%U^55_@FO:YVUI:;"8_E-KIMV^U0.;= (K.L$@LN.G#O\
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M*H=D4/I;;907Z>K40'MUGV%[;&_]!)3S0ZE]8VN_285;F'VRW$NT)_PO\_\
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MC?#J?WF?]-39D8+#78>M$M#6OVOLQX<PG1[OT6[99]#>U)3#[+]8MI!. 27
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M2-6F=-OTFM8[V^[VJ= RZ<:UXN8VJIUAVMH<2&M)]K*V7;_:T>VO:BUGJ;W
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M&/\ Z5G^<%5Q\</Q;6M%;;MUC186 @/ES?4].?H[_=Z?J?VT=F)4TDN:UP/
M+&B/N:DIB^RM^71L>':/X(/9JLJLZNMF51L:&Z/X '9JLI*4DDDDI__3]522
M224T*F6MQ77"^Z&[W"JMM9.CG';6'5.<[^3[D"G)NM?!MRVAS@U@--;3SL>Y
MSG4[7-:_]S\Q.RS!;0[]-7]I!LBMUY9[]S_:[:[]'[_Y"S\"SIK\@V,Q\>FP
MD V;WL(8=S7['OQ\=WN:QUFSU$E-OK%.6T,]+*O-FQT;0T$^^CV_H*V6['?G
M>E[U1KKS-@J&5D[=[18X,N< UI/\W;#/2<]O\O\ XQ6^J486464465V.<QY
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M/MLPW4?9["Q_J,]1CJQH7/;N;O?_ -4Q5J,)C+0*Z<EKJ; \DFD!\Q8&;_\
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M<" S+C  .$))300E       0                     #A"24T#[0
M$ "0     0 ! )     !  $X0DE-!"8       X             /X   #A"
M24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M       ! #A"24T$"@       0  .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #1P    8
M         X\   +     "0!E '@ :  Q #  -P W %\ ,@    $
M                 0             "P    X\
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   X\     4F=H=&QO;F<   +
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   ./     %)G:'1L;VYG   "P     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     $_\
M #A"24T$%       !     $X0DE-! P     %?@    !    ?    *    %T
M  #H@   %=P &  !_]C_X  02D9)1@ ! @  2 !(  #_[0 ,061O8F5?0TT
M ?_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( *  ? ,!(@ "$0$#$0'_W0 $  C_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M/YR[?]/_  B2DP^VMMW'(L<P'Z'V;M_6:H-;U"(.78?$G% 0ZV56/ J>'O/
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M    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '  ( !# %, ,@    $ .$))300&
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M0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8
M,0  86-S<$U31E0     245#('-21T(                  /;6  $
MTRU(4" @
M           18W!R=    5     S9&5S8P   80   !L=W1P=    ?     4
M8FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D
M   49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P
M ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E12
M0P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y
M<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M        $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V
M,3DV-BTR+C$
M                 %A96B        #S40 !     1;,6%E:(
M          !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4
M !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO
M+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M
M9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT
M(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ
M  !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@
M  !,"58 4    %<?YVUE87,          0                        */
M     G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ",
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MH;$B$Y'1(Q2 L,'A0C-B) 7_V@ , P$! A$#$0   /OX
M
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MYDR+6&T N^                                    #@'(  . <@Z'<
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M2-)634]2GROB=EW@
M               =#L6**Q+@ [$N+!&1AR6K+AE(%?'8\RUY=,X.QY%O2XQ;
MTN$<'4QD+G%T#@ZE!DD+L')1Q6):D@R\12!6!;<I@B"IB7'N0),R8%;%/E0G
M!194)T)B>IR=SD           &C<W8FM\U<E%E F1A(2[10QEB:SS9T:F2X)
MG08AF51B@5B5&8\&59BN5(5>78)24Z7[)28_$I(TO:8UF2!B<;#S!<ABZ12)
MC ;:37&7Y+(%VBS909LK)T:VS9":]"[!>4MD4Z4F5P7C,Y3:
M # PU<&2Q5Q=XV+@Y!P#DX.3@ ')P"B"M3L #D'!R#@Y !P<G!R6C+HD6 #@
M'( .#D  '!R             6-,-"O2,/8SN !(R='8
M                    \ST             . <G!R <'(  !P<G!R
M<'(             /GV,M3YWBV)39DF4B2(D9F<98%JS8\4@6_,HR),*3"8K
M8Z$665,KBB27EY"TQM,/,]36N8O%L2:E<DP*8,639Z4B7\(0LD78,I"R!F>:
M4#+PDI;$K BB%+R%)%?&8AB:?08             #6L;)#! U^$R+YEM"O"A
MBNSN8]F[TLZ4.9N@QB-2A49*2LB/)04^6W)R7@-W9Z@U E_#"(N"4 7C*O,,
MC-<Q9)"98F*!<\S5*#-BQJR,12<EE#808\EHRHRW)MB,^35 ;7P =#N
M      :T#9> :A#0T7\,QC7P;Z39X 8J%&F;H!P:4#1\7Z!=<P!+W'V.$T !
MJ%,#2Q19<I4V&$S-/ALD-=YEZ4B1!>4WJE(&R$     &K4VE  \#W
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M88F-9AF7 +F$X,H##8NT34M63<MN4T9'F] N":GC;"      6S,)39,
M#6&;/              :RC9J >9K",K2V9B4;7BMP#$LM.5824M69+%JR0DM
M,>#8:8@EPBZY;@I8S&,A34X;8P     "V)A4;(P     :KC:B
M  #66;-  :ZC'$LR7L-S)Z &(QKG,<BMRZYD&8I%5DM(0N068,XCDQG*,-L!
MDF:FS;(      6P,+C9      #5D;30             :US90     #$8PH-
M7ID.6%/ O.4N2@[E6%@BNCS+TFZ RS!J@-KX     !;4PT-BH     -69M,
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M31W ,%B;DY*G,7B1D.9;%OS'0R?+(%U27F2!>< U2&UL      L&6-,[@
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M):4U.ELB_119L7,)2E2@#Z]"8G(. #@U4FU8Y.0<'!R<@Y.IR=3'\LF9VG
M.#L<G4[' -51M7             .#YT3.4['J>!Z%J"Q1F0>A!D>>AA<4L64
M(,O,7>,9"P!6):PN27I($E9314I.2-*D-A1% ZDO)D3<FQ$G<A2&((L^60,L
M2*):1I*ST/$\S@\3Q)88TGT%             'F:S#9N 2 EI2Y;XR.)$52
M:TBXI@$5<>AEV>9BZ70)F6S+]F-!095Y=$LD9'E,FU0\#N#S(D]#R(4]CS(L
M%ABR9FD3\$(19YG8\SJ1 !JQ-IP            !T-99LW /G#+"%-F3YF^:
M]3Z9P#746Z-6YD8:SBY)<PKPM02L^JXK,   U+D>:QSW* ,6#<*5^6S,.2RA
MDT65)H;["*,[CDH(^, V+F*)?8P\,Y#Z? #5D;30            #R-9ALX
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M:&^LJ  UPF4)?T       &I\VP      %F#'8SP     !K!-GP
M  !P?.L9FG8FQ-CQ!T.#L>1T.3!XR%+PG<EA-" (\\B4GH20A3L1AU)P11KQ
M-A)Y$01AU/ B"5G0ASW/(%!&/)EZ3<A")(8C3D@2:$6>1&F(QOC
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MYP<G!R:XC)0R)   !P#D  &JXVH@     %IC%$V#@'F0YW(@Y . :MC:4
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MP!K/+$F,Q8<S<,W#/XY     -81L]      +)F.!GV     #5";7@
M     #P-6IM1 !P#@Y.0 :TBRIB03<NF64+X%PS'LV#&QH   &K0VE@
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M-9Y(RZ1FZ5&5 68+*&/1GD;Y3W  -19MT      +&&+1L8     !J2-MH
M         !X&KPVE &JTMP09D@#'PW, &MHM46X+MDA*T*K+<F6!9(L>7Q,8
MBY!>0IXO49GFH8RG,2B//$L$9DF3AJ=*Y*J*K(0E1L',;C8H"FC2 9='4E9:
M@CS<0 :G#;&             >9JC-L !KK+"%?'0RO,>S92 :\BF"J3&LN 1
MI,RW!<TM^9"F,9#D&30N"7,-@9IY,[C'0BBW!#ET"KRUI(B *B)@5H9'F*YL
M:!39H9,O"_I@ 5$90FPT U,&V<             \S58;5P     :X#)PR#
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MC%>&&!FR6%(<O$7;-U9BR;&06\/CD-V!9(I0P;-GQOL -2!MO
M  / U/&V@QQ,""XQK=-BY/28E1%K3*@RD-;AD89 GF=0=29%)GF>IY$Z."#)
MH3L&EPW0E)'B1YU(0G!*SU.Q)R:$P+7&(9LI!#E %,E7E!E2E>$Y -09M\
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M*].X->9!%FS*4M024CB^)C65N1Q.BY!39E\3T TZ&XL      LP8>&RH
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MP2HX!YG@2 EQ<HRC                        .#D
M   X.0                                          #J=@  #H=P
M
M
M
M
M
M
M
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M&W3K5)OG@IMJD*SO5A5VE7%YIMJC$+%.-4V,"IUJJ'X.G2JHS'[.=4_A=/\
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MQ#P>(#+[<[3(9RKCD:V:XC4LFCP_^.\'PQ*)@XP*32P=H2.20P%HU(E!_P#
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M\[5#5[#8&?VP(<9\'5O#@>"JK8:$@'5!#C.U(2L2)*08.OBLJ*CCP+Q3]";
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M2#V#>>Q5891/[<GVB\9P23CS[9?M@ <8," )<Z7C63;7)T;N^Y#E]C  X\^
M/; 0XQ@LO&?;'DJLYQ8_]9 FT-IHZQCS=\P.//WOV \Q=ZP L_O:1S#A-VL0
MWY#A%W0Q>QG;NPBGJ>'W3QL*-6UMT('=YP;MXJ%:X+SHLF^?OBQ8*Q8Y<+&%
MW:^V*NEBDCV5_?%AV9G-XD.=K6+N_AP/.Q>#![B$$7<0.S@Z^2OK5,UKVJX
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MLY]=<;7>UTW7FP20;OIUM1*[!ZMK'C"L=;FUZQ@XFTF89,4D^/(0X)#$56F
M'6OZ*5.<A7I^(\$V>AUW YV/O>"^?SQGWQ^"6!P_W-OJS _(=.NELZ$#OP6
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MW8<_3?M"HY_(-2]!IK(4SPNF^\VT8YI Q#QY(S[QMS/YLG_;_6RJ@@&O6?\
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MG_9N1X+@<00S.#PS@Y3:=R:-.)XPO*42XB@I)*@\!PN(6#_M^AY(S4TBX_5
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MVZT*Z=XP575; Q-5!^&C%*?_ -1$' L?^DXSC/\ 3  !!C\8 C#_ ,77_]H
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M8Q:Y<@ESR0"*2Q.R!;>02F'8:*(\R@BR/28-YH^KXPRX\>MM(5RRZLM__]H
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M9CIJ*@JD!@.BL4C6^6MU*O8%],5B"CV]4B3V64DGUIEF48R<M6S,X$"'8(2
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M;L["SY-6&!)QU+H[+ GS:8@(V!?N6#F4FXR;<B>,C'(MA6;K*G %D#D.']X
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ML55$_P"F=MFZR1A3/]IP@FNF10GYB&!-0!*!TS?0?J'I-<6;$SDKH'IU_P!
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M )E+0I*PZ,U<NXS/\1K^AH0DAK<%79&U]=F#AMG4[3Z+':+&TIW'2;M)LYD
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ML^D TN]RD)'&BVK^B3,51M+K+&@7J#IT<=&G?X2S1Y^X+;/3UL;2;(JSE&(
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MGCZ>N/MEX#C@!Y$ \1 Q> $1 ! P?A^ST8!* ^8>)^1$1.7@0 IQYY.4 ,/
M#SQSZ)R0!^V83$ >>"F$1$3 '/ #R/U].8"T0K&<A7;B+=.8R02^\S6<0DFR
MF8E4Z7(%\F$K'(+I_@"B11_#T<WB'*G'W/<>#\%$H>1>?$?RCQ]/?V_8'H0
MH!R' \<@(@//L(@/(_4?1>"!^3^X(\B)>0X'Q$1$2\A]>/KZ\O OE_TN/S?4
M!_O?7W$/?]OX^C ) 'R#@PB(B80Y ?<W/E]0Y^OU]"H9(IE!)]OS,)C'!,1
MPD*8PB)2&$H"(![#P'[ ]%4%(@J%Y\3^( 8!'\>0_$/P'ZAZ#D.>!Y#GD>/<
M!]N?I[AZ\O#\P<\&$1$P /N( 81Y .??^OT/B7Q\A$P^!C%]Q#@1_*8..>?[
M?29/M@!4AY3* B4"C_T@ !#\W'MS]>!$/H(^N )P'Y0X 3 '! X*   \  ![
M?U>WT]<@''T#V$>  O/B !SP !SZ$YDRB<2^(FXX$2^P\"(<<\" <?LX] 4B
M290 XJ< 4/\ K!#@3^__ #Q_;]?1BB0  X^1_$1)Y&Y ?(1*(#Y<A]?K[>@*
M"9?$   #WX#@_F \<\>0'#GGZ\^O,Q0$WD!@$1$>#%#@#%#G@I@#\0]_10!,
M."<^(>X@'ESY!P(\<#R/M]/1OMIE)Y',H;Q]A$YA 3"(_7WX /Z@ /I[>JVY
MEH5B^7I\^%IK"JZ7D>#L(0\Q7PEX\0$/LO/W)/O6OE^*+E0O'!O7D)?S"42B
M/(\B4P  E'W]P_*'_'TF!2 4$AY3 HF I/R>'B4H#X@0">P%_NA^ST "D3V.
M!P]N/SA]#>WX^E1*F ?>'E7@3?X@^/AR;W]Q\?;T7@O'B @' F ?<H$YY >1
M'P  Y'WX] /@'(&\P'D0$IN +^40'DH< 'L'MZ$Q2@!A#@1#D!$!$1^H#^T?
M^'KS$OY^./(#&*;CR*;CR*(" <D#T'!"AP;R]N0]_</?CZA^8?;Z>AX('O\
MA^ !X%)P ?0I? H!P'M[>A#P+XF  ,7C\I@ H$ #E_NGX( ![\^P>A$2@(C[
MB(B(CS^ @(B(@)?P_9^'KV3+_>.;\1Y,I[*";D?S>?X\\^N2D* _F_-P'E^<
MWF?W^OYC>X_T_P"ZM#W:ZU*GDD/U L#6FQP]?*^_1E3.[_2&EGC0'/Z4BI!4
M\/+P P";CD/0'5W7&TB&$Q2G4TZDD*8Q (8X 8TV ")"J%$?V 8/VAZ%0-YQ
M@2 43B<-1HXD @<<G$P3G'B'(>_T]_0.$]TQU1N9;]."Y--I1T1<" "" *EF
MQ(*W _W>?+^CU^G7W?&D7''/V%=/I":W'B!N?M'G /QXCS]/IZ*<FYXZ<IU$
MTB&)IM*,4ZJO())%$)L0,HIP/B4/<?P].SI;;D2A& IE?')I--.5D98QB(@[
M,6:$&PJG(8"^?CY" @'T]%.GM62J$/\ ;$AB:/3C%/\ >.BFEXF+,B!ONG<)
ME+Q_>$Y0#ZASXH;/E"YA6*W J.BU!0?OF!0Q4."3!A^\8J)Q O\ >$"C[>P^
M@%+4\Y4 P$$!3N]9. @ISX" EDQY _B/'[>/7BEJ><*F]_RIWBLG-^7CR]BR
M@C[>0<_U^A-_F30?$!,43?QC7> ,7D#%$?WCP E$/</P]?<2TJ@*I^2A/-.Y
M5TY/-(YDE2>19$0\DU2"4P?4I@$!]_7'^8U#Y_\ [OK_ /Z(?T^O_9BT3_U[
MJ_\ ^B'K_P!F-1/_ %[J_P#^B'KVT:B?^O?7_P#T0]<?YCT/GCG_ .R^O_3Z
M<_\ R1^GH!_S%HG ^X?^E=7_ '_J_P#.'K_V8M$_]>ZO_P#HAZ_]F+1/_7NK
M_P#Z(>O?1:(']=NK_P#Z(>@ NBT4PC[  6ZOB(_U $A[^C"?0Z,4">/F)K;
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M,>A_^O?7_P#T1]<AH]"$!_$+A7A#_P"N/K_V8U#_ /7OK_\ Z(^@XT:B#SR
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M^0'GT8$]!HZ@D$H' EL@3^(F.*90-XOQ\1,H42AS]3!Q]?7OHM$#_P#RZO\
M_HAZ Q[K4BE,=-,IC6.'*!CK?]40!%X "=7_ )H?4WX>B@-VJ("8 ,4!LD,
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M UNCUG3W2%:I\8(P _H(.OMUSD;,RB"3<#F I0$P\G%C\?'4)B*GVP4%EA%
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MLF=04SI% QS?'7TV\SF$YQ)U]SE(#")3D_NIP92A_A*&+^SW] 7_ +N_IZ
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M%$?;&*4'! #GC_Y&<?3^H/0RH](NGR<*<10_>Q,UH!(TZP.2H?8)*-D4VPJ
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M_7Z!ZY,H0H<E#DQB@')S 0@<B(>YCCP'[1]O7D*A +R!>1.4 \A ! .>>.1
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MSBF"@%$1$/\ WR/<.?Z_Y0Y !X'D.0YX$/Q#]@^OH']G\_W* \?3D 'CT
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M@2V>8OT^H?8B-SV#2^\=E&6%W?$+#& \9MU!<0CIF BD]347]9%\AD1L.4U
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M:,L@\Q[@E8UZK=TDD:[L^BUN@5WN2A$42/VDT&4?US% J3ERW,HAXCYF]4%
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M8BGW&&?Z!G\'1VM2M\9/]KW;J=EM)J3*/C2.IF 7<O6#DRJ#90ZWYTNN5=[
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M=RM-;2.>7'JUK-CZ=-L>PNG:[TQF^M5^=X_U^I66M+=;M"E-FB[+4*]T]N;
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M@GO;#$\$[N]/NI].OO4_LQ5-]S&?S;']DDNUG:'5Y#J'(6AOHXN+W3&N0:S
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M<*+@6<4>VZG2+8QO51M-FI\*2M3P05QBW#J/L[:!E8M:,%Z4XK+F9B97A03
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M*@8BI>2J 8!$!:LEOCMZ8F:,RB=!$G7G+T#@L*:9!!=RC6BN'*0@W* E5,J
M^0C[?F\BG-\<W345 ,4XF' ,[$IC%%0?S%+"IE. _<,' EX'DO(#XAZ<+J_'
M)T[%1R<RBHEPVC)% YTOLF%-)&&332*!!$2@0" !OS  &_-Z_3%^.;IZ)?M>
M'FIB%+74X\"IF 5EXY1UYG*'L?[@B \CSR(B*C5/XY>GXI',F8PJXG3%UCB7
MZ>+I:.4=)E* CR &X,/N/T]!_P#0YNH/L(AR.+5$WY2_]7SY,!Y,//YA_'T!
MA^.;J(80$#?EQFIE ?$?R@(?HB@(?MY]A#Z^B ;XY.HX 4#$_P /'*DD/B8/
M'R,*3),5#<$#@1Y, B(@("(^N0^.7J( B;S'[F.558 -]LJ?L"C(P 3Q /RA
M[>7)O[PB/I4?^[FZA"*WB(C_ )+U$Q2B4H%#P(HP$$0$ ]_M^/(^X^_OZX'X
MY.H!O_5<2I7]'U\XT1_#U_[CBZ@__,2H_P#Z&>WIJ=S\?_3I^NRC(^%:N9/K
MSELD\)$14>WB(Q@H]D:N[=+HQT2T2;H@<YOMHI%(7@I0  CR=2>L9&0 !?TB
M>"94FT$I0(! !J2J B %*D4 #CV\0_8'I,\WT?Z@3!T@\4C2O6G&) R8?F#A
M,SNE+"0.#C]./J/[?0#_ * NE'(<  _Z5L*Y  YX !_@3VXY]!_[0#TG_* E
M+_[2KA7Y2C[B ?\ I">P"/KQ#H)TJ O(&\0ZKX6!>0   >/X$XY  #^ST #T
M"Z4&+Y!P7_2MA)0*'YN0'BAAYD'R'DH\\^B)//C]Z4."I*$53#_2WB+<Q3IC
M^405;TE)0./V<\"'("'OZ08+?'OTE4:M2D(W3-U<Q03D(00,4OWPI1'!@ X
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M^7C8\\T7,MC1:R,_/:<CB]EZ?5ZGRRMQ<O(C.[W+4]%!Q"M485FJK'K(2O\
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M])-&C=NU:MTD4&S5JD1!LU;H(IH(-FZ*92))(()I@4A"%*0I0  * >WKZ?\
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M#P;WY$5D^OTV@<P+^96_8'LRW1.+A\21/R@ALJ2( #E,H%X* E2*"11!,H%
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ML78PL6I_(?BGR* R)EU749UZ]8="66MP.>,_.:(9[6):*GVY7;P3(2)C,SF
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MIV&,)3!R4P%R*WB)3!R')1 /?UT2763!(ZO3_KB<2 0Q #G)*IP $/R8H>/
M^X_C_-*81$#%YX$!X]A#@2_T@/\ R_U>B?< 5/ R9R_<\53>:*@J(G$ZA3J"
MHD8?R'Y\R?\ -$!Y'TY$&Z1!>'^ZZ%-%N3]0OX%("[@I40(Y7(!?RF4 XE_#
MVX  ,"BW(>8?]9QR53CDO   !P)0]PX'V^ON//8S;J-%SK;0NU-NIUVV*3E;
M/-3C.5GJ'3&] K*T'%2CMRPJ[9E56B34R3$B)%2IE\_("E %$O$1153^TL@/
M@9!8AC*F5*JB)!34_4&7,*O(?X@F'RYY'DB*/FFBD0B:*)! B2*:10(F1$A
M*"9$TP H 'T /0_;+X@( 7@/H' B/(!^T1'W_;]?KSS_ #/AR216=E(X8?(D
M5TBDLJ#95L3 *>L47:)1^TH"+O[?@8W]PP@  /("!SB)P,H7P,)3<<D#C@O'
M''!1Y$/Q*)A$..?7Z@42BJ"1D2'$I3&22/X?=32,8HF(184BBH #PH)0\N>
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MD6+QT(T-(XI'75; H":\LDIQ]Y X"''D'B(B  )1$ZROQV_+F0J:1ES%_P!
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MNI;]V3IK9&)K]@EX+,UH^VUZN5A!JU="FRJ;3]4@FB8$2=+\;H;G)::PZ_\
MR%L^\=MJ46I<$\VI-?/>]/NSS$NOD6K"*+QU;KB6B?NZ)4=IQK+Q:G<?81%R
M""604G+;GU>D_P!'J>O]@^P</M*&L/:CIVQ7+2)C1,T.M%YW#1"EGSW*9B30
M?I0CI=@WF7\/&E<E%% 2J*;%>;IGVB5C*;AW5V'KB=4UAB[:&O\ ?96B36KD
MOK0(61C*=3J78(2Q-8D\8\F'+F-M _?(51D7]1U0^/*RO>L4_C]4PNIX_P!B
M]&75TIW?JY8<OLE/D*1HW7]@-?CXZ4F7,16US^$H>%7@ID[5ZV=N2MA17TU-
M$IC";.+UX@*;AT<QPJ\F4!X2$7*RAQ-[_F$Y_H'N(>OCS3\C&'_2'AGF)B^)
M@YH,,?Q$@@4R8%,80 HAR4 X'W ?Y;I"8R]I3/2GT<@%93TB.4E*#,G0DF#F
M6J=P;(Q4XLA7KG (NXER[39NU6)'GZ@B"QDP2-_E5I,?6Z>_F[O+7J-QJAW"
M<O\ G6)LY:!JT7*4RGV^>A:ZO()66T0;^T2*#./80S&5GG36.;IM4BG5^T4Q
MP#@0\@$ /R(B(FYXX\N1_9QZ/[FX4#@Y?R" E_$GN01 HEY+["'L(\>X\^N?
M(X&]Q$X GYB83>7D)A3'\P<  ?@ %#]@>@*4  I0        _H#^;\22!COT
MG/\ J4[$.&X(' C%9%'I%V 2=$>\ME@.IY.TOM%^XER4%!]Q* #_ +Y<OT;Q
M1TW#N7W_ #$!10#D0!7N;M7+=H'DJJDR34(82D545/Y#R)N."A_*!3%,81.
M% @\&$W _01$I>?'GZCQZ^,35+ANUKK,_P!TW_R8V?8*)(]JYKJUGT(TS&)=
MQ..4-M88U1Q$T%#$'-=9MT_L,S.'DP5ZH^4<*.G)C=1G.%VW0M#[PUW!(?MY
MV1ERTNGQ-BG,QP2]OX\8VY0DI/56);9=VNEZ1(QD3;8XYRSM>8NIEJT.1R!
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MA!Z=;:=//I)M'. $KK]<9TJD<BAE!Z>9=(9;G*^4:>U@'E*1OT%@M80KPT_
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MZ0U(UX%&3E+S%5-XG_EYYM03!,PB8X%* !SSZ0<J]SZ( N%11(S)4]36E4U
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M3( %:@ $("AO$/H &'CZ^CF_@VJ>2A0(H;^'8?E0@*%6*0X@S_.0JQ . #R
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MM=$HLQ?;!3ZA8L^K\Q7JY.:D_=2NCR<1%/VB[-DYNLF]5<2/@0"N53B8P"/
MA/=JX:_VB4M\O;];N!6):MG=9<NCZTF[9JUFVV:IUB'F;E3J'$O/TU?8N? 6
M@-VIUE')VJ(E^,?_ !$TP;=>?D25#S!3E<1;]6VX-T@31.0JH%6%0!,<H?;3
M.'N;@/52C]BMJM<6N#6>FFIV=?L%C1K]+J+FNL[GI=X5K\>_)2LOIKVUQB$M
M8)(6\;'J23;[J@%.82SN5$T9M&V."9Z@[3DK# V6N4FU'PLZ26Z,,^OTW%L:
MC?I/%U'*/\3HQ3MS^Z04'[IO\)?[4Y#U^V.X63JV#9EV6MB%^J]ES]M5,:U]
MK97]$N4],VMA&UYHS?,:=*'=$!Z<\=^A5_5?:$IBEK>VSKZ[P&9W2]MJ'2+!
M-Y=HD8K>57T)(V2,MM.@W5<)9;%GTQ78AS(,IANQ.V?,TON-OO =(58R^3&F
M6.":/+QI- F:K/9!KL-IE$EL73C7.SS&D9<^IA+[0:5DL9-,'UBG96/:P\2P
MD&SA=R5-=,3:O4C660>V/$\^H^JZ'%P=.N]E794/233W\#R];"NUZ4_S!7LW
M\,/DV;:O_O1PJX1^UX%.8"C'ZGE4L]E*E(25CKZB4W7;!4+1 6JES\A5;K4;
M=4K5'Q-BJUJJ=FBG+&0CWK9%PV<(F*("'OZM^46G4(Z'N-#BK#*VXKR MZ=7
M@!JN9NMHL4#)Z"2!4SYO<H?(6:EG7@QE/WR2"+^M%K]@0/Z9:K3-&<SM2?:#
M2,Q30_@:_0=N2MVBTN$TJH,G%#L]=@[M]B8S6P-K$@JA'N".(0PNTO,I3$"Z
M:ZI?92+I6;Z57,AT96PYAKU>LM T2VN*HWKU;NM#E:&VOU74E"WJ&73=O8M%
M@#220<&6*@?[@2%7UZ=MC>>C*?'WI[$4;+])U*69UN1>VQ))^ZA\TK5NF$$6
ML519F4=J&;E1:1<4Y=**?;*7RH>/UC6(:>N.F056FZ2M'1=E<528<7W/GNMY
M_43W4(8M4C=$O.4Q3RRQ5>=/$9A["-CNDV_@*?G =@)&]3*F<VK1[KDU7-'Y
MQI+VXV:]YNYNZ%^AH7.B54M\6"IM\UGWKU92.220C8E=R8P$ GG<[[4I.-M%
M)N6&V:XU.:8&.K&V:J6?/9*:@I5N8X <[&8B'22R?*8B9-0IA HB) Z'!Y?<
M\^H'7HWEP  '_L+JP($("912*0@'\0#D!  #\H#R ?R6?6=0L+2JT"FL4Y"Q
MSKM%Z[_2IN7K2+C6K./CFSN0E).7F'[=DS:-TU'#IVX223(8YP*,?O\ 1)"=
M:Y^\8K/7O\:4RWTBUUQ5FQ9R3Z)LM)L,,TLT9,-&3Y,XH@W4^X!BBF8Y3E,,
MQN&$WZ.O.9U^8N,#.6)DRD^(R5H[EZWGVIV96YW;Y5JFR_4%(V*HHLW62$I0
M,<"^IW:\+OC*\YQ6YRWUZ;L#"/E?MQ\G1W3MO/-?TY&JRTBL5%D+E(K4%C*-
MET3  F4*09+2^O-[CM#H\5:+%3'TY&MWR"+>RU:7>0\M'*?JT$2&,51H"R0D
M$_FV524'Q!0H?SOB@\ 6*8=)[;D,NFDX.F"0]5;6H=HH9!LL!3N#)E. JG20
M\$C\B*@)E'_?(0 (W)Y[_P!W5OMH$.0I 4[N=AO$Q0,81Y4 /S<\B(_CQP ?
MR]H:=8I(\)FG>+XWR=2Z7J36-D+ XQ[6\OT?2M+&&LD3YEA4J/>XF^-9,AE
M1/(K0+MB+A%8[;[O^=796C9'#-.N_5VTX[2,FQJWZ'J!]=W#L%>,1K5@GG\I
M$X]6K=2\QK->HA1C6K%G(/4'$B:1<?:+%D_4:E'9IE?5>&9:1B_R+Y;0JLM?
M[":-ZR-^RUUP>ZXM'T.V'Q]Y.2]::S>;V-]*MF*4,E *7%^FS2>$.K^H[$A#
M-L-B+?I[CM?,-=K-H5P8774:EV%PJ!S>F=<=39)9?(.XK,\GN[1G),WK5^].
MU2JD:O'M&SQT] O82@M,^SV@YU9.P%VT;$*A0+A)RK!C2K;2J0V>,)IC(U""
M8TV9=7N"DW:K5F:3:\/ <??%911+U\2W3&SK'FM>PKM,QWC2]#HY9&P9M0L6
MQB:UR<"+DKG+5NO)?K;G7-"A:/'-3,F[YZJ]>+($^PQ<."?R]ZPE6P/(P>G'
M9O\ >#02F.#ED&*W87+<2$ 3&!9'DO  (CSZR/$JM7?WO(7'K)U47AX!S;X.
ME'16JD+EMU9(*3-FH&JTR5_=AX%-8T5,P,K"3I4CQT@0C-P=4F&PTE_IV-1(
M68ZCZ!H5G@[[;Z\>BV7#>M&W==[[1,ZRUEG\A%/H>>'1(N236++QK!0B#AH#
M1,GV!]#FF>YUA6<S@P_62*-5H[8'.CT&5U[K?A^P9C-=G+S#ZQC<K6;O_G4^
MT!C&2,)^@86"&@X]O),)AO,,&*"+6GX;FW5NK*5?L-VCVZIV-EKURI]C&\ZO
MV-PSL7F.L)RLACE]>5:6K:&?2=:78QPH3Y&;9@DE/)1+B1C5;O?,E@NLE3F]
M$8:Y+ZM3)J]W*8I&^LK#\D+;MG3^NVH/$\P1F6^52F!IN*G(R"#5<S S@[-&
M/78'="YZ\:Q/YM@D#E&;L:%9:A6:%V+WC[W3IY3IW;I&<Q/,X:2JA'NY4C0&
M>PB+U[)2E7A/UJ2HJP:D>TBF*"7E_> H!_<,G]/8!\# 42\@'TX_V?Q@A^80
M6Z^?(V3@#$ A3%;=6E@.)3(J"(B B'Y3$-[_ -[Q\BFG)K("45\CM73+?.AV
MH.KW9#PA,PI>XVK.K*;7*Q&)UBP?QG+5Z,KDJBK"'48E?K+,A_4))IK#ZMQX
M*V3= P.#5U6K9YELMIRM\++G[?S-8KO=3:> I\4YSY>VXU&RT77*DC(R;=M.
M61_)@M&E!!L;Y$JC4!J.:9IV;^.C!>J&4W(+&NZ=(73(-$W^Z2<'8Z:QA@<0
ME L$7LJ$.+Q%=PN5LV=*%1-YH@-HU>4)4KU,YT_[*ZGT^ZFV7?+M;:%DN@;)
M6LWSBF9Q*[-;*W)6)[2:54:5/O47:;3[; ;T^9LT$TT"G4?7T]"Q"M;UJ64=
MZ^NNOM)C=IFYQ4NMWPK>5L;-VF=VF-S&JM&:5$ELW,RC<^BX@ 2KZ<>@E(F7
M1<JG[";!G6;5/6ZJ_P"I74O"\MB'^N)9Q;KK9L2LNB_QRJ_!.HSD/46:U7TQ
M5Q'/5'BJJTE&"V%-)%=)RG9L2/LEHRS1+%JVRZ-1[2I)UWL)<<4A-/UN6T5G
M2Y>WZ5 /(O8K!'H2SH'\M*L3F6=2:OB=4S=)RI:(AI:Z+,TPFS:?VQANP5S=
M13B6M6RZ!\=<STC:TB]X;$UU*MKP*-]L;VVRI$!2AUX8B+!)#[ACIDI=9M]+
MJSVC8).;7M6#9$[V6+N$J38YO&<WQBHP5TV4V=1CR4BE4@OZL').H]PO5Z_+
M14<(*$CTVS7N!5 CD4[OV?[;8GV.I&&ZGN"FFDR&'K=VZ]VK48>U;N6M"YMA
MK/*Y=+/&L*DB]CXUFLUBVSH[0HBCV:D>OU*S*Z:GVXVHE7TB4MNN/*"6G]1:
M=1FU!K5<SZ3<T&[,&^ASE<3DET/NQRS*%EK,^?J)O3))$4S6PM(7+LUPV/[*
M]=>Z$A UR]6"[3>9SV&]%YGJ&3J]5_WM6H=>\5TCY^UDFER=+LA6C6ZZ:K$K
ME1/TYZQFIN?L;(KW8['[A-0*.CM(^3D*+H5[W[0<LF:'IYJO*M:=96%FTF$_
MB!BLQ,:3@F\K%F4%N^.18U%U&9J$MI-5ZJK5#0);.J\E2:4YN$!CRT187M*J
M[))F%8K!W[4YF#%))(C9M]L$DDB@!"]"56WF9N;I[UV,D90# IP;+*R)C& P
M%$1.(?B'/\NQ9<IDM?W5E?*7(UB8R2S6,M0C+U7Y=5LSL,,A:#)J! V$D,JN
MYAW0B@",NW:F%PVX^^GE&8=C@F)RZ0SME!5NL7^U5^>ON8X6JPKT=7:/I5TJ
M\4SKEXNM%C"N_'],550[(&K%5\Y7;JO%G-:H5.JE&K[EVJ\-!5" B:]#%>JM
MFS)PY&)B6K=B#I9NS324.)14.0@ 8>0].*W0J?4Z37G3Q216@J?78NLQ"CY=
MJV8KNSQT.V:-#.EV;)%,Z@E\SE2+R/MZ<06?U"JTF#</#2"D-3J]%5B(,^.U
M:,3O#1<*U9LA=F8Q[=$ROA]PZ:) ,(^(?SOBR4 _BDA8^Y)SI^X"=8_6QTDB
MKYE'\Q4R'. IF_(83 8?S$+_ +[6CN4RI+FW7NO]XA>."B/=KL*8A"B!2<E(
M'T]N.!_F";[9/(?[P^(<F]P-^;V]_< 'W_9ZK#'KN:QJWJDIL>SNUHUG*K9J
MH)]7,7LT5(Z)29-*I5.UH4*4W&-))1<--2P,V:"<+**$63.@*A#U2QY028S&
M:S[!=ZS388VX2KV,TOK9H=F>0G8778*&BJ++F;QW4.OJ1]IM""S@R)ZO(H.C
M+M1.F50S6<ZNC'R3O%;QI[*'2U-X$HUG*[UEFNV%6IUN?KYLVKE%D;WE4<V%
MI'/7Y;0FH_3<C$#'F*\/UCS*(SR%ZW2M5[S]$J7VI:P6[1&AS+BG]FR:+:J=
MDD4P/E+.'M\%:<RAXA]9GR;Z*<QSZ1%M&JR!&*ZQT3<>0D 0*)N#"'O[_F
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MCKE5=,\!R6*=2.77?'9%!O4(=)"2RG2K&K;-$HDJQ.V!M+UNZ6EV=]*I.4E
M?O%#*K>1SCS YE.]2L(L-$K$I,SU?@)^@PTZC'3-FKK2GSDFF^E$'<JJZFJE
M'-HER8[@WWXQLBT-R@DDF35-CUKKKCM:MB3;<:O:76@=?E4M%U*OXY@_[IV=
M7.:E-5A2T:Y4&?7V&%DX>P3%^PE8-D*)5%DP+ZP"_P"%8/E%6A:)59FTX%+U
MFF-(!Y4:]ML;#S5G?P/_ &5K),E[PQ39*/Q7 7"HHI?<X,F7Q*79L$S>=O/9
MBU:XS:UN&SJS:%IFS6/1*16 VYXTJ%*C9JTV)K+43.XE.SO_ +/Z%M'1S--V
MJF04BFR7#Z3J'V=#URM:M)930YZD7^DR<ZRZ^V!S2-7@2-[K6(48BU9Q-1BC
M>1B'GZ9^1)$ZZ:"B!#*!;L\?:F_L%OHNSU'KE9X6B9OIF@*,-\O=;?VRJ9$B
MXI=1G&\C>Y6#B7*WZ)N93].9(R:YDE>$_5=V/$+Q%Z%F=J6G6L+98QK(,"+R
M%8G92KV6+>1LRTCIF(EZ[9(5TP>LW;9!RV=H*$4*42B ?R_&/YK>*A>O'R*F
M02\ $%#BAU8!3E00Y*)4Q$> 'WX']G^VWX[K[OZ4N&; +D$$$7"YD"Y]/&6*
MBDY42:G5%$IA*54P)F$  P\#ZZ$)HB(I%Z;]< 3$WL8Q/\IJF)3& #&#R,!N
M1]QX'\1^O^U^*<H"86RKCO$!R^: %_4%Z_0IFYQ*82N#"5(JP!X@)0\A$W_,
M_P!]JO)0 0V_N@'! *0@?^UK=A>>2)@4GE^WV^O_ !_VO?E-NX0:K*]+^S@)
M.73D&39JJ.,W)(BRKL"*"W(F*GD)C%,0./?@.?61YGA,M4X.^2>,=2+3 PNA
M/+!#YY>(:@JY/?[)DFB2]88O++&4K5:E7W-<E3-VRRI&C\WW$E$1.F:J/SU;
MK]FT"M9.LFETF7SC8=8E)?HD..;E;=+V' <+2LE7>2.MT3L-3;:^B9*3*]I4
M?]^7>)*P81C.-:(X9.2E4Q*(MV4Q/1:9F)"+WO0',>XU#"^Y>DZENVA)O7-#
M.LK*S_5FR,JDU=.&QW#]J"L:/Z5@@45<KWJ@5JI9^:UW7KA^_P"H6?4]#;3&
MT1W6SY$9G<9C>=5BK)3"M:7?*WEE?+6Z_#)HR;A5HZ^V,HFS09IC@=DIL?@\
M"TQW?='U:'?NMXT:+O=5K-@^1"Q=AHJF,YA+-K<S5J\IUOLHQ+AC!DK[U.42
M78O9"5B?TS4M.8T V 6Z8K]-P%3=\:D]+T2'H?=:Q97O>ZW6TT;3;K(5"1E(
MR ?Y;I4,QB9.2C9E(742FP>1YHM(A39IM5RK^>KYY3JC1_X4LU<[<]FK$IB4
M%#X67+;/UJ@<;O4<Y9:W4'%A23?QMFF9]L@=/[KYW$J/R,2--4T7#^P;O-,Q
MNFIT/7X.&-:K G.M9_<JBXZX=[J^FZ_[6E#4Z1Z_Q3.RU!BF4Y$="=JNP%ND
MW BDC<:;4\/NB(7#Y483-FE_U&PLG^39UW%Z\YCG^%35<L#^DV.4:C6KA0)3
M]ZP#42D9-I]4[9R<B9R#W9Q*IWV%Q.0V[*LW@^OTQ0;O:;JID>N,NG%(Q[1M
M:*,['1:T+/26YPJLN(,UE2O$6B+P3)NUE2%Z^=L*UUBZ[UK2,T)L="U+JU3.
MP]MN$3=:]L^?X5!VS=,NU_3:JUK] TJ3OF&IOG-42C&$5,1,LLN_EAF5'2[B
MG:G.Z#GK/M9ETUK>S==M6O\ J]OV$F0:1;>WS#4:#B4X_EZDE/VK)PZPK2E(
ML:[!TBFY5?J%124 I783D;GT?35\NF^^_3?M-+[$MN<G7-HGZUBF$O,QW:ZJ
MM2TR25BMBO\ >YV1L3=0DDJ1=)\NBLZ0-]LH5S%L2KKFK9_77%@E6T:_F)BQ
MR[^PW&?D+=<;-8;#87\I-35CM-JF'<@_<++C]UTY.8 *' !_+\8903.(?Z>/
MD94,J5$YTRBFAU83(0ZP!X)"8%C>PC[B ?[;LDU^Z+8SCK[M+<CK[950:F<9
MU8$/U'VS>QSI H(@'XAR'X^N@O)@./\ HSZV<G*' ''_ "BJ')P#\ ,/O_M?
MBD('V_%21[O <3)IF. EZ[,S%!-0Q#*)<\>_@8OD'UY_WVK$62 BG^>W=I00
M!<R_@57N[V'.F'W%?)0WD3CZ#P'TXX /]K\ARRHI@0G2+M&0"JJ))E.=3%[@
M4@E,L0Z8.BGX!$I@$#J" <#ZRCLA8:\M9HS/^NO6H[F')+$ADO\ TK(G,J(A
M*2LH+"6-&PD$[LI7DFX:1[]\2.;K U9N5Q31/"VW0^H"574M.42^P4R'=;N"
M1[C5X/NKCG44E@@U97(8>56K5\AMMCKW4GKEBBZF8$GVG#5F99-;UV_PK+93
M22[;G.I=LM#G-7T/:Z,VL67Y-D'<:N9&6.R-&MX/)IWYBP=3+AHSJYX]H[BZ
MR4C9S8#R#ELL;5Z-6NKZ5DL%.TW'ZKFSI/>X9M5M,I6Q]R;KTJC;RC:39VX9
M1CBMZ#3R/)%M&DL,<@U>@W&2_5H*I 5)QU[;Q<OF%&KNB=IH-]V"HD/*9E3Y
MK6MKQ5Q)X<WM-?JZW98\/<</? LU23KCMPG*1Z#5)61<_H2Z?LMZZ_67)82@
M5:C:3 1].MK'L-+Z7E>CY\GH%9L],K6<U]OH#B6\$G<;^Z!A#*OG[0X1BL@D
M(']=X8&D[CL/53+>C_6W'^PE9JM4Q"K,.Q.QAH5!NV@SEWO&>]IZ<W<I9C23
MU;]QIU=NVKSZ5DTU_P!5*MBG:@:K6C9;C9-HZN=L\!ZT.NKYT\TK-+OQ^Y.F
M8%7];@L61@*N,LM6(KM3$_J5JTQ?24Z$/8FSAD9^1NJB8,C<TC<=1MG8W9\]
M^3RVCA>=T+K5;,4A-HZF]HH3%\*H"<IHE+IDO6NOQD; I&VF06FW$\ND1L]3
M625$_E1'NH1L'#:4]IE6=:%#UERH^KD3>7$$Q6MT; /5CJK/(5E8#N$VJIS&
M,H@4IA$1'GU] _L]?3U] _L_9]/[/YOQE"(I"@7KC\C9R@?S^^5?SZH%Y)P'
MV_M_:4$/?W_VV\K3(KA#)8EK*LL+4IC.0C4Z'.'>B@"8"J94&I3^ % 1$_'M
MSQZZ"?9 P(_Z,NM?V0,(F,"/^4-0^T!A-^83?;XY$??G_:_%(H7_ .-".N\9
M50!=4.'*G7N(%J<6_'V50!--8/(1\B>0>/\ >-_OL-)]9-<Z+U_&W'8+N>[K
MM;VS%]OF](8QA.Y?81L]B):TU#5HR!?J'DB_J$WJ<:W-]L_VC(F\?NF*G_GG
M\9!5_$WFY#!^R1A\C*@L7P3'8BIE^T!01Y$#>:8F-P4XE,0BSSLO\82I0( *
M,T.MG8I)N90#&'S(N?;%')"B40 2B)A]A$!#G@"_8VWXL2?X9?N IUZ[5'Y6
M_P">9/\ ]J&#Q3'GV#W^G]?I7[NT?%6J43C]CCK[VM3$B?V"%**G'84WF<'
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M+PW7[LL$J>7:7-'2#3'[R228O7CZ.T>,8S"0B8A"2:?ZD!*LD3RB]LN.7?\
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MZQ^?8J?<[=4OQX#\RO6$W)>/<1_*/X<?B(?;Z7_'BY0 !$?#NOM21SB!B<%
MRW54 ((@8P\B0P>W'MZ=JDZ,?'T+<B:0MVG^M_6Q=.#G4\#@5W_ID102^T0W
MD/DF7GQX 1$0X%4.F'QSM'221Q.V7[F[<Y_6+C[HBW.AUN339IIEY Y#B?S-
MQP8H<B#<?]#_ ,=PN4DSD=&#NOL@).EP\S%<-4 ZY%!LV,0"E!-114_F//D
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M$WY0#UX"<@' OF)!,'EX\@'EX\\^/(\<^@-]PG B!0'R+P)A$"@ #S[B)A
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MSR4,C-NF[UF^58@8JG\OR-J$*(G_ -$G9@G!1%,3$4QZV)'$Z@@?\A"G$>
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M_P# C_Y/?U^/]@_^3T/L;V'C^X;]G/M[>X?T_3UQP;\?J0X![?TB7C_R^O\
MG?\ K)O^7C@/7L!_P^J9R_7G\3% /P]?'&[1;*G9)]6/D32>N$D53&2\IKJ$
MH@5=1( 2_3J*>/@ \B*@A]1]P W!^!^G*9P'Z\>Y1*!B_P#$/7T-_P"L'_\
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M8^ZB)TS%_*)1]A+[>G+E%AV*:%<_1DS[J]R6T<U_(<O#%DGNX(,R\G$W!
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MQ2,3[OR']XS*(&164<%,V<?Y^_J$/)541,!3@!@]A#CV]"8UM[LG$3D4_/\
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M .<  0 2\AP;V-XCQS]>/;U]#?7GCS/X\CSS^7R\?S<^_M[C]?0G G!QY$3
M8P&]P !]P'D.0*']@>C&\1$3@(&$3''D!^H<"80X'\?V^@(0#%* %  !10.
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M;U,WB&F-!ML?UE;TNBQLADUB5>6FT.:YV*N4X:$KR@\O2LHUV],W3.*"9E.
M]8C'QGQA_(Q/QS#*<SAV<M&4WK&@UD&K*D5]LPE63-_VG0DTX>12#[I!733<
M(%,)54R'*)?23MA\5WR3/VHNE&J[B,K?4>311415^RX3,HQ[=KE%9L;GS3'Q
M,4Q?$>!]O2;Z0^+GY*6+'S2(Z?2=/ZG1+)H9P9)!LFJ[D.W:+8JCAXN5),#'
M()U# 4O)C% 3B7XH_D\!4H&$$U*%U6(0_B41*!5B]MS@!CC[>X< /U'TH/\
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M><55F[! TR1!K;*[&O&,E(/$8Z60%5BR5$';<ATA*7HV[WQ)ZMTB1[(2SCM
MMXS#^B ^)DUW-UY_SNB8=JZ;26''VC] I(FD/_-:,XE#B\#]*94Q+9<.F=)J
M<K6+)\?7R^SL)'HY=)WG';5<9.I]7'%GC<WJA(8M3L6<W)S6'**T:R,:'DI(
MDL#),ZA5@]=H*/,W6FV/"G&3=]<7HW7N5ZNH2$$>&RSH3E.TY(_FI1LHYE;U
M%6*P6Q_!HQ9B,V4RQ=G:%^^]33!+<8B-O]JRRU8+F<; _P"F> ZAC.0.?9G,
M4+KHPQCLQ%:/,A'13:LO[)=)E-VJ]<S,4V9)"C^YDRP4@NXS?:]M^_+;'(]$
M=9R;0+8K3'-*_B&9QGOYHU:AV9DAJ]/BW,D2DN(Z4-^DCV#=V$F+I%HV26^T
MG\7" *<*K8#\C;K[ CR(MPC^LGFL7ZAXIJK)E]N?[X?L]_\ :]@G:)2J+-<,
MUQ9)(Y4U"**$H4Z<A#IK%.BH4QB@ @<!*(#P(" ^N@RB:9TDU.G'6\Q4SIBF
M9,XY/6!5 2<F A1-_=]Q 0^GM_,^G_C_ *>/7T]<?C_7ZX#W$/K[_3^OUQQQ
M_3S_ #?BC1*!A:JO^[ZSCV(8I%$>O,:DW4$3B"A/_CDY0 @" B?W_P!\)Y?4
MQO$OMS[B(!Q_1ZS==$CI%LMK?<99JD]%(''Z57NAV!5:B4J!00!H+8Y!0 O'
MBB)0'W#C^9=ZK=&<N[88YUTD^TNV3#!P5$:AGCVTR&;9%682-51 URT[<=0B
MW41!Q)5V#<B;%9=R[3Y:(O$<Z[Q4:)Z=/)7$@[ U>[V?58>[97)5!C>ZAF]L
MJ%DN85ZD)U+6:=9M!@$G<2+-Y'K)RR1V4@Z^VL"=C0Q?7<FUN^-.NNH=C*<D
MXT-K5<@DX#*[Q#9G*Q]TVI./G*[GKD=%FTXM<'2#A=DHW<"N@04RE4ND;HV^
M9-1[%F=?FIG48N:NL:W;4@:8Q@7NB-W\^[!E%29\]_B9E^^!;F%6,2=MSNTT
M06)S:]JJ.N42SY+1C6L+E?H.?9R==K2M" ZUP:S#QDL<S)]7BHB+EN<H+E 2
M_D'S+Y=<[@YR[3<TH_9'9=\Z]4J4O;=6%FJSK>'6N]Q<)4]-I[]BQF*4]UJL
MYG-OHQ%R<73*0:%C'C<KA5-3^9\C "HW()ND79I, <G*FF<PX]<# 0#F'C[Q
MN>$P^HG$ _'UUPF,OR97:;ZIE77Z'8T[^,(VAPZ2,Q4*RUFK1.7*1BYTD/7Z
MM$IN':IV\>_<KG*1!-'R6^X3!-E[T9U5.I6272S8OV&ZISVA=GHMF>^:W5[K
M:2PT=&EJALULO\?YM-P;23DH@4I.*79R[91SY@5RBGF,A=[9C]!VK6F%Q7I>
M/1NY5+0F-AD8&TWNIUR&@M2K<6RK$\I?7%!>GCRIMBJN5F[Q%JBZ/'N?'#U'
M<M5J'MVR8O2MN/@@W%G:[55(6YU2)M[)@O+MXR&;2SU&MS3>0X!!!PK'KE=E
M1_3&!4>3%*(\<<B "/'UX]P^G/H3?;)R80$P^!>1$..!$>.1$./0E,4#%$.!
M*( )1#]@@/MQZX,4I@$0$0$ $!$! 0'@0^H" #_6'HH^)>2?W1\0Y+["'Y1X
MY#V'CV]<\!R/U'CW'U[AZY A.>1-SXEYY$P&$?I]1,'/]?H2F(4P"'B("4!
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MX*!?   3!P7V]@$! ?P] (D 1*;R+SR( 8?^< <\ ;W^OU]Q_:/H2F(!@$!
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M[ )3 /N4?2[(WQ5_(T!VZ95%%RUSJ\=H<IU%4P*V>$[0"U=*!]OR$I#B8"F
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M_P#,@WF5RHR.F00 ?SG3YX!0H^O,GQV_*,8_VRJ@B/4Y!)02F760$/)?1$D
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MZCL%3^/"=+NMAJ-DOT9E3'L/9=DPQGU#.!Y,XC'=KR5UA=!F3L$TK82'$0F
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MX#V#Z!QZY I>?Z@_#D0_Y1]?&"@"H$(&"?(N].@8XE*J9./ZOM2*E3#DJBY
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MT_T_V"'H/S"''/T_X<#[<?3^ST')U!]P$>3CP/ \_@(<>X>@ %#\ (>P^/T
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MBR9_O"3_ $/]HE?\ Q"J\M\7N;CQ ZA5$RH^:!3*?E$1(!@ 0$0$.OEBN\G
MU"G,.M6-K3<G;I2*BZ_!QZV9UILJ$[*3,@,,BU\% 04.NN9$>>!.;R 39OAT
M18\;S> 7V')NQM(I6(RN%UP-#LU4E75UIZRM-/6[#!WZKWU.$=&>$)'KC*L4
M7 )+E*F90-=Z_P!.Q[)M6LO7/$\VDEY&"@\3ME04K%[M-]3A\>J[Y.5>&J\G
M"7#(_-S#RA(ID@[%HY#^Y]PM>TG-,*;V?_._=PP/5ZS/9GED7IM%U:HIV*;8
M(]BZS-S!':B<2C53R3!V1:856:N63YB"J#DBP3K6/MW7]+.)R6F(ZQM6U@S%
M&CSL].I*2-C:322#U.OR4S.-#J.'R;HIEW7D*BH&+[A.S]UK%7# VL'%5*,S
M>D4NN6*'T(FBR32K57,*+G#%M_#MIE=-L-C;1D=$IE,T?.'Y1,()"HH$8UVG
MISO/6K-L2L/6^-8Q5BRC%D*'D\%NLM8J5G][KK_/=+LE%:U_.9*->,;.A7W3
MF8JI#@*C,6RAE1@<8[#=>F/::WUCKYMW<!K4O\M,CTY'/L9QAG$)7N]_^Q8L
M4#%-I6QC)-V<4SC3KR$H!%>2D13,<&T+2NNS;/K_ -1H?,+73:9K&)T6JV[(
M*IOE*/<<UN62N(0UC@X" NE;9+I"K R"9D5V:[5R1-9(2!O76ZV4G.-QN'3R
MVTUIH5>U'/JS<JY5K)I5/<S\1*58;6UDV;O[$>5U'OG:"28M'[9PS,/DB< 8
M9R\KW7+5*1#534=4S/KO28G&;8PM9^NZ#>Q7(F74B1?LLZ1M54F)-)(%5UX]
M%E)OB%7=-Q,8X772G58@K&K*9_,I6RI-3T&4NUP8U&K3-E=Y+)?KYMO7Y>:C
MXU_(H?NMW(C'-U%EA.J1NHJJ-;RO+\!SEU:)&-H'6K5L;I=%Q-&5ZZTS7*-8
M-H;Y=M->8SK2MM*2S3.L>9A8)6=(64?IJ"U5(K^I#">S@'P5DRZT42S]>L9H
MT>&&)X709ZQW2LZ$XD*O"N(AQ_"VQ5^8JZ?Z->+>L'B*"RX&24%0YQ>R2F,Y
M&J_DVLRP?/%LUIAW3]A8I5O.6-E(+F@_ONVUAFV2+U\FJ)R.7B1%E2F4( ^K
M39U<)Q=6PWFS5NZW.<6RVCKRUJN=,8H1=,M\^_6@3N9:RU&.0!*->KF4=,RE
M $E"AZBI^DY/EM0GX"&G*W SE8SVJ0$K"UZS3RMHL<)%2$3%,WT=$6"QKG?O
MFB"J;=T^']0H4RG(C\81@_3K)K8-\B3$P*B*BZ!BQO69V1P@8!#A7Q;BD;D/
M<AQ_'U+;%K2DLK!,I^F4Z%@*X$&I;+K>-"L;&K4VEU!G9)VLPKZ?FY5\'B5R
M_:((H)*K*JII)F,&=MO\ANSEOT;1\T@]/8XE2LYK\QK59C;!,M(..@+O".KS
M&P59L8N0DE%/NR9HXB4#(#^K$R2)%^JE-RJL['HMA[99FTV6O1U=I#))WD.6
M/I1:O-[SOK"<L,/)Y_!C:F#Z),+="36)(1SA(4_RIBI!YO(97V09P<]V#D.M
M"6VCE1E<(BM(+;)NAU@9S0$YSAM7;[<JX]814@V:.VY%")"],S!RW^[O.X1=
M7W%S4, RV/WJ<CD\T74N%^Z^S4O?82 W;**NC*J2%MS*;=9C.+(NUOT+A-DP
M,Y6022.D8_5[+[1,R2>@=O+&XKV/U5C' ]EER,:'+Z%(V*RMDG'W(&K1\7$@
MT5>F!1/]YNF[8H&,H(E(80]CCQR/L!0\#'$QS<"!2E*41$1]=@T6>>;O:+5U
MUU:K8M.YY4\P>S=[O]]N]-K-^J3;+H9&03;3\%.U>V-G1)=ZXC(I!$BRKAPB
MBB=0,FTBC9GV#T1SLE*T>YUC+Z=ERSO8(PV57"M9O=*I;Z))R\2YJMIB-*M3
M>"7_ %:R<6T=HN5G+U!D@=UZPBQ13K231VZTN!T7RD*$]AU<<HUFV".Z_0MG
MW9*5=M#9_%O-MD35PIB_K3BZ9NW!2F9-5G19BJ6RM;D]BJGI$=F>@:34LALM
MKR[-I"5E\_J\?8[U<(DJS>%J+F[:$E" Y*FLX*_BY(3H%;-!<'W-O$QNIOD\
M*K6W6YV\:4!Z[:ZE!=<+>[SW;7>*%:.UWN@FH5\9C$KID1;J.G2B1F@.$%4U
MC8_>I',.T%VIFR9CF&MQUMS#!K/>:M1ZELLW!5O-4M)LL:L6!K%CM4[84&Z$
M65RY? ('4,F5("G-M+*0)RR5R'2B/OR MPR5I\T@[ H !BG.4HF*) 'W'V_K
MZ!@8"_X?3SKTF % 0\2?Y6U?[/ &$1*44RA_+*V&;<E8PL'%2DW+OU"JG28Q
M<.Q6D9!TH5%-54Q4&B!SB!2B80*/ "/ #L_9,([>(/'\.;TB9LEHFL/O)$[!
M3M'G58"H7BD(Q["0&R5URNF5:0\#)O(-NLD>20:"?Q"G6[7RVU<FBZ$URN@5
MVDUY2T6:W7IS5[5=AA(YDFY9L&@MZE2)5^==XZ:M_M-!(!Q7422/C^6U6V6F
M8=[A4\LM=)N9*/8V6=M_\\,EO>[Y!6;599-DR4JUMO\ D68STXU:NFQ4F[:-
M.1TLW74025M^OYNE<)/'*U^N=06K.*E+H5#5J]$QBTE*W/'2HHN;#H5+0%LJ
M@UDFC &\NJF)HT7B!DEE'F@.4]MB'T?J<_CCO*)[!M/A-Q2NU8S(VX3:(Y+)
M5YO;C1###2A<%'I4!0+"&*(B#LY6H]<L)C;\A8-$[6YS:-=Q5E6V#^:B[!F-
M5K+*VN+M)3+1N+*N0DS#OR#%G?"@>35(L1L506Z_V_Y?BH9?;Y,N_P"[;L%>
M0X(5GUZ8H&)Q]?)07X#S]."C_1_OM$\%BK)#L?<P"&(7P)P3NOV&*)"E,94X
M?:Y H_XAN1#Z '\SLDM;R6)UAW>?HE4^K5LM-2<M"VG"-+P#1=#U7/+P+9TJ
M@FK5K*31#J-CE!P1.>@$FSM+]/( =.6V[4"TC=]PR++ZABW7_+L<S2P2U<EW
M.@=B>OMNV3<=%@;9.HRCJ4<UK*T2FA8]R5K%1/ZX2NG[A=+]/MBK75<1KX=H
M\4[FYEL<+ Y-9FM9I]G[*:G ZG1Y#&&+&[Q;QE7JC)Q!_P!\)R*RKJ5=*JNF
MOZ(5Q31W3.I79LR;TRW+]N+%D5K<T>QN=)C+!W2J4=6]+K>L/T9I-G:J+2G1
MG[V*_3*INY4$H=N[! (C[KOO=UZ:WVHP[GMQMFG;!4Y>-S\W\)9ZYNC+/EH>
MO3U06G"HVYBSG:$"\L9%PP_>C=ZM]H$5!$WKK_G;EK5$&,C\@%U^2W>+3FD4
M]J6*YQ)P] <TBK89BT))/'ED&4T6WR+2=E 7*F@ND6Q.ECI"\;MC_P OR*F.
M82D#HSVP*<P%$X@4V%7D!_(!B"?V'Z<AS^T/6,X_1+?6ZM<Y7,.H%JB;?;(M
M[.Q+1UF<QDFE.E1(V<'E6TK*MJFL@PE6JGZ^)?+HOFRA'#<B@4-?_,'KBJ[H
MEBZ2.HNVP=-TR"OL96NINT;GHLQ$UVV2UGMT_$JW2 UQNDB)WBYB23 ZCM5V
MDH'%FL>H7?"KC"-^L77KK)23YC3K;3[!.1O7:=T]W 7_ $X\Y*3+-W<;3$:
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M>J4H*@?XFX]TS$.LW.T.H"W=;L(*!Q!P":RYSM2D(53@2J%)R41 0]")3E$
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M>&3  _4N _S9(@5TN7W5^V0B8F_ND('MZ*"OS&8P9%1583'5^-'.R*HD /)
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MK?(]U/5*N1YX*D^/.9*NR4 QRL%&H)]M4FZY@14#]058I_S% 2 4!$/2A/\
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M )/VC?LNVZ![IZ5U,TRH,ZW-VR<R&RQ-(F\GD7(NP=.FTFQ(J=!4QSMTAC]
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M5A<A3T20['G'%9RMA.Q[B[1<;"XM'D92,@X%\LL\=.%!.3[#8G0OJ17]+Q>
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MS<6FMP=MLM0972*;$52=4ZY*U64B'MCHD\@J*,K"N53Q\JV_P':2R!C)FWO
MI&CK0N6]EV!(?7:]2Y^<I0S< G1*EF"=:B']9?QCVIUI'/:3'PZ;"+.T:HL$
MU$TR%!97SHK]["3,I*9KBMGP&D3$K:[+(3%?SVZ,JM&VL8^2<R9W;>W3\?2X
MY!S/$,68.BAX?J (<Y39GNCM'8H^X9+3LUSVGQ%<[";95\\_@;))5&=I-2L6
M;5^\QU*ML TG6R3QVUDV3I*3<)$,\*N!0 -SR6 HECB:-V*KI*+I4;'Z9H[%
M\;,$!L ,,BID^SM"$_G.3Q2-NETFE>@7,?&MD99VFFD4JYP'&YRST=E-3F!6
MB,N>633QY)FEJ_9H:D3^=1LHZD4WJ;NPF:U&T/VP)2)W:!CN!6,05R$4*>>1
MAHM.=5;BT6FRQ[,)E9IRF(-5I7[/[P4;$!(H F*G@ % .. #CL8SN2>M_I.U
M=US#0-F:US<]:J#::LN0PD%7*6O"H5>VQ*=58DA*O&MI!K' W;RZ3!N#TBX)
M%XNF>UN<W^+/H$Y4[%:M)3[*;@MMTG(TA=V[K**FTN[PXT@(6-=23LY8S]XC
M&C^L<%%OX+JE-D+E[1[+SC+,C"%;ETW1CM+JR1T^.VYNWV=!Q9EB;<#;9XPE
ML3/:?WJJ6PJ+/0-]Y=8Q\68.%=RJT5@%"6S/-X;.>R6Z9S&-:B_D&DC/M[$W
MIE\AAM\O;E6*1)B2DS.I"21+X++& 3<[B\@ZK9H=;?:GIM%MA6.@7,&U6J6S
MR\O9]7@,E9N)EPTR2,O]TFW$[)(P!&*:TQ]MR %.DEX=2H"+A[&K#](XY6,Z
M^1TE<+#(M*\E_EA(XZQ=3[9R^.A<I2$S^6<LV#N3*Y<LSK'63.58QCCM2A_^
MK)D>F**AY> B1.E3:AN%!(H"?L7Z^)N/V#]!^/WP3!-(W3'KBHF7[R3HQ1/E
M%4\^7*)4DE -QSP"9>/H/N' ?R3E7GVZKN$L<++5^8:HO'C!1S%3;!>,DFZ;
MR/7;/6:JS-R<I5D%$UTA'R3.4WOZU.Q4*5U&[WC8)-D\NVD;'H<_I-TD8*#D
MK+)U"G-Y>9\$&E>JKJW29T@33_5NEG9EWBSA<XJ>EP/]L4?NI W^V54IP3%,
MGW07,8#$.851-X^   %XY$!_D3\1#QY-]P!#D1#Q_+P/X#Y>@'_U'_B'^;\2
M[<AB& P=\UU$A1 # 1# *LG^I(Z^I?M'>%3%+_X;][R_^%?[XF("("7D0]N2
M\>1/+GW#W\>>/V#[_AZH+==<ZZ9-@[>D9^:_ZK[3!+M]N9&B7WOMIB(B0!,/
M(<^7/N/U_FUCL-C6K4W'-'Q?.<;4Z[:0_7G)"PT;8:=L]TFM!2L%390H1L_E
M^F89?Y.#>-CR?FY?D0!1H9!,5!DJK6L[Z[Z3UN1[ ZG<FF Z5IMK%&\5/2>I
M]!P:&T2]3"^*N8^.VJC:30G5H5<(HR9G*=FD%D':,FDD=7I_>-<G</WE[UFU
M_%=,E>UUKONA*]A9>D4CH_8^MULPB(KTUGEB;R-7+L4N%LC7CJQ-?UQ%E57I
M22:JS@;#WU_CS.(S.IMZNQE&\>\?K35DQU3K]7<ZC\LE\W5JX5QKID!K4#^^
MPTA&8),KU@Z4&<BK3AJV\ $1 #J#] * "8XF$   #\O(^W\SY&RBI]L#=+NP
MH"?CD"@.;V !'CD.?KZKW6;'U*PTOVK=5.K41 /[A,N:76V)8IEE-LDE)-[6
MXRP.8SPC*\J5)%FW5 %5"E*<I/SA.)]>J?7U9^T8'V^D9VZZAN.@N]%E>ZO8
M>5P%6D;18[VYC+#,V,:/'Y0JDW>G.0S C-HDU:AR(D[ 6*P6G/YFD[-6;O7I
M<*MV(N3*6L,_*=N,WW7-= F8/2\5N\?;UJ!GE:>1;BO6^3L4')*.7$.T-%0*
MR+5"B;#K;;)+) U:A51DUT6CZ]HT38ZZFKU:S3&[?AX8X\H;UC=<TB-&HBLU
M .):X+-HU-TH\+%EDU#KJ;9V4E8FN!CUJZC8=AU,D6]H6=VQ>WT+3M;O-L"5
MJYHDJ,7#_I]";)H.B/%CKJHCY)  @;T7D>1X#D?IR/'N/X_[3H@4ATTP#I-\
MBIU $?=<@ZMT& $DN #DY5#@H;]@%_I_VVY.N3!^FQK5%^2&\#A]FBSJOY#F
M*=,AOR>PF*( /_$!^/HRB0I'4Z6]:U3 55-4O*V/4Y<#&%N!FXF5*IY"8/$1
M-^'[/]I\1O@X7120COD#<K)IHE43<>.&4!NFBLL80,V(!G7F'C[F,7CZ"/\
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MA*8Q57 =?TO\9,!$HF!(0Y#V*(<<JF>]3/C6_5)/TQ1(W[?]@DDG+$7!"'*
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MZI#HOV%!4W+NMRLV. I&$W<_=SG$"D.<IO,X\\_V>W\P"^1?(>> Y#D>..>
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MI.&A(V+1ZCM?3B?[%W>I)A8MKJD)1I:Z3%<6"&GUWKY"+%=*.49O53&=$PF
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M(9>6,V4,9,G)T1_*4>2A\>"2"1T4D^D_6@!(84S<*#D%3^X83H%^S_B*B8P
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M<\"^(<B/ <>W(CP81X_$?<?Q]_YOQ%J"8  M>^1 Y@$@J#P.+98GR3@A_MF
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MBX+[![ 'X>OCN1!0A_'I)UC,8Q$TTRB"N.U-0H F1=<A#%'V,(&,)Q]Q O'
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M%9HY44;($1DI-%<B15Q7("@ID2\?B_ZQ^9SI%.F;Y(B@<A4OTIG1_$O5 Q3
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M$44D_ 0,<H& 0>*O_C@ZW_<!<B4=',OD',=VNDL5<Q7*ZSGJVBT(DU'[95P
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M'R*4).N?$$]FH5V=P>"L\7\AO4J1K4XDD9TDNL+Z,6>N$2IN40)_A(+@!P6
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M4!  7<E[*?(H5!4J!4HTOR#=IB,&WV$D$S"B!=$_5B+DR(G4^XJIR<YN. $
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MX#ZCQ^S^GT;Q\Q IBE,;P,!0\Q#@WD8 *)0*/(B'L >O)/S4#DH")2^P>0E
M!$3"4 #\W_#@?10Y/P8!$IA(8"CP8I1 .0 >?S (>WO^'(^WH $J@"//_,$>
M. ,/YA#D"\@7VYXY]"8I52@ \?XB9TQ$>1 > . "( (?4/8?P$?0$#R\A P@
M D,7DI>/S>X!^4>?8?Q$!]"F')C!_>\  WB/L/ @ ^7( (?A[<AZ_+Y'#P!3
MR3(90H@81 H!X 83&'Q'V#GZ>N0*J8 $P#XIB(E$I1,("4/S (<<#[>P_7CW
M]>7N8! ! " )C& >.! H>X_7T"A!Y*;G@?I]!$! 0_ 0$/Y?BM!1J==9/KU\
MDSA%T)S 5H L.LB0@8A 42.)B+B0HF$IB 80#^\8/0C[CP CP'U'C]G]/H!X
M4]P*8 %,P#P8OD \" "'MZ I?,1,7R+_ (9^#!P4?8?'CZ&#_C[?4!X$""90
M2_4$R&./TY^@!SQQ^/TY]OKZ_+YC^82_W#![E$0-]>/8H!SS]! 0$.>?7)^2
M?F\ \^"@)O(I"E 1'Q$RASE H<\F$0X]%)YB)S"H )E*8R@BD(%4_(4!-P4P
M\<_3G\?7'(_WBE ?82CY& A1 P"(" F,''XCR''H0 P^P>7EX&\/#G@3@;C@
M2$,/!A#V*/UXX'T7GS#R.!  2&]SB?P  $ $HB/N(<"/)0$?P]<<F'^]^8"&
M$OY1X, #Q^8Q3 (" <B AQZY*)A !,!C 0P@4Q#G3.0PE ?$Q3D$!_\ 4AZ#
MR\R&$ 'P,7\P /T\N!$ 'Z?C^(?M];Y]P $HXMJH#Y  AQ_ 5@$W//X> #_P
M]?',5 5"I$Z4]<!("A (<P'R>K&Y.!DTCE$1/SQX@'](_7^4!/Y?FYX\2B;Z
M!R/T^GMZ%+S'[H%$QDQ*)3D'G\I#$-XF Z@ (E#CDQ0Y#V]_0>XCY<\>P?4I
M0.(?7W_*//(>W]/K\WF''(C^0W!2E,!3&,;CP*4H<C[C_= 1#Z#Z*4/(3'#R
M*' >Y>2\F >>!  , ^W/Y??UXE$1. @ I\!Y@82@?Q'W\0$I! 3>_P"4!]_0
M@03CP;PY%,Y0YY]P$3%  X 0$>>!]P_$>/YGQ#&4(!S$@/D2.B8Q!-]M;_)/
M+B>1! >$^43'#R$!^HA^/^^)A_\ !<\?^J\#S_P'CUA;AZY.Z=_QSVM3,H<1
M$Q$4^X&\IMVO'MXD8H)E1 ..  @ 'T#^5( ]_,3!XA_>,8 Y*4.>"AY<<<B8
M  1#U\;NL=KM!L"76[L8^[CZ]VVNMSL\_4\U3[A.IN"C<4R35IPTK'H4&@YA
M"1-FK57K3XS*&*_K[5!P5S)II?<M^0Y#HE(E,<7==EMLZ,P7:ZJZ;?=^[:Y3
M2^RF04'.,)RJ=D;W5;*XK5[:W*PQ]"F7+.?F%(!&+>%0<LRE-Z7V"RP<-V#W
M[ +[\T$6Q9S&?Z#&3.3(X_L6?P.=TE[$YY8"0\I6VV&2(6=1HXCUY*4A62)(
M]=%0XO%M(>9AKW6?1\TRVE]L=!K/9Z/QRVRU'[$0F%8IUTU>M1=/9PNM)5R"
MDDKQJ$Y39IR@^D&ZJS$JC1,'2"R(]!K,UM,]G\]9/D@Z&,"QT5=9NMC/0]QU
M2()>J9/,XI_$LKI!&J"CXSYC((.&A46XN#)$,F4Y=NH,UH>AL[)(S'R?MNU
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M_P V)ZP \?7@<^L9?;CW_'U\=9UT2)*FZ2]:16("*:!BF+DU7(4?MI"5,H&
MO/TY'GD??G^6\R3FSEI+:.I5N?K7(S)*0"GD:5]\N:W S6 R3H:RFF9Y]H2G
M^X5$2^(B/KY",YJ>G=@-0[$YC7)AE=>T.23LKVCZ_5^CN:+V*O\ 7NT>/&E9
M^4NN4VF^-Z,T@I:(G':+&MJKLIYJDJV IG#N^4#;IVF;KG60]2+]<&PW9"G[
M517U]F,X6A#:Y6OWJM8JRAI\6]<J@TEB$++M7 B4%.0$%[CDO=&?D]LR&IZ+
ML.I=1K3M-:2S*T9W'=:]!-B76*G]?6AF;^Q:YL6P1+"U,Y%DFO96L0RD57+I
M-HM%-S=E7NMW"I:EV8QS+HG4:YHI-?&Z9KVSTW2.IZO<%MG^*02L%3'5<7RV
M&?#&R]'@&;Y>#B6J#@SAPHL=8[V\NM.T74*OUD?-K3W%VC"^SC8EA[ VGLST
MC3UCK1)8 G/M,KKM3B<DW#28V/<9;7_U;I^)(8QT9PRKALOTP8:+V1[!R&IA
MUG8=I.^.525]198O37T]F%?QS,LC@LNA("*B(1Q<MF2LUC755,*RKFIOAY.1
M9,J'\OP^%$J@BZA_D3:$%/['L?\ R+S9X(J?= 3_ &/MM#<^'"GF!??P\@'_
M 'M( #Z@?WYX_$G( 'X_EY'_ (>L932,<42Z=W \ 5(D17[0]SNP)4#* DDD
M J&33 3"(>7D(\C^SUM^^0E')I4ACN;6/1&N?EGC5IY=%*TS5D3U:.FBP]@"
M/EYQ% R#$YV:R9WATTS@4IQ.3H=I>;TV4T*X=^],S/,L[RP\T6O2V;/[?:8R
MA:3+:Y-I0\VG5$L3O<F6NRB((_?=V Y&"'YSF,GOO^66T9Q!D1OK?3-=@()2
MUJLI"Y:A<R9B%SH]10B736T-]*U&*-'K/Z<U?,YBTBX,8RK]5P<YOE(M&51$
M'H$+\>19FNU FW7R>NA*E;^W-_SVGTF9S1GG:=185:X7F@LI!"WBDM-HN@7C
MQ9$2:IBYTN_]QY+".M/\$;S/8L5M5]KE]N8+.H6IU*TNY>UKL<PI$G2WS6OV
M9&1DVSM@HE7XDZ+N5<LQ.HFE?F,AO=;6?Y99J/3;/6J;!62<D4)F\Z2&.5^+
MK+2$@%HVV(M-(%:(?*0ZK]*,>MUT%S%7**7IQ)Z[J.-T)O*;ML.39PZK]VF;
MS$S\9E=\8YV\LMP>?P;#-LSEF-ID$HV=1D1"+@Y=8C-22465 /6M=8(#7<]V
M*>9QTY#;'EM5M+]I.#"T*]!4+; 6?]T*0<A)PL9;6YH6<9D740.@X,U=D,U>
MF35[>YNRQY^O*=3+UU%QFG,/XI@("OZ;=>X+.LL,B8-'B$5^ASBA0D];(^.D
M7RR+M5DV1<K(LU_L(H.9&[2%--GEUI6GZWA^K4()U.UM*;K.'Z#.9M?86(MS
M>-AVMNKQYJ!.YCI)-HU%RR72%1!!;[B)/7R,))) NHITM[&D*E^(G'+;%]O@
M0$O!BC^8O(\<_P!'KJ^]<E %'/73%'8IB0#>*CW,JV=03 H!RF_OB' \A[>_
MI!04R =L42(J DF"B93) B<A#B F33,D !XD\0#@/P]"@_;H/VYA()FSQJT<
MMU#$\?SJHK('(H<PD*81$./(H#Q[!Z5EBL&!99=@WB5Y0L>S))+139VX>IQB
MD@1$KXT>1TY44*B*GVR*',<"@)C<O)9&.8I2S\I"NY1-FV)(N"ID(DF59\FD
M1TJ5--, *!CB <!^'MZ?N&D>P:N)0WW)1PVCV;9636$ZAA4DCH))F?"(+'#A
M7R_OF_:/IO',DB-&;1NFU:H-B_92:MD2@FB@V33$"H(H)% B92\%(4  /8./
M4Z!JA5Q+:EFKBU%/7850+0LS5*LBK9!48F/.K$.4!*9V*PD, "7@0]'/(TBF
M2"BG[R,JH]J< Z.JI,M"L9=10R[!0QQE6:2:3GD1^^DF4JGD4./1V:E0K!FJ
MCF,?*-E*]#+(*2$+X_N615269*$5?PP$+^D6, J-@  3$O </%G]/JC]62<&
M=RBC^KU]ZI*N#.(]W]^34<1IU'S@CJ*;*E54$RGW6Z9Q,(D+PD$O',)8B"Y7
M+=*4CV,@DW<@81,Z;D=MU01=G(8Q15+P;Q'\1]_3AR:-8'<NG+1^NX/',#++
MR+'S_1R#A0&Y3+O&8&_P%3"*B''Y#%#V] \C*Q7(YW]U5<73& AVCHRZKUY(
MG7,X;LDU3+F?R+A83B(F%9PHH/YSF,*:$2P9Q;=-51P#6,:-8]I^I7X_4./T
MK1%)$%G'B'F?CR-^(CR//\GP^JMFB:C%')_DQ._44(F19D<,_P 3;).DE'!>
M3&=*J%3$B1Q7.0WF!!1(J8AB\B7R 0Y*/!@_I 0^@AZ<.XFO0<<]=/G<FZ>L
MH:-:NG$I(E13DI199NV2.>4DTVY"N7//WG )D^X8W@7BR,#5.LBSN*YW-L:#
M7846MH<*^7WE[,U%C^GL"RY3"!SNRJF, _7G@0?(+U^$6;2:Z3N1:JQ+!5M(
M/&[1K'MGC]!1N=)XZ;1[%%NFHH!CD02(F ^!"@$.\2A8=)U7F[UI N20\8#F
M#:R)2IOFT*Y_2_?B6SE @)G3;F3(<@ !P-P'$S7)RKUN;KUC3^U8H&7K\1(P
MU@(*A5#!.QCIFHQF .8H"(.$U $0 1#GT>%.P9GAU8_]TK1)VC8T6K$BV%F:
M*4C12_0GC3M!^R* IBD*0B3QX'CU'R#&L5UB_BH!.IQKUE 1#5TPJB1P4)5V
M2Z#--5I7 4*!OT*9BM?( $" /OZB9I:MU]::@6"D9"3*D+&FEX:/5$!48Q,H
M+<7T:R/P'DDBH0AOQ ?2\B$3$?O%T\8R#J1&'C!D7+^,:GCX]^O("U_6K/V,
M<J=!%8ZAE4DCB4I@*(@,P_CJ+38Y_8F[ME8WS&JP35Y863\XG?,YUTBP*O,-
MWXC_ (Y')E2KB')P-Z@$TH&%20JI 3K""<-%D3K21$DVR:5=*5J 0216J1$_
M%I]H/ A2AP4H!Z/'U^)BX)DH[<OU&<-'-(QFH^>+"X=/%6C%)NW4<NES"=50
M2^:IAY,(^MZ$?H&+:J)OK]/X#G_V?CZ^./A4%N>E/73_ ! 2*B!A'+JT<_\
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MEXJ5]H^E]I$;*Q1Z[]E+E&IOIKMOO$RS(WMM'R&QU26<NF#@')RLGCDB7W/
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MUICN[)<&\*CK'QS]G+WG=#3Q2CMJ5!OY%JYA6K?6&TG%M4Y-H0Y8I%E+D(N
M"412"E85F78#2UZ[53V*4D9J>ZQ]FU;5;[E=;/8+I>[U9_W?AS5-2:MENDGS
MI42ID10(*:"12(II%#@W8BYE#@PCSUC[4<E OER(D#%Q4]A*//M[<>_KNOB^
M9=B964T75.JVYTBD1$C@'8V,:R]GL>?62(AHY20D,F9LXY=Y(<(D6<JHH(G,
M4RABD]_6#TJT]C;"PL%<Q7*(.29H]?>RLJBDYBJ5$1#D[:1CL>79R3']X1ZY
M$G:)CMW()B=(QR<#Z(4>T,VB!U2(@HOUV[-)) =0X$#S.?'0*0H"/N(^DF1^
MVOV%%55DB*NL.[&-FH_92.J*A':V1D;KIJ%)^7[9CB(_@'I05.VYF*2:A4?U
M,CA'9-FT564< V220<JX\"2RBJ@AP!1YX'GTL4W=BL)F;\_?!?*]^0!#Q()Q
M^^*F3A]HI2%$QA-P!2@(C[>G!U>[=523:@!G)U,MWT@-B\?5R)\G*#?G\/(0
MY#W]>7^O7/0#CGWH6UA[#_0.9<^A,/?;/>"\"(_P%M@\ ;V*(_\ L,?Q'TH#
M3OSDA/M)$7,+Z'TJ+ 4U/,2>!I2BLBJ*&^V/Y"B8X?L]P]+(H=\\><';HBX7
M*V9W]R9)(OC]U4_V:6<H(H>7^*?GA+_G^/OZ!X7NOF@M!2^^#K]R:,#<S?Q\
MP<D6&D@F=L<GYBJ /@8@@8!$H@/I4C?NSFS@R)?)8K>!TA<Z( <Z1A7*E2#"
MB4%""7DW >8"7Z@/HB9NZ.=E45\OM)FKVDE56$@ )BHI#2/-8Q0$.0* B'/K
MD>YN?D_,!1^[6],2$IA_YI@4HQ1*8/V#P/HQO]9^>^).1,8*YI8E  ^H^04?
M@>/7BKW3HQA^R+@/L4S7'8'3 XIB5(6F>+E6< H !]HHBK^<GY?SD\C&'NC2
M_$GV_,_\![+]I(%5T&R8K*DS8Y$04<.2$+Y<<F, !Z^/#;:YVDI<OE6/Y1WN
MA-+N2,#HB8T^=T& PE*EQ\A'/JE'SKEO/_NA\")6C5Z4#("=1,A$_OIG5+W1
MI)T$F_ZI1TE1]B59)MP2!8RBCY/.#-" FF/)P$_*8^QN!]O29#]X<[,95S^D
M3^S4M:< +C_MG!#F0SQ0J?/Z!;W,(%_*'O\ F+R0[SO)FK,#LP?F(\K6J-%D
M6PJ.$@!RW7S\BS5X)VBG_9E2D7\2^7AXB BX47[Y90BDV\/-16&TE,B@G,S)
MXM#*48I7PD,_3 P("H)/%3R  16\#F6[]9 H1-NFY.9E&:-) !%$SJ%)_P";
MJ.[ 5_$@\I /W0'V$H#[>@41[_XB4IDTE0*Z-<F*H$6 QB>:#RIH+)B %]P$
M ,7_ )P![>N0^0#"N?'RX,[M1!'D_P!L *!JP!C&$P@' !S_ $>B$#Y ,)+Y
MID4Y5>6I'Q!0X$*!A6JZ9""(C]#"4W'N( 'OZ35-W]Q$"*^7@('N B8"!R)B
ME"J^8E\?<!XX$/ISZ,K_ *_,6!$@@!US$NA4"&-SX%.N:I@D0Y_$?$!$!-P/
M'T'T!R=_<4,01\?,"W/Q$PB<  #?PGP/(I&_]9'T46_?#(''F')/L-+TMYA[
M^Y/M5 _D'!1'VY]@$?P'T"R/=K+UDQY^VHC$Z&LFX$H"8X-%"4D0>?;*')OM
M>8E#W'@/?ULU;K7=')Y*;F,FT6,C(Y1&Y,%GSZ1I\RR9-6QI.IM$3G<O%TTN
M?+@#*% ?<Q0'HEF&B]U,*J5^H_4?!ZU;*=)VAR6?K\["YQ7XN6B7D:W8.5!7
M8R3-1$>3" F*/A[>C'6^0+K@E]LIS'34NAB.2@0!,8!:&8 Y^X!0'\GCY?T>
MCB?Y!NMJ8D5%$Q5;J"2GF %$>$U&95#$_,'Y@ 2_7W]AX_\ <A76/W,!?_9A
ML?[P\\!_U?U'CUP;Y"^L("*8*@(Z-'@7P$ $!$_VQ*'(#]/K_1Z!0OR']3P(
M8OD FUZM$,!?$YN3D.X*9/V3'V, #Z.=+Y$NH0D3!43BIN-(0,'VAX/XD6DR
M&4]_IX\B/X /OZ)_]$=Z9!]Q,%2^783-2_D$0#\WE8 \#\C_ '!X,'[/2\>/
MR+]01700*Y$Q-PI2C8Z9B&/PB^3DC,'"H%+_ '$E3J!^)0]O7(_(KU)*(& O
MB;8ZL0WY@*8H@11TF<0$IP'D XYY#GV'T5(GR']1/,5%4Q\MPI!"$,B<$U#*
M*'E"I))%.8 \SF*01]@'V'T! ^0#J8/D1JH0W^=E*\3$>.4FC<WE^\A('FNN
M4!#GDH<F, %*(@U52[^=5@3>12TVV,KL-40,M&H)I+'7336>D/Y_95 X)& J
MQB?F*0Q??U\1P=9>PF9;JM0A[ZN;23,K"VM?\._Q%URJO[E<2YXX_#!E(-V;
MDI%S"*7WDQ2$?N?E_P!V$I@ P#QR AR'L/(?V"'\Y+W$.!$WT'V$!+P(#] Y
M#DH_T&'UD@O  ' ZQW$.<I506(7[W<S?%P!,Y7+H@D*"O'L8H /MXE^GKGCW
M^G/X\?LY_F],I3.M"L-&&V_(/U(RV\,(7]R?HKSGNC7\T%9Z?/#)Q,C(I1LB
MUX$18+,ECF*!3J'2$Q!NE5@NWEHUBE*T70$=RR*X6'+ H><:DM(U*=PK+,%J
M,''1M[C+G3\J";D[FHJ\D2N63AD[D%$W"R"2"2G'ERD' F+P/B<I1$/$?IY<
M!SZ+^4/RAP7V ?$. #@/V>P>O'Q#QXX\> \> #@ X^G  'T]<>)>!]A#@.!_
M#_D]>Z*0_P!:9!_I_9^T?7R%2I&I%C,>FG8M4J0%.7[PCE-F**(J-B%<(IJ@
M;Q,<##XE$3<< /K ]?RR?KU-LI\HZ%Y^II]J@RV6#RZI[!8<1R>X:[,P[@OA
M))YC4[D[F4Q=E5:)K-R'=)*-BJIFK'6:GS4]WDH^MYYUMFV'^?-OH]1N>0:=
MMG:6+ZYPIG6L4C,:_6!HFBQ,@M+,HJ2CU'R3V$?*L7 M# Q+K3F3S>A8M6*'
MFF,-+5#9MNPQ^[U/?T?DCT7I7J3R@7:1RNR5FY9,=]D+Y1@=:(9*2<8Z3;+&
M36>F%M/[-']7,VMV*VFP;%'X&Z1W!Q$W18_6_L]3^N>OL-U@@SJ=CLXL4@:V
M$FH!)DZDT$_$L?*JL7)B&/M5QSRKY%E';2O6SM)UVK\5,7-S.9#![OB.L7S"
MV$LE>'E%)+.ZY+S593D61G=>,<YUDBK,U"F%(V(8=OX=B)CM+;EMQA;NKIF<
M(:+!1MPQ?3;]0;S"RW8[#\:H77-Y"Q4S07J,"L=.,=24>+8QDU%U.3?(@U8]
MQ)+JTWZK;[%X7E].HU-QM>N4^"B,8R?60U[<V^D5*RS]V9Z=,: \:HH$?5^-
M2B(HR;-07)EW1-[A=6S>I[!/UJ[=DW^$Z-=+[&PQ]!CZ;\BZG4F'SFW5VBXX
M]D*^K2FUZ@B5YO"H66<LB3!9#].1VH@=6$O%"Z39\]HS3#<?U71+E<]R) DJ
M5PVS5]:Z]T2D1.>,<HL.DV]^OM>2NTT4HV/=3#Z*61(DP"3638C239[U<RQ.
MPQN?U6W=@X34ML8Y2ZHB>H[+M>!U)'/R6?-_WI>6[O0<,?+RC!\WB9DK>29,
MFS-W*"JT3S2<G.JE+T2PQ74#.NQW9(^?:H>HTW.3;3G6JZ%CG\..[S4"-;%4
M))KFA(J;%-0\FQEI9)&.;2WZ1P'K7=ZUK):YA36G=#.KW9E?*-#[01LA@,+E
M.V;7LT6UT*9E:KUK=76/WQ6NTXZ*L2P3FTY58\=$M$ ="9TK5\^N'2.N9]K%
MJZ_6O430$IN4Q:T,OTHW6[L%V@S[+=>""PIN%)FIS-,'XD8I^YC[(C(RQ",H
MUZQ:N9)*B-++G-0L>[]G:+\=+++*;,;6C7^LD/=^R'7[L3M=IL99EOAKC0LW
M2>1N+2C=5BH-J5FYDL2TCP:_<<+*Y12B=3CTC/+C;<%SR[7*4UED^LU0ON_1
M'8F'B(F+I*5!8,;A#5[7>L=AC%95O+@SD*^Y92K;E591@A8<HJF'4ZZ9U0>P
MV#=1]#NTMJ*U9OM?VKL[GD;?LRFH_-29_*-I;&HQQ:8)A+R9YAK)E.]=N&+-
MTE&*?J:-VK[-ZC,W^Z]D8=&Z-:4M+4Z<SK/(Z.LMQCFJ^<-X+(\TEZNRM,<J
MV!U$/W5A3:?NU R#XYE7'/Q&QQV:!VKK*ODJ7X B;=LB_;4#$&[=7@!.+I\:
M*<KI D)0 R"BB@" )^!O &30"<<>'Z='QX'@1#Q\..!$H?V>AX8,PY'D>&J'
MN/O[C^3W'W'T(J1[%01-Y")VC<XB;@0\A\DQ_-P/U]%YBXX?'GQY9-A\>?KX
M_P"%[<^O_D5&_P#[BU_9Q_\ $OV#QZ%3]SQ7F/'D88UD)C>(B).3"@)ORB8>
M/?VY'T0JL-$JE3,4Z95(YF<J9R#R0Y ,B(%,00Y 0]P]"N,#"BN)4R"L,6Q%
M42HF\T2BH*'F)4C^Y0YX*/N'HJ1X&&.D7GQ3/%L3)E\O[WB04!*'E^/[?0HF
MK< *)C$.9(8>.%(QT^?MG%,6W@)B<CP/'(<^A\*S7R<CY#XPT:7D>3#R/#8.
M1Y.8?ZQ']OHJ2</%)ID#@B9(]H0A \O+@I"H@4H>7O[?CZ#_ +"S]OI_V9'V
M_J_)[>MU.#1J4Q<8U/@_V$2^)1HTX"@";Q 2E.4>!_:'U]O7QUK"T;+*&Z5]
M=A!=:-*BX,BIF=>4(0WZAFBX(F4YA$O/ '_O  @/(B!HN.,!N?(#,FP@;D>1
MY 4O?D?0E-#Q9BF'R,4T>T$IC    B H\"( 'H!- 0IA*8IRB,4Q$0,7GQ,'
M*'L8O(\#]0Y]>)J]!F+]K]/P,2P$/L>/C]G@6_'V?$./'^[Q^'HR!JQ7A0.F
M*1D1A(T4C)&*)!3,F+;P%,2&$!#CC@1#T JTRJ*B7[HE%2N1!Q+]X3&6\1,S
M'@53'$3<?WA$>?0?^PYH?L' ?^DA7_8/V!_YN]@Y]#_[#>@^X@(_^D?7O<0'
MD!'_ ,W>X@/KG_+>A<A[\_P?7OV\_P#\._;Z 1S6@"(#R'-.KH\#^T.8[V'T
M<@99G $5'E0H4BL@500*)0$Y?W9P<0*(A[_AZ43<Y%F#A-99NX6(O0:HJ15P
MT$#-5U"J1)BG6;&#E,P\F(/T$/7PU,Z!2JE36CYU\ABTNE5*[!UPKU)+KI7%
MB@Z+%1B'ZE']<^%4Q1.03+<'_,//^^(FX#CR,01$>/8Q1$ X^GN8H>L@$4CH
M@;3^X1E"'*B4?OF[H=@3+<@0A3@05!$2<_F$!_/[\?S+1#:YH#"J*4?&;AV'
MO;Q=']0WHN-U.60@#W2S)HF_5(MIVSN0B81FU2=R4S()JD;(* BN9,F4SD?>
M,;T=[ET+N-?INWP$90IRU8].S"-=;7N!*G8)IBHVC[([;1\I&NE6DY#NGS1-
MZQ0%PF8[1.^1-5VV\YY4)/LMGN104?3[YI[]IF4Q%Q:E]RR GI)DP;VN)FK$
MU:QCXSMD872QB(KE$BQT[7J5:R3 Z-O$JP4F]&ML73LZ@-C*A?%47<@XO4['
M,RVI/^*':)1=JNG(IOW)#&$ZH@!S7C:K);X1KFF=5&SW2T6QM(-)"*85^FL7
MS^?<E=-EE472K)..53^T0PG,N7[7]\>/6&**U36LG/V-6NS3(X_:<_5H\C:I
M'/XK^)I>)103D)<&4E/4U)Q-0@.#))2D4P>*HG,=N8G\SY$W8L0DQ3Z4=ED_
MW<<BBA'9EL@MJ*93$2$%!3 ZP>0EX$.!_9ZQ76]U@I*=Q2M]5>O,1>8:)J9+
MX5W 7&C4:G)LWM-74(,W#K/)IN@Y1,58#I+\&(8H&#U'Y)(]<=;Q&-@NXG6^
M5+B5$Z^T2O7KL+I^>Q)M;S^AQL?82NZ5I%*D*=6G+=XLC*$4CVL6X9HK-E2)
MIC7J[F'2&TA4F>-W*LU;<KKU/JU8Q-O0LWUP\3<,0C;?*N#2D!+U[:H-XX<U
MEW%M5#2<:M(^ I';N5[A8TL3P=_/[6NE,W23"DTE\[TIU$S419BRTJ)F"Q;&
MNULL&QDU5A!01D6B+I0173(H%QQ^;SC&Y3--,M%AF[UG3B J1JI=[JXG&MJM
M4S8JZFW(PG+4I96B,B^<KIJ.P>IE74,"@ 8,5HE.SRP#4;_:R9U64LKIC1Q1
M,Y;DJUCMC6=N)HEPPBJ307"=?48@^325*>4>M42E\UP,$7M-PQ;)+?J3)K"-
M$-#D:G7Y&RN&M>=)3599R$W^G.YFFM?> F[CDWAEBLU/%5$J9^!]6ZYZ)UTS
M6=H4%7I=G)PT#C2%]E9-E>M5B] GHN&J5<A9>6L$I;]C_0S*Z+=L9P[G$DG9
MS"JG]PG^1M!ZJNHZIZQI9^K$Y7WG3.S9_G$O;J9MUH)-T&S2DS48.LKLLN[
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MQ$DT%1R@X=H@?Z![#R'M]!^G/]?'KGC_ ,/I_P GKV]OY?B+-^I(9 ^7_)$
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MGD1$> ]N1$??]O\ +\AJ2OV_!7ICV-1.(D0$0(KDUI(?R%SP@/L/("<0*40
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M CZ.HIV2P),B:2JQSGV+/"D(B@43K*G,:Q !4D2E$3&'V* >_H'!.PV&F0$
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MSC7%&4@UV"=;4VUBO<VSA4BD6X/&J-6S9NY51*F Y#EG!2%  +GE. H
M4O[F$"@ !] ]"(XYE0F_^*#G5.$X#^ @/[F\>0_#V]',&+9'R<P&$0S:G@8P
M@'')S!$?G-_3[>WH"!C&2@F'/"1,VIQ$@$0* B! A_8?R_M^G_#T";C$\?<$
M ./%SF-+7* ![@!2GAO$I2B'L' ^N_\ :8?'<KK\K7^FO9*3BY^!S"C,YN)D
M"9#<4TG\0]0ADW#*2)^H-XK%,F8@F$2F)]0Z_;U'];,"T'2[;DG2#**\\T/.
MJ<C6/X^[$R./9)!6_5)\D-^K6IM5LMV3F)4/NI'=$1^R19%14JQ%>NW<OKI@
MW9>IZ'C^7:/C.FXWU)R*I:<^U&^]A*UUF=X]8LZ=SKRLOHN6N5S@7<%,%D&"
MC5LX7:O?U9T/U1=TK>9=(ZYCE&QW X;5Y_5K%UEZ^6[0<\TV-[>VCJ_JF63&
M#3DO$Q+F0I4OF<T@_>IRJY#(I&=-OOE_1@Z=W.6^/M[9,[??Q^TQV_5GK?UX
MDH3;_P#*/;(+!=%8Y^VD+1&S4&>LWJRHN$"V-K!)24-YOF9E2$.4NT;MUH^/
M7-9?:J&ZW_,(/KS?,?ZZQEY:[_B-PLF83E*G'C66?YLN5C<X)14JB-C_ $3]
MCXB1T3[H&)C-#W5KTJ<=MM(>:&T6QRY=:\7ZS;>O/Y[=;75;93O],\I:]+LC
M*?SJ2J;^.?J,Y:4;.U8]5VBH#<P 7N@?K'@O03+Z9U3VU?K;4JYH_4BK7JS[
MCJU(HV?Z#HTI=K*UD*FSS2D$4T-G%5TT>TEG9E$5I)YRD";,V_,.S_0[,KAH
M&,6_L/.PULK/4/K?!4W4,SIG<.U=8*VWJ#Q_8',;"NJ(9:&C[-.6A2OPJ*)U
MWYG1FB#I5*.LM)^-IY:Z>[P2I[]8+]$]2^O">9T.HVNQW_/JG'7>[R$\QA()
MTO>LIF8LSHXC#M4&1I%1VG%%%X&:N<9^-:LZHM<F<"M<C5#JAU^E$\."R:7H
M^04E'5) 5P9(QU@T3(YQ!*0A5)=@SBVB4JZ5;QSELX4R"[:5\:]-J%RTOK[5
MNQ%TJU%Z>9AJL9EM:ND#I4U3F=HMU5K!HM56=KV3RJJ*W^&W;(?IRO#M#+D(
M%MM%>Z$149E;3IWG'8NM87H'0WK'EMA?4"SZU=*</9U#4;7=HZ()FMCII1<+
M,)=..0C8:,4D#+?<<"V]4"9'XS:I W3:\EE]?R"OWOJIUDJMFO;!+,=,U:II
MLDUI"1ER-;=2<E=N0F 05BHO]7'-W[EN[=)MRP=IM_0G'RW78<WZ.+Y-U1K'
M5'K)'61MJ':7.]ATLD%6=8EIN-IUN:3\+ESQ^X5FEX1*!:P/!C*N7GV$\OSJ
MA]"J@Z2O5AR6N!>97IYA=>JV?W;:6^P)T>HVE%^DC:8ZW)V[!++!2:#2+=!&
M2,8*BR@-#)N3O\BE?C@RN=C(#3LGQ"[:U7NJ7713+Z-N6^0L#9,>S2QO98L5
M: =WAA;(H3S3:*6K<2YF&2$A(-UG'B5GVCVWJWU%A8_97DW(4+)H7I_@=0/D
MK>JZ/HE6E8EA:JX-B<7JK2+6(C!:+2:+24;R360.H99NX: C\0U$A.M?7J'I
MMFKOR&3=HKD5BN;L(:QR%5QG.R5AS.1;*NMV$J:ON)-19H+A%;].N/FF8A^.
M4FY.G754J"*:***!.O&1$111;)E1;((IA4/%-!J@0J:1 ]B$*!0]@#T0RW3/
MJ>H)"'(05>N6.K"4#B'D!15IIA*!@#@0#CGT<JO23J JFHF*)RGZS8P(F2^X
MZ6^V834X2B7[SU4X_EX$ZAQ^IS<KNR='^GZ;ERT18.7*?6;%BNG+%!<KI%BX
M<?P4*BS-%TF50B0_D*<H" <AZ<,8/IQU3AF;M-))RVC.N>.,47!$14,D#A%M
M3$DEP3,H(E Y3  \^WN/)3*=*>HBAB'^X0X]:,9*8#BHLN8_):=Q]PZ[A101
M]OSJ&'CD1])D<]+.I2P(F Z/W>MV,J_:,4! #)@M2E"$,'D/N ?CZ0+(]0^K
M;\C-,B3%-[UYR)R1BFF;R2(U!:H'%%-,?H4H@ >@(KTYZIK$\ 3.5;KID"A3
M)@90WAP-/Y\?)4P\#S[F,/U$?1?U/2KJ,Y$@D,05>M>.' ATS 9,Q"FIY@()
M1*'T]_8/?T*I>E744%N0,"G^FC%O(IBE,0IRC_!0& Q4CF* \_0QOV^QA4Z4
M]13_ ' .57GK7C8@H502"H!_*GF$?,">_O[^C+H=+NI2+D3@I]\O7#( .*H"
M<04.8E2(H<2F4$0Y-R'(^_OZUJRQG3CJDQL#+-+[(,IACURR)"5;2#.M2#]F
M\2?H5,C\KEM(-DUTSD5(<JI"F*8#  ^N@%WOW3SJEH-JLW4O$IBPVJV]<L<G
M9N=G%Z#7TGTO,2,K3W$C(2KC],5-1=10ZAP3#S,;@!]%55Z(=+U!#D>#]5\,
M4X-YK*%.0ZU'453,15RH8.#< *AN #D>4U9#H7TL?'1)]M([KJQAZQTR@)A(
M!#'I(^(%^X?V#\3<^WOS^G6Z%]+E4/+R%%?JUAZZ)A_PA_.FI1Q*("=!,1^@
MB) ]_;T'ZOH!TA=F_P"<+CJ?A*H"'@"( 4%*,82%(W "% !]BA^SV]*$/\>O
M1X05(!#A_I/PCW IO,O!RT0JQ0 P /L<!]@X$/3M1S\?'2%51[S^H4'JEA8'
M,)N0,8IQHQE"&-S[B \\^A27^/;I,9,42MA*GU=QAMPW(H"A4R"UJ")@,'N'
MF/DH(" "82@!?28$^/'IB/VP, &/UPRM4PB)CG(8XJ5LP*"4RIN1, B(&XY
M/0"M\=W2LX_:41-QUIR,GDFJ7P,4?&K /N CZ5,E\=W3 /O#RH4_7++5DS"
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M7K2UWG)7-9P!S)M-NL*-_K!X3*%X9-PK*EOTI^\P9U@D>5FN54[LZ1 6;JI
M(JI*$)1%)FVP<434)V/K.=&?R+5K_&T_*P$M:HV'K)550/,23VM03Q^1! #J
MBU;*'$H 4?13\&.!Q#Q\ Y'@0$WEX^P^(%#D?Q /6H1W^=V5 \Q)HF_V) =
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M"^/"CUVN7*G2!>P&RR>G=D;1%:W'.W$LP8PE0G([0(B0_4V0["3;2D[*$4;
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M/C7E\BS6VU9E7X^)[_R<%9+#1FGR$J]J96:F$T'*36M2*/7.7D:-'Q!7K_\
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M. $Y12,8+A^4Q3)F >?8.!_ !'T=Z3NIU.%LD"(K*AV*Q\2I?J"D,@!Q+<3
M!ERG#PXY\N?;TJ\#NKU+%HBY%BHZ#L;COV"/BK(MSLC*?QGXD=$6<I%,4W'
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M!MYRLOY_\/\ +P:U@/E_C$]OK^<O[0]"8_:_K40 +Y&$^[Y64"AQR(F$;8
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M9_J"@1Q^ER6@M_OD!8' %6^U $^Z4%P\^#<AY^_U]_1%PZ[X6"Z942IK!DE
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M117ZQ=>5A(("05<6S=02"!DC@)?.M#XB!T"#[?B0H_@'H _TD]9. 446#_V
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>exh1077_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh1077_3.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_X0[_17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  %?D    G
M$  5^0   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,3<Z,#(Z
M,C(@,3@Z-3<Z-3@      Z !  ,    !  $  * "  0    !   "P* #  0
M   !   #CP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   W)
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M#J/J^A795C'&R'!P-;6ML>T![/\ N/5FM>Q_]3_MM )N+3797:QX@^HVI[R
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MP%Q%MNVL.?#6[OY285L+X_9  !:-Q%&H=]-X]_\ @OS_ /P-)3:L_P"4:/\
MB;O^JQU95(8V/3U"DTU,K)IM!+&AL^['_=5U)2DDDDE/_]/U5))))30P'9@P
MJ RJHMV-@FQP,1^[Z+D1F1EO>^MM# :X#I=8UNHG]&]V.&6_];5+[(Y^/4US
M<FJ^JL5^Q[PR6_O5X]]7J?YR@,3++FFRRWMZ@K&0V?W]A^V^WEVSV)*;.5EY
M&-<V^ZIFT5N$,=98=75_FU8SW_\ 13NZK8VHVFAP:.?9D3^=^9]CW_F?N_\
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M<VAO<" S+C  .$))300E       0                     #A"24T#[0
M    $ "0     0 ! )     !  $X0DE-!"8       X             /X
M #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M           ! #A"24T$"@       0  .$))32<0       *  $
M CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #1P    8
M             X\   +     "0!E '@ :  Q #  -P W %\ ,P    $
M                     0             "P    X\
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   X\     4F=H=&QO;F<
M  +     !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   ./     %)G:'1L;VYG   "P     -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     $_\
M     #A"24T$%       !     $X0DE-! P     #>4    !    ?    *
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M*22224I))))2DDDDE*22224I))))2DDDDE*22224_P#_V0 X0DE-!"$
M %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3
M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #(    ! #A"
M24T$!@      !P ( 0$  0$ _^$Y:&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR
M95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM
M971A+R(@>#IX;7!T:STB,RXQ+C$M,3$Q(CX*(" @/')D9CI21$8@>&UL;G,Z
M<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M
M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z>&%P34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]M;2\B/@H@(" @(" @(" \>&%P34TZ1&]C=6UE;G1)1#YU=6ED.C$T
M-#DT1D-"-S-&.44V,3%!1#-"0T5#.$)&,3$W14$W/"]X87!-33I$;V-U;65N
M=$E$/@H@(" @(" @(" \>&%P34TZ26YS=&%N8V5)1#YU=6ED.D5%-#@Q.$1#
M-S-&.44V,3%!1#-"0T5#.$)&,3$W14$W/"]X87!-33I);G-T86YC94E$/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&%P/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AA<#I#<F5A=&5$
M871E/C(P,3<M,#(M,C)4,3@Z-3 Z,3 M,#@Z,# \+WAA<#I#<F5A=&5$871E
M/@H@(" @(" @(" \>&%P.DUO9&EF>41A=&4^,C Q-RTP,BTR,E0Q.#HU-SHU
M."TP.#HP,#PO>&%P.DUO9&EF>41A=&4^"B @(" @(" @(#QX87 Z365T861A
M=&%$871E/C(P,3<M,#(M,C)4,3@Z-3<Z-3@M,#@Z,# \+WAA<#I-971A9&%T
M841A=&4^"B @(" @(" @(#QX87 Z0W)E871O<E1O;VP^061O8F4@4&AO=&]S
M:&]P($-3,B!7:6YD;W=S/"]X87 Z0W)E871O<E1O;VP^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C
M+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+VIP
M96<\+V1C.F9O<FUA=#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @
M(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM
M;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O
M,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C,\+W!H;W1O
M<VAO<#I#;VQO<DUO9&4^"B @(" @(" @(#QP:&]T;W-H;W Z24-#4')O9FEL
M93YS4D="($E%0S8Q.38V+3(N,3PO<&AO=&]S:&]P.DE#0U!R;V9I;&4^"B @
M(" @(" @(#QP:&]T;W-H;W Z2&ES=&]R>2\^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIT:69F/2)H='1P.B\O;G,N861O8F4N8V]M+W1I
M9F8O,2XP+R(^"B @(" @(" @(#QT:69F.D]R:65N=&%T:6]N/C$\+W1I9F8Z
M3W)I96YT871I;VX^"B @(" @(" @(#QT:69F.EA297-O;'5T:6]N/C$T-# P
M,# O,3 P,# \+W1I9F8Z6%)E<V]L=71I;VX^"B @(" @(" @(#QT:69F.EE2
M97-O;'5T:6]N/C$T-# P,# O,3 P,# \+W1I9F8Z65)E<V]L=71I;VX^"B @
M(" @(" @(#QT:69F.E)E<V]L=71I;VY5;FET/C(\+W1I9F8Z4F5S;VQU=&EO
M;E5N:70^"B @(" @(" @(#QT:69F.DYA=&EV941I9V5S=#XR-38L,C4W+#(U
M."PR-3DL,C8R+#(W-"PR-S<L,C@T+#4S,"PU,S$L,C@R+#(X,RPR.38L,S Q
M+#,Q."PS,3DL-3(Y+#4S,BPS,#8L,C<P+#(W,2PR-S(L,S U+#,Q-2PS,S0S
M,CLQ0S5".$%%,S<R,C5!,T(X.35$-C<U,C4S.#0Q0D4W0SPO=&EF9CI.871I
M=F5$:6=E<W0^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIE
M>&EF/2)H='1P.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R(^"B @(" @(" @
M(#QE>&EF.E!I>&5L6$1I;65N<VEO;CXW,#0\+V5X:68Z4&EX96Q81&EM96YS
M:6]N/@H@(" @(" @(" \97AI9CI0:7AE;%E$:6UE;G-I;VX^.3$Q/"]E>&EF
M.E!I>&5L641I;65N<VEO;CX*(" @(" @(" @/&5X:68Z0V]L;W)3<&%C93XQ
M/"]E>&EF.D-O;&]R4W!A8V4^"B @(" @(" @(#QE>&EF.DYA=&EV941I9V5S
M=#XS-C@V-"PT,#DV,"PT,#DV,2PS-S$R,2PS-S$R,BPT,#DV,BPT,#DV,RPS
M-S4Q,"PT,#DV-"PS-C@V-RPS-C@V."PS,S0S-"PS,S0S-RPS-#@U,"PS-#@U
M,BPS-#@U-2PS-#@U-BPS-S,W-RPS-S,W."PS-S,W.2PS-S,X,"PS-S,X,2PS
M-S,X,BPS-S,X,RPS-S,X-"PS-S,X-2PS-S,X-BPS-S,Y-BPT,30X,RPT,30X
M-"PT,30X-BPT,30X-RPT,30X."PT,30Y,BPT,30Y,RPT,30Y-2PT,3<R."PT
M,3<R.2PT,3<S,"PT,3DX-2PT,3DX-BPT,3DX-RPT,3DX."PT,3DX.2PT,3DY
M,"PT,3DY,2PT,3DY,BPT,3DY,RPT,3DY-"PT,3DY-2PT,3DY-BPT,C Q-BPP
M+#(L-"PU+#8L-RPX+#DL,3 L,3$L,3(L,3,L,30L,34L,38L,3<L,3@L,C L
M,C(L,C,L,C0L,C4L,C8L,C<L,C@L,S [-S$Y130U.$,T-T5".3E%,C=&-T$U
M.#8P-C<P-T5",$$\+V5X:68Z3F%T:79E1&EG97-T/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_
M/O_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.
M  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="                  #V
MU@ !     -,M2% @(
M                    $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0
M  'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)8
M65H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,
MAG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P
M    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0
M    0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY
M  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0              $G-2
M1T(@245#-C$Y-C8M,BXQ
M                          !865H@        \U$  0    $6S%A96B
M                    6%E:(        &^B   X]0   Y!865H@
M8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P         6245#
M(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N
M:65C+F-H
M         &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@
M8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M          !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I
M;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !
M6%E:(       3 E6 %    !7'^=M96%S          $
M       "CP    )S:6<@     $-25"!C=7)V        !      %  H #P 4
M !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($
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MF/TI_;K^2_[<_VW____N "%!9&]B90!D0     $# ! # @,&
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ML='A(D($\3,R4A/_V@ , P$! A$#$0   /W\
M
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M.QU /0   #28S@9I            !$P2S@   'R/J#X&N9L&>@Y!&62;'U
M    !\R/LD'. =C@  X.3J<G(  .H.0:3&<3- !V.#J<@'(!P=@ #@^9W.0
M<$4)+ <' .#DY!P<@ ZG8ZG8$7A* ?0      'S(VSTE2+</>> ZGQ.3DJQ4
MBFGS/$=S@Y/04\\153PG4LXJY7#N?,\Y]3U'I*45<N4ZGT+;+B+:*0>0^!]3
MV'H/(?,Y*(?8UO-@STGR*<>@\![#VGP.IY3L?<Z'S/6>0J!@0G=/J
M          <  '4[ '!R< X.3L  =3@[' .QP=3L=3D'(.  #@Y   .0<@Z'
M8Y         !@XR.74 #@I)]RH  &O)G$^IXRK%./2?$]YYBG%9.06^>\J!R
M8$-@      #!QG Y     !@XSB             1LFY!EX X.I$B8D)S#@Y
M(K"A$,9EDX-]BRB.$NXQD7Z9.,<&_AJ68<-@#=PO@ES      (KB5$ '!P#D
MY.I3BI@AU)B@            "-4W+,O@$5Y[BZ2L%TE[FT(!%4;P$9AM4?<]
MIE\V*!R?$^P !:9BPT)/D744,R,8O."4LA<-E"ZBUBRCDK1*H :FFF&6FU/6
M57[YHFG.[F>O!\3[@AQ)C@            "-8W-,N $)QCDRL6$;*&9C>0 B
M/,O&B1R6T9_,UDG)Y3U'F/N=@  1'%9*(4 I!>)U-K2-0S@7H4@L8\YE0E8
M,#&#(WI.*)]%  AN)D0            "- W2,N@&K9^8$SX;)EAGZ/RH $4)
MA4C_ #.)J872;MFLYKZ742#& 3]-P  (FR6,'(    !% 2O@     $/A,&
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M4(WQ* 33'I.01GEG$3)GX^!CPV -4B\"U#: M$P4;/&*"BEPE\F]9+
M 1'$N( !P<@'  (<R8T             BY,<&0SQ'S!ZSQ'<]I2BF'N/D:'F
M]QR=SU'D/,>8^A\RNG!V/H=3['8H9H:25'R*<="GEOG<KI2S@^QP?$C_ "18
MII3CJ58]152B'0^1[CU'<U:)_P              BR)"#(H .A!(?$GD  (P
MBR"&4S05,V])&C\VQDDK1>!9)5BW2L&W1J$?I5(VB6\      B6):0     "
M&LF4             (LR1 O0Y/J<G!1C[%2.AT.YV(PR^B+(W[-DSN4LN<P
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MRV&WYI\9Y,ODD1JF:K%S& R;PQ^2Y      $-A,F      0E$VH
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M4$]143WGQ*,?<'M/*1>DE!Y3VGC/L<'A/*=CTGG/84TU?/T6
M $29)\7< #XD.)@ _0F  1;EDD$YM45(V^)#S\[9<YP7X4@M$M(NPVW-.#]3
MA&T2W      $/1,*      0MDT@            !$:2<EWGV.I]3D^)]#L?
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M!;1<I<!Y"A'U/.6D9)/,12$R0!8AAH^QD$QJ9#+S+M (9R9@
M B:)*2_ 8+(EC3TW!,2'T/4?H;*@"+,E,     .AV.0 1'$N(     !#Z3!
M     $*!->             1*DEI?H . <@X.0"+4E*        (ER6@
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M#+],6FVQK>6T; 'Z#3U  B9)9@     "& F? !\CX'L*85,  A;)I
M      ")DDJ+\!CHQ<:;&P9\3N<&ZIZP1<%;(3#X%\F4S'Q(N1U%[F%R2LT*
M,<F4R6 DG!$62Z      $+9-(      0YDQ@            !I :QET%4*2>
M4^QY#X@ X!KR9!-;BLEV%LEHGG+\*26N7N4 I!?)E0S =36$V?.X.#XGG/H=
MSJ4L^QR?4UA-HBEGN/,>4^A1CWG0X*J48JQ]"84
M
M
M
M
M                       H!3SRE=*(6^7,>D\9[2G'W.I<!;)ZSSE8.IP4
M<X/4><[GO/@?4\!5"HE)*@=#PGT*\?<                         _/@:
M$&G)-,0<&Y)FDA^)1C0\TW)@#/1B@K1&4;Z&\)%0;_&BQDHV,(<RXC,Q91,\
M0A'G)=R!4S@?<DK/F?K&+L                         /@>4^IV.IP?,^
MAP<G!P=CD^!]SX'H.AP<GT/,?0\QR>TZ'8\YT.0=CN>$K9W
M
M
M         !T.X
M                !U.3D
M   X* 5\Y
M
M
M
M
M
M
M                                     /B?4Y
M                        !22J'8                 ZG8
M
M
M
M
M
M
M
M
M                            ' .0       #YGC*@
M
M
M
M
M
M
M                               4HJH
M                 !P<@
M
M
M
M
M
M
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MNO\ ZCTQY[<>2J<)4M&S;\2)F&6UC++ET=*0G/=.0/'>>/S\/4X$AW$<7NM
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MC<E$F_UTQ1FQ"3\#AOA*-3V=0_AP9%6*\%H8;T,F%@7"[J0J1'X4QG;Q?/\
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M@& ^GZMP .GZ.M4T4R#]Y2@4?V@/ZAWTW!KT.I $1 "B)A,8P@!MX )A$3"
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MPYSF I"%Y2X-,8YAT "E*%Z$3&$1#L'W]%50YH\35TC@!B*H\C,/J)G*)2F
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M30PB&@Z]]>DUAY$8+!%8 %%4<MT $U0$Q" *9_Q!M. G4*'81[F /M#HP%Y
MX1,)" H<"Y6H8B5,2B<#F )[X2"0-=1[:=^AUS_A,-! !URK10T$P:E =9[L
M)@'M]_0$_F"PAN, "4O\5Z'N, @)@$ ^OZB E#7]76U3D'@\AOB#:?+%#*;4
MHE P:#/@/PB< '[M0^_I-%7D#A%)581*DDIE:B$45$"&4$$R&G@,<03*)NP#
MV 1].E%/YF^/?C1,<BJG\9\<;$C)@<RA5#?B3:0Q"IF$0'00 HZ^@];V')WC
MT^)\ZK&[F>:<;N2_44%BMEV&Y&RG#YU%P8$SI?ME.(%$->W0*K\G>/2"1CE3
M*HMFG&Z:9E#',D4@'/92E$YE""4 UU$P"'J'2H1?([ TD*"X-5@C\OX^>"BZ
M$IC@V5!O85!37$I!'8.AM 'MT9-/,6*U#D267.0F0JD8Y4&PMBN%C%++B)4D
M!>H@<P]BBJ373<74KQ+-^(5&AU'Z)'2>2J8=N=6*6,WE$BKEFA2,I&N""1P4
M!U1. E/H(:=(LWV>\+,W;@Q2-VKK*5&;N%SG7,U(1%!:=(JJ8SDHI@!0$1.
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M H*;5/R6 N]P<$C:$#4P[1T#L/7;D%A ?V?3*]#']O=L])[_ !;!T^_0?NZ
M@9]PJ)S?LD#*=%$P]A'L7Z[J/8HC_9T !G_"8B/8 #*M%'77TT_Y>[Z]%\>?
M<*J;R[R;,J44^X@@8P&+MG1W%$"B.H=M 'I9XGG/#JC-N8Q5W9,FTH[9 Q-H
M&*LN6;%),Q1,&H&$--0Z-\ME[%[C:F*QO!?ZHMM1*!#&5-XY8VB92J%$3>@
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MRB0VI TZ:XNN.)O;MJ61GSN(91U LU-XTU^\R3F?,B6#0CZ?*QC:?=+S)W!
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M':NAXR?'M\:C=LBH0_[Y3<8! QP-W'MW.NI[>7%XRZA5"G4_AO' !@4#0^I
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M%4=-%3H)B_$K?S,Y9NH")0DUR@37Q@4Q2[1!-,"IOY'@_AI=T0BC1%5NULS
MP-5T?"NT6^0LK4BK!5 G[Q-0!2,83G. F.81D0A.%G'Z5<-EWL+)IF^M6=*.
M>-DRD?,U63^SRK>,EDE%@\W9)U\0B;01$1<S$KPKP;7X:&;'?2$@Z>V6OPL>
MS:&^;</)!P>U,XMLW;; .*JY@(0H:"8 T#JN+%XG<=S1=K43"H+FFI55G:C.
M6QW;=*N.%+9LL*2K(A54$VPK%\**8IEVI)"7'.:,&\<*?A[)E:Y7\+&==N>/
M)6WUF8BFL_RHQ1#RL8Q%&Q)QA&<O&2CEHJBNB#<47*@"!1-J&@!H &.   "
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M>"9L<0(<!5 #Z]M"].$Z[RB]OU$J@;6@2?#O.H@AY$'&\ZHMN71TU@1=@F)
M A042WF,)1)H8AV?)G@*WF5%T"G27XBYW4CT6VXYG(H.1Y7$<*K$(8I4P,B4
MIQ 3")?V09&3Y*<"G#?_ "X/D'/$C.+<_P **@N3-%2\KW?DWK:%* D3U+J/
M8>W1"R7)WV_"M#)LP558\0L[*N4%47+8[TR::G*YFDZ(]9H'*4142!%18.Q_
M$&\QT^2O ULF<5$RF-Q%SL\4*@#-XV(!FYN7;5!8RKM9)UM,8/&"0H@8X'\I
M79F_)WA/ MR$,BT1:\.,Q3ZIU#%,<';M9YS)A_ =,3E+X2D4 Q2[A4 3;0VN
MN7'#!XI\ $ .#>66B8$+IY?A+S@<FW&+V#OH'0F'EEPQ42%+:5(>#^6"ZJ;1
M %#'#FX;4-PZB73T#3MZ]-RH<U^$C54BFYV<WM]Y:=D=D*5,  A%>?2)FQQ,
M0QA,)E>YO3MJ)=_+7A>KIKN'^1S+1 ,';: %#G"82 4 ^\==>BE2Y1<$%"DD
MFJ;C7AOFPIBPQ@.+QXGLY@G*,DD.P$FYA*B?4PF6( !JNFWY)>WJ8XOG)67S
M'$[/B9%XLK7<R7<'3Y3JE;2:ST=BC</(0B0"<BAQ^#I RG(WVYBK"X '9"\6
M.09D$F6\I16;*FY/$.NN "/PF*F37MO^T% +R&]M\VPPE+_S7>1(B(:CH)@+
MR6$ /M !$ UT$=.M3<@O;?$?3:/&'D4GJ.@[>YN2V[N;3[.BE3SK[<($*!MS
MI3C7R+WZ@8X@H" <D 3(*9! NWRCKMUU#70$A6SA[=CM($T 7*''7D,V,=0K
MA(ZQBB'(1V!"JM2F(4!$=HJ;N^G=$S/.WMT,DD!5 R:_&SD3)&73.)?&853\
MBF_C50*40$2E,!]VN@::#'@3+GMKR9_.E\^J[P/R8B][42HIN"M&S?.,G^_$
M@*'(4R@ 8Q@)V#XNHPJ>2/;-2$CAT$H8V&^3JG^3!$YF:C @9C#<LDZ$$U"G
M\9/&/D XF_=]&(POOM8D>@X5 @N,9<KC(K,P2$R!5"I9+6.DLNMH10 *<I"*
M"8!,)0*8R,A<_:Q5E!2_^E,<?\KA0*X$Y-A#MS9! Q42I[_C$==?\/KIREOM
M1RK[:XR'*+."W(.VHR^+^33UG'6I#$F.L3-*S%MTLA1ZL77'<?CQL\7=++O7
M:;E5<Q2'34!)$0C[9[4A(\5OW/S5#Y;_ #2R)DR&."Z1+P*:!R+?LZ',!@,&
MH@(:"V%>Q>U:V/XTRN3DK'+)4#'!71046ZEH:B1-1, *!3&[#KW'MTB"UE]J
M=0Z13%.4*ERV*FL/P$*?M;RBB8HD%0V@' 3'V?"!=YE5F%M]J$@?,'!N@YI7
M+0_E;F2+HDHX_&7^64,X(!>Q5 $A]=1$@%,V!Q:_:I172,BL^!M2.7+@AS%<
M.RK,6Q@N;=0A#M#):+[3&*H0P>,P&U!=LQE/:>*[*9,[:07C.7Q4SJE7;G,W
M7C?J)] 60(KJ?Y@YBFVD N@Z]%%RE[4+H@-2D67:N>6[51^^ QQ4<BV^74(P
M343*0 3%9P)1()=X[@$J!DHGVK5#$3(9T169Y;()++*,UE%BH.!BG(H)%>'2
M3+J0^I2&$1#< %*X.T]J(Q1%0YTDI+ERG\&J_P D .#Q:A!+XSI[_@#<.X $
M TZ( M?:A^:WBHJ?ZGRW(FHW*U H))F&'$4E2/-# KJ8NP?V.W<@M8KVGSID
M 554SS_+DQW"JD@8ORR*QH$Y6Z01@;O(9,P>0VFS0.A4-#^U$Z5(57:V:S7+
M1DHX%1H[(B85EH-Y\H1&0%$Y@\2PJHF.4-AM#"[.O'^U$X4*X$C%(DQRV036
M9BJN8YG2GT1X<RQTCHB!RZ% 2&$2!N I%E1K/M2.EBOCG;-4[GRW9E)$ [;"
MW:.79J4NB=XFQ\Q!7! I1.)#@F7:)3'72QE[5RXB=)0&(YAY5M3I[E&Y7/\
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M]?6T"E O^SH&GW^GIZ]#^GN/Z?L[_P!@?FB!BE, ZZ@)0$!U]=0$.^O6H)D
M0$! 0*4!U -H#V#U HZ?JZT  #[.P!Z>NG]_7<A1[B/<H#W'U'T]1ZU I0'[
MP* ?Z@ZT^S_P]>@=_7]/;3_5U_Q9/00_9+Z#ZAZ>@]:;2Z?=H&G]W6NPFNFW
M7:&NWOVUT].X_P!_6[:7</<3;0U'0- [Z:^G;H=2E'4-!U* ZAV[#V[AVZU
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MLK,TDQ162%XP!^B9=D=ZT!0[AG\ZB03I H4HF* B&H=_RV8AC',0GM,5L4B
M@<A2 KR]?E$1.#<A%S =,1W =0X .TVPI2:_UOW'#HZ H'"?DD &,&I2@.+;
M"!A 2Z* H4HB).^W7N(#IU@\%#E54#$&- 45(0B95#A3(7<<J9#'(F4YNX%
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MC6MDD:<^DA)X"-).-C;=$N8ITY9*N4&LD@=LJ8BQ=G7;37]/I_HZ[Z?V:_\
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MBC\*A!,*QC (&*70#_[S+C(!2I"7Q$]M61(4ZHE53*H<QN9[E0  X@<=N@:
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M Q0T)^D>@,TYL<0U554M#).>"60BH-UA;O \B"S?F"955('8M@V*D(8$Q4,
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M:QUQT;P3!V]O-]F_;]L'+.H90GK9\_$6:%?H91:LHE1@U=$BSU@JY3E(]V/
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M.BHB<J9T52\X\!""NXQR!H0-1]>O^'_?_,_X?;UW'3]?Z]/]?YFFO?[O[O\
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MB97 -CYW%N*Z92 !3"4=/[M*S<*+-<GA.UY7\'*^O&W;F;RHR/6A@;1S"PG
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M@(^O8-.X@8?\ @'V#H/0"8=-1T#L(ZCIKH&@=Q$ Z 0$! 0U 0[@(#Z" _:
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M<;U<V&A7%9@TJ?)6!IP4QGR'F, 5W(9"-K1'\O(+)%N5DW%>DI(L:XH+UL=
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MUSCRMRD6ABC-W'*Z\<GV/+4TC<L5:=M=KI]4OKR0C'B#QM#B[1;MQ:@GN$V
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M=< %,05^$0'00-V'OVZ$R'+_ (NK% Y2;DL_XH.7><@J$+N+;! 3&3 1 /M
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M1X1W$R:MD/:Z/7:U&DI00[,I2.&AGLJF]*JH1)02E Y^!/)7!]"RAE[('&[
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M?3_0'J(^@#T.T#F,!0-L O?0?L VH)F$/MT$=/[0Z,4 ,8P#H!0$@&-WT,)
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MTZ2R,M!V>"F(NN3=<\?F23<)K@^9@.H&U /B#T'MZAW'L/Y/;5VE$3![I/'
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M21']HP:#I\&3,?#V*8NEVJYMQ#_L'+LE3? ?[![:]:ER5C\X".@;;G6QU'4
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MR+U.A0TJBL">J8BB]5,Z*IM'4!VG'OZ]^CJ!P+XP!N#XS#C& TT /41%':4
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M<1'U$>C%-Q>>D1%5TJ#1+/7)-)BD#Q)ZDL@@P3S 5F@U )!0Q$B$*FF?:8H
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M#G%[>2S35)50IG(\T\)( 0QDRF\('16.&\VA== ]1#\P/A$VHZ  ;==0#70
M$0$PZ /8 $>@'00U !T'L(:_8(#W ?Z'EJ\;;TT">W)Q81DP*)UR*/%\Y9>/
M'K#\1TVBJC-DLF=/0ICIIE/W#O\ USW"4TR+JJ'XV7,I4T"J'$PF<19=1(F1
M0PE)KJ8=-I2;A,)2ZB&-@5 H*!0:<"@%4(L4#_AV.W@55,QTU2@;T,41*;U
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MD]Q!H02":L6V52:SC"0"<?.CBR7YP!FC(&!L,V_CO81J9,KU5:64QIC:.O\
MQ:Q-GVKVC(+&[V5'8]Q0OEWY*84/(L64J,09<I&/E%-+CID4F7298RMCSW.\
M-<6+3E^,SSF_/&,.8..LZ6;&F++].4I]E>T7=[$1\K&6U*00B&<A(1%7N58>
M_3G/C,X15Y,T68SHA5,:PG"_BM?W-4M'/#)O%^/HEJM&;LI0.2<I8OK%<FU*
M]:,@1F*X-K(JQ2R+9.0^G-D_$X.^,5;*#RLI<>4:G2D.22LQC:YJW.+S=@UM
MQHYG<:.-,K*\@VJ%V8DKK')^/,TRUQ9K#"Q[*!:LFFKB11\Z@YJR[@^\X29W
M#$E1]Q"H8JS+!7"TW;'#*H8'Y9<-\;.[I8<>LK^ECJU2 X\RB$BXEGS=P:(&
M)<N(Y1",D7 +<JN,T=<,+0:F,U8*8Q?F.D7N6J!9ZX8*Y=\3JU<TI%(<F/KJ
M:D2]<R:XDI0ZL1$QJ<4V>(1DA98])66-5>2%J4QJ\F*E@#F/B>494W,&0D.*
M]W5Q3[@W'C C/DLM2Y2<58ML?4JFW=[)N9L5EED#)2+$91)J@"Q,?Y5OJF(5
MK-85+:TD76!;X.2\32)J_;Y^NL):HW%(BC.492L9$IKJE0=2#9J\.J@B\>)I
ME<&]M@PJ^$$_=)XVG$ !0#. _ .;2%1!1+XTAWJ;C#^P<A1(;X3&#KC-=:GR
MQMO'3+W&];*=XQ7&TVKX7NDC+261J8\Q-9;1,5'+59LZDY!Q5+L,DR!$B!69
M57H+G-YTD#%R)%,_<7O?\2LE<(WO BX.&R''N7MAJZYR7;\G6JR1-=_#XDJT
MP4+1-Q4= L&C6#J\$I\M&-6WR:!B*7O'O.:^4+/Y\K4S)D-EO%-_P>ZM<(Y9
M<>:=Q8N%.@*U(UNQUQ:MY9QI2&QW1)!N_>-9PI'S%1 [<B(SESDN76?J=F7)
M,G;[CB=ZG;<7I91K=IKUYPGF*O7"MV6PTMUDS+1\'7/%S1V@WL#V:9-XR868
M*$0:'3 <6\E.4UNI\I1>(&)9K'V/^3^9\R,7>6.0^2,P3D?8']TS3!NZ=CW&
MN,V>'K'.VAA1XEBZD6K0;6J$4E&(I%05)R/?9:R77)P'O$I^2MUT*4>K/OY/
M\Q6S.^/T#JRE8=3RC*QVJXJEF2%?;'#5!$$O"8HF-A#@^MR%R/3F54RHMDBN
MS)Y''CFU99.QM%WR)=Z);:!/U\^/,E4YQ%7Q^)HU6'<M8M9HPD13\K%,P-_;
MM6RWD.4I0<=S\:7F57D=15LEN\<K0#FI FLU3KY*4WF$ZD[^1;K@P.)"D*L(
MG6W*&KUJGLOY68V6&P3QXP*ZDH9O1TV<M7N.W(2F\BX6P*PKRKO8YA9;7<J:
MBSDQ;@5!.,64*V305V*%CTT^168YVB4KDKCK/^$,<R<9C1&OXF@,=W*]WV.P
MF278TQ"SY&IKJP9#?%0D[ [>SL;'LX]NS<H UWK8UOO'CD7DN7RIDWEMA^_Y
M)>9"?<=T;.WQWCK)>8\S3]]0D9O&[>\YLM6+R9:<0[5K)OI-T-?<-6IP^69-
MO%5GE1SMF-@XD*48N1L4/IW%;B.SG;&4GD:5F\V/6DK07MZI%C<V',\PM))U
M)_#0BX.6[-9N+-/P*8RLJ/+GD/.7S%&1^/UZJ5LGH#!7_)T+QXP#DSC%6\?-
MX"$QG$PR4#/X:R:[8/W9RKR7SY?GTEDW!S&ZQ%+4+E;R!-1L?8DQ+C;(6+"#
MC^&J6?)[!<788#%^1;[(0]8:VJ"D8RLSY(Z5B(-Y'PUA0C&0R2#GPCO(FIIO
M+NW" Z[A$YAW]@  W:ZZ   'V  =@_)[S8$$0V<C.*>]0#E\9@_DLQ")T@,
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M$A@VSO+Q,4>RK5N^7C(<(DS! [ELTLRKE9)RW<BFGX>/]+S! <D^0!,2\_\
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MFORZ1D^%V)"C\OKV RF@B?33OI_30)BNCM3)\T/;W4**9E2G7TYLX**+8HI
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MS'I0Z>>,S3+_ %*_3PN-8UDN#5NMXE#*.$BEUZ$YO:J]V,= ((E3X[8K6/\
M&<$R@4J&?%1,.\P;@_PDU,/8!'K][[5/NR[]/V4>-^-'1=1235#11MG=;O\
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M0_3O+QS* Z_JZ_Z/_MB_]93DQ_[.O7_1_P#;%_ZRG)C_ -G7HH%X]^V,;4P
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M,57#=TF<P#H9,Q@^$>_2]"1O-04O;5 '+JD$LT&>X-6QDBK@X<5HC\TRDW%
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M4!B];%4 5$E=JB8?M ';5M]4LT!&?.(%<L_J,U%L >-SD(J5=H+QVB#I#PJ
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M&,&B%#G\<<58CB5+PZ;"*ICKDU7?;FQU6<H+U-X9!.I*+PV5FL0SF70 8I+
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ME$RB4 TTV_=VZU(=0HAN AA'<*9#[A,F7TW$W&U^+4=?M]-!*81, AM_>?O
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M;]I= W 'W=&* F,!B@4VH^H!ZCVT^(V@:C_XH &@   .U0Y0U Q"AH!41#0
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MYB7#AS'K' V]FX=,UF"RZ1BJ$T%1DY52'L/934-! !Z* Z]B@'<=1[!]H@
M(_\ 80=?V= T[?;]O?\ _,#]3#H&NGVC_JZU#N _U(HDT_:^(-HB(@(#IH(:
M[=!T_P )NW]X ,B=$SD5W)A%!N9LF#87"ORI/$9R\$%2-]@&'R#N-J.A==H?
M]H??_N=3MA]-?(HMD4522:OR8,'AU#K$5;-B$=GD2KM/$ J"LW22,!R^,ZGQ
8;?\ M7$0  $=-1   1T]-?U:_P#=4?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831037456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOCRYST PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">bcrx<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,955,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206,175,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831451024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 22,104<span></span>
</td>
<td class="nump">$ 28,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">1,546<span></span>
</td>
<td class="nump">1,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">32,546<span></span>
</td>
<td class="nump">22,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables from collaborations</a></td>
<td class="nump">8,768<span></span>
</td>
<td class="nump">6,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">1,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,438<span></span>
</td>
<td class="nump">2,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred collaboration expense</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">66,987<span></span>
</td>
<td class="nump">63,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Investments</a></td>
<td class="nump">8,926<span></span>
</td>
<td class="nump">47,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9,922<span></span>
</td>
<td class="nump">5,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DeferredCollaborationExpenseAssets', window );">Deferred collaboration expense</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3,813<span></span>
</td>
<td class="nump">5,468<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">89,847<span></span>
</td>
<td class="nump">122,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,269<span></span>
</td>
<td class="nump">9,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">10,836<span></span>
</td>
<td class="nump">16,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">8,990<span></span>
</td>
<td class="nump">6,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">2,022<span></span>
</td>
<td class="nump">2,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Non-recourse notes payable</a></td>
<td class="nump">28,243<span></span>
</td>
<td class="nump">27,804<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">54,360<span></span>
</td>
<td class="nump">62,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred collaboration revenue</a></td>
<td class="nump">8,184<span></span>
</td>
<td class="nump">9,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LeaseFinancingObligationNetOfCurrent', window );">Lease financing obligation</a></td>
<td class="nump">2,704<span></span>
</td>
<td class="nump">2,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Senior credit facility</a></td>
<td class="nump">22,777<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; shares authorized &#8212; 5,000; no shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; shares authorized &#8212; 200,000; shares issued and outstanding &#8212; 73,782 in 2016 and 73,355 in 2015</a></td>
<td class="nump">738<span></span>
</td>
<td class="nump">734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">566,913<span></span>
</td>
<td class="nump">558,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(566,061)<span></span>
</td>
<td class="num">(510,917)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,578<span></span>
</td>
<td class="nump">47,724<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 89,847<span></span>
</td>
<td class="nump">$ 122,359<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DeferredCollaborationExpenseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents deferred collaboration expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DeferredCollaborationExpenseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LeaseFinancingObligationNetOfCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Financing obligation as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LeaseFinancingObligationNetOfCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt securities classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of debt securities categorized neither as held-to-maturity nor trading which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831152944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">73,782<span></span>
</td>
<td class="nump">73,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">73,782<span></span>
</td>
<td class="nump">73,355<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831383488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">$ 2,269<span></span>
</td>
<td class="nump">$ 6,291<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="nump">9,682<span></span>
</td>
<td class="nump">2,386<span></span>
</td>
<td class="nump">3,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopment', window );">Collaborative and other research and development</a></td>
<td class="nump">14,402<span></span>
</td>
<td class="nump">39,580<span></span>
</td>
<td class="nump">10,550<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total revenues</a></td>
<td class="nump">26,353<span></span>
</td>
<td class="nump">48,257<span></span>
</td>
<td class="nump">13,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of products sold</a></td>
<td class="nump">2,297<span></span>
</td>
<td class="nump">1,368<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">61,008<span></span>
</td>
<td class="nump">72,758<span></span>
</td>
<td class="nump">51,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">11,253<span></span>
</td>
<td class="nump">13,047<span></span>
</td>
<td class="nump">7,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">528<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">74,960<span></span>
</td>
<td class="nump">87,701<span></span>
</td>
<td class="nump">59,379<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(48,607)<span></span>
</td>
<td class="num">(39,444)<span></span>
</td>
<td class="num">(45,771)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">793<span></span>
</td>
<td class="nump">535<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(6,487)<span></span>
</td>
<td class="num">(5,200)<span></span>
</td>
<td class="num">(4,998)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">(Loss) gain on foreign currency derivative</a></td>
<td class="num">(843)<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
<td class="nump">5,487<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (55,144)<span></span>
</td>
<td class="num">$ (43,019)<span></span>
</td>
<td class="num">$ (45,189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.75)<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (0.68)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding (in shares)</a></td>
<td class="nump">73,699<span></span>
</td>
<td class="nump">72,901<span></span>
</td>
<td class="nump">66,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available for sale investments</a></td>
<td class="nump">$ 194<span></span>
</td>
<td class="num">$ (76)<span></span>
</td>
<td class="num">$ (134)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (54,950)<span></span>
</td>
<td class="num">$ (43,095)<span></span>
</td>
<td class="num">$ (45,323)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAndOtherResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative and other research and development during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAndOtherResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831200272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToReportingEntityAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (55,144)<span></span>
</td>
<td class="num">$ (43,019)<span></span>
</td>
<td class="num">$ (45,189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, amortization, and impairment</a></td>
<td class="nump">483<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">17<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">8,487<span></span>
</td>
<td class="nump">9,705<span></span>
</td>
<td class="nump">10,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="nump">558<span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AmortizationOfDiscountAndPremiumOnInvestments', window );">Amortization of premium/discount on investments</a></td>
<td class="nump">523<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeAssets', window );">Change in fair value of foreign currency derivative</a></td>
<td class="num">(811)<span></span>
</td>
<td class="nump">564<span></span>
</td>
<td class="num">(5,487)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="num">(2,525)<span></span>
</td>
<td class="nump">3,247<span></span>
</td>
<td class="num">(7,375)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">1,112<span></span>
</td>
<td class="num">(929)<span></span>
</td>
<td class="num">(683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">3,702<span></span>
</td>
<td class="nump">637<span></span>
</td>
<td class="num">(2,093)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities', window );">Deferred collaboration expense</a></td>
<td class="nump">71<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(10,524)<span></span>
</td>
<td class="nump">13,676<span></span>
</td>
<td class="nump">4,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Interest payable</a></td>
<td class="nump">2,244<span></span>
</td>
<td class="nump">717<span></span>
</td>
<td class="nump">2,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(1,631)<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
<td class="nump">4,429<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities:</a></td>
<td class="num">(53,438)<span></span>
</td>
<td class="num">(13,116)<span></span>
</td>
<td class="num">(38,551)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Acquisition of property and equipment</a></td>
<td class="num">(5,277)<span></span>
</td>
<td class="num">(5,122)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfFurnitureAndFixtures', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">4<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Change in restricted cash</a></td>
<td class="nump">66<span></span>
</td>
<td class="num">(1,462)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(14,106)<span></span>
</td>
<td class="num">(53,830)<span></span>
</td>
<td class="num">(73,875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of investments</a></td>
<td class="nump">42,652<span></span>
</td>
<td class="nump">42,410<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash provided (used) in investing activities:</a></td>
<td class="nump">23,339<span></span>
</td>
<td class="num">(18,004)<span></span>
</td>
<td class="num">(39,980)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale of common stock, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">106,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from common stock issued under stock-based compensation plans</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">5,479<span></span>
</td>
<td class="nump">5,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from senior credit facility</a></td>
<td class="nump">22,658<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_IncreaseDecreaseInFinancingLeaseObligations', window );">Increase in lease financing obligation</a></td>
<td class="nump">329<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities:</a></td>
<td class="nump">23,304<span></span>
</td>
<td class="nump">5,479<span></span>
</td>
<td class="nump">111,907<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">(Decrease) increase in cash and cash equivalents</a></td>
<td class="num">(6,795)<span></span>
</td>
<td class="num">(25,641)<span></span>
</td>
<td class="nump">33,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">28,899<span></span>
</td>
<td class="nump">54,540<span></span>
</td>
<td class="nump">21,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">$ 22,104<span></span>
</td>
<td class="nump">$ 28,899<span></span>
</td>
<td class="nump">$ 54,540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AmortizationOfDiscountAndPremiumOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to the discount and premium on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AmortizationOfDiscountAndPremiumOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents deferred collaboration expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_IncreaseDecreaseInFinancingLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period for financing lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_IncreaseDecreaseInFinancingLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as assets that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToReportingEntityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToReportingEntityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt securities classified as available-for-sale securities, because they are not classified as either held-to-maturity securities or trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfFurnitureAndFixtures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfFurnitureAndFixtures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831543184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2013</a></td>
<td class="nump">$ 591<span></span>
</td>
<td class="nump">$ 420,988<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">$ (422,709)<span></span>
</td>
<td class="num">$ (1,126)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,189)<span></span>
</td>
<td class="num">(45,189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">4,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan sales</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">106,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,177<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2014</a></td>
<td class="nump">720<span></span>
</td>
<td class="nump">542,943<span></span>
</td>
<td class="num">(130)<span></span>
</td>
<td class="num">(467,898)<span></span>
</td>
<td class="nump">75,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,019)<span></span>
</td>
<td class="num">(43,019)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">5,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan sales</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,705<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="nump">734<span></span>
</td>
<td class="nump">558,113<span></span>
</td>
<td class="num">(206)<span></span>
</td>
<td class="num">(510,917)<span></span>
</td>
<td class="nump">47,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,144)<span></span>
</td>
<td class="num">(55,144)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan sales</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,487<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="nump">$ 738<span></span>
</td>
<td class="nump">$ 566,913<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
<td class="num">$ (566,061)<span></span>
</td>
<td class="nump">$ 1,578<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66904339&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811637184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders Equity (Deficit) (Parentheticals) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares (in shares)</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">1,359<span></span>
</td>
<td class="nump">1,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan sales, shares (in shares)</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares (in shares)</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">1,118<span></span>
</td>
<td class="nump">1,258<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821879872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentrations of Risk<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>&nbsp;&#x2014; Significant Accounting Policies and Concentrations of Risk</div></div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">The Company</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1986</div> and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">With the funds available at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company believes these resources will be sufficient to fund its operations into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div> The Company has sustained operating losses for the majority of its corporate history and expects that its <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> expenses will exceed its <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. Accordingly, its planned operations raise doubt about its ability to continue as a going concern. The Company&#x2019;s liquidity needs will be largely determined by the success of operations in regards to the progression of its product candidates in the future. The Company&#x2019;s plans to alleviate the doubt of its going concern, which are probable of effectively being implemented and mitigating these conditions, primarily include its ability to control the timing and spending on its research and development programs and raising additional funds through equity financings. The Company also <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> consider other plans to fund operations including: <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1)</div>&nbsp;securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2)</div>&nbsp;out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3)</div>&nbsp;raising additional capital through debt financings or from other sources; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4)</div>&nbsp;obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5)</div>&nbsp;reducing spending on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more research and development programs by discontinuing development; and/or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6)</div>&nbsp;restructuring operations to change its overhead structure. The Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> issue securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions or registered public offerings, pursuant to its registration statement on Form S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> initially filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015.</div> The Company&#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events and its decisions in the future.</div></div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of Presentation</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, JPR Royalty Sub LLC (&#x201c;Royalty Sub&#x201d;) and MDCP, LLC (&#x201c;MDCP&#x201d;). Both subsidiaries were formed to facilitate financing transactions for the Company. Royalty Sub was formed in connection with a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$30,000</div>&nbsp;financing transaction the Company completed on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011.</div> See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,</div> Royalty Monetization, for a further description of this transaction. MDCP was formed in connection with a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$23,000</div> Senior Credit Facility that the Company closed on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,</div> Senior Credit Facility, for a further description of this transaction. All intercompany transactions and balances have been eliminated.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;). Such consolidated financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.</div></div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Reclassifications</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company adopted Accounting Standards Update No. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">03,</div> <div style="display: inline; font-style: italic;">Interest &#x2013; Imputation of Interest (Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">835</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30):</div> Simplifying the Presentation of Debt Issuance Costs</div>. Accordingly, debt issuance costs of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,196</div> classified as other current assets as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> have been reclassified and netted against non-recourse notes payable to conform to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> presentation.</div></div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</div></div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></div>    <div style="page-break-before: always; margin-top: 6pt">  <div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> </div> <!-- Field: /Page --> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Restricted Cash</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Restricted cash as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> reflects <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$141</div> in royalty revenue paid by Shionogi&nbsp;&amp; Co., Ltd. (&#x201c;Shionogi&#x201d;) designated for interest on the PhaRMA Notes (defined in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3)</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,405</div> the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.&nbsp;</div></div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Investments</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> years and requires an average portfolio maturity of no more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div> months. Some of the securities the Company invests in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> have market risk. This means that a change in prevailing interest rates <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months and which mature at or less than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months from the balance sheet date are classified as current. Investments with a maturity beyond <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months from the balance sheet date are classified as long-term. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company believes that the cost of its investments is recoverable in all material respects.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following tables summarize the fair value of the Company&#x2019;s investments by type. The estimated fair values of the Company&#x2019;s fixed income investments are classified as Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> inputs.</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2016</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br /> Fair Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Obligations of U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,266</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">34</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,298</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,179</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,199</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,962</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,975</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,407</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">77</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(23</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,472</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br /> Fair Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt; width: 35%">Obligations of U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,557</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">88</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(99</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,546</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,820</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">184</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(41</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,963</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,884</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(72</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,838</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70,261</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">292</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(212</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70,347</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></div>  <div style="page-break-before: always; margin-top: 6pt">  <div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following table summarizes the scheduled maturity for the Company&#x2019;s investments at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015.</div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 67%; font-size: 10pt; text-align: left">Maturing in one year or less</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32,546</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,664</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Maturing after one year through two years</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,926</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">28,395</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Maturing after two years</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,288</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,472</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70,347</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table>  </div></div>  <div> </div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivable from Collaborations</div></div>&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, Green Cross Corporation (&#x201c;Green Cross&#x201d;) and Seqirus UK Limited (&#x201c;SUL&#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> the Company had the following receivables.</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2016</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,495</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,495</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,451</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,451</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Green Cross Corporation</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">686</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">686</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">957</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">179</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,136</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,094</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,674</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,768</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,536</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,536</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">469</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">469</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">210</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">28</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">238</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">679</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,564</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,243</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</div></div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivables from Product Sales</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"></div> <div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.</div></div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Inventory</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> the Company&#x2019;s inventory consisted primarily of peramivir work in process and is being manufactured for the Company&#x2019;s partners. Inventory is stated at the lower of cost, determined under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-in, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-out (&#x201c;FIFO&#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> in connection with the FDA approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s inventory consisted of the following:</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of December&nbsp;31,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Work in process</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">500</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,612</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net inventories</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">500</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,612</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table>  </div></div>  <div> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>    <div style="page-break-before: always; margin-top: 6pt">  <div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> </div> <!-- Field: /Page --> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Property and Equipment</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> years. Laboratory equipment, office equipment, and software are depreciated over a life of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years. Furniture and fixtures are depreciated over a life of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seven</div> years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less. Property consists of a leased building which did not meet the sale-leaseback criteria and is recorded at its fair value, less depreciation. The building is being depreciated over a period equal to the expected term of the related lease.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</div></div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Patents and Licenses</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</div></div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accrued Expenses</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally enters into contractual agreements with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt;">  <tr> <td style="width: 5%">&nbsp;</td> <td style="vertical-align: top; width: 2%"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top; width: 1%">&nbsp;</td> <td style="vertical-align: top; width: 91%"><div style="display: inline; font-size: 10pt">fees paid to Clinical Research Organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials;</div></td> <td style="width: 1%">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">fees paid to investigative sites in connection with clinical trials;</div></td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">fees paid to contract manufacturers in connection with the production of the Company&#x2019;s raw materials, drug substance and drug products;&nbsp;and</div></td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td colspan="2" style="vertical-align: top">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top">&nbsp;</td> <td colspan="2" style="vertical-align: top"><div style="display: inline; font-size: 10pt">professional fees.</div></td> </tr>  </table> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">Accrued expenses were comprised of the following:</div> <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 67%; font-size: 10pt; text-align: left">Compensation and benefits</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">425</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">424</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Development costs</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,427</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,398</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Inventory</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">705</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">549</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Professional fees</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">242</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">242</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Duties and taxes</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">56</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">102</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt">Other</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,981</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,522</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total accrued expenses</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,836</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,237</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table>  </div></div>  <div> </div> <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"></div>    <div style="page-break-before: always; margin-top: 6pt">  <div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income Taxes</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</div></div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accumulated Other Comprehensive Loss</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> realized gains of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$11</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$13,</div> respectively, were reclassified out of accumulated other comprehensive loss.</div></div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Revenue Recognition</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery has occurred or services have been rendered; (iii)&nbsp;the seller&#x2019;s price to the buyer is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured.</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-style: italic;">Collaborative and Other Research and Development Arrangements and Royalties</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For arrangements that involve the delivery of more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &#x201c;stand-alone value&#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party evidence of selling price (&#x201c;TPE&#x201d;) and (iii) best estimate of selling price (&#x201c;BESP&#x201d;). The BESP reflects the Company&#x2019;s best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> the Company entered into a License Agreement (the &#x201c;SUL Agreement&#x201d;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&#x201c;EU&#x201d;) marketing approvals. The Company received an upfront payment of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$33,740</div> from SUL, of which <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7,000</div> was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$21,777</div> of the upfront payment was allocated to the license rights and recognized as revenue in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015.</div> Approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3,740</div> of the upfront payment was allocated to the pending sale of inventory and was recognized in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> when the inventory transfer was completed. Approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,223</div> of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div>  <div style="page-break-before: always; margin-top: 6pt">  <div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> receive up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$12,000</div> in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food Branch of Health Canada (&#x201c;Health Canada&#x201d;) for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,</div> <div style="display: inline; font-style: italic;">Milestone Method of Revenue Recognition</div>, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#x201d;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-style: italic;">Product Sales</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from the Company&#x2019;s specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, and prior to the SUL Agreement, the Company sold RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&nbsp;With the completion of the SUL worldwide license of RAPIVAB, SUL will be responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales. With the completion of the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#x2019;s partners, except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party suppliers of market research data to the pharmaceutical industry.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources.&nbsp;&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><div style="display: inline; font-style: italic;"></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><div style="display: inline; font-style: italic;">Rebates and Chargebacks</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 13.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&#x2019;s selling price.&nbsp;As it can take up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&#x2019;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months from point of sale. To the extent actual rebates and chargebacks differ from the Company&#x2019;s estimates, additional reserves <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be required or reserves <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> need to be reversed, either of which would impact current period product revenue.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></div>  <div style="page-break-before: always; margin-top: 6pt">  <div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> </div> <!-- Field: /Page --> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Discounts and Sales Incentives</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Discounts and other sales incentives primarily consist of Inventory Management Agreement (&#x201c;IMA&#x201d;) fees. Per contractual agreements with the Company&#x2019;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&nbsp;With the completion of the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#x2019;s partners, except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales and to provide for discounts and sales incentives.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Product Returns</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recorded the following revenues for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31:</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt; text-align: left">Product sales, net</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,269</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,291</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">33</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Royalty revenue</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,682</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,386</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,025</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Collaborative and other research and development revenues:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">U.S. Department of Health and Human Services</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,449</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,337</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,366</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Green Cross Corporation</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">132</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Shionogi &amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,184</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,184</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,184</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">769</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,927</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total collaborative and other research and development revenues</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,402</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39,580</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,550</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total revenues</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,353</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,257</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,608</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Advertising</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred. The Company did not incur advertising and product promotion expenses in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> Advertising and product promotion expenses were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$103</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$290</div> for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> respectively.</div></div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and Development Expenses</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#x2019;s on-going review of the level of services actually performed.&nbsp;&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, the Company has license agreements with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#x2019;s academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</div></div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></div>    <div style="page-break-before: always; margin-top: 6pt">  <div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> </div> <!-- Field: /Page --> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock-Based Compensation</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &#x201c;performance&#x201d; is deemed to have occurred.</div></div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Interest Expense and Deferred Financing Costs</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest expense for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6,487,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5,200</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,998,</div> respectively, and primarily relates to the issuance of the PhaRMA Notes (defined in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3)</div> and the Senior Credit Facility (defined in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4).</div> Costs directly associated with the issuance of the PhaRMA Notes and the Senior Credit Facility have been capitalized and are netted against the non-recourse notes payable and Senior Credit Facility on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the PhaRMA Notes and the Senior Credit Facility using the effective interest rate method. Amortization of deferred financing costs and original issue discount included in interest expense was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$558,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$439</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$439</div> for each of the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> respectively.</div></div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Lease Financing Obligation</div></div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on the terms of the lease agreement for the new research facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the owner of the building (for accounting purposes only) during the construction period, which ended in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> Accordingly, the Company recorded an asset of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,589</div> at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> representing the Company&#x2019;s leased portion of the building and recorded a corresponding liability. Upon completion of leasehold improvement construction, the Company did not meet the sale-leaseback criteria for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected duration of the lease of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20.5</div> years, and rental payments will be treated as principal and interest payments on the lease financing obligation liability. The underlying accounting for this transaction has no impact on cash flows associated with the underlying lease or construction in process. Interest expense for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> includes <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$408</div> related to the lease financing obligation.</div></div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> the lease financing obligation balance was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,704</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,375,</div> respectively and was recorded as a long term liability on the consolidated balance sheets. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> the remaining future minimum payments under the lease financing obligation are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,768.</div></div></div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Currency Hedge Agreement</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore mark to market adjustments are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark to market adjustments for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> resulted in losses of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,654</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$564</div> and a gain of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5,487,</div> respectively. Mark to market adjustments are determined by a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> party pricing model which uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> in the fair value hierarchy as defined by U.S. GAAP. In addition, realized currency exchange gains of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$811</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,654</div> were recognized in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> respectively, related to the exercise of a U.S. dollar/Japanese yen currency option under the Company&#x2019;s foreign currency hedge. The Company is also required to post collateral in connection with the mark to market adjustments based on defined thresholds. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> no hedge collateral was posted under the Currency Hedge Agreement.</div></div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Net Loss Per Share</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, outstanding warrants, and common shares expected to be issued under the Company&#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> does not include <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,226,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,524</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,991</div> respectively, of potential common shares as their impact would be anti-dilutive.</div></div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.</div></div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;&nbsp;</div> <div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div>    <div style="page-break-before: always; margin-top: 6pt">  <div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Significant Customers and Other Risks</div></div><div style="display: inline; font-style: italic;"> &nbsp;</div></div> <div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Significant Customers</div></div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Prior to the SUL Agreement, the Company relied primarily on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> specialty distributors to purchase and supply the majority of RAPIVAB. These <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> pharmaceutical specialty distributors accounted for greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">90%</div> of all RAPIVAB product sales and accounted for predominantly all of the Company&#x2019;s outstanding receivables from product sales. The loss of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more of these specialty distributors as a customer could have negatively impacted the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis. In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#x2019;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Other than royalty revenues, the Company&#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB and galidesivir (formerly <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">BCX4430)</div> development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#x2019;s collaborative and other research and development revenues. The completion (as with the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts could negatively impact the Company&#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. The Company recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments, except for Japanese government stockpiling sales, goes directly to pay the interest, and then the principal, on the Company&#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#x2019;s drug development activities are performed by a limited group of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Risks from Third Party Manufacturing and Distribution Concentration</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of the Company&#x2019;s product candidates in development.</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Credit Risk</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div> months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.</div></div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div>  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Going Concern</div></div></div> <div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s liquidity needs will be largely determined by the success of operations in regards to the progression of its product candidates in the future. The Company&#x2019;s plans to alleviate the doubt of its going concern, which are probable of effectively being implemented and mitigating these conditions, primarily include its ability to control the timing and spending on its research and development programs and raising additional funds through equity financings. The Company also <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> consider other plans to fund operations including: <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1)</div>&nbsp;securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2)</div>&nbsp;out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3)</div>&nbsp;raising additional capital through debt financings or from other sources; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4)</div>&nbsp;obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5)</div>&nbsp;reducing spending on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more research and development programs by discontinuing development; and/or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6)</div>&nbsp;restructuring operations to change its overhead structure. The Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> issue securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions or registered public offerings, pursuant to its registration statement on Form S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> initially filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015.</div> The Company&#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events and its decisions in the future.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821803024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>&nbsp;&#x2014; Property and Equipment</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Property and equipment consisted of the following at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31:</div></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 67%; font-size: 10pt; text-align: left">Furniture and fixtures</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">540</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Office equipment</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">141</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,122</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Software</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,117</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,427</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Laboratory equipment</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,252</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,004</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Leased equipment</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">63</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Leasehold improvements</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,294</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,610</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Construction in progress</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,821</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt">Building</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,495</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,589</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,839</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,354</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less accumulated depreciation and amortization</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,917</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(14,205</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Property and equipment, net</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,922</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,149</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Depreciation and amortization expense for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$483,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$180</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$177,</div> respectively.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813763856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Royalty Monetization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationTextBlock', window );">Royalty Monetization [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3&#x2014;</div> Royalty Monetization</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 6pt"><div style="display: inline; font-style: italic;">Overview</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 6pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011,</div> the Company completed a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$30,000</div>&nbsp;financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$22,691</div>&nbsp;from the transaction after transaction costs of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,309</div>&nbsp;and the establishment of a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3,000</div>&nbsp;interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2012</div> interest payment.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As part of the transaction, the Company entered into a purchase and sale agreement dated as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011</div> with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i)&nbsp;its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&nbsp;the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#x201c;Currency Hedge Agreement&#x201d;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese yen and milestone payments will paid in U.S. dollars. The Company&#x2019;s collaboration with Shionogi was not impacted as a result of this transaction.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 6pt"><div style="display: inline; font-style: italic;">Non-Recourse Notes Payable</div></div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011,</div> Royalty Sub completed a private placement to institutional investors of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$30,000</div> in aggregate principal amount of its PhaRMA Senior Secured <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14.0%</div> Notes due <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2020</div> (the &#x201c;PhaRMA Notes&#x201d;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011</div> (the &#x201c;Indenture&#x201d;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14%</div>&nbsp;per annum, payable annually in arrears on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1st</div> of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes. &nbsp;&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Royalty Sub&#x2019;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&#x2019;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may,</div> but is not obligated to, make capital contributions to a capital account that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be used to redeem, or on up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> occasion pay any interest shortfall on, the PhaRMA Notes.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div>    <div style="page-break-before: always; margin-top: 6pt">  <div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2013,</div> Royalty Sub paid <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,844</div> of interest on the PhaRMA Notes from royalty payments received from RAPIACTA <div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">&reg;</div> sales from the preceding <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">four</div> calendar quarters. This payment resulted in an obligation shortfall of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,356</div> associated with accrued interest due <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2013.</div> As stipulated under the PhaRMA Notes Indenture, if the amount available for payment on any Payment Date is insufficient to pay all of the interest due on a Payment Date, the shortfall in interest will accrue interest at the interest rate applicable to the PhaRMA Notes compounded annually. Accordingly, commencing in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2013,</div> the Company began accruing interest at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14%</div>&nbsp;per annum on the interest shortfall of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,356.</div> In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August</div> of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> Royalty Sub paid additional interest of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$446,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,882</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$70,</div> respectively, bringing the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2013</div> shortfall down to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$222</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014.</div> Under the terms of the Indenture, Royalty Sub&#x2019;s inability to pay the full amount of interest payable in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2013</div> by the next succeeding Payment Date for the PhaRMA Notes, which was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> constituted an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> balance sheet. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> pursue acceleration of the PhaRMA Notes, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> incur costs associated with liquidating the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is not expected to have a significant impact on the Company&#x2019;s future results of operations or cash flows. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the PhaRMA Notes remain in default.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Indenture does not contain any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the aggregate fair value of the PhaRMA Notes was estimated to be approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div> of its carrying value of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$30,000.</div> The estimated fair value of the PhaRMA Notes is classified as Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> in the fair value hierarchy as defined in U.S. GAAP.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Foreign Currency Hedge</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100</div> yen per dollar for which the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be required to pay a premium in each year from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2020,</div> provided the Currency Hedge Agreement remains in effect. A payment of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,950</div>&nbsp;will be required if, on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div> of the relevant year, the U.S. dollar is worth <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100</div> yen or less as determined in accordance with the Currency Hedge Agreement.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore mark to market adjustments are recognized in the Company&#x2019;s Consolidated Statement of Comprehensive Loss. Cumulative mark to market adjustments in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> resulted in losses of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,654</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$564</div> and a gain of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5,487,</div> respectively. In addition, realized currency exchange gains of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$811</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,654</div> were recognized in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> respectively, related to the exercise of a U.S. dollar/Japanese yen currency option under the Company&#x2019;s foreign currency hedge. The Company is also required to post collateral in connection with the mark to market adjustments based on defined thresholds. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> no collateral was posted under the Currency Hedge Agreement. The Company will not be required at any time to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreement. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the maximum amount of hedge collateral the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be required to post is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7,800.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyMonetizationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyMonetizationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813731632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Senior Credit Facility<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div> &#x2014; Senior Credit Facility</div></div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company closed a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$23,000</div> Senior Credit Facility with an affiliate of MidCap Financial Services, LLC (&#x201c;MidCap&#x201d;), as administrative agent (the &#x201c;Senior Credit Facility&#x201d;). The Senior Credit Facility was fully funded at closing and bears a variable interest rate of LIBOR (which shall not be less than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.5%)</div> plus <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8%.</div> The Senior Credit Facility includes an interest-only payment period through fiscal <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and scheduled monthly principal and interest payments for the subsequent <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div> months. The Company has the option to repay the Senior Credit Facility at any time prior to the scheduled principal repayment date subject to prepayment fees. Final payment of the Senior Credit Facility is subject to a final payment fee equal to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5%</div> of the principal funded under the Senior Credit Facility.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company had borrowings of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$23,000</div> under the Senior Credit Facility bearing an interest rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.6%.</div> The carrying amount of the debt approximates its fair value based on prevailing interest rates as of the balance sheet date. Scheduled principal repayments of the Senior Credit Facility are as follows:</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;">  <tr style="vertical-align: bottom"> <td colspan="5" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Principal Payments</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; text-indent: 0pt">2017</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; text-indent: 0pt; width: 72%">2018</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 25%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,900</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; text-indent: 0pt">2019</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,900</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; text-indent: 0pt">2020</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,900</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; text-indent: 0pt">2021</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,300</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; text-indent: 0pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,000</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div><div style="page-break-before: always; margin-top: 6pt"><div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The debt agreement contains <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> provisions that if deemed probable would create the recognition of an embedded feature; however, at this time we do not believe either provision is probable.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813683296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Lease Obligations and Other Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div>&nbsp;&#x2014; Lease Obligations and Other Contingencies</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has the following minimum payments under operating lease obligations that existed at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016:</div></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;">  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%; font-size: 10pt; text-align: left">2017</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">871</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">2018</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">838</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">2019</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">822</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">2020</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">653</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">2021</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">478</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt; text-align: left">Thereafter</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,489</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total minimum payments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,151</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The obligations in the preceding table are primarily related to the Company&#x2019;s leases for buildings in Birmingham, Alabama and Durham, North Carolina. The lease for the Company&#x2019;s headquarters in Durham, North Carolina expires <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2020.</div> The lease for the Company&#x2019;s research facility in Birmingham, Alabama expires <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2026.</div> Rent expense for operating leases was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$721,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$664</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$633</div> in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> respectively.</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">&nbsp;</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Lease Financing Obligation</div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on the terms of the lease agreement for the new research facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the owner of the building (for accounting purposes only) during the construction period, which ended in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> Accordingly, the Company recorded an asset of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,589</div> at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> representing the Company&#x2019;s leased portion of the building and recorded a corresponding liability. Upon completion of leasehold improvement construction, the Company did not meet the sale-leaseback criteria for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected duration of the lease, and rental payments will be treated as principal and interest payments on the lease financing obligation liability. The underlying accounting for this transaction has no impact on cash flows associated with the underlying lease and or construction in process.</div> <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> the lease financing obligation balance was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,704</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,375,</div> respectively and was recorded as a long term liability on the consolidated balance sheets. The remaining future minimum payments under the lease financing obligation are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,768.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813701872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div>&nbsp;&#x2014; Stockholders&#x2019; Equity</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Sales of Common Stock</div></div></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> the Company filed a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$150,000</div> shelf registration statement on Form S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> with the SEC. This shelf registration statement became effective upon filing and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company filed a post-effective amendment to this registration statement, which allowed for its use by the Company when declared effective by the SEC&#x2019;s staff on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821792032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div>&nbsp;&#x2014; Stock-Based Compensation</div></div> <div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock Incentive Plan</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> stock-based employee compensation plans, the Stock Incentive Plan (&#x201c;Incentive Plan&#x201d;) and the Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). The Incentive Plan was amended and restated in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and approved by the Company&#x2019;s stockholders in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> The ESPP was amended and restated in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> and approved by the Company&#x2019;s stockholders in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014.</div> Stock-based compensation expense of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8,487</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">($8,340</div> of expense related to the Incentive Plan, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$147</div> of expense related to the ESPP) was recognized during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> while <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$9,705</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">($9,485</div> of expense related to the Incentive Plan, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$220</div> of expense related to the ESPP) was recognized during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10,177</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">($9,963</div> of expense related to the Incentive Plan, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$214</div> of expense related to the ESPP) was recognized during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014.</div>&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></div><div style="page-break-before: always; margin-top: 6pt"><div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company accounts for stock-based compensation in accordance with FASB authoritative guidance regarding share-based payments. Total stock-based compensation was allocated as follows:</div> <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December&nbsp;31,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-size: 10pt; text-align: left">Research and development</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,088</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,580</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,906</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,399</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,125</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,271</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total stock-based compensation expense</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,487</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,705</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,177</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&#x2019;s stock at the date of grant. Commencing <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011,</div> stock option awards granted to employees generally vest <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25%</div> each year until fully vested after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">four</div> years. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2013,</div> the Company made retention grants of stock option awards and restricted stock units. These awards vest <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div> each year until fully vested after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> years. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2013</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> the Company issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,032</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,250</div> performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">75%</div> of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2013</div> grants have vested based upon achievement of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> milestones: <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1)</div> successful completion of the OPuS-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> clinical trial, for which vesting occurred in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2)</div> FDA approval of RAPIVAB for which vesting occurred in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">fourth</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3)</div> initiation of a Phase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">BCX7353</div> in healthy volunteers, for which vesting occurred in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015.</div> Thus, as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25%</div> of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2013</div> performance-based grants and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100%</div> of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> performance-based grants remain unvested and no compensation expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to non-employee directors of the Company generally vest monthly over <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year. All stock option awards have contractual terms of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>&nbsp;years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan. <div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Related activity under the Incentive Plan is as follows:</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Awards<br /> Available</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options<br /> Outstanding</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<br /> Average<br /> Exercise<br /> Price</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-size: 10pt">Balance at December&nbsp;31, 2013</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,082</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,986</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.99</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Plan amendment</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,750</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Restricted stock awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(593</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Restricted stock awards cancelled</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,965</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,965</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.99</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards exercised</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,258</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.78</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards cancelled</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">88</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(88</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.83</div></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Balance at December&nbsp;31, 2014</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,362</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,605</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.21</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Restricted stock awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(163</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Restricted stock awards cancelled</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,217</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,217</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.52</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards exercised</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,118</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.36</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards cancelled</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">33</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(33</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.87</div></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Balance at December&nbsp;31, 2015</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,671</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.50</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Plan amendment</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,800</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Restricted stock awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(34</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Restricted stock awards cancelled</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,248</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,248</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.20</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards exercised</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(107</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.63</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards cancelled</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">717</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(717</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.78</div></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance at December&nbsp;31, 2016</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,273</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,095</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">$</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.55</div></td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></div><div style="page-break-before: always; margin-top: 6pt"><div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For stock option awards granted under the Incentive Plan during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value of these awards granted during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.17,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7.72</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8.02,</div> respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. The following explanations describe the assumptions used by the Company to value the stock option awards granted during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014.</div> The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if not yet vested) and the full contractual term. The expected volatility represents the volatility over the most recent period corresponding with the expected life. The Company has assumed no expected dividend yield, as dividends have never been paid to stockholders and will not be for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">zero</div>-coupon government issues with a remaining term equal to the expected term.</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Weighted Average Assumptions for Stock Option Awards Granted under the Incentive Plan</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-size: 10pt; text-align: left">Expected Life</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.5</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.5</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.5</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected Volatility</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">82</div></td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">81</div></td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">87</div></td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Expected Dividend Yield</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.0</div></td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.0</div></td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.0</div></td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Risk-Free Interest Rate</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.4</div></td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.6</div></td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.6</div></td> <td style="font-size: 10pt; text-align: left">%</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The total intrinsic value of stock option awards exercised under the Incentive Plan was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$339</div> during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10,117</div> during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8,522</div> during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014.</div> The intrinsic value represents the total proceeds (fair market value at the date of exercise, less the exercise price, times the number of stock option awards exercised) received by all individuals who exercised stock option awards during the period.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following table summarizes, at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> by price range: <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1)</div>&nbsp;for stock option awards outstanding under the Incentive Plan, the number of stock option awards outstanding, their weighted average remaining life and their weighted average exercise price; and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2)</div>&nbsp;for stock option awards exercisable under the Plan, the number of stock option awards exercisable and their weighted average exercise price:</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;">  <tr style="vertical-align: bottom"> <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td colspan="9" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><div style="display: inline; font-size: 10pt">Outstanding</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><div style="display: inline; font-size: 10pt">Exercisable</div></td> </tr> <tr style="vertical-align: bottom"> <td colspan="2"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; text-decoration: underline;">Range</div></div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: center"><div style="display: inline; font-size: 10pt">Number</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><div style="display: inline; font-size: 10pt">Weighted <br /> Average <br /> Remaining <br /> Life</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><div style="display: inline; font-size: 10pt">Weighted <br /> Average <br /> Exercise <br /> Price</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td colspan="3" style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: center"><div style="display: inline; font-size: 10pt">Number</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><div style="display: inline; font-size: 10pt">Weighted <br /> Average <br /> Exercise <br /> Price</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">$</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; width: 5%"><div style="display: inline; font-size: 10pt">0</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; width: 3%"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">to</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; width: 5%"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3</div></div></td> <td style="width: 2%; font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1,919</div></div></td> <td style="width: 2%; font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">5.7</div></div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 2%; font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">$</div></td> <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1.64</div></div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 2%; font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1,510</div></div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 2%; font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">$</div></td> <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1.53</div></div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">3</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">to</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">6</div></div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">4,749</div></div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">6.9</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">4.02</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">2,578</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">4.48</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">6</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">to</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">9</div></div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1,153</div></div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3.5</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">7.10</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1,118</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">7.11</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">9</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">to</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">12</div></div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3,457</div></div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">7.2</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">11.10</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1,074</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">11.29</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">12</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">to</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">15</div></div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">722</div></div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">8.0</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">12.39</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">195</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">12.73</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">15</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">to</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">18</div></div></td> <td style="font-size: 10pt; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right; padding-bottom: 1.1pt; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">95</div></div></td> <td style="font-size: 10pt; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">8.5</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">15.39</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">24</div></div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">15.39</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">$</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">0</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">to</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">18</div></div></td> <td style="font-size: 10pt; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right; padding-bottom: 2.25pt; border-bottom: Black 2.25pt double"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">12,095</div></div></td> <td style="font-size: 10pt; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">6.6</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">$</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">6.55</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">6,499</div></div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">$</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">5.66</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> </tr>  </table> </div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The weighted average remaining contractual life of stock option awards exercisable under the Incentive Plan at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.6</div> years.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The aggregate intrinsic value of stock option awards outstanding and exercisable under the Incentive Plan at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$20,002.</div> The aggregate intrinsic value represents the value (the period&#x2019;s closing market price, less the exercise price, times the number of in-the-money stock option awards) that would have been received by all stock option award holders under the Incentive Plan had they exercised their stock option awards at the end of the year.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The total fair value of the stock option awards vested under the Incentive Plan was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6,380</div> during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,492</div> during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,844</div> during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014.</div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the number of stock option awards vested and expected to vest under the Incentive Plan is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,013.</div> The weighted average exercise price of these stock option awards is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.53</div> and their weighted average remaining contractual life is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.5</div>&nbsp;years.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div><div style="page-break-before: always; margin-top: 6pt"><div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following table summarizes the changes in the number and weighted-average grant-date fair value of non-vested stock option awards during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016:</div></div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Non-Vested<br /> Stock Option<br /> Awards</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average<br /> Grant-Date Fair<br /> Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 67%; font-size: 10pt">Balance December&nbsp;31, 2015</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,863</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.40</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Stock option awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,248</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.17</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Stock option awards vested</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,278</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.99</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Stock option awards forfeited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(235</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.79</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance December&nbsp;31, 2016</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,598</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.40</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> there was approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$14,541</div> of total unrecognized compensation cost related to non-vested employee stock option awards and restricted stock units granted by the Company. That cost is expected to be recognized as follows: <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6,880</div> in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,649</div> in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,606</div> in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$406</div> in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2020.</div></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Employee Stock Purchase Plan</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has reserved a total of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,475</div>&nbsp;shares of common stock to be purchased under the ESPP, of which <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">422</div>&nbsp;shares remain available for purchase at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> Eligible employees <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> authorize up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15%</div> of their salary to purchase common stock at the lower of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">85%</div> of the beginning or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">85%</div> of the ending price during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month purchase intervals. No more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> shares <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be purchased by any <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> employee at the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month purchase dates and no employee <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> purchase stock having a fair market value at the commencement date of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$25</div> or more in any <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> calendar year.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">75,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">49</div> shares of common stock purchased under the ESPP in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> respectively, at a weighted average price per share of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.36,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8.65</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.29,</div> respectively. Expense of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$147,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$220</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$214</div> related to the ESPP was recognized during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> respectively. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#x201c;look-back&#x201d; option were determined using a Black-Scholes option pricing model. The weighted average grant date fair values of shares granted under the ESPP during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.95,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.93</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.41,</div> respectively.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6772509296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div>&nbsp;&#x2014; Income Taxes</div></div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has incurred net losses since inception and, consequently, has not recorded any U.S.&nbsp;Federal and state income tax expense or benefit. The differences between the Company&#x2019;s effective tax rate and the statutory tax rate in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> are as follows:</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt; text-align: left">Income tax benefit at federal statutory rate (35%)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(19,300</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(15,057</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(15,816</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">State and local income taxes net of federal tax benefit</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,173</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(819</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,286</div></td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Permanent items</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,057</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">560</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">258</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Rate change</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,080</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,012</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Expiration of attribute carryforwards</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">559</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">330</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">373</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Research and development tax credits</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,681</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(10,454</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(748</div></td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Orphan drug credit</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,798</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,307</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Other</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">822</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(218</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(115</div></td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Change in valuation allowance</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,838</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,339</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,312</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Income tax expense</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes the impact of a tax position in its financial statements if it is more likely than not that the position will be sustained on audit based on the technical merits of the position. The Company has concluded that it has an uncertain tax position pertaining to its research and development and orphan drug credit carryforwards. The Company has established these credits based on information and calculations it believes are appropriate and the best estimate of the underlying credit. Any changes to the Company&#x2019;s unrecognized tax benefits are offset by an adjustment to the valuation allowance and there would be no impact on the Company&#x2019;s financial statements. The Company does not expect its unrecognized tax benefits to change significantly over the next <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months.</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-size: 10pt">Balance at January&nbsp;1,</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,085</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">472</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Additions to current period tax positions</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,170</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,616</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Additions to prior period tax positions</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Reductions to prior period tax provisions</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance at December&nbsp;31,</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,255</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,085</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></div><div style="page-break-before: always; margin-top: 6pt"><div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> </div> <!-- Field: /Page --> <div style=" font-size: 10pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s ability to utilize the net operating loss and tax credit carryforwards in the future <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be subject to substantial restrictions in the event of past or future ownership changes as defined in Section&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">382</div> of the Internal Revenue Code of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1986,</div> as amended and similar state tax law.</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Significant components of the Company&#x2019;s deferred tax assets and liabilities are as follows:</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Deferred tax assets:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; font-size: 10pt; text-align: left; text-indent: 10pt">Net federal and state operating losses</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">158,618</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">142,836</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Research and development credits</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">53,231</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,551</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Fixed assets</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,054</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Deferred revenue</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,484</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,240</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock-based compensation</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,952</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,605</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Other</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,849</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,590</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Total deferred tax assets</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">227,134</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">207,876</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Deferred tax liabilities:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Fixed assets</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(674</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Foreign currency derivative</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,415</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,668</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total deferred tax liabilities</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,089</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,668</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(225,045</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(205,208</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net deferred tax assets</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The majority of the Company&#x2019;s deferred tax assets relate to net operating loss and research and development carryforwards that can only be realized if the Company is profitable in future periods. It is uncertain whether the Company will realize any tax benefit related to these carryforwards. Accordingly, the Company has provided a full valuation allowance against the net deferred tax assets due to uncertainties as to their ultimate realization. The valuation allowance will remain at the full amount of the deferred tax assets until it is more likely than not that the related tax benefits will be realized. The Company&#x2019;s valuation allowance increased by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$19,837</div> in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$20,339</div> in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$17,312</div> in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014.</div>&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company had federal operating loss carryforwards of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$431,983,</div> state operating loss carryforwards of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$403,237,</div> and research and development and orphan drug credit carryforwards of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$57,487,</div> which will expire at various dates from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2035.</div> The federal losses begin to expire in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the state losses begin to expire in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and the research and development credit carryforwards begin to expire in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s federal and state operating loss carryforwards include <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15,655</div> of excess tax benefits related to a deduction from the exercise of stock options. The tax benefit of these deductions has not been recognized in deferred tax assets. If utilized, the benefits from these deductions will be recorded as adjustments to additional paid-in capital.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Tax years <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2013</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> remain open to examination by the major taxing jurisdictions to which the Company is subject. Additionally, years prior to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2013</div> are also open to examination to the extent of loss and credit carryforwards from those years. The Company recognizes interest and penalties accrued related to unrecognized tax benefits as components of its income tax provision. However, there were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div></div> </div>provisions or accruals for interest and penalties in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813611440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Employee 401 (k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension and Other Postretirement Benefits Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div>&nbsp;&#x2014; Employee <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">401(k)</div> Plan</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1991,</div> the Company adopted an employee retirement plan <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(&#x201c;401(k)</div> Plan&#x201d;) under Section&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">401(k)</div> of the Internal Revenue Code covering all employees. Employee contributions <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be made to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">401(k)</div> Plan up to limits established by the Internal Revenue Service. Company matching contributions <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be made at the discretion of the Board of Directors. The Company made matching contributions of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$504,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$366</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$361,</div> in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> respectively.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65877416&amp;loc=SL14450702-114947<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65897934&amp;loc=d3e2410-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39675-114964<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66047640&amp;loc=d3e39622-114963<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813736512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Collaborative and Other Research and Development Contracts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>&nbsp;&#x2014; Collaborative and Other Research and Development Contracts</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">U.S.&nbsp;Department of Health and Human Services (&#x201c;BARDA/HHS&#x201d;).</div> In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2007,</div> the U.S.&nbsp;Department of Health and Human Services (&#x201c;BARDA/HHS&#x201d;) awarded the Company a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$102,661,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">four</div>-year contract for the advanced development of peramivir for the treatment of influenza. During <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2009,</div> peramivir clinical development shifted to focus on intravenous delivery and the treatment of hospitalized patients. To support this focus, a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2009</div> contract modification was awarded to extend the i.v. peramivir program and to increase funding by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$77,191.</div> On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011,</div> the Company announced that BARDA/HHS had awarded it a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$55,000</div> contract modification, intended to fund completion of the Phase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> development of i.v. peramivir for the treatment of patients hospitalized with influenza. That contract modification brought the total contract award from BARDA/HHS to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$234,852</div> and provided funding to support the filing of a NDA to seek regulatory approval for i.v. peramivir in the U.S. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2013,</div> BioCryst submitted an NDA filing for i.v. peramivir to the FDA and the NDA was approved in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014.</div> The BARDA/HHS contract expired on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014.</div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div><div style="page-break-before: always; margin-top: 6pt"><div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> the Company announced that BARDA/HHS had awarded the Company a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&nbsp;This BARDA/HHS contract includes a base contract of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$16,265</div> to support galidesivir drug manufacturing, as well as <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$22,855</div> in additional development options that can be exercised by the government, bringing the potential value of the contract to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$39,120.</div> As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> a total of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$20,574</div> has been awarded under exercised options within this contract.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;). </div>In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2013,</div> NIAID/HHS contracted with the Company for the development of galidesivir as a treatment for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5,000</div> to the Company. The goals of this contract, including amendments, are to file IND applications for intravenous (&#x201c;i.v.&#x201d;) and intramuscular (&#x201c;i.m.&#x201d;) galidesivir for the treatment of Marburg virus disease and other hemorrhagic fever virus diseases, including Ebola virus disease, and to conduct an initial Phase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> human clinical trial. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the total NIAID/HHS contract amount to advance the program through the completion of the Phase I clinical program is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$39,477.</div> As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> all options have been exercised under this contract.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contract provisions that are related to the development of galidesivir plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress and the continuation of the contract is based on the Company&#x2019;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Seqirus UK Limited (&#x201c;SUL&#x201d;).</div> On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> the Company and Seqirus UK Limited (&quot;SUL&quot;), a limited company organized under the laws of the United Kingdom and a subsidiary of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the &quot;SUL Agreement&quot;) granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the &quot;Territory&quot;). Peramivir is an intravenous treatment for acute uncomplicated influenza and is currently approved for use in the United States, Canada, Japan, Taiwan and Korea. Peramivir is the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> and only intravenous influenza treatment in the world and was approved by the U.S. Food and Drug Administration in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> for the treatment of acute uncomplicated influenza in patients <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div> years and older who have been symptomatic for no more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> days. The Company retains all rights and associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to pursue government stockpiling outside the U.S.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Pursuant to the SUL Agreement, RAPIVAB will be commercialized by CSL's subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets. SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing approval commitments in connection with the FDA's approval of the NDA, and upon fulfillment will transfer ownership of and financial responsibility for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and the EU, the Company is also responsible for regulatory filings and interactions with the Health Canada and the European Medicines Agency (&quot;EMA&quot;) until marketing approval for RAPIVAB is obtained and assigned to SUL. In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee, composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory and any additional development.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company received an upfront payment of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$33,740,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> receive up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$12,000</div> in additional milestone payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Canada for an adult indication in Canada. The Company is also entitled under the SUL Agreement to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined as <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> - <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30)</div> and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire, on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> years from the date of the SUL Agreement (the &quot;Royalty Term&quot;). The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from SUL.</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></div><div style="page-break-before: always; margin-top: 6pt"><div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Shionogi&nbsp;&amp; Co., Ltd. (&#x201c;Shionogi&#x201d;).</div> In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2007,</div> the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2008,</div> the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan and Taiwan.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Green Cross Corporation (&#x201c;Green Cross&#x201d;).</div> In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2006,</div> the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company received a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-time license fee of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$250.</div> The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Mundipharma International Holdings Limited (&#x201c;Mundipharma&#x201d;).</div> In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2006,</div> the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&#x201c;PNP&#x201d;) inhibitor, for use in oncology (the &#x201c;Original Agreement&#x201d;). Under the terms of the Original Agreement, Mundipharma obtained rights to forodesine in markets across Europe, Asia, and Australasia in exchange for a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10,000</div> up-front payment.</div> <div style=" font-size: 10pt; text-align: center; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company deferred revenue recognition of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10,000</div> up-front payment that was received from Mundipharma in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2006</div> because the Company was involved in the continued development of forodesine. Amortization of this revenue commenced in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2006</div> and was initially scheduled to end in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> which is the date of expiration for the last-to-expire patent covered by the agreement. The Company also deferred revenue recognition of a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5,000</div> payment received from Mundipharma in connection with the initiation of a clinical trial in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2007.</div> Amortization of this revenue commenced in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2007</div> and was initially scheduled to end in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> Under its agreement with AECOM/IRL, the Company paid sublicense payments related to these upfront cash payments received from Mundipharma. Expense recognition of these sublicense payments was deferred and recognized under the same term as the related deferred revenue.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011,</div> the Company entered into the Amended and Restated License and Development Agreement (the &#x201c;Amended and Restated Agreement&#x201d;) with Mundipharma, amending and restating the Original Agreement. Under the terms of the Amended and Restated Agreement, Mundipharma obtained worldwide rights to forodesine. Commencing on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011,</div> Mundipharma controls the development and commercialization of forodesine and assumes all future development and commercialization costs. The Amended and Restated Agreement provides for the possibility of future event payments totaling <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15,000</div> for achieving specified regulatory events for certain indications and tiered royalties ranging from mid to high single-digit percentages of net product sales in each country where forodesine is sold by Mundipharma. These royalties are subject to downward adjustments based on the then-existing patent coverage and/or the availability of generic compounds in each country.</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Amended and Restated Agreement is a multiple element arrangement for accounting purposes, in which the Company is required to deliver to Mundipharma both the worldwide rights to forodesine in the field of oncology and the transfer of product data and know-how to permit Mundipharma to develop and commercialize forodesine (the &#x201c;Knowledge Transfer&#x201d;). The Company accounted for these elements as a combined unit of accounting as they do not have stand-alone value to Mundipharma. The worldwide license rights were granted to Mundipharma on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011</div> and the Knowledge Transfer was completed during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2012.</div> Upon completion of the Knowledge Transfer, the remaining deferred revenue and deferred expense was recognized in full.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (&#x201c;AECOM&#x201d; and &#x201c;IRL&#x201d; respectively).</div> In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2000,</div> the Company licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the &#x201c;Licensors&#x201d;). The lead product candidates from this collaboration are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed product (which range in the aggregate from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,400</div> to almost <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,000</div>&nbsp;per indication) for future development of these inhibitors, single digit royalties on net sales of any resulting product made by the Company, and to share approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> quarter of future payments received from other <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$150</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$500,</div> that are creditable against actual royalties and other payments due to the Licensors. This agreement <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be terminated by the Company at any time by giving <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div>&nbsp;days advance notice or in the event of material uncured breach by the Licensors.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div><div style="page-break-before: always; margin-top: 6pt"><div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010,</div> the Company amended the licensee agreement through which the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-half in the percentage of future payments received from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party sub licensees of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i)&nbsp;any milestone payments the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> receive in the future under its license agreement dated <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2006</div> with Mundipharma and (ii)&nbsp;royalties received from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In consideration for these modifications in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010,</div> the Company issued to the Licensors shares of its common stock with an aggregate value of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5,911</div> and paid the Licensors <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$90</div> in cash. Additionally, at the Company&#x2019;s sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by it to the Licensors under the license agreement <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be made either in cash, in shares of its common stock, or in a combination of cash and shares.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011,</div> the Company further amended its agreements with the Licensors whereby the Licensors agreed to accept a reduction of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-half in the percentage of Net Proceeds (as defined) received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2012,</div> the Company further amended its agreements with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to exclusive worldwide license of galidesivir to BioCryst for any antiviral use.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At its sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be made either in cash, in shares of the Company&#x2019;s common stock, or in a combination of cash and shares.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> the Carbohydrate Chemistry Research Team from Callaghan Innovation Research Limited, formerly Industrial Research Limited, transferred to Victoria University of Wellington (&#x201c;VUW&#x201d;) to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts relating to that intellectual property were transferred to a wholly owned subsidiary of VUW, including the contracts to which BioCryst is a party. The parties executed novation agreements in order to effectuate the transfer. Except for a substitution of parties, the terms and conditions of the contracts are substantially the same</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">The University of Alabama at Birmingham (&#x201c;UAB&#x201d;).</div> The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party partners. The Company has completed the research under the UAB agreements. These <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> agreements have initial <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25</div>-year terms, are automatically renewable for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div>-year terms throughout the life of the last patent and are terminable by the Company upon <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months&#x2019; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties&#x2019; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi, Green Cross and SUL agreements, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813629408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Quarterly Financial Information (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Information [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div>&nbsp;&#x2014; Quarterly Financial Information (Unaudited)</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">First</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Second</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Third</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fourth</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold">2016 Quarters</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 48%; font-size: 10pt; text-indent: 10pt">Revenues</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,820</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,787</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,763</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,983</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Net Loss</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(22,832</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(16,281</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11,528</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,503</div></td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Basic and diluted net loss per share</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.31</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.22</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.16</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.06</div></td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold">2015 Quarters</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-indent: 10pt">Revenues</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,826</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,842</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,987</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,602</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Net (Loss) Income</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(15,164</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,901</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(14,621</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(18,135</div></td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Basic net (loss) income per share</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.21</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.07</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.20</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.25</div></td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Diluted net (loss) income per share</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.21</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.06</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.20</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.25</div></td> <td style="font-size: 10pt; text-align: left">)</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68076893&amp;loc=d3e1570-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e765-108305<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e725-108305<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813773664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div>&nbsp;&#x2014; Recent Accounting Pronouncements</div> &nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18:</div> <div style="display: inline; font-style: italic;">Statement of Cash Flows (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">230):</div> Restricted Cash </div>(&#x201c;ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18&#x201d;).</div> The new standard requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for annual periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> and interim periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the FASB issued Accounting Standards Update No. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15:</div> <div style="display: inline; font-style: italic;">Statement of Cash Flows (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">230):</div> Classification of Certain Cash Receipts and Cash Payments</div> (&#x201c;ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15&#x201d;).</div> The amendments in this update clarify how entities should classify certain cash receipts and cash payments on the Consolidated Statements of Cash Flows. The new guidance also clarifies how the predominance principle should be applied when cash receipts and cash payments have aspects of more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> class of cash flows. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div> will be effective for annual periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> including interim periods within those annual reporting periods, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the FASB issued Accounting Standards Update No. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09:</div> <div style="display: inline; font-style: italic;">Compensation - Stock Compensation (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718):</div> Improvements to Employee Share-Based Payment Accounting</div> (&#x201c;ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09&#x201d;).</div> The amendments in this update simplify several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> will be effective for the Company in fiscal year <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the FASB issued Accounting Standards Update No. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02:</div> <div style="display: inline; font-style: italic;">Leases (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842)</div></div> (&#x201c;ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02&#x201d;).</div> The amendments in this update require lessees, among other things, to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous authoritative guidance. This update also introduces new disclosure requirements for leasing arrangements. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> will be effective for the Company in fiscal year <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019,</div> but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the FASB issued Accounting Standards Update No. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01:</div> <div style="display: inline; font-style: italic;">Financial Instruments - Overall (Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">825</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10):</div> Recognition and Measurement of Financial Assets and Financial Liabilities</div> (&#x201c;ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01&#x201d;).</div> The amendments in this update address certain aspects of recognition, measurement, presentation and disclosure of financial instruments. In particular, the amendments in this update supersede, for public business entities, the requirement to disclose the methods and significant assumptions used in calculating the fair value of financial instruments required to be disclosed for financial instruments measured at amortized cost on the balance sheet. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01</div> will be effective for the Company in fiscal year <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> but early adoption is permitted. The Company does not expect this standard to have a material impact on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> the FASB issued Accounting Standards Update No. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11:</div> <div style="display: inline; font-style: italic;">Inventory (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">330):</div> Simplifying the Measurement of Inventory</div> (&#x201c;ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11&#x201d;),</div> which changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> defines net realizable value as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The update does not apply to inventory that is measured using last-in, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-out or the retail inventory method. The update applies to all other inventory, which includes inventory that is measured using <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-in, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-out or average cost methods. The amendments in ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> will be effective for the Company for fiscal years, and the interim periods within those years, beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> The amendments must be applied prospectively and early adoption is permitted. The Company does not expect this standard to have a material impact on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> the FASB issued Standards Update No. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09:</div> <div style="display: inline; font-style: italic;">Revenue from Contracts with Customers (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606)</div></div> (&#x201c;ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09&#x201d;),</div> which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> the FASB finalized a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year delay in the effective date of this standard, which will now be effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018;</div> however, early adoption is permitted any time after the original effective date, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> The Company is not electing early adoption. Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Change in Accounting Principle<br> -URI http://asc.fasb.org/extlink&amp;oid=6507316<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Direct Effects of a Change in Accounting Principle<br> -URI http://asc.fasb.org/extlink&amp;oid=66092750<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22583-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Indirect Effects of a Change in Accounting Principle<br> -URI http://asc.fasb.org/extlink&amp;oid=6515603<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22580-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01.(b)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Accounting Change<br> -URI http://asc.fasb.org/extlink&amp;oid=6503790<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Retrospective Application<br> -URI http://asc.fasb.org/extlink&amp;oid=6523989<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e765-108305<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e725-108305<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811466496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DescriptionOfCompanyPolicyTextBlock', window );">Description of Company [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">The Company</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1986</div> and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">With the funds available at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company believes these resources will be sufficient to fund its operations into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div> The Company has sustained operating losses for the majority of its corporate history and expects that its <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> expenses will exceed its <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. Accordingly, its planned operations raise doubt about its ability to continue as a going concern. The Company&#x2019;s liquidity needs will be largely determined by the success of operations in regards to the progression of its product candidates in the future. The Company&#x2019;s plans to alleviate the doubt of its going concern, which are probable of effectively being implemented and mitigating these conditions, primarily include its ability to control the timing and spending on its research and development programs and raising additional funds through equity financings. The Company also <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> consider other plans to fund operations including: <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1)</div>&nbsp;securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2)</div>&nbsp;out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3)</div>&nbsp;raising additional capital through debt financings or from other sources; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4)</div>&nbsp;obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5)</div>&nbsp;reducing spending on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more research and development programs by discontinuing development; and/or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6)</div>&nbsp;restructuring operations to change its overhead structure. The Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> issue securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions or registered public offerings, pursuant to its registration statement on Form S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> initially filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015.</div> The Company&#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events and its decisions in the future.</div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of Presentation</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, JPR Royalty Sub LLC (&#x201c;Royalty Sub&#x201d;) and MDCP, LLC (&#x201c;MDCP&#x201d;). Both subsidiaries were formed to facilitate financing transactions for the Company. Royalty Sub was formed in connection with a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$30,000</div>&nbsp;financing transaction the Company completed on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011.</div> See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,</div> Royalty Monetization, for a further description of this transaction. MDCP was formed in connection with a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$23,000</div> Senior Credit Facility that the Company closed on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,</div> Senior Credit Facility, for a further description of this transaction. All intercompany transactions and balances have been eliminated.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;). Such consolidated financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.</div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Reclassifications</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company adopted Accounting Standards Update No. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">03,</div> <div style="display: inline; font-style: italic;">Interest &#x2013; Imputation of Interest (Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">835</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30):</div> Simplifying the Presentation of Debt Issuance Costs</div>. Accordingly, debt issuance costs of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,196</div> classified as other current assets as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> have been reclassified and netted against non-recourse notes payable to conform to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> presentation.</div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Restricted Cash</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Restricted cash as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> reflects <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$141</div> in royalty revenue paid by Shionogi&nbsp;&amp; Co., Ltd. (&#x201c;Shionogi&#x201d;) designated for interest on the PhaRMA Notes (defined in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3)</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,405</div> the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.&nbsp;</div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Investments</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> years and requires an average portfolio maturity of no more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div> months. Some of the securities the Company invests in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> have market risk. This means that a change in prevailing interest rates <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months and which mature at or less than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months from the balance sheet date are classified as current. Investments with a maturity beyond <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months from the balance sheet date are classified as long-term. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company believes that the cost of its investments is recoverable in all material respects.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following tables summarize the fair value of the Company&#x2019;s investments by type. The estimated fair values of the Company&#x2019;s fixed income investments are classified as Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> inputs.</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2016</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br /> Fair Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Obligations of U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,266</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">34</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,298</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,179</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,199</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,962</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,975</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,407</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">77</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(23</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,472</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br /> Fair Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt; width: 35%">Obligations of U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,557</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">88</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(99</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,546</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,820</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">184</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(41</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,963</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,884</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(72</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,838</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70,261</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">292</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(212</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70,347</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></div><div style="page-break-before: always; margin-top: 6pt"><div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following table summarizes the scheduled maturity for the Company&#x2019;s investments at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015.</div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 67%; font-size: 10pt; text-align: left">Maturing in one year or less</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32,546</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,664</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Maturing after one year through two years</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,926</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">28,395</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Maturing after two years</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,288</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,472</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70,347</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivables, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivable from Collaborations</div></div>&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, Green Cross Corporation (&#x201c;Green Cross&#x201d;) and Seqirus UK Limited (&#x201c;SUL&#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> the Company had the following receivables.</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2016</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,495</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,495</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,451</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,451</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Green Cross Corporation</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">686</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">686</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">957</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">179</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,136</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,094</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,674</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,768</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,536</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,536</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">469</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">469</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">210</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">28</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">238</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">679</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,564</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,243</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</div></div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivables from Product Sales</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"></div> <div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.</div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Inventory</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> the Company&#x2019;s inventory consisted primarily of peramivir work in process and is being manufactured for the Company&#x2019;s partners. Inventory is stated at the lower of cost, determined under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-in, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-out (&#x201c;FIFO&#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> in connection with the FDA approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s inventory consisted of the following:</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of December&nbsp;31,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Work in process</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">500</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,612</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net inventories</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">500</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,612</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Property and Equipment</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> years. Laboratory equipment, office equipment, and software are depreciated over a life of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years. Furniture and fixtures are depreciated over a life of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seven</div> years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less. Property consists of a leased building which did not meet the sale-leaseback criteria and is recorded at its fair value, less depreciation. The building is being depreciated over a period equal to the expected term of the related lease.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Patents and Licenses</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AccruedExpensesPolicyTextBlock', window );">Accrued Expenses [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accrued Expenses</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally enters into contractual agreements with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt;"> <tr> <td style="width: 5%">&nbsp;</td> <td style="vertical-align: top; width: 2%"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top; width: 1%">&nbsp;</td> <td style="vertical-align: top; width: 91%"><div style="display: inline; font-size: 10pt">fees paid to Clinical Research Organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials;</div></td> <td style="width: 1%">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">fees paid to investigative sites in connection with clinical trials;</div></td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">fees paid to contract manufacturers in connection with the production of the Company&#x2019;s raw materials, drug substance and drug products;&nbsp;and</div></td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td colspan="2" style="vertical-align: top">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top">&nbsp;</td> <td colspan="2" style="vertical-align: top"><div style="display: inline; font-size: 10pt">professional fees.</div></td> </tr> </table> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">Accrued expenses were comprised of the following:</div> <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 67%; font-size: 10pt; text-align: left">Compensation and benefits</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">425</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">424</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Development costs</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,427</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,398</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Inventory</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">705</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">549</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Professional fees</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">242</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">242</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Duties and taxes</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">56</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">102</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt">Other</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,981</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,522</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total accrued expenses</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,836</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,237</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income Taxes</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accumulated Other Comprehensive Loss</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> realized gains of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$11</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$13,</div> respectively, were reclassified out of accumulated other comprehensive loss.</div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Revenue Recognition</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery has occurred or services have been rendered; (iii)&nbsp;the seller&#x2019;s price to the buyer is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured.</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-style: italic;">Collaborative and Other Research and Development Arrangements and Royalties</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For arrangements that involve the delivery of more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &#x201c;stand-alone value&#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party evidence of selling price (&#x201c;TPE&#x201d;) and (iii) best estimate of selling price (&#x201c;BESP&#x201d;). The BESP reflects the Company&#x2019;s best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> the Company entered into a License Agreement (the &#x201c;SUL Agreement&#x201d;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&#x201c;EU&#x201d;) marketing approvals. The Company received an upfront payment of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$33,740</div> from SUL, of which <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7,000</div> was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$21,777</div> of the upfront payment was allocated to the license rights and recognized as revenue in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015.</div> Approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3,740</div> of the upfront payment was allocated to the pending sale of inventory and was recognized in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> when the inventory transfer was completed. Approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,223</div> of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div><div style="page-break-before: always; margin-top: 6pt"><div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> receive up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$12,000</div> in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food Branch of Health Canada (&#x201c;Health Canada&#x201d;) for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,</div> <div style="display: inline; font-style: italic;">Milestone Method of Revenue Recognition</div>, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#x201d;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-style: italic;">Product Sales</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from the Company&#x2019;s specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, and prior to the SUL Agreement, the Company sold RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&nbsp;With the completion of the SUL worldwide license of RAPIVAB, SUL will be responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales. With the completion of the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#x2019;s partners, except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party suppliers of market research data to the pharmaceutical industry.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources.&nbsp;&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><div style="display: inline; font-style: italic;"></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><div style="display: inline; font-style: italic;">Rebates and Chargebacks</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 13.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&#x2019;s selling price.&nbsp;As it can take up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&#x2019;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months from point of sale. To the extent actual rebates and chargebacks differ from the Company&#x2019;s estimates, additional reserves <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be required or reserves <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> need to be reversed, either of which would impact current period product revenue.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></div><div style="page-break-before: always; margin-top: 6pt"><div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> </div> <!-- Field: /Page --> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Discounts and Sales Incentives</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Discounts and other sales incentives primarily consist of Inventory Management Agreement (&#x201c;IMA&#x201d;) fees. Per contractual agreements with the Company&#x2019;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&nbsp;With the completion of the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#x2019;s partners, except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales and to provide for discounts and sales incentives.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Product Returns</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recorded the following revenues for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31:</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt; text-align: left">Product sales, net</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,269</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,291</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">33</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Royalty revenue</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,682</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,386</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,025</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Collaborative and other research and development revenues:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">U.S. Department of Health and Human Services</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,449</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,337</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,366</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Green Cross Corporation</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">132</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Shionogi &amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,184</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,184</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,184</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">769</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,927</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total collaborative and other research and development revenues</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,402</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39,580</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,550</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total revenues</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,353</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,257</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,608</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Advertising</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred. The Company did not incur advertising and product promotion expenses in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> Advertising and product promotion expenses were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$103</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$290</div> for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> respectively.</div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and Development Expenses</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#x2019;s on-going review of the level of services actually performed.&nbsp;&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, the Company has license agreements with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#x2019;s academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock-Based Compensation</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &#x201c;performance&#x201d; is deemed to have occurred.</div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock', window );">Interest Expense and Deferred Financing Costs [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Interest Expense and Deferred Financing Costs</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest expense for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6,487,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5,200</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,998,</div> respectively, and primarily relates to the issuance of the PhaRMA Notes (defined in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3)</div> and the Senior Credit Facility (defined in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4).</div> Costs directly associated with the issuance of the PhaRMA Notes and the Senior Credit Facility have been capitalized and are netted against the non-recourse notes payable and Senior Credit Facility on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the PhaRMA Notes and the Senior Credit Facility using the effective interest rate method. Amortization of deferred financing costs and original issue discount included in interest expense was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$558,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$439</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$439</div> for each of the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> respectively.</div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasePolicyTextBlock', window );">Lease, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Lease Financing Obligation</div></div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on the terms of the lease agreement for the new research facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the owner of the building (for accounting purposes only) during the construction period, which ended in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> Accordingly, the Company recorded an asset of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,589</div> at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> representing the Company&#x2019;s leased portion of the building and recorded a corresponding liability. Upon completion of leasehold improvement construction, the Company did not meet the sale-leaseback criteria for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected duration of the lease of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20.5</div> years, and rental payments will be treated as principal and interest payments on the lease financing obligation liability. The underlying accounting for this transaction has no impact on cash flows associated with the underlying lease or construction in process. Interest expense for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> includes <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$408</div> related to the lease financing obligation.</div></div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> the lease financing obligation balance was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,704</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,375,</div> respectively and was recorded as a long term liability on the consolidated balance sheets. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> the remaining future minimum payments under the lease financing obligation are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,768.</div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CurrencyHedgeAgreementPolicyTextBlock', window );">Currency Hedge Agreement [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Currency Hedge Agreement</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore mark to market adjustments are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark to market adjustments for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> resulted in losses of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,654</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$564</div> and a gain of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5,487,</div> respectively. Mark to market adjustments are determined by a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> party pricing model which uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> in the fair value hierarchy as defined by U.S. GAAP. In addition, realized currency exchange gains of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$811</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,654</div> were recognized in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> respectively, related to the exercise of a U.S. dollar/Japanese yen currency option under the Company&#x2019;s foreign currency hedge. The Company is also required to post collateral in connection with the mark to market adjustments based on defined thresholds. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> no hedge collateral was posted under the Currency Hedge Agreement.</div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Net Loss Per Share</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"></div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, outstanding warrants, and common shares expected to be issued under the Company&#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> does not include <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,226,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,524</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,991</div> respectively, of potential common shares as their impact would be anti-dilutive.</div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.</div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock', window );">Concentration of Market Risk [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Significant Customers and Other Risks</div></div><div style="display: inline; font-style: italic;"> &nbsp;</div></div> <div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Significant Customers</div></div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Prior to the SUL Agreement, the Company relied primarily on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> specialty distributors to purchase and supply the majority of RAPIVAB. These <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> pharmaceutical specialty distributors accounted for greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">90%</div> of all RAPIVAB product sales and accounted for predominantly all of the Company&#x2019;s outstanding receivables from product sales. The loss of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more of these specialty distributors as a customer could have negatively impacted the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis. In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#x2019;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Other than royalty revenues, the Company&#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB and galidesivir (formerly <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">BCX4430)</div> development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#x2019;s collaborative and other research and development revenues. The completion (as with the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts could negatively impact the Company&#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. The Company recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments, except for Japanese government stockpiling sales, goes directly to pay the interest, and then the principal, on the Company&#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#x2019;s drug development activities are performed by a limited group of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Risks from Third Party Manufacturing and Distribution Concentration</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of the Company&#x2019;s product candidates in development.</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Credit Risk</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div> months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.</div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_GoingConcernPolicyPolicyTextBlock', window );">Going Concern, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Going Concern</div></div></div> <div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s liquidity needs will be largely determined by the success of operations in regards to the progression of its product candidates in the future. The Company&#x2019;s plans to alleviate the doubt of its going concern, which are probable of effectively being implemented and mitigating these conditions, primarily include its ability to control the timing and spending on its research and development programs and raising additional funds through equity financings. The Company also <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> consider other plans to fund operations including: <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1)</div>&nbsp;securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2)</div>&nbsp;out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3)</div>&nbsp;raising additional capital through debt financings or from other sources; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4)</div>&nbsp;obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5)</div>&nbsp;reducing spending on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more research and development programs by discontinuing development; and/or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6)</div>&nbsp;restructuring operations to change its overhead structure. The Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> issue securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions or registered public offerings, pursuant to its registration statement on Form S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> initially filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015.</div> The Company&#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events and its decisions in the future.</div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AccruedExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents accrued expenses policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AccruedExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents concentration of market risk policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ConcentrationOfMarketRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CurrencyHedgeAgreementPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents currency hedge agreement policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CurrencyHedgeAgreementPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DescriptionOfCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of company policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DescriptionOfCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_GoingConcernPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the entity's ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_GoingConcernPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents interest expense and deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2,12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877573&amp;loc=d3e87990-122713<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6872867&amp;loc=d3e40691-111596<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements (both lessor and lessee). This disclosure may address (1) lease classification (that is, operating versus capital), (2) how the term of a lease is determined (for example, the circumstances in which a renewal option is considered part of the lease term), (3) how rental revenue or expense is recognized for a lease that contains rent escalations, (4) an entity's accounting treatment for deferred rent, including that which arises from lease incentives, rent abatements, rent holidays, or tenant allowances (5) an entity's accounting treatment for contingent rental payments and (6) an entity's policy for reviewing, at least annually, the residual values of sales-type and direct-finance leases. The disclosure also may indicate how the entity accounts for its capital leases, leveraged leases or sale-leaseback transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453394&amp;loc=d3e39740-112701<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65670824&amp;loc=d3e14754-158437<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6456037&amp;loc=d3e48589-112741<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65890831&amp;loc=d3e10133-111534<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e4975-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813876256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Available-for-sale Securities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2016</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br /> Fair Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Obligations of U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,266</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">34</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,298</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,179</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,199</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,962</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,975</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,407</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">77</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(23</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,472</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br /> Fair Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt; width: 35%">Obligations of U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,557</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">88</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(99</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,546</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,820</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">184</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(41</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,963</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,884</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(72</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,838</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70,261</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">292</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(212</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70,347</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock', window );">Available For Sale Securities Debt Maturities Fair Value [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 67%; font-size: 10pt; text-align: left">Maturing in one year or less</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32,546</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,664</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Maturing after one year through two years</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,926</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">28,395</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Maturing after two years</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,288</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,472</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70,347</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock', window );">Schedule of Receivables from Collaborations [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2016</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,495</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,495</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,451</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,451</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Green Cross Corporation</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">686</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">686</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">957</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">179</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,136</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,094</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,674</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,768</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,536</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,536</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">469</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">469</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">210</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">28</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">238</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">679</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,564</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,243</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of December&nbsp;31,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Work in process</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">500</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,612</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net inventories</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">500</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,612</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 67%; font-size: 10pt; text-align: left">Compensation and benefits</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">425</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">424</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Development costs</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,427</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,398</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Inventory</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">705</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">549</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Professional fees</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">242</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">242</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Duties and taxes</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">56</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">102</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt">Other</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,981</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,522</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total accrued expenses</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,836</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,237</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock', window );">Schedule of Revenues from Collaborations [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt; text-align: left">Product sales, net</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,269</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,291</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">33</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Royalty revenue</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,682</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,386</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,025</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Collaborative and other research and development revenues:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">U.S. Department of Health and Human Services</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,449</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,337</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,366</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Green Cross Corporation</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">132</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Shionogi &amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,184</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,184</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,184</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">769</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,927</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total collaborative and other research and development revenues</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,402</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39,580</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,550</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total revenues</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,353</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,257</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,608</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available for sale securities debt maturities fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure representing receivables from collaborations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of schedule of revenues from collaborations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813686992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 67%; font-size: 10pt; text-align: left">Furniture and fixtures</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">540</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Office equipment</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">141</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,122</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Software</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,117</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,427</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Laboratory equipment</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,252</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,004</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Leased equipment</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">63</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Leasehold improvements</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,294</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,610</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Construction in progress</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,821</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt">Building</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,495</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,589</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,839</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,354</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less accumulated depreciation and amortization</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,917</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(14,205</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Property and equipment, net</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,922</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,149</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813736512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Senior Credit Facility (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td colspan="5" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Principal Payments</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; text-indent: 0pt">2017</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; text-indent: 0pt; width: 72%">2018</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 25%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,900</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; text-indent: 0pt">2019</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,900</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; text-indent: 0pt">2020</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,900</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; text-indent: 0pt">2021</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,300</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; text-indent: 0pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,000</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813632816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Lease Obligations and Other Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%; font-size: 10pt; text-align: left">2017</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">871</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">2018</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">838</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">2019</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">822</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">2020</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">653</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">2021</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">478</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt; text-align: left">Thereafter</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,489</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total minimum payments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,151</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821923072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December&nbsp;31,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-size: 10pt; text-align: left">Research and development</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,088</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,580</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,906</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,399</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,125</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,271</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total stock-based compensation expense</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,487</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,705</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,177</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Share-based Compensation, Activity [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Awards<br /> Available</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options<br /> Outstanding</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<br /> Average<br /> Exercise<br /> Price</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-size: 10pt">Balance at December&nbsp;31, 2013</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,082</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,986</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.99</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Plan amendment</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,750</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Restricted stock awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(593</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Restricted stock awards cancelled</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,965</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,965</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.99</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards exercised</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,258</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.78</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards cancelled</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">88</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(88</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.83</div></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Balance at December&nbsp;31, 2014</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,362</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,605</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.21</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Restricted stock awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(163</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Restricted stock awards cancelled</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,217</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,217</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.52</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards exercised</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,118</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.36</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards cancelled</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">33</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(33</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.87</div></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Balance at December&nbsp;31, 2015</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,671</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.50</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Plan amendment</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,800</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Restricted stock awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(34</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Restricted stock awards cancelled</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,248</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,248</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.20</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards exercised</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(107</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.63</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock option awards cancelled</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">717</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(717</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.78</div></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance at December&nbsp;31, 2016</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,273</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,095</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">$</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.55</div></td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-size: 10pt; text-align: left">Expected Life</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.5</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.5</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.5</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected Volatility</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">82</div></td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">81</div></td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">87</div></td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Expected Dividend Yield</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.0</div></td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.0</div></td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.0</div></td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Risk-Free Interest Rate</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.4</div></td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.6</div></td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.6</div></td> <td style="font-size: 10pt; text-align: left">%</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td colspan="9" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><div style="display: inline; font-size: 10pt">Outstanding</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><div style="display: inline; font-size: 10pt">Exercisable</div></td> </tr> <tr style="vertical-align: bottom"> <td colspan="2"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; text-decoration: underline;">Range</div></div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: center"><div style="display: inline; font-size: 10pt">Number</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><div style="display: inline; font-size: 10pt">Weighted <br /> Average <br /> Remaining <br /> Life</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><div style="display: inline; font-size: 10pt">Weighted <br /> Average <br /> Exercise <br /> Price</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td colspan="3" style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: center"><div style="display: inline; font-size: 10pt">Number</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><div style="display: inline; font-size: 10pt">Weighted <br /> Average <br /> Exercise <br /> Price</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">$</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; width: 5%"><div style="display: inline; font-size: 10pt">0</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; width: 3%"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">to</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; width: 5%"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3</div></div></td> <td style="width: 2%; font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1,919</div></div></td> <td style="width: 2%; font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">5.7</div></div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 2%; font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">$</div></td> <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1.64</div></div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 2%; font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1,510</div></div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 2%; font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">$</div></td> <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1.53</div></div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">3</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">to</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">6</div></div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">4,749</div></div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">6.9</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">4.02</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">2,578</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">4.48</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">6</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">to</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">9</div></div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1,153</div></div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3.5</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">7.10</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1,118</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">7.11</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">9</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">to</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">12</div></div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3,457</div></div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">7.2</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">11.10</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1,074</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">11.29</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">12</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">to</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">15</div></div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">722</div></div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">8.0</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">12.39</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">195</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">12.73</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">15</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">to</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">18</div></div></td> <td style="font-size: 10pt; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right; padding-bottom: 1.1pt; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">95</div></div></td> <td style="font-size: 10pt; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">8.5</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">15.39</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">24</div></div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">15.39</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">$</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">0</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">to</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">18</div></div></td> <td style="font-size: 10pt; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right; padding-bottom: 2.25pt; border-bottom: Black 2.25pt double"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">12,095</div></div></td> <td style="font-size: 10pt; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">6.6</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">$</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">6.55</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">6,499</div></div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">$</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">5.66</div></div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Non-Vested<br /> Stock Option<br /> Awards</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average<br /> Grant-Date Fair<br /> Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 67%; font-size: 10pt">Balance December&nbsp;31, 2015</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,863</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.40</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Stock option awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,248</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.17</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Stock option awards vested</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,278</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.99</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Stock option awards forfeited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(235</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.79</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance December&nbsp;31, 2016</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,598</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.40</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based compensation plans that may be presented in a single table for outstanding, vested and expected to vest, and exercisable awards. The information that may be disclosed in this table may include, but is not limited to, number of shares, weighted average exercise price, weighted average remaining contractual life, and aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number of fully vested share options (or share units) and share options expected to vest at the date of the latest statement of financial position, weighted-average exercise price (or conversion ratio), aggregate intrinsic value (except for nonpublic entities), and weighted-average remaining contractual term for both options (or share units) currently outstanding and options (or share units) exercisable (or convertible).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6794900192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt; text-align: left">Income tax benefit at federal statutory rate (35%)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(19,300</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(15,057</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(15,816</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">State and local income taxes net of federal tax benefit</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,173</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(819</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,286</div></td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Permanent items</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,057</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">560</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">258</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Rate change</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,080</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,012</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Expiration of attribute carryforwards</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">559</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">330</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">373</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Research and development tax credits</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,681</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(10,454</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(748</div></td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Orphan drug credit</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,798</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,307</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Other</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">822</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(218</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(115</div></td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Change in valuation allowance</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,838</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,339</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,312</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Income tax expense</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-size: 10pt">Balance at January&nbsp;1,</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,085</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">472</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Additions to current period tax positions</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,170</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,616</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Additions to prior period tax positions</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Reductions to prior period tax provisions</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance at December&nbsp;31,</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,255</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,085</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Deferred tax assets:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; font-size: 10pt; text-align: left; text-indent: 10pt">Net federal and state operating losses</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">158,618</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">142,836</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Research and development credits</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">53,231</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,551</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Fixed assets</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,054</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Deferred revenue</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,484</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,240</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Stock-based compensation</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,952</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,605</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Other</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,849</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,590</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Total deferred tax assets</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">227,134</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">207,876</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Deferred tax liabilities:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Fixed assets</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(674</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Foreign currency derivative</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,415</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,668</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total deferred tax liabilities</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,089</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,668</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(225,045</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(205,208</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net deferred tax assets</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=75116239&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813743328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Quarterly Financial Information (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Quarterly Financial Information [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">First</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Second</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Third</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fourth</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold">2016 Quarters</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 48%; font-size: 10pt; text-indent: 10pt">Revenues</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,820</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,787</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,763</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,983</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Net Loss</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(22,832</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(16,281</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11,528</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,503</div></td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Basic and diluted net loss per share</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.31</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.22</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.16</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.06</div></td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold">2015 Quarters</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-indent: 10pt">Revenues</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,826</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,842</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,987</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,602</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Net (Loss) Income</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(15,164</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,901</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(14,621</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(18,135</div></td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Basic net (loss) income per share</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.21</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.07</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.20</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.25</div></td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Diluted net (loss) income per share</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.21</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.06</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.20</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.25</div></td> <td style="font-size: 10pt; text-align: left">)</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=68076893&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6836779584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 23, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 09, 2011 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,777<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,546<span></span>
</td>
<td class="nump">1,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,353<span></span>
</td>
<td class="nump">48,257<span></span>
</td>
<td class="nump">$ 13,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,487<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="nump">4,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">558<span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="nump">$ 439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,839<span></span>
</td>
<td class="nump">19,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LeaseFinancingObligationNetOfCurrent', window );">Lease Financing Obligation, Net of Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,704<span></span>
</td>
<td class="nump">$ 2,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,226<span></span>
</td>
<td class="nump">3,524<span></span>
</td>
<td class="nump">3,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Derivative, Loss on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,654<span></span>
</td>
<td class="nump">$ 564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Derivative, Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="nump">1,654<span></span>
</td>
<td class="nump">$ 5,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=bcrx_BirminghamResearchFacilityMember', window );">Birmingham Research Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LeaseFinancingObligationNetOfCurrent', window );">Lease Financing Obligation, Net of Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,704<span></span>
</td>
<td class="nump">2,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Capital Leases, Future Minimum Payments Due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember', window );">RAPIVAB [Member] | Customer Concentration Risk [Member] | Sales Revenue, Product Line [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_NumberOfMajorCustomers', window );">Number of Major Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember', window );">RAPIVAB [Member] | Customer Concentration Risk [Member] | Sales Revenue, Product Line [Member] | Three Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember', window );">Agreement [Member] | CSL [Member] | RAPIVAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="nump">$ 33,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">21,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone Payment Maximum</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember', window );">Agreement [Member] | CSL [Member] | RAPIVAB [Member] | Revenue from Sale of Inventory to be Recognized When the Inventory Transfer Is Complete [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Deferred Revenue, Additions</a></td>
<td class="nump">3,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember', window );">Agreement [Member] | CSL [Member] | RAPIVAB [Member] | Regulatory Support Revenue for Canadian and EU Marketing Approvals, Portion Recognized Ratably Over Expected Period of Involvement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Deferred Revenue, Additions</a></td>
<td class="nump">1,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember', window );">Agreement [Member] | CSL [Member] | RAPIVAB [Member] | Contingent upon EU Marketing Approval [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember', window );">Laboratory Equipment, Office Equipment and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
<td class="nump">718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,294<span></span>
</td>
<td class="nump">5,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Birmingham Research Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years 182 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,589<span></span>
</td>
<td class="nump">$ 1,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityPeriodOfHighQualityMarketablesecurities', window );">Maturity Period of High Quality Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities', window );">Average Maturity Period of High Quality Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityperiodOfShortTermInvestment', window );">Maturity Period of Short Term Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AveragematurityForPortfolioInvestments', window );">Average Maturity for Portfolio Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityperiodOfShortTermInvestment', window );">Maturity Period of Short Term Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LongtermInvestmentMaturityMinimum', window );">Long-term Investment Maturity, Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember', window );">Royalty Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember', window );">Collateral for Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis=bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember', window );">Debt Issuance Costs Reclassifed from Other Current Assets [Member] | December 31, 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustment', window );">Prior Period Reclassification Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember', window );">Senior Credit Facility [Member] | MidCap Financial Services, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized', window );">Revenue Recognition Royalty and Milestone Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AveragematurityForPortfolioInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average maturity for portfolio investments during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AveragematurityForPortfolioInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average maturity period of high quality marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LeaseFinancingObligationNetOfCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Financing obligation as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LeaseFinancingObligationNetOfCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LongtermInvestmentMaturityMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents long term investment maturity minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LongtermInvestmentMaturityMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityPeriodOfHighQualityMarketablesecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maturity period of high quality marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityPeriodOfHighQualityMarketablesecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityperiodOfShortTermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maturity period of short term investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityperiodOfShortTermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NumberOfMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_NumberOfMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition royalty and milestone revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a reclassification adjustment made to prior period financial statement amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=bcrx_BirminghamResearchFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=bcrx_BirminghamResearchFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=bcrx_ThreeCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=bcrx_ThreeCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_CSLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_CSLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=bcrx_ContingentUponEuMarketingApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=bcrx_ContingentUponEuMarketingApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis=bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementEarlyAdoptionAxis=bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreationDateAxis=bcrx_December312015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreationDateAxis=bcrx_December312015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831429824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentration of Risk - Fair Value of the Company's Investments by Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 41,407<span></span>
</td>
<td class="nump">$ 70,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">41,472<span></span>
</td>
<td class="nump">70,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">20,266<span></span>
</td>
<td class="nump">26,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">20,298<span></span>
</td>
<td class="nump">26,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">6,179<span></span>
</td>
<td class="nump">21,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">6,199<span></span>
</td>
<td class="nump">21,963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">14,962<span></span>
</td>
<td class="nump">21,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 14,975<span></span>
</td>
<td class="nump">$ 21,838<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents available for sale securities accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821851056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentration of Risk - Scheduled Maturity for the Company's Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 32,546<span></span>
</td>
<td class="nump">$ 22,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue', window );">Maturing after one year through two years</a></td>
<td class="nump">8,926<span></span>
</td>
<td class="nump">28,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears', window );">Maturing after two years</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">19,288<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Total investments</a></td>
<td class="nump">$ 41,472<span></span>
</td>
<td class="nump">$ 70,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents available for sale securities debt maturities after one through two years fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents debt maturities after two years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6816917040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentration of Risk - Summary of Receivables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 8,768<span></span>
</td>
<td class="nump">$ 6,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember', window );">Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">5,094<span></span>
</td>
<td class="nump">679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember', window );">Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">3,674<span></span>
</td>
<td class="nump">5,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">3,495<span></span>
</td>
<td class="nump">5,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">3,495<span></span>
</td>
<td class="nump">5,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">3,451<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">3,451<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember', window );">Seqirus UK Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">1,136<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember', window );">Seqirus UK Limited [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">957<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember', window );">Seqirus UK Limited [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 179<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6769314624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentration of Risk - Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 1,612<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Net inventories</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 1,612<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6764496240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentration of Risk - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefits</a></td>
<td class="nump">$ 425<span></span>
</td>
<td class="nump">$ 424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AccruedDevelopmentCosts', window );">Development costs</a></td>
<td class="nump">7,427<span></span>
</td>
<td class="nump">10,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AccruedInventoryExpense', window );">Inventory</a></td>
<td class="nump">705<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Duties and taxes</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,981<span></span>
</td>
<td class="nump">4,522<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 10,836<span></span>
</td>
<td class="nump">$ 16,237<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AccruedDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents accrued development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AccruedDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AccruedInventoryExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accrued inventory expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AccruedInventoryExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831318576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentration of Risk - Summary of Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">$ 2,269<span></span>
</td>
<td class="nump">$ 6,291<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="nump">9,682<span></span>
</td>
<td class="nump">2,386<span></span>
</td>
<td class="nump">3,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">Collaborative and other research and development revenues</a></td>
<td class="nump">14,402<span></span>
</td>
<td class="nump">39,580<span></span>
</td>
<td class="nump">10,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">26,353<span></span>
</td>
<td class="nump">48,257<span></span>
</td>
<td class="nump">13,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">Collaborative and other research and development revenues</a></td>
<td class="nump">12,449<span></span>
</td>
<td class="nump">16,337<span></span>
</td>
<td class="nump">9,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">Collaborative and other research and development revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">Collaborative and other research and development revenues</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">1,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_SeqirusUKLimitedMember', window );">Seqirus UK Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">Collaborative and other research and development revenues</a></td>
<td class="nump">$ 769<span></span>
</td>
<td class="nump">$ 21,927<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaborative and other research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_GreenCrossCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_GreenCrossCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_ShionogiAndCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_ShionogiAndCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_SeqirusUKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_SeqirusUKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6832341872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Property and Equipment (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, Depletion and Amortization</a></td>
<td class="nump">$ 483<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6816187760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 2 - Property and Equipment - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 14,839<span></span>
</td>
<td class="nump">$ 19,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(4,917)<span></span>
</td>
<td class="num">(14,205)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9,922<span></span>
</td>
<td class="nump">5,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">1,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">3,252<span></span>
</td>
<td class="nump">6,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LeasedEquipmentMember', window );">Leased Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">8,294<span></span>
</td>
<td class="nump">5,610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,821<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 1,495<span></span>
</td>
<td class="nump">$ 1,589<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LeasedEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LeasedEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6834842448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Royalty Monetization (Details Textual)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 09, 2011 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 03, 2013 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Derivative, Loss on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,654<span></span>
</td>
<td class="nump">$ 564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Derivative, Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 811<span></span>
</td>
<td class="nump">$ 1,654<span></span>
</td>
<td class="nump">$ 5,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Payments for (Proceeds from) Hedge, Investing Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RequiredForeignCurrencyHedgePerDollar', window );">Required Foreign Currency Hedge Per Dollar | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | Japan, Yen | Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeForwardExchangeRate1', window );">Derivative, Forward Exchange Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | PhaRMA Notes Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PrivatePlacementOfSeniorSecuredNotes', window );">Private Placement of Senior Secured Notes</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 1,882<span></span>
</td>
<td class="nump">$ 446<span></span>
</td>
<td class="nump">$ 1,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCarryingAmountInExcessOfFairValue1', window );">Percentage of Carrying Amount in Excess of Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | PhaRMA Notes Member] | Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaximumAmountOfCollateralRequiredToPost', window );">Maximum Amount of Collateral Required to Post</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | PhaRMA Notes Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes Payable, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | PhaRMA Notes Member] | Shortfall 2013 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | Royalty Monetization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized', window );">Revenue Recognition Royalty and Milestone Revenue Recognized</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet', window );">Revenue Recognition Royalty And Milestone Revenue Recognized, Net</a></td>
<td class="nump">22,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_TransactionCosts', window );">Transaction Costs</a></td>
<td class="nump">4,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Interestreserve', window );">Interest Reserve</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_Interestreserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents interest reserve established as part of the royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_Interestreserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumAmountOfCollateralRequiredToPost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maximum amount of collateral required to post.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumAmountOfCollateralRequiredToPost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCarryingAmountInExcessOfFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of carrying amount in excess of fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCarryingAmountInExcessOfFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PrivatePlacementOfSeniorSecuredNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents private placement of senior secured notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PrivatePlacementOfSeniorSecuredNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RequiredForeignCurrencyHedgePerDollar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Company is required to maintain a foreign currency hedge per dollar under the agreements governing the PhaRMA Notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RequiredForeignCurrencyHedgePerDollar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents revenue recognition royalty and milestone revenue recognized, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition royalty and milestone revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents transaction costs associated with royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeForwardExchangeRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual rate at which a foreign currency can be purchased or sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeForwardExchangeRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3581-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3098-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=bcrx_Shortfall2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=bcrx_Shortfall2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819712976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Senior Credit Facility (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 23, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember', window );">MidCap Financial Services, LLC [Member] | Senior Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentMinimumLibor', window );">Debt Instrument, Minimum LIBOR</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term</a></td>
<td class="text">3 years 120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentFinalPaymentFeePercentage', window );">Debt Instrument, Final Payment Fee, Percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Line of Credit Facility, Interest Rate at Period End</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember', window );">MidCap Financial Services, LLC [Member] | Senior Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentFinalPaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage fee of principal amount of debt at which final payment has been made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentFinalPaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentMinimumLibor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum LIBOR interest that will be added to the basis spread.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentMinimumLibor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6813662448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Senior Credit Facility - Scheduled Principal Repayments of the Credit Facility (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2017</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2018</a></td>
<td class="nump">6.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2019</a></td>
<td class="nump">6.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2020</a></td>
<td class="nump">6.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2021</a></td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 23.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6832384528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Lease Obligations and Other Contingencies (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating Leases, Rent Expense, Net</a></td>
<td class="nump">$ 721<span></span>
</td>
<td class="nump">$ 664<span></span>
</td>
<td class="nump">$ 633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">14,839<span></span>
</td>
<td class="nump">19,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LeaseFinancingObligationNetOfCurrent', window );">Lease Financing Obligation, Net of Current</a></td>
<td class="nump">2,704<span></span>
</td>
<td class="nump">2,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating Leases, Future Minimum Payments Due</a></td>
<td class="nump">6,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=bcrx_BirminghamResearchFacilityMember', window );">Birmingham Research Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LeaseFinancingObligationNetOfCurrent', window );">Lease Financing Obligation, Net of Current</a></td>
<td class="nump">2,704<span></span>
</td>
<td class="nump">2,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating Leases, Future Minimum Payments Due</a></td>
<td class="nump">4,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=bcrx_BirminghamResearchFacilityMember', window );">Birmingham Research Facility [Member] | Long Term Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LeaseFinancingObligationNetOfCurrent', window );">Lease Financing Obligation, Net of Current</a></td>
<td class="nump">2,704<span></span>
</td>
<td class="nump">2,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">8,294<span></span>
</td>
<td class="nump">5,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Birmingham Research Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 1,589<span></span>
</td>
<td class="nump">$ 1,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LeaseFinancingObligationNetOfCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Financing obligation as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LeaseFinancingObligationNetOfCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=bcrx_BirminghamResearchFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=bcrx_BirminghamResearchFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=bcrx_LongTermLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=bcrx_LongTermLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6812169712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Lease Obligations and Other Contingencies - Minimum Payments under Operating Lease Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2017</a></td>
<td class="nump">$ 871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2018</a></td>
<td class="nump">838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2019</a></td>
<td class="nump">822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2020</a></td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2021</a></td>
<td class="nump">478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">2,489<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total minimum payments</a></td>
<td class="nump">$ 6,151<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821873584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Stockholders' Equity (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 03, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaximumAggregateOfferingPrice', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 150<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6833568208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Share-Based Compensation (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,487<span></span>
</td>
<td class="nump">$ 9,705<span></span>
</td>
<td class="nump">$ 10,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,248,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Next Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,273,000<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="nump">2,362,000<span></span>
</td>
<td class="nump">1,082,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,340<span></span>
</td>
<td class="nump">$ 9,485<span></span>
</td>
<td class="nump">$ 9,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 219 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="nump">$ 7.72<span></span>
</td>
<td class="nump">$ 8.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 339<span></span>
</td>
<td class="nump">$ 10,117<span></span>
</td>
<td class="nump">$ 8,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,380<span></span>
</td>
<td class="nump">4,492<span></span>
</td>
<td class="nump">$ 2,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 182 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Employee Stock Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Employee Stock Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Employee Stock Option [Member] | Non-employee Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate', window );">Share-based Compensation Arrangement by Share-based Payment Award, First Vesting Period After Grant Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Employee Stock Option [Member] | Vest 25% Each Year Until Fully Vested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Stock Options and Restricted Stock [Member] | Vest 50% Each Year Until Fully Vested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">1,032,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member] | August 2013 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage', window );">Share-based Compensation Arrangement by Shar-based Payment Award, Awards Unvested, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member] | December 2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage', window );">Share-based Compensation Arrangement by Shar-based Payment Award, Awards Unvested, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">422,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum', window );">Percentage of Salary to Purchase Common Stock, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCommonStockSharesBeginning', window );">Percentage of Common Stock Shares, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount', window );">Shar-based Compensation Arrangement by Shar-based Payment Award, Maximum Number of Shares Per Employee, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock Issued During Period, Shares, Employee Stock Purchase Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">41,000<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased', window );">Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.36<span></span>
</td>
<td class="nump">$ 8.65<span></span>
</td>
<td class="nump">$ 6.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="nump">$ 4.93<span></span>
</td>
<td class="nump">$ 4.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share-based compensation nonvested awards compensation cost expected to be recognized next year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCommonStockSharesBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of common stock shares beginning.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCommonStockSharesBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of salary to purchase common stock maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award first vesting period after grant date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of performance awards that remain unvested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average purchase price of capital shares purchased through an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=bcrx_NonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=bcrx_NonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_Vest25PercentEachYearUntilFullyVestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_Vest25PercentEachYearUntilFullyVestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bcrx_StockOptionsAndRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bcrx_StockOptionsAndRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_Vest50PercentEachYearUntilFullyVestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_Vest50PercentEachYearUntilFullyVestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=bcrx_August2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=bcrx_August2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=bcrx_December2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=bcrx_December2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6653001504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stock-Based Compensation - Stock-based Compensation Allocation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 8,487<span></span>
</td>
<td class="nump">$ 9,705<span></span>
</td>
<td class="nump">$ 10,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">6,088<span></span>
</td>
<td class="nump">7,580<span></span>
</td>
<td class="nump">8,906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 2,399<span></span>
</td>
<td class="nump">$ 2,125<span></span>
</td>
<td class="nump">$ 1,271<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6820475440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Share-Based Compensation - Stock Incentive Plan Activities (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards Available (in shares)</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">2,362<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding (in shares)</a></td>
<td class="nump">10,671<span></span>
</td>
<td class="nump">9,605<span></span>
</td>
<td class="nump">8,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Plan amendment (in shares)</a></td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock awards granted (in shares)</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(163)<span></span>
</td>
<td class="num">(593)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock awards cancelled (in shares)</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable', window );">Stock option awards granted (in shares)</a></td>
<td class="num">(2,248)<span></span>
</td>
<td class="num">(2,217)<span></span>
</td>
<td class="num">(1,965)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock option awards granted (in shares)</a></td>
<td class="nump">2,248<span></span>
</td>
<td class="nump">2,217<span></span>
</td>
<td class="nump">1,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock option awards granted (in dollars per share)</a></td>
<td class="nump">$ 3.20<span></span>
</td>
<td class="nump">$ 11.52<span></span>
</td>
<td class="nump">$ 10.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option awards exercised (in shares)</a></td>
<td class="num">(107)<span></span>
</td>
<td class="num">(1,118)<span></span>
</td>
<td class="num">(1,258)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Stock option awards exercised (in dollars per share)</a></td>
<td class="nump">$ 2.63<span></span>
</td>
<td class="nump">$ 4.36<span></span>
</td>
<td class="nump">$ 4.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable', window );">Stock option awards cancelled (in shares)</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Stock option awards cancelled (in shares)</a></td>
<td class="num">(717)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Stock option awards cancelled (in dollars per share)</a></td>
<td class="nump">$ 10.78<span></span>
</td>
<td class="nump">$ 9.87<span></span>
</td>
<td class="nump">$ 8.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards Available (in shares)</a></td>
<td class="nump">2,273<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">2,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding (in shares)</a></td>
<td class="nump">12,095<span></span>
</td>
<td class="nump">10,671<span></span>
</td>
<td class="nump">9,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 6.55<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="nump">$ 6.21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents share based compensation arrangement by share based payment award options grants in period awards available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options forfeitures in period awards available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6764408160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Share-Based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life (Year)</a></td>
<td class="text">5 years 182 days<span></span>
</td>
<td class="text">5 years 182 days<span></span>
</td>
<td class="text">5 years 182 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="nump">82.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-Free Interest Rate</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6820240112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Share-Based Compensation - Number of Stock Option Awards Exercisable and their Weighted Average Exercise Price (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Exercise Price Range (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Exercise Price Range (in dollars per share)</a></td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Number (in shares) | shares</a></td>
<td class="nump">12,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Weighted Average Remaining Life (Year)</a></td>
<td class="text">6 years 219 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 6.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Number (in shares) | shares</a></td>
<td class="nump">6,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 5.66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange01Member', window );">Exercise Price Range 01 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Exercise Price Range (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Exercise Price Range (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Number (in shares) | shares</a></td>
<td class="nump">1,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Weighted Average Remaining Life (Year)</a></td>
<td class="text">5 years 255 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 1.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Number (in shares) | shares</a></td>
<td class="nump">1,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 1.53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange02Member', window );">Exercise Price Range 02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Exercise Price Range (in dollars per share)</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Exercise Price Range (in dollars per share)</a></td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Number (in shares) | shares</a></td>
<td class="nump">4,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Weighted Average Remaining Life (Year)</a></td>
<td class="text">6 years 328 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 4.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Number (in shares) | shares</a></td>
<td class="nump">2,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 4.48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange03Member', window );">Exercise Price Range 03 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Exercise Price Range (in dollars per share)</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Exercise Price Range (in dollars per share)</a></td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Number (in shares) | shares</a></td>
<td class="nump">1,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Weighted Average Remaining Life (Year)</a></td>
<td class="text">3 years 182 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 7.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Number (in shares) | shares</a></td>
<td class="nump">1,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 7.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange04Member', window );">Exercise Price Range 04 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Exercise Price Range (in dollars per share)</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Exercise Price Range (in dollars per share)</a></td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Number (in shares) | shares</a></td>
<td class="nump">3,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Weighted Average Remaining Life (Year)</a></td>
<td class="text">7 years 73 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 11.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Number (in shares) | shares</a></td>
<td class="nump">1,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 11.29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange05Member', window );">Exercise Price Range 05 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Exercise Price Range (in dollars per share)</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Exercise Price Range (in dollars per share)</a></td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Number (in shares) | shares</a></td>
<td class="nump">722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Weighted Average Remaining Life (Year)</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 12.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Number (in shares) | shares</a></td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 12.73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange06Member', window );">Exercise Price Range 06 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Exercise Price Range (in dollars per share)</a></td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Exercise Price Range (in dollars per share)</a></td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Number (in shares) | shares</a></td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Weighted Average Remaining Life (Year)</a></td>
<td class="text">8 years 182 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 15.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Number (in shares) | shares</a></td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 15.39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange01Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange01Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange02Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange02Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange03Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange03Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange04Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange04Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange05Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange05Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange06Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange06Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6816463616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Share-Based Compensation - Changes in the Number and Weighted-Average Grant-Date Fair Value (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested stock option awards (in shares) | shares</a></td>
<td class="nump">4,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock option awards granted (in shares) | shares</a></td>
<td class="nump">2,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Stock option awards granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Stock option awards vested (in shares) | shares</a></td>
<td class="num">(1,278)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Stock option awards vested (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock option awards forfeited (in shares) | shares</a></td>
<td class="num">(235)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Stock option awards forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Balance December 31, 2016 (in shares) | shares</a></td>
<td class="nump">5,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance December 31, 2016 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6820395424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</a></td>
<td class="nump">$ 19,837<span></span>
</td>
<td class="nump">$ 20,339<span></span>
</td>
<td class="nump">$ 17,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions', window );">Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options</a></td>
<td class="nump">15,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">57,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">431,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 403,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the aggregate tax benefit realized from the exercise of stock options and the conversion of similar instruments during the annual period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Carryforwards<br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6814065136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at federal statutory rate (35%)</a></td>
<td class="num">$ (19,300)<span></span>
</td>
<td class="num">$ (15,057)<span></span>
</td>
<td class="num">$ (15,816)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local income taxes net of federal tax benefit</a></td>
<td class="num">(1,173)<span></span>
</td>
<td class="num">(819)<span></span>
</td>
<td class="num">(1,286)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Permanent items</a></td>
<td class="nump">1,057<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Rate change</a></td>
<td class="nump">1,080<span></span>
</td>
<td class="nump">1,012<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards', window );">Expiration of attribute carryforwards</a></td>
<td class="nump">559<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="nump">373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="num">(4,681)<span></span>
</td>
<td class="num">(10,454)<span></span>
</td>
<td class="num">(748)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount', window );">Orphan drug credit</a></td>
<td class="nump">1,798<span></span>
</td>
<td class="nump">4,307<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">822<span></span>
</td>
<td class="num">(218)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">19,837<span></span>
</td>
<td class="nump">20,339<span></span>
</td>
<td class="nump">17,312<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents orphan drug credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation income tax expense benefit expiration of carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32059-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6769578416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details) (Parentheticals)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6792649840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance</a></td>
<td class="nump">$ 3,085<span></span>
</td>
<td class="nump">$ 472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions to current period tax positions</a></td>
<td class="nump">1,170<span></span>
</td>
<td class="nump">2,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions to prior period tax positions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions to prior period tax provisions</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance</a></td>
<td class="nump">$ 4,255<span></span>
</td>
<td class="nump">$ 3,085<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Unrecognized Tax Benefit<br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6832895568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Net federal and state operating losses</a></td>
<td class="nump">$ 158,618<span></span>
</td>
<td class="nump">$ 142,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">53,231<span></span>
</td>
<td class="nump">48,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">3,484<span></span>
</td>
<td class="nump">4,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">8,952<span></span>
</td>
<td class="nump">8,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">2,849<span></span>
</td>
<td class="nump">2,590<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">227,134<span></span>
</td>
<td class="nump">207,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(674)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains', window );">Foreign currency derivative</a></td>
<td class="num">(1,415)<span></span>
</td>
<td class="num">(2,668)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(2,089)<span></span>
</td>
<td class="num">(2,668)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(225,045)<span></span>
</td>
<td class="num">(205,208)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Liability<br> -URI http://asc.fasb.org/extlink&amp;oid=6510232<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on foreign currency transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821843648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Employee 401 (k) Plan (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined Contribution Plan, Employer Discretionary Contribution Amount</a></td>
<td class="nump">$ 504<span></span>
</td>
<td class="nump">$ 366<span></span>
</td>
<td class="nump">$ 361<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6836706400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Collaborative and Other Research and Development Contracts (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">40 Months Ended</th>
<th class="th" colspan="1">50 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 16, 2015</div></th>
<th class="th"><div>Sep. 30, 2013</div></th>
<th class="th"><div>Feb. 24, 2011</div></th>
<th class="th"><div>May 31, 2010</div></th>
<th class="th"><div>Sep. 30, 2009</div></th>
<th class="th"><div>Jan. 31, 2007</div></th>
<th class="th"><div>Jun. 30, 2006</div></th>
<th class="th"><div>Feb. 28, 2006</div></th>
<th class="th"><div>Jun. 30, 2000</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Feb. 24, 2011</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Nov. 11, 2011</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_CSLLimitedMember', window );">CSL Limited [Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="nump">$ 33,740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone Payment Maximum</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember', window );">Base Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember', window );">Additional Development Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,855,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember', window );">ASPRBARDA Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts', window );">Proceeds from awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,574,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember', window );">Mundipharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_UpfrontPaymentsReceivableAmount', window );">Upfront Payments Receivable Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PotentialMilestonePaymentsReceivable', window );">Potential Milestone Payments Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember', window );">Mundipharma [Member] | Upfront Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember', window );">AECOM and IRL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone Payment Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMinimum', window );">Milestone Payment Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AnnualLicenseFeeMinimum', window );">Annual License Fee Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AnnualLicenseFeeMaximum', window );">Annual License Fee Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AdvanceNoticePeriodForTerminationOfAgreement', window );">Advance Notice Period for Termination of Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement', window );">Stock Issued During Period, Value, for Modification of License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,911,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PaymentsForModificationOfLicenseAgreement', window );">Payments for Modification of License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementContractValue', window );">Collaborative Agreement Contract Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,661,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementAdditionalContractValue', window );">Collaborative Agreement Additional Contract Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,191,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementAdjustedContractValue', window );">Collaborative Agreement Adjusted Contract Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 234,852,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">National Institute of Allergy and Infectious Diseases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts', window );">Proceeds from awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts', window );">Expected Receivable From Awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember', window );">UAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PeriodOfAgreement', window );">Period of Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AdvanceNoticePeriodForTerminationOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents advance notice period for termination of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AdvanceNoticePeriodForTerminationOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualLicenseFeeMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents annual maximum license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualLicenseFeeMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualLicenseFeeMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent minimum annual license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualLicenseFeeMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementAdditionalContractValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative agreement additional contract value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAgreementAdditionalContractValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementAdjustedContractValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaborative agreement adjusted contract value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAgreementAdjustedContractValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementContractValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaborative agreement contract value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAgreementContractValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents expected receivable from awards for research and development contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PaymentsForModificationOfLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents payments for modifications of license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PaymentsForModificationOfLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PeriodOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents period of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PeriodOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PotentialMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents potential milestone payments receivable based on possibility of future event payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PotentialMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents proceeds from awards for research and development contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents stock issued during period value for modification of license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_UpfrontPaymentsReceivableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents upfront payments receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_UpfrontPaymentsReceivableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentContractReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables that are derived from government contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68054760&amp;loc=d3e55295-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentContractReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_CSLLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_CSLLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_UpfrontPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_UpfrontPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6820468848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Quarterly Financial Information (Unaudited) - Schedule of Quarterly Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="nump">$ 8,983<span></span>
</td>
<td class="nump">$ 7,763<span></span>
</td>
<td class="nump">$ 4,787<span></span>
</td>
<td class="nump">$ 4,820<span></span>
</td>
<td class="nump">$ 4,602<span></span>
</td>
<td class="nump">$ 10,987<span></span>
</td>
<td class="nump">$ 25,842<span></span>
</td>
<td class="nump">$ 6,826<span></span>
</td>
<td class="nump">$ 26,353<span></span>
</td>
<td class="nump">$ 48,257<span></span>
</td>
<td class="nump">$ 13,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (4,503)<span></span>
</td>
<td class="num">$ (11,528)<span></span>
</td>
<td class="num">$ (16,281)<span></span>
</td>
<td class="num">$ (22,832)<span></span>
</td>
<td class="num">$ (18,135)<span></span>
</td>
<td class="num">$ (14,621)<span></span>
</td>
<td class="nump">$ 4,901<span></span>
</td>
<td class="num">$ (15,164)<span></span>
</td>
<td class="num">$ (55,144)<span></span>
</td>
<td class="num">$ (43,019)<span></span>
</td>
<td class="num">$ (45,189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.75)<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (0.68)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>77
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MKC_\;L*N-W9O_['Q55 V\.LNY!=02P,$%     @ KH!;2IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULA9AOC^(V$,:_"LK[N\3C_RM
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MK;91D[7+LB5;TMQEVV?:GE9S41S0>O?V _0Z!=+NBW#@?\[Y'<5#UE'VRDL
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MS!+AR!#)!8)P)@N%Z0AU+%%,.MO3B,HQ%@QF';W4K^(,NHV>4UGY0!BQ:AH
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M7^NZ\X%E_"G,Z\:7Z\O-SK]V_64:KIO3"X/335<?SB]#HLL;F<5_4$L#!!0
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MN5Z+86 .&\6[\5^ IA]2^1=02P,$%     @ KH!;2N]N'/VW 0  T@,  !@
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MV8YC-AK>=-,/8O,W+OX!4$L#!!0    ( *Z 6TH.$O# MP$  -(#   8
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MVPDD#CG=TG?'LVA:%QRLR#K>P'=P/[JS\1:;52JA0%N!FABH<WJW/9[2@(^
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M=OYFX_QKK1WX4I(;OT*M?V"S(Z!VP;SWMAG7;'2<[J871.9G7/P#4$L#!!0
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MN<$1ZO"#K8:$QH?C>SS;><QFPYMA^4%L_<;E'U!+ P04    " "N@%M*:B#
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M"FH7S _>-M.:38[#?GY!;'G&Q5]02P,$%     @ KH!;2DM$< _J 0  9@4
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M=',O<VAE970R."YX;6R-F>].XS@4Q5^EZ@-,XWMM)T& !+0=D'8E-*/=_1S
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M6RER[8XALBM%-L^5CLNAWUSX-4G$^CR75ER<3U)C.<ZG7(SSL69DUB1X<4A
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MF8M7>6!,16]-W<IY?%"JNT\2N3FPALH[WK%6_[+CHJ%*+\4^D9U@=&M)39W
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MJ-_=16@+3U&*AD$K&]XB 67J/0:'<V3P%O"G@4'._I%1<N7\Q1C?B]3S34%
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M!7"C("@%&>+I/#X+#8I1DPR:9M  S2*#M4!4>113'"9"82($!@R841//IOE
M<T@-&$0%E(0Q3D-1&FK14&/U'Z@U39X3<XML40PTQTEBE"2VUP4<"YN@"9(%
MNYS8F-30%+8FA0P'25&0% %QG-<,39 MJ"2S*($:QZA -$ <)#E*DB,D$9X
M0MP!P@7%3*+WI-9YQU24I X<AR$!@N,X9H"["2RQDTDT9XU(;!F;K4K"T(6#
M^PE@AN+P ,!- &P70"JR17%BUF/;0.(Z+K@+ &8#B2,%[@.PQ C ?LLSDE.S
M'L0O$@@=.+@; &8'KHIP/X EAH"([/VQ'8%D!!PPN"4 Y@F.EY#@GD"6>,(D
M>O]%SF.C(DP59^:')YC=5_0%\COK#F73>R]"JJO/<$'9"R&YRAC>J=4YJCOK
MK5/QO=3-5+6[\>(V=J1HITMI<+L9;_X"4$L#!!0    ( *Z 6TI&,5P$B0,
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M"+"6LA9*D5RHK+<B69T>,K&NF]M0W9?=:;A[J.6N/^E[IW\WS/X"4$L#!!0
M   ( *Z 6TK-ZPN!+ (  $8'   9    >&PO=V]R:W-H965T<R]S:&5E=#,X
M+GAM;(U5ZVZ;,!1^%<0#U-Q)(H*TI)TV:9.B3MM^.^0DH!K,;"=T;S_;$)K
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M<%2FF^J^Z$_V?J!X.]Q:9+PZ\W]02P,$%     @ KH!;2C>WUS/= 0  &04
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M!?$ :S!_3@1(S5:K5FJE:*NVUTXR!+0&L[83MF]?VQ!$P;V)/>;,^68<V_G
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MR&LL"QK(0NK+G*8U]GS2C52A,"VHQB-8RA^H82V*@<RD?L4>TXI=!\IKW0-
MV<#?'&T!R@22J4!B+&PQ$+;47]9'T#20"/R1?P H':3*3QJAR&E?.#DT+USU
MTE]YU(M=^7IJN@/AR=?KM<J=[ [=O>\;<;,=+D<^W QW-;]GU<OQ5"^>RJ8I
MB_[@_;DL&]<F&07M3#BX;']]R=USTSTF[7,UW)$,+TUY'N]_PNLEU/H_4$L#
M!!0    ( *Z 6TJA@_"D- (  '\&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#0T+GAM;(U5[6Z;,!1]%<0#U'R;1 2I251MTB9%G;;]=LA-0#68VD[HWGZV
M(92!5_5/L&_..3['-I>L8_Q%E #2>:MI(S9N*66[1D@4)=1$/+ 6&O7/F?&:
M2#7E%R1:#N1D2#5%@><EJ"95X^:9J1UXGK&KI%4#!^Z(:UT3_F<+E'4;UW?O
MA>?J4DI=0'G6D@O\ /FS/7 U0Z/*J:JA$15K' [GC?OHK_=8XPW@5P6=F(P=
MG>3(V(N>?#UM7$\; @J%U I$/6ZP TJUD++Q.FBZXY*:.!W?U9],=I7E2 3L
M&/U=G62Y<5/7.<&97*E\9MT7&/+$KC.$_P8WH JNG:@U"D:%^76*JY"L'E24
ME9J\]<^J,<]NT+_3[(1@( 0CP4\^)(0#(7PG1!\2HH$0S0BHCV+V9D\DR3/.
M.H?WI]L2?8G\=:1VO]!%L]GF/[4]0E5O>;1:9>BFA0;,ML<$$XP_(I!2'Y<(
M;$ML@P4]^'>!W1(1SB#[)03'=A.A-6=H^-$T9^S/<O:8Q& :@TFC%,^\+D$K
M[,4SMTN0[_D8VPU'5L/1PG#L>7:!V"H0?R)QCXDG/A,O36>)ER <I]XL\1*4
MKKS$[C>Q^DTL@?]SS[!5 '\B,%X<3!#.[_O. O*#^1$O07Z YW[1Y#6L@5],
MBQ-.P:Z-U+=Y4AV[Z&.@7^-9?:NZ:]\,WV7ZUOR=\$O5".?(I&H2YE4^,R9!
M>?0>U'F4ZFLP3BB<I1YB->9]3^PGDK5#NT?C-R?_"U!+ P04    " "N@%M*
MDTX2[8 #  !C#P  &0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6R-EVUO
MFT ,Q[\*XOT '\]5$JE)-&W2)E6=MKVFR25!!2Z#2]-]^QT/I<0VU?JBP.5O
M^^?C.)\75U4_-R<IM?5:%E6SM$]:G^]<M]F=9)DUCCK+ROQR4'69:?-8']WF
M7,MLWQF5A2L\+W+++*_LU:(;>ZA7"W7115[)A]IJ+F69U7_7LE#7I0WVV\!C
M?CSI=L!=+<[94?Z0^N?YH39/[NAEGY>R:G)56;4\+.U[N-M"VAITBE^YO#:3
M>ZM-Y4FIY_;AZWYI>RV1+.1.MRXR<WF1&UD4K2?#\6=P:H\Q6\/I_9OWSUWR
M)IFGK)$;5?S.]_JTM!/;VLM#=BGTH[I^D4-"H6T-V7^3+[(P\I;$Q-BIHNG^
M6[M+HU4Y>#$H9?;:7_.JNUX'_V]FO($8#,1H -&'!OY@X+\;!!\:!(-!@ S<
M/I5N;K:9SE:+6EVMNG^]YZQ=17 7F-G?M8/=9'>_F>EIS.C+*O3$PGUI'0V:
M=:\1$PV,"M=X'T,(+L1:$',48$,5/I)LJ20.>0B?S=/O[(.;/'V49Z\).TW5
MYQDA4BH1?H19&3]>(GC:@*4-&-H T09,E"@&!$Q5:>2%")B*DC2)>."0!0X9
M8!REUR23*(&3IGR4B(T2,5'0&UI')!<_\3R$PHCBT.-18A8E9E!BA!*3*)]\
M]!8WC 8BM#"WC"A,?1XW87$3!C=!N E=V_A#I1*TWK9,H)F%E+*@*0.:(M"4
M3H<0 4IGPZH O:,MHX(TFME:P./W4.\_H ?1[?02:%9%H!G5!] S&S]0:/ P
M-)!OUG?PHF!$ $Z(=T5.YLUN ,#6DGL0##5@:L&\5/QU;E@50(*Q.9D(DQEL
MOOH 4WZ E%F?3)!P\%ZP852!XT>8FE/%<]!\$0*F"@&NF4!K1XS7ZX81^7B/
M8S3)'"]?@X I0I0WI*^3 694E)@1S2+S!0V8B@:XT \B].'$9.N@LM1)HG3Z
MAS.@)HF3S!06X LA<)60S#JM8$+$9&E3%3Z ;3E/TQ/8+3)?#(&KAF36F5HG
MO#3$S(R,'L.VC.SF'':+S9=&X&ICB+%3\DHC)R345!4[^+S&NA+XZ.]..HU2
MUL>NBVNLG;I4NCVP3T;'3O%>M)T*&E^W'637P;R[Z=O/[UE]S*O&>E+:]$%=
MMW)02DL#Z3EF2D^FXQT?"GG0[6UL[NN^[>L?M#H/+:T[]M6K?U!+ P04
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MHV1+,22D, 4'\'4+ $X\OV\!\#=+GLC!3^XU!D#)'(07BBC-GGP=#-[N+28
M:-%!R$(175P<]-"S6B[/KELKKQ27SHV*!^LT$;9N(*!_[L,X^<;DN>Z4=Q#:
M=$[7WTY":&YJ"59&;F4FV+1I^$G;96+6<FCCPT:+?AQ1:)J3Q5]02P,$%
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M2:AI)N?,M#:S$+0?N[8W_3K*OU!+ P04    " "N@%M*48_IR:T"  #K"0
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M<'?,'I32TOA#3R:SD[EYW2>E/&@[3,RX[:\?_42K9KA:1??[W?H/4$L#!!0
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M2ZX9DZ!*#.[4)+3JG9@- K74VZW:<SLMUI!L< \!FE^CXC]02P,$%     @
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ME;SJ1M,XJEU3<Q'SO2Q.?76>57N'ZD**4[TMLIJ]V>0_4$L#!!0    ( *Z
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M:]Y\Y(C2/2+L,F(_9)A [N--Y5JM@NX"DAX\:3L)67H.2C[+V2&3JBMNE>@
MH31PQX>.J##H>6KN6!G$"3R$R2".M$8 9@*\\C:<[W1^]=97-E^_Y;@YJ :
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M"9+6:6$XEX^.9;8N !S(I4VM:*\12&S5UDM0I"K>5J"P(Q%9]#:RH-:F2:W
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M8\!*4^6TE@_6*G?B]ZAM:" N^"4,&+S*1<S(T4B,>RHE;8[='S]F:^$>[.*
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MAA4V9M*KUV5M5EXC:>VLN,D1M1)H17M=ZT"3YKB$%]/8@L><YN:]%5 9##:
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MV4[D.R//XC0=1.\+6J(M'FQ7MGW@W8DP%,#K+IFD]X##,QY@KIAG6;XR#V9
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MHJ==L/9T4&[Y,0^T5YN)/F'I^7V2Q-0[&4O_JA.T?&-(Y]EL&@.K:/BBAPY
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M&V,@DP&T[3Y["\:]T>A@[J/B3]A&K,/Z8(+@?V  >DZ8],*HW\B@>6TBY^\
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M>NNRW#W(I? YN3+-SZ,6\EZU9^5"@P&H0?W]!Z/BM5;X]<6']Z+]?WS7^90
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MK^C2Z[5V]2*R_&=WO5.J?+UAM75NEEZ[\U^"'FX.RNO8W]=T\Q]02P,$%
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M4$L! A0#%     @ KH!;2A\CSP/     $P(   L              ( !
M %]R96QS+RYR96QS4$L! A0#%     @ KH!;2F;S"V""    L0   !
M         ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "N@%M*
MM&U0$N\    K @  $0              @ &9 0  9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " "N@%M*F5R<(Q &  "<)P  $P              @ &W
M @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( *Z 6TKSW&EUJP(
M  <*   8              "  ?@(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " "N@%M*OY9$NC,$  !?%   &               @ '9
M"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ KH!;2A26
MPC0O @  4P<  !@              ( !0A   'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( *Z 6TJ"="$+Z@,  !81   8
M  "  :<2  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "N
M@%M*Y1*,XAT%  "=&0  &               @ ''%@  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ KH!;2KT."2_- P  WQ$  !@
M         ( !&AP  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( *Z 6TJTTS[=,@(  )P&   8              "  1T@  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "N@%M*[VX<_;<!  #2 P
M&               @ &%(@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ KH!;2@X2\,"W 0  T@,  !@              ( !<B0  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( *Z 6TK;U1_$M@$
M -(#   9              "  5\F  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ KH!;2IH4B(BV 0  T@,  !D              ( !
M3"@  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " "N@%M*
MG92/Z[<!  #2 P  &0              @ $Y*@  >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( *Z 6TI<;E+OM0$  -(#   9
M      "  2<L  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ KH!;2N[-6<.V 0  T@,  !D              ( !$RX  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "N@%M*"S]GB+<!  #2 P
M&0              @ $ ,   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( *Z 6TK)U9Y&M@$  -(#   9              "  >XQ  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ KH!;2LR/U%.W
M 0  T@,  !D              ( !VS,  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " "N@%M*GA0?T+<!  #2 P  &0
M@ ')-0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( *Z
M6THG2]*!M $  -(#   9              "  ;<W  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ KH!;2A8O<6#6 @  M P  !D
M         ( !HCD  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " "N@%M*XP%BL?D!  #+!0  &0              @ &O/   >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( *Z 6TJ'_#-;M@$  -(#
M   9              "  =\^  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ KH!;2FH@P'2V 0  T@,  !D              ( !S$
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " "N@%M*HP5W
MUK(!  #2 P  &0              @ &Y0@  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( *Z 6TI+1' /Z@$  &8%   9
M  "  :)$  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
MKH!;2A!=4:W2 0  G 0  !D              ( !PT8  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " "N@%M* -=;P;8!  #2 P  &0
M            @ ',2   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( *Z 6TH>D:4TF 4  /\>   9              "  ;E*  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ KH!;2I*6F/]( P
MP X  !D              ( !B%   'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " "N@%M*?GCI2O !   V!0  &0              @ $'
M5   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( *Z 6TI-
M_!U-% ,  ',.   9              "  2Y6  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ KH!;2O/C'-"X 0  &@0  !D
M     ( !>5D  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *Z 6TI&,5P$B0,  'H0   9              "
M =]E  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ KH!;
M2LWK"X$L @  1@<  !D              ( !GVD  'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    " "N@%M*-[?7,]T!   9!0  &0
M        @ $";   >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( *Z 6TH:\QC!IP(  , )   9              "  19N  !X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ KH!;2JDM)YGS 0  ?@4
M !D              ( !]'   'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    " "N@%M*D<]6/X\!   9 P  &0              @ $><P
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( *Z 6TIX0VV%
M#04  ) :   9              "  >1T  !X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ KH!;2J&#\*0T @  ?P8  !D
M ( !*'H  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " "N
M@%M*DTX2[8 #  !C#P  &0              @ &3?   >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( *Z 6TK7!0>#&P(  * &   9
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M970U,"YX;6Q02P$"% ,4    " "N@%M*4FIZG-H!  "9!   &0
M    @ %\CP  >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (
M *Z 6TK0Z=-T) (  $8&   9              "  8V1  !X;"]W;W)K<VAE
M971S+W-H965T-3(N>&UL4$L! A0#%     @ KH!;2E&/Z<FM @  ZPD  !D
M             ( !Z),  'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"
M% ,4    " "N@%M*S105U.$!  "9!   &0              @ ',E@  >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( *Z 6TJ#2*>*^P,
M # 4   9              "  >28  !X;"]W;W)K<VAE971S+W-H965T-34N
M>&UL4$L! A0#%     @ KH!;2H'(5X]1 P  IPT  !D              ( !
M%IT  'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " "N@%M*
M:NV)XC-K  #QH $ %               @ &>H   >&PO<VAA<F5D4W1R:6YG
M<RYX;6Q02P$"% ,4    " "N@%M*&LF):EP"  "V"P  #0
M@ $## $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( *Z 6TK2G=63+@0  $8E
M   /              "  8H. 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" "N@%M*90V\O_T!   -(@  &@              @ 'E$@$ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "N@%M*5=WD$-D!  "^(0
M$P              @ $:%0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..00!! +D1   D%P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.6.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>209</ContextCount>
  <ElementCount>337</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>90</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-consolidated-balance-sheets-</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-comprehensive-loss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-cash-flows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Stockholders Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-stockholders-equity-deficit</Role>
      <ShortName>Consolidated Statements of Stockholders Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Stockholders Equity (Deficit) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-consolidated-statements-of-stockholders-equity-deficit-parentheticals</Role>
      <ShortName>Consolidated Statements of Stockholders Equity (Deficit) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentrations of Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 2 - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment</Role>
      <ShortName>Note 2 - Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 3 - Royalty Monetization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-3-royalty-monetization</Role>
      <ShortName>Note 3 - Royalty Monetization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 4 - Senior Credit Facility</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility</Role>
      <ShortName>Note 4 - Senior Credit Facility</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 5 - Lease Obligations and Other Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies</Role>
      <ShortName>Note 5 - Lease Obligations and Other Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 6 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-6-stockholders-equity</Role>
      <ShortName>Note 6 - Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 7 - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation</Role>
      <ShortName>Note 7 - Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 8 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-8-income-taxes</Role>
      <ShortName>Note 8 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 9 - Employee 401 (k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-9-employee-401-k-plan</Role>
      <ShortName>Note 9 - Employee 401 (k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 10 - Collaborative and Other Research and Development Contracts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-10-collaborative-and-other-research-and-development-contracts</Role>
      <ShortName>Note 10 - Collaborative and Other Research and Development Contracts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 11 - Quarterly Financial Information (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-11-quarterly-financial-information-unaudited</Role>
      <ShortName>Note 11 - Quarterly Financial Information (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Document - Note 12 - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-12-recent-accounting-pronouncements</Role>
      <ShortName>Note 12 - Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 2 - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment-tables</Role>
      <ShortName>Note 2 - Property and Equipment (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 4 - Senior Credit Facility (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility-tables</Role>
      <ShortName>Note 4 - Senior Credit Facility (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 5 - Lease Obligations and Other Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies-tables</Role>
      <ShortName>Note 5 - Lease Obligations and Other Contingencies (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 7 - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-tables</Role>
      <ShortName>Note 7 - Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 8 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-tables</Role>
      <ShortName>Note 8 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 11 - Quarterly Financial Information (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-11-quarterly-financial-information-unaudited-tables</Role>
      <ShortName>Note 11 - Quarterly Financial Information (Unaudited) (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 1 - Significant Accounting Policies and Concentration of Risk - Fair Value of the Company's Investments by Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-fair-value-of-the-companys-investments-by-type-details</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentration of Risk - Fair Value of the Company's Investments by Type (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 1 - Significant Accounting Policies and Concentration of Risk - Scheduled Maturity for the Company's Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-scheduled-maturity-for-the-companys-investments-details</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentration of Risk - Scheduled Maturity for the Company's Investments (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 1 - Significant Accounting Policies and Concentration of Risk - Summary of Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-receivables-details</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentration of Risk - Summary of Receivables (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 1 - Significant Accounting Policies and Concentration of Risk - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-inventory-details</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentration of Risk - Inventory (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 1 - Significant Accounting Policies and Concentration of Risk - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-accrued-expenses-details</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentration of Risk - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 1 - Significant Accounting Policies and Concentration of Risk - Summary of Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-1-significant-accounting-policies-and-concentration-of-risk-summary-of-revenues-details</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentration of Risk - Summary of Revenues (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 2 - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment-details-textual</Role>
      <ShortName>Note 2 - Property and Equipment (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 2 - Property and Equipment - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-2-property-and-equipment-property-and-equipment-details</Role>
      <ShortName>Note 2 - Property and Equipment - Property and Equipment (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Note 3 - Royalty Monetization (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-3-royalty-monetization-details-textual</Role>
      <ShortName>Note 3 - Royalty Monetization (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note 4 - Senior Credit Facility (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility-details-textual</Role>
      <ShortName>Note 4 - Senior Credit Facility (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note 4 - Senior Credit Facility - Scheduled Principal Repayments of the Credit Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-4-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details</Role>
      <ShortName>Note 4 - Senior Credit Facility - Scheduled Principal Repayments of the Credit Facility (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Note 5 - Lease Obligations and Other Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies-details-textual</Role>
      <ShortName>Note 5 - Lease Obligations and Other Contingencies (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Note 5 - Lease Obligations and Other Contingencies - Minimum Payments under Operating Lease Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-5-lease-obligations-and-other-contingencies-minimum-payments-under-operating-lease-obligations-details</Role>
      <ShortName>Note 5 - Lease Obligations and Other Contingencies - Minimum Payments under Operating Lease Obligations (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Note 6 - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-6-stockholders-equity-details-textual</Role>
      <ShortName>Note 6 - Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Note 7 - Share-Based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-details-textual</Role>
      <ShortName>Note 7 - Share-Based Compensation (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Note 7 - Stock-Based Compensation - Stock-based Compensation Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-7-stockbased-compensation-stockbased-compensation-allocation-details</Role>
      <ShortName>Note 7 - Stock-Based Compensation - Stock-based Compensation Allocation (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Note 7 - Share-Based Compensation - Stock Incentive Plan Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-stock-incentive-plan-activities-details</Role>
      <ShortName>Note 7 - Share-Based Compensation - Stock Incentive Plan Activities (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Note 7 - Share-Based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details</Role>
      <ShortName>Note 7 - Share-Based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Note 7 - Share-Based Compensation - Number of Stock Option Awards Exercisable and their Weighted Average Exercise Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details</Role>
      <ShortName>Note 7 - Share-Based Compensation - Number of Stock Option Awards Exercisable and their Weighted Average Exercise Price (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Note 7 - Share-Based Compensation - Changes in the Number and Weighted-Average Grant-Date Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-7-sharebased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details</Role>
      <ShortName>Note 7 - Share-Based Compensation - Changes in the Number and Weighted-Average Grant-Date Fair Value (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Note 8 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-details-textual</Role>
      <ShortName>Note 8 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Note 8 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details</Role>
      <ShortName>Note 8 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Note 8 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals</Role>
      <ShortName>Note 8 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details) (Parentheticals)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Note 8 - Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details</Role>
      <ShortName>Note 8 - Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Note 8 - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-8-income-taxes-components-of-deferred-tax-assets-and-liabilities-details</Role>
      <ShortName>Note 8 - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Note 9 - Employee 401 (k) Plan (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-9-employee-401-k-plan-details-textual</Role>
      <ShortName>Note 9 - Employee 401 (k) Plan (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Note 10 - Collaborative and Other Research and Development Contracts (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-10-collaborative-and-other-research-and-development-contracts-details-textual</Role>
      <ShortName>Note 10 - Collaborative and Other Research and Development Contracts (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bcrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Note 11 - Quarterly Financial Information (Unaudited) - Schedule of Quarterly Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20161231/role/statement-note-11-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details</Role>
      <ShortName>Note 11 - Quarterly Financial Information (Unaudited) - Schedule of Quarterly Information (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bcrx-20161231.xml</File>
    <File>bcrx-20161231.xsd</File>
    <File>bcrx-20161231_cal.xml</File>
    <File>bcrx-20161231_def.xml</File>
    <File>bcrx-20161231_lab.xml</File>
    <File>bcrx-20161231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>83
<FILENAME>0001171843-17-001159-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-17-001159-xbrl.zip
M4$L#!!0    ( *Z 6TH@O#60%GL! ,->$@ 1    8F-R>"TR,#$V,3(S,2YX
M;6SL?6ESVTBRX/>-V/^ I^W9=4>0,@G>]G1OT++=K1G9UDKRS)M/'2!0)#$&
M 38.R9Q?OYE954#A(D%2!"6+$]/=% E4965EY55Y_/7_?E\XVCWS ]MS?SEK
MG[?.-.::GF6[LU_.OMXVQ[<7EY=G6A :KF4XGLM^.7.]L__[Z__\'W_]KV;S
M-^8RWPB9I4U6VMT\<BWFO_<63/OO=S=76E-KZV\Z[?$G[>O=A::WVH-F2V_J
MO6;SU[]^G_B._0;_K0$$;D ?[5_.YF&X?//Z]</#PSE^<^[YL]=ZJ]5Y;;L(
M@\G.^//5GWPS,?WOJ<<GMF?ZJR \-[T%O-+NM_5.6SYM>I$;^JOX!1H[8.;Y
MS+M_+7[$ESK-5KNIO!;Y/B"N[#WQ*[[83;]H,;OX'?BAX''VW9P7/X^_T&K2
M+]CN/0O"XE?X;P6KL0.OJ[<'ZY#,GY O.+;[;<W3^//$".(M<0W;#(IAHI\0
MI'8:)-=SW6A1/(<5^J_#U9*]AH>:\!3S;5.^%]AF\43P0\$T0;CT2YZ'7PI>
M"#G56T#U*>!NWO_VT89USP(D,_ET%#1GAK&,GYP:P826('XHV, H]$LQ.WH-
MOYXI)\C*$)-XKO^:_Q@_FMNOAPX]VQZ-1J_IU_C1H.@Y&+/]^K\_7=V:<[8P
MFMDC]SVPMWD+N(FF_15G?1/03S=LJA$4;^8^F_YRAD>X*4_J^?? .A,_XZ[_
M<A;8BZ7#SE[S<?#A-V/3]"-FO6?WS/&6"^:&%UX0!IKIN2'['M[@J/8?A.VV
M3MBVF&DO# >6V^R<:;;URYG9[O2ZPY[>/=,BUQ;O<+IO1@##KX.N/FBU6G]]
MO6[*78#J;0:J5P94N]49#7> ZL/W)7,#%EQ[CFVN[@">=XYG?DL!9_TAZ;/5
M3B%/0M;3._#GK__;"=]:]CV(C94#^V/9P=(Q5F\TVX5=8V^U*8S9G!H+VX$O
M0WO! LUE#YKO+0Q7_!K8_V%OM'9K&9[][UGX]AF.F'WFK;8P_)GMOM'@#ZU%
M_VZWSWO;P// [-D\?*--/,=Z6_TU^A&^"PW86_Z>V'5-;CN.\QH&DF,6?=;V
M7*&Q6+YU)\%RRT&1_(!96$"[;S1]D)N'!K^;,^W"6RP-=Z7-2"UQG!7H,B'H
M-H",T"-"]@TSC Q',V8^8W@8 NW!#N=9&*I@,;TAMCL'J1.FGW0]'PXOQW<X
MMWU+77=S:?CA"G0OU_( Q(>YIRU][]ZVF.:S@!F^.== Z0(6$)_<!JS;C::X
M!A\D2X-^]T*860N8?V^;#)>JP1>:YX,*9_@K6'7D!_#W5)M$ :PE",ZU6U31
MX!MX$'Z2> DTPV=:$$W^S<Q0 X0!Z8-Z #I?$V6W!4/?>[8)$].\\8SX%H@X
MX,"H"'J@3,+O&NP9K R^6 )>/(NF@T-TKJD;Y3,3  TTQS8F("Q#&X8C<9H!
M#;<,IEC8H=BS.7-A'P WL+T+7!5.Z4T<>V:$H,EJ<R/0)@P?<DGWLAHPU\SP
M+5A1():.\.!BQ%]\=02@'>!6F/@H?NN E@2OW]OL@9Z' Z,B#7"QC&"WC(#0
M#O36(&"!/9L #;Q!)&8LET VQL1)E@^H"4"M80YBVT;ZMJ>K!+'AW AA)?>,
M+P6>G@)!(8YQ\;C N>%,"0#8)Y 3-!FNQ4&:P86)L91W\6E\Q @"S[1)=S=!
M(,2( @(F[,>O$JY#9=,0MZX7:BL62AP3Y@ NGU/C@PVH@$?LJ<UHY^,M!*6;
M"&!A_-N#X[)*P<BIWP_D@*E9%X#P.9QHH&\#X#3@,80T1E:\PC2%+8QO\*-
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M[9!5D"DE@"D17G31ON:,/YJ0VIF&GPRA#!I=?5"-5 ZV^I>,_W:KT1D-Z]F
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ML05_806C77M^. 6YYVT9'O/'#48&T*V/"#?(A?8,NQW][-?K]K_:PR2ZIQ(
MY1#S@* OT]_AK/V_"&@\7'TR_&^,R#;!RF.M0!\--JR@(D#*BB[0MSW!^T#[
MGL6A3&-@LB%EREUXO$9;_BJ#HJY&3?Q_._[8:?TARSZ/7;4%B1*\(8>\\ZYY
M23/ .R46!.]6RL7L>X;M$O %6 \SG!!'_#U:&.ZM*'VV,>JC71XK,!BT1^V$
MI+="PZ.A#SL+Z8(.Z*/>?5+HZY6'EO&0GT.A#^O1,6L#[0V20_0DD5=^D=S!
ML,G-V"O PD;<5<89_XB,YPGAK+NFQY'>[V\\L-5PY5H$?O'"]XK&'(QZI3>W
M[6ZW5;KI:T%ZK(5L$8L)"RD-F.N,>L/2LU_+0K:(Q(2%E*LUK5ZOSH7<8(74
MJ*(^<(&!H,RGED&?C<4^IRP3L-TI)U&]JX9L[["TQT9,GF0/B9CR&-%^IS-X
M4HC)'X%#(J;T"(TZ_?Z3PDO5D_0;2 SWPO>"0,;#@:*25[E[I2I0N>%6*^&O
M74?IAO9* ^W;G=UDU+'IO/)^EFEE!][/JG1Y.P>XO9D-XUYX5Z&U^6R6AV6F
MXC*?P%Y6I>FM<=!M/1L<5*7G[7'0?C8XJ'P6V)^V'P5?_WYE+VRPA#:SM5+S
M8=!_GGK-]B@HCQQMC_3GJ<.4(4%=]O;^U0.1\KHC6NI.V=TVK(] URVL5)W8
MW5:LC^C6+:P\"V=GV[%P82[&F/HB#9"[;&_LX-N^G9EA8TZ=F7'$#37?VYUU
M]?9K[-%\:\]<REEQ0^TB"D)O(7M^$D5I2!1K&S?O,JGVZ)7\U^#S4=HCK.EG
M])B(?R1L; !WYZ9+YYW#-G4J'?_:M['K##7"T&Z_7FFQ S;=7<9G#K8#7OK
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ME7*Z KQF%& ;9GCN7C285QWHI3P^Y[I->>GXX;=4R^3K^>VYEE3L:Q A<4:
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M.#/[1Y@S57&'=(0C^&U!-8N<D),WWNZRFNYW?VHW^KWN$3#P4Z^?G];09LC
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MV'@:WY=/YY(5*=U1>=*23Q;"FC9<0VOS>QGRH'QD3:RR*9(MM7:5\6%=@ U
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M M&*]T7:G:<%T7())B^_2*61&[60TO$NV0'SJ2EC,EIX%G>G4%0$J#[Q,?-
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M_@90DH773[!&FU@U]R'4<VCS#B!AH,:9D7<D7PPGB/-I)#I59<$ U%@4)=;
M5 MR$]D.TRX_OT>[UA&N$YYYJ3JF4V2,MG(^,Y0>7T2!&3F&GWUAD7E!W;A"
M[T_AUM$\/(]BSA:>[\^-F6UJ4R */_UD2D7Z .:"D?Z](3V]@"4K0H]0LK%U
M><C2,15SND"*;PU"3%PY/\G?&N1OXA_,\R(X,1AWB90B[J6XPB:N"\(Y^1B%
MME;L:KU,-E6^9M>BP((^UQT,3OI<[?H<F"A28U*2$V-MBFM7SUN)NE/,$Q%Q
MG%B;R%J3HX1RQO2"L+ETHJ YM;\SJSEERNO"B6^GT_/PD*!1%#K\.L,'@L(
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MFL1!D2*JAP)^1$10$GD8%,<S81>)V/>[L$F@S@%,#39CYK"F!6<Y5 *>XE!
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MPU(RW6J48T,Q\;*7;@W"NI?"*!:)Y>>-=S@V(M'31X3<N>Q!EBZL)8#[GI6
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MKDELBA0.H/M^N&(=F@&<(&T&S_J(SXGM/@VD+_#%4]3'6-)9[^)H3@I!!DP
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M+L2S=L"/H ]([1OBD 5"#D8)!GD/CO"[R O^O*!7*ECY/K^JTLV1:#;D1=R
M1-I8*Q;<VF#GD(8^\>00SU]::[PO\N[^\VU<HR\JT1??)[G%O" 8E9K4V^0
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M+/L=+4'W4+$7$F6[GF) )C-^V'VRXR0537\<B!6,!8#(/U!7M^UR?2!6L L
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M^@'S<3!-,+Z7<..:>$;_2&@/',Q<CTF,/3MB:M/D76L>LC(:#8CA:NORRYS
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M&J2'4SF547.0?F"W3(^AI\:%\@!\;,[C82M!P?&Y8?L<!C1G/[;"58DW.1;
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ME,27BX2._TBO!> )"&2IW8V5U*13,>23+GXS'G.D>#R:O=(I-+2 7(BA.-.
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MC%*+W/6U"VB-7(?+!E@Y&E>&/,F[PR<3A@U)J4G9 XN>L Y3U:(Z(V#,H6R
M$X@F9X@W:73FO02P"J(F:P IES"M0X0N%P*;<DI6>*+,)<4X I72:0!B3!54
MC!/$7CSZ4)P+"D[S5D33X@F5\::<5G?ZZ*4A\]B-^ +@1]")TA).^#>V1A<?
M2$-*CV?BRS3S3-8@_R$R7W2#3JCAMOZP"BBE-IVMFVXIXW.=IU#ZLT& +P(6
MR1)"35]7I('L@H+<=D* BEA>/P";D PJRRJE19V\$*#F@4(4B08RXI$?,IO#
MP!(H)0MIK,[IX$Z$^H583#_[LXT<Y2:50;*@WE:JIZ %+-G3G"G2F,EP0F7H
M<'49-4,?=^PQ-QM^I0N)Z?:90V2L[\24O&"K)W/F>$%],2D!.JN'HI-UOA#T
M)$JXI.]"YB2B+QQ7\!C&_!W,J=/,9*QIB%)A4K?N612Y:7@L[_)%RP7N5CG*
M58CJ?#)9M%WWN4RZ<J@:Q9>9;!$3C3YC&G>T^41""&QQ[.LZ>YIGD8CB\U1U
MJ*:+HN?!^;;BL20W&(W4@"()C)-JDQA3HKQ)>K%&H@^X(EG%2Y*TKU/+-9,#
M5C0';-T2:=1;8*,<V4[4%]W3,'N7<1L+C_:MAS#',NE3VV='@$JQCH294PKS
M0;@Q>')6%/SP2^XN=3_^;2)P/Z6] +3RG$R/S4\W*XE2U-3RL^RLH/25U0ZE
M.\=%=0LGJ:@!:^\6<\28IJUC8EF YY/VE/"(+F*0J92&L#(L(UE &SW#* (4
MH5N'\@O@97B&)%LC*W?Q,Q . K1"8(<LJ^FO"EW1;1?S1K .7L1%==.+LN(]
MTOQ5RT%Q$ME8@SQVH#NH[-D,J(/$$(_3:NTU*\[$X3)Q.-FL6I&6S#S2+]#J
MU:F2R_DD7%)%Y.]$./U:V*)^=<<^4QGQJ 4C[TCT"SRT-@['(?]2\@.?-$'*
MD)?WET)T]"-9C4R_ A'L.1.DJ"0O!+W1U,4)N  0N?!#.)L9WY4XX)- :];!
MGG8)DQUVEF#Z +?TQJ74)%KOP-[!CI@9TL[ Y+0;:#=_.I7+^EG,)G_3 #]0
M-EU7SFW\VZO&*_IW",JW^K?<@APO2))A$<(^U%\2FK3@ELFUVI-Y,R2W#"!\
M9O;DNNJ[W[1D.!<<W_O;J_:K7=ZU27]_?FJP2L3NO81#=E_"(3NKFSATK',P
M?7C=:G3L5GM@M[K='S9=H"<^CF9@:#;_^O/S5F4RWS.3;&=C>ET^<N3J&Q8O
M?%/SE]A]>*M:J[%ML5*GB-NM7L'1S#O#XC  &QQI@W2'38.C2N.H77#2\1$1
M="B#_M>,1ZR 6I.SL;MLF[S",G)_+>EXL[[/125#NS=H%2.4DYW^)<._9;<'
M/0/_\W%)N]'JE@/_,M378GM<;[V\I8>X<B[\= TT=<Y-G7\'!BR5 \OYU*85
M]V.""HH3%*QVO08DGUS,-%MVIU/0JGV)M^ST".C9[7;?(.",AD:[5Y*B6PE%
M*X^U_AI@N.HM5E-9;_U@(</"AH8*T% :X>ZL)^&8JUP:+VT;C\%+N@35TT_O
M9\ R_2D7C8WQ/\!+ZS2UV-!0D1ML-P<=<X<-_ W\J\X\3ZJ,WK,_>1"'UM?_
MM3Z*HOH= +%7%H%<[/D,@&.&"@]Z4YDTV2\:]2X/=@;E)P[^-.UAJZ!3PF#]
M6K"^NP)_:B">4\'/(ZXO?D1E GM&J@QYGTVWZMB=1D$'@6%JUX+U]M#N#AH&
MZR\+Z\V&W>U6!.L5,;16*:Q5;W4S(NT($DI;<V]R$FM88S^F.>7%H/],#N3!
M+RE5\>[9[6[!_,CC0>\H',O@_D#<=_!Z'V)T&=Q?+.Z;;;O7&%0'][K,^I$*
MR-)_'E*\MF,[],TM#O;J&K>Q5B[O[WW.=H1BW)LQ:04X3NJ$.[O4^E+F31W9
MM8CFI:MNJYE&0:)%,,X*J,FFUMA@-P&KZ)"Y"/RY3V7X29, #?2J^1,^0FU=
MTJ$#<N9#TA!XPSB"3-> ,1]3(3%]F]F'?(?LZR3?E4Z\*&NV76]E7&#Q'=+(
MDM/O\2_-1G:@'6ZKA->VABL3.%]J\?+!TWQV)\KN&1".3L_L464K9O[(W&SG
MX2)__Y\?X[ V=9S%3W)FD3:RZ#.8E:/E%V!_;UQ_].V7__?_L:S_L_*XZ ,'
MC]RQ"9SW/PB56J-7:S23/]N-_[S%QA4LH#YCOSES=O.=A[6W]Q\_$<W\1Q:
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MWK&[K8H4_E9"2RA0#"B&UXV3?.\#B-<4!QWN[AFT"ZHGIC#LRG#?@ZM>H:+
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M[$5;VI])0ATWXM(U$1?C0S=@,6"YCHC+T:(LIT77)13[].Q!ZZB2\/RWY!+
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MMW[UY_\7+<+&*^AG@3-EF<_>?V?!B(?9#S\'?+1&(V5H\++HI+NAV:!T+;G
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MN]882,C0GVLU@_#K"1;:@Y$G?*C[E@E^7?C>?3P:L3"<Q"X>R66XS]\G]PM
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M;B?(S:T4]VBD6#;:CJ*85!AM1DLH;J%?DXYJB/(JB++9O2[#_=QDN;T+<W5
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M;EWM@<ZV$+<GM $B(S=&C=N:TO6Q_ F\"Z!@^70!+ =O6&B!6F[!I8W@^N
M</$(WG/Y@&W!ZO#$R)]ZL+LQ+&Q%,T90=+PEG>[_^PZW8_AS"!]ZE-;BX%+W
M$?P/[0;?C<\'; : AQMG??3#T!);]FD]'E@3!_[KT7%C%M:M+_"*](.\S?/0
M@JT#P\+WQ2&>%O=&SK#:_6CFNT#'\B<+."$^,/?'S-WT@N>@@&_2MRN :N%!
MK9'KTYL7Q&5A(?Q^Y,_G\"@M5+<$^8D%1AKYP3_""-?6X.O F;[C$PS?Y< 2
M@8/7H(84CIN QWW@??2:@/T9\Y##+D(6/.+[%\0DU39H]W7K%A8:CSF^TK:>
MF#5S  =^:I7AKR;H% *6*+>I@SL$Z@RLIQD?S2S/SYY [35[B!@8JVNEQ#'Z
M67M#^O'X9_S=F &9C*W(E_L:C>(@8.-ZD<NYB_OF6<Y?1'30I^%-',W\ (_Y
M%6YG0+@52]-R&8%TAS+NH__$ O$7GP-)%9 Q_SE@ V^6ZUL@+\+ZQXWF%F<"
M2+A>M[#<WRKTCP/ EXFJUG94]5O%532#JM.AJET 5<6=&5L]&095^Z.JLQU5
M@^)FY5:#W:!J?U1UMZ-JV"[N =AJ_AM<[8^KWE9<=1K%?8W-[DO$U;/ *^Z,
MN7RE3(3M?I]H\5+I&<H/GYU/?ZZULX*^D1__[#8;\'\GPD\^U%XFJC;HSZNH
MZN>BJM7M#PRJSJ@_KZ!JT'DFJZ!I4'5._7D%5<-F/JH:_8Y!U1GUYU54#?)1
M->P:3)U1>\YBJM/(SZIJF2O5? 9RS58NY'J=X?!*8:=E8%6%R+>KSKU\?:PY
M;): JG6HO4Q4%5"=\_6Q3K]C4%4EU?D9?:S9;1M454=U'N3K8^U.MV]052'5
M.5\AZ[=:!E,54IWS%< R;)RJ(^HYR WS)4>K<77 ^[I85#6\4B1MHWC4\E2Y
M "L ?)FH*I*V43QJ>:I< (.J8FD;@^)!RU/E AA4%4S;*!XB/5DN@,%5P;R-
MSOES 0RN"N9M%*]T;&ZM<[Q&7#T+O!T*P,X'O(?M%< /J[4Z]%]8[ NZ^1WF
MJX>?X<7PK3,M5'KT'UK@RW(A:7.^</TE8]IQ!&EN+8S^C]P$?8]_M[IR)^^=
MT>S?S F^8G+ZA]AUEZ)>>9WF6WKE4[^[;C$NXH"]^J51;ZURHV.#KIK8T; 2
MWGCCNZ1R@K[8%U'=QJ&(6G?"*$2]*#R]<R(!]9MX&L,%:#2E:KN"QL]I38;@
M)?MB[NL"N%$\&K$PG,0NGMEE>.+?)_<+P-6$C]ZQ1^;Z"SSH)^["3WQ/O2X?
MG[UV+C[[%X+0#PX/_HD51C=A&,]5K;-LCL"">7.WBD.LT>Z_^N5S]]_-0>O=
M$4"P=7_G@\.FXE\=#H,7 H=-)>8Z'(:7"(=LV3\&PV\]D"%>R$?T^F:^)WF7
MSBBZ![,S&.15B+_Z!5WT&]ST)SG:R4"X4AI]Q^8.]X"WO050!LXHBAVW,,\Y
MGCZ6&AR?8#?S>*[0I''Z09>(^"30+PJ5EXL6YWL>6GJ EF;#X&4[7K9S)9T/
MM0&NO7^WFL-C\.RJ@/8WWWLD/5V%:X12N<[)-_3RR##J(3R2GT\RZ&U(4CC^
MML\$FRUA.(!-:UTK5K#I=H<;<I\O!C;RWQ_\8,(X_'N%C*D/"-HVB9)R6$\3
M &7Q@ME>O;_JT3_+D4\$^MU G7>+5^&[0T>>7KUS"KJ]('@6H=?B?O+N5<!S
MYX:")0KQ5I^$^)$,KZ,?^!2(4#V8$FP?"ZSY%EM.% \81GNPH7KN!$<\%R#7
M_1\' 3*GX0 H5)WA<2W?J@%RW8%R""!;.?&O5[^T!IT-M1<7 LAG]-("BM6J
M^OY<IMBF2LHC;_\4 #J],EH\MZ2SWAOR].<K M0]0Y+K-3'/=?E[QC=84IB\
M0/Y=?X<P^7H/YC,!UJ!XI[R]XL'\3KVS&LXW*#XWBHOD^Q5O?M:O-YL&Q15#
M<8$\P6%Q'U"S66]ME;L&QQ7,+RS>;:W9JO>--*X:CHOD)>[0_1MGXAH<%\3Q
M<T!O%B]=P*%!5P_S]0*EYW;RADVYA[Z[-XZ+25CGOV=%"HMVX*7U7N=$*#\0
MT(8$#C)\BK/:3KVQ6EQ1$4 ;$CC(,"K.^,$PVNKN,R10,1(H8CCMT,"S:6C@
M\FB@B&&U2Y'=Z91N0P/G-+QV*=XS-' \&GC6,"L>?L#YV@8GJSO+RZMH5:E<
ML[F:EH+VF:B+:'6[6]-22H>=06A1XTNWMKJ49]1N#0Q"+PZA[0T(';0 H>U"
MB6,&H55#:&<30K$$J__O?MO@\^+PV=V SR&6O0RV5KT89%8-F;UU9'8:;4*F
MX;;'1&C6UF@4KF8Z-X3YU,-J=,>+;D8C'Z<4>E.:_\=9^ 7._,:%K10'0-AI
MMWO#5@DC8+<,'3UDINIO?L2R0TIWG+":79A[,Q;P*/NDAVT&7/&^9F9^8_KB
M9"IDYV=+0Y258LI2J**II8!JS-L-B+!HQN@=#[\=:8KK0:-;JS3YMM"$V]4C
MG0#K%P6T+]J VPN?$/R&^V^#91A9GX'USIT1BR.X5FYH6[?>J&Z]QBFQ^IQ6
M=6QM1NL/.*35L1XX,(K1S/-=?[JD(;#PG!7-G,@:LQ N+*SI W>>PQ;%#1V+
MIA_ ZWSXPPJ!&%QK[KML%+O,&@?Q-!2_?R"V^XTM+>;]=XG<D7N/OON8CAM>
M." RILQC-/YV8@$J&0@7.2E8;AI -(I#'/DK?A0%S(DPVYG&^X+D27Z&RXIY
MMJ'&:6)OSB)KSL8((6#0;(RS>#D #T\#Y#&%7_%H!K026B-GX3QPET>*'^$D
MW"""%V3W].3@VT9^L/ #FE,,KW['7)S,R_#O$ACN<-#+4!;N%H\P8\[XS]@)
M(A;0A&/ 0K+#.)@Y<]OZS0_@O&^= #BOYV1/QD%*3O%,(4$;=C[B"]PT80C(
M!0G%MD9(?H!Y'YY=S. # C"LYEJC&9L#>(,E;0E)*H:]B!'--,S9IU5IW+%&
M4*N4M,B2-NPF\./I3!!.X&-;&NN;YS]Y.%P97A>#?A"PVC3F8S@MTJ&DX+J5
M7)>90!M-(@; A*'$LL>F#M:* /[#F35Q_:?0FH <!])G2A2%\$/$[8B1LE(_
MZ04_Q9*GW.^_\ (A9B:QA_/''QWN8N:.!7S@]'<!KMZ(;(3G3G:"][:;=LEO
M1%TU^TYM;+OU !<,+A/=W!#GB(=^',!% ?X&-^N!66$\F:"N!6P1;B'BBEB&
M1N5P_?URSC'(C +/\""\IF$,_ 7>-E:[ \XA;RS.+<=CSYT_P."(ELB8B'DK
M=FS-@/_XD@$QJKF4,@D?*^5T_<SAY#QUB0CV?<38^%Q["8!"O'A5R"90\LE0
MXO $_DW,<AT#>3Q33(A7;X _'!#&CN4RTA0RQ!?&"T 6"'%OZN/**0W6R3@(
MT"YT0; @F  HGD8*2*B! T+9&OOQ PCR!S\6N!7">YDYAH-ZCGC)"*V+P,L<
M/56*AC^#M.1_@@#!)82FH&Z."RR/N4L0*2#+YD27#TNBPE"T2$,BS-PC./W4
M"<8$4BFSIG C0_A:$2Q\- :Q!1 $*WA,,E=J1I,8A=DS^T2(T-(@,]DC1Z(G
M<4WPD,MGSFQ+U0@5%'CO W%G>)!-)H!XP*.+_ -_P+'1&RI8<$9$]!RTH:E
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MIZ%.PYK,@YL[W_D\GL/: %8^1A!(5]+R7(ZD)>@DL@15'<\!ZA5]JBPL9)[
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MV]*/49!N[ZH W"X#OC?HC$5[ M_^$%@_TE8PR?WZCSX:!?'*P54-Q-4?_M<
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MACQ$*;8(.$YX Q469-^"!<Z</_+ >O*#;ZB:@FP%]3DDK('^^\!04(%F'4]
M08T#*6)SWXC*N<<"4*03_H#+@!B,A C$7X*<Q+D>$U)<[52HCH523,^<'HX3
M'H21#D?@%/99WNO'4;:1Y(?;#[]GVT_.633SQS;J&8"];RQK*UCL^X)Y(6@L
MPOC0U!R$I=27L-DE&2H",1P5G##?($K6E 8+T KWT7P9Q4% N(JX"\8&_#3B
M<]"((D$P+H=%L!T?8'L2(\U8H)UY_IR/X%N/3<2#N/Q(;O)!:'!3#W@W'/)I
MQF'1*3P;@%)%! 0GX@YL*EZ@284JVH*LKH!-T2Q",G,6<$Y0UNK65_'0VC=V
M1A=\XJX+=M6"L/A?,IM"]F><MB(M"L7R^PL>*/'>B2D<I;"J3I95 2T!+7A,
MP/&)@_&.L/WP[B;!DJ:39Q'VP*9@X2<8$Y8S(LH)0W_$"5?)BEELR?4N&FNY
MOH%-7![.G.F'^5/IITW=;*948)?DYGX9R<TW9/ENK!<X)+QV69 V R6/>,BS
M#)0\(%_H7UE]]X! 3?EY!+M&:*J8/M!MF!RAEX'IIMUK'C*VY_I317YCD:Z9
M'D"A)FA\5K9DL@4N%O&'<JFK&3!U$;&8M6C,PIFRVD/ G&^U!S;Q UC5<9^<
M9:A.5XO\Q4]63QZJ:'!M114^ZO2AW#A)YA__4ZM9'SASQS]9/WZ&0UJUV@4B
M=:.GX%3!HBH2[.D9V$4![7/@+T#K6I+3^?V?,2>7<QG$<4H/7>943)TJFZ#@
M".\R)3+!AUS,H.+HN9\O8G3=Q2%Z-M%[%T:!@Q"O(3!E",#"_!WZEH41GSOB
M%VP2NY;+'T5& W[KA"'#?*:W8ME VP^\;*Q>SN2"#OQZPO#'IZ?4:!8PE@$_
M38&N6Q_%J#'T9":[M6%/$SYB^B<(WM"?1$\(6?S/68\S ;!O.LV'./ XA3]P
MOQ/^'?\.S[_?D(&EL1'\S G9#.ZVQ>?HBJ?4-K%A9XXI*_]E*?GQ()< )7FJ
M^(Z+RUH8XI.1'89+ !&Z+(2W)I=&.J^)@AWQJ['U$',7%5T9$QKS,9PE@KO
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MQHP3KO)]):WH!V,N-$00!C%(NR!RN%?I].!VO7'D?/ JW1[#<O8 VLUH%,1
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M8@N<)PO5&:)^VQH'\92J@TCS$M83?J2<1QH$X+N7=5F2///6J_W7>8D78Q?
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M-D_X=_$*9: YY#!#2+SFC]JRB$!@V%I_6P!<Z./S2S3(T. Z; )C!7L/;KC
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MS?O[SYEU!'+P8\#H!#E:^%SKEY4W/:FY&-E7/OFQ.Z8PQ62-TI](/YK&KA,
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M.D'2F7/V4T.Q:%L[LN31(QW/7W]815(/6Y)E6T^;%WO/I&U9)(N_*E85ZW&
M\]?[.UWW>3Z%$VPW+WNB9[C(C9[HQ[C(WOHDBFS\GKY+=2CBK@DQ=O&;4]&.
M[ZTJ]1/O-#N#E(U1\^SY+O<H88\&S<XP93\TN4<E[5&W6_@&E=QH^"E<+R_U
M&;F_EE3_'IK#YN!2-AHN\[3K7LH>LB5*R6:KTR^&_I5HXLB".'8M)BZ\"Y^.
M 5-E3JK\&4BR5(XLY:E-:_Y';ROPHB!ERNLQ;'+NQTR[T^SU4EJUI\AE^6_
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M?RA%],#Y:=#L75X43>.?^LU.JU4"E7_J-8?#R_B;\B:_&! M1YB#0#3-H*J
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MP^66?FM WH3?M^7['Q!Z8,SP>_C[96D:SZP/V=35(4Q")[ 7#]/G)9E #["
MZG'OM;BL.2\%:?GA5_%Q#%&S9(C@_G!&B-BE+$<,;#@?\.!M+X5#.4OLPJ&<
M=?+BT*'/H>BND1KB"9YP%=<0NSO[BP2<B^*:;)P!7Q56@@2V0G-<!WPTNDZL
MV0KCSS%_T'3M:\W&"-UZ,TJ6?H&]"">A'(*R2$J44)90S@O*'&.Y0#DB>+1X
M.!U(TM[NMWF]0DDJ#3AIP)VT 5=]#@T:$AX/'F$\7-0ZJQD.5U?0/)._-,NU
M7_YUIRTTAZA'BY?HA4JH[ "5.:6U.=.HCCHV[YPCADKD0B54TD/E^",>$N!3
M\0"&ZD/JFK[I37&PBJWP5SYI]I\(+6I5$VUFW+Q/YF!Y"ZN;VQQ?B#JC*N@U
ML>DSJ!(P3X5IJ/RCNA]Q2<3Q[8M$*F6I\T<3W)](!.4EZB-1SPJ2>*61[\R)
MC]_?B$$L1:=29*0N-(.7K'LC-^]+NB&DWHA.6+B/HU04D,C:&5G1;LW3P56*
M]4M41:(JY/^+[;5;;PA%^-"VK%2"93M8(MR01P20/9RL)PJ*K-I;U!0[B<OW
M3ZC4=) HR[R9\Y$C*VGM$DV9M$@_;@1MK%>B9@_4Q#0\.F[H1"]:X@>GT_7P
M0_^$B P9L"L#=BL6L-O;/1&%PSDOKAGX7#.08>Z2:RK*-3M631)PSHMK+GVN
MN91GC>2:BG+-KBE5O1Q3JD*U>?%(JU\8<G]WI;>?X_$=)BGFVZ01$LFQ JR@
M_V0%E]1D-+,(VB7U%B_9<>INHR9%'>#X2<0N16CLA_#<TG B"GJ?AM#(SU+>
M)*F,C*Y>9'1-02,CHR54TD)%1D9+J*2#BHR,KFYD=/4A)2.C963TZ:%>1D;7
M,S*ZWLB2D='5C(RN/JID9'1E(J-K!A89&2U!D6'GFM%5O3&4:5EQ00P)N4C(
MR6#\^@?CUQYE,AB_0L'X=4>3#,:7J-D=-3(8O]Q@_.KAI^?')4$<9BVC-GJ[
M!\+D%G/:]R.U^3#15V7CYSLOR&M*+(NH3]0(,%P2,  \6^>)S$ M,ZW5L[M<
MFI;#GZ4&P5@Q%%53#&I%W+S<*]:?!*L4+I>6^:;H]B-]F/+,$YF8,T/[FXZB
M.,JKOGIX(Q9XNR94UWO$E3Y,;XTW4W\+!#9]?[1,U9TX#Q:_OV*3&3W>_B'L
MC;@^8\<1CI9PV^?M7Y:W*MNA(+IVE .(+-<:A2VQNB#"LAPSL6M<-8+Z=HV?
MKZ$L8TBUS,6SHA-$&?V>0OF;>45\7/X/M3N_S8G_+7V53=]^:_,JJT0*J:H+
MJ6QW6DH?*7T2I4\*2>"9#,\38BAT7MR8-N"0I!]#/><;=^/8E'+D.%@P<OO%
M(M.!0$J$XY((DJ=KSM.2B79GHO8@^&<<$QU[;L#Z$LN#1WNP,SS\GV0-CXMP
MJF(M78(7E<J-@\[N=<^-PS54Q7$]\"\^!G7-41[L?A<PR#%'>9.DW\<6P=!)
M& 3/A&LR08G8;</^<@7J*_G!JP)079DJ  ;]<\*N911+7XU4<^F%G6)^KVV[
MT!IH;-J._40FNF+;VI2HX"=@80>8:^N,;)LX-;^A6J<@/WBBZ)BE2K3#EG@S
MVF]C2CDRJ\PY-97O>Y&T(/D>Z-OF2:*1.W-MAW[=Y5)(MG7+3FJ%2"TLJ36"
M9RFN9!NY^K61JYO $$<N%,^1(J,0D;%)<BDTI-"H@=#P9$(HZ>=AZ9<:V2X5
MGL ;B=_>*^_:PET< 7]O<ELL@>K-;][F^2L-[:)DGL*81S,D\]2?>8*[*)DG
M7^;YICDLV$;5WC355711"D.\\UJSR,0QK6-0.4^&JR)WE0\=O[>2U_+EM77;
MK].G]L<$_:R3^;^)8KW07^B?75U?P==UOTL]+9:+MKI2;K'DO!2<%P ,U)%^
MHO2S-(A #^1Y[<Z$_=8I,2$K79>"D,?(C"FW6C)C)#..3=PS5D,5BHE=K:Z(
M,9DO%(L578.P;9N'<?/0KCO-$('W$3_W.'OLVHZY@!3RM6?X;^^5_YB6>(CE
M)GZ;6X1X'Z4.X*LK&V\COG^\)NY"ECR6L*&!1-SDG<UR/IL@X:P?!94JAC%*
MN5*T7)'RXH3EA63; ]E65I>O6'7YFH)&5I>74$D+%5E=7D(E'51D=?GJ5I>O
M/J1D=?G$G'Y97?XH42^KR]>SNGR]D26KRU>SNGSU475'%#NR;-"59E$.G<V5
MA2#N9V6BZ90*]<93W(*YVK=MV1)&V<((',AT&LX*;C$=J*'VEZLA]P:<T/CV
MN:FKMPNH#((CU-SRR!F&.WIQM^V +VD3MD*R1B1KR/X=E>G?43.PR/X=$A0(
MBA1')&0CN0ZQO.]JCI==SJ28M4LT[8VFSZYE:(YK$?K]9^T=_JJYOK43H.*7
M+S&U-Z;NE%>XWS6ME??MPW2J38CW3_K#9W/J_%"LFOLL4H$-#\$]B"(A& G!
M(\O_E!F1AZ+@&!(996K?7BC 0@17U-Y4036D1$67,2M/,'*=N6E!&>P70R56
M() ?I+5]M;IY)]9$H[:J1<6PCZ?-CUOM>H,K!RH)VS^65A*P90*V(P&;&K =
M"=CR =N5@$T-V)1UPB1@\P1L3P(V-6!3UJB2@,T3L'T)V-2 35DX5@(V3\ .
M)&!3 W8@ 9L$6-FCO/8]RFN/,MFCO$(]RNN.)MFC7*)F=]3('N7E]BBO/GYB
M6K8]/SY=C9ZN1^&\I+H")[&M6?12)5QP.CT/+C5M:3_8O:7](,>.<0._)=B@
MKBW!!KNW!!ODV!(,W]WI!O\<6X3JGR*LGI=1,#33"G_!TQ2@H,O#-.(W]YI*
M%=?/FJ$8$TW116KPW=VXWN)P<ZE>"88X(FT3A[L,'T=O/HEM5"]+,@.R=L:\
M_Y,CP?SW/Q1+4UYU\J3P;B!WIJ&:QBTDV[\JQI\/TRF!CN;TZ[O;JX<GR2K5
M995=IK*^[X&\H30 D%R+NEHKK'[7\?#?N7EE3BJJ1NG8:O'>U3%FS,WXX7YD
MJ+=/=_460XD&S/HBBV(US:"[3W_O;X-'!/Y-)EM,.;)SUKG\?DVH7 '!PJKQ
M166DOBRG%OWYH[+R4T5BH''O&JJVG"O60JDW-+:3152]B2!.E@=$$D8WJ%T"
M1CF.\L!HNPTM,5O#[[Q3J/W5=.@Q;"I809J?S\;LB4R(]@:'J'VUNB,S1;_!
MA= 3/E"LR$/S[X]/3^9*T9W5L_OJ*V#87M2K+(-//LZ5I_L1#EIO,&=)/PZ]
M:"IF"?S-#>%#;VQ+\:@7R*P]ZL4%Y4+#LEW<O<T>O#<-XFA_'T$YS5KB/VIK
M1*G8N TZ4DX(;$H"F.N&3I5HG]96=A"X:K>Y^+]C5R0KKK^);<AEBP$[%$%2
M?SO%\ZO2^AM'9GZH[[8DZB7JJXCZ?/Q)]-WU<;V&2!+RHN9!$ADV6\^PV6JA
M1(:]EAOV6BDTR+#54]QU&79:>-AI0?O?JYC)X /Q>4(,A:Z)=T(Q+6>JZ#J0
MH][H.W'C8B]&#6+!:QFS@8@26+.7HUW3JZ==T\M56HE^)2DD26)3D[%K6<28
MK*";!AG-+$+\2_2Z2I9RF#2Y/0J.GT3L4I@V?X1*R[ONEG<%4"(M[\I8WN6C
M05K>I[CKTO(NT_+.<__[&.'0K9MZSZ>='TED#FOI.:SKVYTG!\1OMZ<!!-J$
ML1([-9>"B3N_==4G!0*HOG3\[+ZYRN/;9/0R"T< ]Q+_6SIRHI,4 V3Z\.N$
M_^L3)5C]?;KU<Q?U<_3Q]NOIX^WGJA<SNVB'>Y(K3=?I9V!=N':@G:&N>VE4
M-5<9#B6&;UM%4:44IJHI@K*]*7TF?VF6:[_\ZTY;:+7OE%XN2G.::=I+V.BM
ME*Q5&FO-Z8Z;,XV^8FS>.9*U:LQ:D5LI6:LLUGIYOB;P"?HFIE^(HCO0SOV+
MNU ,4;-$LEMMV2W]]DH6C&;!%^-5&A\1S!!-%XFB75 D#9#J(K5L/4F:(%5C
M+VF$'!%[23.D8NPE#9$C9SEIBDAE3RI0=8#6J2HZ4GG(&UKRD)<'Y^X0O%)T
M2C[R/"?$N3,G6*I.E#>??2/6XDY37J'^MN:IIG=$L2/+T%YIUH)NQ%Q9/!&;
M*-9D'JX07E?<Q=&(8RB64EDJC7%$%Z%Q6TA_I.B]-=Z([81 ."86((#N$K$?
MII2[35NLMJ[XVUQE(/TC?KDGM.>FM30M2@*(U7LF$]<*<.%1[GK2@D]GWU^>
M?S/?B&5@8.:,4#6 V*<"@;1K/U(TG)P2(A6 3&'P_=$RZ=C."OI0.U3EAU0[
MS"*Y\DTJ?/O<U-7;Q=*BW 9?UURDY RC7::28@<"S7;BM^)(H9T&H%>N1A=N
MS.J-R9V $%[R">_]V,3$D E8H[<&_<7,(G;-I=-.2$@BP GCXK-K&9KC6@2=
M8^_PURFA(G[Y)XR).^45S$736GG?G@ DF'<N;NFG# =0IM33@T+4LD\=!L=E
MWDB;XF!4/$RGVH2<DG#P&CI%K?R$D?!L3IT?BD4")39." VQJS]21,A2C'4O
MQ5@!E,A2C)4IQ5@^&F0IQE/<=5F*L<Q2C'GN_X!U.Z];%9Y!?DW:X=W#LT[W
M^]@B5/J+NS(>16YHIA7^0D304:@\3"-^<Z^I]-C@(8V*+B(0:]M!U9.,&TOU
M(LGCB)3E36,<O467SRU4+X&-.:[RPRQ4F9.8E9C-&K.YR=E:%H ;Y'H:RP)P
MAZ0(U*, 7&T1E&URRV\6(<;8,FU;A+[2;9=0K6WMG(3]E$PFJRQ*_CJ6#%W)
M6J>=]WN$K%65#&7)6C+O^?C9K=(9VK5@05EEL>)5%FN,(FGE5QRNTLZ7C"8M
M_:/F,6GK5XZ]I+5_1.PE[?V*L9>T^(^<Y:3-+ZTJ::G4"F2_/SX]F2O*J*MG
M]]6+0DK5N%2"T -A-!6SE-;9=3.5J#\(]:?7KO?$^66W4>O6_?>D6/>SHEE_
M*+I+KE;>GU\HMT"]+#KT&]%9)1;QW:VQ=!T;O^A('CX1'DX'DD#AFGBT2'Z6
M+FWI)BX/6J?JSI4NTKRA)5V9TCVX.P1ETP;9M*&^Z&554KXI[R/7F9N6R".]
MIA_:CC9!QK=JCK[H-?K*?N1B3VN_L;("%=O G/KOKJ79JC:I_]7$MIW?LNRC
MQ8!LU%*E1BUE[;ELU%)N:XZ2]ETV:JEDHY8BT'!RAH=4^C.%P:E6,I:-6NH"
M;2#+5V7!D'BS6.KFBA"L OCHTGVAY( GZHW&X!HY K>L]!0VF]IZ,-&WX]S@
MB-4=ZZ;*5DN5;+54E;V7K9:JU6JI*KB0K9:JTVJI*IB0K98JT6JI,G"0K98D
M#([202&] @>C0K9:DO)!MEJJ5JNE(A#Q1*@UI4T<HHX5&T+7X#] H3=%!\$8
M_2DW175H/F0I^F=1@[S>0-F?%B(1)HXB$CSKX.%Y%G[0Y8E#)X8>1PJ<YSD5
ML5>@ET,7&TI,C(G$3VT>K/0W45\,E5CHTW]8PO<@P.VKU<T[L2::31XIP<D3
M7$JQZXZ-CUOM>H,J!RJ)"Y-86DG '0*XFJ?4%0JXXTXH*PAP70FXU(#K2L =
M#KB>!%QJP/4DX X'7%\"+C7@^A)PAP-N( &7&G"#XP:<;$->\S;D%4");$->
MF3;DY:-!MB$_Q5V7;<C+;$->Q/Y_4][9=<]8L:S5U+1^*);*]YZE1-1[SV/7
M%]SOX$*/;)\OSEKM&O;\Y=,^@"3B$_B_])__!U!+ P04    " "N@%M*05UJ
M5W,9   Y* $ $0   &)C<G@M,C Q-C$R,S$N>'-D[5U;<^.XL7Y/U?D//'K)
MY(%CRQ[/[DS-;$J^[3K''CN^;)*G%$1"$C,4R 5)V\JO/]T P9M BI(@BQ[K
MR3)QZT9_:#0:#>#+7Y^GOO5(>>0%[&NO_WZ_9U'F!*['QE][#W?VX.[DXJ)G
M13%A+O$#1K_V6-#[ZR__\Z<O_VO;OU)&.8FI:PUGUOTD82[EI\&46O\\OKVT
M;*M_\/FP/[BR'NY/K(/]_D_V_H%]<&3;OWQYCMS/D3.A4V(!!2SZ#!^^]B9Q
M''[>VWMZ>GK_=/@^X..]@_W]_MX_KR[O1-Y>FGGH\.=2[J$7.'P6Q>^=8 IE
M^A_[!X=]E=L)$A;S65;@><C]]Q%UWH^#Q[TT$0L=VOM]NU LX1SZHJY<FHH%
M/Y0+NM33EX$$37;Z[$ST^3%%<%,NX+%'&L7Z(C)-PXWOL>^E+A/%TBX^W,/D
M(8FHRLZ(YT3Z)D02MM OM\ "QI*IO@TWYGOQ+*1[D,F&7)1[3E9N<:%R@<AS
M])1!@H:N* YY37Y(T11((GM,2)B5&9%H* A*$S0B@10>^#32EA$I^D+(GKZ0
M2-$40@;<BO!3*1[MR<1B5J]!YA[#8>UD,G^>PT@Z"/N?/GW:$ZD]B\0Q]X9)
M3,\#/CVE(Y+X0$W"_DB([XT\ZH("\>F4LKB4H9 <$SZF\3<RI5%('-IB'(.V
ML2RA,KQI&/#88G.%F_M;:IK+P"&QT'/%SM-*=X_Z<9359>=UO0<J>GLM"%HP
M9)HHFB\E?]IY!:W):))Z#0WS1? _6Y6S\9/=/UBY,ZJCM$U7J#+X8Y5N:![V
MK2A0A<2OM6G0Z.DV5!2*I;_MO(K50*%7S6VP42SY319$<'Q"</0_MJ:F4;VN
M/G+QR]H#MSICMY&1*H,_[+SP<@3,J?26@U450$$<K<:SUK)IPWBI8/;?*EVP
MP Q8#IQFD#D_'Z\.35'7VMC46:ZMQ%0HI_Y96XM@[^[A9+G'Z!A7!.VDY'->
M*K6*E)I-YC8]DA42OQH$0Q@+8E&1^*:^AJ''1D'Z"3ZBI?196=2W=&0)V^DS
MX0[RVFQA[84\""F//4!;P2@7%4PX'7WMX>+'5K;1OWTR? _FF\HRUT!Y)A=]
M#46H?YF3I\HB++_V(NAHGZ9<OS@[#O&790>*.(DOI-)1IEPZ6I8I*.(QK\,\
MA9PNRQ,4B6!=L)*DL()[R&!Y+N2!.L02PW8#)Q$_"'-M^.O%,QO'(I^*5GH6
MEGNXO5B\R) DMJ\YHT]1F$M,+J?:++9_V=_?MVSK-&VK^'/ 7.M,-&M=Y,U^
MV:NT-4=&$E'WFOTB?E=&1EHXS=%4L(R^]N6J$M:73+\JD;:3M!.P*/ ]5\P2
M0^*+I4@TH32.[#7$W%BM*1GW0;!WJDGX?5)HU#J6C5IWHM&=@'62" F8DO&$
MQAYP'&U(W)5&3 G_H+WPK7<W)1K^LD.#$%3V.;*#$21-H>$)99'W2&T_B(P!
M8F$[IC!QV(2)+"&R@A$D%:BP+H&*'2ATPB+1Q![YP=.FP)#7;PH$'Y8  ;1N
MG6/K.^%KA!/%@?-]$O@NY9%-_TC05D,.'"_>#!J:&C0%CZ/V\+@KD&.="7*L
M=Z>2GMT<LJ0 -V1LK-R^*3Q]-(2GG9&2"9@%,;7[=N2-F0>=0W"UZ B/FL?&
M=@B]Z\!R6JP@ 0L.%.&"# $![D7?UP#7^FV; M9/N&SU(@<LI(13^.<;D&:)
M-4].G#7(B+-N4N(L( YA6" .T7<+Q+UQ3!W8J3=F)MT/, 1#3%T7+[7UFL+"
MSUHLX!+H)FU8"/U,-?S&Y7QH\V!&?!#'-&"@3_^[KM>JJ593,OZDE3$N:6YE
ML]95H=DW+N$/-E3O!=QV.'5A<A\1Q_-A/EU7QK7U&I)R?U\K9;%F$0U;)Z)A
MZSQM^(W+^<CV*?2<'0Q];YQ.M*AB ["3.,[ ./-1AM/>NJ)?IBE3:.AKT8!+
ME$NDQ;K.:1$*_AIIP;D]I^6- ^2CSN9?%PKZ2DT)_4 K=+F.R%O]<[I">./R
M_<F.)K NPKYSA>N0LLC(;%Y?L2DY'VKEC&;]';9L'V/3PA&IFG[CLO[9]AA(
M@MHQ>5Y?GU=J,R75#UJIHH%^(9JS[K&Y-R[)3S:=AGXPHV!1[??M[W;HD[5'
MK+Y24W(]TLH5C?*SM%4+6K7>??^+=0/MOG$!]_=!9_H^&0;H87BD!4L)6R;<
MF8A/+GVD?A JOUW,B1.O/;+7:]P48#[J_3/[P@=8H*Y@N-VFU(E/ISEUPJ(3
MU+UU6/7M/Q+"8\K]F0TD$C!QB5\,$+$31A)8(&$DW)HH6J8M4Z"I<>KA.N#O
MBACK7!%3#%&QWCTH:MZ\:_@ QKE#*ZY9'C#X[4AW^]K@:-&$*4S\7 Y5DHC
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M900IN14F-,E=DT[]T'%=H;B(7\"8W*2,*J.H3<X.#"CW$?L))A?/H3>B]'G
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M-C%T"=M?E-P /2R&":9JK$?Y=G'&0;N\'0N'REGE0&*,>XL.E3Y?^3ZZN)"
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MD<=SCT?Q[V DX-Z^:%1<*RF>7,475Y?LPY4:Z$!,Q,KLI3>8"W:B"Y9R*!P
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M:.J%)>IXL3[YLH==@J[;*8%__Q]02P,$%     @ KH!;2NC!>JH$$   1.P
M !4   !B8W)X+3(P,38Q,C,Q7V-A;"YX;6SM74MSVS@2OF_5_@>MY\PX<N:5
M5#)3BAUG7.7$+MO9F3U-021D84,!6H"TK?GUVR"IIPD0?(AH9?=B2Q0 ]M<
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MJ5CK>C<K#E]-KI=\O^"?@85WCS1^H)\$3Z:FY:>3-I&S(E."V8/)VFS5UB%
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M9&KYC[Z(JY@!966P)=VLOU6 :=8*7KB?06OK!/'SAOH'?4K4=,0C_4^'TCX
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M 0!&*<,I0WC=&@#Y8L^:3A?[0.[86)AI0U&7C:+7V34XQ>VBU@D&&.FF:>\
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M6K2T=D ^$[GY:V.R=(J&)NX(E><2-#8:!;'N[]A['G\DX8.COSLB4;K!&EH
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M1,##W?W9Y/YB<EZCDY A;VJ"F"@JUQ@E>\F(=7ZNA"[E7@9(Y!&R[5,E;F6
MA/.'FYMX&4L?%1&U,?#Y3Q3C])R2+#LG=%7N'T'HC6IS T1]+M(H7BT072(Q
M*<)&!@BX114+7J=9'N=%CJ>S29)@.E_SC9O.,/?+%/R*P(PW9,\!]1G( ) O
MDS,Q<4=_-/'!APN\0K1\6'DZ^PVC)%\PJ+\52Y0^8/H<A[+ITN]M@N05$R;2
MO Z4EQ G:6=??=Q/EF=3=,NX;/>;1_93AD+Q4=MSE#<"U[U1YGQ?K-FC7MTL
MV&$$%S +IM11OO77+:])R)HZR&' ,TPICNZ9K)(6^_-[6)KHT"*MW!$:**E]
M4Z?KR0%S?UR<B&?D'J_J,G23.1,X^2P?;GOI8FGW/V&([IER$P;#+MP]E6YO
M!VUTJT=2U^NY(K0TS&1GZY9CU.C8HYJ:UA/+Z-A^:H[&=K^QO/_4^T^]_W0<
MF3_LB]/9W@DCR_J1M?6N7]<8I0HHZ2V$0H0LYTABR)P$$;F&FD[Z:,$0L9N5
MK1OBX@U*IJ.-$1E @0'GG3>[WJ2GKP!DR WLO08AV<ID"E*[@ 5N#W6]68FB
M#QODKAA*[H# SQ;67#>4PFYREHT)4(EQ ;?LPUR7!B(11IN\U^XS!'?>ZVN/
M1"E8".0Y;URE[G7 &RIU;^%\4X[&4D1NJ"JY!>0MP5]V5]K@2:4;%@#NW-(R
M?1#ER"J0Q]9PQB$(-=AMR&?R4&AP\NA AHSF,$R[9[9/>_)I3S[MZ;33GCJ'
M@B)[F4Y9/$_Y^U6(_8S"D$OW<3H/5B2)PQAGVQ\V!+;G,^F.:"-KJ1M-_7*3
MPI!Q873YPNO%X^R.?V$M"A[6Z&$B!8:4;P57ZLMT]AG1/W!^'V=_*!"IV]<$
MN043W])P_1N.YCM%5(56G8X&"+W 64CC534S_*4 E*X5R-3H9B(!B3#.+U>1
MIM57%$A4[F2 P&MN7\!97N^#4O:K)/BK.$5I6%*2Y2H[JN=0#K(NMF?377TB
MM803MW>P#^(,97$VG1V0UL)FW3H[R)Q &5='^'\N_RSB9Y1P94P-FU9?*-!V
MS[K*R-="K#>DB^R8Y8KB!==AGG%5[TJ'A76[VP=XB6C*ME;&E.;RX1HU7(J]
M[,/9EB13P]'6W 6 G.D&,5/P)EF&\^R*R[WXAK%/)-U>ROU<0'IF6YE0Q3W3
MUMP-@"QOES25V]N'<,,]BVK4RYHZJ-3VFI 6&:BEM0/R:4PH.R5C$MWC,$%9
M5NJ>I=DB^D]1<<F>U"_"U7$8%X#)"M-\S1\(S]E]SN_RE?K6T>WN(CDFQ$PZ
M80>MHJC7W@%*AD^M&TGO&8V>+F"5?ATVXV1>F8M4ETBQWXBS=$X  H!$H^W;
MCONO/U9Q764L#S>(,9F+'U]R=:C'2#Z_RN=7 <JO^I+AZ>PRR^,EHT<TP<V-
M?$;5*!(EO%?9>Y7'Y%56T@+!>93;J-Z/N5<T]8/#J$ XZ>H* \>L:F#[>#O
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M?_>:I#M>ND<YVX3KZ3.FO+P]M\17%6=*[B/)<U^-RU XQ7"V N5ZYJJ\ R^
M1.TA '"'J$*P[F9'G,5TR?A\@9;W.,/L&XO1!>V9"6/N=^S!B_%0?],('/LJ
MY0SM&RW5WPL"R< F<ZKZL3&\P ^5)XC ,7!K 8'](+2V@L\@6;9_,85^C HO
MQD#Y[71PW*J2B;</5.>%79#,:RY3L1\3P_/W*V>RCX2314GU^Z8A]6)G8V'F
MWL4'^K$U/*=OVSL]X!BYO=K+1G][7%",M]!&P[4]B][T8E#A,M:_9#(U?LDO
MDY*G_OYMAN?\!^V90$G2PJ\W1P7QFGP0#:7<P!GCY)#V;;2T,J"5!T\5K3Q)
MH\\Q.X-SDN*ZT<[*U@FWO2@;M:6\$3Z@!\X4J :HP]LNBD@-V5&,(>U5IUD1
MLR&EV\PV_8SR@L;Y>F/+_BV>+_ZG0*5!L#2*\],HPR%O%!\6ME4$;$AY,P-X
M\HPIFN.E"NZ'?K@-R?MF%WI5 WY8$)H_8KKDWK$>.]B0]&<&Y U)Y_DK3!O8
M=;1V)XB& L$,'L>:+X2HR@\6HQ<43^/!'H10G1(H,M7>VJN_2*8*$IH U5Q&
MW;);T1B:0\]U%)4D=T0'16*JRRG4@OP=6E>G[4OG4]:4,\+8NDTB)BKD<<:$
MO<8'[2W;KHWANN;QIFS9>H&"(MML%VO) S;^*J^)Z:Q.E4[G90$$IV:MX6_]
MAO?I5#%"D6PJX8W[ZK<K-WU*XGFYG+<X9]IT=:=WLP] DVO.T2K.45("SJX*
MGG53RZ?U.9I==-0M/T"35W:^ZQO&I=-T]^]N^*")*CL\G]B _?%!$UXF:1Y'
M<5)P1#MU^/(E3(JHJB=3I4[6!^\EHBG;O!F3O1\6B&)V+!===RTH2>>VX-T/
MC-/=3MT/T 2=(_<06SW^"S3'[[LAA"+R-%E\K@CEP9TSDL1D9R<0+N7?WAW@
M9!_ZH_I+^0=.Z#V>?</_^^7^>@OJZ]>OWSW%)*3K+/^.::7E8RKO/_SP_ET)
M+=O0':0DQ\&'8%5?[P%*HP!O[O8@PCF*DRS@+HH";3T,U>,M'%ZP&;=\D*7G
ML!7X+.;!T1O\#?#KUJ\6<5B\%6'L=[QX6?2MA2=M+O"*XC"N(E@P#Q;G/)Y&
M^X+FAKJ#%VYTNE; 1ODFU0E \,]J^6>U9#0K/ZLU:/S &WC2"60RWYM*;O-1
M$LXT2%UIP;9P^D- J]"-8$E2O*&IIVBJ-Z@UP;0+66IBZ?&,5-FYI6$K7/.X
M:2RHW%%?3\KM=:Y5 5D;(S'['Z;/AQ>EK(F!C\L+V^_3H%("OQ<IM4>CLF-,
M9[O*>?=<9Z$X>B1W),N;:-/L:H#8G=[./E?'J52?O^;9,CC+IK,K%-,R=N5]
M$\W=1C!!^@+=?Y[<LBW8_'RTO)$) DJ[';Y+4%51>#JK*MN71B\<E1]MI$FC
MGP$R-[Q3YT"].@WN>+@D8[+&N=/J:(30_= ^U?B_6]RXE7H/9@Y0QX#&!C2]
M0B/[0:D^]WGOAA-ONM;&!@@J@Y%F3#9D?_I!3(JDF0$B]LI'O7(;[E,@:M-5
MD<UP^-V</+\+Z^W(A9./VW]Q(C_N*;&;W_][DB3U!HX/J]+4U*HT'171IDPU
M'8G_Q]V_1,3N_<F^/:,N:)^5]\P-8=Q95O*KG:B[RM#9V7KOY1TNC>S*3ATF
M0QU80X;XA/V)VEQX$J!-3>P36K[?L,T+EI K;NB:Z(UF<,\$HU()CG9RI1(8
ME0%<@SPN72>%)'K@=H0 W%O-52H&'(%1?9ATQ$ @K0Q3-+XB&FVJ-/"M?*AR
MZG5R"484W"$$(H\&<0-"7&U""*.MEH@;(*)0(B$,>>R131!;X\G9>OOC;S&F
MB(8+)CX]XT2R+GJ='8*[3E=%GI44?6A4YS1Z.(3Q&:.LH%6AJ^,)EY[2G<9X
M U#=WU!*U8,.(:I7'+()15Z5Y0"#2F4=M\1+N:RUQLY8 ;C?$1MMZP[%A_9*
M61.7A*ZYP6'SB&%9!SY\'2 NI+^UIWU8>U83+LJ_MIQ(>4JCYXG!<K]K)(6\
M#N"TEORR2W:.LWH;;"_IBSCCP1#L\A9"4.IE'\XF!W095V&\D@M0UM0]X=(-
M(6\\2N+=;^!-K@T/"-_+JBT]HE5@.'=^ATQ??%4"X !=QU%&'#1[ A#<,Y^/
M^_5QOS[N5Q%C_^JC\#$V.A^)CB,?(JI!?,>DAP($<9(TS;K$B)41XD28+(P]
M!K1"_ST1M1)YD2'BD^I;1$^Y&6TVRG#!,Y:77.45"O6SF&C$;X/,U@%PL4%X
MN,?@3FDWSX#C^):3B^A%T(+D\WZ'>"\6A?C:FCSB#AR#M@H/1"VS B1K]I.?
M>K$FO)>K3OL)R]; ?Y ,ZCBC%]X;55WBE\!Q;3>=NVD6VF*>0#*U)6-%+\Z'
M]ZR5.+4 #'\K&1J)+.\%)+]VL:OV8CYX3U6]@:<!-5/C07(JG&<!P2UOASA,
M1:SPWN3R+R""W)V.7T#TY7G,JY_^$:,6W'WK+=BUIIB!+L_PMZMZFT$DK=-C
M5Z,R TB_Y(I=T=U@:;!N2=%V91_C#Q,<)QDH H)6LE\[ZT 1)ZBR_7U*1JG*
M!- *^&N%PZN"A"+Y'"MG[5G9JABA2#E&HK=508.2;SK4 5/%"47J.69@(V]/
M@'N@R/#;$V >*NI>/7&'U$YEU(]!5DJ>05@^]AK,4!CS)R1[UD;5'=9:==1N
MA/6JC_I:!N815DE]:%]A+"PKU*6K@1)RK[]8O^ES$S^1QG)V[:U-%#"-HW.T
MJB/34/+ 5,"8"672JJJJ?4Q4_BOYJ7HK^:KF)DD!P-;6#@J+O:)&5EY,V- U
MT=(D*EG3T1'N/O'K]:8_0UF</:PH1M$T_1W1F&L4\E))>MU= ^0O#"M!V6_H
M(%>]X<GVPZ1TX:ONK@A5.'/:FL, L&_9FM3O]EZFHEH4'4:  ?.&2T%47OE
ML=O) ')_(-^0-")IR4!/*/UC.IMA_E@O8Z2;Z[/IO;2R@U;?$>=+GP $]XSF
M4[Y/(N5[&&+WA3?)%(N:N258NB/%#4=%M,[YX3[W\BU4!9!(M41'?86(3;C/
MB?K&@HBK51\A765ANV@-QONIJ6C@(OZ45X=T,BJ"C $TR;T0(G1-)CB,C7^E
M]P+1M#>#Y-;N]^.)I>W*A69PG"FYUTDOTP-(+NTFZ?CL71"+Y]^L?5M!\>V^
MD#%&NZOZX4<6SM[/93BR2'=5I^(8X]T[Q;&,-.2]26U2<N[9#OWZ,4@PRG!
MGI)X7F9Y90%*HX#P0C@!OWKB=%XE%?>,!C/P)6L!8L9H[14S=A;3)?O. BWO
M<8899RS:0XM4^QB(>;KA4[2M%3;=3M4MYH&.C>\8:/<S029)Y_P O6%7!)^(
M6/8T<VMC^\;^,Y2PF<(/"XSS&_[=@YS- Y-_6W,8 *1>B_8.HP;AWH5;[L )
MI3P+HI0OUM*74]N:PP#0\A1'6X=1@P#"4@N21-?+%27/554<>=!)>P_[,*8K
M3!&_W$OJLJLB+RBN5:E-DLU%(?+":_9V#N^>$73YLL)IAH]?K-?J8Q_*'26,
ML'Q]QXY9GHMX^6<1KTK-L.TA:(V>@&!]HB331O2J$R PK4>=1L\3@^7^*/?A
M=C[<SH?;^1=61AA+U:K\$GTM$R).'1&&]+A5(6)OU4:)OMHWVJ@K;5D67)B
M#D\>KJR*]@C2X3S<_CVQ>"PUTQ,XIE8X=T@G@SU(;C9S(I]8M)::'1X<YRI(
M143/5P*29<T(BCY\"\1B^O"MMQF^I6&9'ED\5Q?#[LC"NCJ& HPTGJN39\AV
M+-!/09:3\ ^N56&:!;Q 5>\:4%IC6HOOZ4!5KTB>316P^9QBQN&X#'-GW'!'
MX["QYI-2AQ';U4\ @G<->-> C&;O&AB?.=5K0%X#&H,&I"LCV)8D?PZR!:+X
MB<FZ4<!:<Z6L%.Q[2I/:XUJ3*#M2UDNJG!3S(LN/WY+<%R1%;8Q4"0W+(=E?
M/HH)$+<R0,(E6U>RQKC.PG_@2W#&E^!\;P5N25D!&T<37OT[V_\3?QJ#FPS"
MG!?B/=M[!.1?&-$K4C1"LO=5\%/TR+[=J,!8_"S\2?I*'$S1[J,#3="3$5IO
MV1'(Z56=H6&^:G**N&7AKJ#A@E'*#7?BLU&QBP'BKE.>71<_MQ D:6: "+92
M&\07,66K0J@D%:>]M0&27KWZ099+DI9K47):=H;G<9HRB:J)/+V>ADE]0 FB
MZT>RX9D] FJIL(UD]1$,D-Y\M.UY@<_6O$FYM6MK:+F9:TIN"[[JC.9R;AF*
M#5]45?6;H-KYHKVIJ9KL4WH5TRS_O7K9H\HEG<QR3#^QCOD%$TU[S$KWCYF:
MD*-#OGWEJM/_2WT7R"OJ#_4-$_#Y#IRNRI3321K=\P?/8GY_55M37%)>HY\!
M,CDO?/BQGH%+%"[X9?J%71W)59$DZ]_+"1)3VZ&[(:)__+X7T9K=#1']9<6.
MYB+DCU#-BH3S;(+Y2K,#JK+BA!?\Q7*RJ@H_U \;2NY68X/:-\).DO)KC+$;
M#[/: 2PPSNIU=@".'S 7\MJIC6T<DBKUG@A:C81<]RZ>DJ"6?+;&-O9)[:+.
M/I(<)8<:VRUAJEE^_ [M >S!O^=P"G>7N32%MK6]:PA?4TRS1;SBZN3EP_3N
MGSB>+_AJ/&/*Y*:MRLLMUEMIN_YEZ[J;^X+]::KU#.GJ-K9Q0&H5I2(GM:F-
M@\1,3&>$+JMH3;[24J);6CL@G_'P+5I*<Y<;FK@C5)[KVMAH%,2ZO_?ON28J
MX8.COSLB4;K!&EH )]/]POL(*U 15ET-9N7_O3*8B5Y"&^(3(YJHRS+T<E<6
M,)OR$FN/"Y36QJS2QIA=IQ7$ _%N:X#<OEYM>I:'HF]$2]1F$S<]Y:K?&]$4
MOL8R*?(%H1+5=K#OC'?*GE&<E,_4D\KK,/#,B3XWH@FLSZ?+%TS#.,/;(ZJT
M@5RG.8W3+ X'.30[?'I\$_OZX)>59QKP2V.?-NOW^9NYM6N@E5>*IXYMXV#X
MKZ9%GN4HC9CL6)U\ \VS[N=/<8(/N&MS*C;E_L B"N!B9%)MJ'2"I)&2Q6?(
M3_F)T_P4$$V_/20$-\>$U&KX/=]3F3#VQ,JW1C1UK\5$+FZ_E@VE)I-!/SCJ
M23PXVN\QWV&,8\X) XM"GH3 RW98F%U=2L8W[=H7K>W5,$_@6!=I(^QOA?IA
MIUS\.9\H[!.%.R4*#T4L"?^XSK("1Q<%W3H3*D.8,$-!O!*]1K,/_S'.$SR=
M7;.S\#F.V&$G83-I6P"D_S/.%_<XJ1ZL6<2K1W*9YD?/@K:!4AOEC<!UKYG4
M\KZ$+1M:."-3_AQ]4YL1D*K#!+Z:@PV,Q_$OY."//4H16D72',Y-&AJ,96V:
MXY&)3=,;Q&F1"P_$T(4,$7G3_424;@6(:!I#,,GQW]WC,5EG7!AW"JZ"K6#^
MB6J*,\@"/WI,!Z$(>/^5TLJ.'VV%<TGV#KBM->C%O3<GBGDM('>J$^GGQ&JG
M"Q5:<#NB678A?=.<07*VCA@WDAMHZ .M8VH^N'EJ9_-.B?'PJG);NN"44L_
MS4X[%QBL*6"WG+EI@:XY/Q_<]26R+6W65%X]$.0MI6M/&\E-U;92;646[=;-
M-[B=%'QNX+955PL>T2Q]!G(##F7G[+51?P3'UX(,7G"\W.1,V8,AR?P'R9VJ
MCJ.17 MMJR,N(:$(Y2=P&\?7:#=[8O@:[<,^_=.EYA@XU4]Q]88/;+>K%IJ=
MF4&R_.T*]NXG1#4GTJY@:.9%AV'KDMJ]\0W.R/ 5:Q6GYF<@4P,F54-QWGZ!
M.&^NLH<5Y^S7$YLS_6( JO*>1?^W[5TI34]3G1]H K&=_!K5V0$I0UO/N%>=
MK9.1JP=(E%>=0Y"B., 40]7YA"+"'T4O#5N86'5Z0,GSME_T49TD*)*]BX>A
M5.<(BA3OYGTQU5F"(K<[>:E.U6X)4F0?KN">ZK2 E-0'KZ:G.CM0)/7>;VFI
M H8B;'=^[TP5*$B)>/C2I:K3 T7 M?ZRFNH$01%QC19!4 4/171M3MXP^#Z'
MZH1 D5-[GR;#UI[>3:>=-\%_">*4-<)!CEYPUO,A<+7!*J 67O_6(4?MR6\S
ME0XN&$U9'H?G_&RE:^DS"-*V0)^3>D0O9SAEBYG?8Y1PP?N*;="-C8Z=)WNI
M%P+8@WW'_I1=ESS(:*WUD'PM*1HB;PR!>&E]CK;FHP7@ON#,EC*N[:=AG,25
M+6#![ZOK] +/,*4XXJ1G&<XS?K=45UJ2D*\\IZ4-<N^![4_*=,4N51Y,<$.R
M[!Q1NIX16MI+!&#;.SAX"P=GF%W["_ES.(V-1OR,S E <'\HE*+N)(UNV#>3
M?S"E)HOB\#@QNZG&77LO7Q'15T1L"?ZU6F@.O9RS>RC.]X_MQK?F-7I @2&I
M;MC6'@B$U@KEBKU.!([[N^%+2K=^H9VFE&W%O3MV B5YC'GV^W6:8\KTS$D8
MTD+X )*!$7V-/M<86S1,HJO,0<38?F:2CN>27;0&\[-4# N6E[+=DMO*@43+
M4*8:+&"<564):/WWXTB2(G464TM#L8O49!*]FF@';ENJGIA$S7P!<EN:O$).
MK Z83_4UNS]]JN^PGE[3!FZ[&]?8-*B:OA7A00F#TC;V*.*#%OTTL$=4<5:@
M!#T9-TFXCKN(9^P4PNRLR8(GG'_%. WR!0Y8DQ5*UUF V=]#7B"9=PC81L8!
M2J.R#1^YR E=[_ZT"758,29)61NF%Z%D.X$=HSELDN@L1L0^2)N1)Y<;ZG=W
M(B/S];TXR:\PV^LH>=C@>=588!LT./*(/8(G ,&]X=I[ 4_""^C>##QN<[[7
MV+W&_D8U=N/"A&WI_M< U^I:\)$=N'\$JP2E/8.KM<:T)C]WH,IJJ#6'RW5D
M7K+CJ>"XRYR'BF9Z$6<A+6MA([K>;R2-*S$SZ(AEQ!. X,5<+^9Z,=>+N5[,
M]6*N*S'7I!QA6\)]_WT0DH2=GH0[E9XK*RCAF9 !K7W]Y:^BW<LB05@7%NJ;
M9CC(MZU)S -2KR99'\]O]:K(Y?GT,W>3W-\T9@_(&^G<YR("'N[NSR;W%Y--
M 2H)&?*F)HB)HG+-4;+W-D[M.9/0I=S+"(G/W#E]2_(XQ'79/4)YR:XX+57D
MZ6PRIQCOG]:OB=7O;X+L-&6,>\.^F6;X"N.#8ARO*)0W'8*8ZN$$)6)>-S5
MS%E9I:2-]\6M#)!P_G!S$R_CHY?!]@D0M3'Q^?V#<<M\NUVUP?TJ<?X5;5T&
M&)#P_Q2\A%-GLB7=!R.Z([%#$;DI='6/0QP_E_6*F*A5%<5BQ]4FL)#=27M'
M[H:80]74X(@&H'UB4Y>>\R+IYX2NR@D59.ZI-C= U/;]M[KFA>1X;FDZ!#'B
MX[FEJ0EBBC2*5PM$ETB\2,)&!@BX1=4AQFN/Q'F18W9!)PFF\W49W5+:S$F1
M,;T!LSM"(J;T&L@ D'J)^&[[3"+^ &$M;]2WJU1LT>YL@N!2.FJ1IX2-3!#
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MZ-V77UE5!V</[HY910<'9_3M 5?!^F&7H[V+SKOHWJB+KEUY!7?0J@&3&1+
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M41;GB)]%)M9>8XT!.BF$;OL^8XT ^B/[NK%E?S78&,!_)<:@[X8:L9?P!"
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M.KW ;,LQ]F(-)EF&\XP?P-5!GR3D*TJ%-?+,#0QN4BY35,;45=NQ&_[F,<!
M%?#I)+_"3!A!R</F/'UU,NE-1;]O@)DJ)L>P"Z-@Y_13@FLH>A,A&P$,S+)"
MRB3Z3Y'E_(86F<HU>X.!5\J\DS2Z8:0DVS9"_UC'4<# W4H-V3W.,!.A%WI
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MQYXZ.+OHF^!.&*V%E1CRP 7[Z.Y%L6L67&"/#K167P>XN!X=="K>/7#!W5T
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M],A;FB!EP0"2><SKY)&;7$:*M*4!4KX\,"$=T5+0G\Y^8V=DSLOW_58L4?J
MZ7,<"FQ/'7L[<._5#VC<LNV3W1"49F6Q]+JHX=X+/&?KLSAAGY_S4[?(6GPS
MIH8%/2$W>(Z2ZM%*7@ZXX!(47^^UN<E1_H3]B>+KMGUY0VZ!E36U3_C>G/)9
M?#VO4@>*1L\3@^7>0[2_+?9/#"DRM4XG 0;4"O%BN06E>S8*,9;CMB/VI)X
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M&(B:G2G9B7 JZ>).S:J>3=%*L:0&R3JC=I4:6G8<0@TP*>0,^C93AO@F8Z>
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M ><E=5YG>7++'BW?$0H)5VG!EYBS^CSJ(BWCC)3K8C2_G&EWT!D%).N\\KO
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M9%4C>D^:%5I"CA#Z>W1^*":HH@__@6JZB@?)#CF G09<;TMYL&U_19<]?@I
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M:1W1&J(C1P\I ,AR27(^^1X6$17\[;HJJRAG\?<]$5[J'\&3 PQT[BM3 (>
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MU56:1WF<BO*&?--0,G2#1\,ZGP*52(6$\_J7#7'44D=7:<9"QH2RA;2(6F-
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M A"*Z#HM(*&RP80*MF'[\KOO_W>8<R,WXSON)MH8M&DD"F3)TX!)__H^M9S
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ML2"C<62G&+,D2=DG458[E>MJ00IV6NGJ(&.<8JBS##FRHSG.D+,09)MI4Z(
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M1LDNITT1\15'%.#N74>W"%2D?@TI1;1,*^Z^SW+JV.<L=0?.8VKMMYN ,5\
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M"PJ-_8=!?8DR=E#2_]O!A'4VNH1FH3 @[;RL"27*%9S_T"$?-E>!E=$B+H;
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MH#*7,QBJT5?)X8=LV;)<I#:QD_!#,.>CKX#C:FOQ+#"*<?6V2*I#*#TV^OI
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M8.W91>U.VCSH/#JA?)E<\/$[^:..%SY<(2I6%)V*I_/?D!]G2_HU?LM7?O*
MR',4B+ZH^FP=)*^IS)-D51*%@#C!. .-)@[JN%&(/M.-L/_-(_TI]0/^;=#R
M*?VS>WDH@AQ0#3<0-GB""3;SA.H_; ]L)$7B14,-F*4K'69&Y8HD/\17T@P%
M/G%H3 F-M2I31^Y$L(0-D[Z0&5I7I=$F"RH$LF5RO+V%JTUYOKF\#'K+'.@>
M!_MBJP0\XJIFS0TFA14AO=A(SA"MSQX5--)S2.NSG8_,^<@$=%OM(^LH'8.^
MD6JM^^THRB81C77N/>?>.VOWGE =PJU%)5M@$A\B6)-EP!:T%)13W$;WLP4O
MO8)X37BZ1C'6%LP!]<CTJT>VQ$%H7["MS-BVH I(Q9'+LK: (;UQ06Y06W)P
M8&BH^JEM2<H!H@.)+K!EP71S0FMP'=L"L/RPEGN:;#FK94HD(& $#,7 *R'#
MCB)PR H8EH%7_X7!(@F?L>6ZDA\=JMY=6PX2-<,!,+P$#,[ "P@#I1QQ**<M
M>Z@C#;0^M,N6RZG?7(Z!7TDNE\/E<G20R]$X7J[7](TT6B2L<8]/?_:#@,GO
M4;+PUCB.@@BENQ^V),J3-%2?V$\J1C.JVB5<! %=B>'U"ZL^CM)[]H8-+\I2
M88:.N'Y<--<LU8WI_)-/OJ)L%J5? 42JSM5!;DZ/A"38_(;"Q=[M"*%59:(&
M0J]0&I!H72+#ZL[[R09 IL(T'5D5F*[\XBN2I'P+@$3P) T$WC(; DJS:A\4
MDEUY*U3Q#(R2-(/LJ):/TL#,P1'4^# ZY$C'\PQ$V^^HNJ]HD02:RB?TS\2%
MGT8I5;Q>DR;9/<TF&XB<]U.F0['_7?^91\]^S"(78+PIS1T*:_L6H"+RE3A6
M>Z2)[(@5%:J6+,GX&965IE26L.KT_AF\]DE"MU9*-?VBNPN,+^"L_MG9%0.#
M\2$;;H*!C*H]$56K)VF*LI1>NE&&[NCR"87;"SS/!$O/="MC MPSLN%F&$@S
MN0 -'M\_"W?,J0BC7C340,VNUX1(9"#)Z)&2;[1F&HDPH<=\A,,9"F(_30NQ
MN;!#A?_)RV5^H(WQ.&OX&!,,XS4BV>8^IKH!%4B8,+*&[WW5Z29R?P)$Q2MZ
M4P!E5?F$H20P53JK\*)4F&F"K<)Y1Q''5#]E&P'ZB8#S7#Y5$Q9V;0\/&R.6
MP6%%\ ZS[E%)B^UYL1+4XDDNC<RED0THC>Q+BJ;SZS2+5I0>'L#U@RQ+'--B
M7G0I92ZES%6,=%$&K:,,@"JD+1M&IO ?IA<"_2.V0 /@%S?UIMIRQ, P:N.0
MLB5F7PVI=N8>6P(MU3!KX!*T);A2!U!-/(FVQ&.JX0=T3]@2^ZT&#M38"4;G
M9YO0@?GFP-C\8A,VS2S_8*Q^M0DK16\U7-RT1R97B6R%XV.5/ Z+WH"#8Y4(
MWBST" Z65;*WHO\,CI)5@K>RZQ2.DU4"=FLO'QPW*V1O?7'G<."L$LOE(5MP
M8*R0R9NFLL!ALDH<5PKGA5LTK1#&(;YL."16R-\MDMK@2%DAC#=)!.LUF;7L
MMR6-5V#=MH+##YYZ>.X1^K6]K+"5;5F =B33]\9^DF&[H;I=LNRS'\7LH3>8
M//@Q>D!!3JCN@M(K])1]\K/J7S=^1'[WXQP5;G1Q-JV>1VK( 7P(EBC,8WKD
M'AAD;^@./,@1I^C*66KU(,V,%#IF:R[4GM)1/J;N_2#+U^QF__6:S\G=6[+@
M7H69+KRW$0O;S5797.\B_RF*2X1%6[/Y TPRN?/AE/I1IL@B;+J+5G;1R@.*
M5@:M\:&LY ;$PC+$QA7'UI\LX(*O7?"U"[YVP=>M@Z_%A[(M^X1S3^(6&HLM
MNX8/C7[[BBV1Q1+,-!AP;(DGEF^\9FJ:+6'$*OBH:>JV! HK[+4F9L;^71?O
MO'45=EG(^V@;<]G,+0%\6H\N!R6*6KD3N)H6D 20!5>)G4%4_6A<[V, A@0;
M;+/.JN>L>LZJ=RY6/>C]X"QVSF+G+';.8N<L=IH48U4QMG]-[[U'GQ]AX@44
MXRCSYG[ %/=-,TT/^+0>-3TEBKK1]( D@#0])7:<4M0PEF-O,I[.[W"R>$1D
MQ4S)BC$=:H]Q6J#3 IT6Z+3 SK1 Z-WAM$"G!3HMT&F!3@O4[AYM(A'VKQ-^
M\&*6^>KAISA:5#%^S&Z(6;-2%OS'(@)14H0#-E(3F[^@1\VQ+9'=*)/-J0+I
MEVV9=BIG0Y7S)J<G _H4)=$J7\W82HZK!M(I:Q.\1BQ.(%D4*>FJZ1,:GNV4
M4Z><.N74*:>=*:<M+AZGKSI]U>FK3E]U^JIV?56;Y-B_$ONSE[*:.T^L7AB]
M/_8%PYJIK-#']:B@JI'4C3H*I0&D?*HQY%3-AJKF-5V;>(/0 R+/48#JR^I-
MXH*XH@A15;_Q+Q26M>>+@G%P];.C]YF$D,-#D$7/4;915,^;/&QXS#]DE+RR
M&&.J%0CX@X<!2G5!3K[Y)#RDG66>E5\V3?/56EZBIMN7#*7?WX00GVIVC)N+
M33V#6]Y0FJ&015&]T$.5_OB(V:^F>4;OD22D<DCQ-T2"*"U8!H$["**<><V9
MUYQYS9G7.C.O@45K9TQSQC1G3'/&-&=,TVY,ZU0/MF6OJ0#:7'&VO\A''\KC
M&14 &9"6>(YE1?18AOIW0OSB146+("IEOS0-EA,^HT=W X".;GP,PA>#' L
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M)]E)^U494["G],]N)02+FDV?CC!&IKC%=-T8E]4-.!NMRUYV6=VO<#F-'L
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M7-$$_AVLS6[;W6$S6!#AUN#N#I[!@J-@!NKN)!HL.IW[]L"8CC_.J@/KC_F
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M=GYDYT=N8S-7,7+8@@R09Q%*JG8%6[:7!NA4M%];G.\:8 .:1[KSOQO(\=(
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M,0QU%Z,V1(#Z]0%V$-KV2EBX3GJ.CFDL*GS@ =-7-9ZW7AK1#\4::=!?^4'
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M-0<A4_IGY"8G293EA,D+-]$+^TG,AGQ"_TP4AQU++[Q=T1/@N2Q-+.0",,-
M;<[Y/ J0^' 'C>V?=.Z1<K%YI,0(G#@*,P?$EJ@/.FS2@)CA>V5%4TPF4''I
M8DM&Z*=5F.F<SDU8P//L&]7,#G1-X3DF'>_\YLYO?O9^\[8*C_.+.[^XHJR%
M6]R9MN E=U4H2Z^VN+0:+B6H]FB+LZLA3 #MSA;O>4.$@'*C+2YU1914[-%@
MB 9>#ZT11'(K.1B>@5=#:[C/P(8R,$[*E<U&@1/<N@L&"MZ<<TQ B2SXM@A'
M+MYG)/$^0TH_;V(^[F##F&RU"DPR[\K;V6&\T% 3]E4,_/T'Q+SWZ/,C3+R
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M8/L ;A^KWT'*\3D<R W"U&RIE@ 3UIJ&3W4@@KU>CX_]GP(-L! B*0I8ZES
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M,#$V,3(S,2YX;6Q02P$"% ,4    " "N@%M*05UJ5W,9   Y* $ $0
M        @ %%>P$ 8F-R>"TR,#$V,3(S,2YX<V102P$"% ,4    " "N@%M*
MZ,%ZJ@00  !$[   %0              @ 'GE $ 8F-R>"TR,#$V,3(S,5]C
M86PN>&UL4$L! A0#%     @ KH!;2O4YR/+?8@  +> ' !4
M ( !'J4! &)C<G@M,C Q-C$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( *Z 6TK.
MHZ)+27P  -$6!P 5              "  3 ( @!B8W)X+3(P,38Q,C,Q7VQA
M8BYX;6Q02P$"% ,4    " "N@%M*"H+@15QC  ##+0@ %0
M@ &LA ( 8F-R>"TR,#$V,3(S,5]P<F4N>&UL4$L%!@     &  8 B@$  #OH
$ @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
